-DOCSTART- -X- O O

Transurethral JJ 1_i
prostate NN 1_i
resection NN 1_i
and CC N
bleeding NN N
: : N
a DT N
randomized JJ N
, , N
placebo NN 7_i
controlled VBD N
trial NN N
of IN N
role NN N
of IN N
finasteride NN 3_i
for IN N
decreasing VBG N
operative JJ N
blood NN N
loss NN N
. . N

PURPOSE NNP N
Bleeding NNP N
associated VBN N
with IN N
transurethral JJ N
prostate NN N
resection NN N
can MD N
often RB N
be VB N
significant JJ N
and CC N
lead JJ N
to TO N
increased VBN N
morbidity NN N
and CC N
occasionally RB N
mortality NN N
. . N

It PRP N
has VBZ N
been VBN N
shown VBN N
that IN N
finasteride NN 3_i
decreases VBZ N
bleeding VBG N
in IN N
patients NNS N
with IN N
hematuria NNS N
of IN N
prostatic JJ N
origin NN N
. . N

We PRP N
hypothesized VBD N
that IN N
bleeding VBG N
in IN N
patients NNS N
undergoing JJ N
transurethral JJ N
prostate NN N
resection NN N
could MD N
be VB N
decreased VBN N
by IN N
giving VBG N
finasteride NN 3_i
for IN N
2 CD N
weeks NNS N
before RB N
surgery NN N
. . N

MATERIALS NNP N
AND NNP N
METHODS NNP N
A NNP N
total JJ N
70 CD N
patients NNS N
scheduled VBN N
to TO N
undergo VB N
elective JJ N
transurethral JJ N
prostate NN N
resection NN N
were VBD N
randomized VBN N
to TO N
receive VB N
5 CD 3_i
mg. NNS 3_i
finasteride JJ 3_i
daily RB 3_i
or CC N
placebo VB 7_i
for IN N
2 CD N
weeks NNS N
before RB N
surgery NN N
. . N

Serum NNP N
hemoglobin NN N
was VBD N
measured VBN N
before IN N
and CC N
after IN N
surgery NN N
, , N
and CC N
the DT N
following JJ N
day NN N
. . N

The DT N
volume NN N
of IN N
irrigation NN N
fluid NN N
used VBN N
and CC N
its PRP$ N
hemoglobin JJ N
concentration NN N
as RB N
well RB N
as IN N
resected VBN N
prostate NN N
weight NN N
were VBD N
recorded VBN N
. . N

RESULTS NNP N
Of IN N
the DT N
68 CD N
patients NNS N
who WP N
underwent JJ N
transurethral JJ N
prostate NN N
resection NN N
2 CD N
were VBD N
withdrawn VBN N
before RB N
surgery NN N
, , N
and CC N
so RB N
32 CD N
received VBD N
finasteride NN 3_i
and CC N
36 CD N
received VBD N
placebo NN 7_i
. . N

There EX N
was VBD N
significantly RB N
less JJR N
mean JJ N
blood NN N
loss NN N
in IN N
irrigation NN N
fluid NN N
in IN N
the DT N
finasteride NN 3_i
group NN N
than IN N
in IN N
the DT N
control NN N
group NN N
( ( N
43.6 CD N
versus NN N
69.3 CD N
gm NN N
. . N

hemoglobin NN N
, , N
p NN N
= NNP N
0.011 CD N
) ) N
. . N

The DT N
mean JJ N
difference NN N
was VBD N
more RBR N
significant JJ N
when WRB N
blood NN N
loss NN N
per IN N
gm NN N
. . N

resected JJ N
prostate NN N
was VBD N
calculated VBN N
( ( N
2.65 CD N
versus NN N
4.65 CD N
gm NN N
. . N

hemoglobin NN N
per IN N
gm NN N
. . N

prostate NN N
, , N
p NN N
< NNP N
0.01 CD N
) ) N
. . N

CONCLUSIONS VB N
This DT N
study NN N
shows VBZ N
that IN N
finasteride NN 3_i
given VBN N
for IN N
2 CD N
weeks NNS N
preoperatively RB N
decreases VBZ N
bleeding VBG N
in IN N
patients NNS N
undergoing JJ N
transurethral JJ N
prostate NN N
resection NN N
. . N

Further NNP N
study NN N
is VBZ N
required VBN N
to TO N
determine VB N
the DT N
optimal JJ N
timing NN N
and CC N
dose JJ N
duration NN N
to TO N
minimize VB N
blood NN N
loss NN N
and CC N
identify VB N
how WRB N
relevant JJ N
such JJ N
a DT N
decrease NN N
in IN N
bleeding NN N
is VBZ N
in IN N
clinical JJ N
practice NN N
. . N

-DOCSTART- -X- O O

Menopausal NNP N
quality NN N
of IN N
life NN N
: : N
RCT NNP N
of IN N
yoga NN 2_i
, , N
exercise NN 2_i
, , N
and CC N
omega-3 JJ 3_i
supplements NNS 3_i
. . N

OBJECTIVE IN N
The DT N
purpose NN N
of IN N
this DT N
study NN N
was VBD N
to TO N
determine VB N
the DT N
efficacy NN N
of IN N
3 CD N
nonhormonal JJ N
therapies NNS N
for IN N
the DT N
improvement NN N
of IN N
menopause-related JJ N
quality NN N
of IN N
life NN N
in IN N
women NNS N
with IN N
vasomotor NN N
symptoms NNS N
. . N

STUDY NNP N
DESIGN NNP N
We PRP N
conducted VBD N
a DT N
12-week JJ N
3 CD N
? . N
2 CD N
randomized VBD N
, , N
controlled VBD N
, , N
factorial JJ N
design NN N
trial NN N
. . N

Peri- NN N
and CC N
postmenopausal JJ N
women NNS N
, , N
40-62 JJ N
years NNS N
old JJ N
, , N
were VBD N
assigned VBN N
randomly RB N
to TO N
yoga VB 2_i
( ( N
n JJ N
= NNP N
107 CD N
) ) N
, , N
exercise NN N
( ( N
n JJ N
= NNP N
106 CD N
) ) N
, , N
or CC N
usual JJ 7_i
activity NN 7_i
( ( N
n JJ N
= NNP N
142 CD N
) ) N
and CC N
also RB N
assigned VBD N
randomly RB N
to TO N
a DT N
double-blind JJ N
comparison NN N
of IN N
omega-3 JJ 3_i
( ( N
n JJ N
= NNP N
177 CD N
) ) N
or CC N
placebo NN 7_i
( ( N
n JJ N
= NNP N
178 CD N
) ) N
capsules NNS N
. . N

We PRP N
performed VBD N
the DT N
following JJ N
interventions NNS N
: : N
( ( N
1 CD N
) ) N
weekly JJ N
90-minute CD N
yoga NN N
classes NNS N
with IN N
daily JJ N
at-home JJ N
practice NN N
, , N
( ( N
2 CD N
) ) N
individualized VBN N
facility-based JJ N
aerobic JJ N
exercise NN N
training NN N
3 CD N
times/week NN N
, , N
and CC N
( ( N
3 CD N
) ) N
0.615 CD N
g JJ N
omega-3 JJ 3_i
supplement NN 3_i
, , N
3 CD N
times/day NN N
. . N

The DT N
outcomes NNS N
were VBD N
assessed VBN N
with IN N
the DT N
following JJ N
scores NNS N
: : N
Menopausal NNP N
Quality NNP N
of IN N
Life NNP N
Questionnaire NNP N
( ( N
MENQOL NNP N
) ) N
total NN N
and CC N
domain NN N
( ( N
vasomotor NN N
symptoms NNS N
, , N
psychosocial JJ N
, , N
physical JJ N
and CC N
sexual JJ N
) ) N
. . N

RESULTS NNP N
Among IN N
355 CD N
randomly NNS N
assigned VBN N
women NNS N
who WP N
average VBP N
age NN N
was VBD N
54.7 CD N
years NNS N
, , N
338 CD N
women NNS N
( ( N
95 CD N
% NN N
) ) N
completed VBD N
12-week JJ N
assessments NNS N
. . N

Mean NNP N
baseline NN N
vasomotor NN N
symptoms JJ N
frequency NN N
was VBD N
7.6/day CD N
, , N
and CC N
the DT N
mean JJ N
baseline NN N
total JJ N
MENQOL NNP N
score NN N
was VBD N
3.8 CD N
( ( N
range NN N
, , N
1-8 CD N
from IN N
better JJR N
to TO N
worse VB N
) ) N
with IN N
no DT N
between-group JJ N
differences NNS N
. . N

For IN N
yoga NN N
compared VBN N
to TO N
usual JJ N
activity NN N
, , N
baseline NN N
to TO N
12-week JJ N
improvements NNS N
were VBD N
seen VBN N
for IN N
MENQOL NNP N
total JJ N
-0.3 NNP N
( ( N
95 CD N
% NN N
confidence NN N
interval NN N
, , N
-0.6 VBP N
to TO N
0 CD N
; : N
P NNP N
= NNP N
.02 NNP N
) ) N
, , N
vasomotor NN N
symptom NN N
domain NN N
( ( N
P NNP N
= NNP N
.02 NNP N
) ) N
, , N
and CC N
sexuality NN N
domain NN N
( ( N
P NNP N
= NNP N
.03 NNP N
) ) N
scores VBZ N
. . N

For IN N
women NNS N
who WP N
underwent VBP N
exercise NN 2_i
and CC N
omega-3 JJ 3_i
therapy NN 3_i
compared VBN N
with IN N
control NN N
subjects NNS N
, , N
improvements NNS N
in IN N
baseline NN N
to TO N
12-week JJ N
total JJ N
MENQOL NNP N
scores NNS N
were VBD N
not RB N
observed VBN N
. . N

Exercise NN N
showed VBD N
benefit NN N
in IN N
the DT N
MENQOL NNP N
physical JJ N
domain NN N
score NN N
at IN N
12 CD N
weeks NNS N
( ( N
P NNP N
= NNP N
.02 NNP N
) ) N
. . N

CONCLUSION NNP N
All NNP N
women NNS N
become VBP N
menopausal JJ N
, , N
and CC N
many JJ N
of IN N
them PRP N
seek VBP N
medical JJ N
advice NN N
on IN N
ways NNS N
to TO N
improve VB N
quality NN N
of IN N
life NN N
; : N
little JJ N
evidence-based JJ N
information NN N
exists NNS N
. . N

We PRP N
found VBD N
that IN N
, , N
among IN N
healthy JJ N
sedentary JJ N
menopausal NN N
women NNS N
, , N
yoga NN N
appears VBZ N
to TO N
improve VB N
menopausal NN N
quality NN N
of IN N
life NN N
; : N
the DT N
clinical JJ N
significance NN N
of IN N
our PRP$ N
finding NN N
is VBZ N
uncertain JJ N
because IN N
of IN N
the DT N
modest JJ N
effect NN N
. . N

-DOCSTART- -X- O O

Acute JJ N
effects NNS N
of IN N
decaffeinated JJ 3_i
coffee NN 3_i
and CC N
the DT N
major JJ N
coffee NN N
components NNS N
chlorogenic JJ 3_i
acid NN N
and CC N
trigonelline NN 3_i
on IN N
glucose JJ N
tolerance NN N
. . N

OBJECTIVE NNP N
Coffee NNP 3_i
consumption NN N
has VBZ N
been VBN N
associated VBN N
with IN N
lower JJR N
risk NN N
of IN N
type NN N
2 CD N
diabetes NNS N
. . N

We PRP N
evaluated VBD N
the DT N
acute JJ N
effects NNS N
of IN N
decaffeinated JJ 3_i
coffee NN 3_i
and CC N
the DT N
major JJ N
coffee NN N
components NNS N
chlorogenic JJ N
acid NN N
and CC N
trigonelline NN N
on IN N
glucose JJ N
tolerance NN N
. . N

RESEARCH NNP N
DESIGN NNP N
AND NNP N
METHODS NNP N
We PRP N
conducted VBD N
a DT N
randomized VBN N
crossover NN N
trial NN N
of IN N
the DT N
effects NNS N
of IN N
12 CD N
g NN N
decaffeinated VBD 3_i
coffee NN 3_i
, , N
1 CD N
g NN N
chlorogenic JJ 3_i
acid NN 3_i
, , N
500 CD N
mg NN N
trigonelline NN 3_i
, , N
and CC N
placebo NN 7_i
( ( N
1 CD N
g NN N
mannitol NN 3_i
) ) 3_i
on IN N
glucose NN N
and CC N
insulin NN N
concentrations NNS N
during IN N
a DT N
2-h JJ N
oral JJ N
glucose NN N
tolerance NN N
test NN N
( ( N
OGTT NNP N
) ) N
in IN N
15 CD N
overweight JJ N
men NNS N
. . N

RESULTS NNP N
Chlorogenic NNP N
acid NN N
and CC N
trigonelline NN N
ingestion NN N
significantly RB N
reduced VBN N
glucose NN N
( ( N
-0.7 JJ N
mmol/l NN N
, , N
P NNP N
= NNP N
0.007 CD N
, , N
and CC N
-0.5 NNP N
mmol/l NN N
, , N
P NNP N
= NNP N
0.024 CD N
, , N
respectively RB N
) ) N
and CC N
insulin NN N
( ( N
-73 JJ N
pmol/l NN N
, , N
P NNP N
= NNP N
0.038 CD N
, , N
and CC N
-117 NNP N
pmol/l NN N
, , N
P NNP N
= NNP N
0.007 CD N
) ) N
concentrations NNS N
15 CD N
min NN N
following VBG N
an DT N
OGTT NNP N
compared VBN N
with IN N
placebo NN N
. . N

None NN N
of IN N
the DT N
treatments NNS N
affected VBD N
insulin NN N
or CC N
glucose JJ N
area NN N
under IN N
the DT N
curve NN N
values NNS N
during IN N
the DT N
OGTT NNP N
compared VBN N
with IN N
placebo NN 7_i
. . 7_i

CONCLUSIONS NNP N
Chlorogenic NNP N
acid NN N
and CC N
trigonelline NN N
reduced VBD N
early JJ N
glucose NN N
and CC N
insulin NN N
responses NNS N
during IN N
an DT N
OGTT NNP N
. . N

-DOCSTART- -X- O O

Prophylactic JJ 3_i
vs NN 3_i
therapeutic JJ 3_i
blood NN 3_i
patch NN 3_i
for IN N
obstetric JJ N
patients NNS N
with IN N
accidental JJ N
dural JJ N
puncture NN N
-- : N
a DT N
randomised JJ N
controlled VBN N
trial NN N
. . N

Epidural JJ 3_i
blood NN 3_i
patch NN 3_i
is VBZ N
a DT N
standard JJ N
treatment NN N
for IN N
obstetric JJ N
patients NNS N
experiencing VBG N
a DT N
severe JJ N
post-dural JJ N
puncture NN N
headache NN N
. . N

Patients NNS N
who WP N
sustained VBD N
an DT N
accidental JJ N
dural JJ N
puncture NN N
during IN N
establishment NN N
of IN N
epidural JJ N
analgesia NN N
during IN N
labour NN N
or CC N
at IN N
caesarean JJ N
delivery NN N
were VBD N
randomly RB N
assigned VBN N
to TO N
receive VB N
a DT N
prophylactic JJ 3_i
epidural JJ 3_i
blood NN 3_i
patch NN 3_i
or CC N
conservative JJ 3_i
treatment NN 3_i
with IN 3_i
a DT 3_i
therapeutic JJ 3_i
epidural JJ 3_i
blood NN 3_i
patch NN 3_i
if IN N
required VBN N
. . N

Eleven NNP N
of IN N
60 CD N
( ( N
18.3 CD N
% NN N
) ) N
patients NNS N
in IN N
the DT N
prophylactic JJ 3_i
epidural JJ 3_i
blood NN 3_i
patch NN 3_i
group NN N
developed VBD N
a DT N
post-dural JJ N
puncture NN N
headache NN N
compared VBN N
with IN N
39 CD N
of IN N
49 CD N
( ( N
79.6 CD N
% NN N
) ) N
in IN N
the DT N
therapeutic JJ 3_i
epidural JJ 3_i
blood NN 3_i
patch NN 3_i
group NN N
( ( N
p JJ N
< NNP N
0.0001 CD N
) ) N
. . N

A DT N
blood NN N
patch NN N
was VBD N
performed VBN N
in IN N
36 CD N
( ( N
73.4 CD N
% NN N
) ) N
of IN N
patients NNS N
in IN N
the DT N
therapeutic JJ N
group NN N
. . N

The DT N
number NN N
of IN N
patients NNS N
who WP N
needed VBD N
a DT N
second JJ N
blood NN N
patch NN N
did VBD N
not RB N
differ VB N
significantly RB N
between IN N
the DT N
two CD N
groups NNS N
: : N
6 CD N
( ( N
10.0 CD N
% NN N
) ) N
for IN N
prophylactic JJ 3_i
epidural JJ 3_i
blood NN 3_i
patch NN 3_i
and CC N
4 CD N
( ( N
11.1 CD N
% NN N
) ) N
for IN N
therapeutic JJ 3_i
epidural JJ 3_i
blood NN 3_i
patch NN 3_i
. . 3_i

We PRP N
conclude VBP N
that IN N
prophylactic JJ 3_i
epidural JJ 3_i
blood NN 3_i
patch NN N
is VBZ N
an DT N
effective JJ N
method NN N
to TO N
reduce VB N
the DT N
development NN N
of IN N
post-dural JJ N
puncture NN N
headache NN N
in IN N
obstetric JJ N
patients NNS N
. . N

-DOCSTART- -X- O O

Behavioral JJ N
effects NNS N
of IN N
Org NNP 3_i
2766 CD 3_i
, , N
a DT N
synthetic JJ N
analog NN N
of IN N
the DT N
adrenocorticotrophic JJ N
hormone NN N
( ( N
4-9 JJ N
) ) N
, , N
in IN N
14 CD N
outpatient JJ N
autistic JJ N
children NNS N
. . N

Fourteen NNP N
children NNS N
( ( N
12 CD N
infantile NN N
autism NN N
full JJ N
syndrome NN N
present NN N
, , N
2 CD N
atypical JJ N
pervasive JJ N
developmental JJ N
disorder NN N
) ) N
between IN N
5 CD N
and CC N
13 CD N
years NNS N
of IN N
age NN N
participated VBN N
in IN N
a DT N
double-blind JJ N
placebo-controlled JJ N
cross-over JJ N
trial NN N
. . N

Each DT N
child NN N
received VBD N
20 CD N
mg NNS N
Org JJ 3_i
2766 CD 3_i
( ( N
synthetic JJ N
analog NN N
of IN N
ACTH NNP N
4-9 JJ N
) ) N
/day NN N
during IN N
4 CD N
weeks NNS N
, , N
or CC N
placebo NN N
in IN N
a DT N
randomly NN N
assigned VBN N
sequence NN N
. . N

Drug JJ N
effects NNS N
were VBD N
monitored VBN N
by IN N
ethological JJ N
playroom NN N
observation NN N
and CC N
by IN N
Aberrant NNP N
Behavior NNP N
Checklist NNP N
ratings NNS N
by IN N
parents NNS N
and CC N
teachers NNS N
. . N

Data NNP N
of IN N
the DT N
playroom NN N
observation NN N
pointed VBD N
to TO N
an DT N
activating VBG N
influence NN N
of IN N
Org NNP N
2766 CD N
, , N
as IN N
revealed VBN N
by IN N
a DT N
significant JJ N
decrease NN N
of IN N
stereotypic NN N
behavior NN N
and CC N
significant JJ N
increases NNS N
in IN N
change NN N
toys NNS N
, , N
locomote NN N
, , N
and CC N
talk NN N
. . N

Checklist JJ N
ratings NNS N
did VBD N
not RB N
show VB N
significant JJ N
changes NNS N
. . N

The DT N
clinical JJ N
implications NNS N
of IN N
these DT N
findings NNS N
are VBP N
discussed VBN N
. . N

-DOCSTART- -X- O O

Psychoeducational NNP 4_i
group NN 4_i
intervention NN 4_i
for IN N
wives NNS N
of IN N
men NNS N
with IN N
prostate NN N
cancer NN N
. . N

OBJECTIVE CC N
The DT N
effects NNS N
of IN N
a DT N
6-week JJ N
psychoeducational JJ 4_i
group NN 4_i
intervention NN 4_i
on IN N
the DT N
distress NN N
, , N
coping NN N
, , N
personal JJ N
growth NN N
, , N
and CC N
marital JJ N
communication NN N
of IN N
wives NNS N
of IN N
men NNS N
diagnosed VBN N
with IN N
prostate JJ N
cancer NN N
were VBD N
evaluated VBN N
using VBG N
a DT N
randomized JJ N
clinical JJ N
trial NN N
. . N

METHODS NNP N
Sixty NNP N
wives NNS N
completed VBD N
measures NNS N
prior RB N
to TO N
random VB N
assignment NN N
to TO N
either VB N
the DT N
psychoeducational JJ 7_i
group NN 7_i
intervention NN 7_i
or CC N
a DT N
no-treatment JJ 7_i
control NN 7_i
group NN 7_i
, , N
and CC N
1 CD N
month NN N
after IN N
completion NN N
of IN N
the DT N
group NN N
. . N

RESULTS NNP N
No NNP N
differences NNS N
with IN N
regard NN N
to TO N
wives NNS N
' POS N
general JJ N
distress NN N
or CC N
cancer-specific JJ N
distress NN N
were VBD N
noted VBN N
. . N

In IN N
comparison NN N
with IN N
the DT N
control NN N
group NN N
, , N
participants NNS N
receiving VBG N
the DT N
intervention NN N
perceived VBD N
that IN N
having VBG N
a DT N
spouse NN N
with IN N
prostate NN N
cancer NN N
had VBD N
made VBN N
positive JJ N
contributions NNS N
to TO N
their PRP$ N
lives NNS N
, , N
reported VBD N
gains NNS N
in IN N
the DT N
use NN N
of IN N
positive JJ N
reappraisal NN N
coping VBG N
and CC N
reductions NNS N
in IN N
denial JJ N
coping NN N
. . N

CONCLUSION NNP N
Although IN N
the DT N
psychoeducational JJ 4_i
intervention NN 4_i
did VBD N
not RB N
result VB N
in IN N
changes NNS N
in IN N
psychological JJ N
distress NN N
, , N
improvements NNS N
in IN N
adaptive JJ N
coping NN N
and CC N
indicators NNS N
of IN N
psychological JJ N
growth NN N
were VBD N
found VBN N
. . N

The DT N
utility NN N
of IN N
group NN N
interventions NNS N
for IN N
spouses NNS N
of IN N
men NNS N
with IN N
prostate NN N
cancer NN N
is VBZ N
discussed VBN N
. . N

-DOCSTART- -X- O O

Effects NNS N
of IN N
interaction NN N
of IN N
RRR-alpha-tocopheryl NNP 3_i
acetate NN 3_i
and CC N
fish JJ 3_i
oil NN 3_i
on IN N
low-density-lipoprotein JJ N
oxidation NN N
in IN N
postmenopausal JJ N
women NNS N
with IN N
and CC N
without IN N
hormone-replacement JJ 3_i
therapy NN 3_i
. . 3_i

We PRP N
evaluated VBD N
the DT N
effects NNS N
of IN N
RRR-alpha-tocpheryl NNP 3_i
acetate NN 3_i
( ( 3_i
alpha-tocopheryl JJ 3_i
acetate NN 3_i
) ) 3_i
and CC N
hormone-replacement JJ 3_i
therapy NN 3_i
( ( 3_i
HRT NNP 3_i
) ) 3_i
on IN N
the DT N
oxidative JJ N
susceptibility NN N
of IN N
low-density NN N
lipoprotein NN N
( ( N
LDL NNP N
) ) N
in IN N
postmenopausal JJ N
women NNS N
consuming VBG N
a DT N
fish JJ 3_i
oil NN 3_i
supplement NN 3_i
. . 3_i

The DT N
independent JJ N
effect NN N
of IN N
fish JJ N
oil NN N
was VBD N
also RB N
assessed VBN N
. . N

Forty-eight JJ N
women NNS N
, , N
equally RB N
divided VBD N
between IN N
women NNS N
using VBG N
and CC N
not RB N
using VBG N
HRT NNP 3_i
, , N
participated VBD N
in IN N
a DT N
double-blind JJ N
crossover NN N
trial NN N
. . N

Each DT N
of IN N
the DT N
four CD N
periods NNS N
lasted VBD N
5 CD N
wk NN N
and CC N
was VBD N
followed VBN N
by IN N
a DT N
4-wk JJ N
washout NN N
interval NN N
. . N

During IN N
each DT N
period NN N
all DT N
subjects NNS N
were VBD N
given VBN N
a DT N
15-g JJ N
supplement NN N
of IN N
fish JJ N
oil NN N
and CC N
either RB N
0 CD N
( ( N
placebo NN 7_i
) ) N
, , N
100 CD N
, , N
200 CD N
, , N
or CC N
400 CD N
mg JJ N
alpha-tocopheryl JJ 3_i
acetate JJ 3_i
daily JJ N
. . N

LDL NNP N
resistance NN N
to TO N
oxidative VB N
modification NN N
was VBD N
assessed VBN N
by IN N
calculating VBG N
lag NN N
time NN N
, , N
propagation NN N
rate NN N
, , N
and CC N
maximum JJ N
production NN N
of IN N
conjugated JJ N
dienes NNS N
. . N

Supplementation NN N
with IN N
fish JJ N
oil NN N
and CC N
placebo NN 7_i
shortened VBN N
lag JJ N
time NN N
and CC N
slowed VBN N
propagation NN N
rate NN N
in IN N
women NNS N
both DT N
using VBG N
and CC N
not RB N
using VBG N
HRT NNP N
. . N

After IN N
subjects NNS N
consumed VBD N
fish JJ N
oil NN N
, , N
supplementation NN N
with IN N
alpha-tocopheryl JJ N
acetate NN N
increased VBD N
plasma NN N
and CC N
LDL NNP N
alpha-tocopherol NN N
contents NNS N
significantly RB N
and CC N
lengthened VBD N
lag NN N
time NN N
( ( N
at IN N
even RB N
the DT N
lowest JJS N
concentration NN N
) ) N
but CC N
had VBD N
no DT N
significant JJ N
effect NN N
on IN N
propagation NN N
rate NN N
or CC N
maximum JJ N
production NN N
compared VBN N
with IN N
values NNS N
measured VBN N
after IN N
consumption NN N
of IN N
fish JJ N
oil NN N
alone RB N
. . N

Women NNP N
not RB N
using VBG N
HRT NNP N
had VBD N
faster JJR N
propagation NN N
rates NNS N
and CC N
higher JJR N
maximum NN N
production NN N
than IN N
women NNS N
using VBG N
HRT NNP N
; : N
after IN N
supplementation NN N
with IN N
fish JJ N
oil NN N
and CC N
alpha-tocopheryl JJ 3_i
acetate NN N
these DT N
differences NNS N
prevailed VBD N
. . N

Supplements NNS N
as RB N
low JJ N
as IN N
100 CD N
mg JJ N
alpha-tocopheryl JJ N
acetate/d NN N
increase VB N
the DT N
resistance NN N
of IN N
LDL NNP N
to TO N
oxidation VB N
when WRB N
fish JJ N
oil NN N
supplements NNS N
are VBP N
used VBN N
. . N

HRT NNP N
and CC N
fish JJ N
oil NN N
supplements NNS N
may MD N
independently RB N
affect VB N
LDL NNP N
oxidative JJ N
susceptibility NN N
. . N

-DOCSTART- -X- O O

Acute JJ N
exposure NN N
to TO N
acid VB N
fog NN N
: : N
influence NN N
of IN N
breathing VBG N
pattern NN N
on IN N
effective JJ N
dose NN N
. . N

Concern JJ N
about IN N
the DT N
possible JJ N
adverse JJ N
health NN N
effects NNS N
of IN N
acid NN N
fog NN N
has VBZ N
been VBN N
fed VBN N
by IN N
two CD N
observations NNS N
: : N
air NN N
pollution NN N
disasters NNS N
earlier RBR N
in IN N
this DT N
century NN N
were VBD N
typically RB N
associated VBN N
with IN N
fog NN N
, , N
and CC N
current JJ N
samples NNS N
of IN N
fog JJ N
water NN N
can MD N
be VB N
strongly RB N
acid JJ N
. . N

To TO N
study VB N
the DT N
acute JJ N
effects NNS N
of IN N
acid JJ N
fog NN N
on IN N
the DT N
lung NN N
, , N
the DT N
authors NNS N
generated VBD N
a DT N
monodisperse JJ 3_i
10 CD 3_i
microM NN 3_i
MMAD NNP 3_i
aerosol NN 3_i
of IN 3_i
H2SO4 NNP 3_i
with IN N
a DT N
pH NN N
of IN N
2.0 CD N
and CC N
a DT N
nominal JJ N
concentration NN N
of IN N
500 CD N
micrograms/m3 NNS N
. . N

They PRP N
exposed VBD N
seven CD N
healthy JJ N
young JJ N
men NNS N
on IN N
alternate NN N
days NNS N
to TO N
acid VB 7_i
or CC 7_i
control VB 7_i
equiosmolar JJ 7_i
NaCl NNP 7_i
aerosol NN 7_i
during IN N
40 CD N
min NNS N
of IN N
resting VBG N
ventilation NN N
and CC N
20 CD N
min NN N
of IN N
exercise NN N
; : N
the DT N
latter NN N
was VBD N
sufficiently RB N
intense JJ N
to TO N
induce VB N
oronasal RP N
breathing VBG N
. . N

Exposure NN N
was VBD N
by IN N
means NNS N
of IN N
a DT N
head NN N
dome NN N
, , N
a DT N
head-only JJ N
exposure NN N
device NN N
that WDT N
permitted VBD N
continuous JJ N
measurement NN N
( ( N
unfettered JJ N
breathing NN N
) ) N
of IN N
Vr NNP N
, , N
f NN N
, , N
VE NNP N
, , N
and CC N
the DT N
onset NN N
and CC N
persistence NN N
of IN N
oronasal NN N
breathing NN N
. . N

In IN N
this DT N
article NN N
the DT N
authors NNS N
compare VBP N
the DT N
relative JJ N
importance NN N
of IN N
parameters NNS N
contributing VBG N
to TO N
the DT N
between-subject JJ N
variability NN N
in IN N
estimated VBN N
hydrogen NN N
ion NN N
dose NN N
to TO N
the DT N
lower JJR N
airways NNS N
( ( N
H+LAW NNP N
) ) N
, , N
based VBN N
on IN N
analysis NN N
of IN N
variance NN N
. . N

Physiologic NNP N
parameters NNS N
accounted VBD N
for IN N
70 CD N
% NN N
of IN N
the DT N
variability NN N
, , N
of IN N
which WDT N
34 CD N
% NN N
was VBD N
due JJ N
to TO N
differences NNS N
in IN N
duration NN N
of IN N
oronasal NN N
breathing NN N
( ( N
tON NN N
) ) N
and CC N
36 CD N
% NN N
to TO N
differences NNS N
in IN N
ventilation NN N
rate NN N
during IN N
oronasal NN N
breathing NN N
( ( N
VE NNP N
( ( N
ON NNP N
) ) N
) ) N
; : N
inhaled VBN N
hydrogen NN N
ion NN N
concentration NN N
[ NNP N
H+ NNP N
] NNP N
, , N
the DT N
environmental JJ N
parameter NN N
, , N
contributed VBD N
only RB N
30 CD N
% NN N
. . N

Minute JJ N
ventilation NN N
at IN N
the DT N
time NN N
of IN N
transition NN N
from IN N
nasal NN N
to TO N
oronasal VB N
breathing VBG N
varied JJ N
significantly RB N
among IN N
subjects NNS N
even RB N
if IN N
normalized VBN N
to TO N
FVC NNP N
, , N
an DT N
index NN N
of IN N
lung NN N
size NN N
. . N

-DOCSTART- -X- O O

Physostigmine JJ 3_i
reverses VBZ N
propofol-induced JJ N
unconsciousness NN N
and CC N
attenuation NN N
of IN N
the DT N
auditory NN N
steady JJ N
state NN N
response NN N
and CC N
bispectral JJ N
index NN N
in IN N
human JJ N
volunteers NNS N
. . N

BACKGROUND IN N
It PRP N
is VBZ N
postulated VBN N
that IN N
alteration NN N
of IN N
central JJ N
cholinergic JJ N
transmission NN N
plays VBZ N
an DT N
important JJ N
role NN N
in IN N
the DT N
mechanism NN N
by IN N
which WDT N
anesthetics NNS N
produce VBP N
unconsciousness JJ N
. . N

The DT N
authors NNS N
investigated VBD N
the DT N
effect NN N
of IN N
altering VBG N
central JJ N
cholinergic JJ N
transmission NN N
, , N
by IN N
physostigmine NN 3_i
and CC N
scopolamine NN 3_i
, , N
on IN N
unconsciousness NN N
produced VBN N
by IN N
propofol NN N
. . N

METHODS NNP N
Propofol NNP 3_i
was VBD N
administered VBN N
to TO N
American NNP N
Society NNP N
of IN N
Anesthesiologists NNP N
physical JJ N
status NN N
1 CD N
( ( N
n JJ N
= NNP N
17 CD N
) ) N
volunteers NNS N
with IN N
use NN N
of IN N
a DT N
computer-controlled JJ N
infusion NN N
pump NN N
at IN N
increasing VBG N
concentrations NNS N
until IN N
unconsciousness JJ N
resulted VBD N
( ( N
inability NN N
to TO N
respond VB N
to TO N
verbal VB N
commands NNS N
, , N
abolition NN N
of IN N
spontaneous JJ N
movement NN N
) ) N
. . N

Central NNP N
nervous JJ N
system NN N
function NN N
was VBD N
assessed VBN N
by IN N
use NN N
of IN N
the DT N
Auditory NNP N
Steady NNP N
State NNP N
Response NNP N
( ( N
ASSR NNP N
) ) N
and CC N
Bispectral NNP N
Index NNP N
( ( N
BIS NNP N
) ) N
analysis NN N
of IN N
electrooculogram NN N
. . N

During IN N
continuous JJ N
administration NN N
of IN N
propofol NN N
, , N
reversal NN N
of IN N
unconsciousness NN N
produced VBN N
by IN N
physostigmine NN 3_i
( ( N
28 CD N
microgram/kg NN N
) ) N
and CC N
block NN N
of IN N
this DT N
reversal NN N
by IN N
scopolamine NN 3_i
( ( N
8.6 CD N
microgram/kg NN N
) ) N
were VBD N
evaluated VBN N
. . N

RESULTS NNP N
Propofol NNP N
produced VBD N
unconsciousness JJ N
at IN N
a DT N
plasma JJ N
concentration NN N
of IN N
3.2 CD N
+/- JJ N
0.8 CD N
( ( N
+/- JJ N
SD NNP N
) ) N
microgram/ml NN N
( ( N
n JJ N
= NNP N
17 CD N
) ) N
. . N

Unconsciousness NN N
was VBD N
associated VBN N
with IN N
reductions NNS N
in IN N
ASSR NNP N
( ( N
0.10 CD N
+/- JJ N
0.08 CD N
microV NN N
[ NNP N
awake VBP N
baseline JJ N
0.32 CD N
+/- JJ N
0.18 CD N
microV NN N
] NN N
, , N
P NNP N
< NNP N
0.001 CD N
) ) N
and CC N
BIS NNP N
( ( N
55.7 CD N
+/- JJ N
8.8 CD N
[ JJ N
awake NN N
baseline NN N
92.4 CD N
+/- JJ N
3.9 CD N
] NN N
, , N
P NNP N
< NNP N
0.001 CD N
) ) N
. . N

Physostigmine NNP N
restored VBD N
consciousness NN N
in IN N
9 CD N
of IN N
11 CD N
subjects NNS N
, , N
with IN N
concomitant JJ N
increases NNS N
in IN N
ASSR NNP N
( ( N
0.38 CD N
+/- JJ N
0.17 CD N
microV NN N
, , N
P NNP N
< NNP N
0.01 CD N
) ) N
and CC N
BIS NNP N
( ( N
75.3 CD N
+/- JJ N
8.3 CD N
, , N
P NNP N
< NNP N
0.001 CD N
) ) N
. . N

In IN N
all DT N
subjects NNS N
( ( N
n JJ N
= NNP N
6 CD N
) ) N
scopolamine NN N
blocked VBD N
the DT N
physostigmine-induced JJ N
reversal NN N
of IN N
unconsciousness NN N
and CC N
the DT N
increase NN N
of IN N
the DT N
ASSR NNP N
and CC N
BIS NNP N
( ( N
ASSR NNP N
and CC N
BIS NNP N
during IN N
propofol-induced JJ N
unconsciousness NN N
: : N
0.09 CD N
+/- JJ N
0.09 CD N
microV NN N
and CC N
58.2 CD N
+/- JJ N
7.5 CD N
, , N
respectively RB N
; : N
ASSR NNP N
and CC N
BIS NNP N
after IN N
physostigmine JJ N
administration NN N
: : N
0.08 CD N
+/- JJ N
0.06 CD N
microV NN N
and CC N
56.8 CD N
+/- JJ N
6.7 CD N
, , N
respectively RB N
, , N
NS NNP N
) ) N
. . N

CONCLUSIONS NNP N
These DT N
findings NNS N
suggest VBP N
that IN N
the DT N
unconsciousness NN N
produced VBN N
by IN N
propofol NN N
is VBZ N
mediated VBN N
at IN N
least JJS N
in IN N
part NN N
via IN N
interruption NN N
of IN N
central JJ N
cholinergic NN N
muscarinic JJ N
transmission NN N
. . N

-DOCSTART- -X- O O

Warfarin NNP 3_i
for IN N
atrial JJ N
fibrillation NN N
. . N

The DT N
patient NN N
's POS N
perspective NN N
. . N

OBJECTIVE UH N
To TO N
determine VB N
the DT N
minimal JJ N
clinically RB N
important JJ N
difference NN N
( ( N
MCID NNP N
) ) N
of IN N
warfarin NN 3_i
therapy NN N
for IN N
the DT N
treatment NN N
of IN N
nonvalvular JJ N
atrial JJ N
fibrillation NN N
from IN N
the DT N
perspective NN N
of IN N
patients NNS N
using VBG N
2 CD N
different JJ N
elicitation NN N
methods NNS N
. . N

DESIGN NNP N
All DT N
patients NNS N
completed VBD N
2 CD N
face-to-face JJ N
interviews NNS N
, , N
which WDT N
were VBD N
2 CD N
weeks NNS N
apart RB N
. . N

For IN N
each DT N
interview NN N
, , N
they PRP N
were VBD N
randomized VBN N
to TO N
receive VB N
1 CD N
of IN N
2 CD N
elicitation NN N
methods NNS N
: : N
ping-ponging NN N
or CC N
starting VBG N
at IN N
the DT N
known JJ N
efficacy NN N
. . N

SETTING CC N
The DT N
practices NNS N
of IN N
2 CD N
university-affiliated JJ N
family NN N
medicine NN N
centers NNS N
( ( N
8 CD N
physicians NNS N
each DT N
) ) N
, , N
14 CD N
community-based JJ N
family NN N
physicians NNS N
, , N
and CC N
2 CD N
cardiologists NNS N
. . N

PATIENTS VB N
Sixty-four JJ N
patients NNS N
with IN N
nonvalvular JJ N
atrial JJ N
fibrillation NN N
who WP N
were VBD N
initiated VBN N
with IN N
warfarin JJ N
therapy NN N
at IN N
least JJS N
3 CD N
months NNS N
before IN N
the DT N
study NN N
. . N

INTERVENTION NNP N
During IN N
each DT N
interview NN N
, , N
the DT N
patients NNS N
' POS N
MCIDs NNP N
were VBD N
determined VBN N
by IN N
using VBG N
( ( N
1 CD N
) ) N
a DT N
pictorial JJ N
flip NN N
chart NN N
to TO N
describe VB N
atrial JJ N
fibrillation NN N
; : N
the DT N
consequences NNS N
of IN N
a DT N
minor JJ N
stroke NN N
, , N
a DT N
major JJ N
stroke NN N
, , N
and CC N
a DT N
major JJ N
bleeding NN N
episode NN N
; : N
the DT N
chance NN N
of IN N
stroke NN N
if IN N
not RB N
taking VBG N
warfarin NN N
; : N
the DT N
chance NN N
of IN N
a DT N
major JJ N
bleeding NN N
episode NN N
if IN N
taking VBG N
warfarin NN N
; : N
examples NNS N
of IN N
the DT N
inconvenience NN N
, , N
minor JJ N
side NN N
effects NNS N
, , N
and CC N
costs NNS N
of IN N
warfarin JJ N
therapy NN N
; : N
and CC N
then RB N
( ( N
2 CD N
) ) N
1 CD N
of IN N
the DT N
2 CD N
elicitation NN N
methods NNS N
to TO N
determine VB N
their PRP$ N
MCIDs NNP N
( ( N
the DT N
smallest JJS N
reduction NN N
in IN N
stroke NN N
risk NN N
at IN N
which WDT N
the DT N
patients NNS N
were VBD N
willing JJ N
to TO N
take VB N
warfarin NN N
) ) N
. . N

Patients NNS N
' POS N
knowledge NN N
of IN N
their PRP$ N
stroke NN N
risk NN N
, , N
acceptability NN N
of IN N
the DT N
interview NN N
process NN N
, , N
and CC N
factors NNS N
determining VBG N
their PRP$ N
preferences NNS N
were VBD N
also RB N
assessed VBN N
. . N

MAIN NNP N
RESULTS NNP N
Given NNP N
a DT N
baseline NN N
risk NN N
of IN N
having VBG N
a DT N
stroke NN N
in IN N
the DT N
next JJ N
2 CD N
years NNS N
, , N
if IN N
not RB N
taking VBG N
warfarin NN 3_i
, , N
of IN N
10 CD N
of IN N
100 CD N
, , N
the DT N
mean JJ N
MCID NNP N
was VBD N
2.01 CD N
of IN N
100 CD N
( ( N
95 CD N
% NN N
confidence NN N
interval NN N
, , N
1.60-2.42 JJ N
) ) N
. . N

Fifty-two JJ N
percent NN N
of IN N
the DT N
patients NNS N
would MD N
take VB N
warfarin NN 3_i
for IN N
an DT N
absolute JJ N
decrease NN N
in IN N
stroke NN N
risk NN N
of IN N
1 CD N
% NN N
over IN N
2 CD N
years NNS N
. . N

Before IN N
eliciting VBG N
their PRP$ N
MCIDs NNP N
, , N
patients NNS N
showed VBD N
poor JJ N
knowledge NN N
of IN N
their PRP$ N
stroke NN N
risk NN N
, , N
which WDT N
improved VBD N
afterward RB N
. . N

The DT N
interview NN N
process NN N
was VBD N
well RB N
accepted VBN N
by IN N
the DT N
patients NNS N
. . N

The DT N
MCID NNP N
using VBG N
the DT N
ping-ponging JJ N
elicitation NN N
method NN N
was VBD N
1.015 CD N
of IN N
100 CD N
smaller JJR N
compared VBN N
with IN N
use NN N
of IN N
the DT N
starting NN N
at IN N
the DT N
known JJ N
efficacy NN N
method NN N
( ( N
P NNP N
= NNP N
.01 NNP N
) ) N
. . N

CONCLUSIONS NN N
We PRP N
were VBD N
able JJ N
to TO N
determine VB N
the DT N
MCID NNP N
of IN N
warfarin NN 3_i
therapy NN 3_i
for IN N
the DT N
prevention NN N
of IN N
stroke NN N
from IN N
the DT N
perspective NN N
of IN N
patients NNS N
with IN N
nonvalvular JJ N
atrial JJ N
fibrillation NN N
. . N

Their PRP$ N
MCIDs NNPS N
were VBD N
much RB N
smaller JJR N
than IN N
those DT N
that WDT N
have VBP N
been VBN N
implied VBN N
by IN N
some DT N
experts NNS N
and CC N
clinicians NNS N
. . N

The DT N
interview NN N
process NN N
, , N
using VBG N
the DT N
flip JJ N
chart NN N
approach NN N
, , N
appeared VBD N
to TO N
improve VB N
the DT N
patients NNS N
' POS N
knowledge NN N
of IN N
their PRP$ N
disease NN N
and CC N
its PRP$ N
consequences NNS N
and CC N
treatment NN N
. . N

The DT N
method NN N
used VBN N
to TO N
elicit VB N
the DT N
patients NNS N
' POS N
MCIDs NNP N
can MD N
have VB N
a DT N
clinically RB N
important JJ N
effect NN N
on IN N
patient NN N
responses NNS N
. . N

The DT N
method NN N
used VBN N
in IN N
our PRP$ N
study NN N
can MD N
be VB N
generalized VBN N
to TO N
other JJ N
conditions NNS N
and CC N
, , N
thus RB N
, , N
could MD N
be VB N
helpful JJ N
in IN N
3 CD N
ways NNS N
: : N
( ( N
1 CD N
) ) N
from IN N
a DT N
clinical JJ N
decision-making NN N
perspective NN N
, , N
it PRP N
could MD N
facilitate VB N
patient-physician JJ N
communication NN N
; : N
( ( N
2 CD N
) ) N
it PRP N
could MD N
clarify VB N
the DT N
patient NN N
perspective NN N
when WRB N
interpreting VBG N
the DT N
results NNS N
of IN N
previously RB N
completed VBN N
trials NNS N
; : N
and CC N
( ( N
3 CD N
) ) N
it PRP N
could MD N
be VB N
used VBN N
to TO N
derive VB N
more RBR N
clinically RB N
relevant JJ N
sample NN N
sizes NNS N
for IN N
randomized JJ N
treatment NN N
trials NNS N
. . N

-DOCSTART- -X- O O

Effectiveness NN N
and CC N
safety NN N
of IN N
the DT N
Levitan NNP 2_i
FPS NNP 2_i
Scope? NNP 2_i
for IN N
tracheal JJ N
intubation NN N
under IN N
general JJ N
anesthesia NN N
with IN N
a DT N
simulated JJ N
difficult JJ N
airway NN N
. . N

PURPOSE NNP N
Studies NNP N
show VBP N
that IN N
the DT N
Levitan NNP 2_i
FPS NNP 2_i
( ( 2_i
first JJ 2_i
pass NN 2_i
success NN 2_i
) ) 2_i
Scope? NNP 2_i
( ( 2_i
LFS NNP 2_i
) ) 2_i
is VBZ N
analogous JJ N
to TO N
a DT N
bougie NN N
in IN N
simulated JJ N
difficult JJ N
airways NNS N
with IN N
comparable JJ N
tracheal JJ N
intubation NN N
success NN N
rates NNS N
. . N

In IN N
this DT N
study NN N
, , N
the DT N
efficacy NN N
and CC N
safety NN N
of IN N
tracheal JJ N
intubation NN N
with IN N
the DT N
LFS NNP N
was VBD N
compared VBN N
with IN N
that DT N
of IN N
the DT N
Macintosh NNP N
laryngoscope NN N
utilizing VBG N
manual JJ N
in-line JJ N
stabilization NN N
( ( N
MILS NNP N
) ) N
to TO N
simulate VB N
difficult JJ N
airways NNS N
. . N

METHODS NNP N
Ninety-four JJ N
subjects NNS N
successfully RB N
completed VBD N
the DT N
trial NN N
. . N

Manual JJ N
in-line JJ N
stabilization NN N
of IN N
the DT N
cervical JJ N
spine NN N
was VBD N
applied VBN N
and CC N
the DT N
initial JJ N
laryngoscopy NN N
was VBD N
performed VBN N
using VBG N
either CC N
the DT N
Macintosh NNP 2_i
or CC N
the DT N
LFS NNP 2_i
in IN N
conjunction NN N
with IN N
the DT N
Macintosh NNP N
. . N

Following VBG N
the DT N
initial JJ N
grading NN N
, , N
a DT N
second JJ N
laryngoscopy NN N
was VBD N
repeated VBN N
using VBG N
the DT N
second JJ N
randomized JJ N
technique NN N
. . N

Cormack-Lehane NNP N
grades NNS N
, , N
percentage NN N
of IN N
glottic JJ N
opening NN N
( ( N
POGO NNP N
) ) N
scores VBZ N
, , N
time NN N
to TO N
intubate VB N
, , N
number NN N
of IN N
intubation NN N
attempts NNS N
, , N
and CC N
the DT N
use NN N
of IN N
alternate NN N
techniques NNS N
were VBD N
recorded VBN N
. . N

The DT N
anesthesiologist NN N
rated VBD N
the DT N
subjective JJ N
difficulty NN N
in IN N
using VBG N
each DT N
technique NN N
with IN N
a DT N
numeric JJ N
rating NN N
scale NN N
and CC N
a DT N
visual JJ N
rating NN N
scale NN N
. . N

RESULTS NNP N
There EX N
was VBD N
no DT N
significant JJ N
difference NN N
in IN N
the DT N
primary JJ N
outcome NN N
good JJ N
laryngoscopic NN N
views NNS N
( ( N
Cormack-Lehane NNP N
grade VBD N
1 CD N
and CC N
2 CD N
) ) N
compared VBN N
with IN N
poor JJ N
laryngoscopic JJ N
views NNS N
( ( N
Cormack-Lehane NNP N
grade VBD N
3 CD N
and CC N
4 CD N
) ) N
between IN N
the DT N
LFS NNP N
and CC N
the DT N
Macintosh NNP N
. . N

There EX N
were VBD N
higher JJR N
POGO NNP N
scores NNS N
with IN N
the DT N
LFS NNP N
compared VBN N
with IN N
the DT N
Macintosh NNP N
( ( N
80 CD N
% NN N
vs JJ N
20 CD N
% NN N
, , N
respectively RB N
; : N
P NNP N
< NNP N
0.0001 CD N
) ) N
, , N
but CC N
this DT N
did VBD N
not RB N
translate VB N
to TO N
easier JJR N
intubations NNS N
, , N
as IN N
documented VBN N
by IN N
the DT N
need NN N
for IN N
an DT N
alternate JJ N
intubation NN N
technique NN N
or CC N
time NN N
to TO N
intubate VB N
( ( N
< JJ N
30 CD N
and CC N
< $ N
60 CD N
sec NN N
, , N
respectively RB N
) ) N
. . N

The DT N
incidence NN N
of IN N
mucosal NN N
trauma NN N
, , N
sore RB N
throat NN N
, , N
and CC N
hemodynamic JJ N
responses NNS N
did VBD N
not RB N
differ VB N
significantly RB N
between IN N
the DT N
two CD N
techniques NNS N
. . N

CONCLUSION VB N
The DT N
LFS NNP N
in IN N
conjunction NN N
with IN N
the DT N
Macintosh NNP 2_i
laryngoscope NN N
does VBZ N
not RB N
improve VB N
the DT N
efficacy NN N
or CC N
safety NN N
of IN N
tracheal JJ N
intubation NN N
in IN N
a DT N
simulated JJ N
difficult JJ N
airway NN N
. . N

-DOCSTART- -X- O O

B-domain NNP 3_i
deleted VBD 3_i
recombinant JJ 3_i
factor NN 3_i
VIII NNP 3_i
preparations NNS 3_i
are VBP N
bioequivalent JJ N
to TO N
a DT N
monoclonal JJ N
antibody NN N
purified VBD N
plasma-derived JJ N
factor NN N
VIII NNP N
concentrate NN N
: : N
a DT N
randomized JJ N
, , N
three-way JJ N
crossover NN N
study NN N
. . N

BACKGROUND NNP N
Deletion NNP N
of IN N
the DT N
B-domain NNP N
of IN N
recombinant JJ N
blood NN N
coagulation NN N
factor NN N
VIII NNP N
( ( N
BDDrFVIII NNP N
) ) N
increases VBZ N
the DT N
manufacturing VBG N
yield NN N
of IN N
the DT N
product NN N
but CC N
does VBZ N
not RB N
impair VB N
in IN N
vitro NN N
or CC N
in IN N
vivo JJ N
functionality NN N
. . N

BDDrFVIII NNP N
( ( N
ReFacto NNP N
) ) N
has VBZ N
been VBN N
developed VBN N
with IN N
the DT N
additional JJ N
benefit NN N
of IN N
being VBG N
formulated VBN N
without IN N
human JJ N
albumin NN N
. . N

OBJECTIVE CC N
The DT N
primary JJ N
objective NN N
of IN N
this DT N
three-way JJ N
crossover-design NN N
study NN N
was VBD N
to TO N
compare VB N
the DT N
pharmacokinetic JJ N
( ( N
PK NNP N
) ) N
parameters NNS N
of IN N
two CD N
BDDrFVIII NNP 3_i
formulations NNS 3_i
( ( N
one CD N
reconstituted VBN N
with IN N
5 CD N
mL NNS N
of IN N
sterile JJ N
water NN N
, , N
the DT N
other JJ N
reconstituted VBD N
with IN N
4 CD N
mL NNS N
sodium JJ N
chloride RB N
0.9 CD N
% NN N
USP NNP N
) ) N
with IN N
those DT N
of IN N
a DT N
plasma-derived JJ N
, , N
full-length JJ 3_i
FVIII NNP 3_i
preparation NN 3_i
( ( 3_i
Hemofil NNP 3_i
M NNP 3_i
) ) 3_i
in IN N
patients NNS N
with IN N
haemophilia PDT N
A DT N
to TO N
determine VB N
bioequivalence NN N
. . N

METHODS VB N
A NNP N
series NN N
of IN N
blood NN N
samples NNS N
were VBD N
collected VBN N
over IN N
a DT N
period NN N
of IN N
48 CD N
h NN N
after IN N
i.v NN N
. . N

administration NN N
of IN N
each DT N
of IN N
the DT N
FVIII NNP 3_i
preparations NNS 3_i
. . 3_i

Plasma NNP N
FVIII NNP N
activity NN N
was VBD N
determined VBN N
using VBG N
a DT N
validated JJ N
chromogenic JJ N
substrate NN N
assay NN N
. . N

Plasma NNP N
FVIII NNP N
activity NN N
vs. FW N
time NN N
curves NNS N
was VBD N
characterized VBN N
for IN N
a DT N
standard JJ N
set NN N
of IN N
PK NNP N
parameter NN N
estimates NNS N
. . N

Two CD N
parameter NN N
estimates NNS N
, , N
the DT N
maximum JJ N
plasma JJ N
concentration NN N
( ( N
Cmax NNP N
) ) N
and CC N
the DT N
area NN N
under IN N
plasma JJ N
concentration NN N
vs. FW N
time NN N
curves NNS N
( ( N
AUCs NNP N
) ) N
, , N
were VBD N
used VBN N
to TO N
evaluate VB N
bioequivalence NN N
. . N

The DT N
two CD N
preparations NNS N
were VBD N
considered VBN N
bioequivalent NN N
if IN N
the DT N
90 CD N
% NN N
confidence NN N
intervals NNS N
for IN N
the DT N
ratio NN N
of IN N
geometric JJ N
means NNS N
for IN N
Cmax NNP N
and CC N
AUCs NNP N
fell VBD N
within IN N
the DT N
bioequivalence NN N
window NN N
of IN N
80 CD N
% NN N
to TO N
125 CD N
% NN N
. . N

RESULTS/CONCLUSION NNP N
Results NNP N
show VBP N
that IN N
each DT N
BDDrFVIII NNP 3_i
formulation NN 3_i
is VBZ N
bioequivalent JJ N
to TO N
Hemofil NNP N
M NNP N
and CC N
the DT N
two CD N
formulations NNS N
of IN N
BDDrFVIII NNP N
are VBP N
bioequivalent JJ N
to TO N
each DT N
other JJ N
. . N

-DOCSTART- -X- O O

Computer-navigated JJ 1_i
versus NN N
conventional JJ 1_i
total JJ 1_i
knee NN 1_i
arthroplasty IN 1_i
a DT N
prospective JJ N
randomized VBN N
trial NN N
. . N

BACKGROUND VB N
The DT N
literature NN N
lacks VBZ N
studies NNS N
that IN N
confirm VBP N
whether IN N
the DT N
improved JJ N
radiographic JJ N
alignment NN N
that WDT N
can MD N
be VB N
achieved VBN N
with IN N
computer-navigated JJ 1_i
total JJ 1_i
knee NN 1_i
arthroplasty NN 1_i
improves VBZ N
patients? JJ N
activities NNS N
of IN N
daily JJ N
living NN N
or CC N
the DT N
durability NN N
of IN N
total JJ N
knee NN N
prostheses NNS N
. . N

The DT N
purpose NN N
of IN N
this DT N
study NN N
was VBD N
to TO N
determine VB N
whether IN N
computer-navigated JJ 1_i
total JJ 1_i
knee NN 1_i
arthroplasty NN 1_i
improves VBZ N
the DT N
clinical JJ N
function NN N
, , N
alignment NN N
, , N
and CC N
survivorship NN N
of IN N
the DT N
components NNS N
. . N

METHODS NNP N
We PRP N
prospectively RB N
compared VBN N
the DT N
results NNS N
of IN N
520 CD N
patients NNS N
with IN N
osteoarthritis NN N
who WP N
underwent VBD N
computer-navigated JJ 1_i
total JJ 1_i
knee NN 1_i
arthroplasty NN 1_i
for IN N
one CD N
knee NN N
and CC N
conventional JJ 1_i
total JJ 1_i
knee NN 1_i
arthroplasty NN 1_i
for IN N
the DT N
other JJ N
. . N

The DT N
assignment NN N
of IN N
the DT N
knee NN N
to TO N
navigation NN N
or CC N
not RB N
was VBD N
done VBN N
randomly RB N
. . N

There EX N
were VBD N
452 CD N
women NNS N
( ( N
904 CD N
knees NNS N
) ) N
and CC N
sixty-eight JJ N
men NNS N
( ( N
136 CD N
knees NNS N
) ) N
with IN N
a DT N
mean JJ N
age NN N
of IN N
sixty-eight JJ N
years NNS N
( ( N
range NN N
, , N
forty-nine JJ N
to TO N
eighty-eight JJ N
years NNS N
) ) N
at IN N
the DT N
time NN N
of IN N
the DT N
index NN N
arthroplasty NN N
. . N

The DT N
mean JJ N
follow-up JJ N
period NN N
was VBD N
10.8 CD N
years NNS N
( ( N
range NN N
, , N
ten VB N
to TO N
twelve VB N
years NNS N
) ) N
. . N

The DT N
patients NNS N
were VBD N
assessed VBN N
clinically RB N
and CC N
radiographically RB N
with IN N
the DT N
rating NN N
system NN N
of IN N
the DT N
Knee NNP N
Society NNP N
and CC N
with IN N
the DT N
Western NNP N
Ontario NNP N
and CC N
McMaster NNP N
Universities NNP N
Osteoarthritis NNP N
Index NNP N
( ( N
WOMAC NNP N
) ) N
score NN N
at IN N
three CD N
months NNS N
, , N
one CD N
year NN N
, , N
and CC N
annually RB N
thereafter RB N
. . N

RESULTS NNP N
Total JJ N
knee NN N
scores NNS N
, , N
knee NN N
function NN N
scores NNS N
, , N
pain NN N
scores NNS N
, , N
WOMAC NNP N
scores VBZ N
, , N
knee VB N
motion NN N
, , N
and CC N
activity NN N
scores NNS N
did VBD N
not RB N
show VB N
statistically RB N
significant JJ N
differences NNS N
between IN N
the DT N
two CD N
groups NNS N
preoperatively RB N
or CC N
at IN N
the DT N
time NN N
of IN N
the DT N
final JJ N
follow-up NN N
. . N

Alignment NNP N
and CC N
the DT N
survivorship NN N
of IN N
the DT N
components NNS N
were VBD N
not RB N
significantly RB N
different JJ N
between IN N
the DT N
two CD N
groups NNS N
. . N

The DT N
Kaplan-Meier NNP N
survivorship NN N
with IN N
revision NN N
as IN N
the DT N
end NN N
point NN N
at IN N
10.8 CD N
years NNS N
was VBD N
98.8 CD N
% NN N
( ( N
95 CD N
% NN N
confidence NN N
interval NN N
[ NNP N
CI NNP N
] NNP N
, , N
0.96 CD N
to TO N
1.00 CD N
) ) N
in IN N
the DT N
computernavigated JJ 1_i
total JJ 1_i
knee NN 1_i
arthroplasty NN 1_i
group NN N
and CC N
99.2 CD N
% NN N
( ( N
95 CD N
% NN N
CI NNP N
, , N
0.96 CD N
to TO N
1.00 CD N
) ) N
in IN N
the DT N
conventional JJ 1_i
total JJ 1_i
knee NN 1_i
arthroplasty NN 1_i
group NN N
. . N

CONCLUSIONS NNP N
Our PRP$ N
data NNS N
demonstrated VBD N
no DT N
difference NN N
in IN N
clinical JJ N
function NN N
or CC N
alignment NN N
and CC N
survivorship NN N
of IN N
the DT N
components NNS N
between IN N
the DT N
knees NNS N
that WDT N
underwent VBD N
computer-navigated JJ 1_i
total JJ 1_i
knee NN 1_i
arthroplasty NN 1_i
and CC N
those DT N
that WDT N
underwent JJ N
conventional JJ 1_i
total JJ 1_i
knee NN 1_i
arthroplasty NN 1_i
. . N

-DOCSTART- -X- O O

Changes NNS N
in IN N
H NNP N
reflex NN N
and CC N
V NNP N
wave VBP N
following VBG N
short-term JJ 2_i
endurance NN 2_i
and CC N
strength NN 2_i
training NN 2_i
. . N

This DT N
study NN N
examined VBD N
the DT N
effects NNS N
of IN N
3 CD N
wk NN N
of IN N
either DT N
endurance NN 2_i
or CC N
strength NN 2_i
training NN 2_i
on IN N
plasticity NN N
of IN N
the DT N
neural JJ N
mechanisms NNS N
involved VBN N
in IN N
the DT N
soleus NN N
H NNP N
reflex NN N
and CC N
V NNP N
wave VBP N
. . N

Twenty-five JJ N
sedentary JJ N
healthy JJ N
subjects NNS N
were VBD N
randomized VBN N
into IN N
an DT N
endurance NN 2_i
group NN 2_i
( ( N
n JJ N
= NNP N
13 CD N
) ) N
or CC N
strength NN 2_i
group NN 2_i
( ( N
n JJ N
= NNP N
12 CD N
) ) N
. . N

Evoked VBN N
V-wave JJ N
, , N
H-reflex NNP N
, , N
and CC N
M-wave NNP N
recruitment NN N
curves NNS N
, , N
maximal JJ N
voluntary JJ N
contraction NN N
( ( N
MVC NNP N
) ) N
, , N
and CC N
time-to-task-failure NN N
( ( N
isometric JJ N
contraction NN N
at IN N
40 CD N
% NN N
MVC NNP N
) ) N
of IN N
the DT N
plantar NN N
flexors NNS N
were VBD N
recorded VBN N
before IN N
and CC N
after IN N
training VBG N
. . N

Following VBG N
strength NN 2_i
training NN 2_i
, , N
MVC NNP N
of IN N
the DT N
plantar NN N
flexors NNS N
increased VBN N
by IN N
14.4 CD N
? . N
5.2 CD N
% NN N
in IN N
the DT N
strength NN N
group NN N
( ( N
P NNP N
< NNP N
0.001 CD N
) ) N
, , N
whereas JJ N
time-to-task-failure NN N
was VBD N
prolonged VBN N
in IN N
the DT N
endurance NN N
group NN N
( ( N
22.7 CD N
? . N
17.1 CD N
% NN N
; : N
P NNP N
< NNP N
0.05 CD N
) ) N
. . N

The DT N
V NNP N
wave-to-maximal JJ N
M NNP N
wave NN N
( ( N
V/M NNP N
( ( N
max NN N
) ) N
) ) N
ratio NN N
increased VBN N
significantly RB N
( ( N
55.1 CD N
? . N
28.3 CD N
% NN N
; : N
P NNP N
< NNP N
0.001 CD N
) ) N
following VBG N
strength NN N
training NN N
, , N
but CC N
the DT N
maximal JJ N
H NNP N
wave-to-maximal JJ N
M NNP N
wave NN N
( ( N
H NNP N
( ( N
max NN N
) ) N
/M NN N
( ( N
max NN N
) ) N
) ) N
ratio NN N
remained VBD N
unchanged JJ N
. . N

Conversely RB N
, , N
in IN N
the DT N
endurance NN N
group NN N
the DT N
V/M NNP N
( ( N
max NN N
) ) N
ratio NN N
was VBD N
not RB N
altered VBN N
, , N
whereas IN N
the DT N
H NNP N
( ( N
max NN N
) ) N
/M NN N
( ( N
max NN N
) ) N
ratio NN N
increased VBN N
by IN N
30.8 CD N
? . N
21.7 CD N
% NN N
( ( N
P NNP N
< NNP N
0.05 CD N
) ) N
. . N

The DT N
endurance NN 2_i
training NN 2_i
group NN N
also RB N
displayed VBD N
a DT N
reduction NN N
in IN N
the DT N
H-reflex NNP N
excitability NN N
threshold NN N
while IN N
the DT N
H-reflex NNP N
amplitude NN N
on IN N
the DT N
ascending VBG N
limb NN N
of IN N
the DT N
recruitment NN N
curve NN N
increased VBD N
. . N

Strength NNP N
training VBG N
only RB N
elicited VBD N
a DT N
significant JJ N
decrease NN N
in IN N
H-reflex NNP N
excitability NN N
threshold NN N
, , N
while IN N
H-reflex NNP N
amplitudes NNS N
over IN N
the DT N
ascending VBG N
limb NN N
remained VBD N
unchanged JJ N
. . N

These DT N
observations NNS N
indicate VBP N
that IN N
the DT N
H-reflex NNP N
pathway NN N
is VBZ N
strongly RB N
involved VBN N
in IN N
the DT N
enhanced JJ N
endurance NN N
resistance NN N
that WDT N
occurs VBZ N
following VBG N
endurance NN 2_i
training NN 2_i
. . N

On IN N
the DT N
contrary JJ N
, , N
the DT N
improvements NNS N
in IN N
MVC NNP N
following VBG N
strength NN N
training NN N
are VBP N
likely JJ N
attributed VBN N
to TO N
increased VBN N
descending VBG N
drive NN N
and/or NN N
modulation NN N
in IN N
afferents NNS N
other JJ N
than IN N
Ia JJ N
afferents NNS N
. . N

-DOCSTART- -X- O O

A DT N
randomized JJ N
comparison NN N
of IN N
the DT N
Endeavor NNP 2_i
zotarolimus-eluting JJ 2_i
stent NN 2_i
versus IN N
the DT N
TAXUS NNP 2_i
paclitaxel-eluting JJ 2_i
stent NN 2_i
in IN N
de FW N
novo FW N
native JJ N
coronary JJ N
lesions NNS N
12-month JJ N
outcomes NNS N
from IN N
the DT N
ENDEAVOR NNP N
IV NNP N
trial NN N
. . N

OBJECTIVES CC N
The DT N
ENDEAVOR NNP N
IV NNP N
( ( N
Randomized NNP N
Comparison NNP N
of IN N
Zotarolimus-Eluting NNP 2_i
and CC N
Paclitaxel-Eluting NNP 2_i
Stents NNP 2_i
in IN N
Patients NNP N
with IN N
Coronary NNP N
Artery NNP N
Disease NNP N
) ) N
trial NN N
evaluated VBD N
the DT N
safety NN N
and CC N
efficacy NN N
of IN N
the DT N
zotarolimus-eluting JJ 2_i
stent NN 2_i
( ( 2_i
ZES NNP 2_i
) ) 2_i
compared VBN N
with IN N
the DT N
paclitaxel-eluting JJ 2_i
stent NN 2_i
( ( 2_i
PES NNP 2_i
) ) 2_i
. . N

BACKGROUND NNP N
First-generation NNP N
drug-eluting NN N
stents NNS N
have VBP N
reduced VBN N
angiographic JJ N
and CC N
clinical JJ N
restenosis NN N
, , N
but CC N
long-term JJ N
safety NN N
remains VBZ N
controversial JJ N
. . N

A DT N
second-generation JJ N
drug-eluting JJ N
stent NN N
, , N
which WDT N
delivers VBZ N
zotarolimus NN 3_i
, , N
a DT N
potent JJ N
antiproliferative JJ N
agent NN N
, , N
via IN N
a DT N
biocompatible JJ N
phosphorylcholine NN N
polymer NN N
on IN N
a DT N
cobalt JJ N
alloy NN N
thin-strut JJ N
stent NN N
has VBZ N
shown VBN N
promising JJ N
experimental JJ N
and CC N
early JJ N
clinical JJ N
results NNS N
. . N

METHODS NNP N
This DT N
is VBZ N
a DT N
prospective JJ N
, , N
randomized VBN N
( ( N
1:1 CD N
) ) N
, , N
single-blind JJ N
, , N
controlled JJ N
trial NN N
comparing VBG N
outcomes NNS N
of IN N
patients NNS N
with IN N
single JJ N
de FW N
novo FW N
coronary JJ N
lesions NNS N
treated VBN N
with IN N
ZES NNP N
or CC N
PES NNP N
. . N

The DT N
primary JJ N
end NN N
point NN N
was VBD N
noninferiority NN N
of IN N
9-month JJ N
target NN N
vessel JJ N
failure NN N
defined VBD N
as IN N
cardiac JJ N
death NN N
, , N
myocardial JJ N
infarction NN N
, , N
or CC N
target VB N
vessel JJ N
revascularization NN N
. . N

RESULTS NNP N
Among IN N
a DT N
total NN N
of IN N
1,548 CD N
patients NNS N
assigned VBN N
to TO N
ZES NNP 2_i
( ( N
n JJ N
= NNP N
773 CD N
) ) N
or CC N
PES NNP N
( ( N
n JJ N
= NNP N
775 CD N
) ) N
, , N
at IN N
9 CD N
months NNS N
, , N
ZES NNP N
was VBD N
noninferior JJ N
to TO N
PES VB N
with IN N
rates NNS N
of IN N
target NN N
vessel JJ N
failure NN N
6.6 CD N
% NN N
versus IN N
7.1 CD N
% NN N
, , N
respectively RB N
( ( N
p NN N
( ( N
noninferiority NN N
) ) N
< NN N
or CC N
= VB N
0.001 CD N
) ) N
. . N

There EX N
were VBD N
fewer JJR N
periprocedural JJ N
myocardial JJ N
infarctions NNS N
with IN N
ZES NNP 2_i
( ( N
0.5 CD N
% NN N
vs. FW N
2.2 CD N
% NN N
; : N
p CC N
= VB N
0.007 CD N
) ) N
, , N
whereas VBP N
at IN N
12 CD N
months NNS N
, , N
there EX N
were VBD N
no DT N
significant JJ N
differences NNS N
between IN N
groups NNS N
in IN N
rates NNS N
of IN N
cardiac JJ N
death NN N
, , N
myocardial JJ N
infarction NN N
, , N
target NN N
vessel NN N
revascularization NN N
, , N
or CC N
stent JJ N
thrombosis NN N
. . N

Although IN N
incidence NN N
of IN N
8-month JJ N
binary JJ N
angiographic JJ N
in-segment JJ N
restenosis NN N
was VBD N
higher RBR N
in IN N
patients NNS N
treated VBN N
with IN N
ZES NNP 2_i
versus NN N
PES NNP N
( ( N
15.3 CD N
% NN N
vs. FW N
10.4 CD N
% NN N
; : N
p CC N
= VB N
0.284 CD N
) ) N
, , N
rates NNS N
of IN N
12-month JJ N
target NN N
lesion NN N
revascularization NN N
were VBD N
similar JJ N
( ( N
4.5 CD N
% NN N
vs. FW N
3.2 CD N
% NN N
; : N
p CC N
= VB N
0.228 CD N
) ) N
, , N
especially RB N
in IN N
patients NNS N
without IN N
planned JJ N
angiographic JJ N
follow-up NN N
( ( N
3.6 CD N
% NN N
vs. FW N
3.2 CD N
% NN N
; : N
p CC N
= VB N
0.756 CD N
) ) N
. . N

CONCLUSIONS NNP N
These DT N
findings NNS N
demonstrate VBP N
that IN N
ZES NNP 2_i
has VBZ N
similar JJ N
clinical JJ N
safety NN N
and CC N
efficacy NN N
compared VBN N
with IN N
PES NNP 2_i
in IN N
simple JJ N
and CC N
medium JJ N
complexity NN N
single JJ N
de FW N
novo FW N
coronary JJ N
lesions NNS N
. . N

( ( N
ENDEAVOR NNP N
IV NNP N
Clinical NNP N
Trial NNP N
; : N
NCT00217269 NNP N
) ) N
. . N

-DOCSTART- -X- O O

Reactive JJ N
balance NN N
adjustments NNS N
to TO N
unexpected JJ 2_i
perturbations NNS 2_i
during IN N
human JJ N
walking NN N
. . N

The DT N
purpose NN N
of IN N
this DT N
investigation NN N
was VBD N
to TO N
determine VB N
the DT N
effect NN N
of IN N
unexpected JJ 2_i
forward NN 2_i
perturbations NNS 2_i
( ( 2_i
FP NNP 2_i
) ) 2_i
during IN N
gait NN N
on IN N
lower JJR N
extremity NN N
joint NN N
mechanics NNS N
and CC N
muscle NN N
Electromyographic NNP N
( ( N
EMG NNP N
) ) N
patterns VBZ N
in IN N
healthy JJ N
adults NNS N
. . N

The DT N
muscles NNS N
surrounding VBG N
the DT N
hip NN N
were VBD N
found VBN N
to TO N
be VB N
most RBS N
important JJ N
in IN N
maintaining VBG N
control NN N
of IN N
the DT N
trunk NN N
and CC N
preventing VBG N
collapse NN N
in IN N
response NN N
to TO N
the DT N
FP NNP N
. . N

Distinct NNP N
lower JJR N
extremity NN N
joint JJ N
moment NN N
and CC N
power NN N
patterns NNS N
were VBD N
observed VBN N
in IN N
response NN N
to TO N
the DT N
FP NNP 2_i
but CC N
an DT N
overall JJ N
positive JJ N
moment NN N
of IN N
support NN N
( ( N
M NNP N
( ( N
s PRP N
) ) N
) ) N
was VBD N
maintained VBN N
. . N

Therefore RB N
, , N
reactive JJ N
balance NN N
control NN N
was VBD N
a DT N
synchronized JJ N
effort NN N
of IN N
the DT N
lower JJR N
extremity NN N
joints NNS N
to TO N
prevent VB N
collapse NN N
during IN N
the DT N
FP NNP 2_i
. . 2_i

-DOCSTART- -X- O O

Lactobacillus NNP 3_i
plantarum NN 3_i
CECT7315 NNP 3_i
and CC 3_i
CECT7316 NNP 3_i
stimulate VBP N
immunoglobulin NN N
production NN N
after IN N
influenza JJ 3_i
vaccination NN 3_i
in IN N
elderly JJ N
. . N

OBJECTIVE IN N
The DT N
effectiveness NN N
of IN N
influenza JJ 3_i
vaccination NN 3_i
in IN N
preventing VBG N
illness NN N
is VBZ N
lower RBR N
in IN N
the DT N
elderly JJ N
; : N
this DT N
is VBZ N
why WRB N
the DT N
ability NN N
of IN N
Lactobacillus NNP 3_i
plantarum NN 3_i
CECT NNP 3_i
7315/7316 CD 3_i
to TO N
stimulate VB N
the DT N
response NN N
to TO N
influenza VB 3_i
vaccination NN 3_i
in IN N
elderly JJ N
was VBD N
evaluated VBN N
. . N

RESEARCH NNP N
METHODS NNP N
AND NNP N
PROCEDURES NNP N
A NNP N
randomized JJ N
, , N
double-blind JJ N
, , N
placebo-controlled JJ 7_i
human JJ N
trial NN N
including VBG N
60 CD N
institutionalized JJ N
volunteers NNS N
aged VBN N
65-85 CD N
years NNS N
was VBD N
performed VBN N
. . N

All PDT N
the DT N
volunteers NNS N
were VBD N
vaccinated VBN N
with IN N
a DT N
trivalent JJ 3_i
influenza NN 3_i
vaccine NN 3_i
( ( 3_i
A/Wisconsin/67/2005 NNP 3_i
NYMC NNP 3_i
X-161B NNP 3_i
( ( 3_i
H3N2 NNP 3_i
) ) 3_i
, , 3_i
A/Solomon NNP 3_i
Islands/3/2006 NNP 3_i
( ( 3_i
H1N1 NNP 3_i
) ) 3_i
and CC 3_i
B/Malaysia/2506/2004 NNP 3_i
) ) 3_i
for IN N
the DT N
Spanish JJ N
vaccine NN N
campaign NN N
2006/2007 CD N
. . N

The DT N
consumption NN N
of IN N
the DT N
probiotic JJ N
began VBD N
between IN N
three CD N
and CC N
four CD N
months NNS N
after IN N
the DT N
vaccination NN N
. . N

Volunteers NNS N
were VBD N
randomly RB N
assigned VBN N
to TO N
one CD N
of IN N
three CD N
following VBG N
groups NNS N
: : N
group NN N
A NNP N
( ( N
receiving VBG N
5*10 CD N
( ( N
9 CD N
) ) N
cfu/day NN N
of IN N
L. NNP 3_i
plantarum NN 3_i
CECT NNP 3_i
7315/7316 CD 3_i
in IN N
20 CD N
g NN N
powdered VBD N
skim JJ N
milk NN N
) ) N
, , N
group NN N
B NNP N
( ( N
receiving VBG N
5*10 CD N
( ( N
8 CD N
) ) N
cfu/day NN N
of IN N
L. NNP 3_i
plantarum NN 3_i
CECT NNP 3_i
7315/7316 CD 3_i
in IN N
20 CD N
g NN N
powdered VBD N
skim JJ N
milk NN N
) ) N
and CC N
group NN N
C NNP N
or CC N
placebo NN 7_i
( ( N
20 CD N
g NN N
powered VBN 7_i
skim JJ 7_i
milk NN 7_i
) ) 7_i
. . 7_i

The DT N
participants NNS N
consumed VBD N
the DT N
probiotic JJ N
during IN N
3 CD N
months NNS N
. . N

RESULTS VB N
The DT N
consumption NN N
of IN N
L. NNP 3_i
plantarum NN 3_i
CECT NNP 3_i
7315/7316 CD 3_i
during IN N
3 CD N
months NNS N
after IN N
influenza JJ 3_i
vaccination NN 3_i
increased VBD N
the DT N
levels NNS N
of IN N
influenza-specific JJ N
IgA NNP N
and CC N
IgG NNP N
antibodies NNS N
. . N

Moreover RB N
, , N
a DT N
trend NN N
towards IN N
an DT N
increase NN N
in IN N
influenza-specific JJ N
IgM NNP N
antibodies NNS N
was VBD N
also RB N
observed VBN N
. . N

CONCLUSION NNP N
L. NNP 3_i
plantarum NN 3_i
CECT7315/7316 NNP 3_i
has VBZ N
an DT N
immunostimulating JJ N
effect NN N
and CC N
could MD N
be VB N
used VBN N
to TO N
improve VB N
the DT N
response NN N
to TO N
influenza VB 3_i
vaccination NN 3_i
in IN N
elderly JJ N
. . N

-DOCSTART- -X- O O

Junctional NNP N
ectopic NN N
tachycardia NN N
after IN N
congenital JJ N
heart NN N
surgery NN N
in IN N
the DT N
current JJ N
surgical JJ N
era NN N
. . N

To TO N
determine VB N
the DT N
incidence NN N
of IN N
postoperative JJ N
junctional JJ N
ectopic NN N
tachycardia NN N
( ( N
JET NNP N
) ) N
in IN N
a DT N
modern JJ N
cohort NN N
of IN N
pediatric JJ N
patients NNS N
, , N
evaluate VBP N
possible JJ N
risk NN N
factors NNS N
for IN N
JET NNP N
, , N
and CC N
examine VB N
the DT N
effects NNS N
of IN N
JET NNP N
on IN N
postoperative JJ N
morbidity NN N
and CC N
mortality NN N
. . N

JET NN N
is VBZ N
common JJ N
after IN N
congenital JJ N
heart NN N
surgery NN N
. . N

JET-related JJ N
mortality NN N
has VBZ N
been VBN N
a DT N
rare JJ N
event NN N
at IN N
our PRP$ N
center NN N
, , N
which WDT N
is VBZ N
different JJ N
from IN N
previous JJ N
reports NNS N
. . N

We PRP N
reviewed VBD N
records NNS N
for IN N
pediatric JJ N
patients NNS N
who WP N
had VBD N
postoperative JJ N
arrhythmias NN N
between IN N
January NNP N
2006 CD N
and CC N
June NNP N
2010 CD N
at IN N
a DT N
large JJ N
tertiary-care JJ N
children NNS N
's POS N
hospital NN N
. . N

We PRP N
performed VBD N
a DT N
matched VBN N
case-control NN N
study NN N
to TO N
identify VB N
risk NN N
factors NNS N
for IN N
JET NNP N
and CC N
a DT N
matched-cohort NN N
study NN N
to TO N
compare VB N
outcomes NNS N
between IN N
patients NNS N
and CC N
controls NNS N
. . N

Whenever NNP N
possible JJ N
, , N
each DT N
JET NNP N
case NN N
was VBD N
randomly RB N
matched VBN N
to TO N
two CD N
controls NNS N
on IN N
the DT N
basis NN N
of IN N
lesion NN N
, , N
repair NN N
, , N
and CC N
surgical JJ N
period NN N
. . N

We PRP N
identified VBD N
54 CD N
patients NNS N
with IN N
JET NNP N
( ( N
incidence NN N
= RB N
1.4 CD N
% NN N
) ) N
. . N

After IN N
multivariate JJ N
logistic JJ N
regression NN N
analysis NN N
, , N
low JJ N
operative JJ N
weight NN N
, , N
cardiopulmonary JJ N
bypass NN N
( ( N
CPB NNP N
) ) N
duration NN N
> $ N
100 CD N
min NN N
, , N
and CC N
immediate JJ N
postoperative JJ N
serum NN N
lactic JJ N
acid NN N
level NN N
> VBD N
20 CD N
mg/dl NNS N
were VBD N
associated VBN N
with IN N
increased JJ N
odds NNS N
of IN N
developing VBG N
JET NNP N
. . N

Patients NNS N
with IN N
JET NNP N
had VBD N
longer RBR N
mechanical JJ N
ventilation NN N
time NN N
, , N
cardiac JJ N
intensive JJ N
care NN N
unit NN N
( ( N
CICU NNP N
) ) N
stay NN N
, , N
and CC N
hospital NN N
stay NN N
. . N

There EX N
was VBD N
only RB N
one CD N
death NN N
in IN N
JET NNP N
group NN N
( ( N
1.8 CD N
% NN N
) ) N
with IN N
no DT N
significant JJ N
difference NN N
compared VBN N
with IN N
the DT N
control NN N
group NN N
. . N

JET NNP N
remains VBZ N
a DT N
relatively RB N
common JJ N
postoperative JJ N
arrhythmia NN N
, , N
but CC N
it PRP N
is VBZ N
less RBR N
frequent JJ N
than IN N
previously RB N
reported VBN N
. . N

JET NNP N
occurs VBZ N
more JJR N
commonly RB N
in IN N
smaller JJR N
patients NNS N
with IN N
longer JJR N
CPB NNP N
runs NNS N
and CC N
significant JJ N
postoperative JJ N
lactic JJ N
acidosis NN N
levels NNS N
. . N

Mortality NNP N
associated VBD N
with IN N
JET NNP N
is VBZ N
lower JJR N
than IN N
historically RB N
reported VBN N
, , N
but CC N
morbidity NN N
remains VBZ N
high JJ N
. . N

-DOCSTART- -X- O O

Effects NNS N
of IN N
weight-bearing JJ 2_i
versus NN N
nonweight-bearing JJ 2_i
exercise NN 2_i
on IN N
function NN N
, , N
walking VBG N
speed NN N
, , N
and CC N
position NN N
sense NN N
in IN N
participants NNS N
with IN N
knee NN N
osteoarthritis NN N
: : N
a DT N
randomized NN N
controlled VBN N
trial NN N
. . N

OBJECTIVE UH N
To TO N
investigate VB N
whether IN N
weight-bearing NN 2_i
( ( 2_i
WB NNP 2_i
) ) 2_i
exercise NN 2_i
enhances VBZ N
functional JJ N
capacity NN N
to TO N
a DT N
greater JJR N
extent NN N
than IN N
nonweight-bearing JJ 2_i
( ( 2_i
NWB NNP 2_i
) ) 2_i
exercise NN 2_i
in IN N
participants NNS N
with IN N
knee NN N
osteoarthritis NN N
. . N

DESIGN NNP N
Randomized NNP N
controlled VBD N
trial NN N
. . N

SETTING NNP N
Kinesiology NNP N
laboratory NN N
. . N

PARTICIPANTS JJ N
Participants NNS N
( ( N
N=106 NNP N
) ) N
were VBD N
randomly RB N
assigned VBN N
to TO N
WB NNP 2_i
exercise NN 2_i
, , N
NWB NNP 2_i
exercise NN 2_i
, , N
or CC N
a DT N
control NN 7_i
group NN 7_i
( ( 7_i
no DT 7_i
exercise NN 7_i
) ) 7_i
. . N

INTERVENTION NNP N
WB NNP 2_i
exercise NN 2_i
and CC N
NWB NNP 2_i
exercise NN 2_i
groups NNS 2_i
underwent VBD N
an DT N
8-week JJ 2_i
knee NN 2_i
extension-flexion NN 2_i
exercise NN 2_i
program NN 2_i
. . N

MAIN NNP N
OUTCOME NNP N
MEASURES NNP N
Western NNP N
Ontario NNP N
and CC N
McMaster NNP N
Universities NNP N
Osteoarthritis NNP N
Index NNP N
( ( N
WOMAC NNP N
) ) N
function NN N
scale NN N
, , N
walking VBG N
speed NN N
, , N
muscle NN N
torque NN N
, , N
and CC N
knee VB N
reposition NN N
error NN N
were VBD N
assessed VBN N
before IN N
and CC N
after IN N
intervention NN N
. . N

RESULTS NNP N
Equally NNP N
significant JJ N
improvements NNS N
were VBD N
apparent JJ N
for IN N
all DT N
outcomes NNS N
after IN N
WB NNP N
exercise NN N
and CC N
NWB NNP N
exercise NN N
, , N
except IN N
for IN N
reposition NN N
error NN N
, , N
for IN N
which WDT N
improvement NN N
was VBD N
greater JJR N
in IN N
the DT N
WB NNP 2_i
exercise NN 2_i
group NN N
. . N

In IN N
contrast NN N
, , N
there EX N
were VBD N
no DT N
improvements NNS N
in IN N
the DT N
control NN N
group NN N
. . N

CONCLUSIONS NNP N
Simple NNP N
knee NNP N
flexion NN N
and CC N
extension NN N
exercises NNS N
( ( 2_i
WB NNP 2_i
and CC N
NWB NNP 2_i
) ) N
performed VBD N
over IN N
8 CD N
weeks NNS N
resulted VBD N
in IN N
significant JJ N
improvement NN N
in IN N
the DT N
WOMAC NNP N
function NN N
scale NN N
and CC N
knee NN N
strength NN N
compared VBN N
with IN N
the DT N
control NN N
group NN N
. . N

NWB NNP 2_i
exercise NN 2_i
alone RB N
may MD N
be VB N
sufficient JJ N
enough RB N
to TO N
improve VB N
function NN N
and CC N
muscle NN N
strength NN N
. . N

The DT N
additional JJ N
benefit NN N
of IN N
WB NNP 2_i
exercise NN 2_i
was VBD N
improved VBN N
position NN N
sense NN N
, , N
which WDT N
may MD N
enhance VB N
complex JJ N
walking NN N
tasks NNS N
( ( N
walking VBG N
on IN N
figure NN N
of IN N
8 CD N
route NN N
and CC N
spongy JJ N
surface NN N
) ) N
. . N

-DOCSTART- -X- O O

Mechanical JJ N
efficiency NN N
and CC N
propulsion NN N
technique NN N
after IN N
7 CD N
weeks NNS N
of IN N
low-intensity JJ N
wheelchair NN N
training NN N
. . N

BACKGROUND NNP N
To TO N
evaluate VB N
the DT N
effect NN N
of IN N
a DT N
7-week JJ N
low-intensity NN N
hand NN N
rim VBZ N
wheelchair JJ N
training VBG N
on IN N
the DT N
submaximal JJ N
metabolic NN N
cost NN N
, , N
mechanical JJ N
efficiency NN N
and CC N
propulsion NN N
technique NN N
in IN N
able-bodied JJ N
participants NNS N
. . N

METHODS JJ N
Participants NNS N
were VBD N
randomly RB N
divided VBN N
over RP N
an DT N
experimental JJ N
group NN N
( ( N
n=14 CC N
) ) N
and CC N
a DT N
control NN N
group NN N
( ( N
n=7 RB N
) ) N
. . N

The DT N
experimental JJ N
group NN N
received VBD N
7 CD N
weeks NNS N
wheelchair JJ 2_i
training NN 2_i
( ( N
3 CD N
week NN N
( ( N
-1 NN N
) ) N
, , N
70 CD N
min NN N
) ) N
at IN N
a DT N
low JJ N
intensity NN N
( ( N
30 CD N
% NN N
of IN N
the DT N
heart NN N
rate NN N
reserve NN N
) ) N
, , N
whereas IN N
the DT N
control NN 4_i
group NN N
did VBD 4_i
not RB 4_i
receive VB 4_i
training NN 4_i
. . N

During IN N
pre- JJ N
and CC N
post-tests NNS N
, , N
submaximal JJ N
exercise NN N
was VBD N
performed VBN N
on IN N
a DT N
stationary JJ N
wheelchair NN 2_i
ergometer NN N
at IN N
fixed JJ N
levels NNS N
of IN N
power NN N
output NN N
. . N

Mechanical JJ N
efficiency NN N
, , N
oxygen NN N
uptake NN N
, , N
heart NN N
rate NN N
, , N
timing VBG N
parameters NNS N
and CC N
stroke NN N
angles NNS N
were VBD N
measured VBN N
. . N

Video NNP N
recordings NNS N
were VBD N
made VBN N
to TO N
determine VB N
the DT N
stroke NN N
pattern NN N
. . N

FINDINGS NNP N
Mechanical NNP N
efficiency NN N
increased VBD N
and CC N
metabolic JJ N
cost NN N
decreased VBN N
significantly RB N
in IN N
the DT N
experimental JJ N
group NN N
compared VBN N
to TO N
the DT N
control NN N
group NN N
. . N

Push NNP N
time NN N
increased VBD N
and CC N
cycle NN N
frequency NN N
decreased VBD N
as IN N
a DT N
result NN N
of IN N
training NN N
. . N

The DT N
stroke NN N
angle NN N
increased VBD N
in IN N
the DT N
experimental JJ N
group NN N
during IN N
the DT N
training NN N
period NN N
. . N

The DT N
experimental JJ N
group NN N
preferred VBD N
double-looping NN N
over IN N
propulsion NN N
, , N
while IN N
the DT N
control NN N
group NN N
mainly RB N
used VBD N
single-looping NN N
over IN N
propulsion NN N
patterns NNS N
during IN N
the DT N
post-test JJ N
. . N

INTERPRETATION VB N
A DT N
low-intensity NN N
, , N
7-week JJ N
training NN N
protocol NN N
has VBZ N
a DT N
beneficial JJ N
effect NN N
on IN N
the DT N
mechanical JJ N
efficiency NN N
and CC N
metabolic JJ N
cost NN N
of IN N
wheelchair NN N
propulsion NN N
in IN N
able-bodied JJ N
participants NNS N
. . N

The DT N
improved JJ N
mechanical JJ N
efficiency NN N
seems VBZ N
to TO N
be VB N
the DT N
result NN N
of IN N
changes NNS N
in IN N
propulsion NN N
technique NN N
that WDT N
were VBD N
found VBN N
. . N

-DOCSTART- -X- O O

Use NNP N
and CC N
limitations NNS N
of IN N
Holter NNP 2_i
electrocardiography NN 2_i
in IN N
assessing VBG N
drug NN N
therapy NN N
of IN N
myocardial JJ N
ischemia NN N
during IN N
the DT N
peri-PTCA JJ N
period NN N
. . N

Incidence NN N
and CC N
pattern NN N
of IN N
myocardial JJ N
ischemia NN N
during IN N
the DT N
peri-PTCA JJ N
( ( N
percutaneous JJ N
transluminal JJ N
coronary JJ N
angioplasty NN N
) ) N
period NN N
and CC N
the DT N
possible JJ N
role NN N
of IN N
continuous JJ 3_i
intravenous JJ 3_i
isosorbide NN 3_i
dinitrate NN 3_i
in IN N
its PRP$ N
prevention NN N
were VBD N
examined VBN N
prospectively RB N
in IN N
30 CD N
patients NNS N
. . N

Holter NNP 2_i
electrocardiographic JJ 2_i
monitoring NN 2_i
was VBD N
performed VBN N
for IN N
21 CD N
+/- JJ N
3 CD N
h NN N
before IN N
PTCA NNP N
and CC N
continued VBN N
during IN N
and CC N
for IN N
41 CD N
+/- JJ N
8 CD N
h NN N
after IN N
the DT N
procedure NN N
. . N

Before IN N
PTCA NNP N
, , N
19 CD N
ischemic JJ N
episodes NNS N
were VBD N
present JJ N
in IN N
10 CD N
( ( N
33 CD N
% NN N
) ) N
of IN N
30 CD N
patients NNS N
. . N

PTCA NNP N
produced VBD N
an DT N
abrupt JJ N
decrease NN N
in IN N
number NN N
( ( N
p JJ N
= NNP N
0.015 CD N
) ) N
and CC N
duration NN N
( ( N
p JJ N
= NNP N
0.03 CD N
) ) N
of IN N
spontaneous JJ N
ischemic JJ N
episodes NNS N
. . N

The DT N
rarity NN N
of IN N
recurrent JJ N
myocardial JJ N
ischemic JJ N
events NNS N
by IN N
Holter NNP 2_i
monitoring NN 2_i
after IN N
PTCA NNP N
negated VBD N
any DT N
attempt NN N
at IN N
assessing VBG N
the DT N
efficacy NN N
of IN N
intravenous JJ N
isosorbide JJ 3_i
dinitrate NN 3_i
in IN N
their PRP$ N
prevention NN N
. . N

Holter NNP 2_i
monitoring NN 2_i
could MD N
not RB N
be VB N
used VBN N
as IN N
an DT N
early JJ N
predictor NN N
of IN N
late JJ N
coronary JJ N
restenosis NN N
. . N

-DOCSTART- -X- O O

Endometrial JJ N
cytodiagnosis NN N
using VBG N
a DT N
new JJ 6_i
softcyte NN 6_i
versus NN N
a DT N
conventional JJ 6_i
endocyte NN 6_i
. . N

A DT N
new JJ N
endometrial JJ N
cytologic NN N
sampling VBG N
device NN N
, , N
softcyte NN N
, , N
was VBD N
used VBN N
in IN N
cytological JJ N
screening NN N
for IN N
endometrial JJ N
cancer NN N
, , N
and CC N
was VBD N
compared VBN N
with IN N
the DT N
endocyte NN 6_i
with IN N
regard NN N
to TO N
manipulability NN N
, , N
adverse JJ N
effects NNS N
( ( N
including VBG N
pain NN N
and CC N
hemorrhage NN N
) ) N
, , N
and CC N
cellular JJ N
findings NNS N
( ( N
including VBG N
the DT N
quantity NN N
of IN N
cells NNS N
collected VBN N
, , N
the DT N
success NN N
rate NN N
, , N
cell NN N
freshness NN N
, , N
and CC N
cellular JJ N
clumping NN N
) ) N
. . N

A DT N
total NN N
of IN N
315 CD N
women NNS N
( ( N
premenopause IN N
251 CD N
, , N
postmenopause RB N
64 CD N
) ) N
were VBD N
randomly RB N
assigned VBN N
to TO N
two CD N
groups NNS N
who WP N
underwent VBP N
the DT N
endometrial JJ 6_i
cytological JJ 6_i
screening NN 6_i
with IN 6_i
either CC 6_i
the DT 6_i
softcyte NN 6_i
or CC N
the DT N
endocyte NN 6_i
. . N

To TO N
assess VB N
the DT N
value NN N
of IN N
the DT N
softcyte NN 6_i
we PRP N
compared VBN N
it PRP N
with IN N
the DT N
endocyte NN 6_i
. . 6_i

Endometrial NNP N
cytology NN N
using VBG N
a DT N
softcyte NN 6_i
or CC N
an DT N
endocyte NN 6_i
achieved VBN N
high JJ N
correct JJ N
diagnosis NN N
rate NN N
for IN N
cancer NN N
, , N
and CC N
both DT N
instruments NNS N
are VBP N
valuable JJ N
as IN N
endometrial JJ N
cytologic NN N
sample NN N
devices NNS N
. . N

The DT N
softcyte NN N
causes VBZ N
only RB N
mild JJ N
pain NN N
on IN N
introduction NN N
and CC N
during IN N
collection NN N
, , N
and CC N
a DT N
large JJ N
quantity NN N
of IN N
cells NNS N
could MD N
be VB N
harvested VBN N
. . N

These DT N
results NNS N
suggest VBP N
that IN N
the DT N
softcyte NN N
is VBZ N
a DT N
useful JJ N
cytologic NN N
sampling VBG N
device NN N
in IN N
screening VBG N
for IN N
endometrial JJ N
cancer NN N
. . N

-DOCSTART- -X- O O

Monitoring VBG N
tumour NN N
cells NNS N
in IN N
the DT N
peripheral JJ N
blood NN N
of IN N
small JJ N
cell NN N
lung NN N
cancer NN N
patients NNS N
. . N

BACKGROUND NNP N
Flow NNP 6_i
cytometry NN 6_i
was VBD N
used VBN N
to TO N
enumerate VB N
tumour JJ N
cells NNS N
in IN N
longitudinal JJ N
studies NNS N
of IN N
peripheral JJ N
blood NN N
from IN N
small JJ N
cell NN N
lung NN N
cancer NN N
( ( N
SCLC NNP N
) ) N
patients NNS N
, , N
together RB N
with IN N
magnetic JJ N
bead NN N
selection NN N
to TO N
isolate VB N
and CC N
identify VB N
these DT N
cells NNS N
. . N

As IN N
part NN N
of IN N
a DT N
trial NN N
, , N
11 CD N
patients NNS N
received VBD N
either RB N
standard JJ N
( ( N
four CD N
weekly RB N
) ) N
chemotherapy NN 3_i
with IN N
ifosfamide NN 3_i
, , N
carboplatin NN 3_i
, , N
and CC N
etoposide RB 3_i
( ( 3_i
ICE NNP 3_i
) ) 3_i
or CC N
accelerated VBN N
( ( N
two CD N
weekly RB N
) ) N
ICE NNP 3_i
with IN 3_i
filgrastim NN 3_i
( ( 3_i
granulocyte JJ 3_i
colony-stimulating NN 3_i
factor NN 3_i
[ IN 3_i
G-CSF NNP 3_i
] NNP 3_i
) ) 3_i
and CC N
autologous JJ 3_i
stem NN 3_i
cell NN 3_i
support NN 3_i
. . N

METHODS NNP N
Fresh NNP N
venous JJ N
blood NN N
was VBD N
taken VBN N
throughout IN N
treatment NN N
and CC N
follow-up NN N
. . N

Aliquots NNS N
were VBD N
stained VBN N
with IN N
a DT N
tumour-specific JJ N
antibody NN N
against IN N
epithelial JJ N
tissue NN N
( ( N
Ber NNP N
EP4 NNP N
) ) N
, , N
verified VBD N
as IN N
a DT N
good JJ N
marker NN N
of IN N
SCLC NNP N
cells NNS N
by IN N
immunohistochemistry NN N
. . N

Matched NNP N
samples NNS N
labelled VBD N
with IN N
Ber NNP N
EP4 NNP N
were VBD N
separated VBN N
magnetically RB N
by IN N
adding VBG N
a DT N
secondary JJ N
bead-antibody NN N
conjugate NN N
for IN N
confirmation NN N
of IN N
tumour NN N
cell NN N
identity NN N
. . N

RESULTS NNP N
Circulating NNP N
tumour JJ N
cells NNS N
were VBD N
detected VBN N
and CC N
monitored VBN N
throughout IN N
treatment NN N
periods NNS N
. . N

An DT N
initial JJ N
rise NN N
in IN N
circulating VBG N
cells NNS N
after IN N
the DT N
first JJ N
cycle NN N
was VBD N
followed VBN N
by IN N
a DT N
fall NN N
in IN N
both DT N
treatment NN N
arms NNS N
to TO N
baseline NN N
levels NNS N
set VBN N
by IN N
normal JJ N
controls NNS N
. . N

This DT N
was VBD N
achieved VBN N
by IN N
week NN N
12 CD N
in IN N
the DT N
accelerated JJ N
treatment NN N
arm NN N
and CC N
by IN N
week NN N
24 CD N
in IN N
the DT N
standard JJ N
arm NN N
. . N

CONCLUSIONS NNP N
Flow NNP N
cytometry NN N
and CC N
magnetic JJ N
bead NN N
isolation NN N
can MD N
be VB N
used VBN N
to TO N
identify VB N
changes NNS N
in IN N
numbers NNS N
of IN N
circulating VBG N
tumour JJ N
cells NNS N
in IN N
patients NNS N
undergoing JJ N
chemotherapy NN 3_i
for IN N
SCLC NNP N
and CC N
thereafter RB N
during IN N
follow-up JJ N
periods NNS N
. . N

Absence NN N
of IN N
tumour JJ N
cells NNS N
may MD N
indicate VB N
a DT N
more RBR N
favourable JJ N
patient NN N
group NN N
who WP N
would MD N
benefit VB N
from IN N
a DT N
more RBR N
intense JJ N
course NN N
of IN N
treatment NN N
. . N

-DOCSTART- -X- O O

A DT N
comparative JJ N
study NN N
of IN N
methyldopa NN 3_i
and CC N
labetalol NN 3_i
in IN N
the DT N
treatment NN N
of IN N
hypertension NN N
. . N

1 CD N
Twenty CD N
patients NNS N
with IN N
essential JJ N
hypertension NN N
completed VBD N
a DT N
double-blind JJ N
, , N
dose-tritrated JJ N
, , N
cross-over JJ N
comparison NN N
of IN N
methyldopa NN 3_i
and CC N
labetalol NN 3_i
. . N

2 CD N
Average JJ N
lying VBG N
BPs NNP N
( ( N
systolic/diastolic JJ N
) ) N
were VBD N
reduced VBN N
by IN N
28/15 CD N
mmHg NNS N
with IN N
methyldopa NN 3_i
and CC N
by IN N
23/15 CD N
mmHg NNS N
with IN N
labetalol NN 3_i
. . 3_i

3 CD N
Average JJ N
standing VBG N
BPs NNP N
( ( N
systolic/diastolic JJ N
) ) N
were VBD N
reduced VBN N
by IN N
29/14 CD N
mmHg NNS N
with IN N
methyldopa NN 3_i
and CC N
by IN N
29/15 CD N
mmHg NNS N
with IN N
labetalol NN 3_i
. . 3_i

4 CD N
Both DT N
lying NN N
and CC N
standing VBG N
heart NN N
rates NNS N
were VBD N
reduced VBN N
with IN N
labetalol NN 3_i
. . 3_i

5 CD N
It PRP N
is VBZ N
concluded VBN N
that IN N
the DT N
antihypertensive JJ N
properties NNS N
of IN N
labetalol NN 3_i
and CC N
methyldopa NN 3_i
are VBP N
similar JJ N
but CC N
that IN N
larger JJR N
patient NN N
populations NNS N
are VBP N
needed VBN N
to TO N
study VB N
the DT N
relative JJ N
incidence NN N
of IN N
subjective JJ N
adverse JJ N
effects NNS N
. . N

-DOCSTART- -X- O O

Intravenous JJ 3_i
or CC 3_i
intramuscular JJ 3_i
teicoplanin NN 3_i
once RB N
daily JJ N
for IN N
skin NN N
and CC N
soft-tissue JJ N
infections NNS N
. . N

Teicoplanin NNP 3_i
is VBZ N
a DT N
new JJ N
glycopeptide NN N
antibiotic JJ N
with IN N
potent JJ N
activity NN N
against IN N
gram-positive JJ N
bacteria NNS N
and CC N
pharmacokinetics NNS N
that WDT N
allow VBP N
once RB N
daily JJ N
administration NN N
. . N

To TO N
study VB N
the DT N
efficacy NN N
and CC N
safety NN N
of IN N
teicoplanin NN 3_i
for IN N
skin NN N
and CC N
soft-tissue NN N
infections NNS N
, , N
75 CD N
patients NNS N
received VBD N
teicoplanin JJ 3_i
intravenously RB 3_i
( ( 3_i
38 CD 3_i
) ) 3_i
or CC 3_i
intramuscularly RB 3_i
( ( N
37 CD N
, , N
of IN N
which WDT N
16 CD N
were VBD N
outpatients NNS N
) ) N
. . N

Of IN N
62 CD N
clinically RB N
evaluable JJ N
patients NNS N
, , N
97 CD N
percent NN N
of IN N
teicoplanin NN 3_i
iv NN N
and CC N
93 CD N
percent NN N
of IN N
teicoplanin NN 3_i
im NN N
patients NNS N
were VBD N
cured VBN N
or CC N
improved VBN N
. . N

All DT N
teicoplanin JJ 3_i
iv NN N
patients NNS N
and CC N
64 CD N
percent NN N
of IN N
teicoplanin NN 3_i
im NN N
patients NNS N
were VBD N
cured VBN N
microbiologically RB N
at IN N
24-48 JJ N
hours NNS N
posttherapy NN N
. . N

Persistence NN N
of IN N
organisms NNS N
frequently RB N
was VBD N
associated VBN N
with IN N
skin JJ N
ulcers NNS N
or CC N
abscess JJ N
cavities NNS N
and CC N
usually RB N
had VBD N
no DT N
bearing NN N
on IN N
clinical JJ N
outcome NN N
. . N

Possible JJ N
adverse JJ N
clinical JJ N
and CC N
laboratory JJ N
reactions NNS N
caused VBN N
by IN N
teicoplanin NN 3_i
occurred VBD N
in IN N
4 CD N
of IN N
38 CD N
teicoplanin JJ N
iv NN N
patients NNS N
( ( N
11 CD N
percent NN N
) ) N
and CC N
in IN N
8 CD N
of IN N
37 CD N
teicoplanin JJ 3_i
im NN N
patients NNS N
( ( N
22 CD N
percent NN N
) ) N
. . N

Reactions NNPS N
were VBD N
mild JJ N
and CC N
resolved VBN N
with IN N
discontinuation NN N
of IN N
teicoplanin NN 3_i
in IN N
most JJS N
cases NNS N
. . N

In IN N
this DT N
study NN N
, , N
teicoplanin NN N
appeared VBD N
to TO N
be VB N
safe JJ N
, , N
efficacious JJ N
, , N
and CC N
convenient NN N
for IN N
both DT N
hospital JJ N
staff NN N
and CC N
patients NNS N
, , N
and CC N
potentially RB N
cost-effective JJ N
for IN N
the DT N
treatment NN N
of IN N
skin NN N
and CC N
soft-tissue JJ N
infections NNS N
. . N

In IN N
particular JJ N
, , N
teicoplanin JJ 3_i
appears VBZ N
to TO N
be VB N
appropriate JJ N
for IN N
outpatient JJ N
parenteral JJ N
therapy NN N
. . N

-DOCSTART- -X- O O

Comparison NNP N
of IN N
thiopentone/guaifenesin NN 3_i
, , N
ketamine/guaifenesin NN 3_i
and CC N
ketamine/midazolam NN 3_i
for IN N
the DT N
induction NN N
of IN N
horses NNS N
to TO N
be VB N
anaesthetised VBN N
with IN N
isoflurane NN N
. . N

Forty-eight JJ N
horses NNS N
subjected VBN N
to TO N
elective VB N
surgery NN N
were VBD N
randomly RB N
assigned VBN N
to TO N
three CD N
groups NNS N
of IN N
16 CD N
horses NNS N
. . N

After IN N
premedication NN N
with IN N
0.1 CD N
mg/kg NNS N
acepromazine VBP 3_i
intramuscularly RB N
and CC N
0.6 CD N
mg/kg NNS N
xylazine JJ 3_i
intravenously RB N
, , N
anaesthesia NN N
was VBD N
induced VBN N
either RB N
with IN N
2 CD N
g NNS N
thiopentone NN 3_i
in IN N
500 CD N
ml NN N
of IN N
a DT N
10 CD N
per IN N
cent NN N
guaifenesin NN 3_i
solution NN N
, , N
given VBN N
intravenously RB N
at IN N
a DT N
dose NN N
of IN N
1 CD N
ml/kg NNS N
( ( N
group NN N
TG NNP N
) ) N
, , N
or CC N
with IN N
100 CD N
mg/kg NNS N
guaifenesin NN 3_i
and CC N
2.2 CD N
mg/kg NN N
ketamine NN 3_i
given VBN N
intravenously RB N
( ( N
group NN N
KG NNP N
) ) N
, , N
or CC N
with IN N
0.06 CD N
mg/kg NNS N
midazolam NN 3_i
, , N
and CC N
2.2 CD N
mg/kg NN N
ketamine NN 3_i
given VBN N
intravenously RB N
( ( N
group NN N
KM NNP N
) ) N
. . N

Anaesthesia NNP N
was VBD N
maintained VBN N
with IN N
isoflurane NN 3_i
. . 3_i

The DT N
mean NN N
( ( N
sd NN N
) ) N
end NN N
tidal JJ N
isoflurane NN 3_i
concentration NN N
( ( N
per IN N
cent NN N
) ) N
needed VBD N
to TO N
maintain VB N
a DT N
light JJ N
surgical JJ N
anaesthesia NN N
( ( N
stage NN N
III NNP N
, , N
plane NN N
2 CD N
) ) N
was VBD N
significantly RB N
lower JJR N
in IN N
group NN N
KM NNP N
( ( N
0.91 CD N
[ RB N
0.03 CD N
] NN N
) ) N
than IN N
in IN N
groups NNS N
TG NNP N
( ( N
1.11 CD N
[ RB N
0.03 CD N
] NN N
) ) N
and CC N
KG NNP N
( ( N
1.14 CD N
[ RB N
0.03 CD N
] NN N
) ) N
. . N

The DT N
mean NN N
( ( N
sd NN N
) ) N
arterial JJ N
pressure NN N
( ( N
mmHg NN N
) ) N
was VBD N
significantly RB N
lower JJR N
in IN N
group NN N
KG NNP N
( ( N
67.4 CD N
[ RB N
2.07 CD N
] NN N
) ) N
than IN N
in IN N
groups NNS N
TC NNP N
( ( N
75.6 CD N
[ RB N
2.23 CD N
] NN N
) ) N
and CC N
KM NNP N
( ( N
81.0 CD N
[ RB N
2.16 CD N
] NN N
) ) N
. . N

There EX N
were VBD N
no DT N
significant JJ N
differences NNS N
in IN N
the DT N
logarithm NN N
of IN N
the DT N
heart NN N
rate NN N
, , N
recovery NN N
time NN N
or CC N
quality NN N
of IN N
recovery NN N
between IN N
the DT N
three CD N
induction NN N
groups NNS N
. . N

However RB N
, , N
pronounced VBD N
ataxia NN N
was VBD N
observed VBN N
in IN N
the DT N
horses NNS N
of IN N
group NN N
KM NNP N
, , N
especially RB N
after IN N
periods NNS N
of IN N
anaesthesia NN N
lasting VBG N
less JJR N
than IN N
75 CD N
minutes NNS N
. . N

-DOCSTART- -X- O O

Phytase NNP 3_i
and CC N
1alpha-hydroxycholecalciferol JJ 3_i
supplementation NN 3_i
of IN N
broiler NN N
chickens NNS N
during IN N
the DT N
starting NN N
and CC N
growing/finishing NN N
phases NNS N
. . N

Supplemental JJ N
1alpha-hydroxycholecalciferol JJ N
( ( N
1alpha-OHD3 JJ N
) ) N
has VBZ N
been VBN N
shown VBN N
to TO N
have VB N
qualitatively RB N
similar JJ N
and CC N
quantitatively RB N
additive JJ N
effects NNS N
to TO N
exogenous JJ N
phytase NN N
. . N

Two CD N
experiments NNS N
were VBD N
conducted VBN N
from IN N
0 CD N
to TO N
35 CD N
d NN N
in IN N
floor NN N
pens NNS N
to TO N
determine VB N
the DT N
additive JJ N
effect NN N
of IN N
phytase NN 3_i
and CC N
1alpha-OHD3 JJ 3_i
when WRB N
supplemented VBN N
to TO N
Ca- NNP 3_i
and CC 3_i
P-deficient NNP 3_i
diets NNS 3_i
. . N

In IN N
both DT N
experiments NNS N
, , N
at IN N
least JJS N
4 CD N
replicates NNS N
per IN N
treatment NN N
( ( N
50 CD N
chicks NNS N
per IN N
replicate NN N
) ) N
were VBD N
used VBN N
. . N

Corn-soybean-meal-and JJ 6_i
soybean-oil-based JJ 6_i
diets NNS 6_i
were VBD N
fed VBN N
and CC N
birds NNS N
were VBD N
raised VBN N
in IN N
a DT N
house NN N
impervious JJ N
to TO N
ultraviolet VB N
light NN N
. . N

During IN N
the DT N
starter JJ N
phase NN N
( ( N
ST NNP N
) ) N
, , N
from IN N
0 CD N
to TO N
18 CD N
d NN N
, , N
chicks NNS N
were VBD N
fed VBN N
a DT N
23 CD N
% NN N
CP NNP N
diet JJ N
containing VBG N
0.60 CD N
% NN N
Ca NNP N
and CC N
0.47 CD N
% NN N
total JJ N
P NNP N
( ( N
tP NN N
) ) N
. . N

During IN N
the DT N
grower/finisher NN N
phase NN N
( ( N
GF NNP N
) ) N
, , N
from IN N
19 CD N
to TO N
35 CD N
d NN N
, , N
birds NNS N
were VBD N
fed VBN N
a DT N
19 CD N
% NN N
CP NNP N
diet JJ N
containing VBG N
0.30 CD N
% NN N
Ca NNP N
and CC N
0.37 CD N
% NN N
tP NN N
. . N

A DT N
combination NN N
of IN N
1,000 CD N
phytase NN N
units/kg NN N
of IN N
Natuphos NNP N
phytase NN N
and CC N
5 CD N
microg/kg NN N
of IN N
1alpha-OHD3 JJ N
( ( N
P+1A NNP N
) ) N
was VBD N
supplemented VBN N
to TO N
some DT N
of IN N
the DT N
feed NN N
during IN N
the DT N
ST NNP N
and CC N
GF NNP N
. . N

Diets NNS N
containing VBG N
adequate NN N
Ca NNP N
and CC N
P NNP N
were VBD N
also RB N
fed VBN N
during IN N
the DT N
ST NNP N
( ( N
0.90 CD N
% NN N
Ca NNP N
, , N
0.68 CD N
% NN N
tP NN N
) ) N
and CC N
GF NNP N
( ( N
0.80 CD N
% NN N
Ca NNP N
, , N
0.67 CD N
% NN N
tP NN N
) ) N
. . N

Performance NN N
characteristics NNS N
and CC N
the DT N
incidence NN N
of IN N
rickets NNS N
and CC N
tibial JJ N
dyschondroplasia NN N
were VBD N
measured VBN N
at IN N
18 CD N
and CC N
35 CD N
d. NN N
In IN N
experiment JJ N
1 CD N
, , N
unsupplemented JJ N
chicks NNS N
performed VBN N
well RB N
but CC N
had VBD N
considerable JJ N
leg JJ N
problems NNS N
. . N

Chicks NNP N
fed VBD N
P+1A NNP N
during IN N
the DT N
ST NNP N
or CC N
GF NNP N
did VBD N
not RB N
perform VB N
as RB N
well RB N
as IN N
birds NNS N
fed VBN N
P+1A NNP N
throughout IN N
. . N

Birds NNS N
fed VBD N
P+1A NNP N
throughout IN N
performed VBN N
as IN N
well RB N
birds NNS N
fed VBD N
the DT N
adequate JJ N
diets NNS N
without IN N
any DT N
indication NN N
of IN N
leg NN N
problems NNS N
. . N

In IN N
experiment JJ N
2 CD N
, , N
unsupplemented JJ N
birds NNS N
performed VBD N
similarly RB N
to TO N
unsupplemented JJ N
birds NNS N
in IN N
experiment JJ N
1 CD N
. . N

However RB N
, , N
chicks NNS N
fed VBP N
the DT N
supplements NNS N
or CC N
the DT N
control JJ N
diets NNS N
did VBD N
not RB N
perform VB N
as RB N
well RB N
or CC N
accumulate VB N
as IN N
much JJ N
bone NN N
ash NN N
as IN N
birds NNS N
in IN N
experiment JJ N
1 CD N
, , N
although IN N
the DT N
diets NNS N
were VBD N
formulated VBN N
identically RB N
in IN N
both DT N
experiments NNS N
. . N

Diets NNS N
with IN N
as RB N
little JJ N
as IN N
0.30 CD N
% NN N
Ca NNP N
and CC N
0.37 CD N
% NN N
tP NN N
appear VBP N
to TO N
be VB N
adequate JJ N
for IN N
broilers NNS N
older JJR N
than IN N
18 CD N
d NN N
if IN N
supplemented VBN N
with IN N
the DT N
correct JJ N
amounts NNS N
of IN N
phytase NN N
and CC N
1alpha-OHD3 JJ N
. . N

However RB N
, , N
there EX N
are VBP N
unknown JJ N
variables NNS N
that WDT N
may MD N
limit VB N
the DT N
potential NN N
of IN N
broilers NNS N
in IN N
terms NNS N
of IN N
bone NN N
mineralization NN N
and CC N
bone NN N
pathology NN N
, , N
even RB N
when WRB N
adequate JJ N
diets NNS N
are VBP N
fed VBN N
. . N

-DOCSTART- -X- O O

Effect NN N
of IN N
hydrochlorothiazide NN 3_i
therapy NN 3_i
on IN N
cardiac JJ N
arrhythmias NN N
in IN N
African-American JJ N
men NNS N
with IN N
systemic JJ N
hypertension NN N
and CC N
moderate VB N
to TO N
severe VB N
left JJ N
ventricular JJ N
hypertrophy NN N
. . N

The DT N
effect NN N
of IN N
hydrochlorothiazide NN 3_i
therapy NN 3_i
on IN N
ventricular JJ N
arrhythmias NN N
was VBD N
studied VBN N
in IN N
45 CD N
hypertensive JJ N
African-American JJ N
men NNS N
with IN N
moderate JJ N
to TO N
severe VB N
left VBN N
ventricular JJ N
( ( N
LV NNP N
) ) N
hypertrophy NN N
. . N

After IN N
medication NN N
washout NN N
, , N
patients NNS N
were VBD N
treated VBN N
with IN N
placebo NN 7_i
followed VBN N
by IN N
hydrochlorothiazide NN 3_i
. . N

Clinical NNP N
, , N
biochemical JJ N
, , N
and CC N
48-hour JJ N
ambulatory NN N
electrocardiographic JJ N
data NN N
was VBD N
collected VBN N
after IN N
each DT N
treatment NN N
phase NN N
. . N

Signal-averaged JJ N
electrocardiograms NNS N
were VBD N
recorded VBN N
in IN N
a DT N
subgroup NN N
of IN N
24 CD N
patients NNS N
. . N

Average JJ N
LV NNP N
posterior NN N
wall NN N
thickness NN N
was VBD N
15 CD N
+/- JJ N
1.1 CD N
mm NN N
, , N
septum VBD N
16 CD N
+/- JJ N
2 CD N
mm NN N
, , N
LV NNP N
mass VBD N
420 CD N
+/- JJ N
90 CD N
g NN N
, , N
and CC N
LV NNP N
mass NNP N
index NN N
212 CD N
= NN N
51 CD N
g/m2 NN N
. . N

Systolic NNP N
blood NN N
pressure NN N
( ( N
BP NNP N
) ) N
was VBD N
168 CD N
+/- JJ N
18 CD N
mm NN N
Hg NNP N
after IN N
the DT N
placebo NN N
phase NN N
and CC N
146 CD N
+/- JJ N
15 CD N
mm NN N
Hg NNP N
after IN N
hydrochlorothiazide NN N
; : N
diastolic JJ N
BP NNP N
was VBD N
103 CD N
+/- JJ N
6 CD N
mm NN N
Hg NNP N
and CC N
89 CD N
+/- JJ N
9 CD N
mm NN N
Hg NNP N
, , N
respectively RB N
. . N

Serum NNP N
potassium NN N
decreased VBD N
significantly RB N
from IN N
4.2 CD N
+/- JJ N
0.4 CD N
mmol/L NN N
to TO N
3.7 CD N
+/- JJ N
0.6 CD N
mmol/L NN N
after IN N
hydrochlorothiazide JJ 3_i
therapy NN 3_i
. . 3_i

The DT N
average JJ N
hourly JJ N
incidence NN N
of IN N
ventricular JJ N
premature NN N
contractions NNS N
was VBD N
22 CD N
with IN N
placebo NN 7_i
and CC N
25 CD N
with IN N
hydrochlorothiazide NN 3_i
. . 3_i

There EX N
were VBD N
3 CD N
and CC N
1 CD N
couplets NNS N
and CC N
0.2 CD N
and CC N
0.2 CD N
runs NNS N
of IN N
ventricular JJ N
tachycardia NN N
per IN N
patient NN N
per IN N
hour NN N
, , N
respectively RB N
. . N

Variables NNS N
of IN N
signal-averaged JJ N
electrocardiography NN N
did VBD N
not RB N
differ VB N
between IN N
the DT N
2 CD N
treatments NNS N
. . N

Thus RB N
, , N
in IN N
hypertensive JJ N
African-American JJ N
men NNS N
with IN N
moderate JJ N
to TO N
severe VB N
LV NNP N
hypertrophy NN N
, , N
hydrochlorothiazide NN 3_i
does VBZ N
not RB N
worsen VB N
ventricular JJ N
arrhythmias NNS N
or CC N
signal-averaged JJ N
electrocardiographic JJ N
variables NNS N
. . N

-DOCSTART- -X- O O

The DT N
effect NN N
of IN N
use NN N
of IN N
pyridostigmine NN 3_i
and CC N
requirement NN N
of IN N
vecuronium NN 3_i
in IN N
patients NNS N
with IN N
myasthenia JJ N
gravis NN N
. . N

CONTEXT NNP N
Patients NNPS N
with IN N
myasthenia NNP N
gravis FW N
receive JJ N
pyridostigmine NN 3_i
, , N
an DT N
anticholinesterase NN 3_i
agent NN 3_i
, , N
as IN N
a DT N
part NN N
of IN N
therapy NN N
. . N

These DT N
patients NNS N
demonstrate VBP N
a DT N
heightened JJ N
sensitivity NN N
towards IN N
non-depolarising JJ N
muscle NN N
relaxants NNS N
. . N

Continuing VBG N
pyridostigmine NN 3_i
till IN N
the DT N
day NN N
of IN N
the DT N
surgery NN N
or CC N
omitting VBG N
it PRP N
on IN N
the DT N
night NN N
before IN N
surgery NN N
could MD N
provide VB N
variable JJ N
results NNS N
with IN N
regards NNS N
to TO N
the DT N
effect NN N
of IN N
vecuronium NN 3_i
. . 3_i

AIMS NNP N
Myographic NNP N
evaluation NN N
of IN N
a DT N
dose NN N
of IN N
vecuronium NN N
in IN N
patients NNS N
with IN N
myasthenia JJ N
gravis NN N
on IN N
pyridostigmine NN N
therapy NN N
. . N

SETTING NN N
AND CC N
DESIGN NNP N
A NNP N
randomised JJ N
, , N
double-blind JJ N
, , N
clinical JJ N
study NN N
conducted VBN N
in IN N
a DT N
teaching JJ N
hospital NN N
. . N

SUBJECTS NNP N
AND NNP N
METHODS NNP N
Medically NNP N
( ( 3_i
oral JJ 3_i
pyridostigmine NN 3_i
) ) 3_i
well-controlled JJ N
adult NN N
patients NNS N
with IN N
myasthenia JJ N
gravis NNS N
who WP N
were VBD N
posted VBN N
for IN N
thymectomy NN 1_i
, , N
were VBD N
randomly RB N
divided VBN N
into IN N
two CD N
groups NNS N
. . N

Patients NNS N
in IN N
Group NNP N
1 CD N
received VBD N
their PRP$ N
last JJ N
dose NN N
of IN N
pyridostigmine NN 3_i
on IN N
the DT N
night NN N
before IN N
surgery NN N
while IN N
those DT N
in IN N
Group NNP N
2 CD N
received VBD N
even RB N
the DT N
morning NN N
dose NN N
of IN N
the DT N
drug NN N
on IN N
the DT N
day NN N
of IN N
surgery NN N
. . N

Neostigmine NNP 3_i
( ( N
1-2 JJ N
mg NN N
) ) N
intravenously RB N
was VBD N
used VBN N
as IN N
rescue JJ N
medication NN N
. . N

Vecuronium NNP 3_i
( ( N
0.01 CD N
mg/kg NN N
) ) N
was VBD N
used VBN N
for IN N
intubation NN N
and CC N
muscle NN N
relaxation NN N
during IN N
trans-sternal JJ 1_i
thymectomy NN 1_i
and CC N
its PRP$ N
effect NN N
was VBD N
reversed VBN N
using VBG N
neostigmine NN N
and CC N
atropine NN N
. . N

RESULTS NNP N
Fourteen JJ N
patients NNS N
( ( N
7 CD N
in IN N
each DT N
group NN N
) ) N
belonging NN N
to TO N
both DT N
sexes NNS N
were VBD N
enrolled VBN N
in IN N
the DT N
study NN N
. . N

The DT N
intubating VBG N
dose NN N
of IN N
vecuronium NN N
showed VBD N
quicker JJR N
onset JJ N
time NN N
( ( N
155 CD N
sec NN N
or CC N
2.7 CD N
min NN N
approx NN N
. . N

) ) N
and CC N
peak JJ N
effect NN N
( ( N
99 CD N
% NN N
T1 NNP N
suppression NN N
) ) N
in IN N
patients NNS N
belonging VBG N
to TO N
Group NNP N
1 CD N
, , N
and CC N
3/7 CD N
( ( N
43 CD N
% NN N
) ) N
complained VBD N
of IN N
respiratory JJ N
discomfort NN N
while IN N
waiting VBG N
for IN N
surgery NN N
. . N

By IN N
giving VBG N
the DT N
morning NN N
dose NN N
of IN N
pyridostigmine NN 3_i
( ( N
Group NNP N
2 CD N
) ) N
, , N
an DT N
identical JJ N
intubating NN N
dose NN N
of IN N
vecuronium NN 3_i
showed VBD N
relative JJ N
resistance NN N
( ( N
peak JJ N
effect-97 NN N
% NN N
T1 NNP N
suppression NN N
) ) N
and CC N
delayed VBN N
onset NN N
time NN N
( ( N
198 CD N
sec NN N
approx. NN N
) ) N
. . N

However RB N
, , N
the DT N
reversal NN N
was VBD N
complete JJ N
at IN N
the DT N
end NN N
of IN N
surgery NN N
in IN N
both CC N
the DT N
regimens NNS N
. . N

CONCLUSIONS NNP N
Omission NNP N
of IN N
the DT N
pyridostigmine NN 3_i
dose NN N
on IN N
the DT N
day NN N
of IN N
surgery NN N
predisposed VBN N
patients NNS N
with IN N
myasthenia JJ N
gravis NN N
to TO N
the DT N
possibility NN N
of IN N
respiratory JJ N
discomfort NN N
and CC N
sensitivity NN N
to TO N
vecuronium NN 3_i
. . 3_i

Continued VBN N
administration NN N
significantly RB N
prolonged VBD N
the DT N
onset JJ N
time NN N
of IN N
vecuronium NN 3_i
and CC N
the DT N
patients NNS N
required VBD N
a DT N
higher JJR N
dose NN N
of IN N
vecuronium NN 3_i
. . 3_i

-DOCSTART- -X- O O

Enhancing VBG N
the DT N
self-esteem NN N
of IN N
inpatient JJ N
alcoholics NNS N
. . N

This DT N
study NN N
examined VBD N
the DT N
effect NN N
of IN N
pairing VBG N
inpatient JJ N
alcoholics NNS N
with IN N
nursing NN 6_i
home NN 6_i
residents NNS 6_i
( ( 6_i
NHRs NNP 6_i
) ) 6_i
on IN N
the DT N
alcoholics NNS N
' POS N
self-esteem NN N
. . N

In IN N
this DT N
PALS NNP N
program NN N
, , N
the DT N
alcoholic JJ N
inpatients NNS N
assumed VBD N
a DT N
helping-companion NN N
relationship NN N
with IN N
the DT N
NHRs NNP N
for IN N
2 CD N
hr NNS N
per IN N
day NN N
during IN N
their PRP$ N
last JJ N
2 CD N
weeks NNS N
of IN N
treatment NN N
. . N

Fifty NNP N
alcoholic JJ N
inpatients NNS N
were VBD N
randomly RB N
assigned VBN N
to TO N
the DT N
PALS NNP 5_i
program NN 5_i
( ( N
n JJ N
= NNP N
25 CD N
) ) N
or CC N
to TO N
the DT N
library NN 5_i
for IN 5_i
free JJ 5_i
reading NN 5_i
time NN 5_i
( ( N
n JJ N
= NNP N
25 CD N
) ) N
. . N

The DT N
Tennessee NNP N
Self-Concept NNP N
Scale NNP N
( ( N
TSCS NNP N
) ) N
was VBD N
administered VBN N
to TO N
all DT N
subjects NNS N
in IN N
both DT N
groups NNS N
before IN N
and CC N
after IN N
the DT N
interventions NNS N
. . N

Of IN N
the DT N
nine CD N
TSCS NNP N
scales NNS N
, , N
the DT N
improvement NN N
on IN N
the DT N
Moral-Ethical JJ N
scale NN N
was VBD N
significantly RB N
greater JJR N
in IN N
the DT N
PALS NNP N
group NN N
. . N

Because IN N
the DT N
alcoholic JJ N
inpatients NNS N
in IN N
the DT N
PALS NNP N
group NN N
engaged VBD N
in IN N
altruistic JJ N
( ( N
moral JJ N
) ) N
behavior NN N
, , N
this DT N
study NN N
provides VBZ N
a DT N
logical JJ N
link NN N
between IN N
the DT N
intervention NN N
and CC N
the DT N
outcome NN N
, , N
which WDT N
has VBZ N
been VBN N
a DT N
prevalent JJ N
weakness NN N
in IN N
previous JJ N
studies NNS N
of IN N
self-esteem NN N
in IN N
alcoholics NNS N
. . N

-DOCSTART- -X- O O

Laser NNP 1_i
conization NN 1_i
versus NN N
cold JJ 1_i
knife NN 1_i
conization NN 1_i
. . 1_i

This DT N
prospective JJ N
, , N
randomized VBN N
study NN N
compares VBZ N
, , N
for IN N
the DT N
first JJ N
time NN N
, , N
measured VBN N
blood NN N
loss NN N
at IN N
conization NN N
and CC N
within IN N
24 CD N
hours NNS N
after IN N
using VBG N
either CC N
the DT N
cold JJ 1_i
knife NN 1_i
technique NN 1_i
or CC N
the DT N
carbon NN 1_i
dioxide NN 1_i
laser NN 1_i
scalpel NN 1_i
. . N

One CD N
hundred CD N
and CC N
ten VB N
consecutive JJ N
patients NNS N
were VBD N
evaluated VBN N
. . N

The DT N
median JJ N
blood NN N
loss NN N
in IN N
the DT N
laser NN N
group NN N
of IN N
55 CD N
patients NNS N
was VBD N
4.6 CD N
milliliters NNS N
at IN N
, , N
and CC N
within IN N
, , N
24 CD N
hours NNS N
after IN N
operation NN N
compared VBN N
with IN N
30.1 CD N
milliliters NNS N
in IN N
the DT N
cold JJ 1_i
knife NN 1_i
group NN N
of IN N
55 CD N
patients NNS N
. . N

More RBR N
important JJ N
, , N
however RB N
, , N
is VBZ N
that IN N
the DT N
corresponding JJ N
figures NNS N
for IN N
the DT N
range NN N
of IN N
bleeding VBG N
were VBD N
0.4 CD N
to TO N
155.4 CD N
milliliters NNS N
and CC N
5.6 CD N
to TO N
1,570.9 CD N
milliliters NNS N
, , N
respectively RB N
. . N

The DT N
incidence NN N
rate NN N
for IN N
bleeding VBG N
complications NNS N
requiring VBG N
surgical JJ N
intervention NN N
was VBD N
1.8 CD N
per IN N
cet NN N
for IN N
the DT N
laser NN N
group NN N
and CC N
14.6 CD N
per IN N
cent NN N
for IN N
the DT N
cold JJ 1_i
knife NN 1_i
group NN N
. . N

This DT N
difference NN N
was VBD N
statistically RB N
significant JJ N
, , N
p RB N
less JJR N
than IN N
0.015 CD N
-- : N
Fischer NNP N
's POS N
exact JJ N
test NN N
. . N

Conization NN N
for IN N
treatment NN N
of IN N
premalignant JJ N
changes NNS N
of IN N
the DT N
cervix NN N
uteri NN N
will MD N
probably RB N
remain VB N
the DT N
treatment NN N
of IN N
choice NN N
for IN N
some DT N
time NN N
to TO N
come VB N
. . N

It PRP N
is VBZ N
our PRP$ N
opinion NN N
that IN N
, , N
in IN N
the DT N
future NN N
, , N
laser JJR 1_i
conization NN N
will MD N
replace VB N
cold JJ 1_i
knife NN 1_i
conization NN N
. . N

-DOCSTART- -X- O O

[ JJ N
Dose-reduced NNP N
antihypertensive JJ 3_i
agents NNS 3_i
-- : N
use NN N
in IN N
complex JJ N
nonmedicamentous JJ 3_i
therapy NN N
of IN N
hypertension NN N
] NNP N
. . N

In IN N
order NN N
to TO N
estimate VB N
the DT N
influence NN N
of IN N
a DT N
non-medicamentous JJ 3_i
therapy NN 3_i
( ( 3_i
CNT NNP 3_i
) ) 3_i
on IN N
the DT N
consumption NN N
of IN N
medicaments NNS N
and CC N
coronary JJ N
risk NN N
in IN N
high JJ N
blood NN N
pressure NN N
73 CD N
hypertensives NNS N
of IN N
a DT N
medicamentously RB N
stabilized VBN N
CNT-group NNP N
were VBD N
examined VBN N
in IN N
comparison NN N
to TO N
a DT N
group NN N
of IN N
the DT N
same JJ N
size NN N
of IN N
patients NNS N
with IN N
hypertension NN N
who WP N
were VBD N
managed VBN N
exclusively RB N
medicamentously RB N
for IN N
behaviour NN N
of IN N
blood NN N
pressure NN N
, , N
need NN N
of IN N
antihypertensive JJ 3_i
drugs NNS 3_i
and CC N
changes NNS N
of IN N
hypertension-associated JJ N
risk NN N
factors NNS N
. . N

After IN N
an DT N
exactly RB N
controlled VBN N
6-month JJ N
treatment NN N
hypertensives NNS N
with IN N
additionally RB N
recommended VBN N
far-reaching NN N
CNT NNP N
showed VBD N
an DT N
economization NN N
of IN N
medicaments NNS N
by IN N
scarcely RB N
the DT N
half NN N
in IN N
comparison NN N
to TO N
the DT N
reference NN N
group NN N
. . N

By IN N
means NNS N
of IN N
suitable JJ N
control NN N
methods VBZ N
a DT N
causal JJ N
non-medicamentously RB 3_i
conditioned JJ N
decrease NN N
of IN N
blood NN N
pressure NN N
could MD N
be VB N
excluded VBN N
. . N

A DT N
different JJ N
need NN N
of IN N
antihypertensive JJ 3_i
drugs NNS 3_i
was VBD N
simulated VBN N
by IN N
the DT N
exacter JJ N
intake NN N
of IN N
medicaments NNS N
in IN N
the DT N
index-patients NNS N
. . N

Notwithstanding VBG N
the DT N
metabolic JJ N
effects NNS N
of IN N
the DT N
additional JJ N
therapy NN N
have VBP N
induced VBN N
a DT N
positive JJ N
change NN N
of IN N
atherogenic JJ N
lipids NNS N
. . N

The DT N
examinations NNS N
indicate VBP N
in IN N
general JJ N
the DT N
difficulty NN N
of IN N
the DT N
judgement NN N
of IN N
efficacy NN N
of IN N
non-medicamentous JJ 3_i
therapeutic JJ 3_i
measures NNS N
in IN N
connection NN N
with IN N
a DT N
rational JJ N
dose-reduced JJ N
long-term JJ N
therapy NN N
with IN N
antihypertensive JJ N
drugs NNS N
. . N

-DOCSTART- -X- O O

Pilot NNP N
comparison NN N
between IN N
potassium NN 1_i
titanyl NN 1_i
phosphate NN 1_i
laser NN 1_i
and CC N
bipolar JJ 1_i
radiofrequency NN 1_i
in IN N
paediatric JJ N
tonsillectomy NN N
. . N

OBJECTIVES NNP N
To TO N
compare VB N
the DT N
advantages NNS N
and CC N
disadvantages NNS N
of IN N
potassium NN 1_i
titanyl NN 1_i
phosphate NN 1_i
laser NN 1_i
with IN N
those DT N
of IN N
bipolar JJ 1_i
radiofrequency NN 1_i
techniques NNS 1_i
, , N
in IN N
paediatric JJ N
tonsillectomy NN N
. . N

STUDY NNP N
DESIGN NNP N
Prospective NNP N
, , N
randomised VBD N
, , N
clinical JJ N
study NN N
. . N

PATIENTS NNP N
AND CC N
METHODS NNP N
From NNP N
July NNP N
2004 CD N
to TO N
April NNP N
2006 CD N
, , N
80 CD N
patients NNS N
aged VBN N
between IN N
10 CD N
and CC N
15 CD N
years NNS N
, , N
with IN N
tonsillectomy NN 1_i
planned VBN N
for IN N
chronic JJ N
tonsillitis NN N
, , N
were VBD N
included VBN N
in IN N
the DT N
study NN N
. . N

Children NNP N
were VBD N
prospectively RB N
randomised VBN N
into IN N
two CD N
equal JJ N
groups NNS N
: : N
potassium NN 1_i
titanyl NN 1_i
phosphate NN 1_i
laser NN 1_i
tonsillectomy NN 1_i
and CC N
bipolar JJ 1_i
radiofrequency NN 1_i
tonsillectomy NN 1_i
. . N

Operative JJ N
time NN N
and CC N
intra-operative JJ N
blood NN N
loss NN N
were VBD N
recorded VBN N
. . N

Patients NNS N
were VBD N
scheduled VBN N
for IN N
follow VB N
up RP N
during IN N
the DT N
first JJ N
, , N
second JJ N
and CC N
fourth JJ N
post-operative JJ N
weeks NNS N
. . N

They PRP N
were VBD N
asked VBN N
to TO N
record VB N
their PRP$ N
pain NN N
and CC N
discomfort NN N
on IN N
a DT N
standardised JJ N
visual JJ N
analogue NN N
scale NN N
, , N
from IN N
zero CD N
( ( N
no DT N
pain NN N
) ) N
to TO N
10 CD N
( ( N
severe JJ N
pain NN N
) ) N
. . N

Post-operative JJ N
complications NNS N
were VBD N
also RB N
recorded VBN N
and CC N
managed VBN N
. . N

RESULTS VB N
The DT N
potassium NN 1_i
titanyl NN 1_i
phosphate VBP 1_i
laser NN 1_i
group NN 1_i
showed VBD N
a DT N
slightly RB N
longer RBR N
operative JJ N
time NN N
( ( N
mean JJ N
12 CD N
minutes NNS N
) ) N
than IN N
the DT N
bipolar JJ N
radiofrequency NN N
group NN N
( ( N
mean JJ N
10 CD N
minutes NNS N
) ) N
. . N

Intra-operative JJ N
blood NN N
loss NN N
was VBD N
significantly RB N
less RBR N
in IN N
the DT N
potassium NN 1_i
titanyl NN 1_i
phosphate VBP 1_i
laser NN 1_i
group NN N
( ( N
mean JJ N
21 CD N
cm3 NN N
) ) N
than IN N
in IN N
the DT N
bipolar JJ 1_i
radiofrequency NN 1_i
group NN 1_i
( ( N
mean JJ N
30 CD N
cm3 NN N
) ) N
. . N

In IN N
the DT N
first JJ N
week NN N
, , N
post-operative JJ N
pain NN N
scores NNS N
were VBD N
less RBR N
in IN N
the DT N
potassium NN 1_i
titanyl NN 1_i
phosphate VBP 1_i
laser NN 1_i
group NN N
than IN N
in IN N
the DT N
bipolar JJ N
radiofrequency NN N
group NN N
( ( N
means VBZ N
7.5 CD N
and CC N
8.5 CD N
, , N
respectively RB N
) ) N
. . N

However RB N
, , N
in IN N
the DT N
second JJ N
week NN N
pain NN N
scores NNS N
increased VBD N
more RBR N
in IN N
the DT N
potassium NN N
titanyl NN N
phosphate VBP N
laser NN N
group NN N
than IN N
in IN N
the DT N
bipolar JJ N
radiofrequency NN N
group NN N
( ( N
means VBZ N
8.5 CD N
and CC N
6 CD N
, , N
respectively RB N
) ) N
. . N

In IN N
the DT N
fourth JJ N
week NN N
, , N
both DT N
groups NNS N
showed VBD N
equal JJ N
and CC N
nearly RB N
normal JJ N
pain NN N
scores NNS N
. . N

No DT N
case NN N
of IN N
reactionary JJ N
post-tonsillectomy JJ N
haemorrhage NN N
was VBD N
recorded VBN N
in IN N
either DT N
group NN N
. . N

Only RB N
one CD N
case NN N
of IN N
secondary JJ N
post-tonsillectomy JJ N
haemorrhage NN N
was VBD N
recorded VBN N
, , N
in IN N
the DT N
potassium NN N
titanyl NN N
phosphate VBP N
laser NN N
group NN N
( ( N
2.5 CD N
per IN N
cent NN N
) ) N
, , N
managed VBD N
conservatively RB N
. . N

CONCLUSION NNP N
Both NNP N
the DT N
potassium NN 1_i
titanyl NN 1_i
phosphate NN 1_i
and CC N
the DT N
bipolar JJ 1_i
radiofrequency NN 1_i
techniques NNS 1_i
were VBD N
safe JJ N
and CC N
easy JJ N
to TO N
use VB N
for IN N
tonsillectomy NN N
, , N
with IN N
reduced VBN N
operative JJ N
time NN N
, , N
blood NN N
loss NN N
and CC N
complication NN N
rates NNS N
and CC N
better JJR N
post-operative JJ N
general JJ N
patient NN N
condition NN N
. . N

Potassium NNP 1_i
titanyl JJ 1_i
phosphate NN 1_i
laser NN 1_i
resulted VBD N
in IN N
reduced JJ N
operative JJ N
bleeding NN N
and CC N
immediate JJ N
post-operative JJ N
pain NN N
, , N
compared VBN N
with IN N
the DT N
bipolar JJ N
radiofrequency NN N
technique NN N
. . N

However RB N
, , N
potassium NN 1_i
titanyl NN 1_i
phosphate VBP 1_i
laser NN 1_i
required VBN N
slightly RB N
more RBR N
operative JJ N
time NN N
and CC N
caused VBD N
more JJR N
late JJ N
post-operative JJ N
pain NN N
than IN N
the DT N
bipolar JJ N
radiofrequency NN N
technique NN N
. . N

The DT N
low JJ N
rate NN N
of IN N
recorded VBN N
complications NNS N
showed VBD N
that IN N
both DT N
techniques NNS N
cause VBP N
little JJ N
damage NN N
to TO N
the DT N
tonsillar JJ N
bed NN N
during IN N
dissection NN N
, , N
thus RB N
minimising VBG N
complications NNS N
. . N

-DOCSTART- -X- O O

Partial JJ N
depletion NN N
of IN N
tissue NN N
factor NN N
pathway NN N
inhibitor NN N
during IN N
subcutaneous JJ N
administration NN N
of IN N
unfractionated JJ N
heparin NN 3_i
, , N
but CC N
not RB N
with IN N
two CD N
low JJ N
molecular JJ N
weight NN N
heparins NNS N
. . N

Tissue NNP N
factor NN N
pathway NN N
inhibitor NN N
( ( N
TFPI NNP N
) ) N
is VBZ N
released VBN N
to TO N
circulating VBG N
blood NN N
after IN N
intravenous JJ N
( ( N
i.v JJ N
. . N

) ) N
and CC N
subcutaneous JJ N
( ( N
s.c. NN N
) ) N
injections NNS N
of IN N
heparins NNS N
, , N
and CC N
may MD N
thus RB N
contribute VB N
to TO N
the DT N
antithrombotic JJ N
effect NN N
of IN N
heparins NNS N
. . N

We PRP N
have VBP N
recently RB N
shown VBN N
that IN N
total JJ N
TFPI NNP N
activity NN N
, , N
plasma VBP N
free JJ N
TFPI NNP N
antigen NN N
, , N
and CC N
heparin NN N
releasable JJ N
TFPI NNP N
were VBD N
partially RB N
depleted VBN N
during IN N
repeated VBN N
and CC N
continuous JJ N
i.v NN N
. . N

infusion NN N
of IN N
unfractionated JJ 3_i
heparin NN 3_i
( ( N
UFH NNP N
) ) N
, , N
but CC N
not RB N
during IN N
s.c. JJ N
treatment NN N
with IN N
a DT N
low JJ N
molecular JJ N
weight NN N
heparin NN N
( ( N
LMWH NNP N
) ) N
. . N

The DT N
difference NN N
may MD N
be VB N
attributed VBN N
to TO N
a DT N
different JJ N
mode NN N
of IN N
action NN N
or CC N
the DT N
different JJ N
mode NN N
of IN N
administration NN N
. . N

In IN N
the DT N
present JJ N
randomized VBN N
cross-over NN N
study NN N
, , N
s.c. JJ N
administration NN N
of IN N
therapeutic JJ N
doses NNS N
of IN N
UFH NNP 3_i
was VBD N
compared VBN N
with IN N
s.c. JJ N
administration NN N
of IN N
two CD N
LMWHs NNP 3_i
. . N

12 CD N
healthy JJ N
male NN N
volunteers NNS N
were VBD N
treated VBN N
for IN N
3 CD N
d NN N
with IN N
UFH NNP 3_i
, , N
250 CD N
U/kg NNP N
twice RB N
daily RB N
, , N
dalteparin NN 3_i
, , N
200 CD N
U/kg NNP N
once RB N
daily RB N
, , N
and CC N
enoxaparin RB 3_i
, , N
1.5 CD N
mg/kg NN N
once RB N
daily JJ N
. . N

Six CD N
participants NNS N
were VBD N
also RB N
treated VBN N
with IN N
UFH NNP 3_i
, , N
300 CD N
U/kg NNP N
once RB N
daily RB N
. . N

On IN N
day NN N
5 CD N
a DT N
single JJ N
dose NN N
of IN N
either DT N
drug NN N
was VBD N
given VBN N
. . N

Peak NNP N
levels NNS N
of IN N
total JJ N
TFPI NNP N
activity NN N
and CC N
free JJ N
TFPI NNP N
antigen NN N
were VBD N
detected VBN N
1 CD N
h NN N
after IN N
injection NN N
, , N
whereas IN N
maximal JJ N
prolongation NN N
of IN N
activated VBN N
partial JJ N
thromboplastin NN N
time NN N
( ( N
APTT NNP N
) ) N
and CC N
peak JJ N
levels NNS N
of IN N
anti-factor JJ N
Xa NNP N
activity NN N
and CC N
anti-factor NN N
IIa NNP N
activity NN N
were VBD N
detected VBN N
after IN N
4 CD N
h. NN N
On IN N
UFH NNP 3_i
administered VBD N
twice RB N
daily RB N
, , N
free JJ N
TFPI NNP N
antigen NN N
decreased VBN N
by IN N
44 CD N
% NN N
from IN N
baseline JJ N
level NN N
before IN N
the DT N
first JJ N
injection NN N
on IN N
day NN N
1 CD N
to TO N
pre-injection NN N
level NN N
on IN N
day NN N
5 CD N
. . N

On IN N
UFH NNP 3_i
administered VBD N
once RB N
daily JJ N
, , N
basal JJ N
free JJ N
TFPI NNP N
antigen NN N
decreased VBN N
by IN N
50 CD N
% NN N
, , N
56 CD N
% NN N
and CC N
27 CD N
% NN N
on IN N
day NN N
2 CD N
, , N
3 CD N
and CC N
5 CD N
respectively RB N
, , N
compared VBN N
with IN N
day NN N
1 CD N
. . N

Minimal JJ N
depletion NN N
of IN N
TFPI NNP N
was VBD N
detected VBN N
during IN N
treatment NN N
with IN N
LMWHs NNP N
. . N

The DT N
study NN N
demonstrates VBZ N
the DT N
different JJ N
modes NNS N
of IN N
action NN N
of IN N
LMWHs NNP 3_i
and CC N
UFH NNP 3_i
and CC N
may MD N
help VB N
to TO N
explain VB N
the DT N
superior JJ N
antithrombotic JJ N
efficacy NN N
of IN N
LMWHs NNP N
. . N

-DOCSTART- -X- O O

Effects NNS N
of IN N
20 CD N
mg NNS N
rosuvastatin NN 3_i
on IN N
VLDL1- NNP N
, , N
VLDL2- NNP N
, , N
IDL- NNP N
and CC N
LDL-ApoB NNP N
kinetics NNS N
in IN N
type NN N
2 CD N
diabetes NNS N
. . N

AIMS/HYPOTHESIS NNP N
In IN N
addition NN N
to TO N
its PRP$ N
efficacy NN N
in IN N
reducing VBG N
LDL-cholesterol NNP N
, , N
rosuvastatin NN 3_i
has VBZ N
been VBN N
shown VBN N
to TO N
significantly RB N
decrease VB N
plasma NN N
triacylglycerol NN N
. . N

The DT N
use NN N
of IN N
rosuvastatin NN 3_i
may MD N
be VB N
beneficial JJ N
in IN N
patients NNS N
with IN N
type JJ N
2 CD N
diabetes NNS N
, , N
who WP N
usually RB N
have VBP N
increased VBN N
triacylglycerol NN N
levels NNS N
. . N

However RB N
, , N
its PRP$ N
effects NNS N
on IN N
the DT N
metabolism NN N
of IN N
triacylglycerol-rich JJ N
lipoproteins NNS N
in IN N
type NN N
2 CD N
diabetic JJ N
patients NNS N
remains VBZ N
unknown JJ N
. . N

METHODS NNP N
We PRP N
performed VBD N
a DT N
randomised JJ N
double-blind NN N
crossover NN N
trial NN N
of IN N
6-week JJ N
treatment NN N
with IN N
placebo NN 7_i
or CC N
rosuvastatin VB 3_i
20 CD N
mg NN N
in IN N
eight CD N
patients NNS N
with IN N
type JJ N
2 CD N
diabetes NNS N
who WP N
were VBD N
being VBG N
treated VBN N
with IN N
oral JJ N
glucose-lowering JJ N
agents NNS N
. . N

In IN N
each DT N
patient NN N
, , N
an DT N
in IN N
vivo NN N
kinetic JJ N
study NN N
of IN N
apolipoprotein NN N
B NNP N
( ( N
ApoB NNP N
) ) N
-containing VBG N
lipoproteins NNS N
with IN N
[ JJ N
13C CD N
] JJ N
leucine NN N
was VBD N
performed VBN N
at IN N
the DT N
end NN N
of IN N
each DT N
treatment NN N
period NN N
. . N

A DT N
central JJ N
randomisation NN N
centre NN N
used VBN N
computer-generated JJ N
tables NNS N
to TO N
allocate VB N
treatments NNS N
. . N

Participants NNS N
, , N
caregivers NNS N
and CC N
those DT N
assessing VBG N
the DT N
outcomes NNS N
were VBD N
blinded VBN N
to TO N
group NN N
assignment NN N
. . N

RESULTS NNP N
Rosuvastatin NNP 3_i
20 CD N
mg NN N
significantly RB N
reduced VBN N
plasma JJ N
LDL-cholesterol NNP N
, , N
triacylglycerol NN N
and CC N
total JJ N
ApoB NNP N
. . N

It PRP N
also RB N
significantly RB N
reduced VBN N
ApoB NNP N
pool NN N
sizes NNS N
of IN N
larger JJR N
triacylglycerol-rich JJ N
VLDL NNP N
particles NNS N
( ( N
VLDL1 NNP N
; : N
p VBZ N
= $ N
0.011 CD N
) ) N
, , N
smaller JJR N
VLDL NNP N
particles NNS N
( ( N
VLDL2 NNP N
; : N
p VBZ N
= $ N
0.011 CD N
) ) N
, , N
intermediate JJ N
density NN N
lipoprotein NN N
( ( N
IDL NNP N
; : N
p VBZ N
= $ N
0.011 CD N
) ) N
and CC N
LDL NNP N
( ( N
p JJ N
= NNP N
0.011 CD N
) ) N
. . N

This DT N
reduction NN N
was VBD N
associated VBN N
with IN N
a DT N
significant JJ N
increase NN N
in IN N
the DT N
total JJ N
fractional JJ N
catabolic NN N
rate NN N
of IN N
VLDL1-ApoB NNP N
( ( N
6.70 CD N
+/- JJ N
3.24 CD N
vs JJ N
4.52 CD N
+/- JJ N
2.34 CD N
pool/day NN N
, , N
p NN N
= NNP N
0.049 CD N
) ) N
, , N
VLDL2-ApoB NNP N
( ( N
8.72 CD N
+/- JJ N
3.37 CD N
vs JJ N
5.36 CD N
+/- JJ N
2.64 CD N
, , N
p NN N
= NNP N
0.011 CD N
) ) N
, , N
IDL-ApoB NNP N
( ( N
7.06 CD N
+/- JJ N
1.68 CD N
vs JJ N
4.21 CD N
+/- JJ N
1.51 CD N
, , N
p NN N
= NNP N
0.011 CD N
) ) N
and CC N
LDL-ApoB NNP N
( ( N
1.02 CD N
+/- JJ N
0.27 CD N
vs JJ N
0.59 CD N
+/- JJ N
0.13 CD N
, , N
p NN N
= NNP N
0.011 CD N
) ) N
. . N

Rosuvastatin NNPS 3_i
did VBD N
not RB N
change VB N
the DT N
production NN N
rates NNS N
of IN N
VLDL2- NNP N
, , N
IDL- NNP N
or CC N
LDL- NNP N
, , N
but CC N
did VBD N
reduce VB N
VLDL1-ApoB NNP N
production NN N
rate NN N
( ( N
12.4 CD N
+/- JJ N
4.5 CD N
vs JJ N
19.5 CD N
+/- JJ N
8.4 CD N
mg NN N
kg NN N
( ( N
-1 JJ N
) ) N
day NN N
( ( N
-1 NNP N
) ) N
, , N
p JJ N
= NNP N
0.035 CD N
) ) N
. . N

No DT N
side NN N
effects NNS N
of IN N
rosuvastatin NN N
were VBD N
observed VBN N
during IN N
the DT N
study NN N
. . N

CONCLUSIONS/INTERPRETATION NNP N
In IN N
type NN N
2 CD N
diabetic JJ N
patients NNS N
rosuvastatin VBP 3_i
20 CD N
mg NN N
not RB N
only RB N
induces VBZ N
a DT N
significant JJ N
increase NN N
of IN N
LDL-ApoB JJ N
catabolism NN N
( ( N
73 CD N
% NN N
) ) N
, , N
but CC N
also RB N
has VBZ N
favourable JJ N
effects NNS N
on IN N
the DT N
catabolism NN N
of IN N
triacylglycerol-rich JJ N
lipoproteins NNS N
, , N
e.g NN N
. . N

a DT N
significant JJ N
increase NN N
in IN N
the DT N
catabolism NN N
of IN N
VLDL1-ApoB NNP N
( ( N
48 CD N
% NN N
) ) N
, , N
VLDL2-ApoB NNP N
( ( N
63 CD N
% NN N
) ) N
and CC N
IDL-ApoB NNP N
( ( N
68 CD N
% NN N
) ) N
, , N
and CC N
a DT N
reduction NN N
in IN N
the DT N
production NN N
rate NN N
of IN N
VLDL1-ApoB NNP N
( ( N
-36 CD N
% NN N
) ) N
. . N

The DT N
effects NNS N
of IN N
rosuvastatin NN 3_i
on IN N
the DT N
metabolism NN N
of IN N
triacylglycerol-rich JJ N
lipoproteins NNS N
may MD N
be VB N
beneficial JJ N
for IN N
prevention NN N
of IN N
atherosclerosis NN N
in IN N
type NN N
2 CD N
diabetic JJ N
patients NNS N
. . N

-DOCSTART- -X- O O

Sunbathing VBG N
and CC N
sunbed VBN N
use NN N
related VBN N
to TO N
self-image NN N
in IN N
a DT N
randomized JJ N
sample NN N
of IN N
Swedish JJ N
adolescents NNS N
. . N

In IN N
1996 CD N
a DT N
randomized JJ N
sample NN N
of IN N
4,020 CD N
Swedish JJ N
adolescents NNS N
from IN N
three CD N
birth NN N
cohorts NNS N
were VBD N
sent VBN N
a DT N
questionnaire NN N
consisting NN N
of IN N
50 CD N
items NNS N
concerning VBG N
habitual JJ N
sun-related JJ N
behaviours NNS N
and CC N
attitudes NNS N
, , N
knowledge NN N
about IN N
melanoma NN N
, , N
risk NN N
perception NN N
and CC N
self-image NN N
. . N

A DT N
total NN N
of IN N
2,615 CD N
questionnaires NNS N
were VBD N
returned VBN N
. . N

Girls NNP N
sunbathed VBD N
and CC N
used VBD N
sunbeds NNS N
more RBR N
than IN N
boys NNS N
at IN N
all DT N
ages NNS N
. . N

Sunbathing VBG N
and CC N
sunbed VBN N
use NN N
increased VBN N
with IN N
age NN N
. . N

Boys NNS N
who WP N
were VBD N
most RBS N
satisfied JJ N
and CC N
girls NNS N
least JJS N
satisfied JJ N
with IN N
themselves PRP N
sunbathed VBD N
most JJS N
. . N

Those DT N
who WP N
were VBD N
least JJS N
satisfied JJ N
with IN N
themselves PRP N
used VBD N
sunbeds NNS N
most RBS N
frequently RB N
. . N

Girls NNP N
reported VBD N
a DT N
higher JJR N
perceived JJ N
susceptibility NN N
to TO N
melanoma VB N
than IN N
did VBD N
boys VB N
. . N

The DT N
perception NN N
of IN N
susceptibility NN N
increased VBN N
with IN N
age NN N
. . N

Those DT N
who WP N
were VBD N
least JJS N
satisfied JJ N
with IN N
themselves PRP N
reported VBD N
feeling VBG N
most RBS N
susceptible JJ N
. . N

The DT N
overall JJ N
main JJ N
reason NN N
for IN N
sunbathing NN N
was VBD N
appearance NN N
, , N
both DT N
for IN N
own JJ N
sunbathing NN N
, , N
and CC N
to TO N
an DT N
even RB N
higher JJR N
degree NN N
, , N
as IN N
a DT N
supposed JJ N
reason NN N
for IN N
other JJ N
adolescents NNS N
' POS N
behaviour NN N
, , N
and CC N
was VBD N
reported VBN N
most JJS N
frequently RB N
by IN N
girls NNS N
and CC N
the DT N
older JJR N
age NN N
groups NNS N
. . N

The DT N
second JJ N
most RBS N
'important JJ N
' POS N
reason NN N
for IN N
sunbathing NN N
was VBD N
'feeling VBG N
warm JJ N
and CC N
comfortable JJ N
' '' N
. . N

Preventive JJ N
programmes NNS N
aimed VBN N
at IN N
a DT N
change NN N
of IN N
sun NN N
related VBN N
behaviours NNS N
among IN N
Swedish JJ N
adolescents NNS N
have VBP N
to TO N
be VB N
tailored VBN N
to TO N
the DT N
climate NN N
and CC N
cultural JJ N
conditions NNS N
and CC N
must MD N
take VB N
into IN N
account NN N
that IN N
having VBG N
a DT N
tan NN N
, , N
and CC N
the DT N
warmth NN N
of IN N
the DT N
sun NN N
, , N
are VBP N
highly RB N
valued VBN N
by IN N
most JJS N
adolescents NNS N
. . N

-DOCSTART- -X- O O

Comparison NNP N
of IN N
the DT N
in IN N
vitro NN N
and CC N
in IN N
vivo JJ N
release NN N
of IN N
digoxin NN 3_i
from IN N
four CD N
different JJ N
soft JJ N
gelatin NN N
capsule NN 3_i
formulations NNS 3_i
. . 3_i

A DT N
blinded JJ N
, , N
four-treatment JJ N
crossover NN N
study NN N
in IN N
16 CD N
normal JJ N
adult NN N
male NN N
volunteers NNS N
compared VBN N
plasma JJ N
concentrations NNS N
and CC N
urinary JJ N
excretion NN N
of IN N
digoxin NN 3_i
, , N
measured VBN N
by IN N
radioimmunoassay NN N
, , N
after IN N
oral JJ N
administration NN N
of IN N
soft JJ 3_i
gelatin NN 3_i
capsule NN 3_i
formulations NNS 3_i
of IN 3_i
digoxin NN 3_i
. . 3_i

Four CD N
0.4-mg JJ N
formulations NNS N
with IN N
different JJ N
in IN N
vitro NN N
burst NN N
times NNS N
and CC N
dissolution NN N
rates NNS N
were VBD N
administered VBN N
, , N
with IN N
2-week JJ N
intervals NNS N
between IN N
treatments NNS N
. . N

The DT N
two CD N
capsules NNS N
with IN N
lowest JJS N
in IN N
vitro NN N
burst NN N
times NNS N
( ( N
2.9 CD N
and CC N
16 CD N
min NN N
) ) N
gave VBD N
comparable JJ N
in IN N
vivo JJ N
results NNS N
. . N

The DT N
other JJ N
two CD N
capsules NNS N
, , N
with IN N
in IN N
vitro NN N
burst NN N
times NNS N
of IN N
62 CD N
and CC N
229 CD N
min NN N
, , N
produced VBD N
significant JJ N
delays NNS N
in IN N
digoxin NN N
absorption NN N
. . N

In IN N
vitro-in JJ N
vivo NN N
correlations NNS N
were VBD N
obtained VBN N
by IN N
comparing VBG N
the DT N
logarithm NN N
of IN N
the DT N
in IN N
vitro JJ N
burst NN N
time NN N
with IN N
time NN N
to TO N
peak VB N
plasma JJ N
level NN N
and CC N
the DT N
time NN N
to TO N
the DT N
first JJ N
measurable JJ N
plasma NN N
level NN N
( ( N
> CD N
or CC N
= VB N
0 CD N
. . N

05 CD N
ng/ml NN N
) ) N
. . N

Also RB N
, , N
the DT N
mean JJ N
time NN N
to TO N
peak VB N
plasma JJ N
level NN N
correlated VBN N
with IN N
the DT N
logarithm NN N
of IN N
the DT N
time NN N
required VBN N
to TO N
release VB N
either RB N
50 CD N
% NN N
or CC N
85 CD N
% NN N
of IN N
the DT N
digoxin NN N
in IN N
vitro NN N
. . N

No DT N
significant JJ N
changes NNS N
were VBD N
found VBN N
in IN N
the DT N
amount NN N
of IN N
digoxin NN 3_i
absorbed VBN N
from IN N
each DT N
capsule NN N
as IN N
determined VBN N
by IN N
urinary JJ N
excretion NN N
or CC N
AUC0-infinity NN N
. . N

-DOCSTART- -X- O O

Autism-Spectrum JJ 6_i
Quotient-Japanese JJ 6_i
version NN N
and CC N
its PRP$ N
short JJ N
forms NNS N
for IN N
screening VBG N
normally RB N
intelligent JJ N
persons NNS N
with IN N
pervasive JJ N
developmental NN N
disorders NNS N
. . N

A DT N
Japanese JJ 6_i
version NN 6_i
of IN 6_i
the DT 6_i
Autism NNP 6_i
Spectrum NNP 6_i
Quotient NNP 6_i
( ( 6_i
AQ NNP 6_i
) ) 6_i
, , 6_i
AQ-J NNP 6_i
was VBD N
administered VBN N
to TO N
25 CD N
normally RB N
intelligent JJ N
high-functioning JJ N
pervasive JJ N
developmental NN N
disorder NN N
( ( N
HPDD NNP N
) ) N
patients NNS N
( ( N
mean JJ N
age NN N
, , N
24.2 CD N
years NNS N
; : N
24 CD N
male NN N
, , N
one CD N
female NN N
) ) N
and CC N
215 CD N
controls NNS N
( ( N
mean JJ N
age NN N
, , N
30.4 CD N
years NNS N
; : N
86 CD N
male NN N
, , N
129 CD N
female NN N
) ) N
randomly RB N
selected VBN N
from IN N
the DT N
general JJ N
population NN N
. . N

The DT N
AQ-J NNP 6_i
had VBD N
satisfactory JJ N
internal JJ N
consistency NN N
reliability NN N
( ( N
Cronbach NNP N
's POS N
alpha NN N
> VBD N
0.70 CD N
in IN N
the DT N
two CD N
groups NNS N
) ) N
, , N
test-retest JJ N
reliability NN N
, , N
and CC N
discriminant JJ N
validity NN N
[ NNP N
i.e NN N
. . N

the DT N
AQ-J NNP N
score NN N
was VBD N
significantly RB N
higher JJR N
in IN N
the DT N
HPDD NNP N
( ( N
mean NN N
, , N
29.6 CD N
) ) N
than IN N
controls NNS N
( ( N
mean NN N
, , N
22.2 CD N
) ) N
] NN N
. . N

At IN N
a DT N
cut-off NN N
of IN N
26 CD N
, , N
the DT N
AQ-J NNP 6_i
had VBD N
satisfactory JJ N
sensitivity NN N
, , N
specificity NN N
, , N
and CC N
negative JJ N
predictive JJ N
value NN N
, , N
but CC N
it PRP N
had VBD N
low JJ N
positive JJ N
predictive NN N
value NN N
( ( N
0.24 CD N
) ) N
possibly RB N
due JJ N
to TO N
the DT N
facts NNS N
that IN N
the DT N
25 CD N
mild JJ N
HPDD NNP N
patients NNS N
scored VBD N
lower JJR N
and CC N
the DT N
controls NNS N
scored VBD N
higher JJR N
on IN N
the DT N
AQ-J NNP 6_i
than IN N
British NNP N
counterparts NNS N
on IN N
the DT N
AQ NNP N
. . N

The DT N
AQ-J-21 NNP 6_i
( ( N
consisting VBG N
of IN N
21 CD N
items NNS N
significantly RB N
associated VBN N
with IN N
HPDD NNP N
diagnosis NN N
) ) N
and CC N
the DT N
AQ-J-10 NNP 6_i
( ( N
consisting VBG N
of IN N
10 CD N
of IN N
the DT N
21 CD N
items NNS N
with IN N
an DT N
effect NN N
size NN N
> NNP N
0.17 CD N
) ) N
had VBD N
higher JJR N
, , N
although IN N
not RB N
satisfactory JJ N
, , N
positive JJ N
predictive JJ N
values NNS N
of IN N
0.35 CD N
and CC N
0.46 CD N
at IN N
cut-offs NNS N
of IN N
12 CD N
and CC N
7 CD N
, , N
respectively RB N
, , N
than IN N
the DT N
AQ-J NNP 6_i
. . 6_i

The DT N
AQ-J JJ 6_i
and CC N
two CD N
short JJ N
forms NNS N
are VBP N
useful JJ N
not RB N
to TO N
predict VB N
but CC N
to TO N
rule VB N
out RP N
mild NN N
HPDD NNP N
, , N
the DT N
most RBS N
difficult JJ N
part NN N
of IN N
HPDD NNP N
to TO N
be VB N
distinguished VBN N
from IN N
non-PDD JJ N
conditions NNS N
, , N
in IN N
persons NNS N
scoring VBG N
under IN N
the DT N
cut-offs NNS N
and CC N
to TO N
consider VB N
professionals NNS N
' POS N
examination NN N
of IN N
HPDD NNP N
in IN N
persons NNS N
scoring VBG N
over IN N
them PRP N
, , N
because IN N
their PRP$ N
negative JJ N
predictive JJ N
values NNS N
were VBD N
satisfactory JJ N
. . N

-DOCSTART- -X- O O

Effect NN N
of IN N
upper JJ N
arm NN N
brachial NN N
basilic NN N
and CC N
prosthetic JJ N
forearm NN N
arteriovenous JJ N
fistula NN N
on IN N
left JJ N
ventricular JJ N
hypertrophy NN N
. . N

BACKGROUND NNP N
Creation NNP N
of IN N
an DT N
arteriovenous JJ N
fistula NN N
( ( N
AVF NNP N
) ) N
may MD N
increase VB N
left VBD N
ventricular JJ N
hypertrophy NN N
in IN N
the DT N
hemodialysis NN N
population NN N
. . N

Aim NNP N
of IN N
this DT N
study NN N
was VBD N
to TO N
compare VB N
the DT N
effects NNS N
of IN N
a DT N
brachial-basilic JJ 2_i
( ( 2_i
BB NNP 2_i
) ) 2_i
AVF NNP 2_i
and CC N
the DT N
prosthetic JJ 2_i
brachial-antecubital JJ 2_i
forearm NN 2_i
loop NN 2_i
access NN 2_i
( ( N
PTFE NNP N
) ) N
on IN N
cardiac JJ N
performance NN N
. . N

METHODS JJ N
Patients NNPS N
were VBD N
randomized VBN N
to TO N
receive VB N
BB-AVF NNP 2_i
or CC 2_i
prosthetic JJ 2_i
brachial-antecubital JJ 2_i
forearm NN 2_i
loop NN 2_i
access NN 2_i
. . 2_i

Before IN N
and CC N
three CD N
months NNS N
after IN N
AVF NNP N
creation NN N
patients NNS N
underwent VBD N
an DT N
echocardiographic JJ N
examination NN N
. . N

Mann-Whitney JJ N
U-test NNP N
was VBD N
used VBN N
to TO N
compare VB N
relative JJ N
increase NN N
between IN N
the DT N
measured JJ N
cardiac JJ N
parameters NNS N
for IN N
the DT N
two CD N
groups NNS N
. . N

RESULTS NNP N
Twenty-seven JJ N
patients NNS N
participated VBN N
in IN N
the DT N
study NN N
. . N

The DT N
relative JJ N
increase NN N
in IN N
left JJ N
ventricular JJ N
parameters NNS N
was VBD N
not RB N
significantly RB N
different JJ N
between IN N
the DT N
two CD N
groups NNS N
. . N

Only RB N
left VBD N
ventricular JJ N
end-diastolic JJ N
diameter NN N
tended VBD N
to TO N
be VB N
of IN N
significance NN N
. . N

Mean NNP N
blood NN N
flow NN N
through IN N
the DT N
brachial JJ N
artery NN N
was VBD N
1680+/-156 JJ N
and CC N
1450+/-221 JJ N
mL/min NNS N
three CD N
months NNS N
after IN N
surgery NN N
for IN N
the DT N
PTFE NNP N
and CC N
the DT N
BB-AVF NNP N
group NN N
, , N
respectively RB N
. . N

CONCLUSION NN N
After IN N
three CD N
months NNS N
of IN N
follow-up NN N
, , N
changes NNS N
in IN N
cardiac JJ N
structure NN N
were VBD N
comparable JJ N
between IN N
patients NNS N
with IN N
BB NNP N
and CC N
PTFE NNP N
AVFs NNP N
. . N

Also RB N
access NN N
flow NN N
was VBD N
comparable JJ N
at IN N
this DT N
time NN N
. . N

In IN N
general JJ N
, , N
the DT N
effects NNS N
of IN N
creation NN N
of IN N
a DT N
fistula NN N
on IN N
LV NNP N
structure NN N
were VBD N
limited VBN N
. . N

Longer RBR N
follow VB N
up RP N
time NN N
may MD N
be VB N
needed VBN N
to TO N
explore VB N
the DT N
long JJ N
term NN N
effects NNS N
of IN N
different JJ N
vascular JJ N
accesses NNS N
on IN N
cardiac JJ N
function NN N
. . N

-DOCSTART- -X- O O

Clonidine NN 3_i
increases VBZ N
the DT N
sweating NN N
threshold NN N
, , N
but CC N
does VBZ N
not RB N
reduce VB N
the DT N
gain NN N
of IN N
sweating VBG N
. . N

We PRP N
tested VBD N
the DT N
hypothesis NN N
that WDT N
clonidine NN 3_i
produces VBZ N
a DT N
dose-dependent JJ N
increase NN N
in IN N
the DT N
sweating NN N
threshold NN N
but CC N
does VBZ N
not RB N
reduce VB N
the DT N
gain NN N
of IN N
sweating VBG N
. . N

Six NNP N
healthy JJ N
male NN N
volunteers NNS N
were VBD N
evaluated VBN N
, , N
each DT N
on IN N
three CD N
separate JJ N
days NNS N
in IN N
random JJ N
order NN N
. . N

In IN N
one CD N
, , N
saline NN 7_i
was VBD N
administered VBN N
; : N
in IN N
another DT N
, , N
a DT N
2-micrograms/kg JJ N
bolus NN N
of IN N
clonidine NN 3_i
was VBD N
followed VBN N
by IN N
an DT N
infusion NN N
at IN N
2 CD N
micrograms.kg-1.h-1 NN N
, , N
and CC N
on IN N
a DT N
third JJ N
day NN N
, , N
a DT N
4-micrograms/kg JJ N
bolus NN N
was VBD N
followed VBN N
by IN N
an DT N
infusion NN N
at IN N
4 CD N
micrograms.kg-1.h-1 JJ N
. . N

Core NN N
temperature NN N
was VBD N
measured VBN N
at IN N
the DT N
tympanic JJ N
membrane NN N
and CC N
mean JJ N
skin NN N
temperature NN N
was VBD N
determined VBN N
from IN N
four CD N
sites NNS N
. . N

A DT N
chest JJ N
sweating NN N
rate NN N
of IN N
40 CD N
g.m-2.h-1 NN N
was VBD N
considered VBN N
significant JJ N
. . N

The DT N
core NN N
temperature NN N
triggering VBG N
sweating NN N
, , N
adjusted VBN N
to TO N
a DT N
designated VBN N
mean NN N
skin JJ N
temperature NN N
of IN N
34 CD N
degrees NNS N
C NNP N
, , N
identified VBD N
the DT N
threshold NN N
for IN N
this DT N
response NN N
. . N

Gain NNP N
was VBD N
defined VBN N
by IN N
the DT N
adjusted VBN N
core NN N
temperature NN N
increase NN N
required VBN N
to TO N
augment VB N
sweating VBG N
from IN N
100 CD N
to TO N
300 CD N
g.m-2.h-1 NN N
. . N

degree JJ N
C-1 NNP N
. . N

Plasma NNP N
clonidine JJ N
concentrations NNS N
were VBD N
0.8 CD N
+/- JJ N
0.1 CD N
and CC N
1.6 CD N
+/- JJ N
0.2 CD N
ng/mL NN N
on IN N
the DT N
small- JJ N
and CC N
large-dose JJ N
days NNS N
, , N
respectively RB N
. . N

Clonidine NNP N
administration NN N
increased VBD N
the DT N
sweating NN N
threshold VBD N
approximately RB N
0.4 CD N
degree JJ N
C NNP N
( ( N
P NNP N
< NNP N
0.05 CD N
) ) N
, , N
but CC N
the DT N
increase NN N
was VBD N
comparable JJ N
at IN N
each DT N
dose NN N
. . N

The DT N
gain NN N
of IN N
sweating NN N
was VBD N
approximately RB N
0.2 CD N
degree JJ N
C NNP N
and CC N
was VBD N
not RB N
influenced VBN N
by IN N
clonidine JJ N
administration NN N
. . N

The DT N
thermoregulatory JJ N
effects NNS N
of IN N
clonidine NN N
thus RB N
resemble JJ N
those DT N
of IN N
volatile JJ N
anesthetics NNS N
, , N
opioids NNS N
, , N
and CC N
propofol NN N
. . N

These DT N
data NNS N
suggest VBP N
that IN N
the DT N
antishivering VBG N
effect NN N
of IN N
clonidine NN N
results NNS N
from IN N
central JJ N
thermoregulatory JJ N
inhibition NN N
rather RB N
than IN N
a DT N
specific JJ N
peripheral JJ N
action NN N
on IN N
thermogenic JJ N
muscular JJ N
activity NN N
. . N

Unlike IN N
other JJ N
sedatives NNS N
and CC N
anesthetics NNS N
, , N
the DT N
concentration-dependence NN N
of IN N
clonidine NN N
demonstrates VBZ N
a DT N
ceiling NN N
beyond IN N
which WDT N
the DT N
administration NN N
of IN N
an DT N
additional JJ N
drug NN N
fails NNS N
to TO N
enhance VB N
the DT N
effect NN N
, , N
suggesting VBG N
that IN N
the DT N
thermoregulatory JJ N
effect NN N
of IN N
clonidine NN N
may MD N
be VB N
limited VBN N
, , N
even RB N
at IN N
high JJ N
plasma NN N
concentrations NNS N
. . N

The DT N
gain NN N
of IN N
sweating NN N
was VBD N
well RB N
preserved JJ N
indicating VBG N
that IN N
this DT N
response NN N
remains VBZ N
effective JJ N
in IN N
the DT N
presence NN N
of IN N
sedatives NNS N
and CC N
anesthetics NNS N
. . N

-DOCSTART- -X- O O

Effect NN N
of IN N
a DT N
multi-faceted JJ 2_i
intervention NN 2_i
on IN N
gingival JJ N
health NN N
among IN N
adults NNS N
with IN N
systemic JJ N
sclerosis NN N
. . N

OBJECTIVES NNP N
To TO N
evaluate VB N
the DT N
effect NN N
of IN N
adaptive JJ 1_i
oral JJ 1_i
hygiene NN 1_i
devices NNS 1_i
and CC N
orofacial JJ 2_i
exercise NN 2_i
to TO N
improve VB N
gingival JJ N
health NN N
among IN N
adults NNS N
with IN N
systemic JJ N
sclerosis NN N
( ( N
SSc NNP N
) ) N
. . N

METHODS NNP N
Forty-eight JJ N
patients NNS N
with IN N
SSc NNP N
were VBD N
assigned VBN N
randomly RB N
to TO N
the DT N
multifaceted VBN 2_i
oral JJ 2_i
health NN 2_i
intervention NN 2_i
or CC N
usual JJ 7_i
dental JJ 7_i
care NN 7_i
control NN N
group NN N
. . N

Participants NNS N
in IN N
the DT N
intervention NN N
group NN N
received VBD N
a DT N
rechargeable JJ N
, , N
powered JJ N
Oral-B? NNP 2_i
oscillating-rotating-pulsating NN 2_i
toothbrush NN 2_i
and CC N
a DT N
Reach? NNP 2_i
Access? NNP 2_i
Flosser NNP 2_i
that WDT N
has VBZ N
a DT N
toothbrush-like JJ N
handle NN N
. . N

For IN N
those DT N
with IN N
an DT N
oral JJ N
aperture NN N
of IN N
less JJR N
than IN N
40 CD N
mm NN N
, , N
orofacial JJ N
exercises NNS N
were VBD N
taught VBN N
. . N

Participants NNS N
in IN N
the DT N
control NN N
group NN N
were VBD N
each DT N
given VBN N
a DT N
manual JJ N
toothbrush NN N
and CC N
dental JJ N
floss NN N
. . N

Participants NNS N
in IN N
both DT N
groups NNS N
received VBD N
instructions NNS N
and CC N
demonstration NN N
on IN N
the DT N
use NN N
of IN N
the DT N
devices NNS N
, , N
and CC N
were VBD N
requested VBN N
to TO N
perform VB N
the DT N
respective JJ N
intervention NN N
twice RB N
a DT N
day NN N
for IN N
6 CD N
months NNS N
. . N

Evaluations NNS N
were VBD N
at IN N
baseline NN N
, , N
3- JJ N
, , N
and CC N
6-months NNS N
. . N

The DT N
main JJ N
outcome NN N
was VBD N
gingival JJ N
index NN N
( ( N
GI NNP N
) ) N
, , N
an DT N
indicator NN N
of IN N
gingival JJ N
inflammation NN N
. . N

RESULTS NNP N
Both NNP N
groups NNS N
showed VBD N
significant JJ N
reduction NN N
in IN N
GI NNP N
scores NNS N
at IN N
6 CD N
months NNS N
( ( N
ps JJ N
< NNP N
0.005 CD N
) ) N
. . N

Reduction NN N
in IN N
GI NNP N
scores NNS N
of IN N
the DT N
intervention NN N
group NN N
at IN N
6 CD N
months NNS N
was VBD N
20.8 CD N
% NN N
which WDT N
is VBZ N
considered VBN N
to TO N
be VB N
clinically RB N
significant JJ N
. . N

Compared VBN N
to TO N
the DT N
control NN N
group NN N
, , N
the DT N
intervention NN N
group NN N
showed VBD N
a DT N
significant JJ N
and CC N
larger JJR N
reduction NN N
in IN N
GI NNP N
score NN N
by IN N
8 CD N
% NN N
at IN N
6 CD N
months NNS N
( ( N
p=0.0007 NN N
) ) N
. . N

CONCLUSIONS JJ N
Results NNP N
support NN N
the DT N
use NN N
of IN N
adaptive JJ 1_i
devices NNS 1_i
and CC N
orofacial JJ 2_i
exercise NN 2_i
to TO N
improve VB N
gingival NN N
health NN N
in IN N
adults NNS N
with IN N
SSc NNP N
when WRB N
compared VBN N
to TO N
use VB N
of IN N
manual JJ 7_i
toothbrushing NN 7_i
and CC N
finger-held JJ 7_i
flossing NN 7_i
. . N

Recommending VBG N
and CC N
educating VBG N
patients NNS N
with IN N
SSc NNP N
to TO N
use VB N
adaptive JJ N
devices NNS N
to TO N
clean VB N
the DT N
tooth NN N
surfaces NNS N
looks VBZ N
promising VBG N
for IN N
long-term JJ N
oral JJ N
health NN N
improvement NN N
. . N

-DOCSTART- -X- O O

Immunological JJ N
changes NNS N
after IN N
minimally RB 1_i
invasive JJ 1_i
or CC N
conventional JJ 1_i
esophageal JJ 1_i
resection NN 1_i
for IN N
cancer NN N
: : N
a DT N
randomized JJ N
trial NN N
. . N

BACKGROUND VB N
This DT N
study NN N
was VBD N
performed VBN N
as IN N
a DT N
substudy NN N
analysis NN N
of IN N
a DT N
randomized JJ N
trial NN N
comparing VBG N
conventional JJ 1_i
open JJ 1_i
esophagectomy NN 1_i
[ NNP N
open JJ N
surgical JJ N
technique NN N
( ( N
OE NNP N
) ) N
] NN N
by IN N
thoracotomy NN 1_i
and CC N
laparotomy NN 1_i
with IN N
minimally RB 1_i
invasive JJ 1_i
esophagectomy NN 1_i
[ NNP N
minimally RB N
invasive JJ N
procedure NN N
( ( N
MIE NNP N
) ) N
] NN N
by IN N
thoracoscopy NN 1_i
and CC N
laparoscopy NN 1_i
. . N

This DT N
additional JJ N
analysis NN N
focuses VBZ N
on IN N
the DT N
immunological JJ N
changes NNS N
and CC N
surgical JJ N
stress NN N
response NN N
in IN N
these DT N
two CD N
randomized VBD N
groups NNS N
of IN N
a DT N
single JJ N
center NN N
. . N

METHODS NNP N
Patients NNPS N
with IN N
a DT N
resectable JJ N
esophageal NN N
cancer NN N
were VBD N
randomized VBN N
to TO N
OE NNP N
( ( N
n JJ N
= NNP N
13 CD N
) ) N
or CC N
MIE NNP N
( ( N
n JJ N
= NNP N
14 CD N
) ) N
. . N

All DT N
patients NNS N
received VBD N
neoadjuvant JJ 3_i
chemoradiotherapy NN 3_i
. . 3_i

The DT N
immunological JJ N
response NN N
was VBD N
measured VBN N
by IN N
means NNS N
of IN N
leukocyte NN N
counts NNS N
, , N
HLA-DR NNP N
expression NN N
on IN N
monocytes NNS N
, , N
the DT N
acute-phase JJ N
response NN N
by IN N
means NNS N
of IN N
C-reactive JJ N
protein NN N
( ( N
CRP NNP N
) ) N
, , N
interleukin-6 JJ N
( ( N
IL-6 NNP N
) ) N
, , N
and CC N
interleukin-8 JJ N
( ( N
IL-8 NNP N
) ) N
, , N
and CC N
the DT N
stress NN N
response NN N
was VBD N
measured VBN N
by IN N
cortisol NN N
, , N
growth NN N
hormone NN N
, , N
and CC N
prolactin NN N
. . N

All DT N
parameters NNS N
were VBD N
determined VBN N
at IN N
baseline NN N
( ( N
preoperatively RB N
) ) N
and CC N
24 CD N
, , N
72 CD N
, , N
96 CD N
, , N
and CC N
168 CD N
h NN N
postoperatively RB N
. . N

RESULTS NNP N
Significant JJ N
differences NNS N
between IN N
the DT N
two CD N
groups NNS N
were VBD N
seen VBN N
in IN N
favor NN N
of IN N
the DT N
MIE NNP N
group NN N
with IN N
regard NN N
to TO N
leukocyte VB N
counts NNS N
, , N
IL-8 NNP N
, , N
and CC N
prolactin NN N
at IN N
168 CD N
h NN N
( ( N
1 CD N
week NN N
) ) N
postoperatively RB N
. . N

For IN N
HLA-DR NNP N
expression NN N
, , N
IL-6 NNP N
, , N
and CC N
CRP NNP N
levels NNS N
, , N
there EX N
were VBD N
no DT N
significant JJ N
differences NNS N
between IN N
the DT N
two CD N
groups NNS N
, , N
although IN N
there EX N
was VBD N
a DT N
clear JJ N
rise NN N
in IN N
levels NNS N
upon IN N
operation NN N
in IN N
both DT N
groups NNS N
. . N

CONCLUSION NNP N
In IN N
this DT N
substudy NN N
of IN N
a DT N
randomized JJ N
trial NN N
comparing VBG N
minimally RB N
invasive JJ N
and CC N
conventional JJ N
open JJ N
esophagectomies NNS N
for IN N
cancer NN N
, , N
significantly RB N
better RBR N
preserved VBN N
leukocyte JJ N
counts NNS N
and CC N
IL-8 JJ N
levels NNS N
were VBD N
observed VBN N
in IN N
the DT N
MIE NNP N
group NN N
compared VBN N
to TO N
the DT N
open JJ N
group NN N
. . N

Both DT N
findings NNS N
can MD N
be VB N
related VBN N
to TO N
fewer JJR N
respiratory NN N
infections NNS N
found VBD N
postoperatively RB N
in IN N
the DT N
MIE NNP N
group NN N
. . N

Moreover RB N
, , N
significant JJ N
differences NNS N
in IN N
the DT N
prolactin NN N
levels NNS N
at IN N
168 CD N
h NN N
after IN N
surgery NN N
imply NN N
that IN N
the DT N
stress NN N
response NN N
is VBZ N
better RBR N
preserved VBN N
in IN N
the DT N
MIE NNP 1_i
group NN N
. . N

These DT N
findings NNS N
indicate VBP N
that IN N
less JJR N
surgical JJ N
trauma NN N
could MD N
lead VB N
to TO N
better JJR N
preserved VBN N
acute-phase NN N
and CC N
stress NN N
responses NNS N
and CC N
fewer JJR N
clinical JJ N
manifestations NNS N
of IN N
respiratory JJ N
infections NNS N
. . N

-DOCSTART- -X- O O

The DT N
dipeptidyl JJ 3_i
peptidase-4 JJ 3_i
inhibitor NN 3_i
PHX1149 NNP 3_i
improves VBZ N
blood NN N
glucose NN N
control NN N
in IN N
patients NNS N
with IN N
type JJ N
2 CD N
diabetes NNS N
mellitus RB N
. . N

AIM NNP N
To TO N
determine VB N
the DT N
efficacy NN N
and CC N
tolerability NN N
of IN N
PHX1149 NNP 3_i
, , N
a DT N
novel JJ N
dipeptidyl NN N
peptidase-4 NN N
( ( N
DPP4 NNP N
) ) N
inhibitor NN N
, , N
in IN N
patients NNS N
with IN N
type JJ N
2 CD N
diabetes NNS N
. . N

METHODS NNP N
This DT N
is VBZ N
a DT N
multicentre NN N
, , N
randomized VBN N
, , N
double-blind JJ N
, , N
placebo-controlled JJ N
, , N
4-week JJ N
study NN N
in IN N
patients NNS N
with IN N
type JJ N
2 CD N
diabetes NNS N
with IN N
suboptimal JJ N
metabolic JJ N
control NN N
. . N

Patients NNS N
with IN N
a DT N
baseline NN N
haemoglobin NN N
A NNP N
( ( N
1c CD N
) ) N
( ( N
HbA NNP N
( ( N
1c CD N
) ) N
) ) N
of IN N
7.3 CD N
to TO N
11.0 CD N
% NN N
were VBD N
randomized VBN N
1 CD N
: : N
1 CD N
: : N
1 CD N
: : N
1 CD N
to TO N
receive VB N
once-daily JJ N
oral JJ N
therapy NN N
with IN N
either DT N
PHX1149 NNP 3_i
( ( N
100 CD N
, , N
200 CD N
or CC N
400 CD N
mg NN N
) ) N
or CC N
placebo NN 7_i
; : N
patients NNS N
were VBD N
on IN N
a DT N
constant JJ N
background NN N
therapy NN N
of IN N
either DT N
metformin NN N
alone RB N
or CC N
metformin JJ N
plus CC N
a DT N
glitazone NN N
. . N

RESULTS NNP N
Treatment NNP N
with IN N
100 CD N
, , N
200 CD N
or CC N
400 CD N
mg NN N
of IN N
PHX1149 NNP N
significantly RB N
decreased VBD N
postprandial JJ N
glucose JJ N
area NN N
under IN N
the DT N
curve NN N
AUC NNP N
( ( N
0-2 JJ N
h NN N
) ) N
by IN N
approximately RB N
20 CD N
% NN N
( ( N
+0.11 JJ N
+/- JJ N
0.50 CD N
, , N
-2.08 VBD N
+/- JJ N
0.51 CD N
, , N
-1.73 VBD N
+/- JJ N
0.49 CD N
and CC N
-1.88 VB N
+/- JJ N
0.48 CD N
mmol/l NN N
x NN N
h NN N
, , N
respectively RB N
, , N
for IN N
placebo NN N
and CC N
100 CD N
, , N
200 CD N
and CC N
400 CD N
mg NN N
( ( N
p JJ N
= NN N
0.002 CD N
, , N
0.008 CD N
and CC N
0.004 CD N
vs. FW N
placebo NN N
) ) N
. . N

Postprandial JJ N
AUC NNP N
( ( N
0-2 JJ N
h NN N
) ) N
of IN N
intact JJ N
glucagon-like JJ N
peptide-1 NN N
, , N
the DT N
principal JJ N
mediator NN N
of IN N
the DT N
biological JJ N
effects NNS N
of IN N
DPP4 NNP N
inhibitors NNS N
, , N
was VBD N
increased VBN N
by IN N
3.90 CD N
+/- JJ N
2.83 CD N
, , N
11.63 CD N
+/- JJ N
2.86 CD N
, , N
16.42 CD N
+/- JJ N
2.72 CD N
and CC N
15.75 CD N
+/- JJ N
2.71 CD N
pmol/l NN N
x NN N
h NN N
, , N
respectively RB N
, , N
for IN N
placebo NN N
and CC N
100 CD N
, , N
200 CD N
and CC N
400 CD N
mg NN N
( ( N
p JJ N
= NN N
0.053 CD N
, , N
0.001 CD N
and CC N
0.002 CD N
vs. FW N
placebo NN N
) ) N
. . N

Mean JJ N
HbA NNP N
( ( N
1c CD N
) ) N
was VBD N
lower JJR N
in IN N
all DT N
dose JJ N
groups NNS N
; : N
the DT N
placebo-corrected JJ N
change NN N
in IN N
the DT N
groups NNS N
receiving VBG N
400 CD N
mg JJ N
PHX1149 NNP N
was VBD N
-0.28 VBN N
% NN N
( ( N
p JJ N
= NNP N
0.02 CD N
) ) N
. . N

DPP4 NNP N
inhibition NN N
on IN N
day NN N
28 CD N
was VBD N
53 CD N
, , N
73 CD N
and CC N
78 CD N
% NN N
at IN N
24 CD N
h NN N
postdose NN N
in IN N
the DT N
groups NNS N
receiving VBG N
100 CD N
, , N
200 CD N
and CC N
400 CD N
mg NN N
PHX1149 NNP N
, , N
respectively RB N
. . N

There EX N
were VBD N
no DT N
differences NNS N
in IN N
adverse JJ N
events NNS N
between IN N
PHX1149-treated NNP N
and CC N
placebo JJ N
subjects NNS N
. . N

CONCLUSIONS NNP N
Addition NNP N
of IN N
the DT N
DPP4 NNP N
inhibitor NN N
PHX1149 NNP N
to TO N
a DT N
stable JJ N
regimen NN N
of IN N
metformin NN N
or CC N
metformin NN N
plus CC N
a DT N
glitazone NN N
in IN N
patients NNS N
with IN N
type JJ N
2 CD N
diabetes NNS N
was VBD N
well RB N
tolerated VBN N
and CC N
improved VBN N
blood NN N
glucose NN N
control NN N
. . N

-DOCSTART- -X- O O

The DT N
costs NNS N
and CC N
effects NNS N
of IN N
a DT N
nutritional JJ 4_i
education NN 4_i
program NN 4_i
following VBG N
work-site JJ N
cholesterol NN N
screening NN N
. . N

OBJECTIVES CC N
The DT N
purpose NN N
of IN N
this DT N
study NN N
was VBD N
to TO N
assess VB N
the DT N
costs NNS N
and CC N
impact NN N
of IN N
a DT N
nutrition JJ 4_i
education NN 4_i
program NN 4_i
following VBG N
a DT N
cholesterol NN N
screening NN N
. . N

METHODS NNP N
Forty NNP N
work-sites NNS N
were VBD N
randomly RB N
assigned VBN N
to TO N
one CD N
of IN N
two CD N
educational JJ 4_i
interventions NNS 4_i
: : 4_i
a DT N
usual JJ 4_i
intervention NN 4_i
of IN 4_i
5 CD 4_i
minutes NNS 4_i
of IN 4_i
counseling NN 4_i
, , 4_i
or CC 4_i
a DT 4_i
special JJ 4_i
intervention NN 4_i
of IN 4_i
2 CD 4_i
hours NNS 4_i
of IN 4_i
behaviorally RB 4_i
based VBN 4_i
education NN 4_i
on IN 4_i
dietary JJ 4_i
changes NNS 4_i
to TO 4_i
lower VB 4_i
serum NN 4_i
cholesterol NN 4_i
. . 4_i

Costs NNS N
were VBD N
monitored VBN N
, , N
and CC N
cholesterol NN N
levels NNS N
were VBD N
retested VBN N
6 CD N
and CC N
12 CD N
months NNS N
later RB N
. . N

RESULTS VB N
The DT N
total JJ N
per-person JJ N
cost NN N
for IN N
screening VBG N
and CC N
the DT N
educational JJ N
intervention NN N
was VBD N
about IN N
$ $ N
50 CD N
. . N

Cholesterol NN N
levels NNS N
differed VBD N
little RB N
between IN N
the DT N
two CD N
intervention NN N
groups NNS N
6 CD N
months NNS N
after IN N
screening VBG N
, , N
but CC N
after IN N
12 CD N
months NNS N
those DT N
in IN N
the DT N
special JJ N
intervention NN N
worksites NNS N
showed VBD N
a DT N
6.5 CD N
% NN N
drop NN N
in IN N
cholesterol NN N
, , N
whereas IN N
those DT N
at IN N
the DT N
usual JJ N
intervention NN N
worksites NNS N
showed VBD N
a DT N
drop NN N
of IN N
only RB N
3.0 CD N
% NN N
. . N

Hence NNP N
a DT N
3.5 CD N
% NN N
cholesterol NN N
reduction NN N
was VBD N
attributable JJ N
to TO N
the DT N
special JJ N
intervention NN N
. . N

CONCLUSIONS VB N
A NNP N
behaviorally RB 4_i
based VBN 4_i
nutrition JJ 4_i
education NN 4_i
program NN 4_i
following VBG N
cholesterol NN N
screening VBG N
can MD N
have VB N
a DT N
meaningful JJ N
impact NN N
on IN N
long-term JJ N
cholesterol NN N
levels NNS N
at IN N
a DT N
low JJ N
cost NN N
. . N

Nutrition NNP 4_i
education NN 4_i
in IN N
work-sites NNS N
may MD N
therefore RB N
be VB N
a DT N
useful JJ N
way NN N
to TO N
lower VB N
the DT N
risk NN N
of IN N
heart NN N
disease NN N
in IN N
communities NNS N
. . N

-DOCSTART- -X- O O

Double-blind NNP N
randomized JJ N
evaluation NN N
of IN N
intercostal JJ 3_i
nerve NN 3_i
blocks NNS 3_i
as IN N
an DT N
adjuvant NN N
to TO N
subarachnoid VB N
administered JJ N
morphine NN 3_i
for IN N
post-thoracotomy JJ N
analgesia NN N
. . N

BACKGROUND NNP N
AND NNP N
OBJECTIVES NNP N
Thoracotomy NNP N
is VBZ N
associated VBN N
with IN N
pain NN N
and CC N
compromised VBD N
pulmonary JJ N
function NN N
. . N

Intercostal NNP 3_i
nerve NN 3_i
blocks NNS 3_i
( ( 3_i
INB NNP 3_i
) ) 3_i
and CC N
subarachnoid JJ 3_i
morphine NN 3_i
( ( 3_i
SM NNP 3_i
) ) 3_i
act NN N
on IN N
different JJ N
portions NNS N
of IN N
the DT N
pain NN N
pathway RB N
. . N

Each DT N
is VBZ N
effective JJ N
for IN N
post-thoracotomy JJ N
pain NN N
relief NN N
. . N

The DT N
combination NN N
of IN N
these DT N
two CD N
modalities NNS N
in IN N
relieving VBG N
post-thoracotomy JJ N
pain NN N
and CC N
improving VBG N
postoperative JJ N
pulmonary JJ N
function NN N
has VBZ N
not RB N
been VBN N
investigated VBN N
. . N

METHODS NNP N
In IN N
a DT N
double-blind NN N
study NN N
, , N
20 CD N
patients NNS N
undergoing JJ N
lateral JJ N
thoracotomy NN 1_i
for IN N
lung NN N
resection NN N
were VBD N
randomized VBN N
to TO N
receive VB N
0.5 CD N
mg NN N
SM NNP 3_i
preoperatively RB N
and CC N
INB NNP 3_i
with IN N
bupivacaine NN 3_i
( ( 3_i
INB+ NNP 3_i
) ) 3_i
prior RB N
to TO N
wound VB N
closure NN N
or CC N
0.5 CD N
mg NNS N
SM NNP 3_i
with IN N
INB NNP 3_i
using VBG N
saline NN 7_i
( ( N
INB- NNP N
) ) N
. . N

Visual JJ N
analog NN N
scale NN N
pain NN N
scores NNS N
at IN N
rest NN N
, , N
with IN N
cough NN N
, , N
and CC N
with IN N
movement NN N
of IN N
the DT N
ipsilateral JJ N
arm NN N
, , N
forced VBD N
expiratory JJ N
volume NN N
in IN N
1 CD N
second JJ N
( ( N
FEV1 NNP N
) ) N
, , N
and CC N
forced VBD N
vital JJ N
capacity NN N
( ( N
FVC NNP N
) ) N
were VBD N
measured VBN N
at IN N
4 CD N
, , N
24 CD N
, , N
48 CD N
, , N
and CC N
72 CD N
hours NNS N
after IN N
the DT N
operation NN N
. . N

Opioid NNP N
use NN N
was VBD N
measured VBN N
during IN N
the DT N
initial JJ N
24 CD N
hours NNS N
after IN N
the DT N
operation NN N
. . N

RESULTS NNP N
At IN N
4 CD N
hours NNS N
, , N
the DT N
INB+ NNP 3_i
group NN N
demonstrated VBD N
better JJR N
FEV1 NNP N
( ( N
56.6 CD N
% NN N
vs. FW N
40.4 CD N
% NN N
of IN N
baseline NN N
, , N
P NNP N
< NNP N
.05 NNP N
) ) N
and CC N
FVC NNP N
values NNS N
( ( N
54.6 CD N
% NN N
vs. FW N
39.6 CD N
% NN N
of IN N
baseline NN N
, , N
P NNP N
< NNP N
.05 NNP N
) ) N
and CC N
less RBR N
resting VBG N
and CC N
cough JJ N
pain NN N
( ( N
P NNP N
< NNP N
.05 NNP N
) ) N
. . N

However RB N
, , N
FEV1 NNP N
continued VBD N
to TO N
decline VB N
in IN N
the DT N
INB+ NNP 3_i
group NN N
at IN N
24 CD N
hours NNS N
to TO N
lower JJR N
than IN N
the DT N
INB- NNP 3_i
group NN N
although IN N
pain NN N
scores NNS N
were VBD N
similar JJ N
beyond IN N
4 CD N
hours NNS N
. . N

Opioid JJ N
usage NN N
during IN N
the DT N
first JJ N
24 CD N
hours NNS N
was VBD N
similar JJ N
( ( 3_i
INB- NNP 3_i
, , N
16.7 CD N
mg NN N
vs. FW N
INB+ NNP 3_i
, , N
13.2 CD N
mg NN N
, , N
P NNP N
= NNP N
.7 NNP N
) ) N
. . N

CONCLUSIONS NNP N
Although IN N
postoperative JJ N
INB NNP 3_i
provided VBD N
modest JJ N
improvements NNS N
in IN N
pain NN N
and CC N
pulmonary JJ N
function NN N
when WRB N
used VBN N
as IN N
an DT N
adjuvant NN N
to TO N
0.5 CD N
mg NNS N
SM NNP 3_i
for IN N
post-thoracotomy JJ N
analgesia NN N
, , N
the DT N
benefits NNS N
were VBD N
transient JJ N
. . N

The DT N
authors NNS N
do VBP N
not RB N
recommend VB N
adding VBG N
INB NNP 3_i
for IN N
patients NNS N
undergoing JJ N
lateral JJ N
thoracotomy NN N
who WP N
receive VBP N
0.5 CD N
mg NN N
SM NNP 3_i
. . 3_i

-DOCSTART- -X- O O

Dose NNP N
response NN N
effect NN N
of IN N
cyclical JJ 3_i
medroxyprogesterone NN 3_i
on IN N
blood NN N
pressure NN N
in IN N
postmenopausal JJ N
women NNS N
. . N

OBJECTIVE VB N
This DT N
study NN N
was VBD N
designed VBN N
to TO N
compare VB N
with IN N
placebo PDT 7_i
the DT N
dose-response JJ N
effect NN N
of IN N
cyclical JJ N
doses NNS N
of IN N
the DT N
C21 NNP 3_i
progestogen NN 3_i
, , N
medroxyprogesterone NN 3_i
acetate NN 3_i
( ( N
MPA NNP N
) ) N
on IN N
blood NN N
pressure NN N
( ( N
BP NNP N
) ) N
when WRB N
administered VBN N
to TO N
normotensive JJ N
postmenopausal NN N
women NNS N
receiving VBG N
a DT N
fixed JJ N
mid-range JJ N
daily JJ N
dose NN N
of IN N
conjugated JJ 3_i
equine NN 3_i
oestrogen NN 3_i
( ( 3_i
CEE NNP 3_i
) ) 3_i
. . 3_i

MATERIALS NNP N
AND CC N
METHODS NNP N
Twenty NNP N
normotensive JJ N
postmenopausal NN N
women NNS N
( ( N
median JJ N
age NN N
53 CD N
years NNS N
) ) N
participated VBD N
in IN N
the DT N
study NN N
which WDT N
used VBD N
a DT N
double-blind JJ N
crossover NN N
design NN N
. . N

There EX N
were VBD N
four CD N
randomised VBN N
treatment NN N
phases NNS N
, , N
each DT N
of IN N
4 CD N
weeks NNS N
duration NN N
. . N

The DT N
four CD N
blinded VBD N
treatments NNS N
were VBD N
MPA NNP 3_i
2.5 CD N
mg NN N
, , N
MPA NNP 3_i
5 CD N
mg NN N
, , N
MPA NNP 3_i
10 CD N
mg NN N
and CC N
matching VBG N
placebo NN 7_i
, , N
taken VBN N
for IN N
the DT N
last JJ N
14 CD N
days NNS N
of IN N
each DT N
28 CD N
day NN N
treatment NN N
cycle NN N
. . N

CEE NNP N
0.625 CD N
mg NN N
was VBD N
also RB N
administered VBN N
once RB N
daily JJ N
as IN N
open JJ N
labelled VBD N
tablets NNS N
to TO N
all DT N
subjects NNS N
throughout IN N
the DT N
study NN N
. . N

Clinic NNP N
BP NNP N
was VBD N
measured VBN N
weekly RB N
with IN N
the DT N
mean JJ N
values NNS N
of IN N
weeks NNS N
3 CD N
and CC N
4 CD N
of IN N
each DT N
phase NN N
used VBN N
for IN N
analysis NN N
. . N

Ambulatory NNP N
BP NNP N
was VBD N
performed VBN N
in IN N
the DT N
final JJ N
week NN N
of IN N
each DT N
phase NN N
. . N

RESULTS NNP N
Compared VBD N
with IN N
the DT N
placebo NN N
phase NN N
, , N
end NN N
of IN N
phase NN N
clinic JJ N
BP NNP N
was VBD N
unchanged JJ N
by IN N
any DT N
of IN N
the DT N
progestogen NN N
treatments NNS N
. . N

There EX N
was VBD N
a DT N
dose-dependent JJ N
decrease NN N
in IN N
ambulatory JJ N
daytime JJ N
diastolic NN N
and CC N
mean JJ N
arterial JJ N
BP NNP N
with IN N
the DT N
progestogen NN N
treatments NNS N
compared VBN N
with IN N
placebo NN N
( ( N
P NNP N
< NNP N
0.05 CD N
) ) N
. . N

CONCLUSION NNP N
In IN N
a DT N
regimen NN N
of IN N
postmenopausal NN N
hormone NN N
replacement NN N
therapy NN N
with IN N
a DT N
fixed JJ N
mid-range JJ N
daily JJ N
dose NN N
of IN N
CEE NNP N
combined VBD N
with IN N
a DT N
cyclical JJ N
regimen NN N
of IN N
a DT N
C21 NNP N
progestogen NN N
spanning VBG N
the DT N
current JJ N
clinical JJ N
dose NN N
range NN N
, , N
the DT N
progestogen NN 3_i
has VBZ N
either CC N
no DT N
effect NN N
or CC N
a DT N
small JJ N
dose-dependent JJ N
reduction NN N
in IN N
clinic NN N
and CC N
ambulatory JJ N
BPs NNP N
over IN N
one CD N
treatment NN N
cycle NN N
. . N

-DOCSTART- -X- O O

Maternal JJ N
breast-milk NN N
and CC N
intestinal JJ N
bifidobacteria NNS N
guide VBP N
the DT N
compositional JJ N
development NN N
of IN N
the DT N
Bifidobacterium NNP N
microbiota NN N
in IN N
infants NNS N
at IN N
risk NN N
of IN N
allergic JJ N
disease NN N
. . N

BACKGROUND IN N
The DT N
sources NNS N
and CC N
the DT N
impact NN N
of IN N
maternal JJ N
bacteria NNS N
on IN N
the DT N
initial JJ N
inoculum NN N
of IN N
the DT N
intestinal JJ N
microflora NN N
of IN N
newborn JJ N
infants NNS N
remain VBP N
elusive JJ N
. . N

OBJECTIVE NN N
To TO N
assess VB N
the DT N
association NN N
between IN N
maternal JJ N
breast-milk NN N
and CC N
fecal JJ N
bifidobacteria NN N
and CC N
infants NNS N
' POS N
fecal JJ N
bifidobacteria NN N
. . N

METHODS NNP N
Sixty-one JJ N
mother-infant JJ N
pairs NNS N
were VBD N
included VBN N
, , N
special JJ N
emphasis NN N
being VBG N
placed VBN N
on IN N
the DT N
maternal JJ N
allergic NN N
status NN N
. . N

Bifidobacteria NNP N
were VBD N
analysed VBN N
by IN N
a DT N
direct JJ N
PCR NNP N
method NN N
in IN N
fecal JJ N
samples NNS N
from IN N
mothers NNS N
at IN N
30-35 JJ N
weeks NNS N
of IN N
gestation NN N
and CC N
from IN N
infants NNS N
at IN N
1 CD N
month NN N
of IN N
age NN N
and CC N
from IN N
breast-milk JJ 2_i
samples NNS 2_i
1 CD N
month NN N
post-partum NN N
. . N

RESULTS NNP N
Fecal NNP N
Bifidobacterium NNP N
adolescentis NN N
and CC N
Bifidobacterium NNP N
bifidum NN N
colonization NN N
frequencies NNS N
and CC N
counts NNS N
among IN N
mother-infant JJ N
pairs NNS N
correlated VBN N
significantly RB N
( ( N
P=0.005 NNP N
and CC N
0.02 CD N
for IN N
frequencies NNS N
, , N
respectively RB N
, , N
and CC N
P=0.002 NNP N
and CC N
0.01 CD N
for IN N
counts NNS N
, , N
respectively RB N
) ) N
. . N

Only JJ N
infants NNS N
of IN N
allergic NN N
, , N
atopic NN N
mothers NNS N
were VBD N
colonized VBN N
with IN N
B. NNP N
adolescentis NN N
. . N

Each DT N
of IN N
the DT N
breast-milk NN N
samples NNS N
contained VBN N
bifidobacteria NNS N
[ NNP N
median JJ N
1.4 CD N
x JJ N
10 CD N
( ( N
3 CD N
) ) N
bacterial JJ N
cells/mL NN N
; : N
interquartile JJ N
range NN N
( ( N
IQR NNP N
) ) N
48.7-3.8 CD N
x $ N
10 CD N
( ( N
3 CD N
) ) N
] NN N
. . N

Bifidobacterium NNP N
longum NN N
was VBD N
the DT N
most RBS N
frequently RB N
detected VBN N
species NNS N
in IN N
breast-milk NN N
. . N

Allergic NNP N
mothers NNS N
had VBD N
significantly RB N
lower JJR N
amounts NNS N
of IN N
bifidobacteria NN N
in IN N
breast-milk NN N
compared VBN N
with IN N
non-allergic JJ N
mothers NNS N
[ VBP N
median JJ N
1.3 CD N
x JJ N
10 CD N
( ( N
3 CD N
) ) N
bacterial NN N
cells/mL NN N
( ( N
IQR NNP N
22.4-3.0 CD N
x NNP N
10 CD N
( ( N
3 CD N
) ) N
) ) N
vs. FW N
5.6 CD N
x $ N
10 CD N
( ( N
3 CD N
) ) N
bacterial NN N
cells/mL NN N
( ( N
1.8 CD N
x RB N
10 CD N
( ( N
3 CD N
) ) N
-1.8 NN N
x $ N
10 CD N
( ( N
4 CD N
) ) N
) ) N
, , N
respectively RB N
, , N
( ( N
P=0.004 NNP N
) ) N
] NN N
, , N
and CC N
their PRP$ N
infants NNS N
had VBD N
concurrently RB N
lower JJR N
counts NNS N
of IN N
bifidobacteria NN N
in IN N
feces NNS N
[ VBP N
3.9 CD N
x JJ N
10 CD N
( ( N
8 CD N
) ) N
bacterial NN N
cells/g NN N
( ( N
IQR NNP N
6.5 CD N
x NN N
10 CD N
( ( N
6 CD N
) ) N
-1.5 NN N
x $ N
10 CD N
( ( N
9 CD N
) ) N
) ) N
in IN N
infants NNS N
of IN N
allergic JJ N
mothers NNS N
, , N
vs. FW N
2.5 CD N
x $ N
10 CD N
( ( N
9 CD N
) ) N
bacterial NN N
cells/g NN N
( ( N
6.5 CD N
x RB N
10 CD N
( ( N
8 CD N
) ) N
-3.2 NN N
x $ N
10 CD N
( ( N
10 CD N
) ) N
) ) N
in IN N
infants NNS N
of IN N
non-allergic JJ N
mothers NNS N
, , N
P=0.013 NNP N
] NNP N
. . N

CONCLUSIONS NNP N
Breast-milk NNP N
contains VBZ N
significant JJ N
numbers NNS N
of IN N
bifidobacteria NN N
and CC N
the DT N
maternal JJ N
allergic NN N
status NN N
further RBR N
deranges VBZ N
the DT N
counts NNS N
of IN N
bifidobacteria NN N
in IN N
breast-milk NN N
. . N

Maternal NNP N
fecal JJ N
and CC N
breast-milk JJ N
bifidobacterial JJ N
counts NNS N
impacted VBN N
on IN N
the DT N
infants NNS N
' POS N
fecal JJ N
Bifidobacterium NN N
levels NNS N
. . N

Breast-milk NNP N
bacteria NN N
should MD N
thus RB N
be VB N
considered VBN N
an DT N
important JJ N
source NN N
of IN N
bacteria NNS N
in IN N
the DT N
establishment NN N
of IN N
infantile JJ N
intestinal JJ N
microbiota NN N
. . N

-DOCSTART- -X- O O

Whole-body JJ 6_i
CT NNP 6_i
screening NN 6_i
: : N
scan JJ N
delay NN N
and CC N
contrast NN 3_i
injection NN 3_i
duration NN N
for IN N
optimal JJ N
enhancement NN N
of IN N
abdominal JJ N
organs NNS N
and CC N
deep JJ N
vessels NNS N
. . N

PURPOSE NNP N
To TO N
assess VB N
the DT N
optimal JJ N
scan JJ N
delays NNS N
and CC N
contrast NN N
injection NN N
durations NNS N
for IN N
contrast-enhanced JJ 6_i
whole-body NN 6_i
computed VBN 6_i
tomography NN 6_i
( ( 6_i
CT NNP 6_i
) ) 6_i
. . 6_i

MATERIALS NNP N
AND CC N
METHODS NNP N
One CD N
hundred VBD N
forty-two JJ N
patients NNS N
were VBD N
randomized VBN N
into IN N
three CD N
groups NNS N
: : N
protocol NN N
A-scan JJ N
delay NN N
of IN N
65 CD N
s NNS N
after IN N
starting VBG N
contrast NN 3_i
injection NN 3_i
over IN N
30 CD N
s NNS N
; : N
protocol CC N
B-105 NNP N
and CC N
70 CD N
s NN N
; : N
and CC N
protocol VB N
C-145 NNP N
and CC N
110 CD N
s NN N
, , N
respectively RB N
. . N

Contrast NNP N
enhancement NN N
and CC N
diagnostic JJ N
acceptability NN N
were VBD N
assessed VBN N
. . N

RESULTS NNP N
Qualitative JJ N
assessment NN N
was VBD N
subtle JJ N
among IN N
the DT N
three CD N
protocols NNS N
. . N

Homogenous JJ N
enhancement NN N
of IN N
deep JJ N
veins NNS N
was VBD N
more RBR N
assuredly RB N
achieved VBN N
with IN N
protocol NN N
C. NNP N
CONCLUSION NNP N
With IN N
protocol NN N
C NNP N
, , N
qualitatively RB N
acceptable JJ N
enhancement NN N
can MD N
be VB N
obtained VBN N
in IN N
whole-body JJ 6_i
CT NNP 6_i
. . 6_i

-DOCSTART- -X- O O

Coagulation NNP 3_i
factor NN 3_i
concentrate NN 3_i
in IN N
the DT N
treatment NN N
of IN N
the DT N
haemorrhagic JJ N
diathesis NN N
of IN N
fulminant JJ N
hepatic JJ N
failure NN N
. . N

To TO N
assess VB N
the DT N
value NN N
of IN N
clotting VBG 3_i
factor NN 3_i
concentrate NN 3_i
infusions NNS 3_i
in IN N
fulminant JJ N
hepatic JJ N
failure NN N
, , N
a DT N
controlled JJ N
trial NN N
was VBD N
performed VBN N
in IN N
which WDT N
nine CD N
patients NNS N
were VBD N
randomly RB N
allocated VBN N
to TO N
treatment NN N
with IN N
either DT N
concentrate NN 3_i
alone RB 3_i
or CC 3_i
concentrate VB 3_i
plus CC 3_i
heparin VB 3_i
. . 3_i

The DT N
five CD N
patients NNS N
receiving VBG N
concentrate VB 3_i
alone RB N
all DT N
died VBD N
, , N
with IN N
major JJ N
bleeding VBG N
as IN N
the DT N
direct JJ N
cause NN N
of IN N
death NN N
in IN N
three CD N
, , N
whereas NNS N
in IN N
the DT N
four CD N
receiving VBG N
heparin NN 3_i
as RB N
well RB N
there EX N
was VBD N
only RB N
one CD N
instance NN N
of IN N
bleeding NN N
and CC N
one CD N
patient NN N
survived VBD N
. . N

Clinical JJ N
evidence NN N
of IN N
intravascular JJ N
coagulation NN N
appeared VBD N
in IN N
two CD N
patients NNS N
treated VBD N
with IN N
concentrate NN 3_i
alone RB N
and CC N
the DT N
laboratory JJ N
evidence NN N
of IN N
this DT N
progressed VBN N
during IN N
the DT N
period NN N
of IN N
infusions NNS N
in IN N
all DT N
patients NNS N
in IN N
both DT N
treatment NN N
groups NNS N
, , N
although IN N
to TO N
a DT N
lesser JJR N
extent NN N
in IN N
those DT N
receiving VBG N
heparin NN 3_i
. . 3_i

Additional JJ N
evidence NN N
for IN N
intravascular JJ N
coagulation NN N
came VBD N
from IN N
the DT N
changes NNS N
observed VBN N
in IN N
factor NN N
VIII NNP N
levels NNS N
which WDT N
, , N
although IN N
initially RB N
high JJ N
in IN N
all DT N
patients NNS N
, , N
fell VBD N
subsequently RB N
, , N
particularly RB N
in IN N
those DT N
given VBN N
concentrate VBP 3_i
alone RB N
. . N

There EX N
was VBD N
some DT N
improvement NN N
in IN N
the DT N
prothrombin NN N
ratio NN N
in IN N
both DT N
groups NNS N
of IN N
patients NNS N
but CC N
not RB N
complete JJ N
correction NN N
, , N
and CC N
serial JJ N
assays NNS N
of IN N
clotting VBG N
factors NNS N
showed VBD N
that IN N
although IN N
factor NN N
II NNP N
rose VBD N
to TO N
high JJ N
levels NNS N
during IN N
treatment NN N
, , N
factors NNS N
IX NNP N
and CC N
X NNP N
showed VBD N
little JJ N
response NN N
. . N

Thus RB N
, , N
the DT N
use NN N
of IN N
concentrate NN N
of IN N
factor NN N
IX NNP N
in IN N
this DT N
trial NN N
, , N
as RB N
well RB N
as IN N
potentiating VBG N
intravascular JJ N
coagulation NN N
, , N
was VBD N
inadequate JJ N
as IN N
replacement NN N
for IN N
the DT N
clotting NN N
factor NN N
deficiencies NNS N
. . N

-DOCSTART- -X- O O

Immunogenicity NN N
and CC N
safety NN N
of IN N
a DT N
plasma-derived JJ 3_i
heat-inactivated JJ 3_i
hepatitis NN 3_i
B NNP 3_i
vaccine NN 3_i
( ( 3_i
CLB NNP 3_i
) ) 3_i
. . N

Studies NNPS N
in IN N
volunteers NNS N
at IN N
a DT N
low JJ N
risk NN N
of IN N
infection NN N
with IN N
hepatitis NN N
B NNP N
virus NN N
. . N

The DT N
safety NN N
and CC N
immunogenicity NN N
of IN N
a DT N
plasma-derived JJ 3_i
heat-inactivated JJ 3_i
hepatitis NN 3_i
B NNP 3_i
vaccine NN 3_i
( ( 3_i
CLB NNP 3_i
) ) 3_i
were VBD N
evaluated VBN N
in IN N
471 CD N
healthy JJ N
human JJ N
volunteers NNS N
, , N
who WP N
, , N
both DT N
in IN N
their PRP$ N
occupations NNS N
and CC N
in IN N
their PRP$ N
private JJ N
lives NNS N
, , N
had VBD N
been VBN N
at IN N
minimal JJ N
risk NN N
of IN N
being VBG N
infected VBN N
with IN N
hepatitis NN N
B NNP N
virus NN N
. . N

The DT N
first JJ N
202 JJ N
individuals NNS N
received VBD N
three CD N
3-micrograms JJ N
doses NNS N
of IN N
heat-inactivated JJ 3_i
hepatitis NN 3_i
B NNP 3_i
surface NN 3_i
antigen NN 3_i
( ( 3_i
HBsAg NNP 3_i
) ) 3_i
at IN N
one-month JJ N
intervals NNS N
( ( N
trial NN N
A DT N
) ) N
. . N

A DT N
total NN N
of IN N
42 CD N
% NN N
one CD N
month NN N
after IN N
the DT N
first JJ N
injection NN N
, , N
84 CD N
% NN N
after IN N
two CD N
months NNS N
, , N
and CC N
93 CD N
% NN N
after IN N
five CD N
months NNS N
had VBD N
become VBN N
anti-HBs JJ N
( ( N
antibody NN N
to TO N
hepatitis VB N
B NNP N
surface NN N
antigen NN N
) ) N
positive JJ N
. . N

In IN N
a DT N
second JJ N
randomized VBN N
study NN N
( ( N
trial NN N
B NNP N
) ) N
, , N
the DT N
immunogenicity NN N
of IN N
five CD N
different JJ N
dosages NNS N
of IN N
the DT N
vaccine NN N
was VBD N
compared VBN N
in IN N
269 CD N
volunteers NNS N
. . N

When WRB N
the DT N
dose NN N
of IN N
HBsAg NNP N
was VBD N
diminished VBN N
from IN N
3 CD N
micrograms NNS N
to TO N
1.5 CD N
, , N
0.6 CD N
, , N
and CC N
0.25 CD N
microgram NN N
, , N
no DT N
decrease NN N
of IN N
the DT N
anti-HBs JJ N
response NN N
was VBD N
observed VBN N
. . N

However RB N
, , N
when WRB N
the DT N
dose NN N
was VBD N
diminished VBN N
to TO N
0.1 CD N
microgram NN N
of IN N
HBsAg NNP N
, , N
the DT N
anti-HBs JJ N
response NN N
dropped VBD N
significantly RB N
to TO N
63 CD N
% NN N
( ( N
p NN N
less JJR N
than IN N
0.001 CD N
) ) N
. . N

In IN N
the DT N
recipients NNS N
of IN N
all DT N
five CD N
vaccine NN N
dosages NNS N
, , N
no DT N
influence NN N
of IN N
sex NN N
and CC N
age NN N
was VBD N
found VBN N
on IN N
the DT N
anti-HBs JJ N
conversion NN N
rates NNS N
. . N

During IN N
the DT N
eight-month JJ N
observation NN N
period NN N
, , N
none NN N
of IN N
the DT N
vaccinees NNS N
became VBD N
HBsAg NNP N
and/or IN N
anti-HBc JJ N
( ( N
antibody NN N
to TO N
hepatitis VB N
B NNP N
core NN N
antigen NN N
) ) N
positive JJ N
, , N
and CC N
none NN N
developed VBD N
antibodies NNS N
associated VBN N
with IN N
autoimmune JJ N
liver NN N
disease NN N
. . N

No DT N
serious JJ N
side NN N
effects NNS N
were VBD N
observed VBN N
. . N

-DOCSTART- -X- O O

Echocardiographic JJ N
evaluation NN N
of IN N
children NNS N
with IN N
systemic JJ N
ventricular JJ N
dysfunction NN N
treated VBN N
with IN N
carvedilol NN 3_i
. . 3_i

Echocardiography NN 2_i
is VBZ N
used VBN N
to TO N
measure VB N
the DT N
therapeutic JJ N
effectiveness NN N
of IN N
heart NN N
failure NN N
therapy NN N
in IN N
adults NNS N
and CC N
children NNS N
. . N

The DT N
purposes NNS N
of IN N
this DT N
study NN N
were VBD N
( ( N
1 CD N
) ) N
to TO N
assess VB N
baseline JJ N
echocardiographic JJ N
predictors NNS N
of IN N
clinical JJ N
outcome NN N
, , N
( ( N
2 CD N
) ) N
to TO N
investigate VB N
changes NNS N
in IN N
echocardiographic JJ N
parameters NNS N
, , N
and CC N
( ( N
3 CD N
) ) N
to TO N
compare VB N
these DT N
echocardiographic JJ N
changes NNS N
with IN N
changes NNS N
in IN N
plasma NN N
levels NNS N
of IN N
b-type JJ N
natriuretic JJ N
peptide NN N
( ( N
BNP NNP N
) ) N
in IN N
a DT N
population NN N
of IN N
children NNS N
with IN N
systemic JJ N
ventricular JJ N
dysfunction NN N
and CC N
symptomatic JJ N
heart NN N
failure NN N
treated VBN N
with IN N
carvedilol NN 3_i
or CC N
placebo NN 7_i
. . N

All DT N
available JJ N
baseline NN N
and CC N
6-month JJ N
echocardiograms NNS N
from IN N
Pediatric NNP N
Carvedilol NNP N
Trial NNP N
( ( N
PCT NNP N
) ) N
participants NNS N
( ( N
carvedilol JJ 3_i
n RB N
= JJ N
161 CD N
; : N
placebo NN 7_i
n IN N
= $ N
55 CD N
) ) N
were VBD N
reviewed VBN N
. . N

Systolic NNP N
and CC N
diastolic JJ N
sphericity NN N
index NN N
( ( N
SI NNP N
; : N
n CC N
= VB N
110 CD N
) ) N
, , N
TEI NNP N
index NN N
( ( N
n JJ N
= NNP N
145 CD N
) ) N
, , N
and CC N
systemic JJ N
ventricular NN N
dP/dt NN N
( ( N
n JJ N
= NNP N
70 CD N
) ) N
were VBD N
measured VBN N
. . N

The DT N
PCT NNP N
composite JJ N
definition NN N
of IN N
clinical JJ N
outcome NN N
( ( N
i.e. FW N
, , N
worsened VBD N
, , N
improved VBN N
, , N
or CC N
unchanged JJ N
) ) N
was VBD N
used VBN N
. . N

For IN N
all DT N
patients NNS N
, , N
baseline VBP N
TEI NNP N
index NN N
was VBD N
a DT N
predictor NN N
of IN N
worsened JJ N
outcome NN N
. . N

Only RB N
children NNS N
treated VBD N
with IN N
carvedilol NN 3_i
showed VBD N
a DT N
significant JJ N
decrease NN N
in IN N
systolic JJ N
SI NNP N
( ( N
P NNP N
B NNP N
0.0001 CD N
) ) N
, , N
diastolic JJ N
SI NNP N
( ( N
P NNP N
B NNP N
0.0001 CD N
) ) N
, , N
and CC N
TEI NNP N
index NN N
( ( N
P NNP N
= NNP N
0.02 CD N
) ) N
. . N

An DT N
inverse JJ N
correlation NN N
between IN N
changes NNS N
in IN N
BNP NNP N
and CC N
changes NNS N
in IN N
dP/dt NN N
( ( N
r JJ N
= NNP N
-0.45 NNP N
, , N
P NNP N
= NNP N
0.04 CD N
) ) N
was VBD N
found VBN N
only RB N
in IN N
the DT N
carvedilol NN 3_i
group NN N
. . N

In IN N
conclusion NN N
, , N
TEI NNP N
index NN N
predicted VBD N
outcome NN N
in IN N
children NNS N
with IN N
systemic JJ N
ventricular JJ N
dysfunction NN N
and CC N
heart NN N
failure NN N
. . N

Carvedilol NN 3_i
may MD N
have VB N
a DT N
beneficial JJ N
effect NN N
on IN N
reversal NN N
of IN N
left JJ N
ventricular JJ N
remodeling NN N
and CC N
global JJ N
ventricular NN N
function NN N
in IN N
pediatric JJ N
heart NN N
failure NN N
. . N

-DOCSTART- -X- O O

Efficacy NN N
of IN N
a DT N
family NN 4_i
practice-based JJ 4_i
lifestyle JJ 4_i
intervention NN 4_i
program NN 4_i
to TO N
increase VB N
physical JJ N
activity NN N
and CC N
reduce VB N
clinical JJ N
and CC N
physiological JJ N
markers NNS N
of IN N
vascular JJ N
health NN N
in IN N
patients NNS N
with IN N
high JJ N
normal JJ N
blood NN N
pressure NN N
and/or RB N
high JJ N
normal JJ N
blood NN N
glucose NN N
( ( N
SNAC NNP N
) ) N
: : N
study NN N
protocol NN N
for IN N
a DT N
randomized VBN N
controlled VBN N
trial NN N
. . N

BACKGROUND NNP N
Previous JJ N
interventions NNS N
to TO N
increase VB N
physical JJ N
activity NN N
and CC N
reduce VB N
cardiovascular JJ N
risk NN N
factors NNS N
have VBP N
been VBN N
targeted VBN N
at IN N
individuals NNS N
with IN N
established VBN N
disease NN N
; : N
less CC N
attention NN N
has VBZ N
been VBN N
given VBN N
to TO N
intervention VB N
among IN N
individuals NNS N
with IN N
high JJ N
risk NN N
for IN N
disease NN N
nor CC N
has VBZ N
there RB N
been VBN N
determination NN N
of IN N
the DT N
influence NN N
of IN N
setting VBG N
in IN N
which WDT N
the DT N
intervention NN N
is VBZ N
provided VBN N
. . N

In IN N
particular JJ N
, , N
family NN N
practice NN N
represents VBZ N
an DT N
ideal JJ N
setting NN N
for IN N
the DT N
provision NN N
and CC N
long-term JJ N
maintenance NN N
of IN N
lifestyle JJ N
interventions NNS N
for IN N
patients NNS N
at IN N
risk NN N
( ( N
ie JJ N
high-normal JJ N
blood NN N
pressure NN N
or CC N
impaired JJ N
glucose JJ N
tolerance NN N
) ) N
. . N

METHODS/DESIGN PDT N
The DT N
Staged NNP N
Nutrition NNP N
and CC N
Activity NNP N
Counseling NNP N
( ( N
SNAC NNP N
) ) N
study NN N
is VBZ N
a DT N
randomized JJ N
clustered JJ N
design NN N
clinical JJ N
trial NN N
that WDT N
will MD N
investigate VB N
the DT N
effectiveness NN N
and CC N
efficacy NN N
of IN N
a DT N
multi-component JJ 4_i
lifestyle JJ 4_i
intervention NN 4_i
on IN N
cardiovascular JJ N
disease NN N
risk NN N
factors NNS N
and CC N
vascular JJ N
function NN N
in IN N
patients NNS N
at IN N
risk NN N
in IN N
primary JJ N
care NN N
. . N

Patients NNS N
will MD N
be VB N
randomized VBN N
by IN N
practice NN N
to TO N
either VB N
a DT N
standard NN 4_i
of IN 4_i
care NN 4_i
lifestyle JJ 4_i
intervention NN 4_i
or CC N
a DT N
behaviourally-based JJ 4_i
, , 4_i
matched VBD 4_i
prescriptive JJ 4_i
physical JJ 4_i
activity NN 4_i
and CC 4_i
diet JJ 4_i
change NN 4_i
program NN 4_i
. . N

The DT N
primary JJ N
goal NN N
is VBZ N
to TO N
increase VB N
physical JJ N
activity NN N
and CC N
improve VB N
dietary JJ N
intake NN N
according VBG N
to TO N
Canada NNP N
's POS N
Guides NNP N
to TO N
Physical NNP N
Activity NNP N
Healthy NNP N
Eating NNP N
over IN N
24 CD N
months NNS N
. . N

The DT N
primary JJ N
intention NN N
to TO N
treat VB N
analysis NN N
will MD N
compare VB N
behavioral JJ N
, , N
physiological JJ N
and CC N
metabolic JJ N
outcomes NNS N
at IN N
6 CD N
, , N
12 CD N
and CC N
24 CD N
months NNS N
post-randomization JJ N
including VBG N
estimation NN N
of IN N
incident JJ N
hypertension NN N
and/or NN N
diabetes VBZ N
. . N

DISCUSSION VB N
The DT N
design NN N
features NNS N
of IN N
our PRP$ N
trial NN N
, , N
and CC N
the DT N
practical JJ N
problems NNS N
( ( N
and CC N
solutions NNS N
) ) N
associated VBN N
with IN N
implementing VBG N
these DT N
design NN N
features NNS N
, , N
particularly RB N
those DT N
that IN N
result NN N
in IN N
potential JJ N
delay NN N
between IN N
recruitment NN N
, , N
baseline NN N
data NNS N
collection NN N
, , N
randomization NN N
, , N
intervention NN N
, , N
and CC N
assessment NN N
will MD N
be VB N
discussed VBN N
. . N

Results NNS N
of IN N
the DT N
SNAC NNP N
trial NN N
will MD N
provide VB N
scientific JJ N
rationale NN N
for IN N
the DT N
implementation NN N
of IN N
this DT N
lifestyle JJ N
intervention NN N
in IN N
primary JJ N
care NN N
. . N

TRIAL NNP N
REGISTRATION NNP N
ISRCTN NNP N
: : N
ISRCTN:42921300 NNP N
. . N

-DOCSTART- -X- O O

Comparison NNP N
of IN N
the DT N
time NN N
required VBN N
to TO N
administer VB N
three CD N
different JJ N
fluke NNS 3_i
and CC 3_i
worm VB 3_i
combination NN 3_i
products NNS 3_i
to TO N
commercial JJ N
beef NN N
cattle NNS N
at IN N
housing NN N
. . N

Larger NNP N
livestock VBD N
units NNS N
, , N
a DT N
decline NN N
in IN N
the DT N
farm NN N
labor NN N
force NN N
, , N
animal JJ N
welfare NN N
concerns NNS N
, , N
and CC N
a DT N
trend NN N
toward IN N
more RBR N
selective JJ N
use NN N
of IN N
drugs NNS N
have VBP N
increased VBN N
the DT N
focus NN N
on IN N
animal NN N
handling NN N
, , N
time NN N
management NN N
, , N
convenience NN N
, , N
and CC N
compliance NN N
in IN N
administering VBG N
veterinary JJ N
therapeutics NNS N
. . N

This DT N
study NN N
was VBD N
undertaken VBN N
to TO N
quantify VB N
and CC N
compare VB N
the DT N
time NN N
needed VBN N
to TO N
treat VB N
commercial JJ N
beef NN N
cattle NNS N
with IN N
three CD 3_i
fluke NNS 3_i
and CC 3_i
worm VB 3_i
combination NN 3_i
products NNS 3_i
with IN N
different JJ N
administration NN N
profiles NNS N
. . N

Young NNP N
beef NN N
cattle NNS N
( ( N
n JJ N
= NNP N
270 CD N
) ) N
weighing VBG N
approximately RB N
400 CD N
kg NNS N
were VBD N
allocated VBN N
to TO N
batches NNS N
of IN N
five CD N
, , N
which WDT N
were VBD N
randomly RB N
assigned VBN N
to TO N
receive VB N
ivermectin NN 3_i
+ NNP N
clorsulon NN 3_i
injection NN 3_i
, , N
ivermectin JJ 3_i
+ JJ N
closantel NN 3_i
injection NN 3_i
, , N
or CC N
levamisole JJ 3_i
+ JJ N
triclabendazole JJ 3_i
oral JJ N
drench NN N
. . N

The DT N
mean JJ N
time NN N
needed VBN N
to TO N
administer VB N
ivermectin JJ 3_i
+ NN N
clorsulon NN 3_i
( ( N
single JJ N
injection NN N
) ) N
to TO N
five CD N
cattle NNS N
was VBD N
31 CD N
seconds NNS N
, , N
which WDT N
was VBD N
significantly RB N
less JJR N
than IN N
the DT N
100 CD N
seconds NNS N
needed VBN N
for IN N
ivermectin JJ 3_i
+ JJ N
closantel NN 3_i
( ( N
two CD N
injections NNS N
) ) N
and CC N
the DT N
126 CD N
seconds NNS N
needed VBN N
for IN N
levamisole JJ 3_i
+ JJ N
triclabendazole NN 3_i
( ( N
P NNP N
< NNP N
.001 NNP N
) ) N
. . N

Such JJ N
quantitative JJ N
data NNS N
can MD N
allow VB N
for IN N
better JJR N
planning NN N
and CC N
selection NN N
of IN N
parasiticide JJ N
treatment NN N
approaches NNS N
at IN N
the DT N
farm NN N
level NN N
. . N

-DOCSTART- -X- O O

The DT N
acute JJ N
effects NNS N
of IN N
fluid JJ N
intake NN N
on IN N
urine JJ N
specific JJ N
gravity NN N
and CC N
fluid JJ N
retention NN N
in IN N
a DT N
mildly RB N
dehydrated JJ N
state NN N
. . N

Many JJ N
athletes NNS N
arrive VBP N
at IN N
training NN N
sessions NNS N
and CC N
competitions NNS N
in IN N
a DT N
mildly RB N
hypohydrated VBN N
( ( N
HYPO NNP N
) ) N
state NN N
and CC N
are VBP N
instructed VBN N
to TO N
drink VB N
fluids NNS N
before IN N
exercise NN N
to TO N
reach VB N
a DT N
euhydrated JJ N
( ( N
HYD NNP N
) ) N
state NN N
. . N

Ten CD N
recreational JJ N
athletes NNS N
( ( N
6 CD N
women NNS N
, , N
4 CD N
men NNS N
; : N
71.9 CD N
? . N
4.6 CD N
kg NN N
, , N
25.2 CD N
? . N
0.9 CD N
years NNS N
) ) N
participated VBD N
in IN N
the DT N
studies NNS N
to TO N
examine VB N
( ( N
a DT N
) ) N
the DT N
day-to-day JJ N
variability NN N
of IN N
morning NN N
urine NN N
specific JJ N
gravity NN N
( ( N
USG NNP N
) ) N
, , N
( ( N
b NN N
) ) N
the DT N
effects NNS N
of IN N
consuming VBG N
600 CD 4_i
ml NN 4_i
of IN 4_i
water NN 4_i
on IN N
the DT N
hydration NN N
status NN N
of IN N
HYD NNP N
and CC N
HYPO NNP N
( ( N
USG NNP N
> NNP N
1.020 CD N
) ) N
subjects NNS N
, , N
and CC N
( ( N
c NN N
) ) N
the DT N
effects NNS N
of IN N
consuming VBG N
water NN 4_i
( ( 4_i
W NNP 4_i
) ) 4_i
, , N
salt-water JJ 4_i
( ( 4_i
SW NNP N
, , N
40 CD N
mM NN N
Na NNP N
) ) N
, , N
a DT N
carbohydrate-electrolyte JJ 4_i
solution NN 4_i
with IN 4_i
3 CD 4_i
% NN 4_i
or CC 4_i
light JJ 4_i
carbohydrate NN 4_i
( ( 4_i
CES-L NNP N
, , N
20 CD N
mM NN N
Na NNP N
) ) N
or CC N
a DT N
CES NN 4_i
with IN 4_i
6 CD 4_i
% NN 4_i
carbohydrate NN 4_i
( ( 4_i
CES NNP N
, , N
20 CD N
mM NN N
Na NNP N
) ) N
on IN N
the DT N
hydration NN N
status NN N
of IN N
HYPO NNP N
subjects NNS N
. . N

The DT N
hydration NN N
status NN N
was VBD N
assessed VBN N
with IN N
USG NNP N
and CC N
body NN N
mass NN N
measures NNS N
and CC N
urine JJ N
volume NN N
collections NNS N
. . N

The DT N
day-to-day JJ N
variability NN N
in IN N
morning NN N
USG NNP N
( ( N
coefficient NN N
of IN N
variation NN N
= FW N
0.2 CD N
? . N
0.1 CD N
% NN N
) ) N
was VBD N
low JJ N
and CC N
the DT N
responses NNS N
to TO N
600 CD N
ml NN N
of IN N
W NNP N
ingestion NN N
were VBD N
repeatable JJ N
. . N

Pretrial JJ N
USG NNP N
was VBD N
1.022 CD N
? . N
0.001 CD N
in IN N
the DT N
HYPO NNP N
trial NN N
and CC N
decreased VBD N
< NNS N
1.020 CD N
by IN N
45 CD N
minutes NNS N
( ( N
1.013 CD N
? . N
0.003 CD N
) ) N
. . N

In IN N
the DT N
CES NNP N
study NN N
, , N
HYPO NNP N
subjects VBZ N
reached VBN N
HYD NNP N
status NN N
at IN N
45 CD N
minutes NNS N
in IN N
all DT N
conditions NNS N
( ( N
W NNP N
1.013 CD N
? . N
0.003 CD N
, , N
SW NNP N
1.013 CD N
? . N
0.003 CD N
, , N
CES-L NNP N
1.011 CD N
? . N
0.003 CD N
, , N
CES NNP N
1.017 CD N
? . N
0.004 CD N
) ) N
because IN N
salt NN N
or CC N
CES NNP N
ingestion NN N
did VBD N
not RB N
affect VB N
fluid NN N
retention NN N
( ( N
W NNP N
68 CD N
% NN N
, , N
SW NNP N
72 CD N
% NN N
, , N
CES-L JJ N
68 CD N
% NN N
, , N
CES NNP N
76 CD N
% NN N
) ) N
. . N

This DT N
study NN N
demonstrated VBD N
that IN N
mildly RB N
HYPO NNP N
subjects NNS N
could MD N
reach VB N
euhydration NN N
within IN N
45 CD N
minutes NNS N
of IN N
the DT N
ingestion NN N
of IN N
600 CD N
ml NN N
of IN N
W NNP N
or CC N
a DT N
combination NN N
of IN N
salt NN N
and CC N
CES NNP N
solutions NNS N
. . N

Following VBG N
this DT N
practice NN N
will MD N
minimize VB N
the DT N
incidence NN N
of IN N
starting VBG N
a DT N
practice NN N
or CC N
competition NN N
hypohydrated VBN N
. . N

-DOCSTART- -X- O O

Hip NNP 2_i
protectors NNS 2_i
improve VBP N
falls VBZ N
self-efficacy NN N
. . N

OBJECTIVES NNP N
To TO N
investigate VB N
the DT N
effect NN N
of IN N
use NN N
of IN N
external JJ 2_i
hip NN 2_i
protectors NNS 2_i
on IN N
subjects NNS N
' POS N
fear NN N
of IN N
falling VBG N
and CC N
falls VBZ N
self-efficacy NN N
( ( N
belief NN N
in IN N
their PRP$ N
own JJ N
ability NN N
to TO N
avoid VB N
falling VBG N
) ) N
. . N

DESIGN NNP N
Randomized NNP N
controlled VBD N
trial NN N
. . N

SETTING CC N
Aged-care JJ N
health NN N
services NNS N
in IN N
Sydney NNP N
, , N
Australia NNP N
. . N

PARTICIPANTS NNP N
131 CD N
women NNS N
aged VBN N
75 CD N
years NNS N
or CC N
older JJR N
, , N
who WP N
had VBD N
two CD N
or CC N
more JJR N
falls NNS N
or CC N
one CD N
fall NN N
requiring VBG N
hospital JJ N
admission NN N
in IN N
the DT N
previous JJ N
year NN N
and CC N
who WP N
live VBP N
at IN N
home NN N
. . N

Sixty-one JJ N
subjects NNS N
were VBD N
in IN N
the DT N
intervention NN N
group NN N
and CC N
70 CD N
in IN N
the DT N
control NN 7_i
group NN N
. . N

INTERVENTION NNP N
Use NNP N
of IN N
external JJ 2_i
hip NN 2_i
protectors NNS 2_i
and CC N
encouragement NN 2_i
to TO 2_i
use VB 2_i
the DT 2_i
protectors NNS 2_i
by IN 2_i
an DT 2_i
adherence NN 2_i
nurse NN 2_i
. . N

MEASUREMENTS CC N
At IN N
the DT N
time NN N
of IN N
enrolment NN N
into IN N
a DT N
wider NN N
study NN N
examining VBG N
the DT N
effect NN N
of IN N
hip NN 2_i
protectors NNS 2_i
on IN N
hip NN N
fractures NNS N
, , N
participants NNS N
recruited VBD N
at IN N
home NN N
completed VBD N
an DT N
assessment NN N
of IN N
fear NN N
of IN N
falling VBG N
and CC N
falls VBZ N
efficacy NN N
as IN N
measured VBN N
by IN N
the DT N
Falls NNP N
Efficacy NNP N
Scale NNP N
and CC N
the DT N
Modified NNP N
Falls NNP N
Efficacy NNP N
Scale NNP N
. . N

At IN N
4-month JJ N
follow-up NN N
, , N
these DT N
scales NNS N
were VBD N
readministered VBN N
by IN N
an DT N
observer NN N
who WP N
was VBD N
not RB N
aware JJ N
of IN N
the DT N
allocation NN N
of IN N
the DT N
participant NN N
to TO N
intervention NN N
or CC N
control NN N
groups NNS N
. . N

RESULTS NNP N
Fear NNP N
of IN N
falling VBG N
and CC N
falls VBZ N
self-efficacy NN N
, , N
as IN N
measured VBN N
by IN N
the DT N
Falls NNP N
Efficacy NNP N
and CC N
Modified NNP N
Falls NNP N
Efficacy NNP N
Scales NNP N
, , N
were VBD N
similar JJ N
at IN N
baseline NN N
in IN N
both DT N
groups NNS N
. . N

Fear NN N
of IN N
falling VBG N
was VBD N
present JJ N
at IN N
follow-up NN N
in IN N
43 CD N
% NN N
of IN N
subjects NNS N
using VBG N
hip NN N
protectors NNS N
and CC N
57 CD N
% NN N
of IN N
the DT N
control NN N
group NN N
( ( N
chi2 JJ N
= NN N
2.58 CD N
, , N
P NNP N
= NNP N
0.11 CD N
) ) N
. . N

Hip NNP 2_i
protector NN 2_i
users NNS N
had VBD N
greater JJR N
improvement NN N
in IN N
falls VBZ N
self-efficacy NN N
at IN N
follow-up JJ N
as IN N
measured VBN N
by IN N
the DT N
Falls NNP N
Efficacy NNP N
Scale NNP N
( ( N
t JJ N
= NN N
2.44 CD N
, , N
P NNP N
= NNP N
0.016 CD N
) ) N
and CC N
the DT N
Modified NNP N
Falls NNP N
Efficacy NNP N
Scale NNP N
( ( N
t JJ N
= NN N
2.08 CD N
, , N
P NNP N
= NNP N
0.039 CD N
) ) N
. . N

CONCLUSION NNP N
Hip NNP 2_i
protectors NNS 2_i
improve VBP N
falls VBZ N
self-efficacy NN N
. . N

As IN N
users NNS N
of IN N
hip NN 2_i
protectors NNS 2_i
feel VBP N
more RBR N
confident JJ N
that IN N
they PRP N
can MD N
complete VB N
tasks NNS N
safely RB N
, , N
they PRP N
may MD N
become VB N
more RBR N
physically RB N
active JJ N
and CC N
require VB N
less JJR N
assistance NN N
with IN N
activities NNS N
of IN N
daily JJ N
living NN N
. . N

-DOCSTART- -X- O O

Comparative JJ N
efficacy NN N
and CC N
safety NN N
of IN N
twice JJ N
daily JJ N
fluticasone NN 3_i
propionate NN 3_i
powder NN 3_i
versus NN N
placebo NN 7_i
in IN N
the DT N
treatment NN N
of IN N
moderate JJ N
asthma NN N
. . N

BACKGROUND NNP N
Fluticasone NNP 3_i
propionate NN 3_i
, , N
an DT N
inhaled JJ N
corticosteroid NN N
with IN N
negligible JJ N
systemic JJ N
bioavailability NN N
via IN N
the DT N
oral JJ N
route NN N
, , N
is VBZ N
efficacious JJ N
in IN N
the DT N
treatment NN N
of IN N
asthma NN N
when WRB N
administered VBN N
via IN N
metered-dose JJ N
inhaler NN N
. . N

OBJECTIVE UH N
To TO N
evaluate VB N
the DT N
efficacy NN N
and CC N
safety NN N
of IN N
inhaled JJ 3_i
fluticasone NN 3_i
propionate NN 3_i
powder NN 3_i
in IN N
patients NNS N
with IN N
moderate JJ N
asthma NNS N
previously RB N
treated VBN N
with IN N
an DT N
inhaled JJ N
corticosteroid NN N
. . N

METHODS NNP N
This DT N
was VBD N
a DT N
randomized JJ N
, , N
double-blind JJ N
, , N
placebo-controlled JJ N
, , N
parallel-group JJ N
, , N
multicenter NN N
study NN N
of IN N
342 CD N
adolescent NN N
and CC N
adult NN N
patients NNS N
with IN N
moderate JJ N
asthma NNS N
[ RB N
forced VBD N
expiratory JJ N
volume NN N
in IN N
1 CD N
second JJ N
( ( N
FEV1 NNP N
) ) N
between IN N
50 CD N
% NN N
and CC N
80 CD N
% NN N
of IN N
predicted JJ N
] NNP N
treated VBD N
previously RB N
by IN N
beclomethasone NN 3_i
dipropionate NN 3_i
or CC N
triamcinolone NN 3_i
acetonide RB 3_i
. . 3_i

Patients NNS N
received VBD N
fluticasone JJ 3_i
propionate NN 3_i
powder NN 3_i
50 CD N
micrograms NNS N
, , N
100 CD N
micrograms NNS N
, , N
250 CD N
micrograms NNS N
, , N
or CC N
placebo NN 7_i
via IN N
a DT N
breath-actuated JJ N
inhalation NN N
device NN N
, , N
the DT N
Diskhaler NNP N
, , N
twice RB N
daily RB N
for IN N
12 CD N
weeks NNS N
. . N

RESULTS JJ N
Patients NNPS N
in IN N
the DT N
fluticasone NN N
propionate NN N
groups NNS N
experienced VBD N
a DT N
mean JJ N
increase NN N
from IN N
baseline NN N
to TO N
endpoint VB N
in IN N
FEV1 NNP N
ranging VBG N
from IN N
0.43 CD N
L NNP N
to TO N
0.47 CD N
L. NNP N
Patients NNPS N
in IN N
the DT N
placebo NN N
group NN N
experienced VBD N
a DT N
mean JJ N
decrease NN N
from IN N
baseline NN N
of IN N
0.22 CD N
L NNP N
( ( N
P NNP N
< NNP N
.001 NNP N
) ) N
. . N

The DT N
probability NN N
of IN N
patients NNS N
remaining VBG N
in IN N
the DT N
study NN N
over IN N
time NN N
without IN N
developing VBG N
signs NNS N
of IN N
exacerbating VBG N
asthma NN N
was VBD N
significantly RB N
greater JJR N
in IN N
the DT N
fluticasone NN N
propionate NN N
groups NNS N
than IN N
in IN N
the DT N
placebo NN N
group NN N
( ( N
P NNP N
= NNP N
.001 NNP N
) ) N
. . N

Asthma NNP N
symptom NN N
scores NNS N
, , N
supplemental JJ N
rescue NN N
albuterol NN N
use NN N
, , N
and CC N
number NN N
of IN N
nighttime JJ N
awakenings NNS N
due JJ N
to TO N
asthma VB N
requiring VBG N
treatment NN N
also RB N
improved VBN N
significantly RB N
with IN N
all DT N
fluticasone NN N
propionate NN N
treatment NN N
regimens NNS N
compared VBN N
with IN N
placebo NN N
( ( N
P NNP N
< NNP N
.001 NNP N
) ) N
. . N

There EX N
were VBD N
no DT N
statistically RB N
significant JJ N
differences NNS N
at IN N
endpoint NN N
among IN N
the DT N
three CD N
fluticasone NN N
propionate NN N
groups NNS N
. . N

No DT N
serious JJ N
drug-related JJ N
adverse JJ N
events NNS N
occurred VBD N
. . N

CONCLUSIONS NNP N
Fluticasone NNP N
propionate NN N
powder NN N
( ( N
50 CD N
, , N
100 CD N
, , N
and CC N
250 CD N
micrograms NNS N
) ) N
was VBD N
well-tolerated JJ N
and CC N
significantly RB N
improved VBN N
lung NN N
function NN N
in IN N
patients NNS N
with IN N
moderate JJ N
asthma NNS N
. . N

-DOCSTART- -X- O O

Comparison NNP N
of IN N
neodymium-doped JJ 1_i
yttrium NN 1_i
aluminum NN 1_i
garnet NN 1_i
laser NN 1_i
treatment NN 1_i
with IN N
cold JJ 1_i
knife NN 1_i
endoscopic NN 1_i
incision NN 1_i
of IN N
urethral JJ N
strictures NNS N
in IN N
male JJ N
patients NNS N
. . N

OBJECTIVE NNP N
To TO N
assess VB N
the DT N
effectiveness NN N
of IN N
visual JJ 1_i
laser NN 1_i
ablation NN 1_i
treatment NN 1_i
with IN 1_i
neodymium-doped JJ 1_i
yttrium NN 1_i
aluminum NN 1_i
garnet NN 1_i
( ( 1_i
Nd NNP 1_i
: : 1_i
YAG NN 1_i
) ) 1_i
laser NN N
in IN N
male JJ N
patients NNS N
with IN N
urethral JJ N
strictures NNS N
and CC N
to TO N
compare VB N
the DT N
effects NNS N
with IN N
those DT N
obtained VBN N
in IN N
patients NNS N
treated VBN N
with IN N
Sachse NNP N
's POS N
optical JJ N
urethrotomy NN N
. . N

MATERIALS NNP N
AND CC N
METHODS NNP N
Fifty NNP N
patients NNS N
aged VBD N
22 CD N
to TO N
83 CD N
( ( N
mean JJ N
age NN N
61.8 CD N
) ) N
with IN N
primary JJ N
( ( N
n JJ N
= NN N
26 CD N
, , N
52 CD N
% NN N
) ) N
and CC N
recurrent NN N
( ( N
n JJ N
= NN N
24 CD N
, , N
48 CD N
% NN N
) ) N
urethral JJ N
strictures VBZ N
0.3 CD N
to TO N
2.4 CD N
cm NNS N
long RB N
qualified VBD N
for IN N
the DT N
study NN N
. . N

The DT N
patients NNS N
were VBD N
randomized VBN N
into IN N
two CD N
groups NNS N
: : N
30 CD N
men NNS N
treated VBD N
using VBG N
visual JJ 1_i
laser NN 1_i
ablation NN 1_i
of IN 1_i
urethral JJ 1_i
strictures NNS 1_i
( ( 1_i
VLASU NNP 1_i
) ) 1_i
with IN 1_i
Nd NNP 1_i
: : 1_i
YAGlaser NN 1_i
and CC N
20 CD N
men NNS N
treated VBN N
by IN N
correction NN N
of IN N
urethral JJ N
strictures NNS N
using VBG N
Sachse NNP 1_i
's POS 1_i
optical JJ 1_i
urethrotomy NN 1_i
. . N

RESULTS VB N
At IN N
12-month JJ N
follow-up NN N
, , N
seven CD N
( ( N
35 CD N
% NN N
) ) N
patients NNS N
who WP N
underwent JJ N
optical JJ 1_i
urethrotomy NN 1_i
and CC N
21 CD N
( ( N
70 CD N
% NN N
) ) N
in IN N
the DT N
VLASU NNP 1_i
group NN N
did VBD N
not RB N
require VB N
repetition NN N
of IN N
the DT N
procedure NN N
. . N

The DT N
choice NN N
of IN N
VLASU NNP 1_i
as IN N
a DT N
method NN N
of IN N
treatment NN N
significantly RB N
decreased VBD N
the DT N
probability NN N
of IN N
therapeutic JJ N
failure NN N
and CC N
recurrence NN N
of IN N
urethral JJ N
strictures NNS N
( ( N
p JJ N
= NNP N
0.02 CD N
) ) N
. . N

CONCLUSION NNP N
VLASU NNP 1_i
can MD N
be VB N
used VBN N
as IN N
a DT N
method NN N
of IN N
treatment NN N
of IN N
this DT N
disorder NN N
. . N

It PRP N
is VBZ N
an DT N
effective JJ N
, , N
modern JJ N
, , N
low-invasive JJ N
, , N
and CC N
repeatable JJ N
technique NN N
and CC N
is VBZ N
technically RB N
simple JJ N
and CC N
easy JJ N
to TO N
master NN N
. . N

It PRP N
can MD N
be VB N
used VBN N
in IN N
cases NNS N
in IN N
which WDT N
introduction NN N
of IN N
a DT N
22 CD N
Char NNP N
optical JJ N
urethrotome NN N
into IN N
the DT N
stricture NN N
site NN N
is VBZ N
impossible JJ N
, , N
as RB N
well RB N
as IN N
for IN N
treatment NN N
of IN N
multiple JJ N
strictures NNS N
during IN N
one CD N
procedure NN N
. . N

-DOCSTART- -X- O O

Double-blind NNP N
comparison NN N
of IN N
the DT N
efficacy NN N
and CC N
safety NN N
of IN N
trandolapril JJ 3_i
2 CD N
mg NN N
and CC N
hydrochlorothiazide VB 3_i
25 CD N
mg NNS N
in IN N
patients NNS N
with IN N
mild-to-moderate JJ N
essential JJ N
hypertension NN N
. . N

Investigator NNP N
Study NNP N
Group NNP N
. . N

This DT N
multicenter NN N
international JJ N
trial NN N
recruited VBD N
205 CD N
patients NNS N
from IN N
16 CD N
investigators NNS N
. . N

After IN N
a DT N
4-week JJ N
, , N
single-blind JJ N
placebo NN 7_i
run-in NN N
, , N
patients NNS N
were VBD N
randomized VBN N
to TO N
receive VB N
16 CD N
weeks NNS N
of IN N
trandolapril JJ 3_i
2 CD N
mg/day NN N
( ( N
68 CD N
patients NNS N
) ) N
, , N
hydrochlorothiazide RB 3_i
( ( 3_i
HCTZ NNP 3_i
) ) 3_i
25 CD N
mg/day NN N
( ( N
68 CD N
patients NNS N
) ) N
, , N
or CC N
the DT N
combination NN N
( ( N
69 CD N
patients NNS N
) ) N
. . N

Morning VBG N
predosing VBG N
supine NN N
diastolic JJ N
blood NN N
pressure NN N
( ( N
DBP NNP N
) ) N
was VBD N
the DT N
primary JJ N
efficacy NN N
measurement NN N
. . N

Intention-to-treat JJ N
analysis NN N
showed VBD N
significant JJ N
decreases NNS N
in IN N
all DT N
three CD N
groups NNS N
in IN N
mean JJ N
( ( N
+/- JJ N
SEM NNP N
) ) N
supine NN N
DBP NNP N
throughout IN N
the DT N
study NN N
, , N
with IN N
no DT N
significant JJ N
differences NNS N
at IN N
week NN N
16 CD N
between IN N
trandolapril NN N
( ( N
-10.6 JJ N
+/- JJ N
1.3 CD N
mm NN N
Hg NNP N
) ) N
and CC N
HCTZ NNP N
( ( N
-10.9 JJ N
+/- JJ N
1.3 CD N
mm NN N
Hg NNP N
) ) N
. . N

The DT N
combination NN N
gave VBD N
a DT N
significantly RB N
greater JJR N
reduction NN N
than IN N
either DT N
drug NN N
alone RB N
( ( N
-15.1 JJ N
+/- JJ N
1.13 CD N
mm NN N
Hg NNP N
) ) N
. . N

Blood NNP N
pressure NN N
was VBD N
normalized VBN N
in IN N
the DT N
combination NN N
group NN N
in IN N
67 CD N
% NN N
of IN N
patients NNS N
, , N
a DT N
significantly RB N
higher JJR N
proportion NN N
than IN N
either DT N
trandolapril NN N
( ( N
63 CD N
% NN N
) ) N
or CC N
HCTZ NNP N
( ( N
60 CD N
% NN N
; : N
p CC N
= VB N
0.04 CD N
) ) N
. . N

Each DT N
treatment NN N
was VBD N
well RB N
tolerated VBN N
. . N

The DT N
incidence NN N
of IN N
adverse JJ N
events NNS N
was VBD N
similar JJ N
in IN N
all DT N
three CD N
groups NNS N
. . N

Trandolapril NNP N
2 CD N
mg NN N
once RB N
daily JJ N
is VBZ N
an DT N
effective JJ N
antihypertensive JJ N
agent NN N
, , N
comparable JJ N
to TO N
HCTZ NNP N
. . N

Furthermore NNP N
, , N
the DT N
combination NN N
of IN N
the DT N
two CD N
drugs NNS N
was VBD N
shown VBN N
to TO N
enhance VB N
the DT N
antihypertensive JJ N
effect NN N
of IN N
the DT N
two CD N
compounds NNS N
alone RB N
. . N

-DOCSTART- -X- O O

Parents NNS N
' POS N
state NN N
and CC N
trait NN N
anxiety NN N
: : N
relationships NNS N
with IN N
anxiety NN N
severity NN N
and CC N
treatment NN N
response NN N
in IN N
adolescents NNS N
with IN N
autism NN N
spectrum NN N
disorders NNS N
. . N

Comorbid NNP N
anxiety NN N
is VBZ N
common JJ N
among IN N
children NNS N
with IN N
Autism NNP N
Spectrum NNP N
Disorder NNP N
( ( N
ASD NNP N
) ) N
, , N
and CC N
parents NNS N
of IN N
children NNS N
with IN N
ASD NNP N
are VBP N
more RBR N
likely JJ N
to TO N
have VB N
anxiety NN N
disorders NNS N
. . N

This DT N
study NN N
investigated VBD N
the DT N
relationship NN N
between IN N
parents NNS 5_i
' POS 5_i
state NN 5_i
and CC 5_i
trait NN 5_i
anxiety NN 5_i
and CC N
parent-reported JJ 4_i
internalizing NN 4_i
and CC 6_i
externalizing VBG 4_i
symptoms NNS 4_i
among IN N
adolescents NNS N
( ( N
n JJ N
= NNP N
30 CD N
) ) N
with IN N
ASD NNP N
, , N
as RB N
well RB N
as IN N
the DT N
relationship NN N
of IN N
parents NNS N
' POS N
anxiety NN N
symptoms NNS N
and CC N
adolescent JJ N
treatment NN N
response NN N
in IN N
the DT N
context NN N
of IN N
a DT N
randomized VBN N
controlled VBN N
trial NN N
. . N

Parental JJ N
state NN N
anxiety NN N
correlated VBD N
with IN N
severity NN N
of IN N
adolescent JJ N
anxiety NN N
, , N
and CC N
trait NN N
anxiety NN N
in IN N
parents NNS N
correlated VBN N
with IN N
parent-reported JJ N
adolescent NN N
internalizing NN N
and CC N
externalizing NN N
symptoms NNS N
. . N

Also RB N
, , N
parents NNS N
of IN N
adolescent JJ N
treatment NN N
responders NNS N
experienced VBD N
a DT N
decrease NN N
in IN N
their PRP$ N
own JJ N
trait NN N
anxiety NN N
. . N

Findings NNS N
highlight VBD N
the DT N
importance NN N
of IN N
considering VBG N
parental JJ N
anxiety NN N
when WRB N
targeting VBG N
anxiety NN N
among IN N
youth NN N
with IN N
ASD NNP N
. . N

-DOCSTART- -X- O O

Randomized VBN N
, , N
double-blind JJ N
, , N
placebo-controlled JJ 7_i
trial NN N
of IN N
oral JJ N
sirolimus NN N
for IN N
restenosis NN N
prevention NN N
in IN N
patients NNS N
with IN N
in-stent JJ N
restenosis NN N
: : N
the DT N
Oral NNP N
Sirolimus NNP 3_i
to TO N
Inhibit NNP N
Recurrent NNP N
In-stent JJ N
Stenosis NNP N
( ( N
OSIRIS NNP N
) ) N
trial NN N
. . N

BACKGROUND NNP N
Despite IN N
recent JJ N
advances NNS N
in IN N
interventional JJ N
cardiology NN N
, , N
including VBG N
the DT N
introduction NN N
of IN N
drug-eluting JJ N
stents NNS N
for IN N
de FW N
novo FW N
coronary JJ N
lesions NNS N
, , N
the DT N
treatment NN N
of IN N
in-stent JJ N
restenosis NN N
( ( N
ISR NNP N
) ) N
remains VBZ N
a DT N
challenging JJ N
clinical JJ N
issue NN N
. . N

Given VBN N
the DT N
efficacy NN N
of IN N
systemic JJ N
sirolimus JJ N
administration NN N
to TO N
prevent VB N
neointimal JJ N
hyperplasia NN N
in IN N
animal JJ N
models NNS N
and CC N
to TO N
halt VB N
and CC N
even RB N
reverse VB N
the DT N
progression NN N
of IN N
allograft NN N
vasculopathy NN N
, , N
the DT N
aim NN N
of IN N
the DT N
present JJ N
double-blind NN N
, , N
placebo-controlled JJ N
study NN N
was VBD N
to TO N
evaluate VB N
the DT N
efficacy NN N
of IN N
a DT N
10-day JJ N
oral JJ N
sirolimus NN N
treatment NN N
with IN N
2 CD N
different JJ N
loading VBG N
regimens NNS N
for IN N
the DT N
prevention NN N
of IN N
recurrent JJ N
restenosis NN N
in IN N
patients NNS N
with IN N
ISR NNP N
. . N

METHODS NNP N
AND CC N
RESULTS NNP N
Three NNP N
hundred VBD N
symptomatic JJ N
patients NNS N
with IN N
ISR NNP N
were VBD N
randomly RB N
assigned VBN N
to TO N
1 CD N
of IN N
3 CD N
treatment NN N
arms NNS N
: : N
placebo NN 7_i
or CC N
usual-dose JJ N
or CC N
high-dose JJ N
sirolimus NN 3_i
. . N

Patients NNS N
received VBD N
a DT N
cumulative JJ N
loading NN N
dose NN N
of IN N
0 CD N
, , N
8 CD N
, , N
or CC N
24 CD N
mg NN N
of IN N
sirolimus JJ N
2 CD N
days NNS N
before IN N
and CC N
the DT N
day NN N
of IN N
repeat NN N
intervention NN N
followed VBN N
by IN N
maintenance NN N
therapy NN N
of IN N
2 CD N
mg/d NN N
for IN N
7 CD N
days NNS N
. . N

Angiographic JJ N
restenosis NN N
at IN N
6-month JJ N
angiography NN N
was VBD N
the DT N
primary JJ N
end NN N
point NN N
of IN N
the DT N
study NN N
. . N

Restenosis NNP N
was VBD N
significantly RB N
reduced VBN N
from IN N
42.2 CD N
% NN N
to TO N
38.6 CD N
% NN N
and CC N
to TO N
22.1 CD N
% NN N
in IN N
the DT N
placebo NN N
, , N
usual-dose JJ N
, , N
and CC N
high-dose JJ N
sirolimus NN N
groups NNS N
, , N
respectively RB N
( ( N
P=0.005 NNP N
) ) N
. . N

Similarly RB N
, , N
the DT N
need NN N
for IN N
target NN N
vessel JJ N
revascularization NN N
was VBD N
reduced VBN N
from IN N
25.5 CD N
% NN N
to TO N
24.2 CD N
% NN N
and CC N
to TO N
15.2 CD N
% NN N
in IN N
the DT N
placebo NN N
, , N
usual-dose JJ N
, , N
and CC N
high-dose JJ N
groups NNS N
, , N
respectively RB N
( ( N
P=0.08 NNP N
) ) N
. . N

The DT N
sirolimus JJ N
blood NN N
concentration NN N
on IN N
the DT N
day NN N
of IN N
the DT N
procedure NN N
correlated VBD N
significantly RB N
with IN N
the DT N
late JJ N
lumen NNS N
loss NN N
at IN N
follow-up JJ N
( ( N
P NNP N
< NNP N
0.001 CD N
) ) N
. . N

CONCLUSIONS NNP N
In IN N
patients NNS N
with IN N
ISR NNP N
, , N
an DT N
oral JJ N
adjunctive JJ N
sirolimus NN N
treatment NN N
with IN N
an DT N
intensified JJ N
loading NN N
regimen NNS N
before IN N
coronary JJ N
intervention NN N
resulted VBD N
in IN N
a DT N
significant JJ N
improvement NN N
in IN N
the DT N
angiographic JJ N
parameters NNS N
of IN N
restenosis NN N
. . N

-DOCSTART- -X- O O

Controlled VBN N
clinical JJ N
trial NN N
of IN N
IV NNP N
cyclophosphamide NN 3_i
versus NN N
IV NNP N
methylprednisolone NN 3_i
in IN N
severe JJ N
neurological JJ N
manifestations NNS N
in IN N
systemic JJ N
lupus NN N
erythematosus NN N
. . N

BACKGROUND NNP N
Severe NNP N
neurological JJ N
involvement NN N
in IN N
systemic JJ N
lupus NN N
erythematosus NN N
( ( N
NPSLE NNP N
) ) N
is VBZ N
one CD N
of IN N
the DT N
most RBS N
dreadful JJ N
complications NNS N
of IN N
the DT N
disease NN N
. . N

OBJECTIVE UH N
To TO N
identify VB N
the DT N
best JJS N
drug NN N
, , N
dose NN N
, , N
and CC N
treatment NN N
. . N

PATIENTS NNP N
AND CC N
METHODS NNP N
The DT N
study NN N
was VBD N
a DT N
controlled JJ N
clinical JJ N
trial NN N
at IN N
two CD N
tertiary JJ N
care NN N
centres NNS N
of IN N
patients NNS N
with IN N
SLE NNP N
according VBG N
to TO N
the DT N
ACR NNP N
criteria NNS N
, , N
with IN N
incident NN N
( ( N
no DT N
more JJR N
than IN N
15 CD N
days NNS N
) ) N
onset NN N
of IN N
severe JJ N
NP NNP N
manifestations NNS N
such JJ N
as IN N
seizures NNS N
, , N
optic JJ N
neuritis NN N
, , N
peripheral JJ N
or CC N
cranial JJ N
neuropathy NN N
, , N
coma NN N
, , N
brainstem NN N
disease NN N
, , N
or CC N
transverse JJ N
myelitis NN N
. . N

Induction NNP N
treatment NN N
with IN N
3 CD N
g NN N
of IN N
IV NNP N
methylprednisolone NN 3_i
( ( N
MP NNP N
) ) N
followed VBN N
by IN N
either DT N
IV NNP N
monthly JJ N
cyclophosphamide NN 3_i
( ( N
Cy NNP N
) ) N
versus NN N
IV NNP 3_i
MP NNP 3_i
bimonthly RB 3_i
every DT N
4 CD N
months NNS N
for IN N
1 CD N
year NN N
and CC N
then RB N
IV NNP N
Cy NNP N
or CC N
IV NNP N
MP NNP N
every DT N
3 CD N
months NNS N
for IN N
another DT N
year NN N
. . N

The DT N
primary JJ N
end NN N
point NN N
was VBD N
response NN N
to TO N
treatment NN N
: : N
at IN N
least JJS N
20 CD N
% NN N
improvement NN N
from IN N
basal JJ N
conditions NNS N
on IN N
clinical JJ N
, , N
laboratory NN N
, , N
or CC N
specific JJ N
neurological JJ N
testing NN N
variables NNS N
. . N

RESULTS NNP N
Overall NNP N
, , N
a DT N
response NN N
rate NN N
of IN N
75 CD N
% NN N
was VBD N
observed VBN N
. . N

Of IN N
the DT N
32 CD N
patients NNS N
studied VBN N
, , N
18/19 CD N
receiving VBG N
Cy NNP N
and CC N
7/13 CD N
receiving VBG N
MP NNP N
responded VBD N
to TO N
treatment NN N
( ( N
p JJ N
< NNP N
0.03 CD N
) ) N
. . N

CONCLUSIONS NNP N
Cy NNP N
seems VBZ N
to TO N
be VB N
more RBR N
effective JJ N
than IN N
MP NNP N
in IN N
the DT N
treatment NN N
of IN N
acute NN N
, , N
severe JJ N
NPSLE NNP N
. . N

-DOCSTART- -X- O O

Glibenclamide NNP 3_i
vs NN N
gliclazide NN 3_i
in IN N
reducing VBG N
oxidative JJ N
stress NN N
in IN N
patients NNS N
of IN N
noninsulin JJ N
dependent JJ N
diabetes VBZ N
mellitus NN N
-- : N
a DT N
double JJ N
blind NN N
randomized VBN N
study NN N
. . N

OBJECTIVE NNP N
Parameters NNPS N
of IN N
oxidative JJ N
stress NN N
were VBD N
quantitated VBN N
in IN N
50 CD N
patients NNS N
with IN N
type JJ N
2 CD N
diabetes NNS N
mellitus VBP N
in IN N
uncontrolled JJ N
state NN N
and CC N
after IN N
control NN N
using VBG N
oral JJ N
glibenclamide NN 3_i
or CC N
gliclazide NN 3_i
. . N

The DT N
estimates NNS N
were VBD N
further RB N
compared VBN N
between IN N
the DT N
two CD N
groups NNS N
irrespective JJ N
of IN N
drug NN N
used VBN N
to TO N
evaluate VB N
the DT N
difference NN N
, , N
if IN N
any DT N
. . N

METHODS NNP N
The DT N
study NN N
was VBD N
a DT N
double JJ N
blind NN N
, , N
uncontrolled JJ N
, , N
noncrossover RB N
and CC N
randomized JJ N
trial NN N
. . N

Fifty JJ N
patients NNS N
of IN N
uncontrolled JJ N
type NN N
2 CD N
diabetes NNS N
were VBD N
divided VBN N
in IN N
to TO N
two CD N
groups NNS N
. . N

Group NNP N
I PRP N
( ( N
25 CD N
patients NNS N
) ) N
received VBD N
capsule NN N
A NNP N
( ( N
glibenclamide NN 3_i
) ) N
while IN N
Group NNP N
II NNP N
( ( N
25 CD N
patients NNS N
) ) N
received VBD N
capsule NN N
B NNP N
( ( N
gliclazide NN 3_i
) ) N
. . N

The DT N
parameters NNS N
studied VBN N
were VBD N
Superoxide NNP N
dismutase NN N
( ( N
SOD NNP N
) ) N
, , N
malonyl-dialdehyde JJ N
( ( N
MDA NNP N
) ) N
and CC N
reduced VBN N
glutathione NN N
( ( N
GSH NNP N
) ) N
. . N

They PRP N
were VBD N
done VBN N
at IN N
( ( N
a DT N
) ) N
uncontrolled JJ N
stage NN N
( ( N
FBS NNP N
-- : N
165 CD N
+/- JJ N
16.7 CD N
mg/dl NN N
, , N
PP NNP N
-- : N
240 CD N
+/- JJ N
30.1 CD N
mg/dl NN N
and CC N
HbA1 NNP N
-- : N
10.5 CD N
+/- JJ N
0.9 CD N
% NN N
in IN N
group NN N
I PRP N
and CC N
FBS NNP N
-- : N
150 CD N
+/- JJ N
15.8 CD N
mg/dl NN N
, , N
PP NNP N
-- : N
246 CD N
+/- JJ N
29.1 CD N
mg/dl NN N
HbA1 NNP N
10.6 CD N
+/- JJ N
0.8 CD N
% NN N
in IN N
group NN N
II NNP N
) ) N
and CC N
during IN N
controlled VBN N
stage NN N
at IN N
12 CD N
weeks NNS N
( ( N
FBS NNP N
-- : N
120 CD N
+/- JJ N
18.5 CD N
mg/dl NN N
, , N
PP NNP N
-- : N
180 CD N
+/- JJ N
19.1 CD N
mg/dl NN N
and CC N
HbA1 NNP N
-- : N
8.4 CD N
+/- JJ N
0.29 CD N
% NN N
in IN N
group NN N
I PRP N
and CC N
FBS NNP N
-- : N
118 CD N
+/- JJ N
17.6 CD N
mg/dl NN N
, , N
PP NNP N
-- : N
176 CD N
+/- JJ N
20.1 CD N
mg/dl NN N
and CC N
HbA1 NNP N
-- : N
8.5 CD N
+/- JJ N
0.39 CD N
% NN N
in IN N
group NN N
II NNP N
patients NNS N
) ) N
. . N

RESULTS VB N
The DT N
significantly RB N
raised VBN N
levels NNS N
of IN N
MDA NNP N
and CC N
SOD NNP N
, , N
and CC N
decreased JJ N
levels NNS N
of IN N
reduced VBN N
glutathione NN N
( ( N
GSH NNP N
) ) N
during IN N
uncontrolled JJ N
stage NN N
of IN N
diabetes NNS N
indicated VBD N
free JJ N
radical JJ N
stress NN N
induced VBD N
lipid JJ N
peroxidation NN N
. . N

The DT N
significant JJ N
fall NN N
of IN N
MDA NNP N
and CC N
SOD NNP N
and CC N
increased VBD N
levels NNS N
of IN N
GSH NNP N
in IN N
blood NN N
in IN N
both DT N
groups NNS N
after IN N
control NN N
revealed VBD N
beneficial JJ N
effects NNS N
of IN N
glycemic JJ N
control NN N
on IN N
oxidative JJ N
stress NN N
. . N

The DT N
levels NNS N
were VBD N
not RB N
normalized VBN N
and CC N
stayed VBD N
higher JJR N
than IN N
those DT N
in IN N
controls NNS N
. . N

On IN N
intergroup JJ N
comparison NN N
; : N
the DT N
control NN N
of IN N
diabetes NNS N
with IN N
gliclazide NN 3_i
( ( N
group NN N
II NNP N
) ) N
showed VBD N
improvement NN N
in IN N
oxidative JJ N
stress NN N
( ( N
MDA NNP N
, , N
GSH NNP N
) ) N
better JJR N
( ( N
p JJ N
< NNP N
0.001 CD N
) ) N
than IN N
glibenclamide NN 3_i
( ( N
group NN N
I PRP N
) ) N
. . N

CONCLUSION NNP N
Oxidative NNP N
stress NN N
in IN N
uncontrolled JJ N
diabetes NNS N
is VBZ N
decreased VBN N
with IN N
glycemic JJ N
control NN N
. . N

The DT N
control NN N
of IN N
diabetes NNS N
with IN N
gliclazide NN 3_i
reduced VBN N
oxidative JJ N
stress NN N
more JJR N
than IN N
glibenclamide NN 3_i
, , N
indicating VBG N
higher JJR N
antioxidant JJ N
properties NNS N
of IN N
gliclazide NN N
. . N

Normalization NN N
of IN N
oxidative JJ N
stress NN N
was VBD N
not RB N
achieved VBN N
. . N

Further JJ N
studies NNS N
are VBP N
required VBN N
to TO N
see VB N
long-term JJ N
effect NN N
of IN N
drug NN N
therapy NN N
in IN N
combating VBG N
oxidative JJ N
stress NN N
after IN N
achieving VBG N
acceptable JJ N
control NN N
of IN N
diabetes NNS N
. . N

-DOCSTART- -X- O O

Nutritional JJ N
orientation NN N
, , N
knowledge NN N
and CC N
quality NN N
of IN N
diet NN N
in IN N
heart NN N
failure NN N
: : N
randomized JJ N
clinical JJ N
trial NN N
. . N

BACKGROUND NNP N
Non-pharmacological JJ N
measures NNS N
are VBP N
recommended VBN N
for IN N
heart NN N
failure NN N
patients NNS N
. . N

However RB N
, , N
most JJS N
studies NNS N
evaluate VBP N
low JJ N
sodium NN N
diet NN N
, , N
while IN N
little JJ N
is VBZ N
known VBN N
about IN N
the DT N
effects NNS N
of IN N
interventions NNS N
to TO N
improve VB N
adherence NN N
and CC N
knowledge NN N
of IN N
patients NNS N
about IN N
diet JJ N
content NN N
. . N

OBJECTIVE UH N
To TO N
evaluate VB N
if IN N
a DT N
global JJ N
nutritional JJ 4_i
orientation NN 4_i
could MD N
affect VB N
nutritional JJ N
knowledge NN N
, , N
adherence NN N
to TO N
food NN N
guidelines NNS N
, , N
anthropometrics NNS N
and CC N
quality NN N
of IN N
life NN N
in IN N
heart NN N
failure NN N
patients NNS N
. . N

METHODS NNP N
Forty NNP N
six CD N
patients NNS N
were VBD N
randomized VBN N
to TO N
intervention VB N
or CC N
control VB N
group NN N
. . N

Both DT N
groups NNS N
received VBD N
usual JJ 4_i
care NN 4_i
with IN 4_i
medical JJ 4_i
and CC 4_i
nursing JJ 4_i
staff NN 4_i
; : 4_i
the DT 4_i
intervention NN 4_i
group NN 4_i
received VBD 4_i
additional JJ 4_i
nutritional JJ 4_i
guidance NN 4_i
about IN 4_i
diet JJ 4_i
and CC 4_i
its PRP$ 4_i
relationship NN 4_i
with IN 4_i
disease NN 4_i
, , 4_i
sources NNS 4_i
of IN 4_i
nutrients NNS 4_i
, , 4_i
and CC 4_i
reduction NN 4_i
of IN 4_i
dietary JJ 4_i
sodium NN 4_i
and CC 4_i
fats NNS 4_i
. . 4_i

Enforcement NN 2_i
of IN 2_i
the DT 2_i
nutritional JJ 2_i
guidance NN 2_i
was VBD N
performed VBN N
after IN N
4 CD N
weeks NNS N
. . N

Both DT N
groups NNS N
were VBD N
evaluated VBN N
at IN N
baseline NN N
, , N
and CC N
after IN N
6 CD N
weeks NNS N
and CC N
6 CD N
months NNS N
. . N

Evaluations NNS N
included VBD N
anthropometric JJ N
parameters NNS N
, , N
sodium NN N
excretion NN N
in IN N
24-hour JJ N
urine NN N
, , N
dietary JJ N
recall NN N
, , N
nutrition NN N
knowledge NN N
and CC N
quality NN N
of IN N
life NN N
questionnaires NNS N
. . N

RESULTS NNP N
Mean NNP N
age NN N
of IN N
included JJ N
patients NNS N
was VBD N
58 CD N
? . N
10 CD N
years NNS N
and CC N
70 CD N
% NN N
were VBD N
male JJ N
. . N

After IN N
6 CD N
months NNS N
of IN N
follow-up NN N
, , N
the DT N
nutritional JJ N
knowledge NN N
of IN N
intervention NN N
group NN N
increased VBD N
compared VBN N
to TO N
control VB N
( ( N
p JJ N
< NNP N
0.05 CD N
) ) N
. . N

Caloric NNP N
, , N
fat NN N
and CC N
sodium NN N
intake NN N
decreased VBN N
in IN N
the DT N
intervention NN N
group NN N
compared VBN N
to TO N
control VB N
( ( N
p JJ N
< NNP N
0.05 CD N
) ) N
. . N

No DT N
significant JJ N
differences NNS N
were VBD N
seen VBN N
in IN N
quality NN N
of IN N
life NN N
or CC N
anthropometric JJ N
parameters NNS N
. . N

CONCLUSIONS NNP N
Nutritional NNP 2_i
orientation NN 2_i
was VBD N
effective JJ N
to TO N
modify VB N
1 CD N
) ) N
knowledge NN N
about IN N
food NN N
and CC N
nutrition NN N
, , N
and CC N
2 CD N
) ) N
quality NN N
of IN N
diet NN N
in IN N
outpatients NNS N
with IN N
heart NN N
failure NN N
. . N

Further JJ N
studies NNS N
are VBP N
necessary JJ N
to TO N
evaluate VB N
the DT N
benefits NNS N
on IN N
quality NN N
of IN N
life NN N
and CC N
prognosis NN N
. . N

-DOCSTART- -X- O O

Sodium NN 3_i
bicarbonate NN 3_i
, , N
N-acetylcysteine NNP 3_i
, , N
and CC N
saline NN 7_i
for IN N
prevention NN N
of IN N
radiocontrast-induced JJ N
nephropathy NN N
. . N

A DT N
comparison NN N
of IN N
3 CD N
regimens NNS N
for IN N
protecting VBG N
contrast-induced JJ N
nephropathy JJ N
in IN N
patients NNS N
undergoing VBG N
coronary JJ 1_i
procedures NNS 1_i
. . 1_i

A DT N
single-center JJ N
prospective NN N
controlled VBN N
trial NN N
. . N

BACKGROUND NNP N
Several NNP N
protective JJ N
therapies NNS N
have VBP N
been VBN N
developed VBN N
to TO N
prevent VB N
contrast-induced JJ N
nephropathy JJ N
( ( N
CIN NNP N
) ) N
. . N

We PRP N
aimed VBD N
to TO N
investigate VB N
the DT N
efficacy NN N
of IN N
sodium NN 3_i
bicarbonate NN 3_i
by IN N
comparing VBG N
2 CD N
other JJ N
regimens NNS N
, , N
including VBG N
combination NN N
of IN N
N-acetylcysteine NNP 1_i
( ( 1_i
NAC NNP 1_i
) ) 1_i
plus CC N
sodium JJ 3_i
chloride NN 3_i
and CC N
sodium NN 3_i
chloride NN 3_i
alone RB N
, , N
to TO N
prevent VB N
CIN NNP N
in IN N
patients NNS N
undergoing VBG N
cardiovascular JJ N
procedures NNS N
. . N

METHODS NNP N
We PRP N
prospectively RB N
enrolled VBD N
264 CD N
patients NNS N
who WP N
were VBD N
scheduled VBN N
for IN N
cardiovascular JJ N
procedures NNS N
and CC N
had VBD N
a DT N
baseline JJ N
creatinine NN N
level NN N
> VBD N
1.2 CD N
mg/dL NN N
. . N

The DT N
patients NNS N
were VBD N
assigned VBN N
1 CD N
of IN N
3 CD N
prophylactic JJ N
regimens NNS N
: : N
infusion NN N
of IN N
sodium NN 3_i
bicarbonate NN 3_i
, , N
sodium NN 3_i
chloride NN 3_i
, , N
sodium NN 3_i
chloride NN 3_i
plus CC N
oral JJ N
NAC NNP 3_i
( ( N
600 CD N
mg RB N
bid NN N
) ) N
. . N

Contrast-induced JJ N
nephropathy NN N
was VBD N
defined VBN N
as IN N
an DT N
increase NN N
in IN N
serum JJ N
creatinine NN N
level NN N
> VBD N
25 CD N
% NN N
or CC N
0.5 CD N
mg/dL NNS N
after IN N
48 CD N
hours NNS N
. . N

RESULTS VB N
There EX N
were VBD N
no DT N
significant JJ N
differences NNS N
among IN N
groups NNS N
regarding VBG N
baseline NN N
demographic JJ N
properties NNS N
and CC N
nephropathy JJ N
risk NN N
factors NNS N
. . N

The DT N
change NN N
in IN N
creatinine JJ N
clearance NN N
was VBD N
significantly RB N
better RBR N
in IN N
the DT N
sodium NN 3_i
bicarbonate NN 3_i
group NN N
than IN N
other JJ N
2 CD N
groups NNS N
( ( N
P NNP N
= NNP N
.007 NNP N
) ) N
. . N

The DT N
incidence NN N
of IN N
CIN NNP N
was VBD N
significantly RB N
lower JJR N
in IN N
the DT N
sodium NN 3_i
bicarbonate NN 3_i
group NN N
( ( N
4.5 CD N
% NN N
) ) N
compared VBN N
with IN N
sodium JJ 3_i
chloride NN 3_i
alone RB N
( ( N
13.6 CD N
% NN N
, , N
P NNP N
= NNP N
.036 NNP N
) ) N
and CC N
tended VBD N
to TO N
be VB N
lower JJR N
than IN N
in IN N
the DT N
combination NN N
group NN N
( ( N
12.5 CD N
% NN N
, , N
P NNP N
= NNP N
.059 NNP N
) ) N
. . N

After IN N
adjusting VBG N
the DT N
Mehran NNP N
nephropathy NN N
risk NN N
score NN N
, , N
the DT N
risk NN N
of IN N
CIN NNP N
significantly RB N
reduced VBD N
with IN N
sodium NN 3_i
bicarbonate NN 3_i
compared VBN N
with IN N
sodium JJ 3_i
chloride NN 3_i
alone RB N
( ( N
adjusted VBN N
risk NN N
ratio NN N
0.29 CD N
, , N
P NNP N
= NNP N
.043 NNP N
) ) N
. . N

CONCLUSIONS NNP N
Hydration NNP N
with IN N
sodium JJ 3_i
bicarbonate NN 3_i
provides VBZ N
better JJR N
protection NN N
against IN N
CIN NNP N
than IN N
the DT N
sodium NN 3_i
chloride JJ 3_i
infusion NN 3_i
does VBZ N
alone RB N
. . N

Combination NNP N
therapy NN N
of IN N
NAC NNP 3_i
plus CC 3_i
sodium JJ 3_i
chloride NN 3_i
did VBD N
not RB N
offer VB N
additional JJ N
benefit NN N
over IN N
hydration NN N
with IN N
sodium JJ 3_i
chloride NN 3_i
alone RB N
. . N

-DOCSTART- -X- O O

[ RB N
Long NNP N
term NN N
observation NN N
in IN N
effects NNS N
of IN N
potassium NN 3_i
and CC N
calcium NN 3_i
supplementation NN 3_i
on IN N
arterial JJ N
blood NN N
pressure NN N
and CC N
sodium NN N
metabolism NN N
in IN N
adolescents NNS N
with IN N
higher JJR N
blood NN N
pressure NN N
] NNP N
. . N

OBJECTIVE NNP N
To TO N
investigate VB N
the DT N
effects NNS N
of IN N
potassium NN 3_i
and CC N
calcium NN 3_i
supplementation NN 3_i
in IN N
table JJ N
salt NN N
on IN N
reduction NN N
of IN N
arterial JJ N
blood NN N
pressure NN N
and CC N
sodium NN N
metabolism NN N
in IN N
adolescents NNS N
with IN N
higher JJR N
blood NN N
pressure NN N
. . N

METHODS CC N
A DT N
single JJ N
blind NN N
placebo-controlled JJ 7_i
trial NN N
was VBD N
carried VBN N
out RP N
for IN N
two CD N
years NNS N
in IN N
220 CD N
adolescents NNS N
with IN N
higher JJR N
blood NN N
pressure NN N
, , N
aged VBD N
18 CD N
- : N
22 CD N
years NNS N
, , N
who WP N
were VBD N
randomly RB N
divided VBN N
into IN N
supplementary JJ N
group NN N
( ( N
n JJ N
= NNP N
110 CD N
) ) N
and CC N
control NN N
group NN N
( ( N
n JJ N
= NNP N
110 CD N
) ) N
. . N

Each DT N
of IN N
the DT N
subjects NNS N
in IN N
the DT N
supplementary JJ N
group NN N
and CC N
their PRP$ N
family NN N
members NNS N
was VBD N
given VBN N
10 CD N
mmol NN N
of IN N
potassium NN 3_i
and CC N
10 CD N
mmol NN N
of IN N
calcium NN 3_i
mixed VBN N
in IN N
their PRP$ N
table JJ N
salt JJ N
daily RB N
for IN N
24 CD N
months NNS N
. . N

RESULTS NNP N
Night NNP N
urinary JJ N
sodium NN N
and CC N
potassium JJ N
excretion NN N
increased VBD N
( ( N
urinary JJ N
Na NNP N
( ( N
+ NNP N
) ) N
, , N
P NNP N
< NNP N
0.05 CD N
; : N
urinary JJ N
K NNP N
( ( N
+ NNP N
) ) N
, , N
P NNP N
< NNP N
0.01 CD N
) ) N
and CC N
blood NN N
pressure NN N
lowered VBN N
by IN N
5.3 CD N
mm NNS N
Hg/1.8 NNP N
mm NN N
Hg NNP N
in IN N
average NN N
from IN N
the DT N
baseline NN N
in IN N
the DT N
supplementary JJ N
group NN N
two CD N
years NNS N
after IN N
potassium NN 3_i
and CC N
calcium NN 3_i
supplementation NN 3_i
, , N
as IN N
compared VBN N
with IN N
that DT N
in IN N
the DT N
control NN N
group NN N
increased VBN N
by IN N
( ( N
1.3/1.7 CD N
) ) N
mm NN N
Hg NNP N
. . N

CONCLUSIONS NNP N
Adequate NNP N
supplement NN 3_i
of IN 3_i
potassium NN 3_i
and CC N
calcium NN 3_i
in IN N
daily JJ N
table JJ N
salt NN N
intake NN N
was VBD N
an DT N
effective JJ N
way NN N
to TO N
prevent VB N
form NN N
hypertension NN N
and CC N
could MD N
promote VB N
their PRP$ N
urinary JJ N
sodium NN N
excretion NN N
and CC N
reduction NN N
of IN N
arterial JJ N
blood NN N
pressure NN N
in IN N
adolescents NNS N
with IN N
higher JJR N
blood NN N
pressure NN N
. . N

-DOCSTART- -X- O O

A DT N
comparison NN N
of IN N
intermittent JJ N
vaginal JJ N
administration NN N
of IN N
misoprostol NN 3_i
with IN N
continuous JJ N
dinoprostone NN 3_i
for IN N
cervical JJ N
ripening NN N
and CC N
labor NN N
induction NN N
. . N

OBJECTIVE CC N
Our PRP$ N
purpose NN N
was VBD N
to TO N
compare VB N
the DT N
effect NN N
of IN N
vaginal JJ N
administration NN N
of IN N
misoprostol NN 3_i
( ( 3_i
Cytotec NNP 3_i
) ) 3_i
with IN N
that DT N
of IN N
dinoprostone NN 3_i
( ( 3_i
Cervidil NNP 3_i
) ) 3_i
on IN N
cervical JJ N
ripening NN N
and CC N
labor NN N
induction NN N
. . N

STUDY NNP N
DESIGN NNP N
Two CD N
hundred VBD N
patients NNS N
with IN N
indications NNS N
for IN N
induction NN N
of IN N
labor NN N
and CC N
unfavorable JJ N
cervical JJ N
examinations NNS N
were VBD N
randomly RB N
assigned VBN N
to TO N
receive VB N
vaginally RB N
administered VBN N
misoprostol NN 3_i
( ( 3_i
prostaglandin JJ 3_i
E1 NNP 3_i
) ) 3_i
or CC N
the DT N
dinoprostone NN 3_i
( ( 3_i
prostaglandin JJ 3_i
E2 NNP 3_i
) ) 3_i
vaginal NN N
insert NN N
. . N

Twenty-five JJ N
microgram JJ N
tablets NNS N
of IN N
misoprostol NN 3_i
were VBD N
placed VBN N
in IN N
the DT N
posterior JJ N
vaginal JJ N
fornix NN N
every DT N
4 CD N
hours NNS N
for IN N
a DT N
maximum NN N
of IN N
six CD N
doses NNS N
. . N

Additional NNP N
misoprostol NN 3_i
was VBD N
not RB N
given VBN N
after IN N
either DT N
spontaneous JJ N
rupture NN N
of IN N
membranes NNS N
, , N
adequate JJ N
cervical JJ N
ripening NN N
( ( N
Bishop NNP N
score NN N
of IN N
> NN N
or CC N
= VB N
8 CD N
or CC N
cervical JJ N
dilatation NN N
of IN N
> NN N
or CC N
= $ N
3 CD N
cm NN N
) ) N
, , N
or CC N
beginning NN N
of IN N
active JJ N
labor NN N
. . N

The DT N
vaginal JJ N
insert NN N
, , N
Cervidil NNP 3_i
, , N
containing VBG N
10 CD N
mg NN N
of IN N
dinoprostone NN 3_i
in IN N
a DT N
timed-release JJ N
preparation NN N
was VBD N
placed VBN N
in IN N
the DT N
posterior JJ N
vaginal JJ N
formix NN N
for IN N
a DT N
maximum JJ N
period NN N
of IN N
24 CD N
hours NNS N
. . N

The DT N
vaginal JJ N
insert NN N
was VBD N
removed VBN N
for IN N
spontaneous JJ N
rupture NN N
of IN N
membranes NNS N
, , N
entry NN N
into IN N
active JJ N
labor NN N
, , N
adequate JJ N
cervical JJ N
ripening NN N
, , N
or CC N
abnormality NN N
of IN N
uterine JJ N
contractile NN N
pattern NN N
or CC N
fetal JJ N
cardiac JJ N
activity NN N
. . N

RESULTS NN N
Of IN N
the DT N
200 CD N
patients NNS N
enrolled VBD N
, , N
99 CD N
were VBD N
randomized VBN N
to TO N
misoprostol VB 3_i
and CC N
101 CD N
to TO N
dinoprostone VB 3_i
. . 3_i

The DT N
average JJ N
interval NN N
from IN N
start NN N
of IN N
induction NN N
to TO N
vaginal JJ N
delivery NN N
was VBD N
1 CD N
hour NN N
shorter NN N
in IN N
the DT N
misoprostol NN 3_i
group NN N
( ( N
1296.7 CD N
+/- JJ N
722.1 CD N
minutes NNS N
) ) N
than IN N
in IN N
the DT N
dinoprostone NN 3_i
group NN N
( ( N
1360.0 CD N
+/- JJ N
792.0 CD N
minutes NNS N
) ) N
, , N
but CC N
this DT N
difference NN N
was VBD N
not RB N
statistically RB N
significant JJ N
( ( N
p JJ N
= NNP N
0.97 CD N
) ) N
. . N

Oxytocin NNP 3_i
augmentation NN N
of IN N
labor NN N
was VBD N
used VBN N
in IN N
50 CD N
( ( N
50.5 CD N
% NN N
) ) N
misoprostol-treated JJ 3_i
patients NNS N
and CC N
43 CD N
( ( N
43.5 CD N
% NN N
) ) N
dinoprostone-treated JJ 3_i
patients NNS N
( ( N
relative JJ N
risk NN N
1.14 CD N
, , N
95 CD N
% NN N
confidence NN N
interval NN N
0.86 CD N
to TO N
1.51 CD N
, , N
p NN N
= NNP N
0.35 CD N
) ) N
. . N

There EX N
were VBD N
no DT N
significant JJ N
differences NNS N
between IN N
routes NNS N
of IN N
delivery NN N
with IN N
misoprostol NN 3_i
or CC N
dinoprostone NN 3_i
. . 3_i

Overall NNP N
, , N
38 CD N
patients NNS N
( ( N
19.3 CD N
% NN N
) ) N
had VBD N
cesarean JJ N
deliveries NNS N
. . N

There EX N
was VBD N
a DT N
significantly RB N
lower JJR N
prevalence NN N
of IN N
tachysystole NN N
( ( N
six CD N
or CC N
more JJR N
uterine JJ N
contractions NNS N
in IN N
a DT N
10-minute JJ N
window NN N
for IN N
two CD N
consecutive JJ N
10-minute JJ N
periods NNS N
) ) N
in IN N
the DT N
misoprostol NN 3_i
group NN N
( ( N
7.1 CD N
% NN N
) ) N
than IN N
in IN N
the DT N
dinoprostone NN 3_i
group NN N
( ( N
18.4 CD N
% NN N
) ) N
( ( N
relative JJ N
risk NN N
0.52 CD N
, , N
95 CD N
% NN N
confidence NN N
interval NN N
0.31 CD N
to TO N
0.89 CD N
, , N
p NN N
= NNP N
0.02 CD N
) ) N
. . N

There EX N
were VBD N
no DT N
significant JJ N
differences NNS N
in IN N
frequency NN N
of IN N
uterine JJ N
hyperstimulation NN N
or CC N
hypertonus NN N
. . N

Abnormal NNP N
fetal JJ N
heart NN N
rate NN N
tracings NNS N
were VBD N
found VBN N
in IN N
23 CD N
( ( N
23.2 CD N
% NN N
) ) N
of IN N
misoprostol-treated JJ 3_i
patients NNS N
and CC N
35 CD N
( ( N
35.7 CD N
% NN N
) ) N
of IN N
dinoprostone-treated JJ 3_i
patients NNS N
( ( N
relative JJ N
risk NN N
0.73 CD N
, , N
95 CD N
% NN N
confidence NN N
interval NN N
0.52 CD N
to TO N
1.01 CD N
, , N
p NN N
= NNP N
0.0546 CD N
) ) N
. . N

No DT N
significant JJ N
differences NNS N
were VBD N
found VBN N
in IN N
meconium NN N
passage NN N
, , N
1- JJ N
or CC N
5-minute JJ N
Apgar NNP N
scores NNS N
< VBP N
7 CD N
, , N
neonatal JJ N
resuscitations NNS N
, , N
or CC N
admissions NNS N
to TO N
the DT N
neonatal JJ N
intensive JJ N
care NN N
unit NN N
between IN N
the DT N
two CD N
groups NNS N
. . N

CONCLUSIONS NNP N
Vaginally NNP N
administered VBD N
misoprostol NN 3_i
is VBZ N
as RB N
effective JJ N
as IN N
dinoprostone NN N
for IN N
cervical JJ N
ripening NN N
and CC N
the DT N
induction NN N
of IN N
labor NN N
. . N

Mean JJ N
time NN N
intervals NNS N
to TO N
delivery NN N
, , N
need NN N
for IN N
oxytocin JJ 3_i
augmentation NN N
, , N
and CC N
routes NNS N
of IN N
delivery NN N
were VBD N
similar JJ N
between IN N
the DT N
two CD N
groups NNS N
. . N

Incidence NN N
of IN N
uterine JJ N
tachysystole NN N
with IN N
misoprostol NN 3_i
every DT N
4 CD N
hours NNS N
was VBD N
significantly RB N
less JJR N
than IN N
with IN N
dinoprostone NN 3_i
. . N

-DOCSTART- -X- O O

Effect NN N
of IN N
a DT N
vitamin/mineral JJ 3_i
supplement NN 3_i
on IN N
children NNS N
and CC N
adults NNS N
with IN N
autism NN N
. . N

BACKGROUND NNP N
Vitamin/mineral NNP 3_i
supplements NNS 3_i
are VBP N
among IN N
the DT N
most RBS N
commonly RB N
used JJ N
treatments NNS N
for IN N
autism NN N
, , N
but CC N
the DT N
research NN N
on IN N
their PRP$ N
use NN N
for IN N
treating VBG N
autism NN N
has VBZ N
been VBN N
limited VBN N
. . N

METHOD NNP N
This DT N
study NN N
is VBZ N
a DT N
randomized JJ N
, , N
double-blind JJ N
, , N
placebo-controlled JJ 7_i
three CD N
month NN N
vitamin/mineral JJ 3_i
treatment NN 3_i
study NN 3_i
. . 3_i

The DT N
study NN N
involved VBD N
141 CD N
children NNS N
and CC N
adults NNS N
with IN N
autism NN N
, , N
and CC N
pre NN N
and CC N
post NN N
symptoms NNS N
of IN N
autism NN N
were VBD N
assessed VBN N
. . N

None NN N
of IN N
the DT N
participants NNS N
had VBD N
taken VBN N
a DT N
vitamin/mineral JJ 3_i
supplement NN 3_i
in IN N
the DT N
two CD N
months NNS N
prior RB N
to TO N
the DT N
start NN N
of IN N
the DT N
study NN N
. . N

For IN N
a DT N
subset NN N
of IN N
the DT N
participants NNS N
( ( N
53 CD N
children NNS N
ages VBZ N
5-16 JJ N
) ) N
pre NN N
and CC N
post NN N
measurements NNS N
of IN N
nutritional JJ N
and CC N
metabolic JJ N
status NN N
were VBD N
also RB N
conducted VBN N
. . N

RESULTS VB N
The DT N
vitamin/mineral JJ 3_i
supplement NN 3_i
was VBD N
generally RB N
well-tolerated JJ N
, , N
and CC N
individually RB N
titrated VBN N
to TO N
optimum JJ N
benefit NN N
. . N

Levels NNP N
of IN N
many JJ N
vitamins NNS N
, , N
minerals NNS N
, , N
and CC N
biomarkers NNS N
improved/increased VBD N
showing VBG N
good JJ N
compliance NN N
and CC N
absorption NN N
. . N

Statistically NNP N
significant JJ N
improvements NNS N
in IN N
metabolic JJ N
status NN N
were VBD N
many JJ N
including VBG N
: : N
total JJ N
sulfate NN N
( ( N
+17 CD N
% NN N
, , N
p NN N
= NNP N
0.001 CD N
) ) N
, , N
S-adenosylmethionine NNP N
( ( N
SAM NNP N
; : N
+6 CD N
% NN N
, , N
p NN N
= NNP N
0.003 CD N
) ) N
, , N
reduced VBD N
glutathione NN N
( ( N
+17 CD N
% NN N
, , N
p NN N
= NNP N
0.0008 CD N
) ) N
, , N
ratio NN N
of IN N
oxidized JJ N
glutathione NN N
to TO N
reduced VB N
glutathione NN N
( ( N
GSSG NNP N
: : N
GSH NNP N
; : N
-27 CD N
% NN N
, , N
p NN N
= NNP N
0.002 CD N
) ) N
, , N
nitrotyrosine JJ N
( ( N
-29 CD N
% NN N
, , N
p NN N
= NNP N
0.004 CD N
) ) N
, , N
ATP NNP N
( ( N
+25 CD N
% NN N
, , N
p NN N
= NNP N
0.000001 CD N
) ) N
, , N
NADH NNP N
( ( N
+28 CD N
% NN N
, , N
p NN N
= NNP N
0.0002 CD N
) ) N
, , N
and CC N
NADPH NNP N
( ( N
+30 CD N
% NN N
, , N
p NN N
= NNP N
0.001 CD N
) ) N
. . N

Most JJS N
of IN N
these DT N
metabolic JJ N
biomarkers NNS N
improved VBN N
to TO N
normal JJ N
or CC N
near-normal JJ N
levels.The JJ N
supplement NN 3_i
group NN N
had VBD N
significantly RB N
greater JJR N
improvements NNS N
than IN N
the DT N
placebo NN 7_i
group NN N
on IN N
the DT N
Parental NNP N
Global NNP N
Impressions-Revised JJ N
( ( N
PGI-R NNP N
, , N
Average NNP N
Change NNP N
, , N
p NN N
= NNP N
0.008 CD N
) ) N
, , N
and CC N
on IN N
the DT N
subscores NNS N
for IN N
Hyperactivity NNP N
( ( N
p JJ N
= NNP N
0.003 CD N
) ) N
, , N
Tantrumming NNP N
( ( N
p JJ N
= NNP N
0.009 CD N
) ) N
, , N
Overall NNP N
( ( N
p NN N
= RB N
0.02 CD N
) ) N
, , N
and CC N
Receptive JJ N
Language NNP N
( ( N
p JJ N
= NNP N
0.03 CD N
) ) N
. . N

For IN N
the DT N
other JJ N
three CD N
assessment NN N
tools VBZ N
the DT N
difference NN N
between IN N
treatment NN N
group NN N
and CC N
placebo NN N
group NN N
was VBD N
not RB N
statistically RB N
significant.Regression JJ N
analysis NN N
revealed VBD N
that IN N
the DT N
degree NN N
of IN N
improvement NN N
on IN N
the DT N
Average JJ N
Change NN N
of IN N
the DT N
PGI-R NNP N
was VBD N
strongly RB N
associated VBN N
with IN N
several JJ N
biomarkers NNS N
( ( N
adj NN N
. . N

R2 NNP N
= VBD N
0.61 CD N
, , N
p NN N
< NNP N
0.0005 CD N
) ) N
with IN N
the DT N
initial JJ N
levels NNS N
of IN N
biotin NN N
and CC N
vitamin NN N
K NNP N
being VBG N
the DT N
most RBS N
significant JJ N
( ( N
p JJ N
< NNP N
0.05 CD N
) ) N
; : N
both DT N
biotin NN N
and CC N
vitamin NN N
K NNP N
are VBP N
made VBN N
by IN N
beneficial JJ N
intestinal JJ N
flora NN N
. . N

CONCLUSIONS NNP N
Oral NNP N
vitamin/mineral JJ 3_i
supplementation NN 3_i
is VBZ N
beneficial JJ N
in IN N
improving VBG N
the DT N
nutritional JJ N
and CC N
metabolic JJ N
status NN N
of IN N
children NNS N
with IN N
autism NN N
, , N
including VBG N
improvements NNS N
in IN N
methylation NN N
, , N
glutathione NN N
, , N
oxidative JJ N
stress NN N
, , N
sulfation NN N
, , N
ATP NNP N
, , N
NADH NNP N
, , N
and CC N
NADPH NNP N
. . N

The DT N
supplement NN 3_i
group NN N
had VBD N
significantly RB N
greater JJR N
improvements NNS N
than IN N
did VBD N
the DT N
placebo NN 7_i
group NN N
on IN N
the DT N
PGI-R JJ N
Average JJ N
Change NN N
. . N

This DT N
suggests VBZ N
that IN N
a DT N
vitamin/mineral JJ 3_i
supplement NN 3_i
is VBZ N
a DT N
reasonable JJ N
adjunct JJ N
therapy NN N
to TO N
consider VB N
for IN N
most JJS N
children NNS N
and CC N
adults NNS N
with IN N
autism NN N
. . N

TRIAL NNP N
REGISTRATION NNP N
CLINICAL NNP N
TRIAL NNP N
REGISTRATION NNP N
NUMBER NNP N
NCT01225198 NNP N
. . N

-DOCSTART- -X- O O

Brief JJ N
report NN N
: : N
imitation NN 5_i
effects NNS N
on IN N
children NNS N
with IN N
autism NN N
. . N

Twenty NNP N
children NNS N
with IN N
autism NN N
( ( N
mean JJ N
age NN N
, , N
5 CD N
years NNS N
) ) N
were VBD N
recruited VBN N
for IN N
the DT N
study NN N
from IN N
a DT N
school NN N
for IN N
children NNS N
with IN N
autism NN N
. . N

The DT N
children NNS N
were VBD N
randomly RB N
assigned VBN N
to TO N
an DT N
imitation NN 5_i
( ( N
n JJ N
= NNP N
10 CD N
) ) N
or CC N
contingently RB 5_i
responsive JJ 5_i
( ( N
n JJ N
= NNP N
10 CD N
) ) N
interaction NN N
group NN N
based VBN N
on IN N
a DT N
stratification NN N
table NN N
for IN N
gender NN N
and CC N
developmental NN N
and CC N
chronological JJ N
age NN N
. . N

The DT N
sessions NNS N
consisted VBD N
of IN N
four CD N
phases NNS N
, , N
with IN N
each DT N
phase NN N
lasting VBG N
3 CD N
minutes NNS N
. . N

In IN N
the DT N
first JJ N
phase NN N
, , N
the DT N
child NN N
walked VBD N
into IN N
a DT N
room NN N
that WDT N
was VBD N
furnished VBN N
with IN N
a DT N
sofa NN N
, , N
a DT N
table NN N
, , N
chairs NNS N
, , N
and CC N
two CD N
sets NNS N
of IN N
identical JJ N
toys NN N
. . N

An DT N
adult NN N
was VBD N
in IN N
the DT N
room NN N
sitting VBG N
very RB N
still RB N
like IN N
a DT N
statue NN N
( ( N
first JJ N
still-face JJ N
condition NN N
) ) N
. . N

In IN N
the DT N
second JJ N
phase NN N
, , N
the DT N
adult NN N
either RB N
imitated VBD N
the DT N
child NN N
or CC N
was VBD N
contingently RB 5_i
responsive JJ 5_i
to TO N
the DT N
child NN N
. . N

In IN N
the DT N
third JJ N
phase NN N
, , N
the DT N
adult NN N
sat VBD N
still RB N
again RB N
( ( N
second JJ N
still-face JJ N
condition NN N
) ) N
, , N
and CC N
in IN N
the DT N
fourth JJ N
phase NN N
, , N
the DT N
adult NN N
engaged VBN N
in IN N
a DT N
spontaneous JJ N
interaction NN N
. . N

During IN N
the DT N
third JJ N
phase NN N
( ( N
the DT N
second JJ N
still-face JJ N
condition NN N
) ) N
, , N
the DT N
children NNS N
in IN N
the DT N
imitation NN 5_i
group NN N
spent VBD N
less JJR N
time NN N
in IN N
gross JJ N
motor NN N
activity NN N
and CC N
more JJR N
time NN N
touching VBG N
the DT N
adult NN N
, , N
as IN N
if IN N
attempting VBG N
to TO N
initiate VB N
an DT N
interaction NN N
. . N

The DT N
contingency NN 4_i
condition NN N
appeared VBD N
to TO N
be VB N
a DT N
more RBR N
effective JJ N
way NN N
to TO N
facilitate VB N
a DT N
distal JJ N
social JJ N
behavior NN N
( ( N
attention NN N
) ) N
, , N
whereas IN N
the DT N
imitative JJ 5_i
condition NN N
was VBD N
a DT N
more RBR N
effective JJ N
way NN N
to TO N
facilitate VB N
a DT N
proximal JJ N
social JJ N
behavior NN N
( ( N
touching VBG N
) ) N
. . N

-DOCSTART- -X- O O

Social JJ 4_i
support NN 4_i
and CC N
abstinence NN 4_i
from IN N
opiates NNS N
and CC N
cocaine NN N
during IN N
opioid JJ 3_i
maintenance NN 3_i
treatment NN 3_i
. . N

Social NNP 4_i
support NN 4_i
may MD N
play VB N
an DT N
important JJ N
role NN N
in IN N
helping VBG N
drug NN N
users NNS N
achieve VBP N
abstinence NN N
; : N
however RB N
these DT N
benefits NNS N
may MD N
depend VB N
on IN N
the DT N
type NN N
of IN N
support NN N
experienced VBN N
. . N

In IN N
this DT N
prospective JJ N
observational NN N
study NN N
, , N
we PRP N
examined VBD N
the DT N
extent NN N
to TO N
which WDT N
general JJ 4_i
and CC 4_i
abstinence-specific JJ 4_i
support NN 4_i
, , 4_i
both DT 4_i
structural JJ 4_i
and CC 4_i
functional JJ 4_i
, , N
predicted JJ N
opiate NN N
and CC N
cocaine NN N
abstinence NN N
in IN N
128 CD N
opioid JJ N
maintenance NN N
patients NNS N
receiving VBG N
either CC N
methadone NN 3_i
or CC N
LAAM NNP 3_i
. . N

A DT N
new JJ N
multidimensional JJ N
self-report NN N
instrument NN N
assessing VBG N
abstinence-specific JJ 4_i
functional JJ N
support NN N
was VBD N
developed VBN N
for IN N
the DT N
study NN N
. . N

Previously RB N
validated VBN N
measures NNS N
were VBD N
used VBN N
to TO N
assess VB N
the DT N
remaining VBG N
types NNS N
of IN N
support NN N
. . N

With IN N
baseline JJ N
abstinence NN N
and CC N
other JJ N
statistically RB N
important JJ N
covariates NNS N
adjusted VBN N
, , N
hierarchical JJ N
logistic JJ N
regression NN N
analyses NNS N
demonstrated VBD N
that IN N
the DT N
associations NNS N
between IN N
social JJ N
support NN N
at IN N
study NN N
baseline NN N
and CC N
biochemically RB N
confirmed VBN N
abstinence NN N
3 CD N
months NNS N
later RB N
varied VBN N
by IN N
type NN N
of IN N
support NN N
and CC N
by IN N
drug NN N
. . N

Greater NNP N
abstinence-specific JJ 4_i
structural JJ N
support NN N
( ( N
operationalized VBN N
as IN N
fewer JJR N
drug NN N
users NNS N
in IN N
the DT N
social JJ N
network NN N
) ) N
and CC N
decreases VBZ N
in IN N
three CD N
types NNS N
of IN N
negative JJ N
abstinence-specific JJ 4_i
functional JJ N
support NN N
( ( N
Complaints NNS N
about IN N
Drug NNP N
Use NNP N
, , N
Drug NNP N
Exposure NNP N
, , N
and CC N
Demoralization NNP N
) ) N
predicted VBD N
cocaine NN N
, , N
but CC N
not RB N
opiate JJ N
abstinence NN N
. . N

There EX N
were VBD N
no DT N
effects NNS N
for IN N
general JJ N
support NN N
, , N
whether IN N
structural JJ N
or CC N
functional JJ N
, , N
on IN N
abstinence NN N
from IN N
either DT N
drug NN N
. . N

Interventions NNS N
that WDT N
focus VBP N
on IN N
modifying VBG N
patients NNS N
' POS N
abstinence-specific JJ 4_i
support NN N
may MD N
be VB N
helpful JJ N
in IN N
reducing VBG N
the DT N
high JJ N
rates NNS N
of IN N
cocaine NN N
use NN N
disorders NNS N
in IN N
this DT N
population NN N
. . N

-DOCSTART- -X- O O

The DT N
effects NNS N
of IN N
hypoxemia NN N
on IN N
cardiac JJ N
output NN N
. . N

A DT N
dose-response JJ N
curve NN N
. . N

To TO N
establish VB N
a DT N
dose-response JJ N
curve NN N
for IN N
the DT N
effects NNS N
of IN N
isocapnic JJ N
hypoxemia NN N
on IN N
cardiac JJ N
output NN N
( ( N
CO NNP N
) ) N
, , N
we PRP N
studied VBD N
20 CD N
healthy JJ N
men NNS N
, , N
aged VBD N
20 CD N
to TO N
34 CD N
years NNS N
, , N
using VBG N
a DT N
tight-fitting JJ 6_i
face NN 6_i
mask NN 6_i
and CC 6_i
an DT 6_i
isocapnic JJ 6_i
partial NN 6_i
rebreathing NN 6_i
system NN 6_i
( ( N
a DT N
modified VBN N
anesthesia NN N
machine NN N
) ) N
. . N

We PRP N
blended VBD N
oxygen NN 6_i
and CC N
hypoxic NN 6_i
gas NN 6_i
to TO N
achieve VB N
arterial JJ N
oxygen NN N
saturations NNS N
( ( N
SaO2 NNP N
) ) N
of IN N
80 CD N
, , N
85 CD N
, , N
and CC N
90 CD N
percent NN N
; : N
subjects NNS N
also RB N
breathed VBD N
100 CD 6_i
percent NN 6_i
oxygen NN 6_i
and CC N
room NN 6_i
air NN 6_i
( ( N
RA NNP N
) ) N
. . N

Target NNP N
SaO2 NNP N
and CC N
end-tidal JJ N
carbon NN N
dioxide NN N
were VBD N
continuously RB N
monitored VBN N
using VBG N
an DT N
ear JJ N
oximeter NN N
and CC N
CO2 NNP N
gas NN N
analyzer NN N
. . N

Subjects NNS N
experienced VBD N
the DT N
five CD N
SaO2 NNP N
measurements NNS N
in IN N
random JJ N
order NN N
. . N

CO NNP N
was VBD N
measured VBN N
noninvasively RB N
at IN N
approximately RB N
two-minute JJ N
intervals NNS N
, , N
using VBG N
continuous-wave JJ N
Doppler NNP N
echocardiography NN N
. . N

Mean NNP N
cardiac JJ N
output NN N
increased VBD N
with IN N
increasing VBG N
hypoxemia NN N
from IN N
6.84 CD N
L/min NNP N
at IN N
FIo2 NNP N
1.0 CD N
to TO N
8.44 CD N
L/min NNP N
at IN N
SaO2 NNP N
80 CD N
percent NN N
( ( N
p NN N
less JJR N
than IN N
0.0005 CD N
) ) N
; : N
the DT N
increase NN N
was VBD N
entirely RB N
due JJ N
to TO N
increased JJ N
heart NN N
rate NN N
. . N

We PRP N
concluded VBD N
that IN N
cardiac JJ N
output NN N
increases NNS N
significantly RB N
in IN N
a DT N
dose-response JJ N
manner NN N
in IN N
response NN N
to TO N
acute VB N
isocapnic JJ N
hypoxemia NN N
in IN N
normal JJ N
persons NNS N
. . N

-DOCSTART- -X- O O

Enhanced NNP 4_i
small JJ 4_i
group NN 4_i
instruction NN 4_i
using VBG 4_i
choral JJ 4_i
responding NN 4_i
and CC 4_i
student NN 4_i
interaction NN 4_i
for IN N
children NNS N
with IN N
autism NN N
and CC N
developmental JJ N
disabilities NNS N
. . N

The DT N
use NN N
of IN N
effective JJ 4_i
instructional JJ 4_i
strategies NNS 4_i
in IN N
small JJ N
groups NNS N
was VBD N
investigated VBN N
to TO N
determine VB N
learning JJ N
effects NNS N
for IN N
24 CD N
elementary JJ N
age NN N
students NNS N
with IN N
autism NN N
and CC N
developmental JJ N
disabilities NNS N
. . N

Effective JJ N
strategies NNS N
included VBD N
( ( N
a DT N
) ) N
the DT 4_i
use NN 4_i
of IN 4_i
choral JJ 4_i
responding NN 4_i
; : 4_i
( ( N
b NN N
) ) N
the DT 4_i
use NN 4_i
of IN 4_i
student-to-student JJ 4_i
responding NN 4_i
; : 4_i
( ( N
c NN N
) ) N
the DT 4_i
rotation NN 4_i
of IN 4_i
materials NNS 4_i
every DT 4_i
5 CD 4_i
minutes NNS 4_i
during IN 4_i
the DT 4_i
30-minute JJ 4_i
group NN 4_i
while IN 4_i
teaching VBG 4_i
2 CD 4_i
to TO 4_i
3 CD 4_i
concepts NNS 4_i
; : 4_i
and CC 4_i
( ( N
d NN N
) ) N
the DT 4_i
use NN 4_i
of IN 4_i
random NN 4_i
, , 4_i
unpredictable JJ 4_i
trials NNS 4_i
for IN 4_i
student NN 4_i
responding VBG 4_i
. . 4_i

Thirty-minute JJ N
language NN N
groups NNS N
were VBD N
targeted VBN N
to TO N
teach VB N
receptive JJ N
and CC N
expressive JJ N
skills NNS N
using VBG N
pictures NNS N
and CC N
common JJ N
objects NNS N
across IN N
five CD N
categories NNS N
( ( N
e.g. NN N
, , N
household NN N
items NNS N
, , N
foods NNS N
) ) N
. . N

Results JJ N
showed VBD N
increased JJ N
opportunities NNS N
to TO N
respond VB N
, , N
increased JJ N
levels NNS N
of IN N
responding VBG N
and CC N
academic JJ N
engagement NN N
, , N
higher JJR N
gains NNS N
on IN N
weekly JJ N
criterion-referenced JJ N
pre- NN N
and CC N
posttests NNS N
, , N
and CC N
decreased VBD N
passive JJ N
and CC N
inappropriate JJ N
student NN N
behavior NN N
during IN N
interventions NNS N
. . N

-DOCSTART- -X- O O

Mechanisms NNP N
underlying VBG N
the DT N
lack NN N
of IN N
effect NN N
of IN N
implantable JJ 1_i
cardioverter-defibrillator JJ 1_i
therapy NN 1_i
on IN N
mortality NN N
in IN N
high-risk JJ N
patients NNS N
with IN N
recent JJ N
myocardial JJ N
infarction NN N
: : N
insights NNS N
from IN N
the DT N
Defibrillation NNP N
in IN N
Acute NNP N
Myocardial NNP N
Infarction NNP N
Trial NNP N
( ( N
DINAMIT NNP N
) ) N
. . N

BACKGROUND NNP N
although IN N
implantable JJ 1_i
cardioverter-defibrillators NNS 1_i
( ( N
ICDs NNP N
) ) N
lower JJR N
mortality NN N
in IN N
stable JJ N
patients NNS N
with IN N
low JJ N
ejection NN N
fraction NN N
late RB N
after IN N
myocardial JJ N
infarction NN N
, , N
randomized VBN N
trials NNS N
of IN N
ICD NNP 1_i
versus FW N
control NN N
subjects NNS N
implanted VBD N
early RB N
after IN N
myocardial JJ N
infarction NN N
do VBP N
not RB N
show VB N
mortality NN N
benefit NN N
. . N

Our PRP$ N
objective NN N
was VBD N
to TO N
investigate VB N
possible JJ N
mechanisms NNS N
underlying VBG N
the DT N
lack NN N
of IN N
mortality NN N
benefit NN N
in IN N
the DT N
Defibrillation NNP N
in IN N
Acute NNP N
Myocardial NNP N
Infarction NNP N
Trial NNP N
( ( N
DINAMIT NNP N
) ) N
. . N

METHODS NNP N
AND CC N
RESULTS NNP N
this DT N
is VBZ N
a DT N
secondary JJ N
analysis NN N
of IN N
the DT N
prospective JJ N
randomized JJ N
clinical JJ N
trial NN N
. . N

Outpatients NNS N
with IN N
recent JJ N
( ( N
6 CD N
to TO N
40 CD N
days NNS N
) ) N
acute VBP N
myocardial JJ N
infarction NN N
, , N
left VBD N
ventricular JJ N
dysfunction NN N
( ( N
ejection JJ N
fraction NN N
< VBD N
35 CD N
% NN N
) ) N
, , N
and CC N
low JJ N
heart NN N
rate NN N
variability NN N
were VBD N
randomized VBN N
to TO N
ICD NNP 1_i
( ( N
n=311 NN N
) ) N
or CC N
to TO N
standard VB 7_i
medical JJ 7_i
therapy NN 7_i
( ( N
n=342 JJ N
) ) N
. . N

In IN N
a DT N
competing-risks JJ N
analysis NN N
, , N
those DT N
factors NNS N
that WDT N
increased VBD N
the DT N
risk NN N
of IN N
arrhythmic JJ N
death NN N
also RB N
increased VBD N
the DT N
risk NN N
of IN N
nonarrhythmic JJ N
deaths NNS N
. . N

After IN N
adjustment NN N
for IN N
these DT N
factors NNS N
, , N
receiving VBG N
an DT N
ICD NNP N
was VBD N
associated VBN N
with IN N
a DT N
decreased JJ N
risk NN N
of IN N
arrhythmic JJ N
death NN N
( ( N
hazard JJ N
ratio NN N
, , N
0.33 CD N
; : N
95 CD N
% NN N
confidence NN N
interval NN N
, , N
0.15 CD N
to TO N
0.71 CD N
) ) N
but CC N
an DT N
increase NN N
in IN N
nonarrhythmic JJ N
death NN N
( ( N
hazard JJ N
ratio NN N
, , N
1.70 CD N
; : N
95 CD N
% NN N
confidence NN N
interval NN N
, , N
1.00 CD N
to TO N
2.80 CD N
) ) N
. . N

In IN N
an DT N
adjusted JJ N
time-dependent JJ N
analysis NN N
, , N
patients NNS N
receiving VBG N
an DT N
ICD NNP N
and CC N
having VBG N
appropriate JJ N
ICD NNP N
therapy NN N
had VBD N
a DT N
15.1 CD N
% NN N
yearly RB N
hazard NN N
of IN N
mortality NN N
compared VBN N
with IN N
5.2 CD N
% NN N
in IN N
ICD NNP N
patients NNS N
with IN N
no DT N
appropriate JJ N
therapy NN N
( ( N
P NNP N
< NNP N
0.001 CD N
) ) N
. . N

The DT N
reduction NN N
in IN N
sudden JJ N
death NN N
in IN N
ICD NNP N
patients NNS N
was VBD N
completely RB N
offset VBN N
by IN N
increased JJ N
nonarrhythmic JJ N
deaths NNS N
, , N
which WDT N
were VBD N
greatest JJS N
in IN N
patients NNS N
receiving VBG N
ICD NNP N
shock NN N
therapy NN N
( ( N
hazard JJ N
ratio NN N
, , N
6.0 CD N
; : N
95 CD N
% NN N
confidence NN N
interval NN N
, , N
2.8 CD N
to TO N
12.7 CD N
) ) N
. . N

CONCLUSIONS NNP N
in IN N
patients NNS N
receiving VBG N
ICDs NNP N
early RB N
after IN N
myocardial JJ N
infarction NN N
, , N
those DT N
factors NNS N
that WDT N
are VBP N
associated VBN N
with IN N
arrhythmia NN N
requiring VBG N
ICD NNP N
therapy NN N
are VBP N
also RB N
associated VBN N
with IN N
a DT N
high JJ N
risk NN N
of IN N
nonsudden JJ N
death NN N
, , N
negating VBG N
the DT N
benefit NN N
of IN N
ICDs NNP N
in IN N
this DT N
setting NN N
. . N

-DOCSTART- -X- O O

Relation NN N
of IN N
total JJ N
homocysteine NN N
and CC N
lipid JJ N
levels NNS N
in IN N
children NNS N
to TO N
premature VB N
cardiovascular JJ N
death NN N
in IN N
male JJ N
relatives NNS N
. . N

We PRP N
assessed VBD N
the DT N
relative JJ N
importance NN N
of IN N
lipid JJ N
, , N
apo JJ N
B NNP N
, , N
lipoprotein NN N
( ( N
a DT N
) ) N
[ NN N
Lp NNP N
( ( N
a DT N
) ) N
] NN N
, , N
and CC N
total JJ N
homocysteine NN N
( ( N
tHcy NN N
) ) N
levels NNS N
in IN N
children NNS N
in IN N
relation NN N
to TO N
premature VB N
cardiovascular JJ N
disease NN N
in IN N
family NN N
members NNS N
. . N

Parents NNS N
of IN N
381 CD N
girls NNS N
and CC N
375 CD N
boys NNS N
age NN N
8-12 JJ N
y NN N
completed VBN N
family NN 6_i
history NN 6_i
questionnaires NNS 6_i
. . 6_i

Nonfasting VBG N
serum JJ N
lipid JJ N
and CC N
lipoproteins NNS N
and CC N
plasma NN N
tHcy NN N
and CC N
cysteine NN N
levels NNS N
were VBD N
measured VBN N
in IN N
the DT N
children NNS N
. . N

Serum NNP N
folate NN N
and CC N
vitamin NN N
B12 NNP N
levels NNS N
were VBD N
determined VBN N
in IN N
a DT N
random JJ N
subsample NN N
of IN N
23 CD N
% NN N
of IN N
the DT N
children NNS N
, , N
who WP N
participated VBD N
in IN N
a DT N
food NN N
frequency NN N
interview NN N
. . N

Children NNP N
whose WP$ N
parents NNS N
reported VBD N
hypercholesterolemia NN N
had VBD N
higher JJR N
total JJ N
and CC N
non-HDL JJ N
cholesterol NN N
and CC N
apo NN N
B NNP N
levels NNS N
than IN N
the DT N
rest NN N
, , N
but CC N
these DT N
levels NNS N
were VBD N
not RB N
associated VBN N
with IN N
cardiovascular JJ N
disease NN N
. . N

tHcy NN N
levels NNS N
were VBD N
similar JJ N
in IN N
girls NNS N
and CC N
boys NNS N
. . N

tHcy NN N
was VBD N
higher RBR N
in IN N
children NNS N
whose WP$ N
father NN N
, , N
grandfather NN N
, , N
or CC N
uncle NN N
died VBN N
at IN N
age NN N
< NN N
or CC N
= $ N
55 CD N
y NN N
of IN N
myocardial JJ N
infarction NN N
or CC N
sudden JJ N
cardiac JJ N
arrest NN N
( ( N
n JJ N
= NNP N
42 CD N
) ) N
than IN N
in IN N
control NN N
children NNS N
[ VBP N
5.92 CD N
mumol/L NN N
( ( N
95 CD N
% NN N
confidence NN N
interval NN N
[ NNP N
CI NNP N
] NNP N
of IN N
5.47-6.36 NNP N
) ) N
versus NN N
5.25 CD N
mumol/L NN N
( ( N
95 CD N
% NN N
CI NNP N
, , N
5.16-5.34 JJ N
) ) N
] NN N
, , N
also RB N
after IN N
adjustment NN N
for IN N
socioeconomic JJ N
group NN N
. . N

Intake NNP N
and CC N
serum NN N
levels NNS N
of IN N
vitamin NN N
B12 NNP N
and CC N
folate NN N
were VBD N
within IN N
recommended VBN N
or CC N
reference NN N
ranges NNS N
. . N

In IN N
a DT N
stepwise NN N
multiple JJ N
regression NN N
analysis NN N
, , N
serum NN N
folate NN N
( ( N
negative JJ N
correlation NN N
) ) N
, , N
plasma JJ N
creatinine NN N
, , N
and CC N
sugar RB N
intake VB N
as IN N
percent NN N
of IN N
dietary JJ N
energy NN N
( ( N
positive JJ N
correlations NNS N
) ) N
were VBD N
significantly RB N
associated VBN N
with IN N
tHcy NN N
( ( N
multiple JJ N
r NN N
= NN N
0.44 CD N
, , N
adjusted VBN N
r2 NN N
= VBZ N
18 CD N
% NN N
; : N
95 CD N
% NN N
CI NNP N
, , N
5-30 JJ N
% NN N
) ) N
. . N

Our PRP$ N
data NNS N
show VBP N
that IN N
a DT N
modest JJ N
elevation NN N
in IN N
tHcy NN N
in IN N
children NNS N
was VBD N
related VBN N
to TO N
premature VB N
cardiovascular JJ N
death NN N
in IN N
their PRP$ N
male NN N
relatives NNS N
and CC N
may MD N
partly RB N
account VB N
for IN N
the DT N
contribution NN N
of IN N
family NN N
history NN N
to TO N
risk NN N
of IN N
cardiovascular JJ N
disease NN N
. . N

tHcy NN N
may MD N
be VB N
modifiable JJ N
through IN N
the DT N
diet NN N
, , N
even RB N
in IN N
children NNS N
with IN N
apparently RB N
adequate JJ N
vitamin JJ N
nutriture NN N
. . N

-DOCSTART- -X- O O

A DT N
prospective JJ N
randomised JJ N
comparison NN N
of IN N
sublingual JJ 3_i
and CC 3_i
vaginal JJ 3_i
misoprostol NN 3_i
in IN N
second JJ N
trimester NN N
termination NN N
of IN N
pregnancy NN N
. . N

OBJECTIVE UH N
To TO N
compare VB N
the DT N
efficacy NN N
, , N
side NN N
effects NNS N
and CC N
acceptability NN N
of IN N
sublingual JJ 3_i
and CC 3_i
vaginal JJ 3_i
misoprostol NN 3_i
for IN N
second JJ N
trimester NN N
medical JJ N
abortion NN N
. . N

DESIGN NNP N
Prospective NNP N
randomised VBD N
controlled VBN N
trial NN N
. . N

SETTING NN N
Tertiary JJ N
referral JJ N
unit NN N
and CC N
a DT N
teaching JJ N
hospital NN N
. . N

POPULATION NNP N
Two CD N
hundred VBD N
and CC N
twenty-four JJ N
women NNS N
at IN N
12 CD N
to TO N
20 CD N
weeks NNS N
of IN N
gestation NN N
. . N

METHODS NNP N
The DT N
women NNS N
were VBD N
randomised VBN N
to TO N
receive VB N
either DT N
sublingual JJ 3_i
or CC 3_i
vaginal JJ 3_i
misoprostol NN 3_i
400 CD 3_i
microg NN 3_i
every DT N
3 CD N
hours NNS N
for IN N
a DT N
maximum NN N
of IN N
five CD N
doses NNS N
. . N

The DT N
course NN N
of IN N
misoprostol NN 3_i
was VBD N
repeated VBN N
if IN N
the DT N
woman NN N
did VBD N
not RB N
abort VB N
within IN N
24 CD N
hours NNS N
. . N

MAIN NNP N
OUTCOME NNP N
MEASURES NNP N
The DT N
success NN N
rate NN N
at IN N
48 CD N
hours NNS N
, , N
induction-to-abortion NN N
interval NN N
and CC N
the DT N
side NN N
effects NNS N
. . N

RESULTS NNP N
There EX N
was VBD N
no DT N
significant JJ N
difference NN N
in IN N
the DT N
success NN N
rate NN N
at IN N
48 CD N
hours NNS N
( ( N
sublingual JJ N
: : N
91 CD N
% NN N
; : N
vaginal JJ N
: : N
95 CD N
% NN N
) ) N
. . N

However RB N
, , N
the DT N
success NN N
rate NN N
at IN N
24 CD N
hours NNS N
was VBD N
significantly RB N
higher JJR N
in IN N
the DT N
vaginal JJ N
group NN N
( ( N
85 CD N
% NN N
) ) N
compared VBN N
with IN N
the DT N
sublingual JJ N
group NN N
( ( N
64 CD N
% NN N
) ) N
. . N

There EX N
was VBD N
no DT N
difference NN N
in IN N
the DT N
median JJ N
induction-to-abortion NN N
interval NN N
( ( N
sublingual JJ N
: : N
13.8 CD N
hours NNS N
; : N
vaginal JJ N
: : N
12.0 CD N
hours NNS N
) ) N
. . N

Significantly RB N
more JJR N
women NNS N
in IN N
the DT N
sublingual JJ N
group NN N
preferred VBD N
the DT N
route NN N
to TO N
which WDT N
they PRP N
were VBD N
assigned VBN N
when WRB N
compared VBN N
with IN N
the DT N
vaginal JJ N
group NN N
. . N

The DT N
incidence NN N
of IN N
fever NN N
was VBD N
also RB N
less RBR N
in IN N
the DT N
sublingual JJ N
group NN N
. . N

CONCLUSION NNP N
The DT N
use NN N
of IN N
vaginal JJ 3_i
misoprostol NN 3_i
for IN N
second JJ N
trimester NN N
medical JJ N
abortion NN N
resulted VBD N
in IN N
a DT N
higher JJR N
success NN N
rate NN N
than IN N
sublingual JJ N
misoprostol NN 3_i
at IN N
24 CD N
hours NNS N
but CC N
the DT N
abortion NN N
rate NN N
was VBD N
similar JJ N
at IN N
48 CD N
hours NNS N
. . N

Vaginal NNP 3_i
misoprostol NN 3_i
should MD N
be VB N
the DT N
regimen NNS N
of IN N
choice NN N
but CC N
sublingual JJ 3_i
misoprostol NN 3_i
is VBZ N
also RB N
an DT N
effective JJ N
alternative NN N
. . N

-DOCSTART- -X- O O

Smoking VBG N
cessation NN N
with IN N
smokeless JJ 6_i
tobacco NN 6_i
and CC N
group NN 4_i
therapy NN 4_i
: : 6_i
an DT N
open JJ N
, , N
randomized VBN N
, , N
controlled VBN N
trial NN N
. . N

Smokeless NNP 6_i
tobacco NN 6_i
might MD N
be VB N
effective JJ N
as IN N
an DT N
adjunct NN N
for IN N
smoking VBG N
cessation NN N
. . N

We PRP N
evaluated VBD N
the DT N
efficacy NN N
of IN N
smokeless NN 6_i
tobacco NN 6_i
and CC N
group NN 4_i
support NN 4_i
for IN N
smoking VBG N
cessation NN N
in IN N
an DT N
open JJ N
, , N
randomized VBN N
study NN N
that WDT N
compared VBN N
smokeless NN 6_i
tobacco NN 6_i
plus CC N
group NN 4_i
support NN 4_i
versus NN N
group NN 6_i
support NN 6_i
only RB 4_i
. . N

The DT N
study NN N
enrolled VBD N
263 CD N
healthy JJ N
smokers NNS N
( ( N
M NNP N
( ( N
age NN N
) ) N
= VBZ N
49 CD N
years NNS N
) ) N
who WP N
smoked VBD N
a DT N
mean NN N
of IN N
24 CD N
cigarettes/day NN N
, , N
with IN N
a DT N
mean NN N
of IN N
31 CD N
pack-years NNS N
. . N

Smokeless NNP 6_i
tobacco NN 6_i
was VBD N
provided VBN N
for IN N
7 CD N
weeks NNS N
( ( N
or CC N
up RB N
to TO N
12 CD N
) ) N
, , N
combined VBN N
with IN N
eight CD N
group NN 4_i
support NN 4_i
visits NNS 4_i
provided VBN 4_i
by IN 4_i
nurses NNS 4_i
. . N

The DT N
control NN 7_i
group NN 7_i
received VBD N
group NN 6_i
support NN 6_i
only RB 4_i
. . N

Smoking VBG N
cessation NN N
rates NNS N
were VBD N
statistically RB N
significantly RB N
better RBR N
in IN N
the DT N
smokeless NN N
tobacco NN N
group NN N
than IN N
in IN N
the DT N
control NN N
group NN N
during IN N
the DT N
first JJ N
7 CD N
weeks NNS N
. . N

Point-prevalence NN N
abstinence NN N
rates NNS N
at IN N
7 CD N
weeks NNS N
were VBD N
36.4 CD N
% NN N
versus IN N
20.8 CD N
% NN N
( ( N
OR NNP N
= VBZ N
2.52 CD N
, , N
p NN N
= NNP N
.001 NNP N
) ) N
, , N
respectively RB N
; : N
and CC N
continuous JJ N
abstinence NN N
rates NNS N
from IN N
weeks NNS N
4 CD N
to TO N
7 CD N
were VBD N
31.5 CD N
% NN N
versus IN N
19.2 CD N
% NN N
( ( N
OR NNP N
= VBZ N
1.94 CD N
, , N
p NN N
= NNP N
.023 NNP N
) ) N
, , N
respectively RB N
. . N

The DT N
primary JJ N
outcomes NNS N
( ( N
i.e. JJ N
, , N
6-month JJ N
point NN N
prevalence NN N
) ) N
were VBD N
23.1 CD N
% NN N
versus IN N
20.8 CD N
% NN N
, , N
respectively RB N
( ( N
OR NNP N
= VBZ N
1.31 CD N
, , N
ns NN N
) ) N
. . N

Smokeless NNP 6_i
tobacco NN 6_i
was VBD N
relatively RB N
well RB N
tolerated VBN N
, , N
although IN N
15 CD N
subjects NNS N
( ( N
11.2 CD N
% NN N
) ) N
stopped VBD N
use NN N
due JJ N
to TO N
adverse JJ N
events NNS N
. . N

A DT N
total NN N
of IN N
25 CD N
subjects NNS N
( ( N
17.5 CD N
% NN N
) ) N
were VBD N
still RB N
using VBG N
smokeless JJ N
tobacco NN N
after IN N
6 CD N
months NNS N
. . N

This DT N
trial NN N
demonstrated VBD N
short-term JJ N
efficacy NN N
of IN N
smokeless JJ 6_i
tobacco NN 6_i
in IN N
combination NN N
with IN N
group NN N
support NN N
for IN N
smoking VBG N
cessation NN N
but CC N
no DT N
long-term JJ N
efficacy NN N
. . N

-DOCSTART- -X- O O

Pilot NNP N
study NN N
of IN N
Panax NNP 3_i
quinquefolius NN 3_i
( ( 3_i
American NNP 3_i
ginseng NN 3_i
) ) 3_i
to TO N
improve VB N
cancer-related JJ N
fatigue NN N
: : N
a DT N
randomized JJ N
, , N
double-blind JJ N
, , N
dose-finding JJ N
evaluation NN N
: : N
NCCTG NNP N
trial NN N
N03CA NNP N
. . N

PURPOSE NNP N
This DT N
pilot NN N
trial NN N
sought VBD N
to TO N
investigate VB N
whether IN N
any DT N
of IN N
three CD N
doses NNS N
of IN N
American JJ 3_i
ginseng NN 3_i
( ( 3_i
Panax NNP 3_i
quinquefolius RB 3_i
) ) 3_i
might MD N
help VB N
cancer-related JJ N
fatigue NN N
. . N

A DT N
secondary JJ N
aim NN N
was VBD N
to TO N
evaluate VB N
toxicity NN N
. . N

METHODS NNP N
Eligible JJ N
adults NNS N
with IN N
cancer NN N
were VBD N
randomized VBN N
in IN N
a DT N
double-blind JJ N
manner NN N
, , N
to TO N
receive VB N
American JJ 3_i
ginseng NN 3_i
in IN N
doses NNS N
of IN N
750 CD N
, , N
1,000 CD N
, , N
or CC N
2,000 CD N
mg/day NN N
or CC N
placebo VB 7_i
given VBN N
in IN N
twice JJ N
daily JJ N
dosing NN N
over IN N
8 CD N
weeks NNS N
. . N

Outcome NNP N
measures NNS N
included VBD N
the DT N
Brief NNP N
Fatigue NNP N
Inventory NNP N
, , N
vitality NN N
subscale NN N
of IN N
the DT N
Medical NNP N
Outcome NNP N
Scale NNP N
Short NNP N
Form-36 NNP N
( ( N
SF-36 NNP N
) ) N
, , N
and CC N
the DT N
Global NNP N
Impression NNP N
of IN N
Benefit NNP N
Scale NNP N
at IN N
4 CD N
and CC N
8 CD N
weeks NNS N
. . N

RESULTS NNP N
Two CD N
hundred VBD N
ninety NN N
patients NNS N
were VBD N
accrued VBN N
to TO N
this DT N
trial NN N
. . N

Nonsignificant JJ N
trends NNS N
for IN N
all DT N
outcomes NNS N
were VBD N
seen VBN N
in IN N
favor NN N
of IN N
the DT N
1,000- JJ N
and CC N
2,000-mg/day JJ N
doses NNS N
of IN N
American JJ 3_i
ginseng NN 3_i
. . 3_i

Area NNP N
under IN N
the DT N
curve NN N
analysis NN N
of IN N
activity NN N
interference NN N
from IN N
the DT N
Brief NNP N
Fatigue NNP N
Inventory NNP N
was VBD N
460-467 JJ N
in IN N
the DT N
placebo NN 7_i
group NN N
and CC N
750 CD N
mg/day NN N
group NN N
versus VBD N
480-551 CD N
in IN N
the DT N
1,000- JJ N
and CC N
2,000-mg/day JJ N
arms NNS N
, , N
respectively RB N
. . N

Change NN N
from IN N
baseline NN N
in IN N
the DT N
vitality NN N
subscale NN N
of IN N
the DT N
SF-36 NNP N
was VBD N
7.3-7.8 JJ N
in IN N
the DT N
placebo NN 7_i
and CC N
the DT N
750-mg/day JJ N
arm NN N
, , N
versus NN N
10.5-14.6 JJ N
in IN N
the DT N
1,000- JJ N
and CC N
2,000-mg/day JJ N
arms NNS N
. . N

Over NNP N
twice RB N
as RB N
many JJ N
patients NNS N
on IN N
ginseng NN 3_i
perceived VBD N
a DT N
benefit NN N
and CC N
were VBD N
satisfied VBN N
with IN N
treatment NN N
over IN N
those DT N
on IN N
placebo NN 7_i
. . 7_i

There EX N
were VBD N
no DT N
significant JJ N
differences NNS N
in IN N
any DT N
measured JJ N
toxicities NNS N
between IN N
any DT N
of IN N
the DT N
arms NNS N
. . N

CONCLUSION NN N
There EX N
appears VBZ N
to TO N
be VB N
some DT N
activity NN N
and CC N
tolerable JJ N
toxicity NN N
at IN N
1,000-2,000 CD N
mg/day JJ N
doses NNS N
of IN N
American JJ 3_i
ginseng NN 3_i
with IN N
regard NN N
to TO N
cancer-related JJ N
fatigue NN N
. . N

Thus NNP N
, , N
further JJ N
study NN N
of IN N
American NNP 3_i
ginseng NN 3_i
is VBZ N
warranted VBN N
. . N

-DOCSTART- -X- O O

Effects NNS N
of IN N
bifidobacterium NN 3_i
breve VBP 3_i
supplementation NN N
on IN N
intestinal JJ N
flora NNS N
of IN N
low JJ N
birth NN N
weight NN N
infants NNS N
. . N

BACKGROUND IN N
It PRP N
is VBZ N
known VBN N
that IN N
the DT N
bifidobacteria NN N
flora VBP N
play NN N
important JJ N
roles NNS N
in IN N
mucosal NN N
host NN N
defense NN N
and CC N
can MD N
prevent VB N
infectious JJ N
diseases NNS N
. . N

Because IN N
bacterial JJ N
populations NNS N
develop VBP N
during IN N
the DT N
first JJ N
day NN N
of IN N
life NN N
, , N
the DT N
authors NNS N
examined VBD N
whether IN N
the DT N
early JJ N
administration NN N
of IN N
bifidobacteria NN N
has VBZ N
a DT N
positive JJ N
effect NN N
on IN N
the DT N
health NN N
of IN N
low JJ N
birth NN N
weight NN N
infants NNS N
. . N

METHODS NNP N
The DT N
effects NNS N
of IN N
oral JJ N
administration NN N
of IN N
Bifidobacterium NNP 3_i
breve NN 3_i
( ( 3_i
B. NNP 3_i
breve VBP 3_i
) ) 3_i
supplements NNS 3_i
were VBD N
studied VBN N
in IN N
a DT N
controlled JJ N
trial NN N
with IN N
low JJ N
birth NN N
weight NN N
infants NNS N
( ( N
average JJ N
birth NN N
weight NN N
1489 CD N
g NN N
) ) N
. . N

The DT N
infants NNS N
were VBD N
divided VBN N
into IN N
three CD N
groups NNS N
: : N
Group NNP N
A NNP N
and CC N
B NNP N
received VBD N
a DT N
dose NN N
of IN N
1.6 CD N
x NNS N
10 CD N
( ( N
8 CD N
) ) N
cells NNS N
of IN N
B. NNP N
breve VBP N
supplement NN N
twice RB N
a DT N
day NN N
, , N
commencing VBG N
either CC N
from IN N
several JJ N
hours NNS N
after IN N
birth NN N
( ( N
group NN N
A NNP N
) ) N
or CC N
24 CD N
h NN N
after IN N
birth NN N
( ( N
group NN N
B NNP N
) ) N
. . N

Group NNP N
C NNP N
, , N
the DT N
control NN 7_i
group NN 7_i
, , N
received VBD N
no DT N
supplement NN N
. . N

RESULTS CC N
There EX N
were VBD N
no DT N
significant JJ N
differences NNS N
in IN N
birth NN N
weight NN N
, , N
treatment NN N
with IN N
antibiotics NNS N
, , N
and CC N
the DT N
starting JJ N
time NN N
of IN N
breast-feeding NN N
among IN N
the DT N
three CD N
groups NNS N
. . N

A DT N
Bifidobacterium-predominant JJ N
flora NN N
was VBD N
formed VBN N
at IN N
an DT N
average NN N
of IN N
2 CD N
weeks NNS N
after IN N
birth NN N
in IN N
group NN N
A NNP N
and CC N
at IN N
an DT N
average NN N
of IN N
4 CD N
weeks NNS N
after IN N
birth NN N
in IN N
group NN N
B NNP N
, , N
while IN N
no DT N
Bifidobacterium NNP N
was VBD N
isolated VBN N
in IN N
eight CD N
out IN N
of IN N
10 CD N
infants NNS N
in IN N
group NN N
C NNP N
during IN N
the DT N
observation NN N
period NN N
of IN N
7 CD N
weeks NNS N
. . N

In IN N
comparison NN N
between IN N
group NN N
A NNP N
and CC N
B NNP N
, , N
Bifidobacterium NNP N
was VBD N
detected VBN N
significantly RB N
earlier RBR N
in IN N
group NN N
A NNP N
, , N
and CC N
the DT N
number NN N
of IN N
Enterobacteriaceae NNP N
present NN N
in IN N
the DT N
infants NNS N
at IN N
2 CD N
weeks NNS N
after IN N
birth NN N
was VBD N
significantly RB N
lower JJR N
in IN N
group NN N
A NNP N
. . N

CONCLUSION NNP N
The DT N
results NNS N
of IN N
the DT N
present JJ N
study NN N
suggest VBP N
that IN N
very RB N
early JJ N
administration NN N
of IN N
B. NNP N
breve VBP N
to TO N
low JJ N
birth NN N
weight NN N
infants NNS N
is VBZ N
useful JJ N
in IN N
promoting VBG N
the DT N
colonization NN N
of IN N
the DT N
Bifidobacterium NNP N
and CC N
the DT N
formation NN N
of IN N
a DT N
normal JJ N
intestinal JJ N
flora NN N
. . N

-DOCSTART- -X- O O

Treatment NN N
with IN N
metformin NN 3_i
of IN N
non-diabetic JJ N
men NNS N
with IN N
hypertension NN N
, , N
hypertriglyceridaemia NN N
and CC N
central JJ N
fat JJ N
distribution NN N
: : N
the DT N
BIGPRO NNP N
1.2 CD N
trial NN N
. . N

BACKGROUND NNP N
In IN N
the DT N
BIGPRO NNP N
1 CD N
trial NN N
, , N
one CD N
year NN N
of IN N
treatment NN N
with IN N
metformin NN 3_i
in IN N
non-diabetic JJ N
obese JJ N
subjects NNS N
with IN N
a DT N
central JJ N
fat JJ N
distribution NN N
had VBD N
no DT N
significant JJ N
effect NN N
on IN N
fasting VBG N
plasma JJ N
triglyceride JJ N
concentration NN N
or CC N
on IN N
blood NN N
pressure NN N
despite IN N
a DT N
decrease NN N
in IN N
weight NN N
, , N
fasting VBG N
plasma JJ N
insulin NN N
and CC N
glucose JJ N
concentrations NNS N
. . N

To TO N
re-evaluate VB N
the DT N
effect NN N
of IN N
metformin NN 3_i
on IN N
fasting VBG N
triglyceride JJ N
concentration NN N
and CC N
on IN N
blood NN N
pressure NN N
, , N
the DT N
BIGPRO NNP N
1.2 CD N
trial NN N
included VBD N
non-diabetic JJ N
men NNS N
( ( N
n=168 NN N
) ) N
with IN N
a DT N
fasting VBG N
plasma NN N
triglyceride JJ N
concentration NN N
> NN N
or CC N
=1.7 NN N
and CC N
< NN N
or CC N
=6.5 NN N
mmol/l NN N
, , N
high JJ N
blood NN N
pressure NN N
( ( N
systolic JJ N
> NN N
or CC N
=140 NN N
and CC N
< NN N
or CC N
=180 VB N
and/or JJ N
diastolic JJ N
> NN N
or CC N
=90 NN N
and CC N
< NN N
or CC N
=105 NN N
mmHg NN N
, , N
or CC N
treatment NN N
for IN N
hypertension NN N
) ) N
and CC N
a DT N
waist-to-hip JJ N
ratio NN N
> NN N
or CC N
=0.95 NN N
. . N

METHODS NNP N
A DT N
randomised JJ N
double-blind JJ N
trial NN N
comparing VBG N
metformin NN 3_i
treatment NN N
( ( N
850 CD N
mg RB N
bid NN N
) ) N
with IN N
placebo NN 7_i
. . N

RESULTS NNP N
Metformin NNP 3_i
had VBD N
no DT N
significant JJ N
effect NN N
either DT N
on IN N
blood NN N
pressure NN N
or CC N
plasma NN N
triglyceride JJ N
concentration NN N
. . N

In IN N
comparison NN N
with IN N
the DT N
placebo NN 7_i
group NN N
, , N
fasting VBG N
plasma JJ N
insulin NN N
( ( N
p JJ N
< NNP N
0.04 CD N
) ) N
, , N
total JJ N
cholesterol NN N
( ( N
p JJ N
< NNP N
0.05 CD N
) ) N
and CC N
Apo NNP N
B NNP N
( ( N
p JJ N
< NNP N
0.008 CD N
) ) N
concentrations NNS N
decreased VBD N
more RBR N
in IN N
the DT N
metformin NN N
group NN N
in IN N
the DT N
BIGPRO NNP N
1 CD N
. . N

2 CD N
trial NN N
, , N
confirming VBG N
most JJS N
of IN N
the DT N
previous JJ N
results NNS N
of IN N
the DT N
BIGPRO NNP N
1 CD N
trial NN N
. . N

Tissue NNP N
plasminogen NN N
activator NN N
antigen NN N
concentration NN N
decreased VBN N
significantly RB N
( ( N
p JJ N
< NNP N
0.01 CD N
) ) N
only RB N
in IN N
the DT N
metformin NN 3_i
group NN N
, , N
but CC N
this DT N
was VBD N
not RB N
significantly RB N
different JJ N
from IN N
the DT N
placebo NN 7_i
group NN N
( ( N
p JJ N
< NNP N
0.12 CD N
) ) N
; : N
further RB N
, , N
there EX N
were VBD N
no DT N
significant JJ N
differences NNS N
in IN N
the DT N
change NN N
in IN N
plasminogen NN N
activator NN N
inhibitor NN N
1 CD N
. . N

CONCLUSIONS VB N
The DT N
consistency NN N
of IN N
the DT N
two CD N
BIGPRO NNP N
trials NNS N
supports VBZ N
the DT N
conclusion NN N
that IN N
metformin VBZ 3_i
affects NNS N
several JJ N
cardiovascular JJ N
risk NN N
factors NNS N
favourably RB N
in IN N
non-diabetic JJ N
subjects NNS N
with IN N
a DT N
central JJ N
fat JJ N
distribution NN N
. . N

-DOCSTART- -X- O O

The DT N
influence NN N
of IN N
breast NN N
size NN N
on IN N
late JJ N
radiation NN N
effects NNS N
and CC N
association NN N
with IN N
radiotherapy NN N
dose JJ N
inhomogeneity NN N
. . N

A DT N
prospective JJ N
assessment NN N
of IN N
late JJ N
changes NNS N
in IN N
breast NN N
appearance NN N
in IN N
559 CD N
patients NNS N
after IN N
tumour JJ 1_i
excision NN 1_i
and CC N
radiotherapy NN 2_i
for IN N
early JJ N
breast NN N
cancer NN N
noted VBD N
a DT N
strong JJ N
association NN N
with IN N
breast NN N
size NN N
. . N

Only RB N
3/48 CD N
( ( N
6 CD N
% NN N
) ) N
patients NNS N
with IN N
small JJ N
breasts NNS N
developed VBD N
moderate JJ N
or CC N
severe JJ N
late JJ N
changes NNS N
compared VBN N
with IN N
94/423 CD N
( ( N
22 CD N
% NN N
) ) N
with IN N
medium NN N
sized VBN N
breasts NNS N
and CC N
34/88 CD N
( ( N
39 CD N
% NN N
) ) N
patients NNS N
with IN N
large JJ N
breasts NNS N
( ( N
p JJ N
< NNP N
0.001 CD N
) ) N
. . N

One CD N
possibility NN N
is VBZ N
that IN N
greater JJR N
radiation NN N
changes NNS N
are VBP N
related VBN N
to TO N
greater JJR N
dose JJ N
inhomogeneity NN N
in IN N
women NNS N
with IN N
large JJ N
breasts NNS N
. . N

To TO N
explore VB N
this DT N
hypothesis NN N
, , N
radiation NN N
dose JJ N
distributions NNS N
were VBD N
assessed VBN N
in IN N
a DT N
separate JJ N
group NN N
of IN N
37 CD N
women NNS N
in IN N
whom WP N
three-level JJ N
transverse NN N
computer NN N
tomographic JJ N
images NNS N
of IN N
the DT N
breast NN N
in IN N
the DT N
treatment NN N
position NN N
were VBD N
available JJ N
. . N

A DT N
significant JJ N
correlation NN N
was VBD N
found VBN N
between IN N
breast NN N
size NN N
and CC N
dose NN N
inhomogeneity NN N
which WDT N
may MD N
account VB N
for IN N
the DT N
marked JJ N
changes NNS N
in IN N
breast NN N
appearance NN N
reported VBD N
in IN N
women NNS N
with IN N
large JJ N
breasts NNS N
. . N

-DOCSTART- -X- O O

Effects NNS N
of IN N
sibutramine NN 3_i
on IN N
thermogenesis NN N
in IN N
obese JJ N
patients NNS N
assessed VBD N
via IN N
immersion NN N
calorimetry NN N
. . N

Glucose NNP N
utilization JJ N
studies NNS N
show VBP N
that IN N
sibutramine-induced JJ 3_i
thermogenesis NN N
is VBZ N
mediated VBN N
via IN N
selective JJ N
sympathetic JJ N
activation NN N
of IN N
brown JJ N
adipose JJ N
tissue NN N
. . N

The DT N
goal NN N
of IN N
the DT N
present JJ N
study NN N
was VBD N
to TO N
use VB N
a DT N
new JJ N
calorimetry NN N
method NN N
in IN N
which WDT N
resting VBG N
metabolic JJ N
rate NN N
is VBZ N
enhanced VBN N
to TO N
evaluate VB N
the DT N
effects NNS N
of IN N
sibutramine JJ 3_i
treatment NN N
on IN N
thermogenesis NN N
. . N

Sixty NNP N
obese JJ N
women NNS N
were VBD N
included VBN N
in IN N
the DT N
study NN N
. . N

Subjects NNS N
were VBD N
divided VBN N
into IN N
2 CD N
equal JJ N
groups-the JJ N
placebo NN 7_i
and CC N
sibutramine JJ 3_i
treatment NN N
groups NNS N
. . N

The DT N
sibutramine NN 3_i
group NN N
was VBD N
given VBN N
sibutramine JJ 3_i
10 CD N
mg JJ N
daily RB N
for IN N
12 CD N
wk NN N
. . N

At IN N
baseline NN N
and CC N
at IN N
the DT N
end NN N
of IN N
the DT N
12-wk JJ N
treatment NN N
period NN N
, , N
thermogenic JJ N
measurements NNS N
were VBD N
taken VBN N
with IN N
the DT N
use NN N
of IN N
water NN N
immersion NN N
calorimetry NN N
. . N

Subjects NNS N
were VBD N
examined VBN N
at IN N
weeks NNS N
4 CD N
, , N
8 CD N
, , N
and CC N
12 CD N
of IN N
treatment NN N
to TO N
identify VB N
adverse JJ N
effects NNS N
. . N

Body NNP N
mass NN N
index NN N
, , N
measured VBN N
at IN N
31.5+/-2.05 JJ N
kg/m2 NN N
in IN N
the DT N
placebo NN N
group NN N
, , N
decreased VBN N
to TO N
30.4+/-2.94 JJ N
kg/m NN N
( ( N
2 CD N
) ) N
after IN N
12 CD N
wk NN N
( ( N
P=.07 NNP N
) ) N
. . N

In IN N
the DT N
sibutramine NN 3_i
group NN N
, , N
it PRP N
decreased VBD N
from IN N
33.5+/-4.1 JJ N
kg/m NN N
( ( N
2 CD N
) ) N
to TO N
30.9+/-4.8 JJ N
kg/m NN N
( ( N
2 CD N
) ) N
( ( N
P NNP N
< NNP N
.05 NNP N
) ) N
. . N

In IN N
the DT N
sibutramine NN 3_i
group NN N
, , N
mean VBP N
thermogenic JJ N
response NN N
changed VBD N
from IN N
a DT N
baseline NN N
value NN N
of IN N
1.27+/-0.29 JJ N
kcal/kg/h NN N
to TO N
1.44+/-0.13 JJ N
kcal/kg/h NN N
after IN N
12 CD N
wk NN N
of IN N
treatment NN N
. . N

In IN N
the DT N
placebo NN N
group NN N
, , N
the DT N
baseline NN N
value NN N
was VBD N
1.56+/-0.27 JJ N
kcal/kg/h NN N
; : N
it PRP N
changed VBD N
to TO N
1.33+/-0.36 JJ N
kcal/kg/h NN N
at IN N
the DT N
end NN N
of IN N
12 CD N
wk NN N
. . N

The DT N
findings NNS N
of IN N
this DT N
study NN N
suggest VBP N
that IN N
sibutramine NN N
treatment NN N
promotes VBZ N
thermogenesis NN N
, , N
thus RB N
facilitating VBG N
weight JJ N
loss NN N
. . N

Calorimetry NNP N
enhances VBZ N
resting VBG N
metabolism NN N
through IN N
more RBR N
efficient JJ N
heat NN N
transfer NN N
from IN N
the DT N
body NN N
. . N

-DOCSTART- -X- O O

Perioperative JJ N
fever NN N
and CC N
outcome NN N
in IN N
surgical JJ N
patients NNS N
with IN N
aneurysmal JJ N
subarachnoid JJ N
hemorrhage NN N
. . N

OBJECTIVE IN N
We PRP N
examined VBD N
the DT N
incidence NN N
of IN N
perioperative JJ N
fever NN N
and CC N
its PRP$ N
relationship NN N
to TO N
outcome VB N
among IN N
patients NNS N
enrolled VBN N
in IN N
the DT N
Intraoperative NNP N
Hypothermia NNP N
for IN N
Aneurysm NNP N
Surgery NNP N
Trial NNP N
. . N

METHODS NNP N
One CD N
thousand NN N
patients NNS N
with IN N
initial JJ N
World NNP N
Federation NNP N
of IN N
Neurological NNP N
Surgeons NNP N
grades NNS N
of IN N
I PRP N
to TO N
III NNP N
undergoing VBG N
clipping NN N
of IN N
intracranial JJ N
aneurysms NNS N
after IN N
subarachnoid JJ N
hemorrhage NN N
were VBD N
randomized VBN N
to TO N
intraoperative VB 6_i
normothermia NN 6_i
( ( N
36 CD N
degrees NNS N
C-37 JJ N
degrees NNS N
C NNP N
) ) N
or CC N
hypothermia NN 6_i
( ( N
32.5 CD N
degrees NNS N
C-33.5 JJ N
degrees NNS N
C NNP N
) ) N
. . N

Fever NNP N
( ( N
> CD N
or CC N
=38.5 VB N
degrees NNS N
C NNP N
) ) N
and CC N
other JJ N
complications NNS N
( ( N
including VBG N
infections NNS N
) ) N
occurring VBG N
between IN N
admission NN N
and CC N
discharge NN N
( ( N
or CC N
death NN N
) ) N
were VBD N
recorded VBN N
. . N

Functional NNP N
and CC N
neuropsychologic JJ N
outcomes NNS N
were VBD N
assessed VBN N
3 CD N
months NNS N
postoperatively RB N
. . N

The DT N
primary JJ N
outcome NN N
variable NN N
for IN N
the DT N
trial NN N
was VBD N
dichotomized VBN N
Glasgow NNP N
Outcome NNP N
Scale NNP N
( ( N
good JJ N
outcome NN N
versus IN N
all DT N
others NNS N
) ) N
. . N

RESULTS NNP N
Fever NNP N
was VBD N
reported VBN N
in IN N
41 CD N
% NN N
of IN N
patients NNS N
. . N

In IN N
97 CD N
% NN N
of IN N
these DT N
, , N
fever RB N
occurred VBD N
in IN N
the DT N
postoperative JJ N
period NN N
. . N

The DT N
median JJ N
time NN N
from IN N
surgery NN N
to TO N
first VB N
fever NN N
was VBD N
3 CD N
days NNS N
. . N

All DT N
measures NNS N
of IN N
outcome NN N
were VBD N
worse JJR N
in IN N
patients NNS N
who WP N
developed VBD N
fever NN N
, , N
even RB N
in IN N
those DT N
without IN N
infections NNS N
or CC N
who WP N
were VBD N
World NNP N
Federation NNP N
of IN N
Neurological NNP N
Surgeons NNP N
grade VBD N
I. NNP N
Logistic NNP N
regression NN N
analyses NNS N
were VBD N
performed VBN N
to TO N
adjust VB N
for IN N
differences NNS N
in IN N
preoperative JJ N
factors NNS N
( ( N
e.g. NN N
, , N
age NN N
, , N
Fisher NNP N
grade NN N
, , N
initial JJ N
neurological JJ N
status NN N
) ) N
. . N

This DT N
demonstrated VBD N
that IN N
fever NN N
continued VBD N
to TO N
be VB N
significantly RB N
associated VBN N
with IN N
most JJS N
outcome JJ N
measures NNS N
, , N
even RB N
when WRB N
infection NN N
was VBD N
added VBN N
to TO N
the DT N
model NN N
. . N

An DT N
alternative JJ N
stepwise NN N
model NN N
selection NN N
process NN N
including VBG N
all DT N
fever-related JJ N
measures NNS N
from IN N
the DT N
preoperative NN N
and CC N
intraoperative JJ N
period NN N
( ( N
e.g. JJ N
, , N
hydrocephalus JJ N
, , N
duration NN N
of IN N
surgery NN N
, , N
intraoperative JJ N
blood NN N
loss NN N
) ) N
resulted VBD N
in IN N
the DT N
loss NN N
of IN N
significance NN N
for IN N
dichotomized JJ N
Glasgow NNP N
Outcome NNP N
Scale NNP N
, , N
but CC N
significant JJ N
associations NNS N
between IN N
fever NN N
and CC N
several JJ N
other JJ N
outcome JJ N
measures NNS N
remained VBD N
. . N

After IN N
adding VBG N
postoperative JJ N
delayed VBN N
ischemic JJ N
neurological JJ N
deficits NNS N
to TO N
the DT N
model NN N
, , N
only RB N
worsened VBD N
National NNP N
Institutes NNPS N
of IN N
Health NNP N
Stroke NNP N
Scale NNP N
score NN N
, , N
Barthel NNP N
Activities NNP N
of IN N
Daily NNP N
Living NNP N
index NN N
, , N
and CC N
discharge NN N
destination NN N
( ( N
home NN N
versus IN N
other JJ N
) ) N
remained VBD N
independently RB N
associated VBN N
with IN N
fever NN N
. . N

CONCLUSION NNP N
These DT N
findings NNS N
suggest VBP N
that IN N
fever NN N
is VBZ N
associated VBN N
with IN N
worsened JJ N
outcome NN N
in IN N
surgical JJ N
subarachnoid JJ N
hemorrhage NN N
patients NNS N
, , N
although IN N
, , N
because IN N
the DT N
association NN N
between IN N
fever NN N
and CC N
the DT N
primary JJ N
outcome NN N
measure NN N
for IN N
the DT N
trial NN N
is VBZ N
dependent JJ N
on IN N
the DT N
covariates NNS N
used VBN N
in IN N
the DT N
analysis NN N
( ( N
particularly RB N
operative JJ N
events NNS N
and CC N
delayed VBN N
ischemic JJ N
neurological JJ N
deficits NNS N
) ) N
, , N
we PRP N
can MD N
not RB N
rule VB N
out IN N
the DT N
possibility NN N
that IN N
fever NN N
is VBZ N
a DT N
marker NN N
for IN N
other JJ N
events NNS N
. . N

Only RB N
a DT N
formal JJ N
trial NN N
of IN N
fever NN N
treatment NN N
or CC N
prevention NN N
can MD N
address VB N
this DT N
issue NN N
. . N

-DOCSTART- -X- O O

Concurrent NNP N
alcohol NN 4_i
dependence NN 4_i
among IN N
methadone-maintained JJ N
cocaine NN N
abusers NNS N
is VBZ N
associated VBN N
with IN N
greater JJR N
abstinence NN N
. . N

Concurrent NNP 4_i
alcohol NN 4_i
dependence NN 4_i
( ( 4_i
AD NNP 4_i
) ) 4_i
among IN N
polysubstance NN N
abusers NNS N
has VBZ N
been VBN N
associated VBN N
with IN N
negative JJ N
consequences NNS N
, , N
although IN N
it PRP N
may MD N
not RB N
necessarily RB N
lead VB N
to TO N
poor JJ N
treatment NN N
outcomes NNS N
. . N

One CD N
of IN N
the DT N
most RBS N
efficacious JJ N
treatments NNS N
for IN N
cocaine NN N
abuse NN N
is VBZ N
contingency JJ 4_i
management NN 4_i
( ( 4_i
CM NNP 4_i
) ) 4_i
, , N
but CC N
little JJ N
research NN N
has VBZ N
explored VBN N
the DT N
impact NN N
of IN N
AD NNP 4_i
on IN N
abstinence NN N
outcomes NNS N
, , N
particularly RB N
among IN N
patients NNS N
in IN N
methadone JJ N
maintenance NN N
. . N

Using VBG N
data NNS N
from IN N
three CD N
trials NNS N
of IN N
CM NNP N
for IN N
cocaine NN N
use NN N
, , N
we PRP N
compared VBN N
baseline JJ N
characteristics NNS N
and CC N
posttreatment NN N
and CC N
follow-up JJ N
cocaine NN N
outcomes NNS N
between IN N
methadone-maintained JJ 3_i
, , N
cocaine-dependent JJ 3_i
patients NNS N
( ( N
N NNP N
= NNP N
193 CD N
) ) N
with IN 4_i
and CC 4_i
without IN 4_i
concurrent JJ 4_i
AD NNP 4_i
, , 4_i
randomized VBN 4_i
to TO 4_i
standard VB 4_i
care NN 4_i
( ( 4_i
SC NNP 4_i
) ) 4_i
with IN 4_i
or CC 4_i
without IN 4_i
CM NNP 4_i
. . 4_i

Patients NNS N
with IN 4_i
and CC 4_i
without IN 4_i
concurrent JJ 4_i
AD NNP 4_i
had VBD N
similar JJ N
baseline NN N
characteristics NNS N
, , N
with IN N
the DT N
exception NN N
that WDT N
AD NNP 4_i
patients NNS N
reported VBD N
more RBR N
alcohol NN N
use NN N
. . N

AD NN 4_i
patients NNS N
achieved VBN N
longer JJR N
durations NNS N
of IN N
cocaine NN N
abstinence NN N
and CC N
were VBD N
more RBR N
likely JJ N
to TO N
submit VB N
a DT N
cocaine-negative JJ N
sample NN N
at IN N
follow-up JJ N
than IN N
non-AD JJ 4_i
patients NNS N
. . N

Patients NNS N
randomized VBD N
to TO N
CM NNP 4_i
achieved VBD N
better RBR N
outcomes NNS N
than IN N
those DT N
randomized VBN N
to TO N
SC NNP 4_i
, , N
but CC N
there EX N
was VBD N
no DT N
interaction NN N
between IN N
treatment NN N
condition NN N
and CC N
AD NNP 4_i
status NN N
. . N

These DT N
findings NNS N
suggest VBP N
that IN N
cocaine-using JJ N
methadone NN N
patients NNS N
with IN N
AD NNP 4_i
achieve VBP N
greater JJR N
cocaine NN N
abstinence NN N
than IN N
their PRP$ N
non-AD JJ 4_i
counterparts NNS N
and CC N
should MD N
not RB N
necessarily RB N
be VB N
viewed VBN N
as IN N
more RBR N
difficult JJ N
to TO N
treat VB N
. . N

-DOCSTART- -X- O O

[ JJ N
Effects NNS N
of IN N
small JJ 2_i
needle-knife JJ 2_i
comprehensive JJ 2_i
therapy NN 2_i
on IN N
pain NN N
and CC N
lumbar NN N
flexion NN N
range NN N
in IN N
the DT N
chronic JJ N
nonspecific NN N
low JJ N
back RB N
pain NN N
patient NN N
] NN N
. . N

OBJECTIVE UH N
To TO N
observe VB N
therapeutic JJ N
effect NN N
of IN N
small JJ 2_i
needle-knife JJ 2_i
comprehensive JJ 2_i
therapy NN 2_i
on IN N
pain NN N
and CC N
lumbar NN N
flexion NN N
range NN N
in IN N
the DT N
chronic JJ N
nonspecific NN N
low JJ N
back RB N
pain NN N
patient NN N
. . N

METHODS NNP N
Three CD N
hundred VBD N
and CC N
five CD N
cases NNS N
were VBD N
randomly RB N
divided VBN N
into IN N
a DT N
needle-knife JJ 2_i
group NN 2_i
of IN N
153 CD N
cases NNS N
and CC N
a DT N
physiotherapy NN 2_i
group NN 2_i
of IN N
152 CD N
cases NNS N
. . N

The DT N
needle-knife JJ 2_i
group NN N
were VBD N
treated VBN N
with IN N
small JJ 2_i
needle-knife JJ 2_i
releasing NN 2_i
therapy NN 2_i
, , 2_i
blocking VBG 2_i
and CC 2_i
functional JJ 2_i
training NN 2_i
. . 2_i

The DT N
physiotherapy NN 2_i
group NN N
were VBD N
treated VBN N
with IN N
ultra-short JJ 2_i
wave NN 2_i
, , 2_i
modulated VBD 2_i
medium NN 2_i
frequency NN 2_i
current JJ 2_i
, , 2_i
massage NN 2_i
and CC 2_i
functional JJ 2_i
training NN 2_i
. . 2_i

Pain NN N
was VBD N
assessed VBN N
by IN N
visual JJ N
analogue NN N
scale NN N
( ( N
VAS NNP N
) ) N
and CC N
the DT N
lumbar NN N
flexion NN N
range NN N
was VBD N
determined VBN N
before IN N
and CC N
after IN N
treatment NN N
. . N

RESULTS NNP N
After IN N
treatment NN N
, , N
the DT N
pain NN N
and CC N
the DT N
lumbar NN N
flexion NN N
range NN N
were VBD N
significantly RB N
improved VBN N
in IN N
the DT N
two CD N
groups NNS N
; : N
and CC N
after IN N
treatment NN N
, , N
the DT N
VAS NNP N
score NN N
and CC N
the DT N
lumbar NN N
flexion NN N
range NN N
were VBD N
( ( N
1.60 CD N
+/- JJ N
0.38 CD N
) ) N
points NNS N
and CC N
( ( N
65.76 CD N
+/- JJ N
15.11 CD N
) ) N
cm NN N
in IN N
the DT N
needle-knife JJ 2_i
group NN N
and CC N
( ( N
4.59 CD N
+/- JJ N
1.09 CD N
) ) N
points NNS N
and CC N
( ( N
53.74 CD N
+/- JJ N
15.13 CD N
) ) N
cm NN N
in IN N
the DT N
physiotherapy NN N
group NN N
, , N
respectively RB N
, , N
the DT N
needle-knife JJ 2_i
group NN N
being VBG N
significantly RB N
better JJR N
than IN N
the DT N
physiotherapy NN N
group NN N
( ( N
P NNP N
< NNP N
0.01 CD N
) ) N
. . N

Follow-up NNP N
survey NN N
of IN N
6-36 JJ N
months NNS N
showed VBD N
that IN N
the DT N
VAS NNP N
score NN N
and CC N
the DT N
lumbar NN N
flexion NN N
range NN N
in IN N
the DT N
needle-knife JJ 2_i
group NN N
were VBD N
superior JJ N
to TO N
those DT N
in IN N
the DT N
physiotherapy NN 2_i
group NN N
. . N

CONCLUSION NNP N
Small NNP 2_i
needle-knife JJ 2_i
comprehensive JJ 2_i
therapy NN 2_i
can MD N
significantly RB N
improve VB N
pain NN N
and CC N
lumbar NN N
flexion NN N
range NN N
in IN N
the DT N
chronic JJ N
nonspecific NN N
low JJ N
back RB N
pain NN N
patient NN N
, , N
with IN N
a DT N
stable JJ N
long-term JJ N
therapeutic JJ N
effect NN N
. . N

-DOCSTART- -X- O O

The DT N
aging VBG N
motor NN N
system NN N
as IN N
a DT N
model NN N
for IN N
plastic JJ N
changes NNS N
of IN N
GABA-mediated NNP N
intracortical JJ N
inhibition NN N
and CC N
their PRP$ N
behavioral JJ N
relevance NN N
. . N

Since IN N
GABAA-mediated JJ N
intracortical JJ N
inhibition NN N
has VBZ N
been VBN N
shown VBN N
to TO N
underlie VB N
plastic NN N
changes NNS N
throughout IN N
the DT N
lifespan NN N
from IN N
development NN N
to TO N
aging VBG N
, , N
here RB N
, , N
the DT N
aging VBG N
motor NN N
system NN N
was VBD N
used VBN N
as IN N
a DT N
model NN N
to TO N
analyze VB N
the DT N
interdependence NN N
of IN N
plastic JJ N
alterations NNS N
within IN N
the DT N
inhibitory JJ N
motorcortical JJ N
network NN N
and CC N
level NN N
of IN N
behavioral JJ N
performance NN N
. . N

Double-pulse JJ 2_i
transcranial JJ 2_i
magnetic JJ 2_i
stimulation NN 2_i
( ( 2_i
dpTMS NN 2_i
) ) 2_i
was VBD 2_i
used VBN 2_i
to TO 2_i
examine VB 2_i
inhibition NN 2_i
by IN 2_i
means NNS 2_i
of IN 2_i
short-interval JJ 2_i
intracortical JJ 2_i
inhibition NN 2_i
( ( 2_i
SICI NNP 2_i
) ) 2_i
of IN 2_i
the DT 2_i
contralateral JJ 2_i
primary JJ 2_i
motor NN 2_i
cortex NN 2_i
in IN N
a DT N
sample NN N
of IN N
64 CD N
healthy JJ N
right-handed JJ N
human JJ N
subjects NNS N
covering VBG N
a DT N
wide JJ N
range NN N
of IN N
the DT N
adult NN N
lifespan NN N
( ( N
age NN N
range NN N
20-88 CD N
years NNS N
, , N
mean VB N
47.6 CD N
? . N
20.7 CD N
, , N
34 CD N
female NN N
) ) N
. . N

SICI NNP N
was VBD N
evaluated VBN N
during IN N
resting VBG N
state NN N
and CC N
in IN N
an DT N
event-related JJ N
condition NN N
during IN N
movement NN N
preparation NN N
in IN N
a DT N
visually RB N
triggered VBN N
simple JJ N
reaction NN N
time NN N
task NN N
. . N

In IN N
a DT N
subgroup NN N
( ( N
N NNP N
= NNP N
23 CD N
) ) N
, , N
manual JJ N
motor NN N
performance NN N
was VBD N
tested VBN N
with IN N
tasks NNS N
of IN N
graded VBN N
dexterous JJ N
demand NN N
. . N

Weak JJ N
resting-state JJ N
inhibition NN N
was VBD N
associated VBN N
with IN N
an DT N
overall JJ N
lower JJR N
manual JJ N
motor NN N
performance NN N
. . N

Better RBR N
event-related JJ N
modulation NN N
of IN N
inhibition NN N
correlated VBN N
with IN N
better JJR N
performance NN N
in IN N
more RBR N
demanding JJ N
tasks NNS N
, , N
in IN N
which WDT N
fast RB N
alternating VBG N
activation NN N
of IN N
cortical JJ N
representations NNS N
are VBP N
necessary JJ N
. . N

Declining VBG N
resting-state JJ N
inhibition NN N
was VBD N
associated VBN N
with IN N
weakened JJ N
event-related JJ N
modulation NN N
of IN N
inhibition NN N
. . N

Therefore NN N
, , N
reduced VBD N
resting-state JJ N
inhibition NN N
might MD N
lead VB N
to TO N
a DT N
subsequent JJ N
loss NN N
of IN N
modulatory JJ N
capacity NN N
, , N
possibly RB N
reflecting VBG N
malfunctioning VBG N
precision NN N
in IN N
GABAAergic NNP N
neurotransmission NN N
; : N
the DT N
consequence NN N
is VBZ N
an DT N
inevitable JJ N
decline NN N
in IN N
motor NN N
function NN N
. . N

-DOCSTART- -X- O O

[ JJ N
Methodologic NNP N
comparison NN N
of IN N
the DT N
polyfrequency NN 2_i
oscillation NN 2_i
method NN 2_i
, , N
transcutaneous JJ N
oxygen NN N
pressure NN N
measurement NN N
and CC N
body NN N
plethysmography NN N
in IN N
bronchial JJ N
provocation NN N
with IN N
methacholine JJ 3_i
] NN N
. . N

A DT N
bronchial JJ N
provocation NN N
challenge NN N
test NN N
was VBD N
conducted VBN N
with IN N
30 CD N
subjects NNS N
using VBG N
metacholin NN 3_i
. . 3_i

In IN N
randomised JJ N
sequence NN N
lung NN N
function NN N
analysis NN N
tests NNS N
were VBD N
carried VBN N
out RP N
with IN N
the DT N
bodyplethysmograph NN 2_i
( ( N
Raw NNP N
, , N
FEV1 NNP N
) ) N
and CC N
the DT N
polyfrequent JJ N
oscillation NN N
method NN N
( ( N
resistance NN N
, , N
reactance NN N
between IN N
2 CD N
and CC N
52 CD N
Hz NNP N
) ) N
, , N
whereas IN N
the DT N
transcutaneous JJ 3_i
oxygen NN 3_i
pressure NN 3_i
( ( N
tc-PO2 JJ N
) ) N
was VBD N
measured VBN N
continuously RB N
. . N

Correlations NNS N
between IN N
the DT N
various JJ N
parameters NNS N
, , N
the DT N
change NN N
of IN N
the DT N
values NNS N
at IN N
PD60 NNP N
sGaw NN N
in IN N
relation NN N
to TO N
the DT N
initial JJ N
values NNS N
, , N
the DT N
interindividual JJ N
variability NN N
and CC N
the DT N
reactivity NN N
were VBD N
determined VBN N
. . N

Medium JJ N
correlations NNS N
were VBD N
found VBN N
for IN N
the DT N
oscillatory NN N
parameters NNS N
and CC N
Raw NNP N
, , N
whereas IN N
for IN N
tc-PO2 NN N
and CC N
Raw NNP N
the DT N
correlation NN N
was VBD N
markedly RB N
lower JJR N
. . N

In IN N
terms NNS N
of IN N
percentage NN N
the DT N
greatest JJS N
change NN N
was VBD N
found VBN N
in IN N
reactance NN N
, , N
in IN N
relation NN N
to TO N
the DT N
initial JJ N
value NN N
, , N
followed VBN N
by IN N
Raw NNP N
and CC N
FEV1 NNP N
. . N

The DT N
interindividual JJ N
variability NN N
resulted VBD N
in IN N
the DT N
highest JJS N
values NNS N
for IN N
the DT N
reactance NN N
, , N
followed VBN N
by IN N
Raw NNP N
and CC N
FEV1 NNP N
. . N

Interindividual NNP N
variability NN N
showed VBD N
the DT N
highest JJS N
values NNS N
for IN N
the DT N
reactance NN N
before IN N
oscillatory JJ N
resistance NN N
and CC N
Raw NNP N
. . N

In IN N
respect NN N
of IN N
reactivity NN N
, , N
reactance NN N
also RB N
had VBD N
the DT N
highest JJS N
values NNS N
. . N

Overall JJ N
evaluation NN N
showed VBD N
that IN N
bodyplethysmography NN 2_i
and CC N
the DT N
polyfrequent JJ 2_i
oscillation NN 2_i
method NN 2_i
( ( N
reactance NN N
or CC N
resonance NN N
frequency NN N
) ) N
are VBP N
comparably RB N
sensitive JJ N
. . N

-DOCSTART- -X- O O

Differential JJ N
effects NNS N
of IN N
amino NN N
acid NN N
and CC N
ketoacid VB N
on IN N
protein NN N
metabolism NN N
in IN N
humans NNS N
. . N

We PRP N
examined VBD N
the DT N
effects NNS N
of IN N
insulin NN N
, , N
amino JJ N
acid NN N
( ( N
AA NNP N
) ) N
, , N
and CC N
branched-chain JJ N
ketoacid NN N
( ( N
KA NNP N
) ) N
availability NN N
on IN N
leucine JJ N
kinetics NNS N
in IN N
eight CD N
healthy JJ N
volunteers NNS N
( ( N
age NN N
= VBZ N
22 CD N
+/- JJ N
2 CD N
y NN N
, , N
body NN N
mass NN N
index NN N
= VBD N
24 CD N
+/- JJ N
1 CD N
kg NN N
) ) N
by IN N
using VBG N
the DT N
euglycemic JJ 1_i
insulin NN 1_i
clamp NN 1_i
and CC 1_i
[ JJ 1_i
1-14C JJ 1_i
] NNP 1_i
leucine NN 1_i
turnover NN 1_i
techniques NNS 1_i
. . 1_i

Four CD N
experimental JJ N
conditions NNS N
were VBD N
studied VBN N
: : N
study NN N
I PRP N
, , N
hyperinsulinemia NN N
; : N
study NN N
II NNP N
, , N
hyperinsulinemia NN N
with IN N
maintenance NN N
of IN N
basal NN N
plasma NN N
AA NNP N
and CC N
branched-chain JJ N
KA NNP N
concentrations NNS N
; : N
study NN N
III NNP N
, , N
hyperinsulinemia NN N
with IN N
hyperaminoacidemia NN N
and CC N
basal NN N
plasma VBP N
branched-chain NN N
KA NNP N
concentrations NNS N
; : N
and CC N
study VB N
IV NNP N
, , N
hyperinsulinemia NN N
plus CC N
basal NN N
plasma VBP N
AA NNP N
concentrations NNS N
and CC N
elevated VBD N
branched-chain NN N
KA NNP N
levels NNS N
. . N

Basal NNP N
endogenous JJ N
leucine NN N
flux NN N
( ( N
ELF NNP N
) ) N
averaged VBD N
1.20 CD N
+/- JJ N
0.05 CD N
( ( N
mumol.kg-1.min-1 NN N
, , N
mean JJ N
+/- JJ N
SE NNP N
) ) N
; : N
basal CC N
leucine JJ N
oxidation NN N
( ( N
LOX NNP N
) ) N
was VBD N
0.25 CD N
+/- JJ N
0.01 CD N
; : N
and CC N
basal VB N
non-oxidative JJ N
leucine NN N
disposal NN N
( ( N
NOLD NNP N
) ) N
was VBD N
0.95 CD N
+/- JJ N
0.04 CD N
. . N

ELF NNP N
significantly RB N
decreased VBD N
in IN N
study NN N
I PRP N
( ( N
0.77 CD N
+/- JJ N
0.06 CD N
mumol.kg-1.min-1 NN N
, , N
P NNP N
< VBZ N
0.01 CD N
versus NN N
basal NN N
) ) N
. . N

When WRB N
plasma NN N
AA NNP N
and CC N
branched-chain JJ N
KA NNP N
were VBD N
either RB N
maintained VBN N
at IN N
their PRP$ N
basal NN N
levels NNS N
( ( N
study VB N
II NNP N
) ) N
or CC N
increased VBN N
above IN N
baseline NN N
values NNS N
( ( N
studies NNS N
III NNP N
and CC N
IV NNP N
) ) N
, , N
ELF NNP N
declined VBD N
further RBR N
( ( N
0.64 CD N
+/- JJ N
0.05 CD N
, , N
0.66 CD N
+/- JJ N
0.02 CD N
, , N
and CC N
0.66 CD N
+/- JJ N
0.03 CD N
mumol.kg-1.min-1 NN N
, , N
respectively RB N
; : N
all DT N
Ps NNP N
< NNP N
0.01 CD N
versus NN N
basal NN N
and CC N
P NNP N
< NNP N
0.01 CD N
versus NN N
study NN N
I PRP N
) ) N
. . N

LOX NNP N
declined VBD N
in IN N
study NN N
I PRP N
( ( N
0.12 CD N
+/- JJ N
0.02 CD N
mumol.kg-1.min-1 NN N
, , N
P NNP N
< VBZ N
0.01 CD N
versus NN N
basal NN N
) ) N
but CC N
increased VBD N
significantly RB N
in IN N
studies NNS N
II NNP N
, , N
III NNP N
, , N
and CC N
IV NNP N
( ( N
0.31 CD N
+/- JJ N
0.04 CD N
, , N
0.37 CD N
+/- JJ N
0.03 CD N
, , N
and CC N
0.40 CD N
+/- JJ N
0.03 CD N
mumol.kg-1.min-1 NN N
, , N
respectively RB N
, , N
all DT N
Ps NNP N
< NNP N
0.01 CD N
versus NN N
basal NN N
, , N
P NNP N
< NNP N
0.05 CD N
study NN N
IV NNP N
versus NN N
study NN N
II NNP N
, , N
and CC N
P NNP N
< NNP N
0.05 CD N
study NN N
III NNP N
versus NN N
study NN N
II NNP N
) ) N
. . N

NOLD NNP N
declined VBD N
in IN N
study NN N
I PRP N
( ( N
0.65 CD N
+/- JJ N
0.05 CD N
mumol/kg.min NN N
, , N
P NNP N
< VBZ N
0.01 CD N
versus NN N
basal NN N
) ) N
, , N
whereas IN N
neither CC N
the DT N
maintenance NN N
of IN N
basal NN N
plasma IN N
AA/branched-chain NNP N
KA NNP N
levels NNS N
( ( N
study NN N
II NNP N
; : N
0.89 CD N
+/- JJ N
0.2 CD N
mumol.kg-1.min-1 NN N
) ) N
nor CC N
the DT N
elevation NN N
of IN N
plasma JJ N
branched-chain JJ N
KA NNP N
concentration NN N
( ( N
study JJ N
IV NNP N
; : N
0.96 CD N
+/- JJ N
0.1 CD N
mumol.kg-1.min-1 NN N
) ) N
increased VBD N
NOLD NNP N
above IN N
baseline NN N
level NN N
. . N

A DT N
stimulation NN N
of IN N
NOLD NNP N
was VBD N
observed VBN N
only RB N
when WRB N
plasma JJ N
AA NNP N
levels NNS N
were VBD N
increased VBN N
( ( N
study NN N
III NNP N
; : N
1.23 CD N
+/- JJ N
0.03 CD N
mumol/kg.min NN N
, , N
P NNP N
< VBZ N
0.01 CD N
versus NN N
basal NN N
) ) N
. . N

In IN N
conclusion NN N
, , N
the DT N
present JJ N
data NNS N
do VBP N
not RB N
support VB N
the DT N
concept NN N
of IN N
a DT N
direct JJ N
anabolic JJ N
action NN N
of IN N
ketoanalogs NNS N
but CC N
do VBP N
provide VB N
additional JJ N
evidence NN N
for IN N
the DT N
pivotal JJ N
role NN N
of IN N
AA NNP N
availability NN N
in IN N
the DT N
stimulation NN N
of IN N
whole-body NN N
protein NN N
synthesis NN N
. . N

-DOCSTART- -X- O O

Gastric JJ N
ulcer NN N
treatment NN N
with IN N
intravenous JJ N
human JJ 3_i
epidermal JJ 3_i
growth NN 3_i
factor NN 3_i
: : 3_i
a DT N
double-blind NN N
controlled VBN N
clinical JJ N
study NN N
. . N

We PRP N
introduced VBD N
a DT N
double-blind NN N
controlled VBN N
clinical JJ N
study NN N
to TO N
compare VB N
intravenous JJ 3_i
human JJ 3_i
epidermal JJ 3_i
growth NN 3_i
factor NN 3_i
( ( 3_i
hEGF NN 3_i
) ) 3_i
to TO N
cetraxate VB 3_i
hydrochloride NN 3_i
( ( 3_i
CH NNP 3_i
) ) 3_i
, , N
an DT N
antiulcer JJ N
drug NN N
, , N
for IN N
their PRP$ N
healing NN N
effect NN N
on IN N
gastric JJ N
ulcers NNS N
. . N

We PRP N
also RB N
prospected VBD N
an DT N
oral JJ N
use NN N
of IN N
EGF NNP 3_i
on IN N
the DT N
basis NN N
of IN N
our PRP$ N
experimental JJ N
evidence NN N
. . N

In IN N
the DT N
clinical JJ N
trial NN N
, , N
the DT N
rate NN N
of IN N
ulcer NN N
healing VBG N
within IN N
8 CD N
weeks NNS N
was VBD N
77.9 CD N
% NN N
( ( N
67/86 CD N
) ) N
in IN N
patients NNS N
receiving VBG N
6 CD N
micrograms NNS N
EGF NNP 3_i
intravenously RB N
twice RB N
a DT N
week NN N
, , N
being VBG N
significantly RB N
greater JJR N
than IN N
51.7 CD N
% NN N
( ( N
45/87 CD N
) ) N
in IN N
those DT N
given VBN N
CH NNP 3_i
. . 3_i

Taking VBG N
together RB N
all DT N
aspects NNS N
assessed VBD N
including VBG N
the DT N
healing NN N
rate NN N
, , N
pain NN N
relief NN N
, , N
blood NN N
examination NN N
and CC N
adverse JJ N
reactions NNS N
, , N
we PRP N
judged VBD N
the DT N
hEGF NN 3_i
to TO N
be VB N
a DT N
useful JJ N
and CC N
safe JJ N
anticuler NN N
drug NN N
. . N

In IN N
rats NNS N
, , N
50 CD N
micrograms/kg NN N
mouse NN N
EGF NNP N
( ( N
mEGF NN N
) ) N
and CC N
2 CD N
% NN N
hydroxypropyl NN 3_i
cellulose NN 3_i
( ( N
HPC NNP N
) ) N
or CC N
1.0 CD N
g/kg JJ N
sucralfate NN N
given VBN N
by IN N
gastric JJ N
intubation NN N
significantly RB N
raised VBD N
the DT N
residual JJ N
mEGF NN N
levels NNS N
in IN N
both DT N
gastric JJ N
luminal JJ N
content NN N
( ( N
HPC NNP N
: : N
x JJ N
30 CD N
; : N
sucralfate NN N
: : N
x RB N
300 CD N
as RB N
high JJ N
as IN N
those DT N
in IN N
EGF NNP N
alone RB N
) ) N
and CC N
tissue NN N
( ( N
HPC NNP N
: : N
x JJ N
60 CD N
; : N
sucralfate NN N
: : N
x JJ N
100 CD N
) ) N
. . N

In IN N
addition NN N
, , N
the DT N
combined JJ N
treatments NNS N
significantly RB N
promoted VBD N
healing NN N
of IN N
rat NN N
gastric JJ N
ulcers NNS N
whereas VBP N
each DT N
agent NN N
alone RB N
had VBD N
no DT N
significant JJ N
effect NN N
as IN N
compared VBN N
with IN N
control NN N
( ( N
saline NN N
) ) N
. . N

This DT N
indicated VBD N
the DT N
beneficial JJ N
effect NN N
on IN N
ulcers NNS N
of IN N
oral JJ N
administration NN N
of IN N
EGF NNP 3_i
with IN N
agents NNS N
allowing VBG N
it PRP N
to TO N
remain VB N
at IN N
high JJ N
levels NNS N
in IN N
the DT N
stomach NN N
, , N
whereas IN N
most JJS N
reports NNS N
suggested VBD N
less RBR N
effect NN N
of IN N
oral JJ N
EGF NNP N
on IN N
healing NN N
of IN N
gastroduodenal JJ N
ulcers NNS N
. . N

Subsequent JJ N
to TO N
the DT N
clinical JJ N
study NN N
, , N
evaluation NN N
of IN N
oral JJ N
use NN N
of IN N
EGF NNP 3_i
may MD N
be VB N
expected VBN N
as IN N
the DT N
next JJ N
step NN N
in IN N
the DT N
treatment NN N
of IN N
ulcers NNS N
. . N

The DT N
experimental JJ N
evidence NN N
above IN N
would MD N
possibly RB N
be VB N
a DT N
guide NN N
for IN N
such JJ N
trial NN N
. . N

-DOCSTART- -X- O O

Study NN N
of IN N
the DT N
vaginal JJ N
tolerance NN N
to TO N
Acidform NNP 3_i
, , 3_i
an DT 3_i
acid-buffering JJ 3_i
, , 3_i
bioadhesive JJ 3_i
gel NN 3_i
. . 3_i

Vaginal JJ N
tolerance NN N
tests NNS N
were VBD N
performed VBN N
with IN N
a DT N
new JJ N
potential JJ N
microbicidal NN N
and CC N
spermicidal JJ N
product NN N
, , N
an DT N
acid-buffering JJ 3_i
vaginal JJ 3_i
gel NN 3_i
( ( 3_i
Acidform NNP 3_i
) ) 3_i
without IN 3_i
or CC 3_i
with IN 3_i
nonoxynol-9 JJ 3_i
( ( 3_i
N-9 NNP 3_i
) ) 3_i
. . 3_i

The DT N
potential JJ N
advantages NNS N
over IN N
other JJ N
vaginal JJ N
products NNS N
include VBP N
keeping VBG N
a DT N
low JJ N
pH NN N
, , N
decrease NN N
of IN N
the DT N
irritating VBG N
effect NN N
of IN N
N-9 NNP 3_i
on IN N
the DT N
cervix NN N
or CC N
vaginal JJ N
mucosa NN N
associated VBN N
with IN N
greater JJR N
retention NN N
of IN N
the DT N
product NN N
after IN N
application NN N
, , N
and CC N
decreasing VBG N
messiness NN N
as IN N
compared VBN N
to TO N
other JJ N
vaginal JJ N
products NNS N
. . N

Three CD N
groups NNS N
of IN N
six CD N
women NNS N
were VBD N
admitted VBN N
and CC N
randomly RB N
assigned VBN N
to TO N
use VB N
Acidform NNP 3_i
with IN N
0 CD N
% NN N
, , N
2.5 CD N
% NN N
, , N
and CC N
5 CD N
% NN N
N-9 NNP 3_i
. . 3_i

Colposcopic NNP N
evaluation NN N
for IN N
vulvar NN N
, , N
vaginal JJ N
, , N
and CC N
cervical JJ N
signs NNS N
of IN N
irritation NN N
was VBD N
performed VBN N
and CC N
photographs NNS N
were VBD N
taken VBN N
, , N
following VBG N
a DT N
specific JJ N
World NNP N
Health NNP N
Organization NNP N
protocol NN N
, , N
at IN N
time NN N
0 CD N
, , N
and CC N
after IN N
24 CD N
h NN N
and CC N
6 CD N
days NNS N
of IN N
application NN N
of IN N
the DT N
gel NN N
. . N

No DT N
irritation NN N
or CC N
symptom NN N
was VBD N
reported VBN N
by IN N
users NNS N
of IN N
Acidform NNP 3_i
without IN 3_i
N-9 NNP 3_i
. . 3_i

A NNP N
generalized JJ N
and CC N
intense JJ N
erythema NN N
in IN N
cervix NN N
was VBD N
observed VBN N
in IN N
10 CD N
of IN N
12 CD N
Acidform/N-9 JJ 3_i
users NNS N
and CC N
abrasion NN N
occurred VBD N
in IN N
nine CD N
of IN N
them PRP N
. . N

Vulvar NNP N
irritation NN N
was VBD N
seen VBN N
in IN N
seven CD N
of IN N
these DT N
10 CD N
volunteers NNS N
. . N

N-9 JJ N
concentration NN N
in IN N
the DT N
gel NN N
( ( N
2.5 CD N
% NN N
or CC N
5.0 CD N
% NN N
) ) N
was VBD N
not RB N
related VBN N
to TO N
the DT N
findings NNS N
. . N

No DT N
ulcer NN N
, , N
exulceration NN N
, , N
or CC N
de-epithelialization NN N
was VBD N
observed VBN N
. . N

Acidform VB 3_i
without IN 3_i
N-9 NNP 3_i
was VBD N
well RB N
tolerated VBN N
by IN N
volunteers NNS N
, , N
but CC N
it PRP N
was VBD N
unable JJ N
to TO N
protect VB N
the DT N
cervix NN N
, , N
vagina NN N
, , N
and CC N
vulva NN N
from IN N
the DT N
N-9 JJ N
effects NNS N
. . N

-DOCSTART- -X- O O

The DT N
effects NNS N
of IN N
physical JJ 5_i
and CC 5_i
emotional JJ 5_i
status NN 5_i
on IN N
adherence NN N
to TO N
a DT N
low-fat JJ 6_i
dietary JJ 6_i
pattern NN 6_i
in IN N
the DT N
Women NNP N
's POS N
Health NNP N
Initiative NNP N
. . N

OBJECTIVE NNP N
To TO N
examine VB N
whether IN N
the DT N
effects NNS N
of IN N
physical JJ N
and CC N
emotional JJ N
status NN N
on IN N
adherance NN N
to TO N
a DT N
low-fat JJ 4_i
( ( 4_i
20 CD 4_i
% NN 4_i
energy NN 4_i
) ) 4_i
dietary JJ 4_i
pattern NN 4_i
are VBP N
mediated VBN N
by IN N
participation NN N
in IN N
an DT N
intervention NN 4_i
program NN 4_i
( ( 4_i
attending VBG 4_i
sessions NNS 4_i
and CC 4_i
self-monitoring NN 4_i
) ) 4_i
. . 4_i

DESIGN VB N
The DT N
Baron NNP N
and CC N
Kenny NNP N
mediator NN N
model NN N
, , N
a DT N
series NN N
of IN N
4 CD N
regression NN N
analyses NNS N
, , N
was VBD N
used VBN N
to TO N
evaluate VB N
whether IN N
: : N
a DT N
) ) N
physical JJ N
and CC N
emotional JJ N
status NN N
predicted VBD N
program NN N
participation NN N
, , N
b NN N
) ) N
program NN N
participation NN N
predicted VBD N
dietary JJ N
adherence NN N
, , N
c NN N
) ) N
physical JJ N
and CC N
emotional JJ N
status NN N
factors NNS N
predicted VBD N
dietary JJ 6_i
adherence NN 6_i
, , N
and CC N
, , N
ultimately RB N
d NN N
) ) N
the DT N
effects NNS N
of IN N
physical JJ N
and CC N
emotional JJ N
status NN N
on IN N
dietary JJ N
adherence NN N
were VBD N
mediated VBN N
by IN N
program NN N
participation NN N
. . N

SUBJECTS/SETTING NNP N
Data NNP N
from IN N
13,277 CD N
postmenopausal JJ N
women NNS N
randomly RB N
assigned VBN N
to TO N
the DT N
low-fat JJ 4_i
intervention NN 4_i
arm NN N
of IN N
the DT N
Women NNP N
's POS N
Health NNP N
Initiative NNP N
Dietary NNP N
Modification NNP N
Trial NNP N
. . N

INTERVENTION NNP N
The DT N
nutrition NN N
goals NNS N
for IN N
women NNS N
randomly RB N
assigned VBN N
to TO N
the DT N
low-fat JJ 4_i
intervention NN 4_i
were VBD N
to TO N
reduce VB 4_i
total JJ 4_i
fat JJ 4_i
intake NN 4_i
to TO 4_i
20 CD 4_i
% NN 4_i
or CC 4_i
less JJR 4_i
of IN 4_i
energy NN 4_i
from IN 4_i
fat JJ 4_i
and CC 4_i
to TO 4_i
consume VB 4_i
5 CD 4_i
or CC 4_i
more JJR 4_i
fruit/vegetable JJ 4_i
servings NNS 4_i
daily RB 4_i
and CC 4_i
6 CD 4_i
or CC 4_i
more JJR 4_i
grain JJ 4_i
servings NNS 4_i
daily RB 4_i
. . 4_i

MAIN NNP N
OUTCOME NNP N
MEASURES NNP N
Year NNP N
1 CD N
program NN N
participation NN N
( ( N
degree NN N
of IN N
attending VBG N
group NN N
sessions NNS N
and CC N
submitting VBG N
fat JJ N
scores NNS N
) ) N
and CC N
adherence NN N
to TO N
the DT N
low-fat JJ 4_i
dietary JJ 4_i
pattern NN 4_i
( ( N
percent JJ N
energy NN N
from IN N
fat NN N
) ) N
as IN N
predicted VBN N
by IN N
baseline JJ N
physical JJ N
and CC N
emotional JJ N
status NN N
( ( N
eight CD N
SF-36 NNP N
Health NNP N
Survey NNP N
subscales VBZ N
) ) N
. . N

RESULTS NNP N
Participating VBG N
in IN N
the DT N
dietary JJ 4_i
intervention NN 4_i
program NN 4_i
reduced VBN N
( ( N
mediated VBN N
) ) N
the DT N
negative JJ N
effect NN N
of IN N
poorer JJR N
mental JJ N
health NN N
on IN N
dietary JJ N
adherence NN N
by IN N
15 CD N
% NN N
. . N

Additional JJ N
findings NNS N
included VBD N
that IN N
a DT N
10 CD N
% NN N
increase NN N
in IN N
physical JJ N
functioning NN N
increased VBD N
session NN N
attendance NN N
by IN N
0.4 CD N
% NN N
( ( N
P NNP N
< NNP N
.001 NNP N
) ) N
and CC N
a DT N
10 CD N
% NN N
increase NN N
in IN N
mental JJ N
health NN N
predicted VBD N
a DT N
decrease NN N
in IN N
percent NN N
energy NN N
from IN N
fat NN N
of IN N
0.3 CD N
% NN N
( ( N
P NNP N
< NNP N
.001 NNP N
) ) N
. . N

Program NNP N
participation NN N
had VBD N
a DT N
marked JJ N
effect NN N
on IN N
dietary JJ N
adherence NN N
: : N
a DT N
10 CD N
% NN N
increase NN N
in IN N
session NN N
attendance NN N
predicted VBD N
a DT N
1.2 CD N
% NN N
decrease NN N
in IN N
percent NN N
energy NN N
from IN N
fat JJ N
( ( N
P NNP N
< NNP N
.001 NNP N
) ) N
. . N

APPLICATIONS/CONCLUSIONS NNP N
Understanding NNP N
and CC N
using VBG N
instruments NNS N
to TO N
assess VB N
the DT N
physical JJ N
and CC N
emotional JJ N
status NN N
of IN N
a DT N
target NN N
population NN N
will MD N
help VB N
dietetic JJ N
professionals NNS N
promote VBP N
healthful JJ N
dietary JJ N
change NN N
and CC N
maintenance NN N
. . N

-DOCSTART- -X- O O

Effects NNS N
of IN N
tonabersat NN 3_i
on IN N
migraine NN N
with IN N
aura NN N
: : N
a DT N
randomised JJ N
, , N
double-blind JJ N
, , N
placebo-controlled JJ N
crossover NN N
study NN N
. . N

BACKGROUND NNP N
Migraine NNP N
with IN N
aura NN N
is VBZ N
thought VBN N
likely RB N
to TO N
be VB N
caused VBN N
by IN N
cortical JJ N
spreading VBG N
depression NN N
( ( N
CSD NNP N
) ) N
. . N

Tonabersat NNP 3_i
inhibits VBZ N
CSD NNP N
, , N
and CC N
we PRP N
therefore RB N
investigated VBD N
whether IN N
tonabersat NN N
has VBZ N
a DT N
preventive JJ N
effect NN N
in IN N
migraine NN N
with IN N
aura NN N
. . N

METHODS NNP N
In IN N
this DT N
randomised JJ N
, , N
double-blind JJ N
, , N
placebo-controlled JJ N
crossover NN N
trial NN N
, , N
40 CD N
mg NN N
tonabersat NN 3_i
once IN N
daily JJ N
was VBD N
compared VBN N
with IN N
matched JJ N
placebo NN 7_i
in IN N
patients NNS N
who WP N
had VBD N
at IN N
least JJS N
one CD N
aura NN N
attack NN N
per IN N
month NN N
during IN N
the DT N
past JJ N
3 CD N
months NNS N
. . N

Randomisation NN N
was VBD N
by IN N
computer-generated JJ N
list NN N
. . N

Patients NNS N
kept VBD N
a DT N
detailed JJ N
diary NN N
to TO N
enable VB N
objective JJ N
diagnosis NN N
of IN N
each DT N
attack NN N
as IN N
migraine NN N
with IN N
aura NN N
, , N
migraine NN N
without IN N
aura NN N
, , N
or CC N
other JJ N
type NN N
of IN N
headache NN N
. . N

Primary JJ N
endpoints NNS N
were VBD N
a DT N
reduction NN N
in IN N
aura NN N
attacks NNS N
with IN N
or CC N
without IN N
headache NN N
and CC N
a DT N
reduction NN N
in IN N
migraine JJ N
headache NN N
days NNS N
with IN N
or CC N
without IN N
an DT N
aura NN N
. . N

Analysis NN N
was VBD N
per IN N
protocol NN N
. . N

This DT N
trial NN N
is VBZ N
registered VBN N
, , N
number NN N
NCT00332007 NNP N
. . N

FINDINGS NNP N
39 CD N
patients NNS N
were VBD N
included VBN N
in IN N
the DT N
study NN N
, , N
of IN N
whom WP N
31 CD N
were VBD N
included VBN N
in IN N
the DT N
statistical JJ N
analysis NN N
of IN N
efficacy NN N
. . N

Median JJ N
( ( N
IQR NNP N
) ) N
attacks NNS N
of IN N
aura NN N
were VBD N
reduced VBN N
from IN N
3.2 CD N
( ( N
1.0-5.0 JJ N
) ) N
per IN N
12 CD N
weeks NNS N
on IN N
placebo NN 7_i
to TO N
1.0 CD N
( ( N
0-3.0 CD N
) ) N
on IN N
tonabersat NN N
( ( N
p=0.01 NN N
) ) N
, , N
whereas VBP N
the DT N
other JJ N
primary JJ N
outcome JJ N
measure NN N
, , N
median JJ N
migraine NN N
headache NN N
days NNS N
with IN N
or CC N
without IN N
aura NN N
, , N
was VBD N
not RB N
significantly RB N
different JJ N
between IN N
placebo NN 7_i
and CC N
tonabersat NN 3_i
groups NNS N
( ( N
3.0 CD N
days NNS N
in IN N
each DT N
group NN N
; : N
p=0.09 NN N
) ) N
. . N

Tonabersat NNP N
was VBD N
well RB N
tolerated VBN N
but CC N
overall JJ N
had VBD N
more RBR N
side-effects NNS N
than IN N
placebo NN N
. . N

INTERPRETATION NNP N
Tonabersat NNP 3_i
showed VBD N
a DT N
preventive JJ N
effect NN N
on IN N
attacks NNS N
of IN N
migraine NN N
aura NN N
but CC N
no DT N
efficacy NN N
on IN N
non-aura JJ N
attacks NNS N
, , N
in IN N
keeping VBG N
with IN N
its PRP$ N
known JJ N
inhibitory JJ N
effect NN N
on IN N
CSD NNP N
. . N

The DT N
results NNS N
support VBD N
the DT N
theory NN N
that IN N
auras NNS N
are VBP N
caused VBN N
by IN N
CSD NNP N
and CC N
that IN N
this DT N
phenomenon NN N
is VBZ N
not RB N
involved VBN N
in IN N
attacks NNS N
without IN N
aura NN N
. . N

FUNDING NN N
Minster NNP N
Pharmaceuticals NNP N
; : N
Lundbeck NNP N
Foundation NNP N
. . N

-DOCSTART- -X- O O

Reduced VBN N
platelet NN N
thromboxane NN N
formation NN N
after IN N
long-term JJ N
administration NN N
of IN N
a DT N
dihydropyridine JJ 3_i
calcium NN 3_i
channel NN 3_i
blocker NN 3_i
: : N
a DT N
prospective JJ N
, , N
double-blind JJ N
, , N
placebo-controlled JJ N
study NN N
with IN N
nitrendipine NN 3_i
in IN N
borderline JJ N
hypertensive JJ N
patients NNS N
with IN N
IDDM-type NNP N
diabetes NNS N
mellitus NN N
. . N

Twenty-nine JJ N
IDDM NNP N
patients NNS N
with IN N
borderline JJ N
hypertension NN N
were VBD N
randomly RB N
allocated VBN N
to TO N
placebo VB 7_i
or CC N
nitrendipine VB 3_i
treatment NN N
. . N

Nitrendipine NNP 3_i
was VBD N
given VBN N
orally RB N
at IN N
a DT N
dosage NN N
of IN N
20 CD N
mg NNS N
once RB N
daily RB N
over IN N
4 CD N
weeks NNS N
. . N

Stimulated VBN N
platelet NN N
thromboxane NN N
formation NN N
at IN N
rest NN N
and CC N
after IN N
standardized VBN N
, , N
non JJ N
exhausting VBG N
exercise NN N
was VBD N
measured VBN N
by IN N
standard JJ N
methods NNS N
. . N

In IN N
addition NN N
, , N
plasma NN N
levels NNS N
of IN N
platelet NN N
factor NN N
4 CD N
and CC N
aggregation NN N
responses NNS N
to TO N
collagen VB N
and CC N
ADP NNP N
were VBD N
determined VBN N
. . N

In IN N
the DT N
treatment NN N
group NN N
thromboxane NN N
formation NN N
after IN N
stimulation NN N
with IN N
collagen NN N
( ( N
0.3 CD N
and CC N
1.0 CD N
micrograms/ml NN N
) ) N
and CC N
1 CD N
mM NN N
arachidonic JJ N
acid NN N
( ( N
AA NNP N
) ) N
was VBD N
reduced VBN N
in IN N
the DT N
resting NN N
state NN N
. . N

Exercise NN N
induced JJ N
change NN N
of IN N
thromboxane NN N
synthesis NN N
in IN N
response NN N
to TO N
1.0 CD N
micrograms/ml NNS N
collagen NN N
was VBD N
significantly RB N
lower JJR N
as IN N
compared VBN N
to TO N
placebo VB 7_i
( ( N
p JJ N
< NNP N
0.05 CD N
) ) N
. . N

In IN N
parallel JJ N
, , N
PF4 NNP N
plasma NN N
levels NNS N
were VBD N
significantly RB N
lowered VBN N
( ( N
p JJ N
< NNP N
0.05 CD N
) ) N
. . N

Whole JJ N
blood NN N
aggregation NN N
after IN N
collagen NN N
stimulation NN N
( ( N
1.0 CD N
micrograms/ml NN N
) ) N
was VBD N
reduced VBN N
after IN N
4 CD N
weeks NNS N
of IN N
nitrendipine JJ 3_i
treatment NN N
, , N
but CC N
ADP NNP N
( ( N
5 CD N
microM NN N
) ) N
induced VBD N
aggregation NN N
was VBD N
not RB N
. . N

These DT N
effects NNS N
of IN N
nitrendipine NN 3_i
were VBD N
not RB N
seen VBN N
in IN N
platelet NN N
rich JJ N
plasma NN N
. . N

In IN N
conclusion NN N
long-term JJ N
nitrendipine JJ 3_i
treatment NN N
may MD N
inhibit VB N
collagen NN N
dependent JJ N
platelet NN N
activation NN N
in IN N
the DT N
blood NN N
of IN N
diabetic JJ N
patients NNS N
with IN N
borderline JJ N
hypertension NN N
. . N

-DOCSTART- -X- O O

In-hospital JJ N
costs NNS N
of IN N
self-expanding JJ 1_i
nitinol JJ 1_i
stent NN 1_i
implantation NN 1_i
versus NN N
balloon NN 1_i
angioplasty NN 1_i
in IN N
the DT N
femoropopliteal JJ N
artery NN N
( ( N
the DT N
VascuCoil NNP N
Trial NNP N
) ) N
. . N

PURPOSE NNP N
Although IN N
several JJ N
prospective JJ N
studies NNS N
have VBP N
examined VBN N
the DT N
safety NN N
and CC N
efficacy NN N
of IN N
stent JJ 1_i
placement NN 1_i
for IN N
femoropopliteal JJ N
arterial JJ N
disease NN N
, , N
the DT N
current JJ N
cost NN N
of IN N
these DT N
procedures NNS N
is VBZ N
unknown JJ N
. . N

To TO N
estimate VB N
and CC N
compare VB N
hospital NN N
costs NNS N
associated VBN N
with IN N
conventional JJ 1_i
balloon NN 1_i
angioplasty NN 1_i
( ( 1_i
percutaneous JJ 1_i
transluminal NN 1_i
angioplasty NN 1_i
[ NNP 1_i
PTA NNP 1_i
] NNP 1_i
) ) 1_i
and CC N
stent JJ 1_i
placement NN 1_i
for IN N
patients NNS N
with IN N
symptomatic JJ N
peripheral JJ N
arterial JJ N
disease NN N
, , N
the DT N
authors NNS N
performed VBD N
a DT N
prospective JJ N
economic JJ N
evaluation NN N
in IN N
conjunction NN N
with IN N
the DT N
Intracoil NNP N
Femoropopliteal NNP N
Stent NNP N
Trial NNP N
( ( N
VascuCoil NNP N
) ) N
. . N

MATERIALS NNP N
AND CC N
METHODS NNP N
Between NNP N
May NNP N
1997 CD N
and CC N
December NNP N
1999 CD N
, , N
266 CD N
patients NNS N
with IN N
stenotic JJ N
or CC N
occluded VBN N
superficial JJ N
femoral JJ N
or CC N
popliteal JJ N
arteries NNS N
were VBD N
prospectively RB N
randomized VBN N
to TO N
treatment NN N
with IN N
the DT N
IntraCoil NNP 1_i
stent NN 1_i
or CC N
PTA NNP 1_i
. . 1_i

Detailed NNP N
resource NN N
use NN N
and CC N
cost NN N
data NNS N
for IN N
each DT N
patient NN N
's POS N
initial JJ N
revascularization NN N
procedure NN N
and CC N
ensuing VBG N
hospitalization NN N
were VBD N
collected VBN N
and CC N
analyzed VBN N
on IN N
an DT N
intention-to-treat JJ N
basis NN N
. . N

RESULTS NNP N
Compared VBD N
with IN N
conventional JJ 1_i
balloon NN 1_i
angioplasty NN 1_i
, , N
stent JJ 1_i
placement NN 1_i
did VBD N
not RB N
improve VB N
clinical JJ N
outcomes NNS N
but CC N
increased JJ N
procedure NN N
duration NN N
, , N
equipment NN N
costs NNS N
, , N
and CC N
physician JJ N
services NNS N
. . N

As IN N
a DT N
result NN N
, , N
initial JJ N
hospital NN N
costs NNS N
were VBD N
approximately RB N
3,500 CD N
dollars NNS N
higher JJR N
for IN N
patients NNS N
randomized VBN N
to TO N
the DT N
IntraCoil NNP 1_i
stent NN 1_i
, , N
compared VBN N
with IN N
PTA NNP 1_i
( ( N
8,435 CD N
dollars NNS N
vs RB N
4,980 CD N
dollars NNS N
; : N
P NNP N
< NNP N
.001 NNP N
) ) N
. . N

CONCLUSIONS NNP N
As IN N
performed VBN N
in IN N
the DT N
VascuCoil NNP N
trial NN N
, , N
primary JJ N
stent NN N
placement NN N
for IN N
femoropopliteal JJ N
disease NN N
did VBD N
not RB N
improve VB N
clinical JJ N
outcomes NNS N
but CC N
increased VBD N
initial JJ N
treatment NN N
costs NNS N
by IN N
more JJR N
than IN N
3,000 CD N
dollars NNS N
. . N

Because IN N
there EX N
were VBD N
no DT N
substantial JJ N
differences NNS N
in IN N
subsequent JJ N
clinical JJ N
outcomes NNS N
between IN N
the DT N
two CD N
treatments NNS N
, , N
it PRP N
is VBZ N
unlikely JJ N
that IN N
these DT N
increased VBN N
initial JJ N
costs NNS N
would MD N
be VB N
offset VBN N
by IN N
savings NNS N
in IN N
follow-up JJ N
costs NNS N
. . N

These DT N
findings NNS N
suggest VBP N
that IN N
a DT N
strategy NN N
of IN N
routine JJ N
stent NN 2_i
implantation NN N
for IN N
patients NNS N
undergoing VBG N
femoropopliteal JJ N
PTA NNP 2_i
is VBZ N
not RB N
optimal JJ N
on IN N
economic JJ N
grounds NNS N
and CC N
that DT N
PTA NNP 2_i
with IN N
provisional JJ 2_i
stent JJ 2_i
implantation NN 2_i
is VBZ N
preferred VBN N
. . N

-DOCSTART- -X- O O

Combined VBN 3_i
typhoid JJ 3_i
fever NN 3_i
and CC 3_i
hepatitis VB 3_i
A DT 3_i
vaccine NN 3_i
: : 3_i
comparison NN N
of IN N
immunogenicity NN N
and CC N
safety NN N
to TO N
concomitant VB N
monovalent JJ N
vaccine NN N
over IN N
3 CD N
years NNS N
. . N

BACKGROUND IN N
The DT N
safety NN N
and CC N
immunogenicity NN N
of IN N
Viatim NNP 3_i
, , N
a DT N
combined JJ 3_i
hepatitis NN 3_i
A NNP 3_i
( ( 3_i
HA NNP 3_i
) ) 3_i
and CC 3_i
typhoid JJ 3_i
fever NN 3_i
( ( 3_i
Vi NNP 3_i
) ) 3_i
vaccine NN 3_i
, , N
were VBD N
compared VBN N
with IN N
the DT N
monovalent JJ 3_i
component NN 3_i
vaccines VBZ 3_i
up IN N
to TO N
and CC N
1 CD N
month NN N
after IN N
a DT N
booster NN N
dose NN N
at IN N
3 CD N
years NNS N
. . N

METHODS NNP N
Healthy NNP N
, , N
adult NN N
volunteers NNS N
were VBD N
randomized VBN N
to TO N
receive VB N
Viatim NNP 3_i
( ( N
group NN N
A NNP N
, , N
n JJ N
= NNP N
179 CD N
) ) N
or CC N
separate JJ 3_i
HA NNP 3_i
and CC 3_i
Vi NNP 3_i
vaccines NNS 3_i
( ( N
group NN N
B NNP N
, , N
n JJ N
= NNP N
181 CD N
) ) N
; : N
subgroups NNS N
were VBD N
boosted VBN N
after IN N
3 CD N
years NNS N
with IN N
Viatim NNP 3_i
( ( N
groups NNS N
C NNP N
and CC N
D NNP N
, , N
n JJ N
= NN N
56 CD N
and CC N
46 CD N
, , N
respectively RB N
) ) N
. . N

Local JJ N
and CC N
systemic JJ N
reactions NNS N
were VBD N
recorded VBN N
for IN N
28 CD N
days NNS N
postvaccination NN N
. . N

Seroconversion NN N
and CC N
seroprotection NN N
rates NNS N
and CC N
geometric JJ N
mean NN N
antibody NN N
concentrations NNS N
were VBD N
measured VBN N
at IN N
14 CD N
and CC N
28 CD N
days NNS N
, , N
1 CD N
, , N
2 CD N
, , N
and CC N
3 CD N
years NNS N
postvaccination NN N
, , N
and CC N
28 CD N
days NNS N
after IN N
the DT N
booster NN N
dose NN N
. . N

RESULTS NNP N
Local NNP N
and CC N
systemic JJ N
safety NN N
profiles NNS N
were VBD N
equivalent JJ N
between IN N
the DT N
two CD N
groups NNS N
. . N

Immediate NNP N
local JJ N
reactions NNS N
were VBD N
infrequent JJ N
( ( N
1 CD N
in IN N
group NN N
A NNP N
and CC N
2 CD N
in IN N
group NN N
B NNP N
) ) N
. . N

Local JJ N
reactions NNS N
, , N
consisting VBG N
mostly RB N
of IN N
mild NN N
or CC N
moderate JJ N
pain NN N
, , N
were VBD N
least JJS N
frequent JJ N
with IN N
monovalent JJ N
HA NNP N
. . N

Antibody NNP N
concentrations NNS N
to TO N
both DT N
antigens NNS N
were VBD N
similar JJ N
in IN N
groups NNS N
A NNP N
and CC N
B NNP N
, , N
in IN N
which WDT N
HA NNP N
seroprotection NN N
rates NNS N
( ( N
> CD N
or CC N
= VB N
20 CD N
mIU/mL NN N
) ) N
were VBD N
respectively RB N
, , N
98.7 CD N
% NN N
and CC N
100 CD N
% NN N
at IN N
day NN N
28 CD N
, , N
and CC N
99.1 CD N
% NN N
and CC N
99.0 CD N
% NN N
after IN N
3 CD N
years NNS N
, , N
achieving VBG N
100 CD N
% NN N
after IN N
the DT N
booster NN N
. . N

Vi NNP N
seroprotection NN N
rates NNS N
( ( N
> CD N
or CC N
= VB N
1 CD N
microg/mL NN N
) ) N
of IN N
85.2 CD N
% NN N
and CC N
84.9 CD N
% NN N
after IN N
28 CD N
days NNS N
fell VBD N
to TO N
32.1 CD N
% NN N
and CC N
35.6 CD N
% NN N
after IN N
3 CD N
years NNS N
, , N
increasing VBG N
to TO N
67.3 CD N
% NN N
and CC N
69.8 CD N
% NN N
after IN N
the DT N
booster NN N
dose NN N
. . N

CONCLUSIONS VB N
The DT N
combined JJ 3_i
HA/Vi NNP 3_i
vaccine NN 3_i
, , 3_i
Viatim NNP 3_i
, , N
had VBD N
equivalent JJ N
tolerability NN N
and CC N
safety NN N
and CC N
was VBD N
as IN N
rapidly RB N
immunogenic JJ N
as IN N
its PRP$ N
component NN N
monovalent NN N
vaccines NNS N
when WRB N
given VBN N
concurrently RB N
. . N

A DT N
booster NN N
dose NN N
after IN N
3 CD N
years NNS N
significantly RB N
increased VBD N
antibody NN N
levels NNS N
with IN N
some DT N
evidence NN N
of IN N
relative JJ N
hyporesponsiveness NN N
of IN N
the DT N
typhoid JJ N
response NN N
. . N

-DOCSTART- -X- O O

Short-term JJ N
studies NNS N
on IN N
the DT N
use NN N
of IN N
glycerol NN 3_i
as IN N
an DT N
osmotic JJ N
agent NN N
in IN N
continuous JJ N
ambulatory JJ N
peritoneal JJ N
dialysis NN N
( ( N
CAPD NNP N
) ) N
. . N

The DT N
use NN N
of IN N
glycerol NN 3_i
as IN N
an DT N
osmotic JJ N
agent NN N
in IN N
two CD N
different JJ N
concentrations NNS N
( ( N
92 CD N
mmol/l NN N
and CC N
272 CD N
mmol/l NN N
) ) N
in IN N
peritoneal JJ N
dialysis NN N
fluid NN N
was VBD N
investigated VBN N
over IN N
3 CD N
days NNS N
in IN N
six CD N
patients NNS N
on IN N
continuous JJ N
ambulatory JJ N
peritoneal JJ N
dialysis NN N
and CC N
compared VBN N
with IN N
two CD N
concentrations NNS N
of IN N
glucose NN 7_i
( ( N
76 CD N
mmol/l NN N
and CC N
215 CD N
mmol/l NN N
) ) N
in IN N
the DT N
same JJ N
patients NNS N
. . N

The DT N
calorific JJ N
value NN N
of IN N
the DT N
absorbed JJ N
osmotic JJ N
agent NN N
was VBD N
lower JJR N
, , N
by IN N
19 CD N
% NN N
with IN N
isotonic JJ N
and CC N
22 CD N
% NN N
with IN N
hypertonic JJ N
solutions NNS N
, , N
when WRB N
glycerol NN 3_i
was VBD N
used VBN N
in IN N
place NN N
of IN N
glucose NN 7_i
. . N

However RB N
, , N
glycerol NN N
provided VBD N
significantly RB N
lower JJR N
total JJ N
ultrafiltration NN N
than IN N
glucose NN N
at IN N
each DT N
concentration NN N
, , N
despite IN N
a DT N
higher JJR N
initial JJ N
osmotic JJ N
pressure NN N
of IN N
the DT N
glycerol-based JJ N
solutions NNS N
. . N

Thus RB N
, , N
the DT N
higher JJR N
concentration NN N
of IN N
glycerol NN N
required VBN N
to TO N
provide VB N
equal JJ N
ultrafiltration NN N
may MD N
offset VB N
any DT N
calorific JJ N
advantage NN N
. . N

Equilibration NN N
of IN N
creatinine NN N
and CC N
urea NN N
was VBD N
slower JJR N
and CC N
creatinine JJ N
clearance NN N
lower RBR N
with IN N
glycerol NN 3_i
. . N

Solutions NNS N
containing VBG N
glycerol NN 3_i
were VBD N
initially RB N
less JJR N
acid JJ N
( ( N
pH JJ N
6.5 CD N
) ) N
than IN N
those DT N
containing VBG N
glucose NN N
( ( N
pH JJ N
5.1 CD N
) ) N
. . N

Blood NNP N
glycerol NN N
levels NNS N
, , N
which WDT N
were VBD N
in IN N
the DT N
physiological JJ N
range NN N
with IN N
glucose NN N
as IN N
the DT N
osmotic JJ N
agent NN N
, , N
reached VBD N
a DT N
peak JJ N
80-fold JJ N
greater JJR N
at IN N
4.3 CD N
+/- JJ N
0.8 CD N
mmol/l NN N
during IN N
dialysis NN N
with IN N
fluid NN N
containing VBG N
glycerol NN 3_i
at IN N
272 CD N
mmol/l NN N
and CC N
eightfold VB N
higher JJR N
at IN N
0.42 CD N
+/- JJ N
0.09 CD N
mmol/l NN N
with IN N
glycerol NN 3_i
at IN N
92 CD N
mmol/l NN N
. . N

There EX N
was VBD N
no DT N
evidence NN N
of IN N
haemolysis NN N
or CC N
other JJ N
toxic JJ N
effect NN N
despite IN N
these DT N
levels NNS N
. . N

The DT N
rise NN N
in IN N
blood NN N
glucose NN N
and CC N
insulin NN N
noted VBD N
during IN N
the DT N
use NN N
of IN N
glucose-based JJ N
solutions NNS N
was VBD N
not RB N
found VBN N
with IN N
glycerol NN 3_i
. . N

Circulating NNP N
levels NNS N
of IN N
lactate NN N
, , N
pyruvate NN N
, , N
alanine NN N
, , N
non-esterified JJ N
fatty JJ N
acids NNS N
and CC N
the DT N
ketone NN N
bodies NNS N
were VBD N
similar JJ N
with IN N
the DT N
two CD N
agents NNS N
. . N

Although IN N
these DT N
short-term JJ N
studies NNS N
have VBP N
shown VBN N
no DT N
conclusive JJ N
advantage NN N
of IN N
glycerol NN 3_i
over IN N
glucose JJ 7_i
, , N
long-term JJ N
effects NNS N
of IN N
glycerol NN 3_i
, , N
particularly RB N
on IN N
circulating VBG N
lipid JJ N
levels NNS N
, , N
will MD N
determine VB N
its PRP$ N
future JJ N
role NN N
as IN N
an DT N
osmotic JJ N
agent NN N
in IN N
continuous JJ N
ambulatory JJ N
peritoneal JJ N
dialysis NN N
. . N

-DOCSTART- -X- O O

Comparison NNP N
of IN N
patient-controlled JJ 3_i
and CC N
nurse-administered JJ 3_i
analgesia NN 3_i
using VBG N
intravenous JJ N
fentanyl NN N
during IN N
labor NN N
. . N

Preliminary JJ N
observations NNS N
have VBP N
shown VBN N
that IN N
fentanyl NN 3_i
citrate NN 3_i
, , N
a DT N
potent JJ N
narcotic JJ N
, , N
is VBZ N
helpful JJ N
during IN N
labor NN N
without IN N
undue JJ N
side NN N
effects NNS N
. . N

This DT N
randomized JJ N
prospective JJ N
investigation NN N
compared VBN N
the DT N
patient-controlled JJ 3_i
administration NN 3_i
of IN 3_i
fentanyl NN 3_i
with IN N
that DT N
of IN N
administration NN 3_i
by IN 3_i
nurses NNS 3_i
on IN 3_i
request NN 3_i
. . 3_i

Eighty NNP N
healthy JJ N
women NNS N
beginning VBG N
active JJ N
labor NN N
( ( N
cervical JJ N
dilation NN N
4 CD N
cm NN N
) ) N
at IN N
term NN N
were VBD N
assigned VBN N
to TO N
receive VB N
fentanyl NN 3_i
intravenously RB N
by IN N
either CC N
patient-controlled JJ 3_i
administration NN N
( ( N
n=37 JJ N
) ) N
or CC N
nurse JJ 3_i
administration NN 3_i
on IN N
demand NN N
( ( N
n=43 JJ N
) ) N
. . N

Pain NNP N
intensity NN N
measurements NNS N
during IN N
early JJ N
and CC N
late JJ N
labor NN N
revealed VBD N
the DT N
degree NN N
of IN N
analgesia NN N
to TO N
be VB N
the DT N
same JJ N
in IN N
both DT N
groups NNS N
. . N

The DT N
delay NN N
in IN N
setting VBG N
up RP N
the DT N
infusion NN N
system NN N
and CC N
the DT N
short JJ N
time NN N
between IN N
requesting VBG N
analgesia NN N
and CC N
vaginal JJ N
delivery NN N
were VBD N
limitations NNS N
with IN N
self-administration NN N
. . N

Maternal JJ N
oversedation NN N
and CC N
vomiting VBG N
did VBD N
not RB N
occur VB N
. . N

Neonatal NNP N
naloxone NN N
therapy NN N
was VBD N
used VBN N
infrequently RB N
, , N
umbilical JJ N
serum NN N
levels NNS N
of IN N
fentanyl NN N
were VBD N
the DT N
same JJ N
in IN N
both DT N
groups NNS N
, , N
and CC N
postnatal JJ N
neuroadaptive JJ N
testing NN N
revealed VBD N
comparable JJ N
results NNS N
in IN N
both DT N
groups NNS N
. . N

Despite IN N
the DT N
usefulness NN N
of IN N
fentanyl NN N
during IN N
labor NN N
, , N
administration NN 3_i
by IN 3_i
the DT 3_i
patient NN 3_i
had VBD N
no DT N
advantages NNS N
over IN N
administration NN 3_i
by IN 3_i
the DT 3_i
nurses NNS 3_i
in IN N
significantly RB N
reducing VBG N
drug NN N
use NN N
, , N
improving VBG N
pain NN N
relief NN N
, , N
or CC N
avoiding VBG N
drowsiness NN N
. . N

-DOCSTART- -X- O O

Factors NNS N
predictive VBP N
of IN N
severe JJ N
hypoglycemia NN N
in IN N
type NN N
1 CD N
diabetes NNS N
: : N
analysis NN N
from IN N
the DT N
Juvenile NNP N
Diabetes NNP N
Research NNP N
Foundation NNP N
continuous JJ N
glucose JJ N
monitoring VBG N
randomized VBN N
control NN N
trial NN N
dataset NN N
. . N

OBJECTIVE NNP N
Identify NNP N
factors NNS N
predictive VBP N
of IN N
severe JJ N
hypoglycemia NN N
( ( N
SH NNP N
) ) N
and CC N
assess VB N
the DT N
clinical JJ N
utility NN N
of IN N
continuous JJ 6_i
glucose JJ 6_i
monitoring NN 6_i
( ( 6_i
CGM NNP 6_i
) ) 6_i
to TO N
warn VB N
of IN N
impending VBG N
SH NNP N
. . N

RESEARCH NNP N
DESIGN NNP N
AND NNP N
METHODS NNP N
In IN N
a DT N
multicenter NN N
randomized VBN N
clinical JJ N
trial NN N
, , N
436 CD N
children NNS N
and CC N
adults NNS N
with IN N
type JJ N
1 CD N
diabetes NNS N
were VBD N
randomized VBN N
to TO N
a DT N
treatment NN N
group NN N
that WDT N
used VBD N
CGM NNP 6_i
( ( N
N NNP N
= NNP N
224 CD N
) ) N
, , N
or CC N
a DT N
control NN 7_i
group NN N
that WDT N
used VBD N
standard JJ 7_i
home NN 7_i
blood NN 7_i
glucose JJ 7_i
monitoring NN 7_i
( ( N
N NNP N
= NNP N
212 CD N
) ) N
and CC N
completed VBD N
12 CD N
months NNS N
of IN N
follow-up NN N
. . N

After IN N
6 CD N
months NNS N
, , N
the DT N
original JJ N
control NN N
group NN N
initiated VBD N
CGM NNP 6_i
while IN N
the DT N
treatment NN N
group NN N
continued VBD N
use NN N
of IN N
CGM NNP N
for IN N
6 CD N
months NNS N
. . N

Baseline NNP N
risk NN N
factors NNS N
for IN N
SH NNP N
were VBD N
evaluated VBN N
over IN N
12 CD N
months NNS N
of IN N
follow-up JJ N
using VBG N
proportional JJ N
hazards NNS N
regression NN N
. . N

CGM-derived JJ N
indices NNS N
of IN N
hypoglycemia NN N
were VBD N
used VBN N
to TO N
predict VB N
episodes NNS N
of IN N
SH NNP N
over IN N
a DT N
24-h JJ N
time NN N
horizon NN N
. . N

RESULTS VB N
The DT N
SH NNP N
rate NN N
was VBD N
17.9 CD N
per IN N
100 CD N
person-years NNS N
, , N
and CC N
a DT N
higher JJR N
rate NN N
was VBD N
associated VBN N
with IN N
the DT N
occurrence NN N
of IN N
SH NNP N
in IN N
the DT N
prior JJ N
6 CD N
months NNS N
and CC N
female JJ N
sex NN N
. . N

SH NNP N
frequency NN N
increased VBD N
eightfold RB N
when WRB N
30 CD N
% NN N
of IN N
CGM NNP 6_i
values NNS N
were VBD N
? . N
70 CD N
mg/dL NN N
on IN N
the DT N
prior JJ N
day NN N
( ( N
4.5 CD N
vs. FW N
0.5 CD N
% NN N
; : N
P NNP N
< NNP N
0.001 CD N
) ) N
, , N
but CC N
the DT N
positive JJ N
predictive JJ N
value NN N
( ( N
PPV NNP N
) ) N
was VBD N
low JJ N
( ( N
< JJ N
5 CD N
% NN N
) ) N
. . N

Results NNS N
were VBD N
similar JJ N
for IN N
hypoglycemic JJ N
area NN N
under IN N
the DT N
curve NN N
and CC N
the DT N
low JJ N
blood NN N
glucose NN N
index NN N
calculated VBN N
by IN N
CGM NNP 6_i
. . N

CONCLUSIONS NNP N
SH NNP N
in IN N
the DT N
6 CD N
months NNS N
prior RB N
to TO N
the DT N
study NN N
was VBD N
the DT N
strongest JJS N
predictor NN N
of IN N
SH NNP N
during IN N
the DT N
study NN N
. . N

CGM-measured JJ N
hypoglycemia NN N
over IN N
a DT N
24-h JJ N
span NN N
is VBZ N
highly RB N
associated VBN N
with IN N
SH NNP N
the DT N
following JJ N
day NN N
( ( N
P NNP N
< NNP N
0.001 CD N
) ) N
, , N
but CC N
the DT N
PPV NNP N
is VBZ N
low JJ N
. . N

-DOCSTART- -X- O O

[ JJ N
Effect NNP N
of IN N
liu NN 3_i
wei NN 3_i
di NN 3_i
huang NN 3_i
or CC N
jin NN 3_i
gui NN 3_i
shen NN 3_i
qi JJ 3_i
decoction NN 3_i
as IN N
on IN N
adjuvant JJ N
treatment NN N
in IN N
small JJ N
cell NN N
lung NN N
cancer NN N
] NNP N
. . N

Eighty-three JJ N
patients NNS N
with IN N
small JJ N
cell NN N
lung NN N
cancer NN N
were VBD N
randomized VBN N
with IN N
or CC N
without IN N
using VBG N
a DT N
traditional JJ 3_i
Chinese JJ 3_i
Kidney-tonifying NNP 3_i
decoction NN 3_i
( ( N
Liu NNP 3_i
Wei NNP 3_i
Di NNP 3_i
Huang NNP 3_i
or CC N
Jin NNP 3_i
Gui NNP 3_i
Shen NNP 3_i
Qi NNP 3_i
medicinal JJ 3_i
decoction NN 3_i
) ) N
in IN N
chemotherapy NN N
or CC N
radiotherapy NN N
courses NNS N
. . N

74 CD N
patients NNS N
were VBD N
availble JJ N
to TO N
be VB N
analysis NN N
. . N

The DT N
two CD N
treatment NN N
groups NNS N
were VBD N
well-matched JJ N
in IN N
age NN N
, , N
sex NN N
, , N
stage NN N
and CC N
performance NN N
status NN N
. . N

There EX N
was VBD N
a DT N
statistically RB N
significant JJ N
difference NN N
in IN N
response NN N
rate NN N
and CC N
the DT N
median JJ N
survival NN N
between IN N
two CD N
groups NNS N
. . N

The DT N
overall JJ N
response NN N
rate NN N
( ( N
CR+PR NNP N
) ) N
was VBD N
91.5 CD N
% NN N
for IN N
Chinese JJ 3_i
herb NN 3_i
group NN N
and CC N
46.9 CD N
% NN N
for IN N
control NN N
group NN N
( ( N
P NNP N
less JJR N
than IN N
0.001 CD N
) ) N
. . N

The DT N
median JJ N
survival NN N
was VBD N
16 CD N
months NNS N
for IN N
the DT N
traditional JJ N
Chinese JJ 3_i
Kidney-tonifying NNP 3_i
decoction NN 3_i
group NN N
, , N
and CC N
10 CD N
months NNS N
for IN N
the DT N
control NN N
group NN N
( ( N
P NNP N
less JJR N
than IN N
0.05 CD N
) ) N
. . N

Survival JJ N
curve NN N
( ( N
Kaplan-meire NNP N
's POS N
) ) N
of IN N
the DT N
Chinese NNP N
herb NN N
group NN N
was VBD N
better JJR N
than IN N
that DT N
of IN N
the DT N
control NN N
group NN N
. . N

10 CD N
patients NNS N
of IN N
Chinese JJ 3_i
herb NN 3_i
group NN N
was VBD N
alive JJ N
beyond IN N
more JJR N
than IN N
2 CD N
years NNS N
. . N

Until IN N
now RB N
, , N
4 CD N
patients NNS N
in IN N
the DT N
Chinese JJ 3_i
herb NN 3_i
group NN N
, , N
one CD N
in IN N
the DT N
control NN N
group NN N
are VBP N
still RB N
enjoying VBG N
their PRP$ N
disease-free JJ N
life NN N
for IN N
more JJR N
than IN N
7 CD N
years NNS N
. . N

Hematologic NNP N
toxicities NNS N
were VBD N
observed VBN N
much RB N
frequently RB N
in IN N
the DT N
patients NNS N
of IN N
the DT N
control NN N
group NN N
( ( N
P NNP N
less JJR N
than IN N
0.005 CD N
and CC N
0.01/WBC CD N
and CC N
BPC NNP N
) ) N
. . N

Results NNS N
of IN N
animal JJ N
experiments NNS N
with IN N
the DT N
same JJ N
traditional JJ N
medicinal JJ N
decoctions NNS N
as IN N
used VBN N
in IN N
clinic NN N
have VBP N
showed VBN N
immuno-enhancement JJ N
activities NNS N
. . N

These DT N
results NNS N
have VBP N
showed VBN N
that IN N
the DT N
traditional JJ 3_i
Chinese JJ 3_i
Kidney-tonifying NNP 3_i
decoction NN 3_i
may MD N
enhance VB N
non-specific JJ N
immunology NN N
activities NNS N
and CC N
may MD N
be VB N
much JJ N
useful JJ N
for IN N
solid JJ N
cancer NN N
patients NNS N
as IN N
an DT N
adjuvant JJ N
treatment NN N
. . N

-DOCSTART- -X- O O

The DT N
ScanBrit NNP N
randomised VBD N
, , N
controlled VBD N
, , N
single-blind JJ N
study NN N
of IN N
a DT N
gluten- JJ 6_i
and CC 6_i
casein-free JJ 6_i
dietary JJ 6_i
intervention NN 6_i
for IN N
children NNS N
with IN N
autism NN N
spectrum NN N
disorders NNS N
. . N

There EX N
is VBZ N
increasing VBG N
interest NN N
in IN N
the DT N
use NN N
of IN N
gluten- JJ 6_i
and CC 6_i
casein-free JJ 6_i
diets NNS 6_i
for IN N
children NNS N
with IN N
autism NN N
spectrum NN N
disorders NNS N
( ( N
ASDs NNP N
) ) N
. . N

We PRP N
report VBP N
results NNS N
from IN N
a DT N
two-stage NN N
, , N
24-month JJ N
, , N
randomised VBN N
, , N
controlled VBN N
trial NN N
incorporating VBG N
an DT N
adaptive JJ N
'catch-up NN N
' POS N
design NN N
and CC N
interim JJ N
analysis NN N
. . N

Stage NN N
1 CD N
of IN N
the DT N
trial NN N
saw VBD N
72 CD N
Danish JJ N
children NNS N
( ( N
aged VBN N
4 CD N
years NNS N
to TO N
10 CD N
years NNS N
11 CD N
months NNS N
) ) N
assigned VBD N
to TO N
diet VB N
( ( N
A DT N
) ) N
or CC N
non-diet JJ 7_i
( ( N
B NNP N
) ) N
groups NNS N
by IN N
stratified JJ N
randomisation NN N
. . N

Autism NNP N
Diagnostic NNP N
Observation NNP N
Schedule NNP N
( ( N
ADOS NNP N
) ) N
and CC N
the DT N
Gilliam NNP N
Autism NNP N
Rating NNP N
Scale NNP N
( ( N
GARS NNP N
) ) N
were VBD N
used VBN N
to TO N
assess VB N
core NN N
autism NN N
behaviours NNS N
, , N
Vineland NNP N
Adaptive NNP N
Behaviour NNP N
Scales NNP N
( ( N
VABS NNP N
) ) N
to TO N
ascertain VB N
developmental JJ N
level NN N
, , N
and CC N
Attention-Deficit NNP N
Hyperactivity NNP N
Disorder NNP N
- : N
IV NNP N
scale NN N
( ( N
ADHD-IV NNP N
) ) N
to TO N
determine VB N
inattention NN N
and CC N
hyperactivity NN N
. . N

Participants NNS N
were VBD N
tested VBN N
at IN N
baseline NN N
, , N
8 CD N
, , N
and CC N
12 CD N
months NNS N
. . N

Based VBN N
on IN N
per IN N
protocol NN N
repeated VBN N
measures NNS N
analysis NN N
, , N
data NNS N
for IN N
26 CD N
diet JJ N
children NNS N
and CC N
29 CD N
controls NNS N
were VBD N
available JJ N
at IN N
12 CD N
months NNS N
. . N

At IN N
this DT N
point NN N
, , N
there EX N
was VBD N
a DT N
significant JJ N
improvement NN N
to TO N
mean VB N
diet JJ N
group NN N
scores NNS N
( ( N
time*treatment JJ N
interaction NN N
) ) N
on IN N
sub-domains NNS N
of IN N
ADOS NNP N
, , N
GARS NNP N
and CC N
ADHD-IV NNP N
measures NNS N
. . N

Surpassing VBG N
of IN N
predefined JJ N
statistical JJ N
thresholds NNS N
as IN N
evidence NN N
of IN N
improvement NN N
in IN N
group NN N
A NNP N
at IN N
12 CD N
months NNS N
sanctioned VBD N
the DT N
re-assignment NN N
of IN N
group NN N
B NNP N
participants NNS N
to TO N
active JJ N
dietary JJ N
treatment NN N
. . N

Stage NN N
2 CD N
data NNS N
for IN N
18 CD N
group NN N
A NNP N
and CC N
17 CD N
group NN N
B NNP N
participants NNS N
were VBD N
available JJ N
at IN N
24 CD N
months NNS N
. . N

Multiple NNP N
scenario NN N
analysis NN N
based VBN N
on IN N
inter- JJ N
and CC N
intra-group JJ N
comparisons NNS N
showed VBD N
some DT N
evidence NN N
of IN N
sustained JJ N
clinical JJ N
group NN N
improvements NNS N
although IN N
possibly RB N
indicative JJ N
of IN N
a DT N
plateau NN N
effect NN N
for IN N
intervention NN N
. . N

Our PRP$ N
results NNS N
suggest VBP N
that IN N
dietary JJ 6_i
intervention NN 6_i
may MD N
positively RB N
affect VB N
developmental JJ N
outcome NN N
for IN N
some DT N
children NNS N
diagnosed VBN N
with IN N
ASD NNP N
. . N

In IN N
the DT N
absence NN N
of IN N
a DT N
placebo NN 7_i
condition NN N
to TO N
the DT N
current JJ N
investigation NN N
, , N
we PRP N
are VBP N
, , N
however RB N
, , N
unable JJ N
to TO N
disqualify VB N
potential JJ N
effects NNS N
derived VBN N
from IN N
intervention NN N
outside IN N
of IN N
dietary JJ N
changes NNS N
. . N

Further JJ N
studies NNS N
are VBP N
required VBN N
to TO N
ascertain VB N
potential JJ N
best- NN N
and CC N
non-responders NNS N
to TO N
intervention NN N
. . N

The DT N
study NN N
was VBD N
registered VBN N
with IN N
ClincialTrials.gov NNP N
, , N
number NN N
NCT00614198 NNP N
. . N

-DOCSTART- -X- O O

Morphological JJ N
onset NN N
and CC N
early JJ N
diagnosis NN N
in IN N
apical JJ N
hypertrophic JJ N
cardiomyopathy NN N
: : N
a DT N
long JJ N
term NN N
analysis NN N
with IN N
nuclear JJ 6_i
magnetic JJ 6_i
resonance NN 6_i
imaging NN 6_i
. . 6_i

OBJECTIVES VB N
A DT N
long-term JJ N
follow-up NN N
study NN N
with IN N
nuclear JJ 6_i
magnetic JJ 6_i
resonance NN 6_i
( ( 6_i
NMR NNP 6_i
) ) 6_i
imaging NN 6_i
was VBD N
undertaken VBN N
to TO N
detect VB N
the DT N
morphological JJ N
onset NN N
and CC N
to TO N
establish VB N
the DT N
early JJ N
diagnosis NN N
in IN N
apical JJ N
hypertrophic JJ N
cardiomyopathy NN N
( ( N
HCM NNP N
) ) N
. . N

BACKGROUND VB N
A DT N
spadelike JJ N
configuration NN N
on IN N
left JJ N
ventriculogram NN N
( ( N
LVG NNP N
) ) N
is VBZ N
regarded VBN N
as IN N
a DT N
diagnostic JJ N
criterion NN N
for IN N
the DT N
classical JJ N
apical JJ N
HCM NNP N
. . N

There EX N
also RB N
exists VBZ N
a DT N
segmented JJ N
hypertrophy NN N
at IN N
the DT N
apical JJ N
level NN N
without IN N
indicating VBG N
the DT N
spadelike NN N
features NNS N
( ( N
a DT N
nonspade NN N
configuration NN N
) ) N
. . N

To TO N
detect VB N
the DT N
hypertrophied JJ N
myocardium NN N
of IN N
the DT N
nonspade JJ N
configuration NN N
, , N
circumferential JJ N
scrutiny NN N
of IN N
the DT N
apex NN N
is VBZ N
required VBN N
. . N

Although IN N
both DT N
configurations NNS N
can MD N
be VB N
underlying JJ N
causes NNS N
of IN N
giant JJ N
negative JJ N
T NNP N
waves NNS N
, , N
etiological JJ N
relationship NN N
between IN N
the DT N
two CD N
is VBZ N
not RB N
clarified VBN N
. . N

METHODS NNP N
The DT N
criteria NN N
for IN N
the DT N
spadelike NN N
configuration NN N
defined VBN N
on IN N
left JJ N
ventricular JJ N
short-axis JJ N
NMR NNP 6_i
images NNS 6_i
were VBD N
as IN N
follows VBZ N
: : N
( ( N
apical JJ N
maximal NN N
thickness NN N
> NN N
or CC N
= $ N
15 CD N
mm NN N
) ) N
, , N
( ( N
apical JJ N
anterior NN N
thickness NN N
over IN N
basal JJ N
anterior JJ N
thickness NN N
> NN N
or CC N
= VB N
1.3 CD N
) ) N
and CC N
( ( N
apical JJ N
posterior NN N
thickness NN N
over IN N
basal JJ N
posterior JJ N
thickness NN N
> NN N
or CC N
=1.3 NN N
) ) N
. . N

Thirteen JJ N
patients NNS N
who WP N
had VBD N
predominant JJ N
hypertrophy NN N
( ( N
> CD N
or CC N
= VB N
15 CD N
mm NN N
) ) N
at IN N
the DT N
apical JJ N
level NN N
without IN N
the DT N
spadelike NN N
configuration NN N
underwent JJ N
NMR NNP 6_i
imaging VBG 6_i
twice RB N
before RB N
and CC N
after IN N
54+/-10 JJ N
months NNS N
' POS N
follow-up NN N
. . N

RESULTS NNP N
Apical NNP N
hypertrophy NN N
that WDT N
had VBD N
been VBN N
confined VBN N
to TO N
the DT N
lateral JJ N
wall NN N
in IN N
four CD N
, , N
the DT N
anterior-lateral JJ N
wall NN N
in IN N
two CD N
, , N
and CC N
the DT N
septal-anterior JJ N
wall NN N
in IN N
one CD N
developed NN N
to TO N
become VB N
circumferential JJ N
hypertrophy NN N
that WDT N
fulfilled VBD N
the DT N
criteria NNS N
for IN N
the DT N
spadelike NN N
configuration NN N
after IN N
the DT N
follow-up JJ N
period NN N
. . N

CONCLUSIONS VB N
The DT N
spadelike NN N
configuration NN N
can MD N
begin VB N
with IN N
the DT N
nonspade JJ N
configuration NN N
and CC N
therefore NN N
, , N
both DT N
can MD N
constitute VB N
a DT N
single JJ N
disease NN N
entity NN N
of IN N
apical JJ N
HCM NNP N
. . N

The DT N
early JJ N
diagnosis NN N
of IN N
apical JJ N
HCM NNP N
can MD N
be VB N
achieved VBN N
by IN N
identifying VBG N
the DT N
hypertrophy NN N
frequently RB N
confined VBN N
to TO N
the DT N
lateral JJ N
wall NN N
at IN N
the DT N
apical JJ N
level NN N
. . N

-DOCSTART- -X- O O

Comparing VBG N
the DT N
effectiveness NN N
of IN N
peer NN 4_i
mentoring NN 4_i
and CC N
student NN 4_i
mentoring NN 4_i
in IN N
a DT N
35-week JJ N
fitness NN N
program NN N
for IN N
older JJR N
adults NNS N
. . N

To TO N
investigate VB N
the DT N
applicability NN N
and CC N
effectiveness NN N
of IN N
a DT N
peer-mentored JJ 2_i
exercise NN 2_i
program NN 2_i
, , N
this DT N
study NN N
compared VBN N
the DT N
retention NN N
and CC N
participation NN N
rates NNS N
, , N
and CC N
physical JJ N
improvements NNS N
of IN N
older JJR N
adults NNS N
trained VBN N
by IN N
peer NN 2_i
mentors NNS 2_i
( ( 2_i
PM NNP 2_i
) ) 2_i
to TO N
a DT N
group NN N
trained VBN N
by IN N
young JJ 2_i
qualified JJ 2_i
student NN 2_i
mentors NNS 2_i
( ( 2_i
SM NNP 2_i
) ) 2_i
. . N

A DT N
group NN N
of IN N
older JJR N
adults NNS N
were VBD N
prepared VBN N
as IN N
peer NN N
mentors NNS N
through IN N
a DT N
30-week JJ N
preparation NN N
program NN N
. . N

Later NNP N
, , N
60 CD N
older JJR N
adults NNS N
( ( N
mean VB N
? . N
SD NNP N
age NN N
: : N
68.7 CD N
? . N
6.1 CD N
years NNS N
) ) N
were VBD N
recruited VBN N
and CC N
randomly RB N
assigned VBN N
to TO N
either CC N
the DT N
PM NNP N
or CC N
SM NNP N
group NN N
. . N

Both DT N
groups NNS N
completed VBD N
an DT N
identical JJ N
35-week JJ N
fitness NN N
program NN N
. . N

Pre- NNP N
, , N
midterm- JJ N
and CC N
post-training JJ N
assessments NNS N
of IN N
fitness NN N
were VBD N
completed VBN N
and CC N
rates NNS N
of IN N
participation NN N
and CC N
retention NN N
were VBD N
documented VBN N
. . N

The DT N
same JJ N
retention NN N
rates NNS N
were VBD N
observed VBN N
in IN N
the DT N
two CD N
groups NNS N
, , N
but CC N
SM NNP N
group NN N
had VBD N
higher JJR N
participation NN N
. . N

Both DT N
groups NNS N
improved VBN N
significantly RB N
in IN N
all DT N
measures NNS N
of IN N
fitness NN N
and CC N
there EX N
were VBD N
no DT N
significant JJ N
post-test JJ N
differences NNS N
between IN N
the DT N
groups NNS N
in IN N
the DT N
fitness NN N
measures NNS N
. . N

Findings NNS N
suggest VBP N
that IN N
the DT N
peer NN N
mentor NN N
model NN N
is VBZ N
applicable JJ N
in IN N
an DT N
older JJR N
adult NN N
exercise NN N
program NN N
and CC N
may MD N
be VB N
as RB N
effective JJ N
as IN N
a DT N
program NN N
mentored VBN N
by IN N
young JJ N
professionals NNS N
. . N

-DOCSTART- -X- O O

A DT N
description NN N
of IN N
the DT N
clinical JJ N
characteristics NNS N
at IN N
baseline NN N
of IN N
patients NNS N
recruited VBN N
into IN N
the DT N
Carvedilol NNP 3_i
or CC N
Metoprolol NNP 3_i
European JJ N
Trial NNP N
( ( N
COMET NNP N
) ) N
. . N

BACKGROUND NNP N
& CC N
AIMS NNP N
The DT N
COMET NNP N
trial NN N
was VBD N
a DT N
prospective JJ N
, , N
double-blind JJ N
, , N
randomised JJ N
trial NN N
comparing VBG N
carvedilol NN 3_i
, , N
a DT N
comprehensive JJ N
adrenergic NN N
receptor NN N
antagonist NN 3_i
, , N
with IN N
metoprolol NN 3_i
, , N
a DT N
beta-1-selective JJ 3_i
agent NN 3_i
in IN N
patients NNS N
with IN N
heart NN N
failure NN N
and CC N
left VBD N
ventricular JJ N
systolic JJ N
dysfunction NN N
. . N

The DT N
trial NN N
showed VBD N
a DT N
reduction NN N
in IN N
mortality NN N
with IN N
carvedilol NN 3_i
that WDT N
was VBD N
consistent JJ N
across IN N
subgroups NNS N
. . N

The DT N
purpose NN N
of IN N
this DT N
report NN N
is VBZ N
to TO N
describe VB N
in IN N
greater JJR N
detail NN N
the DT N
heterogeneity NN N
of IN N
this DT N
population NN N
at IN N
baseline NN N
with IN N
particular JJ N
reference NN N
to TO N
the DT N
impact NN N
of IN N
symptomatic JJ N
severity NN N
, , N
age NN N
and CC N
gender NN N
on IN N
patient JJ N
characteristics NNS N
. . N

METHODS NNP N
A NNP N
descriptive JJ N
report NN N
using VBG N
data NNS N
entered VBN N
in IN N
the DT N
COMET NNP N
study NN N
data-base NN N
. . N

RESULTS VB N
The DT N
characteristics NNS N
of IN N
the DT N
population NN N
studied VBN N
were VBD N
similar JJ N
to TO N
those DT N
reported VBN N
in IN N
previous JJ N
trials NNS N
of IN N
beta-blockers NNS N
. . N

Almost NNP N
all DT N
patients NNS N
were VBD N
receiving VBG N
diuretics NNS 3_i
and CC N
ACE NNP 3_i
inhibitors NNS 3_i
with IN N
few JJ N
patients NNS N
taking VBG N
angiotensin JJ 3_i
receptor NN 3_i
blockers NNS 3_i
. . 3_i

As IN N
expected VBN N
, , N
older JJR N
patients NNS N
had VBD N
more RBR N
co-morbidity JJ N
. . N

Older JJR N
patients NNS N
and CC N
women NNS N
reported VBD N
worse JJR N
symptoms NNS N
and CC N
poorer JJR N
well-being JJ N
despite IN N
similar JJ N
ventricular JJ N
dimensions NNS N
and CC N
systolic JJ N
dysfunction NN N
. . N

NT-proBNP NNP N
was VBD N
higher RBR N
in IN N
patients NNS N
with IN N
more RBR N
severe JJ N
symptoms NNS N
and CC N
older JJR N
patients NNS N
but CC N
not RB N
in IN N
women NNS N
, , N
although IN N
differences NNS N
in IN N
NT-proBNP NNP N
may MD N
have VB N
been VBN N
confounded VBN N
by IN N
differences NNS N
in IN N
renal JJ N
function NN N
. . N

CONCLUSION NNP N
Age NNP N
and CC N
gender NN N
, , N
as RB N
well RB N
as IN N
the DT N
severity NN N
of IN N
cardiac JJ N
dysfunction NN N
, , N
appear VBP N
to TO N
have VB N
an DT N
important JJ N
effect NN N
on IN N
the DT N
severity NN N
of IN N
heart NN N
failure NN N
symptoms NNS N
and CC N
patient JJ N
'well-being NN N
' POS N
. . N

This DT N
could MD N
have VB N
important JJ N
implications NNS N
for IN N
the DT N
relationship NN N
between IN N
symptoms NNS N
and CC N
prognosis NN N
and CC N
therefore RB N
the DT N
way NN N
in IN N
which WDT N
patients NNS N
are VBP N
selected VBN N
for IN N
clinical JJ N
trials NNS N
and CC N
the DT N
goals NNS N
of IN N
treatment NN N
. . N

This DT N
will MD N
be VB N
the DT N
subject NN N
of IN N
further JJ N
analyses NNS N
. . N

-DOCSTART- -X- O O

Tetracaine NNP 3_i
( ( 3_i
ametop NN 3_i
) ) 3_i
compared VBN N
to TO N
placebo VB N
for IN N
reducing VBG N
pain NN N
associated VBN N
with IN N
intramuscular JJ N
injection NN N
of IN N
palivizumab NN N
( ( N
synagis NN N
) ) N
. . N

Infants NNS N
receive VBP N
many JJ N
painful JJ N
immunizations NNS N
before IN N
they PRP N
are VBP N
2 CD N
years NNS N
old JJ N
. . N

The DT N
purpose NN N
of IN N
this DT N
study NN N
was VBD N
to TO N
evaluate VB N
if IN N
topical JJ 3_i
tetracaine NN 3_i
reduces VBZ N
the DT N
pain NN N
of IN N
intramuscular JJ N
palivizumab NNS 3_i
compared VBN N
to TO N
placebo VB 7_i
. . 7_i

There EX N
were VBD N
two CD N
study NN N
injections NNS N
, , N
one CD N
with IN N
tetracaine NN 3_i
and CC N
one CD N
with IN N
placebo NN 7_i
. . 7_i

Pain NN N
was VBD N
scored VBN N
by IN N
their PRP$ N
parents NNS N
and CC N
a DT N
pediatric JJ N
nurse NN N
. . N

Topical JJ N
tetracaine NN 3_i
was VBD N
not RB N
associated VBN N
with IN N
a DT N
significant JJ N
reduction NN N
in IN N
pain NN N
score NN N
, , N
although IN N
it PRP N
did VBD N
lead VB N
to TO N
faster VB N
recovery NN N
times NNS N
. . N

Additional JJ N
pain-reduction NN N
strategies NNS N
are VBP N
required VBN N
. . N

-DOCSTART- -X- O O

Salbutamol NNP 3_i
or CC N
mist NN 3_i
in IN N
acute JJ N
bronchiolitis NN N
. . N

BACKGROUND IN N
The DT N
role NN N
of IN N
bronchodilators NNS N
in IN N
the DT N
treatment NN N
of IN N
bronchiolitis NN N
remains VBZ N
controversial JJ N
. . N

METHODS VB N
A DT N
double-blind NN N
, , N
placebo NN N
controlled VBD N
trial NN N
was VBD N
performed VBN N
to TO N
evaluate VB N
the DT N
clinical JJ N
response NN N
to TO N
nebulized VBN N
salbutamol NN 3_i
. . 3_i

One CD N
hundred CD N
and CC N
fifty-six JJ N
infants NNS N
aged VBN N
between IN N
7 CD N
weeks NNS N
and CC N
24 CD N
months NNS N
who WP N
had VBD N
had VBN N
an DT N
episode NN N
of IN N
wheezing NN N
and CC N
other JJ N
signs NNS N
and CC N
symptoms NNS N
of IN N
bronchiolitis NN N
were VBD N
randomized VBN N
to TO N
three CD N
groups NNS N
as IN N
follows VBZ N
: : N
( ( N
i NN N
) ) N
nebulized VBD 3_i
salbutamol NN 3_i
was VBD N
administered VBN N
to TO N
52 CD N
patients NNS N
in IN N
group NN N
I PRP N
at IN N
a DT N
dose NN N
of IN N
0.15 CD N
mg/kg NNS N
in IN N
2 CD N
mL JJ N
saline NN 7_i
; : 7_i
( ( N
ii NN N
) ) N
saline NN 7_i
was VBD N
nebulized VBN N
to TO N
52 CD N
patients NNS N
in IN N
group NN N
II NNP N
and CC N
( ( N
iii NN N
) ) N
in IN N
group NN N
III NNP N
52 CD N
patients NNS N
received JJ N
mist NN 3_i
in IN N
a DT N
tent NN N
. . N

All DT N
three CD N
groups NNS N
were VBD N
administered VBN N
oxygen NN 3_i
during IN N
the DT N
procedures NNS N
. . N

Treatment NNP N
was VBD N
repeated VBN N
with IN N
the DT N
same JJ N
agent NN N
after IN N
30 CD N
min NN N
if IN N
the DT N
respiratory NN N
score NN N
was VBD N
5 CD N
or CC N
more JJR N
. . N

Respiratory JJ N
rate NN N
, , N
heart NN N
rate NN N
, , N
oxygen NN N
saturation NN N
and CC N
presence NN N
of IN N
cyanosis NN N
, , N
wheezing VBG N
, , N
retractions NNS N
were VBD N
recorded VBN N
before IN N
and CC N
after IN N
each DT N
treatment NN N
. . N

RESULTS VB N
The DT N
decrease NN N
in IN N
the DT N
respiratory NN N
score NN N
was VBD N
5.2 CD N
+/- JJ N
1.8 CD N
, , N
0.82 CD N
+/- JJ N
2.4 CD N
and CC N
1.7 CD N
+/- JJ N
1.3 CD N
in IN N
group NN N
I PRP N
, , N
II NNP N
and CC N
III NNP N
, , N
respectively RB N
. . N

The DT N
decrease NN N
in IN N
group NN N
I PRP N
was VBD N
significantly RB N
higher JJR N
than IN N
in IN N
the DT N
other JJ N
groups NNS N
. . N

Heart NNP N
rate NN N
was VBD N
similar JJ N
between IN N
groups NNS N
. . N

Oxygen NNP N
saturation NN N
decreased VBD N
in IN N
group NN N
I PRP N
without IN N
reaching VBG N
statistical JJ N
significance NN N
. . N

CONCLUSIONS NNP N
Salbutamol NNP 3_i
was VBD N
shown VBN N
to TO N
be VB N
effective JJ N
and CC N
safe JJ N
in IN N
the DT N
treatment NN N
of IN N
acute JJ N
bronchiolitis NN N
. . N

-DOCSTART- -X- O O

Niacin NNP 3_i
revisited VBD N
. . N

A DT N
randomized JJ N
, , N
controlled JJ N
trial NN N
of IN N
wax-matrix JJ N
sustained-release JJ N
niacin NN 3_i
in IN N
hypercholesterolemia NN N
. . N

Two CD N
hundred VBD N
one CD N
male NN N
and CC N
female JJ N
subjects NNS N
, , N
aged VBD N
20 CD N
to TO N
70 CD N
years NNS N
, , N
with IN N
elevated VBN N
low-density NN N
lipoprotein NN N
cholesterol NN N
values NNS N
( ( N
in IN N
the DT N
75th CD N
to TO N
95th CD N
percentiles NNS N
) ) N
, , N
participated VBN N
in IN N
a DT N
randomized NN N
, , N
controlled VBN N
, , N
double-blind NN N
study NN N
using VBG N
a DT N
new JJ N
form NN N
of IN N
niacin NN 3_i
( ( 3_i
Enduracin NNP 3_i
) ) 3_i
, , N
which WDT N
employs VBZ N
a DT N
wax-matrix JJ N
vehicle NN N
for IN N
sustained JJ N
release NN N
. . N

Four CD N
niacin JJ 3_i
treatment NN N
groups NNS N
( ( N
daily JJ N
doses NNS N
of IN N
2000 CD N
, , N
1500 CD N
, , N
1250 CD N
, , N
and CC N
1000 CD N
mg NN N
) ) N
were VBD N
compared VBN N
with IN N
placebo- JJ 7_i
and CC N
diet-treated JJ 7_i
controls NNS 7_i
to TO N
determine VB N
side-effect JJ N
profile NN N
and CC N
optimal JJ N
range NN N
of IN N
efficacy NN N
. . N

The DT N
groups NNS N
given VBN N
2000 CD N
and CC N
1500 CD N
mg NN N
demonstrated VBD N
significant JJ N
reductions NNS N
in IN N
values NNS N
of IN N
low-density NN N
lipoprotein NN N
cholesterol NN N
( ( N
-26 CD N
% NN N
and CC N
-19.3 CD N
% NN N
, , N
respectively RB N
) ) N
, , N
total JJ N
cholesterol NN N
( ( N
-18.4 CD N
% NN N
and CC N
-13.3 NNP N
% NN N
) ) N
, , N
and CC N
total JJ N
cholesterol-high-density NN N
lipoprotein NN N
cholesterol NN N
ratio NN N
( ( N
-20.4 CD N
% NN N
and CC N
-19.4 CD N
% NN N
) ) N
when WRB N
compared VBN N
with IN N
diet- JJ N
and CC N
placebo-treated JJ N
controls NNS N
. . N

Smaller NN N
improvements NNS N
were VBD N
seen VBN N
in IN N
high-density NN N
lipoprotein NN N
cholesterol NN N
and CC N
triglyceride NN N
levels NNS N
. . N

Blood NNP N
chemistry NN N
monitoring NN N
indicated VBD N
that DT N
reduction NN N
in IN N
low-density NN N
lipoprotein NN N
cholesterol NN N
level NN N
strongly RB N
correlated VBN N
with IN N
an DT N
increase NN N
in IN N
baseline JJ N
levels NNS N
of IN N
some DT N
enzymes NNS N
for IN N
niacin-treated JJ N
subjects NNS N
. . N

The DT N
improved JJ N
side-effect JJ N
profile NN N
of IN N
the DT N
wax-matrix JJ N
form NN N
of IN N
niacin NN 3_i
was VBD N
particularly RB N
notable JJ N
. . N

The DT N
dropout NN N
rate NN N
due JJ N
to TO N
side VB N
effects NNS N
was VBD N
only RB N
3.4 CD N
% NN N
and CC N
was VBD N
coupled VBN N
with IN N
good JJ N
medication NN N
compliance NN N
. . N

-DOCSTART- -X- O O

Epirubicin NNP 3_i
and CC N
cyclophosphamide VB 3_i
versus NN N
epirubicin NN 3_i
and CC N
docetaxel NN 3_i
as IN N
first-line JJ N
therapy NN N
for IN N
women NNS N
with IN N
metastatic JJ N
breast NN N
cancer NN N
: : N
final JJ N
results NNS N
of IN N
a DT N
randomised JJ N
phase NN N
III NNP N
trial NN N
. . N

BACKGROUND VB N
This DT N
randomised JJ N
phase NN N
III NNP N
trial NN N
was VBD N
carried VBN N
out IN N
to TO N
compare VB N
the DT N
efficacy NN N
and CC N
safety NN N
of IN N
epirubicin NN 3_i
and CC N
cyclophosphamide NN 3_i
( ( 3_i
EC NNP 3_i
) ) 3_i
with IN N
epirubicin NN 3_i
and CC N
docetaxel NN 3_i
( ( 3_i
Taxotere NNP 3_i
) ) 3_i
( ( 3_i
ED NNP 3_i
) ) 3_i
as IN N
first-line JJ N
chemotherapy NN N
for IN N
metastatic JJ N
breast NN N
cancer NN N
. . N

PATIENTS NNP N
AND CC N
METHODS NNP N
Patients NNP N
( ( N
n JJ N
= NNP N
240 CD N
) ) N
were VBD N
randomly RB N
assigned VBN N
to TO N
receive VB N
either DT N
ED NNP 3_i
( ( 3_i
epirubicin JJ 3_i
75 CD N
mg/m NN N
( ( N
2 CD N
) ) N
and CC N
docetaxel $ 3_i
75 CD N
mg/m NN N
( ( N
2 CD N
) ) N
) ) N
or CC N
EC NNP 3_i
( ( 3_i
epirubicin VBP 3_i
90 CD N
mg/m NN N
( ( N
2 CD N
) ) N
and CC N
cyclophosphamide $ 3_i
600 CD N
mg/m NN N
( ( N
2 CD N
) ) N
) ) N
. . N

The DT N
primary JJ N
end NN N
point NN N
was VBD N
objective JJ N
response NN N
rate NN N
( ( N
ORR NNP N
) ) N
. . N

Secondary JJ N
end NN N
points NNS N
were VBD N
progression-free JJ N
survival NN N
( ( N
PFS NNP N
) ) N
, , N
overall JJ N
survival NN N
( ( N
OS NNP N
) ) N
, , N
and CC N
safety NN N
. . N

RESULTS NNP N
ORR NNP N
for IN N
patients NNS N
randomly RB N
assigned VBN N
to TO N
receive VB N
EC NNP 3_i
and CC N
ED NNP 3_i
were VBD N
42 CD N
% NN N
and CC N
47 CD N
% NN N
, , N
respectively RB N
( ( N
P NNP N
= NNP N
0.63 CD N
) ) N
. . N

Median JJ N
PFS NNP N
[ NNP N
10.1 CD N
versus NN N
10.3 CD N
months NNS N
; : N
hazard VBN N
ratio NN N
( ( N
HR NNP N
) ) N
0.98 CD N
; : N
log-rank JJ N
P NNP N
= NNP N
0.38 CD N
] NN N
and CC N
OS NNP N
( ( N
19.9 CD N
versus NN N
30.0 CD N
months NNS N
; : N
HR NNP N
0.663 CD N
; : N
log-rank JJ N
P NNP N
= NNP N
0.21 CD N
) ) N
were VBD N
comparable JJ N
in IN N
both DT N
arms NNS N
. . N

Although IN N
grade JJ N
3/4 CD N
leucopenia NN N
occurred VBD N
more RBR N
frequently RB N
with IN N
ED NNP 3_i
( ( N
81 CD N
% NN N
versus IN N
73 CD N
% NN N
; : N
P NNP N
= NNP N
0.01 CD N
) ) N
, , N
there EX N
were VBD N
no DT N
significant JJ N
differences NNS N
in IN N
the DT N
incidence NN N
of IN N
febrile JJ N
neutropenia NN N
and CC N
grade VBD N
3/4 CD N
infections NNS N
. . N

Grade VB N
3/4 CD N
non-haematologic JJ N
toxicity NN N
was VBD N
infrequent JJ N
in IN N
both DT N
arms NNS N
. . N

Congestive JJ N
heart NN N
failure NN N
was VBD N
observed VBN N
in IN N
one CD N
patient NN N
in IN N
each DT N
arm NN N
. . N

CONCLUSION NN N
In IN N
this DT N
randomised JJ N
trial NN N
, , N
no DT N
differences NNS N
in IN N
the DT N
efficacy NN N
study VBD N
end JJ N
points NNS N
were VBD N
observed VBN N
between IN N
the DT N
two CD N
treatment NN N
arms NNS N
. . N

-DOCSTART- -X- O O

Perioperative JJ N
myocardial JJ N
infarctions NNS N
are VBP N
common JJ N
and CC N
often RB N
unrecognized JJ N
in IN N
patients NNS N
undergoing VBG N
hip JJ N
fracture NN N
surgery NN N
. . N

BACKGROUND IN N
The DT N
aim NN N
of IN N
this DT N
prospective JJ N
cohort NN N
study NN N
was VBD N
to TO N
assess VB N
the DT N
incidence NN N
and CC N
characteristics NNS N
of IN N
acute JJ N
myocardial JJ N
infarction NN N
in IN N
patients NNS N
undergoing JJ N
surgery NN N
for IN N
acute JJ N
hip NN N
fracture NN N
. . N

METHODS NNP N
A NNP N
consecutive JJ N
cohort NN N
of IN N
patients NNS N
( ( N
n JJ N
= NN N
200 CD N
, , N
68 CD N
men NNS N
) ) N
referred VBD N
to TO N
acute VB 1_i
surgical JJ 1_i
correction NN 1_i
of IN 1_i
hip NN 1_i
fracture NN 1_i
was VBD N
studied VBN N
. . N

Troponin NNP 6_i
T NNP 6_i
( ( 6_i
TnT NNP 6_i
) ) 6_i
measurements NNS 6_i
and CC N
electrocardiographic JJ 6_i
( ( 6_i
ECG NNP 6_i
) ) 6_i
recordings NNS 6_i
were VBD N
performed VBN N
at IN N
admission NN N
, , N
before IN N
operation NN N
, , N
and CC N
on IN N
the DT N
first JJ N
and CC N
2nd CD N
postoperative JJ N
days NNS N
, , N
which WDT N
were VBD N
used VBN N
for IN N
diagnosis NN N
. . N

RESULTS VB N
The DT N
age NN N
of IN N
the DT N
patients NNS N
ranged VBD N
from IN N
32 CD N
to TO N
98 CD N
years NNS N
( ( N
mean NN N
, , N
80.8 CD N
years NNS N
) ) N
, , N
and CC N
65 CD N
patients NNS N
had VBD N
a DT N
history NN N
of IN N
coronary JJ N
artery NN N
disease NN N
. . N

A DT N
significant JJ N
rise NN N
in IN N
TnT NNP N
as IN N
a DT N
sign NN N
of IN N
myocardial JJ N
infarction NN N
was VBD N
observed VBN N
in IN N
71 CD N
patients NNS N
( ( N
35.5 CD N
% NN N
) ) N
, , N
and CC N
25 CD N
of IN N
them PRP N
had VBD N
a DT N
TnT NNP N
elevation NN N
exceeding VBG N
five CD N
times NNS N
the DT N
upper JJ N
normal JJ N
limit NN N
. . N

TnT NNP N
elevation NN N
was VBD N
observed VBN N
in IN N
36 CD N
patients NNS N
( ( N
51 CD N
% NN N
) ) N
already RB N
before RB N
surgery NN N
. . N

Seven CD N
patients NNS N
( ( N
10 CD N
% NN N
) ) N
had VBD N
ST NNP N
elevation NN N
myocardial JJ N
infarction NN N
, , N
23 CD N
patients NNS N
( ( N
32 CD N
% NN N
) ) N
had VBD N
new JJ N
ST NNP N
depressions NNS N
, , N
and CC N
21 CD N
patients NNS N
( ( N
30 CD N
% NN N
) ) N
had VBD N
no DT N
new JJ N
ST NNP N
segment NN N
changes NNS N
in IN N
the DT N
serial JJ N
electrocardiographic JJ N
recordings NNS N
. . N

In IN N
40 CD N
patients NNS N
( ( N
56 CD N
% NN N
) ) N
, , N
the DT N
perioperative JJ N
myocardial JJ N
infarction NN N
was VBD N
the DT N
first JJ N
manifestation NN N
of IN N
coronary JJ N
artery NN N
disease NN N
. . N

Multivariate NNP N
logistic JJ N
regression NN N
revealed VBD N
that IN N
old JJ N
age NN N
( ( N
odds NNS N
ratio VBP N
[ CD N
OR NNP N
] NNP N
, , N
1.06 CD N
; : N
95 CD N
% NN N
confidence NN N
interval NN N
[ NNP N
CI NNP N
] NNP N
, , N
1.02-1.10 JJ N
; : N
p VB N
= $ N
0.002 CD N
) ) N
, , N
earlier JJR N
revascularization NN N
( ( N
OR NNP N
, , N
3.29 CD N
; : N
95 CD N
% NN N
CI NNP N
1.12-9.73 CD N
; : N
p CC N
= VB N
0.03 CD N
) ) N
, , N
and CC N
heart NN N
failure NN N
( ( N
OR NNP N
, , N
2.42 CD N
; : N
95 CD N
% NN N
CI NNP N
1.04-5.61 CD N
; : N
p CC N
= VB N
0.04 CD N
) ) N
were VBD N
independent JJ N
predictors NNS N
of IN N
TnT NNP N
elevation NN N
. . N

Majority NNP N
of IN N
myocardial JJ N
infarctions NNS N
were VBD N
asymptomatic JJ N
or CC N
unrecognized JJ N
. . N

Evidence-based JJ N
medications NNS N
of IN N
myocardial JJ N
infarction NN N
were VBD N
seldom RB N
started VBN N
and CC N
cardiologist NN N
was VBD N
consulted VBN N
in IN N
12 CD N
patients NNS N
( ( N
16.9 CD N
% NN N
) ) N
. . N

CONCLUSION JJ N
Patients NNS N
with IN N
hip JJ N
fracture NN N
often RB N
develop VBZ N
asymptomatic JJ N
and CC N
clinically RB N
unrecognized JJ N
perioperative JJ N
myocardial JJ N
infarctions NNS N
. . N

Earlier JJR N
diagnosis NN N
and CC N
appropriate JJ N
treatment NN N
of IN N
cardiac JJ N
infarction NN N
may MD N
improve VB N
survival NN N
of IN N
hip NN N
fracture NN N
patients NNS N
. . N

LEVEL NNP N
OF IN N
EVIDENCE NNP N
Epidemiologic NNP N
study NN N
, , N
level NN N
III NNP N
. . N

-DOCSTART- -X- O O

Effect NN N
of IN N
acute NN 2_i
exercise NN 2_i
on IN N
executive NN N
function NN N
in IN N
children NNS N
with IN N
attention NN N
deficit NN N
hyperactivity NN N
disorder NN N
. . N

This DT N
study NN N
was VBD N
conducted VBN N
to TO N
determine VB N
the DT N
effect NN N
of IN N
acute NN 2_i
aerobic JJ 2_i
exercise NN 2_i
on IN N
executive NN N
function NN N
in IN N
children NNS N
with IN N
attention NN N
deficit NN N
hyperactivity NN N
disorder NN N
( ( N
ADHD NNP N
) ) N
. . N

Forty NNP N
children NNS N
with IN N
ADHD NNP N
were VBD N
randomly RB N
assigned VBN N
into IN N
exercise NN N
or CC N
control NN N
groups NNS N
. . N

Participants NNS N
in IN N
the DT N
exercise NN N
group NN N
performed VBD N
a DT N
moderate JJ 2_i
intensity NN 2_i
aerobic JJ 2_i
exercise NN 2_i
for IN 2_i
30 CD 2_i
min NN 2_i
, , N
whereas IN N
the DT N
control NN N
group NN N
watched VBD N
a DT N
running/exercise-related JJ 6_i
video NN 6_i
. . 6_i

Neuropsychological JJ N
tasks NNS N
, , N
the DT N
Stroop NNP N
Test NNP N
and CC N
the DT N
Wisconsin NNP N
Card NNP N
Sorting NNP N
Test NNP N
( ( N
WCST NNP N
) ) N
, , N
were VBD N
assessed VBN N
before IN N
and CC N
after IN N
each DT N
treatment NN N
. . N

The DT N
results NNS N
indicated VBD N
that IN N
acute JJ N
exercise NN N
facilitated VBN N
performance NN N
in IN N
the DT N
Stroop NNP N
Test NNP N
, , N
particularly RB N
in IN N
the DT N
Stroop NNP N
Color-Word NNP N
condition NN N
. . N

Additionally RB N
, , N
children NNS N
in IN N
the DT N
exercise NN N
group NN N
demonstrated VBD N
improvement NN N
in IN N
specific JJ N
WCST NNP N
performances NNS N
in IN N
Non-perseverative JJ N
Errors NNS N
and CC N
Categories NNP N
Completed NNP N
, , N
whereas VBZ N
no DT N
influences NNS N
were VBD N
found VBN N
in IN N
those DT N
performances NNS N
in IN N
the DT N
control NN N
group NN N
. . N

Tentative JJ N
explanations NNS N
for IN N
the DT N
exercise NN N
effect NN N
postulate NN N
that WDT N
exercise NN N
allocates VBZ N
attention NN N
resources NNS N
, , N
influences VBZ N
the DT N
dorsolateral JJ N
prefrontal NN N
cortex NN N
, , N
and CC N
is VBZ N
implicated VBN N
in IN N
exercise-induced JJ N
dopamine NN N
release NN N
. . N

These DT N
findings NNS N
are VBP N
promising VBG N
and CC N
additional JJ N
investigations NNS N
to TO N
explore VB N
the DT N
efficacy NN N
of IN N
exercise NN 2_i
on IN N
executive NN N
function NN N
in IN N
children NNS N
with IN N
ADHD NNP N
are VBP N
encouraged VBN N
. . N

-DOCSTART- -X- O O

[ JJ N
Clinical NNP N
observation NN N
on IN N
different JJ N
acupuncture NN 2_i
and CC N
moxibustion NN 3_i
therapies NNS N
for IN N
treatment NN N
of IN N
postsurgical JJ N
gastroparesis NN N
syndrome NN N
] NNP N
. . N

OBJECTIVE NNP N
To TO N
optimize VB N
therapy NN N
of IN N
acupuncture NN 2_i
and CC N
moxibustion NN 3_i
for IN N
postsurgical JJ N
gastroparesis NN N
syndrome NN N
( ( N
PGS NNP N
) ) N
. . N

METHODS NNP N
Forty-one JJ N
cases NNS N
of IN N
PGS NNP N
were VBD N
randomly RB N
divided VBN N
into IN N
3 CD N
groups NNS N
in IN N
order NN N
of IN N
visiting VBG N
. . N

Group NNP N
A NNP N
( ( N
n JJ N
= NNP N
17 CD N
) ) N
were VBD N
treated VBN N
by IN N
warming VBG N
needle JJ N
moxibustion NN 3_i
, , N
group NN N
B NNP N
( ( N
n JJ N
= NNP N
12 CD N
) ) N
by IN N
acupuncture NN 2_i
plus CC N
auricular JJ 2_i
point NN 2_i
sticking NN 2_i
, , N
and CC N
group NN N
C NNP N
( ( N
n JJ N
= NNP N
12 CD N
) ) N
by IN N
routine JJ 2_i
acupuncture NN 2_i
. . 2_i

Changes NNS N
of IN N
gastric JJ N
drainage NN N
volume NN N
, , N
therapeutic JJ N
times NNS N
and CC N
cured JJ N
rate NN N
were VBD N
investigated VBN N
in IN N
the DT N
3 CD N
groups NNS N
. . N

RESULTS NNP N
All PDT N
the DT N
3 CD N
therapeutic JJ N
methods NNS N
could MD N
significantly RB N
decrease VB N
gastric JJ N
drainage NN N
volume NN N
. . N

The DT N
cured JJ N
rate NN N
was VBD N
100.0 CD N
% NN N
and CC N
the DT N
therapeutic JJ N
times NNS N
was VBD N
( ( N
7.24 CD N
+/- JJ N
3.87 CD N
) ) N
in IN N
the DT N
group NN N
A NNP N
, , N
66.7 CD N
% NN N
, , N
( ( N
9.83 CD N
+/- JJ N
4.60 CD N
) ) N
times NNS N
in IN N
the DT N
group NN N
B NNP N
and CC N
75.0 CD N
% NN N
, , N
( ( N
15.25 CD N
+/- JJ N
3.81 CD N
) ) N
times NNS N
in IN N
the DT N
group NN N
C NNP N
, , N
with IN N
significant JJ N
differences NNS N
in IN N
the DT N
cured JJ N
rate NN N
and CC N
the DT N
therapeutic JJ N
times NNS N
among IN N
the DT N
3 CD N
groups NNS N
( ( N
P NNP N
< NNP N
0.05 CD N
, , N
P NNP N
< NNP N
0.01 CD N
) ) N
. . N

CONCLUSION NNP N
The DT N
warming VBG N
needle JJ N
moxibustion NN 3_i
is VBZ N
the DT N
best JJS N
method NN N
for IN N
PGS NNP N
, , N
with IN N
less RBR N
therapeutic JJ N
times NNS N
, , N
high JJ N
cured VBN N
rate NN N
and CC N
rapid JJ N
effect NN N
. . N

-DOCSTART- -X- O O

Induction NNP 3_i
chemotherapy NN 3_i
in IN N
head NN N
and CC N
neck NN N
cancer NN N
: : N
results NNS N
of IN N
a DT N
phase NN N
III NNP N
trial NN N
. . N

Between IN N
December NNP N
1982 CD N
and CC N
October NNP N
1986 CD N
, , N
131 CD N
patients NNS N
with IN N
stage JJ N
II-III-IV NNP N
squamous JJ N
cell NN N
carcinoma NN N
of IN N
the DT N
oropharynx NN N
or CC N
oral JJ N
cavity NN N
were VBD N
randomized VBN N
to TO N
induction VB N
chemotherapy NN 3_i
, , N
consisting VBG N
of IN N
bleomycin NN 3_i
( ( N
10 CD N
mg/m2/day NN N
in IN N
continuous JJ N
infusion NN N
from IN N
day NN N
1 CD N
to TO N
day NN N
5 CD N
) ) N
, , N
methotrexate NN 3_i
( ( N
120 CD N
mg/m2 NN N
on IN N
day NN N
2 CD N
) ) N
followed VBN N
by IN N
folinic JJ 3_i
acid NN 3_i
, , N
5-fluorouracil JJ 3_i
( ( N
5 CD N
FU NNP N
) ) N
( ( N
600 CD N
mg/m2 NN N
on IN N
day NN N
2 CD N
) ) N
, , N
and CC N
cisplatin NN 3_i
( ( N
120 CD N
mg/m2 NN N
on IN N
day NN N
4 CD N
) ) N
every DT N
4 CD N
weeks NNS N
for IN N
a DT N
total NN N
of IN N
three CD N
cycles NNS N
followed VBN N
by IN N
definitive JJ N
locoregional JJ N
treatment NN N
versus IN N
locoregional JJ N
treatment NN N
alone RB N
. . N

The DT N
modalities NNS N
of IN N
definitive JJ N
treatment NN N
( ( N
radiotherapy JJ 1_i
+/- JJ N
surgery NN 1_i
) ) N
were VBD N
chosen VBN N
prior RB N
to TO N
randomization NN N
. . N

A DT N
total NN N
of IN N
116 CD N
patients NNS N
were VBD N
evaluable JJ N
. . N

Of IN N
55 CD N
patients NNS N
in IN N
the DT N
chemotherapy NN 3_i
arm NN N
, , N
four CD N
( ( N
7 CD N
% NN N
) ) N
had VBD N
a DT N
complete JJ N
response NN N
( ( N
CR NNP N
) ) N
and CC N
23 CD N
( ( N
42 CD N
% NN N
) ) N
a DT N
partial JJ N
response NN N
( ( N
PR NNP N
) ) N
following VBG N
the DT N
induction NN N
regimen NNS N
. . N

At IN N
the DT N
completion NN N
of IN N
locoregional JJ N
treatment NN N
, , N
76 CD N
% NN N
( ( N
42 CD N
of IN N
55 CD N
) ) N
of IN N
patients NNS N
in IN N
the DT N
experimental JJ N
group NN N
were VBD N
in IN N
CR NNP N
compared VBN N
to TO N
89 CD N
% NN N
( ( N
54 CD N
of IN N
61 CD N
) ) N
in IN N
the DT N
control NN N
group NN N
. . N

There EX N
was VBD N
no DT N
difference NN N
in IN N
survival NN N
, , N
cause-specific JJ N
survival NN N
, , N
and CC N
pattern NN N
of IN N
relapse NN N
between IN N
both DT N
groups NNS N
. . N

The DT N
median JJ N
survival NN N
was VBD N
22 CD N
months NNS N
in IN N
the DT N
chemotherapy NN N
group NN N
and CC N
29 CD N
months NNS N
in IN N
the DT N
control NN N
group NN N
. . N

Responders NNS N
to TO N
chemotherapy VB N
did VBD N
not RB N
fare VB N
better JJR N
than IN N
nonresponders NNS N
. . N

Chemotherapy-related JJ N
toxicities NNS N
were VBD N
few JJ N
and CC N
most JJS N
of IN N
them PRP N
related VBN N
to TO N
cisplatin VB N
which WDT N
was VBD N
reduced VBN N
to TO N
100 CD N
mg/m2 NN N
for IN N
35 CD N
patients NNS N
. . N

There EX N
were VBD N
no DT N
treatment-related JJ N
deaths NNS N
and CC N
, , N
in IN N
the DT N
experimental JJ N
arm NN N
of IN N
the DT N
trial NN N
, , N
no DT N
increased VBN N
morbidity NN N
from IN N
locoregional JJ N
treatment NN N
. . N

This DT N
induction NN N
regimen NN N
does VBZ N
not RB N
offer VB N
any DT N
advantages NNS N
over IN N
standard JJ N
treatment NN N
. . N

-DOCSTART- -X- O O

Timing VBG N
for IN N
delivering VBG N
individualized JJ 4_i
patient JJ 4_i
education NN 4_i
intervention NN 4_i
to TO N
Coronary NNP N
Artery NNP N
Bypass NNP N
Graft NNP N
patients NNS N
: : N
An DT N
RCT NNP N
. . N

BACKGROUND NNP N
The DT N
primary JJ N
focus NN N
of IN N
this DT N
study NN N
is VBZ N
on IN N
the DT N
timing NN N
of IN N
the DT N
delivery NN N
of IN N
education NN N
to TO N
patients NNS N
who WP N
had VBD N
CABG NNP 1_i
surgery NN 1_i
. . 1_i

AIM NNP N
To TO N
determine VB N
the DT N
efficacy NN N
of IN N
an DT N
individualized JJ 4_i
telephone NN 4_i
patient JJ 4_i
education NN 4_i
intervention NN 4_i
, , N
delivered VBN N
at IN N
two CD N
different JJ N
points NNS N
in IN N
time NN N
( ( N
1-2 JJ N
days NNS N
pre-discharge JJ N
versus JJ N
1-2 JJ N
days NNS N
post-discharge NN N
) ) N
in IN N
enhancing VBG N
the DT N
CABG NNP N
patient NN N
's POS N
knowledge NN N
of IN N
self-care JJ N
behaviours NNS N
, , N
performance NN N
of IN N
self-care JJ N
behaviours NNS N
, , N
and CC N
symptom JJ N
frequency NN N
. . N

METHOD NNP N
A NNP N
randomized VBD N
clinical JJ N
trial NN N
that WDT N
included VBD N
a DT N
convenience NN N
sample NN N
of IN N
first JJ N
time NN N
CABG NNP N
patients NNS N
. . N

Individuals NNS N
who WP N
received VBD N
education NN 4_i
pre-discharge NN 4_i
were VBD N
compared VBN N
to TO N
individuals NNS N
who WP N
received VBD N
education NN N
post-discharge NN N
on IN N
the DT N
outcomes NNS N
. . N

RESULTS NNP N
Results NNP N
indicated VBD N
no DT N
statistically RB N
significant JJ N
difference NN N
in IN N
outcomes NNS N
between IN N
the DT N
two CD N
time NN N
points NNS N
. . N

As NNP N
well RB N
, , N
anxiety NN N
levels NNS N
were VBD N
found VBN N
to TO N
be VB N
significantly RB N
higher JJR N
in IN N
the DT N
pre-discharge NN N
group NN N
than IN N
the DT N
post-discharge JJ N
group NN N
. . N

CONCLUSIONS VB N
The DT N
individualized JJ N
nature NN N
of IN N
the DT N
educational JJ 4_i
intervention NN 4_i
may MD N
have VB N
accounted VBN N
for IN N
non-significant JJ N
findings NNS N
reported VBN N
in IN N
outcomes NNS N
between IN N
the DT N
two CD N
time NN N
points NNS N
. . N

PRACTICE NNP N
IMPLICATIONS NNP N
Nurses NNP N
may MD N
consider VB N
assessing VBG N
anxiety NN N
levels NNS N
prior RB N
to TO N
delivery NN N
of IN N
educational JJ N
interventions NNS N
, , N
implement JJ N
interventions NNS N
aimed VBN N
at IN N
reducing VBG N
anxiety NN N
levels NNS N
, , N
and CC N
provide VB N
individualized JJ N
teaching NN N
. . N

-DOCSTART- -X- O O

Pegfilgrastim NN 3_i
for IN N
peripheral JJ N
CD34+ NNP N
mobilization NN N
in IN N
patients NNS N
with IN N
solid JJ N
tumours NNS N
. . N

The DT N
efficacy NN N
of IN N
pegfilgrastim+/-chemotherapy NN 3_i
for IN N
mobilizing VBG N
stem NN N
cells NNS N
in IN N
patients NNS N
with IN N
solid JJ N
tumours NN N
was VBD N
assessed VBN N
. . N

In IN N
cycle NN N
0 CD N
, , N
a DT N
14-day JJ N
prechemotherapy NN N
cycle NN N
, , N
patients NNS N
( ( N
N=61 NNP N
) ) N
were VBD N
randomized VBN N
open-label NN N
to TO N
single JJ N
doses NNS N
of IN N
pegfilgrastim NN 3_i
( ( N
6 CD N
, , N
12 CD N
or CC N
18 CD N
mg NN N
) ) N
on IN N
day NN N
1 CD N
, , N
or CC N
daily RB N
filgrastim NNS 3_i
( ( N
10 CD N
microg/kg NN N
) ) N
for IN N
< NN N
or CC N
=7 JJ N
days NNS N
. . N

Mean JJ N
peak JJ N
peripheral JJ N
CD34+ NNP N
cell NN N
counts NNS N
increased VBD N
with IN N
pegfilgrastim NN 3_i
dose NN N
, , N
but CC N
were VBD N
significantly RB N
higher JJR N
than IN N
filgrastim JJR 3_i
only RB N
at IN N
the DT N
18 CD N
mg NN N
dose NN N
( ( N
10.17 CD N
vs RB N
4.96 CD N
x JJ N
10 CD N
( ( N
4 CD N
) ) N
/ml NN N
; : N
P=0.014 NNP N
) ) N
. . N

In IN N
the DT N
clinically NN N
relevant JJ N
period NN N
of IN N
days NNS N
3-7 CD N
, , N
both DT N
12 CD N
and CC N
18 CD N
mg NN N
pegfilgrastim NN 3_i
doses NNS N
produced VBD N
significantly RB N
higher JJR N
peak NN N
CD34+ NNP N
counts VBZ N
( ( N
8.18 CD N
and CC N
9.96 CD N
vs NN N
4.51 CD N
x NN N
10 CD N
( ( N
4 CD N
) ) N
/ml NN N
for IN N
filgrastim NN 3_i
; : 3_i
P=0.034 NNP N
and CC N
0.006 CD N
) ) N
. . N

In IN N
cycle NN N
1 CD N
, , N
patients NNS N
received VBD N
carboplatin/paclitaxel NNS 3_i
on IN N
day NN N
1 CD N
, , N
followed VBD N
from IN N
day NN N
2 CD N
by IN N
pegfilgrastim JJ 3_i
6-18 JJ N
mg NN N
or CC N
daily JJ N
filgrastim NN 3_i
( ( N
5 CD N
microg/kg/day NN N
for IN N
< NN N
or CC N
=14 NNP N
days NNS N
) ) N
as IN N
per IN N
randomization NN N
in IN N
cycle NN N
0 CD N
. . N

There EX N
were VBD N
no DT N
significant JJ N
differences NNS N
in IN N
mean JJ N
peak NN N
CD34+ NNP N
count NN N
between IN N
pegfilgrastim NN 3_i
and CC N
filgrastim NN 3_i
, , N
but CC N
there EX N
was VBD N
an DT N
advantage NN N
for IN N
pegfilgrastim NN 3_i
18 CD N
mg NN N
in IN N
the DT N
relevant JJ N
period NN N
of IN N
days NNS N
7-12 NNP N
( ( N
3.14 CD N
vs RB N
1.19 CD N
x JJ N
10 CD N
( ( N
4 CD N
) ) N
/ml NN N
; : N
P=0.043 NNP N
) ) N
. . N

A DT N
single JJ N
pegfilgrastim NN 3_i
dose NN N
( ( N
> CD N
or CC N
=6 VB N
mg NN N
) ) N
could MD N
be VB N
substituted VBN N
for IN N
daily JJ N
filgrastim NN 3_i
in IN N
cytokine-only JJ N
peripheral JJ N
CD34+ NNP N
cell NN N
mobilization NN N
. . N

-DOCSTART- -X- O O

Comparison NNP N
of IN N
the DT N
effect NN N
of IN N
gonadotropin-releasing NN 3_i
hormone NN 3_i
analog NN 3_i
( ( 3_i
Diphereline NNP 3_i
) ) 3_i
and CC N
Cabergoline NNP 3_i
( ( 3_i
Dostinex NNP 3_i
) ) 3_i
treatment NN N
on IN N
uterine JJ N
myoma NN N
regression NN N
. . N

OBJECTIVE UH N
To TO N
investigate VB N
the DT N
effect NN N
of IN N
cabergoline NN 3_i
( ( 3_i
Dostinex NNP 3_i
, , 3_i
a DT 3_i
dopamine JJ 3_i
agonist NN 3_i
) ) 3_i
on IN N
the DT N
myoma NN N
growth NN N
compared VBN N
to TO N
Diphereline NNP 3_i
( ( 3_i
a DT 3_i
gonadotropin-releasing NN 3_i
hormone NN 3_i
agonist NN 3_i
) ) 3_i
. . 3_i

METHODS NNP N
This DT N
study NN N
took VBD N
place NN N
in IN N
the DT N
Department NNP N
of IN N
Obstetrics NNP N
and CC N
Gynecology NNP N
of IN N
Tabriz NNP N
University NNP N
of IN N
Medical NNP N
Sciences NNPS N
, , N
Tabriz NNP N
, , N
Iran NNP N
from IN N
July NNP N
2004 CD N
to TO N
December NNP N
2005 CD N
. . N

Fifty NNP N
women NNS N
with IN N
uterine JJ N
myoma NN N
, , N
who WP N
met VBD N
the DT N
criteria NNS N
of IN N
the DT N
study NN N
thoroughly RB N
, , N
were VBD N
randomly RB N
allocated VBN N
into IN N
2 CD N
equal JJ N
groups NNS N
to TO N
take VB N
either DT N
Diphereline NNP 3_i
or CC N
Cabergoline NNP 3_i
. . 3_i

The DT N
first JJ N
Group NNP N
took VBD N
3.75 CD N
mg NN N
of IN N
Diphereline NNP 3_i
4 CD N
times NNS N
every DT N
28 CD N
days NNS N
and CC N
the DT N
second JJ N
group NN N
took VBD N
0.5 CD N
mg NN N
of IN N
Cabergoline NNP 3_i
once RB N
a DT N
week NN N
for IN N
6 CD N
weeks NNS N
. . N

RESULTS VB N
The DT N
Cabergoline NNP 3_i
was VBD N
well RB N
tolerated VBN N
and CC N
fewer JJR N
adverse JJ N
effects NNS N
were VBD N
noted VBN N
. . N

The DT N
tumor NN N
regressed VBD N
significantly RB N
and CC N
volume NN N
reduction NN N
rate NN N
of IN N
individual JJ N
tumor NN N
nodule NN N
varied VBD N
from IN N
46-53 CD N
% NN N
. . N

The DT N
gonadotropin NN 3_i
releasing VBG 3_i
hormone JJ 3_i
agonist NN 3_i
group NN N
all DT N
responded VBD N
to TO N
the DT N
treatment NN N
, , N
and CC N
volume NN N
reduction NN N
rate NN N
of IN N
the DT N
individual JJ N
tumor NN N
nodule NN N
varied VBD N
from IN N
21-97 CD N
% NN N
. . N

The DT N
extent NN N
of IN N
tumor NN N
shrinkage NN N
was VBD N
positively RB N
correlated VBN N
to TO N
the DT N
number NN N
of IN N
nodules NNS N
( ( N
p=0.881 NN N
, , N
p NN N
< VBD N
0.005 CD N
and CC N
0.701 CD N
, , N
p NN N
< NNP N
0.005 CD N
) ) N
. . N

CONCLUSION NNP N
In IN N
light NN N
of IN N
therapeutic JJ N
efficacy NN N
and CC N
few JJ N
adverse JJ N
effects NNS N
, , N
the DT N
dopamine NN 3_i
agonists NNS 3_i
may MD N
hold VB N
promise NN N
as IN N
novel JJ N
treatment NN N
modalities NNS N
for IN N
leiomyoma NN N
. . N

Further JJ N
studies NNS N
are VBP N
warranted VBN N
to TO N
determine VB N
the DT N
optimal JJ N
strategy NN N
for IN N
the DT N
treatment NN N
of IN N
leiomyoma NN N
through IN N
these DT N
agents NNS N
. . N

-DOCSTART- -X- O O

Secretin NNP 3_i
and CC N
sleep NN N
in IN N
children NNS N
with IN N
autism NN N
. . N

The DT N
objectives NNS N
of IN N
this DT N
pilot NN N
study NN N
were VBD N
1 CD N
) ) N
to TO N
examine VB N
possible JJ N
effects NNS N
of IN N
secretin JJ 3_i
infusions NNS N
on IN N
sleep-wake JJ N
state NN N
organization NN N
in IN N
children NNS N
with IN N
autism NN N
, , N
and CC N
2 CD N
) ) N
to TO N
assess VB N
the DT N
feasibility NN N
of IN N
home NN N
recordings NNS N
using VBG N
time-lapse JJ N
videosomnography NN N
in IN N
children NNS N
with IN N
autism NN N
. . N

Participants NNS N
were VBD N
a DT N
subset NN N
of IN N
subjects NNS N
from IN N
two CD N
double JJ N
blind NN N
, , N
placebo-control NN N
, , N
multi-center JJ N
clinical JJ N
trials NNS N
. . N

One CD N
trial NN N
, , N
the DT N
UC NNP N
Irvine NNP N
study NN N
, , N
assessed VBD N
the DT N
effects NNS N
of IN N
porcine NN 3_i
secretin NN 3_i
vs. FW 3_i
saline NN 7_i
infusions NNS 7_i
on IN N
children NNS N
's POS N
behavior NN N
, , N
language NN N
and CC N
IQ NNP N
. . N

The DT N
UC NNP N
Davis NNP N
trial NN N
assessed VBD N
the DT N
effects NNS N
of IN N
synthetic JJ 3_i
human JJ 3_i
secretin NN 3_i
vs. FW N
saline NN 7_i
infusions NNS 7_i
on IN N
behavior NN N
, , N
language NN N
and CC N
gastrointestinal JJ N
function NN N
. . N

The DT N
sleep NN N
study NN N
enrolled VBD N
some DT N
of IN N
the DT N
children NNS N
from IN N
each DT N
of IN N
the DT N
two CD N
trials NNS N
to TO N
observe VB N
possible JJ N
secretin JJ N
effects NNS N
on IN N
sleep NN N
. . N

To TO N
examine VB N
sleep NN N
, , N
the DT N
UC NNP N
Irvine NNP N
trial NN N
used VBD N
the DT N
Children NNP N
's POS N
Sleep NNP N
Habits NNP N
Questionnaire NNP N
and CC N
daily JJ N
sleep NN N
diaries NNS N
, , N
whereas IN N
the DT N
UC NNP N
Davis NNP N
study NN N
used VBD N
home-recorded JJ N
time-lapse JJ N
videosomnography NN N
. . N

Because IN N
of IN N
the DT N
small JJ N
sample NN N
size NN N
, , N
the DT N
results NNS N
from IN N
both DT N
trials NNS N
are VBP N
preliminary JJ N
. . N

They PRP N
suggest VBP N
that IN N
secretin NN 3_i
, , 3_i
porcine NN 3_i
or CC 3_i
synthetic JJ 3_i
, , N
does VBZ N
not RB N
improve VB N
sleep-wake NN N
state NN N
organization NN N
dramatically RB N
. . N

-DOCSTART- -X- O O

Hyperbaric NNP 3_i
oxygen NN 3_i
attenuation NN N
of IN N
lipopolysaccharide-induced JJ N
acute NN N
lung NN N
injury NN N
involves VBZ N
heme JJ N
oxygenase-1 NN N
. . N

BACKGROUND NNP N
Hyperbaric NNP 3_i
oxygen NN 3_i
( ( 3_i
HBO NNP 3_i
) ) 3_i
attenuates VBZ N
lipopolysaccharide JJ N
( ( N
LPS NNP N
) ) N
-induced VBD N
acute JJ N
lung NN N
injury NN N
. . N

This DT N
beneficial JJ N
effect NN N
of IN N
HBO NNP N
involves VBZ N
inhibition NN N
of IN N
inducible JJ N
nitric JJ N
oxide NN N
synthase NN N
( ( N
iNOS NN N
) ) N
expression NN N
and CC N
subsequent JJ N
nitric JJ N
oxide NN N
( ( N
NO NNP N
) ) N
biosynthesis NN N
. . N

We PRP N
sought VBD N
to TO N
investigate VB N
the DT N
role NN N
of IN N
heme JJ N
oxygenase-1 JJ N
( ( N
HO-1 NNP N
) ) N
on IN N
this DT N
HBO NNP N
inhibition NN N
of IN N
iNOS JJ N
induction NN N
and CC N
acute NN N
lung NN N
injury NN N
in IN N
septic JJ N
rat NN N
lungs NNS N
. . N

METHODS NNP N
Before IN N
the DT N
experiment NN N
, , N
72 CD N
rats NNS N
were VBD N
randomly RB N
allocated VBN N
to TO N
receive VB N
HBO NNP 3_i
or CC N
air NN 3_i
treatment NN 3_i
. . N

With IN N
or CC N
without IN N
HBO NNP 3_i
pre-treatment NN N
, , N
the DT N
rats NNS N
were VBD N
further RB N
divided VBN N
into IN N
the DT N
following JJ N
subgroups NNS N
( ( N
n JJ N
= NNP N
6 CD N
) ) N
: : N
( ( N
i NN N
) ) N
LPS NNP 3_i
injection NN 3_i
, , N
( ( N
ii NN N
) ) N
normal JJ 7_i
saline NN 7_i
( ( 7_i
N/S NNP 7_i
) ) 7_i
injection NN 7_i
, , N
( ( N
iii NN N
) ) N
hemin NN 3_i
( ( 3_i
a DT 3_i
HO-1 NNP 3_i
inducer NN 3_i
) ) 3_i
plus CC 3_i
LPS NNP 3_i
, , N
( ( N
iv NN N
) ) N
hemin NN 3_i
alone RB N
, , N
( ( N
v NN N
) ) N
tin NN 3_i
protoporphyrin NN 3_i
( ( 3_i
SnPP NNP 3_i
; : 3_i
a DT 3_i
HO-1 NNP 3_i
inhibitor NN 3_i
) ) 3_i
plus CC 3_i
LPS NNP 3_i
, , N
and CC N
( ( N
vi NN N
) ) N
SnPP NNP 3_i
alone RB N
. . N

All DT N
rats NNS N
were VBD N
maintained VBN N
for IN N
6 CD N
h NN N
and CC N
then RB N
sacrificed VBD N
with IN N
a DT N
high-dose JJ 3_i
pentobarbital JJ 3_i
injection NN 3_i
. . 3_i

Lung NNP N
injuries NNS N
and CC N
relevant JJ N
enzymes NNS N
expression NN N
were VBD N
thus RB N
assayed VBN N
. . N

RESULTS NNP N
Histological NNP N
analysis NN N
, , N
PMNs/alveoli NNP N
ratio NN N
, , N
and CC N
wet/dry JJ N
weight NN N
ratio NN N
measurements NNS N
demonstrated VBD N
that IN N
LPS NNP N
caused VBD N
significant JJ N
lung JJ N
injury NN N
and CC N
HBO NNP N
and/or VBP N
hemin NN N
significantly RB N
attenuated VBD N
this DT N
LPS-induced JJ N
lung NN N
injury NN N
. . N

Increased VBD N
pulmonary JJ N
iNOS NN N
expression NN N
and CC N
NO DT N
production NN N
were VBD N
associated VBN N
with IN N
lung JJ N
injury NN N
. . N

Induction NN N
of IN N
HO-1 NNP N
, , N
by IN N
HBO NNP N
and/or NN N
hemin NN N
, , N
significantly RB N
attenuated VBD N
this DT N
LPS-induced JJ N
iNOS NN N
expression NN N
and CC N
acute NN N
lung NN N
injury NN N
. . N

SnPP NNP N
, , N
on IN N
the DT N
contrary JJ N
, , N
offset VB N
the DT N
effects NNS N
of IN N
HBO NNP 3_i
and CC N
worsened VBD N
the DT N
LPS-induced NNP N
lung NN N
injury NN N
. . N

CONCLUSIONS NNP N
HBO NNP 3_i
may MD N
act VB N
through IN N
inhibiting VBG N
pulmonary JJ N
iNOS NN N
expression NN N
to TO N
attenuate VB N
LPS-induced NNP N
acute NN N
lung NN N
injury NN N
in IN N
septic JJ N
rats NNS N
. . N

Furthermore RB N
, , N
this DT N
HBO NNP 3_i
attenuation NN N
of IN N
iNOS JJ N
expression NN N
involves VBZ N
HO-1 NNP N
induction NN N
. . N

-DOCSTART- -X- O O

Comparison NNP N
of IN N
rectal JJ N
midazolam NN 3_i
and CC N
diazepam NN 3_i
for IN N
premedication NN N
in IN N
pediatric JJ N
dental JJ N
patients NNS N
. . N

Rectally RB N
administered VBN N
midazolam NN 3_i
( ( N
0.35 CD N
mg/kg NN N
) ) N
and CC N
diazepam NN 3_i
( ( N
0.70 CD N
mg/kg NN N
) ) N
were VBD N
compared VBN N
with IN N
each DT N
other JJ N
and CC N
with IN N
placebo NN 7_i
for IN N
preanesthetic JJ N
medication NN N
in IN N
children NNS N
undergoing VBG N
dental JJ N
extractions NNS N
. . N

All DT N
rectal JJ 3_i
medications NNS 3_i
were VBD N
very RB N
well RB N
accepted VBN N
, , N
but CC N
mask JJ N
acceptance NN N
, , N
improvement NN N
in IN N
anxiety NN N
, , N
and CC N
sedation NN N
were VBD N
best RBS N
in IN N
the DT N
midazolam NN 3_i
group NN N
. . N

Improvement NNP N
in IN N
anxiety NN N
and CC N
sedation NN N
were VBD N
significantly RB N
better RBR N
in IN N
the DT N
two CD N
drug NN N
groups NNS N
than IN N
in IN N
those DT N
patients NNS N
who WP N
had VBD N
received VBN N
placebo NN 7_i
. . 7_i

Thirty NNP N
minutes NNS N
after IN N
rectal JJ N
administration NN N
of IN N
midazolam NNS 3_i
, , N
patients NNS N
showed VBD N
a DT N
decrease NN N
in IN N
both DT N
systolic JJ N
and CC N
diastolic JJ N
blood NN N
pressure NN N
and CC N
heart NN N
rate NN N
. . N

Although IN N
these DT N
decreases NNS N
differed VBD N
significantly RB N
from IN N
the DT N
premedication NN N
values NNS N
, , N
they PRP N
were VBD N
probably RB N
of IN N
little JJ N
clinical JJ N
importance NN N
. . N

Only RB N
minor JJ N
adverse JJ N
effects NNS N
were VBD N
observed VBN N
in IN N
this DT N
study NN N
. . N

Overall NNP N
rectally RB N
administered VBD N
midazolam NNS 3_i
appeared VBD N
to TO N
be VB N
somewhat RB N
more RBR N
efficacious JJ N
than IN N
diazepam NN 3_i
. . 3_i

-DOCSTART- -X- O O

Ten-year JJ N
incidence NN N
of IN N
myocardial JJ N
infarction NN N
and CC N
prognosis NN N
after IN N
infarction NN N
. . N

Department NNP N
of IN N
Veterans NNP N
Affairs NNP N
Cooperative NNP N
Study NNP N
of IN N
Coronary NNP N
Artery NNP N
Bypass NNP N
Surgery NNP N
. . N

BACKGROUND NNP N
The DT N
10-year JJ N
incidence NN N
of IN N
myocardial JJ N
infarction NN N
( ( N
fatal JJ N
and CC N
nonfatal JJ N
) ) N
and CC N
the DT N
prognosis NN N
after IN N
infarction NN N
were VBD N
evaluated VBN N
in IN N
686 CD N
patients NNS N
with IN N
stable JJ N
angina NNS N
who WP N
were VBD N
randomly RB N
assigned VBN N
to TO N
medical JJ 3_i
or CC N
surgical JJ 1_i
treatment NN N
in IN N
the DT N
Veterans NNPS N
Administration NNP N
Cooperative NNP N
Study NNP N
of IN N
Coronary NNP N
Artery NNP N
Bypass NNP N
Surgery NNP N
. . N

METHODS NNP N
AND CC N
RESULTS NNP N
Myocardial NNP N
infarction NN N
was VBD N
defined VBN N
by IN N
either DT N
new JJ N
Q NNP N
wave VBP N
findings NNS N
or CC N
clinical JJ N
symptoms NNS N
compatible JJ N
with IN N
myocardial JJ N
infarction NN N
accompanied VBN N
by IN N
serum NN N
enzyme NN N
elevations NNS N
with IN N
or CC N
without IN N
electrocardiographic JJ N
findings NNS N
. . N

Treatment JJ N
comparisons NNS N
were VBD N
made VBN N
according VBG N
to TO N
original JJ N
treatment NN N
assignment NN N
; : N
35 CD N
% NN N
of IN N
the DT N
medical JJ N
cohort NN N
had VBD N
bypass NN 1_i
surgery NN 1_i
during IN N
the DT N
10-year JJ N
follow-up JJ N
period NN N
. . N

The DT N
overall JJ N
cumulative JJ N
infarction NN N
rate NN N
was VBD N
somewhat RB N
higher JJR N
in IN N
patients NNS N
assigned VBN N
to TO N
surgery VB 1_i
( ( N
36 CD N
% NN N
) ) N
than IN N
in IN N
medical JJ N
patients NNS N
( ( N
31 CD N
% NN N
) ) N
( ( N
p JJ N
= NNP N
0.13 CD N
) ) N
due JJ N
to TO N
perioperative JJ N
infarctions NNS N
( ( N
13 CD N
% NN N
) ) N
and CC N
an DT N
accelerated JJ N
infarction NN N
rate NN N
after IN N
the DT N
fifth JJ N
year NN N
of IN N
follow-up NN N
( ( N
average JJ N
, , N
2.4 CD N
% NN N
/yr NN N
in IN N
the DT N
surgical JJ N
group NN N
versus VBD N
1.4 CD N
% NN N
/yr NN N
in IN N
the DT N
medical JJ N
group NN N
) ) N
. . N

The DT N
10-year JJ N
cumulative JJ N
incidence NN N
of IN N
death NN N
or CC N
myocardial JJ N
infarction NN N
was VBD N
also RB N
higher JJR N
in IN N
surgical JJ N
( ( N
54 CD N
% NN N
) ) N
than IN N
in IN N
medical JJ N
( ( N
49 CD N
% NN N
) ) N
patients NNS N
( ( N
p JJ N
= NNP N
0.20 CD N
) ) N
. . N

According VBG N
to TO N
the DT N
Cox NNP N
model NN N
, , N
the DT N
estimated VBN N
risk NN N
of IN N
death NN N
after IN N
infarction NN N
was VBD N
59 CD N
% NN N
lower JJR N
in IN N
surgical JJ N
than IN N
in IN N
medical JJ N
patients NNS N
( ( N
p NN N
less JJR N
than IN N
0.0001 CD N
) ) N
. . N

The DT N
reduction NN N
in IN N
postinfarction NN N
mortality NN N
with IN N
surgery NN N
was VBD N
most RBS N
striking JJ N
in IN N
the DT N
first JJ N
month NN N
after IN N
the DT N
event NN N
: : N
99 CD N
% NN N
in IN N
the DT N
first JJ N
month NN N
( ( N
p NN N
less JJR N
than IN N
0.0001 CD N
) ) N
and CC N
49 CD N
% NN N
subsequently RB N
( ( N
p NN N
less JJR N
than IN N
0.0001 CD N
) ) N
. . N

The DT N
estimated VBN N
risk NN N
of IN N
death NN N
in IN N
the DT N
absence NN N
of IN N
infarction NN N
was VBD N
nearly RB N
identical JJ N
regardless NN N
of IN N
treatment NN N
( ( N
p JJ N
= NNP N
0.75 CD N
) ) N
. . N

Exclusion NN N
of IN N
perioperative JJ N
infarctions NNS N
did VBD N
not RB N
alter VB N
the DT N
findings NNS N
. . N

CONCLUSIONS NNP N
Although IN N
surgery NN N
does VBZ N
not RB N
reduce VB N
the DT N
incidence NN N
of IN N
myocardial JJ N
infarction NN N
overall RB N
, , N
it PRP N
does VBZ N
reduce VB N
the DT N
risk NN N
of IN N
mortality NN N
after IN N
infarction NN N
, , N
particularly RB N
in IN N
the DT N
first JJ N
30 CD N
days NNS N
after IN N
the DT N
event NN N
( ( N
fatal JJ N
infarctions NNS N
) ) N
. . N

-DOCSTART- -X- O O

Creon NNP 3_i
10,000 CD 3_i
Minimicrospheres NNP 3_i
vs. FW N
Creon NNP 3_i
8,000 CD 3_i
microspheres NNS 3_i
-- : N
an DT N
open JJ N
randomised VBN N
crossover NN N
preference NN N
study NN N
. . N

Creon NNP 3_i
10,000 CD 3_i
Minimicrospherestrade NNP 3_i
mark NN 3_i
( ( 3_i
Creon NNP 3_i
) ) 3_i
10,000 CD 3_i
MMS NNP 3_i
) ) 3_i
is VBZ N
a DT N
pancreatic JJ N
enzyme NN N
formulation NN N
that IN N
contains VBZ N
smaller JJR N
spheres NNS N
of IN N
pancreatin NN N
in IN N
a DT N
50 CD N
% NN N
smaller JJR N
capsule NN N
than IN N
conventional JJ N
microspheres NNS 3_i
( ( 3_i
Creon NNP 3_i
) ) 3_i
8,000 CD 3_i
) ) 3_i
. . 3_i

This DT N
three-centre JJ N
study NN N
investigated VBD N
the DT N
preference NN N
of IN N
cystic JJ N
fibrosis NN N
( ( N
CF NNP N
) ) N
patients NNS N
for IN N
these DT N
products NNS N
. . N

In IN N
one CD N
centre NN N
, , N
72 CD N
h NN N
stool NN N
fat JJ N
excretion NN N
and CC N
coefficient NN N
of IN N
fat JJ N
absorption NN N
( ( N
CFA NNP N
) ) N
were VBD N
also RB N
compared VBN N
. . N

Fifty-nine JJ N
patients NNS N
with IN N
a DT N
mean JJ N
age NN N
10 CD N
years NNS N
( ( N
range VB N
3-17 NNP N
) ) N
took VBD N
Creon NNP N
8,000 CD N
ms NN N
for IN N
14 CD N
days NNS N
and CC N
were VBD N
then RB N
randomised VBN N
to TO N
28 CD N
days NNS N
of IN N
Creon NNP 3_i
8,000 CD 3_i
ms NN 3_i
followed VBN N
by IN N
28 CD N
days NNS N
of IN N
Creon NNP 3_i
10,000 CD 3_i
MMS NNP 3_i
, , N
or CC N
vice NN N
versa NN N
. . N

Dosing NNP N
was VBD N
lipase NN N
for IN N
lipase NN N
according VBG N
to TO N
the DT N
labelled VBN N
declaration NN N
. . N

At IN N
the DT N
end NN N
of IN N
the DT N
second JJ N
treatment NN N
period NN N
, , N
51 CD N
of IN N
54 CD N
patients NNS N
who WP N
completed VBD N
the DT N
study NN N
expressed VBD N
a DT N
preference NN N
, , N
with IN N
a DT N
statistically RB N
significant JJ N
preference NN N
in IN N
favour NN N
of IN N
Creon NNP N
10,000 CD N
MMS NNP N
( ( N
47/51 CD N
; : N
87 CD N
% NN N
) ) N
vs. FW N
Creon NNP N
8,000 CD N
ms NN N
( ( N
4/51 CD N
; : N
7.4 CD N
% NN N
; : N
P NNP N
< NNP N
0.0001 CD N
) ) N
. . N

Stool NNP N
fat NN N
( ( N
g/day NN N
) ) N
and CC N
CFA NNP N
( ( N
% NN N
) ) N
were VBD N
measured VBN N
in IN N
24 CD N
patients NNS N
at IN N
the DT N
end NN N
of IN N
each DT N
treatment NN N
period NN N
: : N
the DT N
products NNS N
were VBD N
therapeutically RB N
equivalent JJ N
( ( N
Creon JJ 3_i
10,000 CD N
: : N
8.4 CD N
g/day NN N
, , N
91.3 CD N
% NN N
CFA NNP N
; : N
Creon NNP N
8,000 CD N
: : N
6.7 CD N
g/day NN N
, , N
93.5 CD N
% NN N
CFA NNP N
) ) N
. . N

Both DT N
products NNS N
were VBD N
well RB N
tolerated VBN N
. . N

In IN N
conclusion NN N
, , N
in IN N
CF NNP N
children NNS N
we PRP N
found VBD N
a DT N
clear JJ N
preference NN N
for IN N
Creon NNP N
10,000 CD N
MMS NNP N
compared VBN N
with IN N
Creon NNP N
8,000 CD N
ms NN N
with IN N
no DT N
difference NN N
in IN N
fat JJ N
absorption NN N
between IN N
the DT N
two CD N
products NNS N
. . N

Creon NNP 3_i
10,000s CD N
smaller JJR N
capsules NNS N
are VBP N
easier JJR N
to TO N
take VB N
and CC N
should MD N
aid VB N
patient NN N
compliance NN N
. . N

-DOCSTART- -X- O O

Moderate NNP 3_i
sodium NN 3_i
restriction NN 3_i
, , N
angiotensin NN 3_i
converting VBG 3_i
enzyme JJ 3_i
inhibition NN 3_i
, , N
and CC N
thiazide RB 3_i
diuretic JJ 3_i
in IN N
the DT N
management NN N
of IN N
essential JJ N
hypertension NN N
. . N

Dietary NNP 2_i
sodium JJ 2_i
restriction NN 2_i
alone RB N
is VBZ N
effective JJ N
in IN N
lowering VBG N
blood NN N
pressure NN N
in IN N
some DT N
, , N
but CC N
not RB N
all DT N
, , N
patients NNS N
with IN N
essential JJ N
hypertension NN N
. . N

Homeostatic JJ N
mechanisms NNS N
, , N
including VBG N
activation NN N
of IN N
the DT N
renin-aldosterone NN N
system NN N
, , N
may MD N
counteract VB N
the DT N
effects NNS N
of IN N
sodium JJ 2_i
restriction NN N
. . N

Angiotensin NNP 3_i
converting VBG 3_i
enzyme NN 3_i
( ( 3_i
ACE NNP 3_i
) ) 3_i
inhibitors NNS 3_i
are VBP N
also RB N
effective JJ N
as IN N
sole JJ N
therapy NN N
in IN N
many JJ N
patients NNS N
with IN N
essential JJ N
hypertension NN N
, , N
but CC N
may MD N
be VB N
less RBR N
effective JJ N
in IN N
those DT N
with IN N
low-renin JJ N
hypertension NN N
. . N

The DT N
combination NN N
of IN N
dietary JJ 3_i
sodium NN 3_i
restriction NN 3_i
with IN N
blockade NN N
of IN N
the DT N
renin NN N
system NN N
by IN N
an DT N
ACE NNP 3_i
inhibitor NN 3_i
is VBZ N
a DT N
particularly RB N
effective JJ N
way NN N
to TO N
improve VB N
blood NN N
pressure NN N
control NN N
. . N

Addition NNP N
of IN N
a DT N
thiazide JJ 3_i
diuretic NN 3_i
will MD N
reduce VB N
pressure NN N
further RBR N
. . N

-DOCSTART- -X- O O

Transcutaneous JJ 2_i
electrical JJ 2_i
nerve NN 2_i
stimulation NN 2_i
following VBG N
appendicectomy NN N
: : N
the DT N
placebo NN N
effect NN N
. . N

A DT N
controlled JJ N
trial NN N
was VBD N
undertaken VBN N
to TO N
compare VB N
the DT N
efficacy NN N
of IN N
transcutaneous JJ 2_i
electrical JJ 2_i
nerve NN 2_i
stimulation NN 2_i
( ( 2_i
TENS NNP 2_i
) ) 2_i
with IN N
standard JJ N
intramuscular JJ N
opiate NN 3_i
analgesia NN 3_i
in IN N
the DT N
management NN N
of IN N
postoperative JJ N
pain NN N
following VBG N
appendicectomy NN N
. . N

Consecutive JJ N
patients NNS N
undergoing VBG N
emergency NN 1_i
appendicectomy NN 1_i
were VBD N
randomised VBN N
into IN N
control NN N
, , N
sham NN 2_i
TENS NNP 2_i
and CC N
active JJ 2_i
TENS NNP 2_i
groups NNS 2_i
. . N

There EX N
was VBD N
a DT N
significant JJ N
decrease NN N
in IN N
pain NN N
severity NN N
and CC N
analgesic JJ N
intake NN N
in IN N
both DT N
active JJ 2_i
and CC 2_i
sham JJ 2_i
TENS NNP 2_i
groups NNS N
when WRB N
compared VBN N
with IN N
the DT N
control NN 7_i
group NN 7_i
( ( N
P NNP N
less JJR N
than IN N
0.01 CD N
) ) N
. . N

No DT N
difference NN N
was VBD N
demonstrated VBN N
in IN N
pain NN N
severity NN N
between IN N
active JJ 2_i
and CC 2_i
sham JJ 2_i
TENS NNP 2_i
groups NNS N
but CC N
the DT N
active JJ 2_i
TENS NNP 2_i
group NN N
required VBD N
slightly RB N
less JJR N
analgesia NN N
. . N

These DT N
results NNS N
suggest VBP N
that IN N
the DT N
major JJ N
benefit NN N
of IN N
TENS NNP 2_i
in IN N
the DT N
postappendicectomy NN N
patient NN N
is VBZ N
due JJ N
to TO N
its PRP$ N
'placebo JJ N
effect NN N
' POS N
and CC N
its PRP$ N
use NN N
in IN N
this DT N
situation NN N
can MD N
not RB N
be VB N
recommended VBN N
. . N

-DOCSTART- -X- O O

Dissociation NN N
between IN N
cortical JJ N
activation NN N
and CC N
cognitive JJ N
performance NN N
under IN N
pharmacological JJ N
blood NN N
pressure NN N
elevation NN N
in IN N
chronic JJ N
hypotension NN N
. . N

The DT N
present JJ N
study NN N
explored VBD N
the DT N
impact NN N
of IN N
pharmacological JJ 3_i
blood NN 3_i
pressure NN 3_i
elevation NN 3_i
on IN N
cortical JJ N
activation NN N
and CC N
reaction NN N
time NN N
in IN N
chronic JJ N
hypotension NN N
. . N

Effects NNS N
of IN N
the DT N
sympathomimetic JJ N
etilefrine NN N
were VBD N
investigated VBN N
in IN N
50 CD N
hypotensive JJ N
persons NNS N
based VBN N
on IN N
a DT N
randomized VBN N
, , N
placebo-controlled JJ 7_i
double JJ N
blind NN N
design NN N
. . N

As IN N
an DT N
indicator NN N
of IN N
cortical JJ N
excitability NN N
, , N
the DT N
contingent NN N
negative JJ N
variation NN N
( ( N
CNV NNP N
) ) N
, , N
induced VBN N
by IN N
a DT N
constant JJ N
foreperiod NN N
reaction NN N
time NN N
task NN N
, , N
was VBD N
assessed VBN N
at IN N
frontal JJ N
( ( N
F3 NNP N
, , N
Fz NNP N
, , N
F4 NNP N
) ) N
and CC N
central JJ N
( ( N
C3 NNP N
, , N
Cz NNP N
, , N
C4 NNP N
) ) N
scalp NN N
sites NNS N
. . N

Etilefrine NNP 3_i
provoked VBD N
a DT N
decrease NN N
in IN N
the DT N
frontal NN N
and CC N
central JJ N
CNV NNP N
. . N

In IN N
contrast NN N
, , N
shorter JJR N
reaction NN N
times NNS N
were VBD N
observed JJ N
following JJ N
drug NN N
administration NN N
. . N

The DT N
degree NN N
of IN N
pharmacologically RB N
induced VBN N
blood NN N
pressure NN N
elevation NN N
was VBD N
correlated VBN N
to TO N
CNV NNP N
attrition NN N
as RB N
well RB N
as IN N
to TO N
performance NN N
enhancement NN N
. . N

Inhibitory JJ N
effects NNS N
of IN N
baroreceptor NN N
activation NN N
on IN N
cortical JJ N
excitability NN N
and CC N
enhanced VBD N
cerebral JJ N
blood NN N
flow NN N
are VBP N
considered VBN N
to TO N
be VB N
involved VBN N
in IN N
mediating VBG N
the DT N
effects NNS N
of IN N
blood NN N
pressure NN N
elevation NN N
on IN N
cerebral JJ N
functioning NN N
. . N

Implications NNS N
for IN N
the DT N
treatment NN N
of IN N
chronic JJ N
hypotension NN N
are VBP N
discussed VBN N
. . N

-DOCSTART- -X- O O

White NNP N
coat NN N
effect NN N
detected VBD N
using VBG N
self-monitoring NN 2_i
of IN 2_i
blood NN 2_i
pressure NN 2_i
at IN 2_i
home NN 2_i
: : N
comparison NN N
with IN N
ambulatory JJ N
blood NN N
pressure NN N
. . N

The DT N
objective NN N
of IN N
the DT N
study NN N
was VBD N
to TO N
investigate VB N
whether IN N
home NN 2_i
blood NN 2_i
pressure NN 2_i
( ( 2_i
HBP NNP 2_i
) ) 2_i
is VBZ N
a DT N
reliable JJ N
alternative NN N
to TO N
ambulatory VB 2_i
blood NN 2_i
pressure NN 2_i
( ( 2_i
ABP NNP 2_i
) ) 2_i
for IN N
the DT N
detection NN N
of IN N
the DT N
white JJ N
coat NN N
effect NN N
( ( N
WCE NNP N
) ) N
. . N

Hypertensive JJ N
patients NNS N
were VBD N
randomized VBN N
to TO N
measure VB N
HBP NNP 2_i
for IN N
2 CD N
weeks NNS N
or CC N
ABP NNP 2_i
for IN N
24 CD N
h. PDT N
The DT N
alternative JJ N
measurement NN N
was VBD N
then RB N
performed VBN N
. . N

Clinic NNP N
blood NN N
pressure NN N
( ( N
CBP NNP N
) ) N
was VBD N
measured VBN N
in IN N
the DT N
beginning NN N
and CC N
end NN N
of IN N
the DT N
study NN N
. . N

Subjects NNS N
with IN N
a DT N
difference NN N
of IN N
> NN N
or CC N
= $ N
20 CD N
mm NN N
Hg NNP N
systolic NN N
or CC N
> NN N
or CC N
= $ N
10 CD N
mm NN N
Hg NNP N
diastolic VBZ N
BP NNP N
between IN N
CBP NNP N
and CC N
awake VB N
ABP NNP 2_i
or CC N
CBP NNP N
and CC N
HBP NNP 2_i
, , N
were VBD N
classified VBN N
as IN N
clinic JJ N
reactors NNS N
. . N

A DT N
total NN N
of IN N
189 CD N
patients NNS N
completed VBD N
the DT N
study NN N
( ( N
79 CD N
on IN N
stable JJ N
antihypertensive JJ N
treatment NN N
) ) N
. . N

There EX N
was VBD N
no DT N
difference NN N
in IN N
the DT N
magnitude NN N
of IN N
WCE NNP N
assessed VBD N
using VBG N
the DT N
ABP NNP 2_i
or CC N
the DT N
HBP NNP 2_i
method NN N
( ( N
mean JJ N
discrepancy NN N
, , N
systolic JJ N
BP NNP N
: : N
-1.5 JJ N
+/- JJ N
11.7 CD N
mm NN N
Hg NNP N
, , N
95 CD N
% NN N
CI NNP N
-3.2 NNP N
, , N
0.2 CD N
; : N
diastolic JJ N
BP NNP N
: : N
0.9 CD N
+/- JJ N
7.0 CD N
, , N
95 CD N
% NN N
CI NNP N
-0.1 NNP N
, , N
1.9 CD N
) ) N
. . N

A NNP N
strong JJ N
association NN N
existed VBD N
between IN N
WCE NNP N
calculated VBD N
using VBG N
the DT N
HBP NNP N
or CC N
the DT N
ABP NNP 2_i
method NN N
( ( N
r VB N
= RB N
0.64/0.59 CD N
systolic/diastolic JJ N
, , N
P NNP N
< NNP N
.001 NNP N
) ) N
. . N

The DT N
proportion NN N
of IN N
patients NNS N
classified VBN N
as IN N
clinic JJ N
reactors NNS N
was VBD N
identical JJ N
using VBG N
the DT N
HBP NNP 2_i
or CC N
the DT N
ABP NNP 2_i
method NN N
( ( N
25.9 CD N
% NN N
) ) N
. . N

Agreement NN N
between IN N
methods NNS N
in IN N
the DT N
classification NN N
of IN N
clinic JJ N
reactors NNS N
was VBD N
found VBN N
in IN N
147 CD N
patients NNS N
( ( N
78 CD N
% NN N
) ) N
. . N

The DT N
sensitivity NN N
and CC N
specificity NN N
of IN N
the DT N
HBP NNP 2_i
method NN N
to TO N
classify VB N
correctly RB N
clinic JJ N
reactors NNS N
( ( N
ABP NNP 2_i
method RB N
used VBD N
as IN N
the DT N
standard NN N
) ) N
were VBD N
57 CD N
% NN N
and CC N
85 CD N
% NN N
, , N
respectively RB N
, , N
whereas VBD N
its PRP$ N
positive JJ N
and CC N
negative JJ N
predictive JJ N
value NN N
were VBD N
57 CD N
% NN N
and CC N
85 CD N
% NN N
. . N

These DT N
results NNS N
indicate VBP N
that IN N
HBP NNP 2_i
is VBZ N
not RB N
appropriate JJ N
as IN N
an DT N
alternative NN N
to TO N
ABP NNP 2_i
diagnostic JJ N
testing NN N
in IN N
the DT N
detection NN N
of IN N
WCE NNP N
. . N

Nevertheless NNP N
, , N
HBP NNP 2_i
appears VBZ N
useful JJ N
as IN N
a DT N
screening JJ N
test NN N
for IN N
the DT N
detection NN N
of IN N
this DT N
phenomenon NN N
. . N

-DOCSTART- -X- O O

Step-down JJ N
approach NN N
using VBG N
either CC N
cyclosporin VB 3_i
A DT 3_i
or CC N
methotrexate NN 3_i
as IN N
maintenance NN N
therapy NN N
in IN N
early JJ N
rheumatoid NN N
arthritis NN N
. . N

OBJECTIVE UH N
To TO N
evaluate VB N
the DT N
feasibility NN N
and CC N
outcome NN N
of IN N
the DT N
step-down JJ N
approach NN N
using VBG N
either CC N
cyclosporin VB 3_i
A NNP 3_i
( ( 3_i
CSA NNP 3_i
) ) 3_i
or CC N
methotrexate NN 3_i
( ( 3_i
MTX NNP 3_i
) ) 3_i
as IN N
maintenance NN N
therapy NN N
following VBG N
6 CD N
months NNS N
treatment NN N
with IN N
these DT N
2 CD N
agents NNS N
in IN N
combination NN N
in IN N
early JJ N
, , N
nonerosive JJ N
rheumatoid NN N
arthritis NN N
( ( N
RA NNP N
) ) N
. . N

METHODS NNP N
Fifty-seven JJ N
patients NNS N
younger JJR N
than IN N
65 CD N
years NNS N
with IN N
early JJ N
, , N
nonerosive JJ N
RA NNP N
were VBD N
first RB N
treated VBN N
with IN N
CSA NNP 3_i
and CC N
MTX NNP 3_i
in IN N
combination NN N
for IN N
6 CD N
months NNS N
. . N

They PRP N
were VBD N
then RB N
randomly RB N
stepped VBD N
down RB N
to TO N
single-agent JJ N
maintenance NN N
treatment NN N
for IN N
another DT N
18 CD N
months NNS N
. . N

Safety NNP N
, , N
clinical JJ N
efficacy NN N
, , N
survival NN N
on IN N
treatment NN N
, , N
and CC N
radiographic JJ N
progression NN N
were VBD N
evaluated VBN N
. . N

RESULTS VB N
When WRB N
being VBG N
treated VBN N
with IN N
combination NN N
therapy NN N
, , N
7 CD N
of IN N
the DT N
57 CD N
patients NNS N
( ( N
12.3 CD N
% NN N
) ) N
withdrew NN N
because IN N
of IN N
adverse JJ N
events NNS N
. . N

Of IN N
the DT N
remaining VBG N
50 CD N
patients NNS N
, , N
42 CD N
( ( N
84.0 CD N
% NN N
) ) N
were VBD N
American JJ N
College NNP N
of IN N
Rheumatology NNP N
( ( N
ACR NNP N
) ) N
20 CD N
% NN N
responders NNS N
, , N
30 CD N
( ( N
60.0 CD N
% NN N
) ) N
were VBD N
ACR NNP N
50 CD N
% NN N
responders NNS N
, , N
and CC N
23 CD N
( ( N
46.0 CD N
% NN N
) ) N
were VBD N
ACR NNP N
70 CD N
% NN N
responders NNS N
. . N

At IN N
month NN N
6 CD N
, , N
22 CD N
patients NNS N
were VBD N
randomized VBN N
to TO N
CSA NNP 3_i
and CC N
27 CD N
to TO N
MTX NNP 3_i
. . 3_i

During IN N
this DT N
trial NN N
period NN N
, , N
the DT N
treatment NN N
was VBD N
discontinued VBN N
by IN N
16 CD N
patients NNS N
taking VBG N
CSA NNP 3_i
( ( N
mainly RB N
because IN N
of IN N
loss NN N
of IN N
efficacy NN N
) ) N
and CC N
by IN N
4 CD N
taking VBG N
MTX NNP 3_i
. . 3_i

At IN N
month NN N
24 CD N
, , N
the DT N
probability NN N
( ( N
+/- JJ N
SEM NNP N
) ) N
of IN N
survival NN N
on IN N
treatment NN N
was VBD N
0.273 CD N
+/- JJ N
0.09 CD N
for IN N
CSA NNP 3_i
and CC N
0.852 CD N
+/- JJ N
0.07 CD N
for IN N
MTX NNP 3_i
. . 3_i

Of IN N
the DT N
6 CD N
CSA NNP N
patients NNS N
who WP N
completed VBD N
the DT N
trial NN N
, , N
4 CD N
( ( N
66.7 CD N
% NN N
) ) N
were VBD N
ACR NNP N
20 CD N
% NN N
responders NNS N
, , N
and CC N
3 CD N
( ( N
50 CD N
% NN N
) ) N
were VBD N
both DT N
ACR NNP N
50 CD N
% NN N
and CC N
ACR NNP N
70 CD N
% NN N
responders NNS N
. . N

Of IN N
the DT N
23 CD N
completers NNS N
in IN N
the DT N
MTX NNP 3_i
arm NN N
, , N
21 CD N
( ( N
91.3 CD N
% NN N
) ) N
were VBD N
ACR NNP N
20 CD N
% NN N
responders NNS N
, , N
18 CD N
( ( N
78.3 CD N
% NN N
) ) N
were VBD N
ACR NNP N
50 CD N
% NN N
, , N
and CC N
10 CD N
( ( N
43.5 CD N
% NN N
) ) N
were VBD N
ACR NNP N
70 CD N
% NN N
responders NNS N
. . N

The DT N
treatment NN N
was VBD N
not RB N
responsible JJ N
for IN N
severe JJ N
adverse JJ N
events NNS N
. . N

Radiography NNP N
showed VBD N
a DT N
slow JJ N
progression NN N
in IN N
the DT N
damage NN N
score NN N
and CC N
number NN N
of IN N
eroded JJ N
joints NNS N
in IN N
both DT N
treatment NN N
groups NNS N
. . N

CONCLUSION NNP N
Stepping VBG N
down RP N
to TO N
single JJ N
agent JJ N
maintenance NN N
therapy NN N
following VBG N
6 CD N
months NNS N
of IN N
combination NN N
treatment NN N
with IN N
CSA NNP 3_i
and CC N
MTX NNP 3_i
in IN N
early JJ N
RA NNP N
was VBD N
only RB N
successful JJ N
with IN N
MTX NNP 3_i
. . 3_i

Because IN N
this DT N
treatment NN N
did VBD N
not RB N
prevent VB N
some DT N
radiographic JJ N
progression NN N
, , N
other JJ N
approaches NNS N
( ( N
e.g. NN N
, , N
step-up JJ N
approach NN N
) ) N
may MD N
be VB N
more JJR N
appropriate JJ N
in IN N
early JJ N
RA NNP N
. . N

-DOCSTART- -X- O O

Cytokine NN N
levels NNS N
and CC N
systemic JJ N
toxicity NN N
in IN N
patients NNS N
undergoing VBG N
isolated JJ 3_i
limb NN 3_i
perfusion NN 3_i
with IN N
high-dose JJ 3_i
tumor NN 3_i
necrosis NN 3_i
factor NN 3_i
, , N
interferon NN 3_i
gamma NN 3_i
, , N
and CC N
melphalan NN 3_i
. . N

PURPOSE NNP N
Isolated NNP 3_i
limb NN 3_i
perfusion NN 3_i
( ( 3_i
ILP NNP 3_i
) ) 3_i
with IN N
tumor NN 3_i
necrosis NN 3_i
factor NN 3_i
( ( 3_i
TNF NNP 3_i
) ) 3_i
, , N
interferon JJ 3_i
gamma NN 3_i
, , N
and CC N
melphalan NN 3_i
( ( 3_i
M NNP 3_i
) ) 3_i
has VBZ N
been VBN N
reported VBN N
to TO N
result VB N
in IN N
high JJ N
response NN N
rates NNS N
for IN N
extremity NN N
melanoma NN N
and CC N
sarcoma NN N
. . N

We PRP N
have VBP N
evaluated VBN N
the DT N
relationship NN N
of IN N
systemic JJ N
TNF NNP N
exposure NN N
to TO N
induction NN N
of IN N
several JJ N
secondary JJ N
mediators NNS N
and CC N
incidence NN N
of IN N
systemic JJ N
toxicity NN N
. . N

PATIENTS NNP N
AND CC N
METHODS NNP N
Nineteen NNP N
patients NNS N
with IN N
extremity NN N
melanoma NN N
( ( N
n JJ N
= NNP N
16 CD N
) ) N
or CC N
sarcoma NN N
( ( N
n JJ N
= NNP N
3 CD N
) ) N
, , N
underwent JJ N
90-minute JJ N
ILP NNP 3_i
with IN 3_i
TNF-alpha NNP 3_i
, , N
interferon NN 3_i
gamma NN 3_i
( ( N
0.2 CD N
mg NN N
) ) N
, , N
and CC N
M NNP 3_i
( ( N
10 CD N
to TO N
13 CD N
mg/L NN N
of IN N
limb NN N
volume NN N
) ) N
( ( 3_i
TNF/IFN/M NNP 3_i
) ) 3_i
( ( N
n JJ N
= NNP N
12 CD N
) ) N
, , N
or CC N
M NNP 3_i
alone RB N
( ( N
n JJ N
= NNP N
7 CD N
) ) N
. . N

Continuous JJ N
intraoperative JJ N
monitoring NN N
( ( N
CIM NNP N
) ) N
for IN N
systemic JJ N
leak NN N
from IN N
the DT N
perfusion NN N
circuit NN N
was VBD N
performed VBN N
using VBG N
radioactive JJ N
iodine-131 JJ 3_i
albumin NN 3_i
. . 3_i

Cytokine NN N
levels NNS N
in IN N
the DT N
perfusate NN N
and CC N
systemic JJ N
circulation NN N
during IN N
and CC N
after IN N
ILP NNP N
were VBD N
measured VBN N
by IN N
enzyme-linked JJ 3_i
immunosorbent NN 3_i
assay NN 3_i
. . 3_i

RESULTS NNP N
Systemic NNP N
leaks VBZ N
> CD N
or CC N
= VB N
1 CD N
% NN N
from IN N
the DT N
perfusion NN N
circuit NN N
occurred VBD N
in IN N
six CD N
patients NNS N
who WP N
received VBD N
TNF/IFN/M NNP N
and CC N
in IN N
four CD N
who WP N
received VBD N
M NNP N
alone RB N
. . N

Hypotension NNP N
that IN N
required VBD N
vasopressor NN N
support NN N
occurred VBD N
in IN N
six CD N
of IN N
six CD N
patients NNS N
with IN N
evidence NN N
of IN N
a DT N
leak NN N
( ( N
> CD N
or CC N
= VB N
1 CD N
% NN N
) ) N
and CC N
zero CD N
of IN N
six CD N
patients NNS N
without IN N
a DT N
leak NN N
( ( N
< JJ N
1 CD N
% NN N
) ) N
. . N

These DT N
six CD N
patients NNS N
had VBD N
significantly RB N
higher JJR N
peak JJ N
systemic JJ N
TNF NNP N
levels NNS N
during IN N
and CC N
after IN N
perfusion NN N
than IN N
patients NNS N
without IN N
a DT N
leak NN N
( ( N
2.8 CD N
and CC N
8.2 CD N
ng/mL JJ N
v NN N
0.7 CD N
and CC N
2.0 CD N
ng/mL NN N
, , N
respectively RB N
; : N
P NNP N
< NNP N
.05 NNP N
) ) N
. . N

All PDT N
patients NNS N
who WP N
received VBD N
TNF/IFN/M NNP N
had VBD N
significantly RB N
greater JJR N
increases NNS N
in IN N
systemic JJ N
interleukin-6 JJ N
( ( N
IL-6 NNP N
) ) N
levels NNS N
than IN N
in IN N
patients NNS N
with IN N
M NNP N
alone RB N
( ( N
12,395 CD N
+/- JJ N
10,374 CD N
pg/mL NN N
v NN N
79.4 CD N
+/- JJ N
7.2 CD N
pg/mL NN N
, , N
respectively RB N
; : N
P NNP N
< NNP N
.001 NNP N
) ) N
. . N

Intracellular JJ N
adhesion NN N
molecule NN N
( ( N
ICAM NNP N
) ) N
, , N
IL-8 NNP N
, , N
and CC N
TNF-R JJ N
levels NNS N
were VBD N
also RB N
increased VBN N
after IN N
ILP NNP N
with IN N
TNF/IFN/M NNP N
. . N

CONCLUSION NNP N
ILP NNP N
with IN N
TNF/IFN/M NNP N
can MD N
be VB N
safely RB N
performed VBN N
, , N
as IN N
I131 NNP N
albumin VBP N
provides VBZ N
a DT N
sensitive JJ N
measure NN N
of IN N
systemic JJ N
leakage NN N
from IN N
the DT N
perfusion NN N
circuit NN N
. . N

Patients NNS N
with IN N
a DT N
measured JJ N
leak NN N
of IN N
> NN N
or CC N
= VB N
1 CD N
% NN N
develop NN N
mild NN N
and CC N
transient JJ N
postoperative JJ N
hypotension NN N
with IN N
significantly RB N
higher JJR N
systemic JJ N
TNF NNP N
levels NNS N
and CC N
lower JJR N
perfusate NN N
TNF NNP N
levels NNS N
than IN N
in IN N
patients NNS N
without IN N
leaks NNS N
. . N

-DOCSTART- -X- O O

Sex NN N
risk NN N
behavior NN N
among IN N
adolescent JJ N
and CC N
young JJ N
adult NN N
children NNS N
of IN N
opiate JJ N
addicts NNS N
: : N
outcomes NNS N
from IN N
the DT N
focus NN N
on IN N
families NNS N
prevention VBP N
trial NN N
and CC N
an DT N
examination NN N
of IN N
childhood NN N
and CC N
concurrent JJ N
predictors NNS N
of IN N
sex NN N
risk NN N
behavior NN N
. . N

This DT N
study NN N
reports VBZ N
on IN N
rates NNS N
and CC N
predictors NNS N
of IN N
sex NN N
risk NN N
behavior NN N
among IN N
a DT N
sample NN N
of IN N
adolescent NN N
and CC N
young JJ N
adult NN N
children NNS N
of IN N
parents NNS N
enrolled VBN N
in IN N
methadone NN 3_i
treatment NN N
for IN N
opiate JJ N
addiction NN N
. . N

Data NNS N
are VBP N
from IN N
151 CD N
participants NNS N
( ( N
80 CD N
males NNS N
, , N
71 CD N
females NNS N
) ) N
in IN N
the DT N
Focus NNP N
on IN N
Families NNP N
( ( N
FOF NNP N
) ) N
project NN N
, , N
a DT N
randomized JJ N
trial NN N
of IN N
a DT N
family NN 4_i
intervention NN 4_i
and CC N
a DT N
study NN N
of IN N
the DT N
development NN N
of IN N
at-risk JJ N
children NNS N
. . N

The DT N
study NN N
participants NNS N
are VBP N
children NNS N
of IN N
parents NNS N
enrolled VBN N
in IN N
methadone NN 3_i
treatment NN N
between IN N
1990 CD N
and CC N
1993 CD N
. . N

Participants NNS N
were VBD N
interviewed VBN N
in IN N
2005 CD N
when WRB N
they PRP N
ranged VBD N
in IN N
age NN N
from IN N
15 CD N
to TO N
29 CD N
years NNS N
. . N

In IN N
the DT N
year NN N
prior RB N
to TO N
the DT N
follow-up NN N
, , N
79 CD N
% NN N
of IN N
the DT N
males NNS N
and CC N
83 CD N
% NN N
of IN N
females NNS N
were VBD N
sexually RB N
active JJ N
, , N
26 CD N
% NN N
of IN N
males NNS N
and CC N
10 CD N
% NN N
of IN N
females NNS N
had VBD N
more JJR N
than IN N
one CD N
partner NN N
in IN N
the DT N
prior JJ N
year NN N
, , N
and CC N
34 CD N
% NN N
of IN N
males NNS N
and CC N
24 CD N
% NN N
of IN N
females NNS N
reported VBN N
having VBG N
sex NN N
outside IN N
of IN N
a DT N
committed JJ N
relationship NN N
. . N

Twenty-four CD N
percent NN N
of IN N
males NNS N
and CC N
17 CD N
% NN N
of IN N
females NNS N
met VBD N
criteria NNS N
for IN N
high-risk JJ N
sexual JJ N
behavior NN N
, , N
reporting VBG N
casual JJ N
or CC N
multiple JJ N
partners NNS N
in IN N
the DT N
prior JJ N
year NN N
and CC N
inconsistent NN N
condom NN N
use NN N
. . N

Participants NNS N
in IN N
the DT N
intervention NN 6_i
and CC N
control NN 7_i
conditions NNS N
did VBD N
not RB N
differ VB N
significantly RB N
in IN N
terms NNS N
of IN N
any DT N
measure NN N
of IN N
sex NN N
risk NN N
behavior NN N
examined VBN N
. . N

None NN N
of IN N
the DT N
measures NNS N
of IN N
parent NN N
behavior NN N
and CC N
family NN N
processes NNS N
derived VBN N
from IN N
data NNS N
at IN N
baseline NN N
of IN N
the DT N
FOF NNP N
study NN N
predicted VBD N
whether IN N
participants NNS N
engaged VBN N
in IN N
high-risk JJ N
sex NN N
. . N

Among IN N
measures NNS N
derived VBN N
from IN N
data NNS N
collected VBN N
at IN N
long-term JJ N
follow-up NN N
, , N
however RB N
, , N
having VBG N
ever RB N
met VBN N
criteria NNS N
for IN N
substance NN N
abuse NN N
or CC N
dependence NN N
predicted VBN N
greater JJR N
likelihood NN N
of IN N
high-risk JJ N
sexual JJ N
behavior NN N
, , N
and CC N
being VBG N
married VBD N
or CC N
being VBG N
in IN N
a DT N
romantic JJ N
relationship NN N
was VBD N
associated VBN N
with IN N
lower JJR N
likelihood NN N
of IN N
high-risk JJ N
sexual JJ N
behavior NN N
. . N

The DT N
findings NNS N
point NN N
to TO N
the DT N
important JJ N
role NN N
of IN N
committed JJ N
relationships NNS N
in IN N
regulating VBG N
sex NN N
risk NN N
behavior NN N
among IN N
this DT N
population NN N
, , N
as RB N
well RB N
as IN N
heightened VBN N
levels NNS N
of IN N
sex NN N
risk NN N
behavior NN N
associated VBN N
with IN N
substance NN N
abuse NN N
or CC N
dependence NN N
. . N

-DOCSTART- -X- O O

Effects NNS N
of IN N
long-term JJ 3_i
vitamin NN 3_i
E NNP 3_i
supplementation NN 3_i
on IN N
cardiovascular JJ N
events NNS N
and CC N
cancer NN N
: : N
a DT N
randomized NN N
controlled VBN N
trial NN N
. . N

CONTEXT NNP N
Experimental NNP N
and CC N
epidemiological JJ N
data NNS N
suggest VBP N
that IN N
vitamin NN 3_i
E NNP 3_i
supplementation NN 3_i
may MD N
prevent VB N
cancer NN N
and CC N
cardiovascular JJ N
events NNS N
. . N

Clinical JJ N
trials NNS N
have VBP N
generally RB N
failed VBN N
to TO N
confirm VB N
benefits NNS N
, , N
possibly RB N
due JJ N
to TO N
their PRP$ N
relatively RB N
short JJ N
duration NN N
. . N

OBJECTIVE UH N
To TO N
evaluate VB N
whether IN N
long-term JJ 3_i
supplementation NN 3_i
with IN 3_i
vitamin JJ 3_i
E NN 3_i
decreases VBZ N
the DT N
risk NN N
of IN N
cancer NN N
, , N
cancer NN N
death NN N
, , N
and CC N
major JJ N
cardiovascular JJ N
events NNS N
. . N

DESIGN NNP N
, , N
SETTING NNP N
, , N
AND NNP N
PATIENTS NNP N
A NNP N
randomized JJ N
, , N
double-blind JJ N
, , N
placebo-controlled JJ N
international JJ N
trial NN N
( ( N
the DT N
initial JJ N
Heart NNP N
Outcomes NNP N
Prevention NNP N
Evaluation NNP N
[ NNP N
HOPE NNP N
] NNP N
trial NN N
conducted VBD N
between IN N
December NNP N
21 CD N
, , N
1993 CD N
, , N
and CC N
April NNP N
15 CD N
, , N
1999 CD N
) ) N
of IN N
patients NNS N
at IN N
least JJS N
55 CD N
years NNS N
old JJ N
with IN N
vascular JJ N
disease NN N
or CC N
diabetes VBZ N
mellitus NN N
was VBD N
extended VBN N
( ( N
HOPE-The NNP N
Ongoing NNP N
Outcomes NNP N
[ NNP N
HOPE-TOO NNP N
] NNP N
) ) N
between IN N
April NNP N
16 CD N
, , N
1999 CD N
, , N
and CC N
May NNP N
26 CD N
, , N
2003 CD N
. . N

Of IN N
the DT N
initial JJ N
267 CD N
HOPE NNP N
centers NNS N
that WDT N
had VBD N
enrolled VBN N
9541 CD N
patients NNS N
, , N
174 CD N
centers NNS N
participated VBN N
in IN N
the DT N
HOPE-TOO NNP N
trial NN N
. . N

Of IN N
7030 CD N
patients NNS N
enrolled VBN N
at IN N
these DT N
centers NNS N
, , N
916 CD N
were VBD N
deceased VBN N
at IN N
the DT N
beginning NN N
of IN N
the DT N
extension NN N
, , N
1382 CD N
refused VBD N
participation NN N
, , N
3994 CD N
continued VBD N
to TO N
take VB N
the DT N
study NN N
intervention NN N
, , N
and CC N
738 CD N
agreed VBD N
to TO N
passive VB N
follow-up NN N
. . N

Median JJ N
duration NN N
of IN N
follow-up NN N
was VBD N
7.0 CD N
years NNS N
. . N

INTERVENTION NNP N
Daily NNP N
dose NN N
of IN N
natural JJ 3_i
source NN 3_i
vitamin NN 3_i
E NNP 3_i
( ( N
400 CD N
IU NNP N
) ) N
or CC N
matching VBG N
placebo NN 7_i
. . N

MAIN NNP N
OUTCOME NNP N
MEASURES NNP N
Primary NNP N
outcomes NNS N
included VBD N
cancer NN N
incidence NN N
, , N
cancer NN N
deaths NNS N
, , N
and CC N
major JJ N
cardiovascular JJ N
events NNS N
( ( N
myocardial JJ N
infarction NN N
, , N
stroke NN N
, , N
and CC N
cardiovascular JJ N
death NN N
) ) N
. . N

Secondary JJ N
outcomes NNS N
included VBD N
heart NN N
failure NN N
, , N
unstable JJ N
angina NN N
, , N
and CC N
revascularizations NNS N
. . N

RESULTS NNP N
Among IN N
all DT N
HOPE NNP N
patients NNS N
, , N
there EX N
were VBD N
no DT N
significant JJ N
differences NNS N
in IN N
the DT N
primary JJ N
analysis NN N
: : N
for IN N
cancer NN N
incidence NN N
, , N
there EX N
were VBD N
552 CD N
patients NNS N
( ( N
11.6 CD N
% NN N
) ) N
in IN N
the DT N
vitamin NN 3_i
E NNP 3_i
group NN N
vs VBD N
586 CD N
( ( N
12.3 CD N
% NN N
) ) N
in IN N
the DT N
placebo NN 7_i
group NN N
( ( N
relative JJ N
risk NN N
[ NNP N
RR NNP N
] NNP N
, , N
0.94 CD N
; : N
95 CD N
% NN N
confidence NN N
interval NN N
[ NNP N
CI NNP N
] NNP N
, , N
0.84-1.06 NNP N
; : N
P NNP N
= NNP N
.30 NNP N
) ) N
; : N
for IN N
cancer NN N
deaths NNS N
, , N
156 CD N
( ( N
3.3 CD N
% NN N
) ) N
vs NN N
178 CD N
( ( N
3.7 CD N
% NN N
) ) N
, , N
respectively RB N
( ( N
RR NNP N
, , N
0.88 CD N
; : N
95 CD N
% NN N
CI NNP N
, , N
0.71-1.09 NNP N
; : N
P NNP N
= NNP N
.24 NNP N
) ) N
; : N
and CC N
for IN N
major JJ N
cardiovascular JJ N
events NNS N
, , N
1022 CD N
( ( N
21.5 CD N
% NN N
) ) N
vs NN N
985 CD N
( ( N
20.6 CD N
% NN N
) ) N
, , N
respectively RB N
( ( N
RR NNP N
, , N
1.04 CD N
; : N
95 CD N
% NN N
CI NNP N
, , N
0.96-1.14 NNP N
; : N
P NNP N
= NNP N
.34 NNP N
) ) N
. . N

Patients NNS N
in IN N
the DT N
vitamin NN 3_i
E NNP 3_i
group NN N
had VBD N
a DT N
higher JJR N
risk NN N
of IN N
heart NN N
failure NN N
( ( N
RR NNP N
, , N
1.13 CD N
; : N
95 CD N
% NN N
CI NNP N
, , N
1.01-1.26 JJ N
; : N
P NNP N
= NNP N
.03 NNP N
) ) N
and CC N
hospitalization NN N
for IN N
heart NN N
failure NN N
( ( N
RR NNP N
, , N
1.21 CD N
; : N
95 CD N
% NN N
CI NNP N
, , N
1.00-1.47 JJ N
; : N
P NNP N
= NNP N
.045 NNP N
) ) N
. . N

Similarly RB N
, , N
among IN N
patients NNS N
enrolled VBN N
at IN N
the DT N
centers NNS N
participating VBG N
in IN N
the DT N
HOPE-TOO NNP N
trial NN N
, , N
there EX N
were VBD N
no DT N
differences NNS N
in IN N
cancer NN N
incidence NN N
, , N
cancer NN N
deaths NNS N
, , N
and CC N
major JJ N
cardiovascular JJ N
events NNS N
, , N
but CC N
higher JJR N
rates NNS N
of IN N
heart NN N
failure NN N
and CC N
hospitalizations NNS N
for IN N
heart NN N
failure NN N
. . N

CONCLUSION NNP N
In IN N
patients NNS N
with IN N
vascular JJ N
disease NN N
or CC N
diabetes VBZ N
mellitus NNS N
, , N
long-term JJ 3_i
vitamin NN 3_i
E NNP 3_i
supplementation NN 3_i
does VBZ N
not RB N
prevent VB N
cancer NN N
or CC N
major JJ N
cardiovascular JJ N
events NNS N
and CC N
may MD N
increase VB N
the DT N
risk NN N
for IN N
heart NN N
failure NN N
. . N

-DOCSTART- -X- O O

Transdermal NNP N
scopolamine NN 3_i
patch NN N
in IN N
addition NN N
to TO N
ondansetron VB 3_i
for IN N
postoperative JJ N
nausea NN N
and CC N
vomiting VBG N
prophylaxis NN N
in IN N
patients NNS N
undergoing VBG N
ambulatory JJ N
cosmetic JJ N
surgery NN N
. . N

STUDY NNP N
OBJECTIVE NNP N
To TO N
determine VB N
the DT N
efficacy NN N
of IN N
transdermal JJ N
scopolamine NN 3_i
in IN N
addition NN N
to TO N
ondansetron VB 3_i
in IN N
decreasing VBG N
the DT N
incidence NN N
of IN N
postoperative JJ N
nausea NN N
and CC N
vomiting NN N
( ( N
PONV NNP N
) ) N
. . N

DESIGN NNP N
Randomized NNP N
controlled VBD N
trial NN N
. . N

SETTING NN N
Academic NNP N
hospital NN N
. . N

PATIENTS CC N
126 CD N
ASA NNP N
physical JJ N
status NN N
I PRP N
and CC N
II NNP N
patients NNS N
undergoing VBG N
outpatient JJ N
plastic NN N
surgery NN N
with IN N
three CD N
or CC N
more JJR N
risk NN N
factors NNS N
for IN N
PONV NNP N
. . N

INTERVENTIONS NNP N
Patients NNPS N
were VBD N
randomly RB N
assigned VBN N
to TO N
one CD N
of IN N
two CD N
groups NNS N
to TO N
receive VB N
( ( N
Group NNP N
1 CD N
) ) N
a DT N
transdermal JJ N
scopolamine NN 3_i
( ( N
TDS NNP N
) ) N
patch NN N
or CC N
( ( N
Group NNP N
2 CD N
) ) N
, , N
a DT N
placebo JJ 7_i
patch NN N
two CD N
hours NNS N
before IN N
surgery NN N
. . N

MEASUREMENTS NNP N
Occurrence NNP N
of IN N
vomiting VBG N
, , N
severity NN N
of IN N
nausea NN N
using VBG N
a DT N
visual JJ N
analog NN N
scale NN N
( ( N
VAS NNP N
) ) N
, , N
rescue JJ N
medication NN N
, , N
pain VBP N
intensity NN N
and CC N
pain NN N
medications NNS N
, , N
and CC N
side JJ N
effects NNS N
were VBD N
recorded VBN N
every DT N
hour NN N
until IN N
discharge NN N
from IN N
hospital NN N
, , N
then RB N
every DT N
4 CD N
hours NNS N
thereafter RB N
for IN N
a DT N
total NN N
of IN N
24 CD N
hours NNS N
. . N

MAIN NNP N
RESULTS NNP N
A NNP N
statistically RB N
significant JJ N
reduction NN N
in IN N
postoperative JJ N
nausea NN N
between IN N
8 CD N
and CC N
24 CD N
hours NNS N
in IN N
patients NNS N
receiving VBG N
TDS NNP N
was VBD N
noted VBN N
. . N

CONCLUSIONS NNP N
Transdermal NNP N
scopolamine NN 3_i
in IN N
addition NN N
to TO N
ondansetron VB N
benefits NNS N
patients NNS N
at IN N
high JJ N
risk NN N
for IN N
PONV NNP N
undergoing JJ N
outpatient NN N
plastic NN N
surgery NN N
for IN N
up IN N
to TO N
20 CD N
hours NNS N
after IN N
surgery NN N
. . N

-DOCSTART- -X- O O

Migration NN N
of IN N
the DT N
acetabular JJ N
component NN N
: : N
effect NN N
of IN N
cement NN 2_i
pressurization NN 2_i
and CC N
significance NN N
of IN N
early JJ N
radiolucency NN N
: : N
a DT N
randomized JJ N
5-year JJ N
study NN N
using VBG N
radiostereometry NN 6_i
. . 6_i

BACKGROUND NNP N
Cementing NNP N
technique NN N
is VBZ N
a DT N
crucial JJ N
factor NN N
in IN N
prosthesis NN N
fixation NN N
. . N

No DT N
randomized JJ N
studies NNS N
have VBP N
been VBN N
published VBN N
, , N
however RB N
, , N
comparing VBG N
the DT N
outcome NN N
of IN N
conventional JJ N
fingerpacking NN N
with IN N
the DT N
outcome NN N
of IN N
pressurization NN N
of IN N
the DT N
cement NN N
prior RB N
to TO N
cup VB N
insertion NN N
. . N

PATIENTS NNP N
AND CC N
METHODS NNP N
We PRP N
randomized VBD N
50 CD N
THAs NNP N
to TO N
either VB N
fingerpacking NN 6_i
or CC N
sequential JJ 2_i
pressurization NN 2_i
( ( 6_i
including VBG 6_i
individual JJ 6_i
pressurization NN 6_i
of IN 6_i
each DT 6_i
anchorage NN 6_i
hole NN 6_i
) ) 6_i
and CC N
followed VBD N
the DT N
patients NNS N
with IN N
RSA NNP 6_i
for IN N
5 CD N
years NNS N
. . N

The DT N
penetration NN N
of IN N
cement NN N
into IN N
the DT N
anchorage NN N
holes NNS N
was VBD N
measured VBN N
on IN N
digital JJ N
radiographs NN N
. . N

Postoperative JJ N
radiolucent NN N
lines NNS N
around IN N
the DT N
cup NN N
were VBD N
correlated VBN N
to TO N
later RBR N
RSA NNP N
results NNS N
. . N

For IN N
clinical JJ N
evaluation NN N
, , N
we PRP N
used VBD N
SF-36 NNP N
and CC N
HHS NNP N
. . N

RESULTS VB N
The DT N
pressurized JJ N
group NN N
of IN N
THAs NNP N
was VBD N
more RBR N
stable JJ N
regarding VBG N
changes NNS N
in IN N
inclination NN N
. . N

We PRP N
found VBD N
no DT N
other JJ N
difference NN N
in IN N
the DT N
migratory NN N
behavior NN N
. . N

The DT N
cement NN N
penetration NN N
into IN N
the DT N
anchorage NN N
holes NNS N
was VBD N
deeper RBR N
with IN N
the DT N
pressurization NN N
technique NN N
than IN N
with IN N
fingerpacking NN N
. . N

For IN N
the DT N
whole JJ N
group NN N
taken VBN N
together RB N
, , N
there EX N
was VBD N
a DT N
strong JJ N
relation NN N
between IN N
the DT N
presence NN N
of IN N
radiolucent NN N
lines NNS N
as IN N
measured VBN N
on IN N
the DT N
postoperative JJ N
radiograph NN N
and CC N
later JJ N
migration NN N
observed VBN N
by IN N
RSA NNP N
at IN N
2 CD N
and CC N
5 CD N
years NNS N
. . N

INTERPRETATION NNP N
Pressurization NNP N
of IN N
the DT N
cement NN N
produced VBD N
better JJR N
cement NN N
penetration NN N
and CC N
increased VBD N
the DT N
cup NN N
stability NN N
in IN N
terms NNS N
of IN N
changes NNS N
in IN N
inclination NN N
. . N

Early JJ N
findings NNS N
of IN N
radiolucent NN N
lines NNS N
can MD N
predict VB N
later RB N
unfavorable JJ N
cup NN N
migration NN N
. . N

-DOCSTART- -X- O O

Randomized VBN N
trial NN N
of IN N
tailored JJ N
skin NN N
cancer NN N
prevention NN N
for IN N
children NNS N
: : N
the DT N
Project NNP N
SCAPE NNP N
family NN N
study NN N
. . N

This DT N
study NN N
evaluated VBD N
a DT N
tailored VBN 4_i
intervention NN 4_i
to TO N
promote VB 2_i
sun NN 2_i
protection NN 2_i
in IN N
parents NNS N
and CC N
their PRP$ N
children NNS N
, , N
hypothesizing VBG N
that IN N
the DT N
tailored VBN N
intervention NN N
would MD N
lead VB N
to TO N
improved JJ N
skin NN N
cancer NN N
prevention NN N
behaviors NNS N
compared VBN N
to TO N
generic JJ N
materials NNS N
. . N

Families NNS N
were VBD N
recruited VBN N
through IN N
schools NNS N
and CC N
community NN N
centers NNS N
and CC N
were VBD N
included VBN N
if IN N
there EX N
was VBD N
1 CD N
child NN N
in IN N
Grades NNP N
1-3 JJ N
at IN N
moderate JJ N
to TO N
high JJ N
risk NN N
for IN N
skin JJ N
cancer NN N
. . N

Participants NNS N
were VBD N
randomized VBN N
into IN N
one CD N
of IN N
two CD N
intervention NN N
groups NNS N
: : N
a DT N
tailored JJ 4_i
intervention NN 4_i
, , 4_i
in IN 4_i
which WDT 4_i
they PRP 4_i
received VBD 4_i
personalized JJ 4_i
skin NN 4_i
cancer NN 4_i
education NN 4_i
through IN 4_i
the DT 4_i
mail NN 4_i
; : 4_i
or CC 4_i
a DT 4_i
control NN 4_i
group NN 4_i
who WP 4_i
received VBD 4_i
generic JJ 4_i
skin NN 4_i
cancer NN 4_i
information NN 4_i
materials NNS 4_i
. . 4_i

Before IN N
and CC N
after IN N
intervention NN N
, , N
parents NNS N
completed VBD N
questionnaires NNS N
about IN N
their PRP$ N
and CC N
their PRP$ N
children NNS N
's POS N
skin NN N
cancer NN N
risk NN N
and CC N
prevention NN N
knowledge NN N
and CC N
behaviors NNS N
. . N

Parents NNS N
also RB N
completed VBD N
4-day JJ N
sun NN N
exposure NN N
and CC N
protection NN N
diaries NNS N
for IN N
their PRP$ N
child NN N
and CC N
themselves PRP N
. . N

Tailored VBN N
group NN N
participants NNS N
demonstrated VBD N
significantly RB N
greater JJR N
positive JJ N
changes NNS N
in IN N
prevention NN N
behavior NN N
after IN N
the DT N
intervention NN N
, , N
including VBG N
children NNS N
's POS N
use NN N
of IN N
sunscreen NN N
, , N
shirts NNS N
, , N
and CC N
hats NNS N
, , N
and CC N
parents NNS N
' POS N
use NN N
of IN N
shade NN N
, , N
and CC N
skin JJ N
examinations NNS N
. . N

Effect JJ N
sizes NNS N
were VBD N
small JJ N
and CC N
perceived JJ N
benefits NNS N
and CC N
social JJ N
norms NNS N
mediated VBN N
intervention NN N
effects NNS N
. . N

Findings NNS N
from IN N
this DT N
study NN N
support VBD N
the DT N
efficacy NN N
of IN N
focusing VBG N
tailored VBN N
communications NNS N
to TO N
families NNS N
in IN N
order NN N
to TO N
change VB N
skin JJ N
cancer NN N
prevention NN N
practices NNS N
in IN N
young JJ N
children NNS N
. . N

-DOCSTART- -X- O O

Allogeneic NNP 3_i
marrow NN 3_i
transplantation NN 3_i
in IN N
patients NNS N
with IN N
chronic JJ N
myeloid NN N
leukemia NN N
in IN N
the DT N
chronic JJ N
phase NN N
: : N
a DT N
randomized JJ N
trial NN N
of IN N
two CD N
irradiation NN N
regimens NNS N
. . N

A DT N
randomized JJ N
trial NN N
was VBD N
performed VBN N
to TO N
compare VB N
two CD N
regimens NNS N
of IN N
total JJ 6_i
body NN 6_i
irradiation NN 6_i
in IN N
patients NNS N
with IN N
chronic JJ N
myeloid NN N
leukemia NN N
treated VBN N
by IN N
allogeneic JJ 3_i
marrow NN 3_i
transplantation NN 3_i
while IN N
in IN N
the DT N
chronic JJ N
phase NN N
. . N

All DT N
patients NNS N
received VBD N
cyclophosphamide JJ 3_i
120 CD N
mg/kg NN N
followed VBN N
by IN N
total JJ 6_i
body NN 6_i
irradiation NN 6_i
and CC N
marrow NN 3_i
from IN 3_i
HLA-identical JJ 3_i
siblings NNS 3_i
. . N

Cyclosporine NNP 3_i
and CC N
methotrexate NN 3_i
were VBD N
used VBN N
for IN N
prophylaxis NN N
against IN N
acute JJ N
graft-versus-host JJ N
disease NN N
. . N

Fifty-seven JJ N
patients NNS N
were VBD N
randomized VBN N
to TO N
receive VB N
2.0 CD N
Gy NNP N
fractions NNS N
of IN N
irradiation NN 6_i
daily NN N
for IN N
6 CD N
days NNS N
and CC N
59 CD N
were VBD N
randomized VBN N
to TO N
receive VB N
2.25 CD N
Gy NNP N
fractions NNS N
daily RB N
for IN N
7 CD N
days NNS N
. . N

The DT N
probabilities NNS N
of IN N
relapse NN N
at IN N
4 CD N
years NNS N
were VBD N
0.25 CD N
for IN N
the DT N
12.0 CD N
Gy NNP N
group NN N
and CC N
0.00 CD N
for IN N
the DT N
15.75 CD N
Gy NNP N
group NN N
( ( N
P NNP N
= NNP N
.008 NNP N
) ) N
. . N

The DT N
actuarial JJ N
probabilities NNS N
of IN N
survival NN N
and CC N
relapse-free JJ N
survival NN N
at IN N
4 CD N
years NNS N
were VBD N
0.60 CD N
and CC N
0.58 CD N
among IN N
the DT N
patients NNS N
who WP N
received VBD N
12.0 CD N
Gy NNP N
compared VBN N
with IN N
0.66 CD N
and CC N
0.66 CD N
for IN N
those DT N
who WP N
received VBD N
15.75 CD N
Gy NNP N
. . N

The DT N
4-year JJ N
probabilities NNS N
of IN N
transplant-related JJ N
mortality NN N
were VBD N
0.24 CD N
and CC N
0.34 CD N
respectively RB N
( ( N
P NNP N
= NNP N
.13 NNP N
) ) N
while IN N
the DT N
probability NN N
of IN N
moderate JJ N
to TO N
severe VB N
acute JJ N
graft-versus-host JJ N
disease NN N
was VBD N
0.33 CD N
for IN N
the DT N
12.0 CD N
Gy NNP N
group NN N
and CC N
0.44 CD N
for IN N
the DT N
15.75 CD N
Gy NNP N
group NN N
( ( N
P NNP N
= NNP N
.15 NNP N
) ) N
. . N

The DT N
lower JJR N
relapse NN N
probability NN N
in IN N
the DT N
patients NNS N
receiving VBG N
the DT N
higher JJR N
dose NN N
of IN N
total JJ 6_i
body NN 6_i
irradiation NN 6_i
did VBD N
not RB N
result VB N
in IN N
improved JJ N
survival NN N
because IN N
mortality NN N
from IN N
causes VBZ N
other JJ N
than IN N
relapse NN N
was VBD N
increased VBN N
. . N

-DOCSTART- -X- O O

Pedantic JJ 5_i
speaking NN 5_i
style NN N
differentiates VBZ N
Asperger NNP N
syndrome NN N
from IN N
high-functioning JJ N
autism NN N
. . N

Asperger NNP N
syndrome NN N
( ( N
AS IN N
) ) N
is VBZ N
a DT N
pervasive JJ N
developmental NN N
disorder NN N
recently RB N
introduced VBD N
as IN N
a DT N
new JJ N
diagnostic JJ N
category NN N
in IN N
the DT N
ICD-10 NNP N
and CC N
the DT N
DSM-IV NNP N
. . N

Along IN N
with IN N
motor NN N
clumsiness NN N
, , N
pedantic JJ 5_i
speech NN 5_i
has VBZ N
been VBN N
proposed VBN N
as IN N
a DT N
clinical JJ N
feature NN N
of IN N
AS NNP N
. . N

However RB N
, , N
few JJ N
attempts NNS N
have VBP N
been VBN N
made VBN N
to TO N
define VB N
and CC N
measure VB N
this DT N
symptom NN N
. . N

We PRP N
studied VBD N
17 CD N
patients NNS N
with IN N
AS NNP N
( ( N
ICD-10 NNP N
; : N
14 CD N
male NN N
, , N
3 CD N
female NN N
; : N
mean JJ N
age NN N
16.4 CD N
years NNS N
, , N
mean JJ N
full-scale JJ N
IQ NNP N
97 CD N
) ) N
and CC N
compared VBN N
them PRP N
with IN N
a DT N
control NN N
group NN N
of IN N
13 CD N
patients NNS N
with IN N
normal-intelligence JJ N
autism NN N
or CC N
high-functioning JJ N
autism NN N
( ( N
HFA NNP N
) ) N
( ( N
ICD-10/DSM-III-R NNP N
; : N
12 CD N
male NN N
, , N
1 CD N
female NN N
; : N
mean JJ N
age NN N
15.5 CD N
years NNS N
, , N
mean JJ N
full-scale JJ N
IQ NNP N
81.2 CD N
) ) N
. . N

An DT N
operational JJ N
definition NN N
of IN N
pedantic JJ N
speech NN N
was VBD N
formulated VBN N
and CC N
a DT N
rating NN N
scale NN N
devised VBD N
. . N

13 CD N
( ( N
76 CD N
% NN N
) ) N
of IN N
the DT N
AS NNP N
patients NNS N
were VBD N
rated VBN N
as IN N
pedantic JJ 5_i
compared VBN N
to TO N
4 CD N
( ( N
31 CD N
% NN N
) ) N
of IN N
the DT N
HFA NNP N
group NN N
( ( N
chi JJ N
2 CD N
= JJ N
6.3 CD N
; : N
p NN N
= NNP N
.01 NNP N
) ) N
. . N

Results VB N
suggest JJS N
that IN N
pedantic JJ 5_i
speech NN 5_i
is VBZ N
common JJ N
in IN N
AS NNP N
and CC N
may MD N
help VB N
differentiate VB N
AS IN N
from IN N
high-functioning JJ N
autism NN N
. . N

-DOCSTART- -X- O O

Chemotherapy NN N
of IN N
large JJ N
bowel NN N
carcinoma NN N
-- : N
fluorouracil NN 3_i
( ( 3_i
FU NNP 3_i
) ) 3_i
+ VBP N
hydroxyurea NN 3_i
( ( 3_i
HU NNP 3_i
) ) 3_i
vs. FW N
methyl-CCNU NN 3_i
, , N
oncovin NN 3_i
, , N
fluorouracil NN 3_i
, , N
and CC N
streptozotocin NN 3_i
( ( 3_i
MOF-Strep NNP 3_i
) ) 3_i
. . N

An DT N
Eastern JJ N
Cooperative NNP N
Oncology NNP N
Group NNP N
study NN N
. . N

In IN N
this DT N
prospective JJ N
randomized NN N
study NN N
of IN N
initial JJ N
chemotherapy NN N
for IN N
advanced JJ N
measurable JJ N
metastatic JJ N
large JJ N
bowel NN N
carcinoma NN N
, , N
the DT N
response NN N
rate NN N
was VBD N
6/32 CD N
( ( N
19 CD N
% NN N
) ) N
for IN N
FU NNP N
+ NNP N
HU NNP N
and CC N
5/32 CD N
( ( N
16 CD N
% NN N
) ) N
for IN N
MOF-Strep NNP N
; : N
the DT N
estimated JJ N
median JJ N
survival NN N
is VBZ N
43 CD N
weeks NNS N
for IN N
both DT N
treatments NNS N
. . N

Patients NNS N
who WP N
received VBD N
MOF-Strep NNP N
experienced VBD N
substantially RB N
greater JJR N
vomiting VBG N
and CC N
hematologic JJ N
toxicity NN N
than IN N
patients NNS N
who WP N
received VBD N
FU NNP N
+ NNP N
HU NNP N
( ( N
p NN N
less JJR N
than IN N
0.001 CD N
) ) N
. . N

-DOCSTART- -X- O O

LNH-84 JJ N
regimen NNS N
: : N
a DT N
multicenter NN N
study NN N
of IN N
intensive JJ N
chemotherapy NN N
in IN N
737 CD N
patients NNS N
with IN N
aggressive JJ N
malignant JJ N
lymphoma NN N
. . N

From IN N
July NNP N
1984 CD N
to TO N
September NNP N
1987 CD N
, , N
737 CD N
patients NNS N
with IN N
aggressive JJ N
malignant JJ N
lymphoma NN N
( ( N
ML NNP N
) ) N
were VBD N
treated VBN N
by IN N
an DT N
intensive JJ 3_i
regimen NNS 3_i
( ( 3_i
LNH-84 NNP 3_i
) ) 3_i
comprising VBG N
three CD N
or CC N
four CD N
courses NNS N
of IN N
doxorubicin NN 3_i
, , N
75 CD N
mg/m2 NN N
; : N
cyclophosphamide NN 3_i
, , N
1,200 CD N
mg/m2 NN N
; : N
vindesine NN 3_i
, , N
2 CD N
mg/m2 NN N
x NN N
2 CD N
; : N
bleomycin NN 3_i
, , N
10 CD N
mg NN N
x NN N
2 CD N
; : N
and CC N
prednisolone NN 3_i
, , N
60 CD N
mg/m2 NN N
x NN N
5 CD N
( ( N
ACVB NNP N
) ) N
, , N
consolidation NN N
with IN N
high-dose JJ N
methotrexate NN 3_i
, , N
ifosfamide NN 3_i
, , N
etoposide RB 3_i
, , N
asparaginase NN 3_i
, , N
and CC N
cytarabine NN 3_i
, , N
and CC N
a DT N
randomized VBN N
late JJ N
intensification NN N
with IN N
two CD N
courses NNS N
of IN N
cytarabine NN 3_i
, , N
cyclophosphamide NN 3_i
, , N
teniposide NN 3_i
, , N
bleomycin NN 3_i
, , N
and CC N
prednisone NN 3_i
( ( N
AraCVmB NNP N
) ) N
. . N

Four CD N
hundred VBD N
forty-two JJ N
patients NNS N
had VBD N
intermediate-grade JJ N
ML NNP N
, , N
221 CD N
highgrade NN N
ML NNP N
, , N
and CC N
74 CD N
unclassified JJ N
ML NNP N
. . N

Most JJS N
of IN N
the DT N
patients NNS N
had VBD N
advanced JJ N
disease NN N
: : N
stage NN N
IIE NNP N
( ( N
23 CD N
% NN N
) ) N
, , N
III NNP N
( ( N
13 CD N
% NN N
) ) N
, , N
or CC N
IV NNP N
( ( N
47 CD N
% NN N
) ) N
; : N
38 CD N
% NN N
disseminated JJ N
nodes NNS N
; : N
38 CD N
% NN N
two CD N
or CC N
more JJR N
extranodal JJ N
sites NNS N
; : N
and CC N
41 CD N
% NN N
a DT N
tumoral JJ N
mass NN N
greater JJR N
than IN N
10 CD N
cm NN N
. . N

Five CD N
hundred VBD N
fifty-three JJ N
patients NNS N
( ( N
75 CD N
% NN N
) ) N
went VBD N
into IN N
complete JJ N
remission NN N
( ( N
CR NNP N
) ) N
, , N
63 CD N
( ( N
9 CD N
% NN N
) ) N
into IN N
partial JJ N
remission NN N
, , N
62 CD N
( ( N
8 CD N
% NN N
) ) N
failed VBD N
to TO N
respond VB N
, , N
and CC N
59 CD N
( ( N
8 CD N
% NN N
) ) N
died VBD N
during IN N
ACVB NNP N
courses NNS N
, , N
17 CD N
of IN N
them PRP N
from IN N
progression NN N
of IN N
the DT N
disease NN N
. . N

With IN N
a DT N
median JJ N
follow-up NN N
of IN N
23 CD N
months NNS N
, , N
the DT N
estimated VBN N
2-year JJ N
overall JJ N
survival NN N
time NN N
to TO N
failure NN N
( ( N
TTF NNP N
) ) N
, , N
and CC N
time NN N
to TO N
relapse VB N
( ( N
TTR NNP N
) ) N
survival NN N
are VBP N
67 CD N
% NN N
, , N
56 CD N
% NN N
, , N
and CC N
67 CD N
% NN N
, , N
respectively RB N
. . N

Patients NNS N
receiving VBG N
a DT N
late JJ N
intensification NN N
had VBD N
the DT N
same JJ N
relapse NN N
rate NN N
as IN N
the DT N
other JJ N
patients NNS N
. . N

A DT N
persistent JJ N
fibronecrotic JJ N
mass NN N
was VBD N
found VBN N
in IN N
150 CD N
patients NNS N
( ( N
20 CD N
% NN N
) ) N
and CC N
did VBD N
not RB N
influence VB N
the DT N
relapse NN N
rate NN N
. . N

Toxicity NNP N
was VBD N
mainly RB N
neutropenia JJ N
and CC N
infection NN N
during IN N
the DT N
ACVB NNP N
courses NNS N
, , N
with IN N
40 CD N
patients NNS N
( ( N
5 CD N
% NN N
) ) N
dying VBG N
from IN N
septic JJ N
complications NNS N
while IN N
responding VBG N
to TO N
treatment NN N
. . N

Fifty-three JJ N
percent NN N
of IN N
the DT N
patients NNS N
had VBD N
a DT N
neutropenia NN N
less JJR N
than IN N
0.500 CD N
x JJ N
10 CD N
( ( N
9 CD N
) ) N
/L NN N
, , N
58 CD N
% NN N
fever NN N
( ( N
6 CD N
% NN N
grade JJ N
4 CD N
) ) N
, , N
and CC N
49 CD N
% NN N
a DT N
documented JJ N
infection NN N
( ( N
8 CD N
% NN N
grade JJ N
4 CD N
) ) N
. . N

These DT N
results NNS N
obtained VBD N
with IN N
the DT N
LNH-84 JJ N
regimen NNS N
demonstrate VBP N
that IN N
this DT N
therapeutic JJ N
scheme NN N
is VBZ N
an DT N
effective JJ N
treatment NN N
for IN N
aggressive JJ N
ML NNP N
. . N

-DOCSTART- -X- O O

Bitewing NNP N
film NN N
quality NN N
: : N
a DT N
clinical JJ N
comparison NN N
of IN N
the DT N
loop NN 1_i
vs. FW N
holder NN 1_i
techniques NNS 1_i
. . N

OBJECTIVE NNP N
To TO N
compare VB N
in IN N
vivo JJ N
bitewing NN N
film NN N
quality NN N
using VBG N
the DT N
holder NN 1_i
versus IN 1_i
the DT 1_i
paper NN 1_i
loop NN 1_i
technique NN 1_i
. . N

METHOD NNP N
AND CC N
MATERIALS NNP N
Four NNP N
bitewing VBG N
films NNS N
were VBD N
taken VBN N
from IN N
the DT N
right NN N
and CC N
left VBD N
premolar JJ N
and CC N
molar JJ N
regions NNS N
of IN N
45 CD N
dental JJ N
students NNS N
using VBG N
both DT N
the DT N
bitewing NN N
holder NN 1_i
and CC 1_i
paper NN 1_i
loop NN 1_i
techniques NNS 1_i
. . N

A DT N
total NN N
of IN N
360 CD N
films NNS N
were VBD N
taken VBN N
and CC N
assessed VBN N
by IN N
an DT N
experienced JJ N
practitioner NN N
not RB N
apprised VBN N
of IN N
the DT N
bitewing NN 1_i
technique NN 1_i
used VBN N
. . N

Of IN N
interest NN N
were VBD N
: : N
( ( N
1 CD N
) ) N
the DT N
number NN N
of IN N
overlaps NNS N
and CC N
the DT N
percentage NN N
of IN N
teeth NNS N
showing VBG N
the DT N
alveolar JJ N
crest NN N
; : N
( ( N
2 CD N
) ) N
proper NN N
film NN N
positioning NN N
; : N
and CC N
( ( N
3 CD N
) ) N
the DT N
percentage NN N
of IN N
cone NN N
cutting NN N
. . N

A DT N
Poisson NNP N
regression NN N
using VBG N
generalized VBN N
estimating VBG N
equations NNS N
( ( N
GEEs NNP N
) ) N
was VBD N
used VBN N
to TO N
estimate VB N
the DT N
difference NN N
in IN N
overlap NN N
between IN N
the DT N
two CD N
techniques NNS N
. . N

For IN N
proper JJ N
positioning NN N
and CC N
cone NN N
cutting NN N
, , N
logistic JJ N
regressions NNS N
using VBG N
GEEs NNP N
were VBD N
used VBN N
. . N

RESULTS VB N
The DT N
average JJ N
number NN N
of IN N
horizontal JJ N
overlaps NNS N
for IN N
the DT N
loop NN 1_i
and CC N
holder NN 1_i
techniques NNS 1_i
at IN N
the DT N
right JJ N
premolar NN N
, , N
right JJ N
molar NN N
, , N
left VBD N
premolar JJ N
, , N
and CC N
left VBD N
molar NN N
were VBD N
1.64 CD N
, , N
2.11 CD N
, , N
2.16 CD N
, , N
2.78 CD N
, , N
and CC N
1.64 CD N
, , N
2.00 CD N
, , N
2.00 CD N
, , N
2.18 CD N
, , N
respectively RB N
. . N

The DT N
loop NN 1_i
technique NN 1_i
was VBD N
1.11 CD N
times NNS N
more RBR N
likely JJ N
to TO N
cause VB N
overlapping VBG N
than IN N
the DT N
holder NN 1_i
technique NN 1_i
. . 1_i

The DT N
highest JJS N
percentage NN N
of IN N
teeth NNS N
showing VBG N
the DT N
alveolar JJ N
crest NN N
by IN N
the DT N
loop NN 1_i
technique NN 1_i
was VBD N
97.8 CD N
% NN N
in IN N
the DT N
mandibular JJ N
second JJ N
premolar NN N
and CC N
first JJ N
molar NN N
. . N

With IN N
respect NN N
to TO N
film NN N
positioning NN N
, , N
the DT N
loop NN 1_i
technique NN 1_i
was VBD N
1.12 CD N
times NNS N
more RBR N
likely JJ N
to TO N
cause VB N
improper JJ N
positioning NN N
than IN N
the DT N
holder NN 1_i
technique NN 1_i
. . 1_i

Both DT N
techniques NNS N
demonstrated VBN N
minimal JJ N
cone NN N
cutting NN N
( ( N
1 CD N
in IN N
the DT N
loop NN N
versus NN N
0 CD N
in IN N
the DT N
holder NN N
) ) N
. . N

CONCLUSION VB N
The DT N
quality NN N
of IN N
bitewing VBG N
films NNS N
taken VBN N
by IN N
the DT N
loop NN 1_i
and CC 1_i
holder NN 1_i
techniques NNS 1_i
was VBD N
not RB N
significantly RB N
different JJ N
. . N

-DOCSTART- -X- O O

Comparative JJ N
drug NN N
effects NNS N
and CC N
abuse NN N
liability NN N
of IN N
lorazepam NN 3_i
, , N
buspirone NN 3_i
, , N
and CC N
secobarbital NN 3_i
in IN N
nondependent JJ N
subjects NNS N
. . N

The DT N
pharmacologic JJ N
effects NNS N
of IN N
lorazepam NN 3_i
( ( N
2 CD N
mg NN N
) ) N
, , N
buspirone NN 3_i
( ( N
20 CD N
mg NN N
, , N
10 CD N
mg NN N
) ) N
, , N
secobarbital JJ 3_i
( ( N
100 CD N
mg NN N
) ) N
, , N
and CC N
placebo NN 7_i
were VBD N
compared VBN N
in IN N
15 CD N
male NN N
, , N
experienced VBD N
, , N
intermittent JJ N
nontherapeutic JJ N
drug NN N
users NNS N
. . N

All DT N
drugs NNS N
produced VBD N
a DT N
drug NN N
effect NN N
, , N
however RB N
, , N
buspirone RB 3_i
20 CD N
mg NN N
was VBD N
significantly RB N
less JJR N
liked JJ N
than IN N
were VBD N
lorazepam JJ 3_i
, , N
secobarbital JJ 3_i
, , N
or CC N
buspirone RB 3_i
10 CD N
mg NN N
( ( N
p NN N
less JJR N
than IN N
.05 NN N
) ) N
but CC N
not RB N
placebo VB 7_i
. . 7_i

Lorazepam NNP 3_i
was VBD N
liked VBN N
better RBR N
than IN N
were VBD N
other JJ N
drugs NNS N
only RB N
at IN N
1 CD N
hour NN N
and CC N
only RB N
compared VBN N
with IN N
buspirone NN 3_i
20 CD N
and CC N
placebo NN 7_i
. . 7_i

Compared VBN N
with IN N
other JJ N
drugs NNS N
, , N
lorazepam JJ 3_i
drug NN N
effects NNS N
were VBD N
greater JJR N
and CC N
resulted VBD N
in IN N
more RBR N
prolonged JJ N
impairment NN N
of IN N
a DT N
motor NN N
tracking VBG N
task NN N
, , N
standing VBG N
steadiness NN N
, , N
and CC N
memory NN N
. . N

Buspirone CD 3_i
20 CD N
mg NNS N
significantly RB N
impaired JJ N
memory NN N
at IN N
1 CD N
hour NN N
compared VBN N
with IN N
placebo NN 3_i
. . 3_i

Subjects NNS N
were VBD N
more RBR N
likely JJ N
to TO N
identify VB N
buspirone NN 3_i
as IN N
unfamiliar JJ N
. . N

Because IN N
buspirone NN 3_i
20 CD N
mg NN N
was VBD N
less JJR N
liked JJ N
than IN N
were VBD N
other JJ N
drugs NNS N
, , N
dose JJ N
escalation NN N
as IN N
part NN N
of IN N
drug NN N
abuse NN N
is VBZ N
not RB N
likely JJ N
to TO N
occur VB N
. . N

Lorazepam NNP 3_i
also RB N
was VBD N
not RB N
particularly RB N
liked VBN N
and CC N
was VBD N
not RB N
different JJ N
from IN N
placebo NN 7_i
on IN N
most JJS N
subjective JJ N
abuse-relevant JJ N
measures NNS N
. . N

-DOCSTART- -X- O O

Learning VBG N
about IN N
the DT N
equal JJ N
sign NN N
: : N
does VBZ N
comparing VBG N
with IN N
inequality NN N
symbols NNS N
help VB N
? . N
This DT N
study NN N
investigated VBD N
whether IN N
instruction NN 6_i
that WDT 6_i
involves VBZ 6_i
comparing VBG 6_i
the DT 6_i
equal JJ 5_i
sign NN 5_i
with IN 6_i
other JJ 6_i
relational JJ 6_i
symbols NNS 6_i
is VBZ N
more RBR N
effective JJ N
at IN N
imparting VBG N
a DT N
relational JJ N
interpretation NN N
of IN N
the DT N
equal JJ 5_i
sign NN 5_i
than IN N
instruction NN 6_i
about IN 6_i
the DT 6_i
equal JJ 5_i
sign NN 5_i
alone RB 6_i
. . N

Third- JJ N
and CC N
fourth-grade JJ N
students NNS N
in IN N
a DT N
comparing NN 4_i
symbols NNS 4_i
group NN 4_i
learned VBD 4_i
about IN 4_i
the DT 4_i
greater JJR 4_i
than IN 4_i
, , 4_i
less JJR 4_i
than IN 4_i
, , 4_i
and CC 4_i
equal JJ 5_i
signs NNS 5_i
and CC 4_i
had VBD 4_i
the DT 4_i
opportunity NN 4_i
to TO 4_i
compare VB 4_i
the DT 4_i
inequality NN 4_i
symbols VBZ 4_i
with IN 4_i
the DT 4_i
equal JJ 5_i
sign NN 5_i
. . N

Students NNS N
in IN N
an DT N
equal JJ 5_i
sign NN 5_i
group NN 4_i
learned VBD 4_i
about IN 4_i
the DT 4_i
equal JJ 5_i
sign NN 5_i
only RB 4_i
. . 4_i

A NNP N
third JJ N
group NN N
of IN N
students NNS N
served VBD N
as IN N
a DT N
control NN 7_i
group NN 7_i
. . N

Three CD N
aspects NNS N
of IN N
students NNS N
' POS N
knowledge NN N
were VBD N
assessed VBN N
before IN N
and CC N
after IN N
the DT N
lesson NN N
: : N
( ( N
a DT N
) ) N
conceptual JJ N
understanding NN N
of IN N
the DT N
equal JJ N
sign NN N
, , N
( ( N
b NN N
) ) N
equation NN N
encoding NN N
, , N
and CC N
( ( N
c NN N
) ) N
problem NN N
solving VBG N
. . N

Students NNS N
in IN N
the DT N
comparing NN N
symbols NNS N
group NN N
showed VBD N
greater JJR N
gains NNS N
in IN N
conceptual JJ N
understanding NN N
from IN N
pretest NN N
to TO N
posttest VB N
than IN N
students NNS N
in IN N
the DT N
other JJ N
two CD N
groups NNS N
, , N
and CC N
students NNS N
in IN N
the DT N
comparing NN N
symbols NNS N
group NN N
also RB N
scored VBD N
higher JJR N
on IN N
a DT N
posttest NN N
that WDT N
assessed VBD N
knowledge NN N
about IN N
inequality NN N
symbols NNS N
and CC N
inequality NN N
problem NN N
solving VBG N
. . N

Thus RB N
, , N
they PRP N
learned VBD N
about IN N
three CD N
symbols NNS N
in IN N
the DT N
same JJ N
amount NN N
of IN N
time NN N
as IN N
other JJ N
students NNS N
learned VBD N
about IN N
the DT N
equal JJ N
sign NN N
alone RB N
or CC N
not RB N
at IN N
all DT N
. . N

Therefore NNP N
, , N
an DT N
instructional JJ N
approach NN N
involving VBG N
comparison NN N
can MD N
be VB N
an DT N
effective JJ N
tool NN N
for IN N
learning VBG N
about IN N
concepts NNS N
in IN N
mathematics NNS N
. . N

-DOCSTART- -X- O O

Oral NNP N
health NN N
impacts NNS N
on IN N
daily JJ N
living NN N
related VBN N
to TO N
four CD N
different JJ N
treatment NN N
protocols NNS N
for IN N
chronic JJ N
periodontitis NN N
. . N

BACKGROUND IN N
The DT N
aims NNS N
of IN N
this DT N
study NN N
were VBD N
to TO N
evaluate VB N
the DT N
oral JJ N
health NN N
impacts NNS N
perceived VBN N
by IN N
patients NNS N
submitted VBN N
to TO N
different JJ N
treatments NNS N
of IN N
chronic JJ N
periodontitis NN N
and CC N
their PRP$ N
association NN N
with IN N
clinical JJ N
parameters NNS N
. . N

METHODS NNP N
Sixty NNP N
patients NNS N
were VBD N
assigned VBN N
to TO N
one CD N
of IN N
the DT N
following JJ N
therapeutic JJ N
groups NNS N
: : N
control NN N
, , N
treated VBN N
with IN N
full-mouth JJ 2_i
scaling NN 2_i
and CC N
root NN 2_i
planing NN 2_i
( ( 2_i
SRP NNP 2_i
) ) 2_i
; : N
test $ N
1 CD N
, , N
treated VBN N
with IN N
SRP NNP 1_i
and CC N
400 CD N
mg NNS N
systemically RB N
administered VBN N
metronidazole NN 3_i
( ( N
MET NNP N
) ) N
three CD N
times NNS N
per IN N
day NN N
for IN N
10 CD N
days NNS N
; : N
test JJS N
2 CD N
, , N
treated VBN N
with IN N
SRP NNP 2_i
and CC N
professional JJ 2_i
supragingival NN 2_i
plaque NN 2_i
removal NN 2_i
( ( 2_i
PP NNP 2_i
) ) 2_i
every DT N
week NN N
for IN N
3 CD N
months NNS N
; : N
and CC N
test VB N
3 CD N
, , N
treated VBN N
with IN N
SRP NNP 1_i
and CC N
MET NNP 3_i
plus CC N
PP NNP N
. . N

Clinical NNP N
periodontal JJ N
measurements NNS N
and CC N
data NNS N
regarding VBG N
patients NNS N
' POS N
oral JJ N
health NN N
impacts NNS N
( ( N
perceived VBN N
impacts NNS N
on IN N
bleeding VBG N
gums NNS N
, , N
gingival JJ N
recession NN N
, , N
sensitivity NN N
to TO N
cold VB N
, , N
packing VBG N
foods NNS N
, , N
aesthetics NNS N
, , N
bad JJ N
breath NN N
, , N
and CC N
tooth DT N
mobility NN N
) ) N
were VBD N
collected VBN N
at IN N
baseline NN N
and CC N
3 CD N
months NNS N
after IN N
therapy NN N
. . N

RESULTS NNP N
All NNP N
groups NNS N
presented VBD N
significant JJ N
improvement NN N
in IN N
oral JJ N
health NN N
perceived VBD N
impacts NNS N
. . N

There EX N
was VBD N
no DT N
statistically RB N
significant JJ N
difference NN N
in IN N
the DT N
improvement NN N
of IN N
oral JJ N
health NN N
impacts NNS N
among IN N
groups NNS N
subjected VBN N
to TO N
different JJ N
treatments NNS N
. . N

The DT N
clinical JJ N
data NNS N
of IN N
percentage NN N
of IN N
deep JJ N
probing VBG N
depth NN N
, , N
deep JJ N
clinical JJ N
attachment NN N
level NN N
, , N
and CC N
bleeding VBG N
on IN N
probing VBG N
were VBD N
found VBN N
to TO N
be VB N
correlated VBN N
significantly RB N
with IN N
oral JJ N
health NN N
impacts NNS N
. . N

CONCLUSIONS NNP N
Periodontal NNP 2_i
treatment NN 2_i
leads VBZ N
to TO N
a DT N
significant JJ N
reduction NN N
of IN N
self-perceived JJ N
impacts NNS N
regardless RB N
of IN N
the DT N
non-surgical JJ N
treatment NN N
protocol NN N
employed VBN N
. . N

Most JJS N
of IN N
the DT N
clinical JJ N
data NNS N
were VBD N
associated VBN N
with IN N
oral JJ N
health NN N
impacts NNS N
. . N

-DOCSTART- -X- O O

Short- JJ N
and CC N
long-term JJ N
effects NNS N
of IN N
tactile JJ 2_i
massage NN 2_i
on IN N
salivary JJ N
cortisol NN N
concentrations NNS N
in IN N
Parkinson NNP N
's POS N
disease NN N
: : N
a DT N
randomised JJ N
controlled VBN N
pilot NN N
study NN N
. . N

BACKGROUND NNP N
Parkinson NNP N
's POS N
disease NN N
( ( N
PD NNP N
) ) N
is VBZ N
a DT N
chronic JJ N
neurodegenerative JJ N
disorder NN N
with IN N
limited JJ N
knowledge NN N
about IN N
the DT N
normal JJ N
function NN N
and CC N
effects NNS N
of IN N
non-pharmacological JJ 6_i
therapies NNS 6_i
on IN N
the DT N
hypothalamic-pituitary-adrenal JJ N
( ( N
HPA NNP N
) ) N
axis NN N
. . N

The DT N
aim NN N
of IN N
the DT N
study NN N
was VBD N
to TO N
analyse VB N
the DT N
basal NN N
diurnal JJ N
and CC N
total JJ N
secretion NN N
of IN N
salivary JJ N
cortisol NN N
in IN N
short- JJ N
and CC N
long-term JJ N
aspects NNS N
of IN N
tactile JJ 2_i
massage NN 2_i
( ( 2_i
TM NNP 2_i
) ) 2_i
. . 6_i

METHODS NNP N
DESIGN NNP N
Prospective NNP N
, , N
Controlled NNP N
and CC N
Randomised VBD N
Multicentre NNP N
Trial NNP N
. . N

SETTING NN N
AND JJ N
INTERVENTIONS NNP N
Forty-five NNP N
women NNS N
and CC N
men NNS N
, , N
aged VBN N
50-79 CD N
years NNS N
, , N
were VBD N
recruited VBN N
. . N

Twenty-nine NN N
of IN N
them PRP N
were VBD N
blindly RB N
randomised VBN N
to TO N
tactile VB 6_i
massage NN 6_i
( ( 6_i
TM NNP 6_i
) ) 6_i
and CC N
16 CD N
of IN N
them PRP N
to TO N
the DT N
control NN 7_i
group NN N
, , N
rest NN 7_i
to TO 7_i
music NN 7_i
( ( 7_i
RTM NNP 7_i
) ) 7_i
. . 7_i

Ten CD N
interventions NNS N
were VBD N
given VBN N
during IN N
8 CD N
weeks NNS N
followed VBN N
by IN N
a DT N
26 CD N
weeks NNS N
of IN N
follow JJ N
up RB N
. . N

Salivary JJ N
cortisol NN N
was VBD N
collected VBN N
at IN N
8 CD N
am VBP N
, , N
1 CD N
pm NN N
, , N
8 CD N
pm NN N
, , N
and CC N
8 CD N
am VBP N
the DT N
next JJ N
day NN N
, , N
on IN N
five CD N
occasions NNS N
. . N

With IN N
the DT N
first JJ N
and CC N
eighth JJ N
interventions NNS N
, , N
it PRP N
was VBD N
collected VBN N
immediately RB N
before IN N
and CC N
after IN N
intervention NN N
. . N

MAIN NNP N
OUTCOME NNP N
MEASURES NNP N
The DT N
primary JJ N
aim NN N
was VBD N
to TO N
assess VB N
and CC N
compare VB N
cortisol JJ N
concentrations NNS N
before IN N
and CC N
immediately RB N
after IN N
intervention NN N
and CC N
also RB N
during IN N
the DT N
follow-up JJ N
period NN N
. . N

The DT N
secondary JJ N
aim NN N
was VBD N
to TO N
assess VB N
the DT N
impact NN N
of IN N
age NN N
, , N
gender NN N
, , N
body NN N
mass NN N
index NN N
( ( N
BMI NNP N
) ) N
, , N
duration NN N
and CC N
severity NN N
of IN N
PD NNP N
, , N
effects NNS N
of IN N
interventional JJ N
time-point NN N
of IN N
the DT N
day NN N
, , N
and CC N
levodopa JJ N
doses NNS N
on IN N
cortisol JJ N
concentration NN N
. . N

RESULTS VB N
The DT N
median JJ N
cortisol NN N
concentrations NNS N
for IN N
all DT N
participants NNS N
were VBD N
16.0 CD N
, , N
5.8 CD N
, , N
2.8 CD N
, , N
and CC N
14.0 CD N
nmol/L NN N
at IN N
baseline NN N
, , N
later RB N
reproduced VBD N
four CD N
times NNS N
without IN N
significant JJ N
differences NNS N
. . N

Cortisol NNP N
concentrations NNS N
decreased VBD N
significantly RB N
after IN N
TM NNP 2_i
intervention NN N
but CC N
no DT N
change NN N
in IN N
diurnal JJ N
salivary JJ N
cortisol NN N
pattern NN N
was VBD N
found VBN N
. . N

The DT N
findings NNS N
of IN N
reduced JJ N
salivary JJ N
cortisol NN N
concentrations NNS N
immediately RB N
after IN N
the DT N
interventions NNS N
are VBP N
in IN N
agreement NN N
with IN N
previous JJ N
studies NNS N
. . N

However RB N
, , N
there EX N
was VBD N
no DT N
significant JJ N
difference NN N
between IN N
the DT N
TM NNP 2_i
and CC N
control NN N
groups NNS N
. . N

There EX N
were VBD N
no DT N
significant JJ N
correlations NNS N
between IN N
cortisol JJ N
concentrations NNS N
and CC N
age NN N
, , N
gender NN N
, , N
BMI NNP N
, , N
time-point NN N
for IN N
intervention NN N
, , N
time NN N
interval NN N
between IN N
anti-parkinson JJ N
pharmacy NN N
intake NN N
and CC N
sampling NN N
, , N
levodopa NN N
doses NNS N
, , N
duration NN N
, , N
or CC N
severity NN N
of IN N
PD NNP N
. . N

CONCLUSIONS NNP N
Diurnal NNP N
salivary JJ N
cortisol NN N
rhythm NN N
was VBD N
normal JJ N
. . N

Salivary JJ N
cortisol NN N
concentrations NNS N
were VBD N
significantly RB N
reduced VBN N
after IN N
the DT N
TM NNP 2_i
intervention NN N
and CC N
after IN N
RTM NNP 7_i
, , N
but CC N
there EX N
were VBD N
no DT N
significant JJ N
differences NNS N
between IN N
the DT N
groups NNS N
and CC N
no DT N
sustained JJ N
long-term JJ N
effect NN N
. . N

No CC N
associations NNS N
were VBD N
seen VBN N
between IN N
salivary JJ N
cortisol NN N
concentration NN N
and CC N
clinical JJ N
and/or NN N
pharmacological JJ N
characteristics NNS N
. . N

TRIAL NNP N
REGISTRATION NNP N
ClinicalTrial.gov NNP N
, , N
NCT01734876 NNP N
and CC N
FoU NNP N
Sweden NNP N
108881 CD N
. . N

-DOCSTART- -X- O O

A DT N
randomized JJ N
, , N
evaluator-blind JJ N
, , N
multicenter JJ N
comparison NN N
of IN N
the DT N
efficacy NN N
and CC N
tolerability NN N
of IN N
Perlane NNP 3_i
versus NN N
Zyplast NNP 3_i
in IN N
the DT N
correction NN N
of IN N
nasolabial JJ N
folds NNS N
. . N

Bovine NNP 3_i
collagen NN 3_i
is VBZ N
widely RB N
used VBN N
as IN N
a DT N
dermal JJ N
filler NN N
for IN N
facial JJ N
soft-tissue JJ N
augmentation NN N
, , N
but CC N
it PRP N
provides VBZ N
only RB N
temporary JJ N
cosmetic JJ N
improvement NN N
. . N

Nonanimal NNP 3_i
stabilized VBD 3_i
hyaluronic JJ 3_i
acid NN 3_i
has VBZ N
reduced VBN N
potential JJ N
for IN N
immunogenicity NN N
and CC N
hypersensitivity NN N
and CC N
may MD N
provide VB N
a DT N
more RBR N
durable JJ N
aesthetic JJ N
result NN N
. . N

Sixty-eight JJ N
patients NNS N
with IN N
prominent JJ N
nasolabial JJ N
folds NNS N
were VBD N
randomized VBN N
to TO N
intradermal VB N
treatment NN N
with IN N
nonanimal JJ 3_i
stabilized VBN 3_i
hyaluronic JJ 3_i
acid NN 3_i
gel NN 3_i
( ( 3_i
Perlane NNP 3_i
) ) 3_i
and CC N
bovine JJ 3_i
collagen NN 3_i
( ( 3_i
Zyplast NNP 3_i
) ) 3_i
on IN N
contralateral JJ N
sides NNS N
of IN N
the DT N
face NN N
. . N

On IN N
achievement NN N
of IN N
optimal JJ N
cosmetic JJ N
result NN N
( ( N
baseline NN N
) ) N
, , N
patients NNS N
were VBD N
followed VBN N
up RP N
for IN N
6 CD N
months NNS N
; : N
bilateral JJ N
retreatment NN N
with IN N
Perlane NNP 3_i
was VBD N
offered VBN N
at IN N
6 CD N
or CC N
9 CD N
months NNS N
after IN N
baseline NN N
. . N

Responses NNS N
were VBD N
evaluated VBN N
at IN N
2 CD N
, , N
4 CD N
, , N
6 CD N
, , N
9 CD N
, , N
and CC N
12 CD N
months NNS N
after IN N
baseline NN N
. . N

Investigator-based JJ N
and CC N
patient-based JJ N
ratings NNS N
indicated VBD N
that IN N
Perlane NNP 3_i
was VBD N
more RBR N
effective JJ N
than IN N
Zyplast NNP 3_i
in IN N
maintaining VBG N
cosmetic JJ N
correction NN N
. . N

According VBG N
to TO N
investigator-based JJ N
Wrinkle NNP N
Severity NNP N
Rating NNP N
Scale NNP N
assessments NNS N
at IN N
6 CD N
and CC N
9 CD N
months NNS N
after IN N
baseline NN N
, , N
Perlane NNP 3_i
was VBD N
superior JJ N
in IN N
50.0 CD N
percent NN N
and CC N
48.8 CD N
percent NN N
of IN N
patients NNS N
, , N
respectively RB N
, , N
whereas IN N
Zyplast NNP 3_i
was VBD N
superior JJ N
in IN N
10.3 CD N
percent NN N
and CC N
14.0 CD N
percent NN N
of IN N
patients NNS N
, , N
respectively RB N
( ( N
p JJ N
< NNP N
0.0004 CD N
) ) N
. . N

Investigator-based JJ N
Global NNP N
Aesthetic NNP N
Improvement NNP N
Scale NNP N
assessment NN N
at IN N
9 CD N
months NNS N
after IN N
baseline NN N
indicated VBD N
that IN N
Perlane NNP 3_i
was VBD N
superior JJ N
in IN N
48.8 CD N
percent NN N
of IN N
patients NNS N
, , N
whereas IN N
Zyplast NNP 3_i
was VBD N
superior JJ N
in IN N
14.0 CD N
percent NN N
of IN N
patients NNS N
( ( N
p JJ N
= NNP N
0.0025 CD N
) ) N
. . N

Optimal NNP N
cosmetic JJ N
result NN N
was VBD N
achieved VBN N
with IN N
a DT N
smaller JJR N
volume NN N
of IN N
Perlane NNP 3_i
than IN N
Zyplast NNP 3_i
( ( N
mean NN N
, , N
1.2 CD N
ml NN N
versus NN N
2.1 CD N
ml NN N
) ) N
. . N

Local JJ N
injection-site JJ N
reactions NNS N
( ( N
redness NN N
, , N
swelling VBG N
, , N
pruritus NN N
, , N
and CC N
induration NN N
) ) N
were VBD N
less RBR N
frequent JJ N
with IN N
Perlane NNP 3_i
than IN N
with IN N
Zyplast NNP 3_i
. . 3_i

Delayed-onset JJ N
reactions NNS N
were VBD N
rare JJ N
and CC N
did VBD N
not RB N
reoccur VB N
after IN N
Perlane NNP 3_i
retreatment NN N
. . N

Perlane NNP 3_i
has VBZ N
acceptable JJ N
long-term JJ N
safety NN N
and CC N
offers VBZ N
a DT N
longer-lasting JJ N
aesthetic JJ N
improvement NN N
than IN N
Zyplast NNP 3_i
. . 3_i

-DOCSTART- -X- O O

Extracorporeal NNP 2_i
shock NN 2_i
wave NN 2_i
therapy NN 2_i
( ( 2_i
ESWT NNP 2_i
) ) 2_i
in IN N
patients NNS N
with IN N
chronic JJ N
proximal JJ N
plantar NN N
fasciitis NN N
: : N
a DT N
2-year JJ N
follow-up NN N
. . N

The DT N
aim NN N
of IN N
this DT N
study NN N
was VBD N
to TO N
compare VB N
the DT N
effect NN N
of IN N
extracorporeal NN 2_i
shock NN 2_i
wave VBP 2_i
therapy NN 2_i
( ( N
ESWT NNP N
) ) N
in IN N
patients NNS N
with IN N
chronically RB N
painful JJ N
proximal JJ N
plantar NN N
fasciitis NN N
with IN N
a DT N
further JJ N
conventional JJ N
conservative JJ N
treatment NN N
. . N

Forty-seven JJ N
patients NNS N
( ( N
49 CD N
feet NNS N
) ) N
with IN N
a DT N
previously RB N
unsuccessful JJ N
nonsurgical JJ N
treatment NN N
of IN N
at IN N
least JJS N
6 CD N
months NNS N
were VBD N
randomized VBN N
to TO N
two CD N
groups NNS N
. . N

Heel NNP 2_i
cups NNS 2_i
had VBD N
to TO N
be VB N
worn VBN N
throughout IN N
the DT N
study NN N
. . N

Group NNP N
1 CD N
( ( N
25 CD N
heels NNS N
) ) N
was VBD N
treated VBN N
immediately RB N
with IN N
three CD N
sessions NNS N
of IN N
ESWT NNP 2_i
( ( N
3000 CD N
shock NN N
waves/session NN N
of IN N
0.2 CD N
mJ/mm2 NN N
) ) N
at IN N
weekly JJ N
intervals NNS N
. . N

The DT N
patients NNS N
of IN N
group NN N
2 CD N
( ( N
24 CD N
heels NNS N
) ) N
continued VBD N
nonsurgical JJ N
treatment NN N
( ( N
iontophoresis NN 3_i
with IN 3_i
diclofenac NN 3_i
and CC N
an DT N
oral JJ N
nonsteroidal JJ 3_i
anti-inflammatory JJ 3_i
drug NN 3_i
) ) N
for IN N
12 CD N
weeks NNS N
. . N

After IN N
this DT N
period NN N
they PRP N
were VBD N
treated VBN N
using VBG N
the DT N
protocol NN N
of IN N
group NN N
1 CD N
. . N

No DT N
significant JJ N
difference NN N
of IN N
pain NN N
and CC N
walking NN N
time NN N
after IN N
further JJ N
nonsurgical JJ N
treatment NN N
( ( N
3 CD N
months NNS N
) ) N
was VBD N
seen VBN N
in IN N
group NN N
2 CD N
. . N

At IN N
12 CD N
weeks NNS N
after IN N
ESWT NNP N
, , N
the DT N
pain NN N
estimation NN N
on IN N
the DT N
visual JJ N
analogue NN N
scale NN N
( ( N
VAS NNP N
) ) N
for IN N
activities NNS N
of IN N
daily JJ N
living NN N
diminished VBN N
significantly RB N
by IN N
62.9 CD N
% NN N
in IN N
group NN N
1 CD N
and CC N
by IN N
63.0 CD N
% NN N
in IN N
group NN N
2 CD N
. . N

The DT N
comfortable JJ N
walking NN N
time NN N
had VBD N
increased VBN N
significantly RB N
in IN N
both DT N
groups NNS N
. . N

Two CD N
years NNS N
after IN N
ESWT NNP N
, , N
pain NN N
during IN N
activities NNS N
of IN N
daily JJ N
living NN N
decreased VBN N
by IN N
94 CD N
% NN N
in IN N
group NN N
1 CD N
and CC N
by IN N
90 CD N
% NN N
in IN N
group NN N
2 CD N
on IN N
the DT N
VAS NNP N
and CC N
the DT N
comfortable JJ N
walking NN N
time NN N
had VBD N
increased VBN N
significantly RB N
in IN N
both DT N
groups NNS N
. . N

-DOCSTART- -X- O O

Shorter NNP N
treatment NN N
for IN N
vaginal JJ N
candidosis NN N
: : N
comparison NN N
between IN N
single-dose JJ N
oral JJ N
fluconazole NN 3_i
and CC N
three-day JJ N
treatment NN N
with IN N
local JJ N
miconazole NN 3_i
. . 3_i

Fluconazole NNP 3_i
is VBZ N
an DT N
effective JJ N
, , N
simple JJ N
and CC N
safe JJ N
, , N
although IN N
slightly RB N
expensive JJ N
, , N
agent NN N
for IN N
the DT N
treatment NN N
of IN N
vaginal JJ N
candidosis NN N
. . N

Single-dose JJ N
fluconazole NN 3_i
( ( N
150 CD N
mg NN N
) ) N
administered VBD N
orally RB N
in IN N
capsule NN N
form NN N
was VBD N
compared VBN N
with IN N
three-day JJ N
local JJ N
treatment NN N
with IN N
miconazole JJ 3_i
pessaries NNS N
in IN N
the DT N
treatment NN N
of IN N
vaginal JJ N
candidosis NN N
in IN N
a DT N
randomized JJ N
study NN N
in IN N
Finland NNP N
. . N

Cure NN N
rates NNS N
were VBD N
good JJ N
( ( N
> JJ N
80 CD N
% NN N
) ) N
in IN N
randomized VBN N
patient NN N
groups NNS N
assessed VBD N
both DT N
clinically RB N
and CC N
by IN N
the DT N
results NNS N
of IN N
yeast JJ N
cultures NNS N
. . N

Oral JJ N
administration NN N
was VBD N
preferred VBN N
to TO N
local JJ N
therapy NN N
by IN N
patients NNS N
in IN N
both DT N
the DT N
miconazole NN 3_i
and CC N
fluconazole JJ 3_i
groups NNS N
. . N

For IN N
the DT N
time NN N
being VBG N
, , N
fluconazole NN 3_i
is VBZ N
not RB N
recommended VBN N
for IN N
use NN N
during IN N
pregnancy NN N
or CC N
lactation NN N
. . N

-DOCSTART- -X- O O

Clinically RB N
relevant JJ N
improvement NN N
of IN N
recurrence-free JJ N
survival NN N
with IN N
5-aminolevulinic JJ 3_i
acid NN 3_i
induced VBD N
fluorescence NN N
diagnosis NN N
in IN N
patients NNS N
with IN N
superficial JJ N
bladder NN N
tumors NNS N
. . N

PURPOSES NNP N
Fluorescence NNP N
diagnosis NN N
induced VBN N
by IN N
5-aminolevulinic JJ 3_i
acid NN 3_i
enables VBZ N
more RBR N
thorough JJ N
transurethral JJ N
resection NN N
of IN N
superficial JJ N
bladder NN N
carcinoma NNS N
compared VBN N
with IN N
conventional JJ N
white JJ N
light NN N
. . N

We PRP N
performed VBD N
a DT N
prospective JJ N
, , N
single JJ N
institution NN N
, , N
randomized VBN N
trial NN N
to TO N
investigate VB N
whether IN N
the DT N
residual JJ N
tumor NN N
rate NN N
and CC N
long-term JJ N
tumor NN N
recurrence NN N
can MD N
be VB N
decreased VBN N
by IN N
fluorescence NN N
diagnosis NN N
. . N

MATERIALS NNP N
AND NNP N
METHODS NNP N
A NNP N
total NN N
of IN N
301 CD N
patients NNS N
underwent JJ N
transurethral JJ 1_i
resection NN 1_i
of IN N
bladder NN N
tumors NNS N
with IN N
white JJ N
light NN N
or CC N
fluorescence NN N
diagnosis NN N
. . N

Transurethral JJ 1_i
resection NN 1_i
was VBD N
repeated VBN N
5 CD N
to TO N
6 CD N
weeks NNS N
later RB N
to TO N
evaluate VB N
the DT N
residual JJ N
tumor NN N
rate NN N
. . N

To TO N
determine VB N
recurrence-free JJ N
survival JJ N
patient NN N
followup NN N
was VBD N
performed VBN N
every DT N
3 CD N
months NNS N
by IN N
white JJ N
light JJ N
cystoscopy NN N
and CC N
urine JJ N
cytology NN N
. . N

Recurrence-free JJ N
survival NN N
was VBD N
analyzed VBN N
via IN N
Kaplan-Meier NNP N
methods NNS N
and CC N
multivariable JJ N
Cox NNP N
regression NN N
analysis NN N
. . N

RESULTS VB N
A DT N
total NN N
of IN N
191 CD N
patients NNS N
with IN N
superficial JJ N
bladder NN N
carcinoma NN N
were VBD N
available JJ N
for IN N
efficacy NN N
analysis NN N
. . N

The DT N
residual JJ N
tumor NN N
rate NN N
was VBD N
25.2 CD N
% NN N
in IN N
the DT N
white JJ N
light JJ N
arm NN N
versus NN N
4.5 CD N
% NN N
in IN N
the DT N
fluorescence NN N
diagnosis NN N
arm NN N
( ( N
p JJ N
< NNP N
0.0001 CD N
) ) N
. . N

Median JJ N
followup NN N
in IN N
the DT N
white JJ N
light JJ N
arm NN N
in IN N
103 CD N
cases NNS N
was VBD N
21.2 CD N
months NNS N
( ( N
range VB N
4 CD N
to TO N
40 CD N
) ) N
compared VBN N
with IN N
20.5 CD N
( ( N
range NN N
3 CD N
to TO N
40 CD N
) ) N
in IN N
the DT N
88 CD N
in IN N
the DT N
fluorescence NN N
diagnosis NN N
arm NN N
. . N

Recurrence-free JJ N
survival NN N
in IN N
the DT N
fluorescence NN N
diagnosis NN N
group NN N
was VBD N
89.6 CD N
% NN N
after IN N
12 CD N
and CC N
24 CD N
months NNS N
compared VBN N
with IN N
73.8 CD N
% NN N
and CC N
65.9 CD N
% NN N
, , N
respectively RB N
, , N
in IN N
the DT N
white JJ N
light NN N
group NN N
( ( N
p JJ N
= NNP N
0.004 CD N
) ) N
. . N

This DT N
superiority NN N
proved VBD N
to TO N
be VB N
independent JJ N
of IN N
risk NN N
group NN N
. . N

The DT N
adjusted JJ N
hazard NN N
ratio NN N
of IN N
fluorescence NN N
diagnosis NN N
versus IN N
white JJ N
light JJ N
transurethral JJ N
resection NN N
was VBD N
0.33 CD N
( ( N
95 CD N
% NN N
confidence NN N
interval NN N
0.16 CD N
to TO N
0.67 CD N
) ) N
. . N

CONCLUSIONS NNP N
Fluorescence NNP N
diagnosis NN N
is VBZ N
significantly RB N
superior JJ N
to TO N
conventional JJ N
white JJ N
light JJ N
transurethral JJ N
resection NN N
with IN N
respect NN N
to TO N
the DT N
residual JJ N
tumor NN N
rate NN N
and CC N
recurrence-free JJ N
survival NN N
. . N

The DT N
differences NNS N
in IN N
recurrence-free JJ N
survival NN N
imply NN N
that WDT N
fluorescence NN N
diagnosis NN N
is VBZ N
a DT N
clinically RB N
relevant JJ N
procedure NN N
for IN N
decreasing VBG N
the DT N
number NN N
of IN N
tumor NN N
recurrences NNS N
. . N

-DOCSTART- -X- O O

PROCLAIM NN N
: : N
pilot NN N
study NN N
to TO N
examine VB N
the DT N
effects NNS N
of IN N
clopidogrel NN 3_i
on IN N
inflammatory JJ N
markers NNS N
in IN N
patients NNS N
with IN N
metabolic JJ N
syndrome JJ N
receiving VBG N
low-dose JJ N
aspirin NN 3_i
. . 3_i

Metabolic NNP N
syndrome NN N
is VBZ N
associated VBN N
with IN N
intravascular JJ N
inflammation NN N
, , N
as IN N
determined VBN N
by IN N
increased JJ N
levels NNS N
of IN N
inflammatory NN N
biomarkers NNS N
and CC N
an DT N
increased VBN N
risk NN N
of IN N
ischemic JJ N
atherothrombotic JJ N
events NNS N
. . N

Evidence NN N
suggests VBZ N
that IN N
atherothrombosis NN N
and CC N
intravascular JJ N
inflammation NN N
share NN N
predictive JJ N
biomarkers NNS N
, , N
including VBG N
high-sensitivity JJ N
C-reactive JJ N
protein NN N
, , N
CD40 NNP N
ligand NN N
, , N
P-selectin NNP N
, , N
and CC N
N-terminal JJ N
pro-brain JJ N
natriuretic JJ N
peptide NN N
. . N

Patients NNS N
who WP N
had VBD N
metabolic JJ N
syndrome NN N
were VBD N
randomized VBN N
to TO N
receive VB N
clopidogrel NN 3_i
75 CD N
mg/day JJ N
plus CC N
aspirin JJ 3_i
81 CD N
mg/day NN N
( ( N
n JJ N
= NNP N
89 CD N
) ) N
or CC N
placebo JJ 7_i
plus CC N
aspirin JJ 3_i
81 CD N
mg/day NN N
( ( N
n JJ N
= NNP N
92 CD N
) ) N
for IN N
9 CD N
weeks NNS N
to TO N
assess VB N
the DT N
efficacy NN N
of IN N
each DT N
treatment NN N
in IN N
suppression NN N
of IN N
inflammatory JJ N
markers NNS N
. . N

Change NN N
from IN N
baseline NN N
in IN N
the DT N
levels NNS N
of IN N
high-sensitivity NN N
C-reactive JJ N
protein NN N
, , N
CD40 NNP N
ligand NN N
, , N
P-selectin NNP N
, , N
and CC N
N-terminal JJ N
pro-brain JJ N
natriuretic JJ N
peptide NN N
at IN N
6 CD N
weeks NNS N
was VBD N
assessed VBN N
to TO N
evaluate VB N
each DT N
treatment NN N
. . N

There EX N
was VBD N
a DT N
significant JJ N
difference NN N
at IN N
Week JJ N
6 CD N
in IN N
model-adjusted JJ N
CD40-ligand NNP N
levels NNS N
in IN N
favor NN N
of IN N
clopidogrel NN 3_i
plus CC N
aspirin JJ 3_i
compared VBN N
with IN N
placebo NN 7_i
plus CC N
aspirin NN 3_i
in IN N
both DT N
the DT N
intent-to-treat JJ N
population NN N
( ( N
difference NN N
between IN N
least-squares NNS N
means NNS N
= VBP N
-186.5 NNP N
; : N
95 CD N
% NN N
confidence NN N
interval NN N
, , N
-342.3 NN N
to TO N
-30.8 VB N
; : N
P NNP N
= NNP N
0.02 CD N
) ) N
and CC N
the DT N
per-protocol JJ N
population NN N
( ( N
P NNP N
= NNP N
0.05 CD N
) ) N
. . N

No DT N
significant JJ N
differences NNS N
were VBD N
observed VBN N
between IN N
the DT N
treatment NN N
arms NNS N
for IN N
high-sensitivity JJ N
C-reactive JJ N
protein NN N
, , N
P-selectin NNP N
, , N
and CC N
N-terminal JJ N
pro-brain JJ N
natriuretic JJ N
peptide NN N
. . N

There EX N
were VBD N
no DT N
deaths NNS N
or CC N
serious JJ N
adverse JJ N
events NNS N
in IN N
either DT N
treatment NN N
arm NN N
. . N

Data NNS N
from IN N
this DT N
study NN N
suggest VBP N
that IN N
clopidogrel NN 3_i
can MD N
decrease VB N
the DT N
expression NN N
of IN N
the DT N
CD40-ligand NNP N
biomarker NN N
. . N

-DOCSTART- -X- O O

Effects NNS N
of IN N
three CD N
oral JJ N
analgesics NNS 3_i
on IN N
postoperative JJ N
pain NN N
following VBG N
root JJ N
canal JJ N
preparation NN N
: : N
a DT N
controlled JJ N
clinical JJ N
trial NN N
. . N

AIM NNP N
To TO N
compare VB N
the DT N
effects NNS N
of IN N
single JJ N
doses NNS N
of IN N
three CD N
oral JJ N
medications NNS N
on IN N
postoperative JJ N
pain NN N
following VBG N
instrumentation NN N
of IN N
root NN N
canals NNS N
in IN N
teeth NN N
with IN N
irreversible JJ N
pulpitis NN N
. . N

METHODOLOGY NNP N
In IN N
this DT N
double-blind JJ N
clinical JJ N
trial NN N
, , N
100 CD N
patients NNS N
who WP N
had VBD N
anterior CC N
or CC N
premolar JJ N
teeth NNS N
with IN N
irreversible JJ N
pulpitis NN N
without IN N
any DT N
signs NNS N
and CC N
symptoms NNS N
of IN N
acute NN N
or CC N
chronic JJ N
apical JJ N
periodontitis NN N
and CC N
moderate VB N
to TO N
severe VB N
pain NN N
were VBD N
divided VBN N
by IN N
balanced JJ N
block NN N
random NN N
allocation NN N
into IN N
four CD N
groups NNS N
of IN N
25 CD N
each DT N
, , N
a DT N
control NN 7_i
group NN 7_i
receiving VBG N
a DT N
placebo NN 7_i
medication NN N
, , N
and CC N
three CD N
experimental JJ N
groups NNS N
receiving VBG N
a DT N
single JJ N
dose NN N
of IN N
either DT N
Tramadol NNP 3_i
( ( N
100 CD N
mg NN N
) ) N
, , N
Novafen NNP 3_i
( ( N
325 CD N
mg NN N
of IN N
paracetamol NN 3_i
, , N
200 CD N
mg NN N
ibuprofen NN 3_i
and CC N
40 CD N
mg NNS N
caffeine VBP 3_i
anhydrous JJ 3_i
) ) N
or CC N
Naproxen NNP 3_i
( ( N
500 CD N
mg NN N
) ) N
immediately RB N
after IN N
the DT N
first JJ N
appointment NN N
where WRB N
the DT N
pulp NN N
was VBD N
removed VBN N
, , N
and CC N
the DT N
canals NNS N
were VBD N
fully RB N
prepared VBN N
. . N

The DT N
intensity NN N
of IN N
pain NN N
was VBD N
scored VBN N
based VBN N
on IN N
10-point JJ N
VAS NNP N
before IN N
and CC N
after IN N
treatment NN N
for IN N
up IN N
to TO N
24 CD N
h NN N
postoperatively RB N
. . N

Data NNS N
were VBD N
submitted VBN N
to TO N
repeated VBN N
analysis NN N
of IN N
variance NN N
. . N

RESULTS NNP N
At IN N
the DT N
6 CD N
, , N
12 CD N
and CC N
24 CD N
h NNS N
postoperative JJ N
intervals NNS N
after IN N
drug NN N
administration NN N
, , N
the DT N
intensity NN N
of IN N
pain NN N
was VBD N
significantly RB N
lower JJR N
in IN N
the DT N
experimental NN N
groups NNS N
than IN N
in IN N
the DT N
placebo NN 3_i
group NN N
( ( N
P NNP N
< NNP N
0.01 CD N
) ) N
. . N

Tramadol NNP 3_i
was VBD N
significantly RB N
less RBR N
effective JJ N
( ( N
P NNP N
< NNP N
0.05 CD N
) ) N
than IN N
Naproxen NNP 3_i
, , N
and CC N
Novafen NNP 3_i
that WDT N
were VBD N
similar JJ N
to TO N
each DT N
other JJ N
( ( N
P NNP N
> NNP N
0.05 CD N
) ) N
. . N

CONCLUSION VB N
A DT N
single JJ N
oral JJ N
dose NN N
of IN N
Naproxen NNP 3_i
, , N
Novafen NNP 3_i
and CC N
Tramadol NNP 3_i
taken VBN N
immediately RB N
after IN N
treatment NN N
reduced VBD N
postoperative JJ N
pain NN N
following VBG N
pulpectomy NN N
and CC N
root JJ N
canal JJ N
preparation NN N
of IN N
teeth NNS N
with IN N
irreversible JJ N
pulpitis NN N
. . N

-DOCSTART- -X- O O

0.1 CD N
% NN N
bupivacaine NN 3_i
does VBZ N
not RB N
reduce VB N
the DT N
requirement NN N
for IN N
epidural JJ N
fentanyl NN N
infusion NN N
after IN N
major JJ N
abdominal JJ N
surgery NN N
. . N

BACKGROUND NNP N
AND NNP N
OBJECTIVES NNP N
Although IN N
local JJ N
anesthesia NN N
has VBZ N
been VBN N
demonstrated VBN N
to TO N
potentiate VB N
spinal JJ N
morphine NN N
analgesia NN N
in IN N
animal JJ N
studies NNS N
, , N
results NNS N
comparing VBG N
epidural JJ N
local JJ N
anesthesia/opioid NN N
mixtures NNS N
with IN N
opioid JJ N
alone NN N
are VBP N
contradictory JJ N
in IN N
clinical JJ N
studies NNS N
. . N

The DT N
hypothesis NN N
was VBD N
that IN N
, , N
although IN N
the DT N
concentration NN N
of IN N
bupivacaine NN 3_i
( ( N
0.1 CD N
% NN N
) ) N
was VBD N
low JJ N
to TO N
minimize VB N
its PRP$ N
adverse JJ N
effects NNS N
, , N
if IN N
the DT N
infusion NN N
rate NN N
of IN N
a DT N
fentanyl/bupivacaine JJ 3_i
solution NN N
was VBD N
closely RB N
adjusted VBN N
according VBG N
to TO N
need NN N
, , N
the DT N
presence NN N
bupivacaine NN N
would MD N
reduce VB N
the DT N
requirement NN N
for IN N
epidural JJ N
fentanyl NN N
. . N

METHODS NNP N
Forty NNP N
patients NNS N
were VBD N
randomly RB N
assigned VBN N
to TO N
receive VB N
either DT N
fentanyl NN 3_i
( ( N
10 CD N
micrograms/mL NN N
) ) N
or CC N
a DT N
fentanyl/bupivacaine NN 3_i
( ( N
0.1 CD N
% NN N
) ) N
mixture NN N
epidurally RB N
corresponding VBG N
to TO N
the DT N
dermatome NN N
of IN N
the DT N
surgical JJ N
incision NN N
in IN N
a DT N
double-blind JJ N
fashion NN N
for IN N
the DT N
first JJ N
18 CD N
hours NNS N
after IN N
major JJ N
abdominal JJ N
surgery NN N
. . N

The DT N
infusion NN N
was VBD N
titrated VBN N
for IN N
each DT N
patient NN N
to TO N
the DT N
rate NN N
required VBN N
for IN N
pain NN N
relief NN N
during IN N
forced VBN N
inspiration NN N
( ( N
pain NN N
score NN N
< NN N
or CC N
= $ N
2 CD N
, , N
maximum JJ N
10 CD N
) ) N
. . N

Pain NN N
scores NNS N
, , N
the DT N
fentanyl JJ N
doses NNS N
required VBN N
, , N
plasma JJ N
concentrations NNS N
of IN N
fentanyl NN N
at IN N
18 CD N
hours NNS N
, , N
and CC N
the DT N
incidence NN N
and CC N
severity NN N
of IN N
adverse JJ N
effects NNS N
were VBD N
recorded VBN N
. . N

RESULTS JJ N
Patients NNPS N
reported VBD N
similar JJ N
median JJ N
pain NN N
scores NNS N
and CC N
were VBD N
equally RB N
satisfied VBN N
with IN N
pain NN N
relief NN N
in IN N
both DT N
groups NNS N
. . N

The DT N
mean NN N
required VBN N
post-operative JJ N
fentanyl JJ N
infusion NN N
rate NN N
( ( N
57.7 CD N
+/- JJ N
19.5 CD N
micrograms/h NN N
) ) N
and CC N
the DT N
plasma NN N
concentrations NNS N
( ( N
0.84 CD N
+/- JJ N
0.36 CD N
ng/mL NN N
) ) N
in IN N
the DT N
fentanyl NN N
group NN N
were VBD N
comparable JJ N
to TO N
the DT N
infusion NN N
rate NN N
( ( N
54.4 CD N
+/- JJ N
19.2 CD N
micrograms/h NN N
) ) N
and CC N
the DT N
plasma NN N
concentrations NNS N
( ( N
0.86 CD N
+/- JJ N
0.36 CD N
ng/mL NN N
) ) N
in IN N
the DT N
fentanyl/bupivacaine NN N
group NN N
. . N

Respiratory NNP N
and CC N
cardiovascular JJ N
functions NNS N
were VBD N
preserved VBN N
, , N
and CC N
the DT N
incidence NN N
of IN N
nausea NN N
, , N
pruritus NN N
, , N
and CC N
periods NNS N
of IN N
drowsiness NN N
or CC N
sleep NN N
were VBD N
similar JJ N
in IN N
both DT N
groups NNS N
. . N

CONCLUSIONS NNP N
In IN N
low JJ N
concentrations NNS N
( ( N
0.1 CD N
% NN N
) ) N
, , N
bupivacaine NN 3_i
did VBD N
not RB N
reduce VB N
the DT N
titrated JJ N
dose NN N
of IN N
epidural JJ N
fentanyl NN N
required VBN N
for IN N
adequate JJ N
pain NN N
relief NN N
during IN N
forced VBN N
inspiration NN N
after IN N
major JJ N
abdominal JJ N
surgery NN N
. . N

The DT N
incidence NN N
and CC N
severity NN N
of IN N
adverse JJ N
effects NNS N
were VBD N
also RB N
comparable JJ N
whether IN N
or CC N
not RB N
low-dose JJ N
bupivacaine NN 3_i
infusion NN N
was VBD N
used VBN N
. . N

-DOCSTART- -X- O O

Immunologic NNP N
response NN N
after IN N
laparoscopic NN N
colon NN N
cancer NN N
operation NN N
within IN N
an DT N
enhanced JJ N
recovery NN N
program NN N
. . N

OBJECTIVE NN N
It PRP N
has VBZ N
been VBN N
demonstrated VBN N
that IN N
colon NN N
operation NN N
combined VBN N
with IN N
fast-track NN N
( ( N
FT NNP N
) ) N
surgery NN N
and CC N
laparoscopic NN N
technique NN N
can MD N
shorten VB N
the DT N
length NN N
of IN N
hospital NN N
stay NN N
, , N
accelerate JJ N
recovery NN N
of IN N
intestinal JJ N
function NN N
, , N
and CC N
reduce VB N
the DT N
occurrence NN N
of IN N
post-operative JJ N
complications NNS N
. . N

However RB N
, , N
there EX N
are VBP N
no DT N
reports NNS N
regarding VBG N
the DT N
combined JJ N
effects NNS N
of IN N
FT NNP N
colon NN N
operation NN N
and CC N
laparoscopic NN N
technique NN N
on IN N
humoral JJ N
inflammatory NN N
cellular JJ N
immunity NN N
. . N

METHODS NNP N
This DT N
was VBD N
a DT N
prospective JJ N
, , N
controlled VBD N
study NN N
. . N

One CD N
hundred VBD N
sixty-three JJ N
colon NN N
cancer NN N
patients NNS N
underwent VBD N
the DT N
traditional JJ 1_i
protocol NN 1_i
and CC 1_i
open JJ 1_i
operation NN 1_i
( ( N
traditional JJ N
open JJ N
group NN N
, , N
n=42 RB N
) ) N
, , N
the DT N
traditional JJ 1_i
protocol NN 1_i
and CC 1_i
laparoscopic NN 1_i
operation NN 1_i
( ( N
traditional JJ N
laparoscopic NN N
group NN N
, , N
n=40 RB N
) ) N
, , N
the DT N
FT NNP 1_i
protocol NN 1_i
and CC 1_i
open JJ 1_i
operation NN 1_i
( ( N
FT NNP N
open JJ N
group NN N
, , N
n=41 RB N
) ) N
, , N
or CC N
the DT N
FT NNP 1_i
protocol NN 1_i
and CC 1_i
laparoscopic NN 1_i
operation NN 1_i
( ( N
FT NNP N
laparoscopic NN N
group NN N
, , N
n=40 RB N
) ) N
. . N

Blood NN N
samples NNS N
were VBD N
taken VBN N
prior RB N
to TO N
operation NN N
as RB N
well RB N
as IN N
on IN N
days NNS N
1 CD N
, , N
3 CD N
, , N
and CC N
5 CD N
after IN N
operation NN N
. . N

The DT N
number NN N
of IN N
lymphocyte JJ N
subpopulations NNS N
was VBD N
determined VBN N
by IN N
flow JJ N
cytometry NN N
, , N
and CC N
serum VB N
interleukin-6 JJ N
and CC N
C-reactive JJ N
protein NN N
levels NNS N
were VBD N
measured VBN N
. . N

Post-operative JJ N
hospital NN N
stay NN N
, , N
post-operative JJ N
morbidity NN N
, , N
readmission NN N
rate NN N
, , N
and CC N
in-hospital JJ N
mortality NN N
were VBD N
recorded VBN N
. . N

RESULTS NNP N
Compared VBD N
with IN N
open JJ N
operation NN N
, , N
laparoscopic JJ N
colon NN N
operation NN N
effectively RB N
inhibited VBD N
the DT N
release NN N
of IN N
post-operative JJ N
inflammatory JJ N
factors NNS N
and CC N
yielded VBD N
good JJ N
protection NN N
via IN N
post-operative JJ N
cell NN N
immunity NN N
. . N

FT NNP N
surgery NN N
had VBD N
a DT N
better RBR N
protective JJ N
role NN N
with IN N
respect NN N
to TO N
the DT N
post-operative JJ N
immune NN N
system NN N
compared VBN N
with IN N
traditional JJ N
peri-operative JJ N
care NN N
. . N

Inflammatory JJ N
reactions NNS N
, , N
based VBN N
on IN N
interleukin-6 JJ N
and CC N
C-reactive JJ N
protein NN N
levels NNS N
, , N
were VBD N
less JJR N
intense JJ N
following VBG N
FT NNP N
laparoscopic NN N
operation NN N
compared VBN N
to TO N
FT NNP N
open JJ N
operation NN N
; : N
however RB N
, , N
there EX N
were VBD N
no DT N
differences NNS N
in IN N
specific JJ N
immunity NN N
( ( N
CD3+ NNP N
and CC N
CD4+ NNP N
counts NNS N
, , N
and CC N
the DT N
CD4+/CD8+ NNP N
ratio NN N
) ) N
during IN N
these DT N
two CD N
types NNS N
of IN N
surgical JJ N
procedures NNS N
. . N

Post-operative JJ N
hospital NN N
stay NN N
in IN N
patients NNS N
randomized VBN N
to TO N
the DT N
FT NNP N
laparoscopic NN N
group NN N
was VBD N
significantly RB N
shorter JJR N
than IN N
in IN N
the DT N
other JJ N
three CD N
treatment NN N
groups NNS N
( ( N
P NNP N
< NNP N
0.01 CD N
) ) N
. . N

Post-operative JJ N
complications NNS N
in IN N
patients NNS N
who WP N
underwent VBP N
FT NNP N
laparoscopic NN N
treatment NN N
were VBD N
less JJR N
than IN N
in IN N
the DT N
other JJ N
three CD N
treatment NN N
groups NNS N
( ( N
P NNP N
< NNP N
0.05 CD N
) ) N
. . N

There EX N
were VBD N
no DT N
significant JJ N
differences NNS N
between IN N
the DT N
four CD N
treatment NN N
groups NNS N
regarding VBG N
readmission NN N
rate NN N
and CC N
in-hospital JJ N
mortality NN N
. . N

CONCLUSIONS VB N
The DT N
laparoscopic NN N
technique NN N
and CC N
FT NNP N
surgery NN N
rehabilitation NN N
program NN N
effectively RB N
inhibited VBD N
release NN N
of IN N
post-operative JJ N
inflammatory JJ N
factors NNS N
with IN N
a DT N
reduction NN N
in IN N
peri-operative JJ N
trauma NN N
and CC N
stress NN N
, , N
which WDT N
together RB N
played VBD N
a DT N
protective JJ N
role NN N
on IN N
the DT N
post-operative JJ N
immune NN N
system NN N
. . N

Combining VBG N
two CD N
treatment NN N
measures NNS N
during IN N
colon NN N
operation NN N
produced VBD N
better RBR N
protective JJ N
effects NNS N
via IN N
the DT N
immune JJ N
system NN N
. . N

The DT N
beneficial JJ N
clinical JJ N
effects NNS N
support NN N
that IN N
the DT N
better-preserved JJ N
post-operative JJ N
immune NN N
system NN N
may MD N
also RB N
contribute VB N
to TO N
the DT N
improvement NN N
of IN N
post-operative JJ N
results NNS N
in IN N
FT NNP N
laparoscopic NN N
patients NNS N
. . N

-DOCSTART- -X- O O

A DT N
double-blind JJ N
randomized JJ N
clinical JJ N
evaluation NN N
of IN N
enamel JJ 3_i
matrix NNS 3_i
derivative JJ 3_i
proteins NNS 3_i
for IN N
the DT N
treatment NN N
of IN N
proximal JJ N
class-II JJ N
furcation NN N
involvements NNS N
. . N

OBJECTIVE IN N
The DT N
aim NN N
of IN N
the DT N
present JJ N
randomized VBN N
, , N
double-blind JJ N
study NN N
was VBD N
to TO N
evaluate VB N
the DT N
clinical JJ N
response NN N
of IN N
proximal JJ N
furcations NNS N
treated VBN N
with IN N
enamel JJ 3_i
matrix NNS 3_i
derivative JJ 3_i
proteins NNS 3_i
( ( 3_i
EMD NNP 3_i
) ) 3_i
. . 3_i

MATERIAL NNP N
AND NNP N
METHODS NNP N
Fifteen NNP N
patients NNS N
, , N
each DT N
with IN N
a DT N
pair NN N
of IN N
contralateral JJ N
class-II JJ N
proximal JJ N
furcation NN N
involvements NNS N
, , N
presenting VBG N
probing VBG N
depths NNS N
( ( N
PDs NNP N
) ) N
> VBP N
/=5 JJ N
mm NN N
and CC N
bleeding NN N
on IN N
probing VBG N
( ( N
BOP NNP N
) ) N
were VBD N
selected VBN N
. . N

The DT N
patients NNS N
were VBD N
randomly RB N
assigned VBN N
to TO N
: : N
control NN 7_i
group NN 7_i
( ( N
n=15 NN N
) ) N
- : N
open JJ 7_i
flap NN 7_i
debridement NN 7_i
( ( 7_i
OFD NNP 7_i
) ) 7_i
+24 CD 7_i
% NN 7_i
ethylenediaminetetraacetic JJ 7_i
acid NN 7_i
( ( 7_i
EDTA NNP 7_i
) ) 7_i
conditioning NN 7_i
; : 3_i
test CC N
group NN N
( ( N
n=15 NN N
) ) N
- : N
OFD+24 CD 3_i
% NN 3_i
EDTA NNP 3_i
conditioning+EMD NN 3_i
application NN 3_i
. . 3_i

Plaque NNP N
index NN N
( ( N
PI NNP N
) ) N
, , N
BOP NNP N
, , N
PD NNP N
, , N
gingival NN N
margin NN N
position NN N
( ( N
GMP NNP N
) ) N
, , N
relative JJ N
vertical NN N
and CC N
horizontal JJ N
clinical JJ N
attachment NN N
level NN N
( ( N
RVCAL NNP N
and CC N
RHCAL NNP N
) ) N
, , N
vertical JJ N
and CC N
horizontal JJ N
bone NN N
level NN N
( ( N
VBL NNP N
and CC N
HBL NNP N
) ) N
and CC N
furcation JJ N
closure NN N
were VBD N
evaluated VBN N
immediately RB N
before IN N
and CC N
2 CD N
, , N
4 CD N
and CC N
6 CD N
months NNS N
after IN N
the DT N
surgeries NNS N
. . N

RESULTS NNP N
At IN N
6 CD N
months NNS N
, , N
the DT N
RVCAL NNP N
gains NNS N
of IN N
the DT N
control NN N
and CC N
test NN N
group NN N
were VBD N
0.39 CD N
+/- JJ N
1.00 CD N
and CC N
0.54 CD N
+/- JJ N
0.95 CD N
mm NN N
, , N
while IN N
the DT N
RHCAL NNP N
gains NNS N
were VBD N
1.21 CD N
+/- JJ N
2.28 CD N
and CC N
1.36 CD N
+/- JJ N
1.26 CD N
mm NN N
( ( N
p JJ N
> NNP N
0.05 CD N
) ) N
. . N

The DT N
VBL NNP N
and CC N
HBL NNP N
gains NNS N
of IN N
the DT N
control NN N
group NN N
were VBD N
1.04 CD N
+/- JJ N
1.12 CD N
and CC N
1.00 CD N
+/- JJ N
1.79 CD N
mm NN N
, , N
and CC N
0.82 CD N
+/- JJ N
1.82 CD N
and CC N
1.17 CD N
+/- JJ N
1.38 CD N
mm NN N
for IN N
the DT N
test NN N
group NN N
( ( N
p JJ N
> NNP N
0.05 CD N
) ) N
. . N

In IN N
addition NN N
, , N
a DT N
statistical JJ N
difference NN N
was VBD N
observed VBN N
in IN N
the DT N
number NN N
of IN N
the DT N
remaining VBG N
class-II JJ N
furcations NNS N
between IN N
the DT N
test NN N
and CC N
control NN N
groups NNS N
( ( N
p JJ N
< NNP N
0.05 CD N
) ) N
in IN N
this DT N
period NN N
. . N

CONCLUSION VB N
It PRP N
may MD N
be VB N
concluded VBN N
that IN N
the DT N
use NN N
of IN N
EMD NNP 3_i
in IN N
proximal JJ N
furcations NNS N
did VBD N
not RB N
promote VB N
a DT N
superior JJ N
reduction NN N
in IN N
PD NNP N
or CC N
a DT N
gain NN N
in IN N
clinical JJ N
and CC N
osseous JJ N
attachment NN N
levels NNS N
, , N
but CC N
resulted VBD N
in IN N
a DT N
higher JJR N
rate NN N
of IN N
class-II NN N
to TO N
class-I JJ N
furcation NN N
conversion NN N
. . N

-DOCSTART- -X- O O

The DT N
effect NN N
of IN N
body NN N
positioning VBG N
upon IN N
maximal JJ 3_i
oxygenation NN 3_i
of IN N
patients NNS N
with IN N
unilateral JJ N
lung NN N
pathology NN N
. . N

A DT N
quasi-experimental JJ N
, , N
repeated-measures JJ N
cross-over NN N
design NN N
study NN N
on IN N
the DT N
effect NN N
of IN N
body NN N
position NN N
on IN N
oxygenation NN 3_i
( ( 3_i
SaO2 NNP 3_i
) ) 3_i
blood NN N
pressure NN N
, , N
respiration NN N
and CC N
pulse NN N
in IN N
patients NNS N
with IN N
unilateral JJ N
lung NN N
pathology NN N
was VBD N
conducted VBN N
. . N

Previous JJ N
research NN N
strongly RB N
suggests VBZ N
that IN N
positioning VBG N
with IN N
the DT N
healthy JJ N
( ( N
unaffected JJ N
) ) N
lung NN N
in IN N
the DT N
dependent JJ N
lateral NN N
( ( N
down RP N
) ) N
position NN N
is VBZ N
related VBN N
to TO N
improved VBN N
oxygenation NN N
, , N
but CC N
knowledge VBP N
about IN N
whether IN N
this DT N
effect NN N
is VBZ N
maintained VBN N
over IN N
time NN N
is VBZ N
lacking VBG N
. . N

The DT N
purpose NN N
of IN N
this DT N
investigation NN N
was VBD N
to TO N
determine VB N
: : N
( ( N
1 CD N
) ) N
Is VBZ N
positioning VBG N
with IN N
the DT N
unaffected JJ N
lung NN N
in IN N
the DT N
dependent JJ N
lateral JJ N
position NN N
related VBN N
to TO N
increased VBN N
arterial JJ N
blood NN N
saturation NN N
levels NNS N
and CC N
decreased VBD N
blood NN N
pressure NN N
, , N
pulse NN N
and CC N
respiration NN N
? . N
( ( N
2 CD N
) ) N
What WP N
is VBZ N
the DT N
relationship NN N
between IN N
the DT N
dependent JJ N
variables NNS N
-- : N
oxygenation NN N
saturation NN N
levels NNS N
, , N
blood NN N
pressure NN N
, , N
pulse NN N
and CC N
respiration NN N
-- : N
and CC N
the DT N
independent JJ N
variables NNS N
-- : N
body NN N
position NN N
and CC N
time NN N
in IN N
the DT N
position NN N
? . N
Thirty-nine JJ N
patients NNS N
with IN N
unilateral JJ N
lung NN N
pathology NN N
were VBD N
positioned VBN N
on IN N
their PRP$ N
sides NNS N
with IN N
the DT N
unaffected JJ N
lung NN N
down RP N
, , N
on IN N
their PRP$ N
sides NNS N
with IN N
the DT N
affected JJ N
lung NN N
down RB N
, , N
and CC N
also RB N
in IN N
semi-Fowler NN N
's POS N
position NN N
. . N

Arterial NNP 2_i
( ( 2_i
SaO2 NNP 2_i
) ) 2_i
blood NN 2_i
saturation NN 2_i
and CC N
vital JJ 2_i
signs NNS 2_i
were VBD N
measured VBN N
at IN N
baseline NN N
0 CD N
, , N
15 CD N
and CC N
30 CD N
minutes NNS N
. . N

There EX N
was VBD N
no DT N
statistically RB N
significant JJ N
relationship NN N
between IN N
oxygenation NN N
level NN N
or CC N
systolic JJ N
blood NN N
pressure NN N
. . N

Diastolic NNP N
blood NN N
pressure NN N
, , N
respiration NN N
and CC N
pulse NN N
did VBD N
vary JJ N
significantly RB N
with IN N
position NN N
. . N

-DOCSTART- -X- O O

Small NN N
but CC N
important JJ N
errors NNS N
in IN N
cardiovascular JJ N
risk NN N
calculation NN N
by IN N
practice NN N
nurses NNS N
: : N
a DT N
cross-sectional JJ N
study NN N
in IN N
randomised JJ N
trial NN N
setting NN N
. . N

BACKGROUND NNP N
Practice NNP N
nurses NNS N
play VBP N
an DT N
increasingly RB N
important JJ N
role NN N
in IN N
the DT N
prevention NN N
of IN N
cardiovascular JJ N
diseases NNS N
but CC N
we PRP N
do VBP N
not RB N
have VB N
evidence NN N
about IN N
the DT N
accuracy NN N
of IN N
their PRP$ N
cardiovascular JJ N
risk NN N
assessments NNS N
during IN N
real JJ N
practice NN N
consultations NNS N
. . N

OBJECTIVES NNP N
To TO N
examine VB N
how WRB N
nurses NNS N
perform VBP N
with IN N
regard NN N
to TO N
absolute VB N
10-year JJ N
cardiovascular JJ N
risk NN N
assessment NN N
in IN N
actual JJ N
practice NN N
. . N

DESIGN NNP N
Cross-sectional JJ N
study NN N
. . N

SETTING NN N
This DT N
study NN N
was VBD N
nested VBN N
in IN N
the DT N
IMPALA NNP N
study NN N
, , N
a DT N
clustered VBN N
randomised VBN N
controlled VBN N
trial NN N
involving VBG N
24 CD N
general JJ N
practices NNS N
in IN N
The DT N
Netherlands NNP N
. . N

PARTICIPANTS VB N
24 CD N
practice NN N
nurses NNS N
, , N
trained VBN N
in IN N
10-year JJ N
cardiovascular JJ N
risk NN N
assessment NN N
, , N
calculated VBD N
the DT N
risk NN N
of IN N
a DT N
total NN N
of IN N
421 CD N
patients NNS N
without IN N
established VBN N
cardiovascular JJ N
diseases NNS N
but CC N
eligible JJ N
for IN N
cardiovascular JJ N
risk NN N
assessment NN N
. . N

METHODS NNP N
The DT N
main JJ N
outcome NN N
measure NN N
was VBD N
the DT N
accuracy NN 6_i
of IN 6_i
risk NN 6_i
assessments NNS 6_i
, , N
defined VBN N
as IN N
( ( N
1 CD N
) ) N
the DT N
difference NN N
between IN N
the DT N
10-year JJ N
cardiovascular JJ N
risk NN N
percentage NN N
calculated VBN N
by IN N
nurses NNS 6_i
and CC N
an DT N
independent JJ N
assessor NN N
, , N
and CC N
( ( N
2 CD N
) ) N
the DT N
agreement NN N
between IN N
the DT N
treatment NN N
categories NNS N
assigned VBN N
by IN N
the DT N
nurses NNS 6_i
( ( N
low JJ N
, , N
moderate JJ N
or CC N
high JJ N
risk NN N
) ) N
and CC N
those DT N
assigned VBN N
by IN N
the DT N
independent JJ N
assessor NN N
. . N

RESULTS VB N
Thirty-one NNP N
( ( N
7.4 CD N
% NN N
) ) N
of IN N
the DT N
calculated JJ N
risk NN N
percentages NNS N
differed VBN N
by IN N
more JJR N
than IN N
our PRP$ N
preset NN N
limits NNS N
, , N
25 CD N
( ( N
81 CD N
% NN N
) ) N
being VBG N
underestimations NNS N
. . N

Elderly JJ N
patients NNS N
( ( N
OR NNP N
1.1 CD N
, , N
95 CD N
% NN N
CI NNP N
1.0-1.1 CD N
) ) N
, , N
male JJ N
patients NNS N
( ( N
vs. FW N
female NN N
OR NNP N
3.1 CD N
, , N
95 CD N
% NN N
CI NNP N
1.2-7.3 CD N
) ) N
, , N
and CC N
smoking NN N
patients NNS N
( ( N
vs. IN N
non-smoking NN N
OR NNP N
3.8 CD N
, , N
95 CD N
% NN N
CI NNP N
1.7-8.9 CD N
) ) N
were VBD N
more RBR N
likely JJ N
to TO N
have VB N
their PRP$ N
cardiovascular JJ N
risk NN N
miscalculated VBD N
. . N

Ten NNP N
( ( N
28 CD N
% NN N
) ) N
of IN N
the DT N
36 CD N
patients NNS N
who WP N
should MD N
be VB N
assigned VBN N
to TO N
the DT N
high-risk JJ N
treatment NN N
category NN N
according VBG N
to TO N
the DT N
independent JJ N
calculation NN N
, , N
were VBD N
missed VBN N
as IN N
high-risk JJ N
patients NNS N
by IN N
the DT N
practice NN N
nurses NNS N
. . N

CONCLUSIONS VB N
The DT N
overall JJ N
standard NN N
of IN N
accuracy NN N
of IN N
cardiovascular JJ 6_i
risk NN 6_i
assessment NN 6_i
by IN N
trained JJ N
practice NN N
nurses NNS N
in IN N
actual JJ N
practice NN N
is VBZ N
high JJ N
. . N

However RB N
, , N
a DT N
significant JJ N
number NN N
of IN N
high-risk JJ N
patients NNS N
were VBD N
misclassified VBN N
, , N
with IN N
the DT N
probability NN N
that IN N
it PRP N
led VBD N
to TO N
missed VBN N
opportunities NNS N
for IN N
risk-reducing JJ N
interventions NNS N
. . N

As IN N
cardiovascular JJ N
risk NN N
assessments NNS N
are VBP N
frequently RB N
done VBN N
by IN N
nurses NNS N
in IN N
general JJ N
practice NN N
, , N
further JJ N
specific JJ N
training NN N
should MD N
be VB N
considered VBN N
to TO N
prevent VB N
undertreatment NN N
. . N

-DOCSTART- -X- O O

1999 CD N
WHO/ISH NNP N
Guidelines NNP N
applied VBD N
to TO N
a DT N
1999 CD N
MONICA NNP N
sample NN N
from IN N
northern JJ N
Sweden NNP N
. . N

BACKGROUND NNP N
Treating NNP N
hypertension NN N
with IN N
drugs NNS N
is VBZ N
so RB N
far RB N
the DT N
most RBS N
cost-effective JJ N
way NN N
to TO N
reduce VB N
this DT N
important JJ N
risk NN N
factor NN N
for IN N
cardiovascular JJ N
disease NN N
( ( N
CVD NNP N
) ) N
. . N

It PRP N
is VBZ N
, , N
however RB N
, , N
important JJ N
to TO N
determine VB N
absolute NN N
risk NN N
, , N
and CC N
thereby RB N
estimate VB N
indication NN N
for IN N
drug NN N
treatment NN N
, , N
in IN N
order NN N
to TO N
maintain VB N
a DT N
cost-effective JJ N
drug NN N
treatment NN N
. . N

WHO/ISH NNP N
Hypertension NNP N
Guidelines NNP N
from IN N
1999 CD N
propose NN N
a DT N
risk NN N
stratification NN N
for IN N
estimating VBG N
absolute NN N
risk NN N
for IN N
CVD NNP N
based VBN N
on IN N
blood NN N
pressure NN N
and CC N
additional JJ N
risk NN N
factors NNS N
, , N
target NN N
organ JJ N
damage NN N
( ( N
TOD NNP N
) ) N
and CC N
CVD NNP N
. . N

OBJECTIVES NNP N
We PRP N
studied VBD N
the DT N
consequences NNS N
of IN N
applying VBG N
the DT N
recent JJ N
WHO/ISH NNP 3_i
risk NN 3_i
stratification NN 3_i
scheme NN 3_i
to TO N
a DT N
MONICA NNP N
sample NN N
of IN N
6000 CD N
subjects NNS N
from IN N
a DT N
geographically RB N
defined VBN N
population NN N
in IN N
northern JJ N
Sweden NNP N
, , N
regarding VBG N
indications NNS N
for IN N
treatment NN N
, , N
target VB N
blood NN N
pressure NN N
and CC N
risk NN N
distribution NN N
. . N

METHODS NNP N
We PRP N
have VBP N
risk-classified JJ N
each DT N
of IN N
these DT N
patients NNS N
using VBG N
a DT N
computer NN 6_i
program NN 6_i
, , N
according VBG N
to TO N
the DT N
WHO/ISH NNP N
scheme NN N
. . N

Data NNP N
on IN N
TOD NNP N
were VBD N
not RB N
available JJ N
. . N

RESULTS NNP N
In IN N
all DT N
, , N
917 CD N
( ( N
15 CD N
% NN N
) ) N
had VBD N
drug-treated JJ N
hypertension NN N
. . N

Three-quarters NNS N
( ( N
n JJ N
= NNP N
737 CD N
) ) N
were VBD N
inadequately RB N
treated VBN N
, , N
with IN N
blood NN N
pressure NN N
levels NNS N
at IN N
or CC N
above VB N
140 CD N
or CC N
90 CD N
mmHg NN N
. . N

1773 CD N
( ( N
30 CD N
% NN N
of IN N
5997 CD N
) ) N
untreated JJ N
subjects NNS N
had VBD N
a DT N
blood NN N
pressure NN N
of IN N
140/90 CD N
or CC N
above RB N
; : N
16 CD N
% NN N
in IN N
the DT N
low- JJ N
, , N
62 CD N
% NN N
in IN N
the DT N
medium- NN N
, , N
8 CD N
% NN N
in IN N
the DT N
high- NN N
, , N
and CC N
14 CD N
% NN N
in IN N
the DT N
very-high-risk JJ N
group NN N
. . N

The DT N
corresponding JJ N
risk-group JJ N
pattern NN N
for IN N
the DT N
inadequately RB N
treated JJ N
hypertensives NNS N
( ( N
n JJ N
= NNP N
737 CD N
) ) N
was VBD N
5.5 CD N
, , N
48.3 CD N
, , N
11.1 CD N
and CC N
35.2 CD N
% NN N
, , N
respectively RB N
. . N

If IN N
we PRP N
shifted VBD N
the DT N
target NN N
blood NN N
pressure NN N
from IN N
below IN N
140/90 CD N
to TO N
below VB N
130/85 CD N
for IN N
drug-treated JJ N
subjects NNS N
under IN N
60 CD N
( ( N
n JJ N
= NNP N
278 CD N
) ) N
the DT N
number NN N
of IN N
inadequately RB N
treated JJ N
subjects NNS N
increased VBN N
by IN N
34 CD N
( ( N
12.2 CD N
% NN N
of IN N
278 CD N
) ) N
; : N
14 CD N
in IN N
the DT N
low-risk JJ N
group NN N
, , N
15 CD N
in IN N
the DT N
medium-risk JJ N
group NN N
, , N
and CC N
only RB N
five CD N
in IN N
the DT N
high- JJ N
or CC N
very-high-risk JJ N
groups NNS N
. . N

CONCLUSIONS NNP N
Only RB N
one-fifth NN N
of IN N
the DT N
drug-treated JJ N
hypertensives NNS N
were VBD N
well RB N
controlled VBN N
. . N

Moreover RB N
, , N
the DT N
incidence NN N
of IN N
newly RB N
detected VBN N
blood NN N
pressure NN N
elevation NN N
was VBD N
high JJ N
. . N

The DT N
majority NN N
of IN N
younger JJR N
subjects NNS N
with IN N
high JJ N
blood NN N
pressure NN N
had VBD N
low JJ N
risk NN N
, , N
but CC N
in IN N
those DT N
aged VBN N
45-54 CD N
this DT N
had VBD N
already RB N
risen VBN N
to TO N
a DT N
medium NN N
risk NN N
. . N

Changing VBG N
the DT N
target NN N
blood NN N
pressure NN N
to TO N
below IN N
130/85 CD N
, , N
for IN N
subjects NNS N
aged VBN N
below IN N
60 CD N
, , N
as IN N
recommended VBN N
by IN N
WHO/ISH NNP N
, , N
affects VBZ N
predominantly RB N
low- JJ N
and CC N
medium-risk JJ N
groups NNS N
. . N

-DOCSTART- -X- O O

VLDL NNP N
, , N
apolipoproteins VBZ N
B NNP N
, , N
CIII NNP N
, , N
and CC N
E NNP N
, , N
and CC N
risk NN N
of IN N
recurrent JJ N
coronary JJ N
events NNS N
in IN N
the DT N
Cholesterol NNP N
and CC N
Recurrent NNP N
Events NNP N
( ( N
CARE NNP N
) ) N
trial NN N
. . N

BACKGROUND NNP N
Plasma NNP N
triglyceride NN N
concentration NN N
has VBZ N
been VBN N
an DT N
inconsistent JJ N
independent JJ N
risk NN N
factor NN N
for IN N
coronary JJ N
heart NN N
disease NN N
, , N
perhaps RB N
because IN N
of IN N
the DT N
metabolic JJ N
heterogeneity NN N
among IN N
VLDL NNP N
particles NNS N
, , N
the DT N
main JJ N
carriers NNS N
of IN N
triglycerides NNS N
in IN N
plasma NN N
. . N

METHODS NNP N
AND CC N
RESULTS NNP N
We PRP N
conducted VBD N
a DT N
prospective JJ N
, , N
nested JJ N
case-control NN N
study NN N
in IN N
the DT N
Cholesterol NNP N
and CC N
Recurrent NNP N
Events NNP N
( ( N
CARE NNP N
) ) N
trial NN N
, , N
a DT N
randomized JJ N
placebo-controlled JJ 7_i
trial NN N
of IN N
pravastatin NN 3_i
in IN N
4159 CD N
patients NNS N
with IN N
myocardial JJ N
infarction NN N
and CC N
average JJ N
LDL NNP N
concentrations NNS N
at IN N
baseline NN N
( ( N
115 CD N
to TO N
174 CD N
mg/dL NNS N
, , N
mean VBP N
139 CD N
mg/dL NN N
) ) N
. . N

Baseline NNP N
concentrations NNS N
of IN N
VLDL-apolipoprotein NNP N
( ( N
apo NN N
) ) N
B NNP N
( ( N
the DT N
VLDL NNP N
particle NN N
concentration NN N
) ) N
, , N
VLDL NNP N
lipids NNS N
, , N
and CC N
apoCIII NN N
and CC N
apoE NN N
in IN N
VLDL+LDL NNP N
and CC N
in IN N
HDL NNP N
were VBD N
compared VBN N
in IN N
patients NNS N
who WP N
had VBD N
either CC N
a DT N
myocardial JJ N
infarction NN N
or CC N
coronary JJ N
death NN N
( ( N
cases NNS N
, , N
n=418 NN N
) ) N
with IN N
those DT N
in IN N
patients NNS N
who WP N
did VBD N
not RB N
have VB N
a DT N
cardiovascular JJ N
event NN N
( ( N
control NN N
subjects VBZ N
, , N
n=370 NN N
) ) N
in IN N
5 CD N
years NNS N
of IN N
follow-up JJ N
. . N

VLDL-cholesterol NN N
, , N
VLDL-triglyceride NNP N
, , N
VLDL-apoB NNP N
, , N
apoCIII NN N
and CC N
apoE NN N
in IN N
VLDL+LDL NNP N
and CC N
apoE NN N
in IN N
HDL NNP N
were VBD N
all DT N
interrelated VBN N
, , N
and CC N
each DT N
was VBD N
a DT N
univariate JJ N
predictor NN N
of IN N
subsequent JJ N
coronary JJ N
events NNS N
. . N

The DT N
significant JJ N
independent JJ N
predictors NNS N
were VBD N
VLDL-apoB NNP N
( ( N
relative JJ N
risk NN N
[ NNP N
RR NNP N
] VBZ N
3.2 CD N
for IN N
highest JJS N
to TO N
lowest JJS N
quintiles NNS N
, , N
P NNP N
: : N
=0.04 NN N
) ) N
, , N
apoCIII RB N
in IN N
VLDL+LDL NNP N
( ( N
RR NNP N
2.3 CD N
, , N
P NNP N
: : N
=0.04 NN N
) ) N
, , N
and CC N
apoE NN N
in IN N
HDL NNP N
( ( N
RR NNP N
1.8 CD N
, , N
P NNP N
: : N
=0.02 NN N
) ) N
. . N

Plasma NNP N
triglycerides NNS N
, , N
a DT N
univariate JJ N
predictor NN N
of IN N
coronary JJ N
events NNS N
( ( N
RR NNP N
1.6 CD N
, , N
P NNP N
: : N
=0.03 NN N
) ) N
, , N
was VBD N
not RB N
related VBN N
to TO N
coronary JJ N
events NNS N
( ( N
RR NNP N
1.3 CD N
, , N
P NNP N
: : N
=0.6 NN N
) ) N
when WRB N
apoCIII NN N
in IN N
VLDL+LDL NNP N
was VBD N
included VBN N
in IN N
the DT N
model NN N
, , N
whereas JJ N
apoCIII NN N
remained VBD N
significant JJ N
. . N

Adjustment NN N
for IN N
LDL- NNP N
and CC N
HDL-cholesterol NNP N
did VBD N
not RB N
affect VB N
these DT N
results NNS N
. . N

CONCLUSIONS NNP N
The DT N
plasma JJ N
concentrations NNS N
of IN N
VLDL NNP N
particles NNS N
and CC N
apoCIII NN N
in IN N
VLDL NNP N
and CC N
LDL NNP N
are VBP N
more RBR N
specific JJ N
measures NNS N
of IN N
coronary JJ N
heart NN N
disease NN N
risk NN N
than IN N
plasma JJ N
triglycerides NNS N
perhaps RB N
because IN N
their PRP$ N
known VBN N
metabolic NN N
properties NNS N
link VBP N
them PRP N
more RBR N
closely RB N
to TO N
atherosclerosis NN N
. . N

-DOCSTART- -X- O O

Effect NN N
of IN N
ranolazine NN 3_i
on IN N
A1C NNP N
and CC N
glucose JJ N
levels NNS N
in IN N
hyperglycemic JJ N
patients NNS N
with IN N
non-ST JJ N
elevation NN N
acute NN N
coronary JJ N
syndrome NN N
. . N

OBJECTIVE IN N
We PRP N
determined VBD N
the DT N
relationships NNS N
between IN N
glycemia NN N
at IN N
randomization NN N
, , N
concurrent JJ 3_i
antidiabetic JJ 3_i
therapy NN 3_i
, , N
and CC N
change NN N
in IN N
A1C NNP N
and CC N
fasting VBG N
plasma NN N
glucose NN N
( ( N
FPG NNP N
) ) N
in IN N
patients NNS N
with IN N
diabetes NNS N
receiving VBG N
standard JJ N
treatment NN N
for IN N
diabetes NNS N
and CC N
randomized VBN N
to TO N
ranolazine VB 3_i
or CC N
placebo VB 7_i
within IN N
the DT N
MERLIN-TIMI-36 NNP N
( ( N
MERLIN NNP N
) ) N
study NN N
. . N

Ranolazine NNP 3_i
is VBZ N
a DT N
novel JJ N
first-in-class JJ N
drug NN N
approved VBD N
for IN N
treating VBG N
angina JJ N
pectoris NN N
. . N

RESEARCH NNP N
DESIGN NNP N
AND NNP N
METHODS NNP N
Randomization NNP N
and CC N
4-month JJ N
glycemic NN N
and CC N
antidiabetes VBZ 3_i
drug NN 3_i
usage NN N
data NNS N
from IN N
MERLIN NNP N
were VBD N
analyzed VBN N
using VBG N
Spotfire NNP N
and CC N
SAS NNP N
version NN N
9.1 CD N
software NN N
. . N

RESULTS NNP N
In IN N
patients NNS N
with IN N
diabetes NNS N
and CC N
A1C NNP N
of IN N
> NNP N
or=8-10 JJ N
% NN N
at IN N
randomization NN N
( ( N
n JJ N
= NNP N
171 CD N
) ) N
, , N
there EX N
was VBD N
an DT N
absolute JJ N
A1C NNP N
reduction NN N
in IN N
the DT N
ranolazine NN 3_i
group NN N
of IN N
1.2 CD N
% NN N
( ( N
95 CD N
% NN N
CI NNP N
-1.4 NNP N
to TO N
-1.0 VB N
) ) N
, , N
and CC N
the DT N
placebo-adjusted JJ 7_i
( ( N
n JJ N
= NNP N
182 CD N
) ) N
decrease NN N
in IN N
A1C NNP N
by IN N
ranolazine NN N
was VBD N
0.59 CD N
% NN N
( ( N
95 CD N
% NN N
CI NNP N
-0.99 NNP N
to TO N
-0.20 VB N
, , N
P NNP N
< NNP N
0.001 CD N
) ) N
. . N

In IN N
patients NNS N
with IN N
FPG NNP N
of IN N
150-400 JJ N
mg/dl NN N
at IN N
randomization NN N
, , N
ranolazine NN 3_i
( ( N
n JJ N
= NNP N
131 CD N
) ) N
compared VBN N
with IN N
placebo NN 7_i
( ( N
n JJ N
= NNP N
147 CD N
) ) N
reduced VBN N
FPG NNP N
by IN N
25.7 CD N
mg/dl NNS N
( ( N
95 CD N
% NN N
CI NNP N
-43.3 NNP N
to TO N
-8.1 VB N
, , N
P NNP N
= NNP N
0.001 CD N
) ) N
. . N

When WRB N
changes NNS N
in IN N
either DT N
A1C NNP N
or CC N
FPG NNP N
were VBD N
correlated VBN N
to TO N
A1C NNP N
or CC N
FPG NNP N
at IN N
randomization NN N
, , N
the DT N
slopes NNS N
were VBD N
significantly RB N
steeper JJR N
for IN N
ranolazine NN 3_i
than IN N
placebo NN 7_i
( ( N
A1C NNP N
, , N
P NNP N
= NNP N
0.046 CD N
; : N
FPG NNP N
, , N
P NNP N
< NNP N
0.001 CD N
) ) N
, , N
indicating VBG N
that IN N
lowering VBG N
of IN N
A1C NNP N
and CC N
FPG NNP N
by IN N
ranolazine NN 3_i
is VBZ N
related VBN N
to TO N
hyperglycemia VB N
at IN N
randomization NN N
. . N

Ranolazine NNP N
, , N
compared VBN N
with IN N
placebo NN N
, , N
was VBD N
not RB N
associated VBN N
with IN N
serious JJ N
hypoglycemic JJ N
events NNS N
, , N
associated VBN N
with IN N
significant JJ N
changes NNS N
in IN N
concurrent JJ N
antidiabetic JJ 3_i
therapy NN 3_i
, , N
or CC N
dependent NN N
on IN N
a DT N
history NN N
of IN N
angina NN N
. . N

CONCLUSIONS NNP N
Ranolazine NNP 3_i
, , N
when WRB N
added VBN N
to TO N
concurrent VB N
antidiabetes NNS N
treatment NN N
, , N
lowers NNS N
FPG NNP N
and CC N
A1C NNP N
in IN N
patients NNS N
with IN N
cardiovascular JJ N
disease NN N
and CC N
poorly RB N
controlled VBN N
diabetes NNS N
. . N

-DOCSTART- -X- O O

Effect NN N
of IN N
testosterone NN 3_i
and CC N
a DT N
nutritional JJ 3_i
supplement NN 3_i
, , N
alone RB N
and CC N
in IN N
combination NN N
, , N
on IN N
hospital JJ N
admissions NNS N
in IN N
undernourished JJ N
older JJR N
men NNS N
and CC N
women NNS N
. . N

BACKGROUND NNP N
In IN N
older JJR N
people NNS N
, , N
undernutrition NN N
is VBZ N
associated VBN N
with IN N
increased JJ N
hospitalization NN N
rates NNS N
and CC N
mortality NN N
. . N

Because IN N
weight JJ N
loss NN N
in IN N
older JJR N
people NNS N
often RB N
reflects VBZ N
a DT N
disproportionate JJ N
reduction NN N
of IN N
skeletal JJ N
muscle NN N
, , N
anabolic JJ N
treatments NNS N
may MD N
be VB N
beneficial JJ N
. . N

OBJECTIVE NNP N
Our PRP$ N
aim NN N
was VBD N
to TO N
evaluate VB N
the DT N
hypothesis NN N
that WDT N
testosterone NN 3_i
treatment NN N
and CC N
a DT N
nutritional JJ 3_i
supplement NN 3_i
have VBP N
additive JJ N
benefits NNS N
. . N

DESIGN NNP N
Oral NNP N
testosterone NN 3_i
undecanoate NN 3_i
( ( N
40 CD N
mg NNS N
daily RB N
for IN N
women NNS N
, , N
80 CD N
mg NN N
twice RB N
daily RB N
for IN N
men NNS N
) ) N
and CC N
an DT N
oral JJ N
nutritional JJ 3_i
supplement NN 3_i
( ( N
475 CD N
kcal/d NN N
) ) N
were VBD N
administered VBN N
, , N
alone RB N
or CC N
combined VBN N
, , N
for IN N
1 CD N
y NNS N
to TO N
49 CD N
community-dwelling NN N
, , N
undernourished JJ N
people NNS N
[ VBP N
Mini NNP N
Nutritional NNP N
Assessment NNP N
score VBD N
< JJ N
24 CD N
and CC N
low JJ N
body NN N
weight NN N
( ( N
body JJ N
mass NN N
index NN N
, , N
in IN N
kg/m NN N
( ( N
2 CD N
) ) N
: : N
< $ N
22 CD N
) ) N
or CC N
recent JJ N
weight JJ N
loss NN N
( ( N
> JJ N
7.5 CD N
% NN N
over IN N
3 CD N
mo NNS N
) ) N
] VBP N
aged VBN N
> $ N
65 CD N
y NN N
( ( N
mean JJ N
age NN N
: : N
77 CD N
y NN N
; : N
26 CD N
women NNS N
and CC N
23 CD N
men NNS N
) ) N
. . N

Hospital JJ N
admissions NNS N
and CC N
other JJ N
variables NNS N
were VBD N
assessed VBN N
. . N

RESULTS NNP N
In IN N
subjects NNS N
receiving VBG N
combined VBN N
testosterone NN 3_i
and CC N
nutritional JJ 3_i
supplements NNS 3_i
( ( N
n JJ N
= NNP N
11 CD N
) ) N
, , N
there EX N
were VBD N
no DT N
hospital NN N
admissions NNS N
, , N
whereas IN N
there EX N
were VBD N
9 CD N
admissions NNS N
( ( N
2 CD N
elective NN N
) ) N
in IN N
13 CD N
subjects NNS N
in IN N
the DT N
no-treatment JJ N
group NN N
, , N
4 CD N
in IN N
the DT N
testosterone-treated JJ 3_i
group NN N
( ( N
n JJ N
= NNP N
12 CD N
) ) N
, , N
and CC N
5 CD N
in IN N
the DT N
supplement-treated JJ 3_i
group NN N
( ( N
n JJ N
= NNP N
13 CD N
) ) N
; : N
P NNP N
= VBD N
0.06 CD N
with IN N
no-treatment JJ N
compared VBN N
with IN N
combined JJ N
treatment NN N
. . N

When WRB N
compared VBN N
with IN N
the DT N
no-treatment JJ N
group NN N
, , N
the DT N
combined-treatment JJ 3_i
group NN N
had VBD N
significantly RB N
fewer JJR N
subjects NNS N
admitted VBN N
to TO N
hospital VB N
( ( N
0 CD N
compared VBN N
with IN N
5 CD N
, , N
P NNP N
= NNP N
0.03 CD N
) ) N
, , N
fewer JJR N
days NNS N
in IN N
hospital NN N
( ( N
0 CD N
compared VBN N
with IN N
74 CD N
, , N
P NNP N
= NNP N
0.041 CD N
) ) N
, , N
and CC N
a DT N
longer JJR N
time NN N
to TO N
hospital VB N
admission NN N
( ( N
P NNP N
= NNP N
0.017 CD N
) ) N
. . N

CONCLUSIONS NNP N
In IN N
undernourished JJ N
older JJR N
people NNS N
, , N
combined VBN N
treatment NN N
with IN N
testosterone NN 3_i
and CC N
nutritional JJ 3_i
supplementation NN 3_i
reduced VBD N
the DT N
number NN N
of IN N
people NNS N
hospitalized VBN N
and CC N
the DT N
duration NN N
of IN N
hospital NN N
admissions NNS N
, , N
which WDT N
are VBP N
important JJ N
endpoints NNS N
in IN N
this DT N
group NN N
. . N

Larger NNP N
, , N
confirmatory NN N
studies NNS N
are VBP N
now RB N
needed VBN N
. . N

This DT N
trial NN N
was VBD N
registered VBN N
before IN N
commencement NN N
at IN N
clinical JJ N
trials.gov NN N
as IN N
NCT00117000 NNP N
. . N

-DOCSTART- -X- O O

Motion NNP 2_i
style NN 2_i
acupuncture NN 2_i
treatment NN 2_i
( ( 2_i
MSAT NNP 2_i
) ) 2_i
for IN N
acute NN N
low JJ N
back RB N
pain NN N
with IN N
severe JJ N
disability NN N
: : N
a DT N
multicenter NN N
, , N
randomized VBN N
, , N
controlled VBN N
trial NN N
protocol NN N
. . N

BACKGROUND NNP N
Acupuncture NNP N
is VBZ N
widely-used JJ N
to TO N
treat VB N
patients NNS N
with IN N
low JJ N
back RB N
pain NN N
, , N
despite IN N
insufficient JJ N
evidence NN N
of IN N
the DT N
technique NN N
's POS N
efficacy NN N
for IN N
acute NN N
back RB N
pain NN N
. . N

Motion NNP 2_i
style NN 2_i
acupuncture NN 2_i
treatment NN 2_i
( ( 2_i
MSAT NNP 2_i
) ) 2_i
is VBZ N
a DT N
non-traditional JJ N
acupuncture NN N
treatment NN N
requiring VBG N
a DT N
patient NN N
to TO N
exercise VB N
while IN N
receiving VBG N
acupuncture NN N
. . N

In IN N
Korea NNP N
, , N
MSAT NNP N
is VBZ N
used VBN N
to TO N
reduce VB N
musculoskeletal JJ N
pain NN N
and CC N
improve VB N
functional JJ N
status NN N
. . N

The DT N
study NN N
aims VBZ N
to TO N
evaluate VB N
the DT N
effect NN N
of IN N
MSAT NNP N
on IN N
acute NN N
low JJ N
back RB N
pain NN N
with IN N
severe JJ N
disability NN N
. . N

METHODS/DESIGN NNP N
This DT N
study NN N
is VBZ N
a DT N
multicenter NN N
, , N
randomized VBN N
, , N
active-controlled JJ N
trial NN N
with IN N
two CD N
parallel JJ N
arms NNS N
. . N

Participants NNS N
with IN N
acute NN N
low JJ N
back RB N
pain NN N
and CC N
severe JJ N
functional JJ N
disability NN N
, , N
defined VBD N
as IN N
an DT N
Oswestry NNP N
Disability NNP N
Index NNP N
( ( N
ODI NNP N
) ) N
value NN N
> $ N
60 CD N
% NN N
, , N
will MD N
be VB N
randomly RB N
allocated VBN N
to TO N
the DT N
acupuncture NN 2_i
group NN N
and CC N
the DT N
nonsteroidal JJ 3_i
anti-inflammatory JJ 3_i
drug NN 3_i
( ( 3_i
NSAID NNP 3_i
) ) 3_i
injection NN 3_i
group NN 3_i
. . N

The DT N
acupuncture NN N
group NN N
will MD N
receive VB N
MSAT NNP 2_i
and CC N
the DT N
NSAID NNP 3_i
injection NN 3_i
group NN 3_i
will MD N
receive VB N
an DT N
intramuscular JJ N
injection NN N
of IN N
diclofenac NN 3_i
. . 3_i

All DT N
procedures NNS N
will MD N
be VB N
limited VBN N
to TO N
one CD N
session NN N
and CC N
the DT N
symptoms NNS N
before IN N
and CC N
after IN N
treatment NN N
will MD N
be VB N
measured VBN N
by IN N
assessors NNS N
blinded VBD N
to TO N
treatment NN N
allocation NN N
. . N

The DT N
primary JJ N
outcome NN N
will MD N
be VB N
measured VBN N
at IN N
30 CD N
minutes NNS N
after IN N
treatment NN N
using VBG N
the DT N
numerical JJ N
rating NN N
scale NN N
( ( N
NRS NNP N
) ) N
of IN N
low JJ N
back RB N
pain NN N
while IN N
the DT N
patient NN N
is VBZ N
moving VBG N
. . N

Secondary JJ N
outcomes NNS N
will MD N
be VB N
measured VBN N
at IN N
30 CD N
minutes NNS N
after IN N
treatment NN N
using VBG N
the DT N
NRS NNP N
of IN N
leg NN N
pain NN N
, , N
ODI NNP N
, , N
patient NN N
global JJ N
impression NN N
of IN N
change NN N
, , N
range NN N
of IN N
motion NN N
( ( N
ROM NNP N
) ) N
of IN N
the DT N
lumbar NN N
spine NN N
, , N
and CC N
degrees NNS N
of IN N
straight JJ N
leg NN N
raising VBG N
( ( N
SLR NNP N
) ) N
. . N

Post-treatment JJ N
follow-up NN N
will MD N
be VB N
performed VBN N
to TO N
measure VB N
primary JJ N
and CC N
secondary JJ N
outcomes NNS N
with IN N
the DT N
exception NN N
of IN N
ROM NNP N
and CC N
SLR NNP N
at IN N
2 CD N
, , N
4 CD N
, , N
and CC N
24 CD N
weeks NNS N
after IN N
treatment NN N
. . N

DISCUSSION NNP N
The DT N
results NNS N
of IN N
this DT N
trial NN N
will MD N
be VB N
discussed VBN N
. . N

TRIAL NNP N
REGISTRATION NNP N
ClinicalTrial.gov NNP N
NCT01315561 NNP N
. . N

-DOCSTART- -X- O O

Clofarabine NNP 3_i
? . 3_i
fludarabine NN 3_i
with IN N
once RB N
daily JJ N
i.v NN N
. . N

busulfan NN N
as IN N
pretransplant JJ N
conditioning NN N
therapy NN N
for IN N
advanced JJ N
myeloid NN N
leukemia NN N
and CC N
MDS NNP N
. . N

Although IN N
a DT N
combination NN N
of IN N
i.v NN N
. . N

busulfan NN N
( ( N
Bu NNP N
) ) N
and CC N
fludarabine NN 3_i
( ( N
Flu NNP N
) ) N
is VBZ N
a DT N
safe JJ N
, , N
reduced-toxicity JJ N
conditioning NN N
program NN N
for IN N
acute JJ N
myelogenous JJ N
leukemia/myelodysplastic JJ N
syndromes NNS N
( ( N
AML/MDS NNP N
) ) N
, , N
recurrent JJ N
leukemia NN N
posttransplantation NN N
remains VBZ N
a DT N
problem NN N
. . N

To TO N
enhance VB N
the DT N
conditioning NN N
regimen NN N
's POS N
antileukemic JJ N
effect NN N
, , N
we PRP N
decided VBD N
to TO N
supplant VB N
Flu NNP N
with IN N
clofarabine NN 3_i
( ( N
Clo NNP N
) ) N
, , N
and CC N
assayed VBD N
the DT N
interactions NNS N
of IN N
these DT N
nucleoside JJ N
analogs NNS N
alone RB N
and CC N
in IN N
combination NN N
with IN N
Bu NNP N
in IN N
Bu-resistant NNP N
human NN N
cell NN N
lines NNS N
in IN N
vitro NN N
. . N

We PRP N
found VBD N
pronounced VBD N
synergy NN N
between IN N
each DT N
nucleoside NN N
and CC N
the DT N
alkylator NN N
but CC N
even RB N
more RBR N
enhanced JJ N
cytotoxic NN N
synergy NN N
when WRB N
the DT N
nucleoside JJ N
analogs NNS N
were VBD N
combined VBN N
prior RB N
to TO N
exposing VBG N
the DT N
cells NNS N
to TO N
Bu NNP N
. . N

We PRP N
then RB N
designed VBD N
a DT N
4-arm JJ N
clinical JJ N
trial NN N
in IN N
patients NNS N
with IN N
myeloid JJ N
leukemia NN N
undergoing VBG N
allogeneic JJ N
stem NN N
cell NN N
transplantation NN N
( ( N
allo-SCT JJ N
) ) N
. . N

Patients NNS N
were VBD N
adaptively RB N
randomized VBN N
as IN N
follows VBZ N
: : N
Arm JJ N
I-Clo NN N
: : N
Flu CD N
10:30 CD N
mg/m NN N
( ( N
2 CD N
) ) N
, , N
Arm NNP N
II-20:20 NNP N
mg/m NN N
( ( N
2 CD N
) ) N
, , N
Arm NNP N
III-30:10 NNP N
mg/m NN N
( ( N
2 CD N
) ) N
, , N
and CC N
Arm NNP N
IV-single-agent NNP N
Clo NNP N
at IN N
40 CD N
mg/m NN N
( ( N
2 CD N
) ) N
. . N

The DT N
nucleoside JJ N
analog NN N
( ( N
s PRP N
) ) N
were/was NN N
infused VBN N
over IN N
1 CD N
hour NN N
once RB N
daily JJ N
for IN N
4 CD N
days NNS N
, , N
followed VBD N
on IN N
each DT N
day NN N
by IN N
Bu NNP N
, , N
infused VBD N
over IN N
3 CD N
hours NNS N
to TO N
a DT N
pharmacokinetically RB N
targeted VBN N
daily JJ N
area NN N
under IN N
the DT N
curve NN N
( ( N
AUC NNP N
) ) N
of IN N
6000 CD N
?Mol-min NN N
? . N
10 CD N
% NN N
. . N

Fifty-one CD N
patients NNS N
have VBP N
been VBN N
enrolled VBN N
with IN N
a DT N
minimum JJ N
follow-up JJ N
exceeding VBG N
100 CD N
days NNS N
. . N

There EX N
were VBD N
32 CD N
males NNS N
and CC N
19 CD N
females NNS N
, , N
with IN N
a DT N
median JJ N
age NN N
of IN N
45 CD N
years NNS N
( ( N
range NN N
: : N
6-59 JJ N
) ) N
. . N

Nine JJ N
patients NNS N
had VBD N
chronic JJ N
myeloid NN N
leukemia NN N
( ( N
CML NNP N
) ) N
( ( N
BC NNP N
: : N
2 CD N
, , N
second JJ N
AP NNP N
: : N
3 CD N
, , N
and CC N
tyrosine-kinase JJ N
inhibitor NN N
refractory NN N
first RB N
chronic JJ N
phase NN N
[ NNP N
CP NNP N
] NN N
: : N
4 CD N
) ) N
. . N

Forty-two JJ N
patients NNS N
had VBD N
AML NNP N
: : N
14 CD N
were VBD N
induction NN N
failures NNS N
, , N
8 CD N
in IN N
first JJ N
chemotherapy-refractory JJ N
relapse NN N
, , N
7 CD N
in IN N
untreated JJ N
relapse NN N
, , N
3 CD N
in IN N
second JJ N
or CC N
subsequent JJ N
relapse NN N
, , N
4 CD N
were VBD N
in IN N
second JJ N
complete JJ N
remission NN N
( ( N
CR NNP N
) ) N
, , N
and CC N
3 CD N
in IN N
second JJ N
CR NNP N
without IN N
platelet NN N
recovery NN N
( ( N
CRp NNP N
) ) N
, , N
2 CD N
were VBD N
in IN N
high-risk JJ N
CR1 NNP N
. . N

Finally NNP N
, , N
1 CD N
patient NN N
was VBD N
in IN N
first JJ N
CRp NNP N
. . N

Graft-versus-host NNP N
disease NN N
( ( N
GVHD NNP N
) ) N
prophylaxis NN N
was VBD N
tacrolimus JJ N
and CC N
mini-methorexate JJ N
( ( N
MTX NNP N
) ) N
, , N
and CC N
those DT N
who WP N
had VBD N
an DT N
unrelated JJ N
or CC N
1 CD N
antigen-mismatched JJ N
donor NN N
received VBD N
low-dose JJ N
rabbit-ATG NN N
( ( N
Thymoglobulin? NNP N
) ) N
. . N

All DT N
patients NNS N
engrafted VBN N
. . N

Forty-one CD N
patients NNS N
had VBD N
active JJ N
leukemia NN N
at IN N
the DT N
time NN N
of IN N
transplant NN N
, , N
and CC N
35 CD N
achieved VBN N
CR NNP N
( ( N
85 CD N
% NN N
) ) N
. . N

Twenty CD N
of IN N
the DT N
42 CD N
AML NNP N
patients NNS N
and CC N
5 CD N
of IN N
9 CD N
CML NNP N
patients NNS N
are VBP N
alive JJ N
with IN N
a DT N
projected JJ N
median JJ N
overall JJ N
survival NN N
( ( N
OS NNP N
) ) N
of IN N
23 CD N
months NNS N
. . N

Marrow NNP N
and CC N
blood NN N
( ( N
T NNP N
cell NN N
) ) N
chimerism NN N
studies NNS N
at IN N
day NN N
+100 NNP N
revealed VBD N
that IN N
both DT N
in IN N
the DT N
lower-dose JJ N
Clo NNP N
groups NNS N
( ( N
groups NNS N
1+2 CD N
) ) N
and CC N
the DT N
higher-dose JJ N
Clo NNP N
groups NNS N
( ( N
groups NNS N
3+4 CD N
) ) N
, , N
the DT N
patients NNS N
had VBD N
a DT N
median NN N
of IN N
100 CD N
% NN N
donor NN N
( ( N
T NNP N
cell NN N
) ) N
-derived VBD N
DNA NNP N
. . N

There EX N
has VBZ N
been VBN N
no DT N
secondary JJ N
graft NN N
failure NN N
. . N

In IN N
the DT N
first JJ N
100 CD N
days NNS N
, , N
1 CD N
patient NN N
died VBD N
of IN N
pneumonia NN N
, , N
and CC N
1 CD N
of IN N
liver NN N
GVHD NNP N
. . N

We PRP N
conclude VBP N
that IN N
( ( N
1 CD N
) ) N
Clo NNP N
? . N
Flu NNP N
with IN N
i.v NN N
. . N

Bu NNP N
as IN N
pretransplant JJ N
conditioning NN N
is VBZ N
safe JJ N
in IN N
high-risk JJ N
myeloid JJ N
leukemia NN N
patients NNS N
; : N
( ( N
2 CD N
) ) N
clofarabine NN N
is VBZ N
sufficiently RB N
immunosuppressive JJ N
to TO N
support VB N
allo-SCT NN N
in IN N
myeloid JJ N
leukemia NN N
; : N
and CC N
( ( N
3 CD N
) ) N
the DT N
median JJ N
OS NNP N
of IN N
23 CD N
months NNS N
in IN N
this DT N
high-risk JJ N
patient NN N
population NN N
is VBZ N
encouraging VBG N
. . N

Additional JJ N
studies NNS N
to TO N
evaluate VB N
the DT N
antileukemic JJ N
efficacy NN N
of IN N
Clo NNP N
? . N
Flu NNP N
with IN N
i.v NN N
. . N

Bu NNP N
as IN N
pretransplant JJ N
conditioning NN N
therapy NN N
are VBP N
warranted VBN N
. . N

-DOCSTART- -X- O O

Treatment NN N
of IN N
stable JJ N
angina NN N
of IN N
effort NN N
with IN N
verapamil NN 3_i
: : 3_i
a DT N
double-blind NN N
, , N
placebo-controlled JJ 7_i
randomized VBN N
crossover NN N
study NN N
. . N

The DT N
effects NNS N
of IN N
verapamil NN 3_i
were VBD N
assessed VBN N
in IN N
26 CD N
patients NNS N
with IN N
stable JJ N
exertional JJ N
angina NN N
pectoris NN N
in IN N
a DT N
double-blind JJ N
, , N
placebo-controlled JJ N
, , N
randomized VBN N
crossover NN N
protocol NN N
using VBG N
serial JJ N
treadmill NN N
tests NNS N
. . N

Verapamil NNP 3_i
, , N
480 CD N
mg/day NN N
, , N
reduced VBD N
anginal JJ N
frequency NN N
from IN N
5.6 CD N
+/- JJ N
7.3 CD N
to TO N
2.2 CD N
+/- JJ N
3.9 CD N
attacks NNS N
per IN N
week NN N
( ( N
p NN N
less JJR N
than IN N
0.001 CD N
) ) N
and CC N
nitroglycerin JJ 3_i
consumption NN N
from IN N
3.4 CD N
+/- JJ N
4.9 CD N
to TO N
1.2 CD N
+/- JJ N
2.5 CD N
tablets NNS N
per IN N
week NN N
( ( N
p NN N
less JJR N
than IN N
0.05 CD N
) ) N
compared VBN N
with IN N
placebo NN 7_i
. . 7_i

Treadmill NNP N
time NN N
increased VBD N
from IN N
6.4 CD N
+/- JJ N
2.1 CD N
minutes NNS N
during IN N
the DT N
placebo NN 7_i
phase NN N
to TO N
7.5 CD N
+/- JJ N
1.8 CD N
minutes NNS N
during IN N
the DT N
verapamil JJ 3_i
phase NN N
( ( N
p NN N
less JJR N
than IN N
0.001 CD N
) ) N
. . N

Verapamil NNP 3_i
's POS 3_i
beneficial JJ N
effect NN N
appeared VBD N
to TO N
be VB N
related VBN N
, , N
in IN N
part NN N
, , N
to TO N
a DT N
10 CD N
% NN N
reduction NN N
of IN N
the DT N
rate-pressure JJ N
product NN N
at IN N
rest NN N
( ( N
p IN N
less JJR N
than IN N
0.05 CD N
) ) N
and CC N
a DT N
12 CD N
% NN N
reduction NN N
during IN N
submaximal JJ N
exercise NN N
( ( N
p NN N
less JJR N
than IN N
0.001 CD N
) ) N
. . N

Verapamil NNP 3_i
also RB N
caused VBD N
less JJR N
marked JJ N
ST-segment JJ N
depressions NNS N
at IN N
peak NN N
exercise NN N
( ( N
p NN N
less JJR N
than IN N
0.05 CD N
) ) N
at IN N
a DT N
similar JJ N
rate-pressure NN N
product NN N
, , N
suggesting VBG N
a DT N
favorable JJ N
redistribution NN N
of IN N
coronary JJ N
blood NN N
flow NN N
to TO N
the DT N
ischemic JJ N
zone NN N
. . N

Side JJ N
effects NNS N
from IN N
verapamil NN 3_i
were VBD N
minimal JJ N
, , N
consisting VBG N
mainly RB N
of IN N
constipation NN N
( ( N
six CD N
patients NNS N
) ) N
. . N

Verapamil NNP 3_i
appears VBZ N
to TO N
be VB N
a DT N
safe JJ N
and CC N
effective JJ N
drug NN N
for IN N
treating VBG N
angina NN N
of IN N
effort NN N
. . N

-DOCSTART- -X- O O

Information NNP 4_i
source NN 4_i
affects VBZ N
peers NNS N
' POS N
initial JJ N
attitudes NNS N
toward IN N
autism NN N
. . N

Authors NNS N
examined VBD N
the DT N
effects NNS N
of IN N
information NN N
source NN N
on IN N
peers NNS N
' POS N
cognitive NN N
and CC N
behavioral JJ N
attitudes NNS N
toward IN N
an DT N
unfamiliar JJ N
child NN N
with IN N
autism NN N
. . N

Children NNP N
( ( N
N=296 NNP N
; : N
M NNP N
age=10.21 IN N
years NNS N
) ) N
received VBD N
information NN N
about IN N
an DT N
unfamiliar JJ N
child NN N
with IN N
autism NN N
from IN N
one CD N
of IN N
the DT N
following JJ N
sources NNS N
: : N
( ( N
a DT N
) ) N
videotape NN 4_i
, , N
( ( N
b NN N
) ) N
teacher NN 4_i
, , N
( ( N
c NN N
) ) N
hypothetical JJ 4_i
mother NN 4_i
, , N
( ( N
d NN N
) ) N
hypothetical JJ 4_i
father NN 4_i
, , N
or CC N
( ( N
e NN N
) ) N
hypothetical JJ 4_i
doctor NN 4_i
. . 4_i

Interactive JJ N
effects NNS N
between IN N
source NN N
, , N
and CC N
sex NN N
and CC N
grade NN N
were VBD N
found VBN N
for IN N
cognitive JJ N
and CC N
behavioral JJ N
attitudes NNS N
. . N

Fifth-graders NNS N
reported VBD N
more RBR N
favorable JJ N
cognitive JJ N
and CC N
behavioral JJ N
attitudes NNS N
when WRB N
information NN N
was VBD N
provided VBN N
by IN N
extra-familial JJ N
sources NNS N
( ( N
i.e. NN N
, , N
doctor NN N
) ) N
versus NN N
parent NN N
sources NNS N
. . N

Mother NNP N
yielded VBD N
more RBR N
persuasive JJ N
effects NNS N
on IN N
behavioral JJ N
attitudes NNS N
for IN N
third-graders NNS N
versus JJ N
fifth-graders NNS N
. . N

Attitudes NNS N
toward IN N
autism NN N
differ VBP N
depending VBG N
on IN N
who WP N
provides VBZ N
information NN N
about IN N
the DT N
disability NN N
. . N

Persuasion NNP N
theory NN N
appears VBZ N
useful JJ N
to TO N
guide VB N
evaluation NN N
of IN N
educational JJ N
interventions NNS N
to TO N
improve VB N
attitudes NNS N
towards IN N
autism NN N
. . N

Implications NNS N
of IN N
the DT N
findings NNS N
, , N
study NN N
limitations NNS N
, , N
and CC N
recommendations NNS N
for IN N
future JJ N
research NN N
are VBP N
discussed VBN N
. . N

-DOCSTART- -X- O O

B-type JJ 6_i
natriuretic JJ 6_i
peptide NN 6_i
in IN N
the DT N
evaluation NN N
and CC N
management NN N
of IN N
dyspnoea NN N
in IN N
primary JJ N
care NN N
. . N

OBJECTIVES IN N
The DT N
rapid JJ N
and CC N
accurate JJ N
diagnosis NN N
of IN N
heart NN N
failure NN N
in IN N
primary JJ N
care NN N
is VBZ N
a DT N
major JJ N
unmet JJ N
clinical JJ N
need NN N
. . N

We PRP N
evaluated VBD N
the DT N
additional JJ N
use NN N
of IN N
B-type NNP 6_i
natriuretic JJ 6_i
peptide NN 6_i
( ( 6_i
BNP NNP 6_i
) ) 6_i
levels NNS N
. . N

DESIGN VB N
A DT N
randomized NN N
controlled VBN N
trial NN N
. . N

SETTING CC N
Twenty-nine JJ N
primary JJ N
care NN N
physicians NNS N
in IN N
Switzerland NNP N
and CC N
Germany NNP N
coordinated VBN N
by IN N
the DT N
University NNP N
Hospital NNP N
Basel NNP N
, , N
Switzerland NNP N
. . N

SUBJECTS NNP N
A NNP N
total NN N
of IN N
323 CD N
consecutive JJ N
patients NNS N
presenting VBG N
with IN N
dyspnoea NN N
. . N

INTERVENTIONS NNP N
Assignment NNP N
in IN N
a DT N
1 CD N
: : N
1 CD N
ratio NN N
to TO N
a DT N
diagnostic JJ 6_i
strategy NN 6_i
including VBG 6_i
point-of-care JJ 6_i
measurement NN 6_i
of IN 6_i
BNP NNP 6_i
( ( N
n JJ N
= NNP N
163 CD N
) ) N
or CC N
standard JJ 7_i
assessment NN 7_i
without IN 7_i
BNP NNP 7_i
( ( N
n JJ N
= NNP N
160 CD N
) ) N
. . N

The DT N
total JJ N
medical JJ N
cost NN N
at IN N
3 CD N
months NNS N
was VBD N
the DT N
primary JJ N
end-point NN N
. . N

Secondary JJ N
end-points NNS N
were VBD N
diagnostic JJ N
certainty NN N
, , N
time NN N
to TO N
appropriate VB N
therapy NN N
, , N
functional JJ N
capacity NN N
, , N
hospitalization NN N
and CC N
mortality NN N
. . N

The DT N
final JJ N
diagnosis NN N
was VBD N
adjudicated VBN N
by IN N
a DT N
physician NN N
blinded VBN N
to TO N
the DT N
BNP NNP N
levels NNS N
. . N

RESULTS NNP N
Heart NNP N
failure NN N
was VBD N
the DT N
final JJ N
diagnosis NN N
in IN N
34 CD N
% NN N
of IN N
patients NNS N
. . N

The DT N
number NN N
of IN N
hospitalizations NNS N
, , N
functional JJ N
status NN N
and CC N
total JJ N
medical JJ N
cost NN N
at IN N
3 CD N
months NNS N
[ JJ N
median JJ N
$ $ N
1655 CD N
, , N
interquartile JJ N
range NN N
( ( N
IQR NNP N
) ) N
, , N
850-3331 JJ N
vs. IN N
$ $ N
1541 CD N
, , N
IQR NNP N
859-2827 CD N
; : N
P NNP N
= VBD N
0.68 CD N
] NNS N
were VBD N
similar JJ N
in IN N
both DT N
groups NNS N
. . N

BNP NNP N
increased VBD N
diagnostic JJ N
certainty NN N
as IN N
defined VBN N
by IN N
the DT N
need NN N
for IN N
further JJ N
diagnostic JJ N
work-up NN N
( ( N
33 CD N
% NN N
vs. FW N
45 CD N
% NN N
; : N
P NNP N
= NNP N
0.02 CD N
) ) N
and CC N
accelerated VBD N
the DT N
initiation NN N
of IN N
the DT N
appropriate JJ N
treatment NN N
( ( N
13 CD N
days NNS N
vs. FW N
25 CD N
days NNS N
; : N
P NNP N
= NNP N
0.01 CD N
) ) N
. . N

The DT N
area NN N
under IN N
the DT N
receiver-operating JJ N
characteristics NNS N
curve NN N
for IN N
BNP NNP N
to TO N
identify VB N
heart NN N
failure NN N
was VBD N
0.87 CD N
( ( N
95 CD N
% NN N
confidence NN N
interval NN N
, , N
0.81-0.93 JJ N
) ) N
. . N

CONCLUSIONS VB N
The DT N
use NN N
of IN N
BNP NNP 6_i
levels NNS 6_i
in IN N
primary JJ N
care NN N
did VBD N
not RB N
reduce VB N
total JJ N
medical JJ N
cost NN N
, , N
but CC N
improved VBD N
some DT N
of IN N
the DT N
secondary JJ N
end-points NNS N
including VBG N
diagnostic JJ N
certainty NN N
and CC N
time NN N
to TO N
initiation NN N
of IN N
appropriate JJ N
treatment NN N
. . N

-DOCSTART- -X- O O

[ JJ N
Effects NNS N
of IN N
transcutaneous JJ 2_i
electrical JJ 2_i
stimulation NN 2_i
of IN 2_i
auricular JJ 2_i
Shenmen NNP 2_i
point NN 2_i
on IN N
postoperative JJ N
nausea NN N
and CC N
vomiting NN N
and CC N
patient-controlled JJ N
epidural JJ N
analgesia NN N
in IN N
cesarean JJ N
section NN N
] NNP N
. . N

OBJECTIVE NNP N
To TO N
investigate VB N
the DT N
effects NNS N
of IN N
transcutaneous JJ N
electrical JJ N
stimulation NN N
of IN N
auricular JJ N
Shenmen NNP N
point NN N
on IN N
postoperative JJ N
nausea NN N
and CC N
vomiting NN N
and CC N
patient-controlled JJ N
epidural JJ N
analgesia NN N
in IN N
cesarean JJ N
section NN N
. . N

METHODS NNP N
After IN N
IRB NNP N
approval NN N
and CC N
informed JJ N
consent NN N
, , N
one CD N
hundred CD N
and CC N
eighty VB N
singleton NN N
primiparas IN N
undergoing VBG N
elective JJ N
cesarean JJ N
section NN N
, , N
in IN N
Qingdao NNP N
Municipal NNP N
Hospital NNP N
, , N
and CC N
Qingdao NNP N
Hiser NNP N
Medical NNP N
Center NNP N
, , N
from IN N
November NNP N
2011 CD N
to TO N
March NNP N
2012 CD N
, , N
were VBD N
randomly RB N
assigned VBN N
to TO N
three CD N
groups NNS N
: : N
transcutaneous JJ 2_i
electrical JJ 2_i
stimulation NN 2_i
of IN 2_i
auricular JJ 2_i
Shenmen NNP 2_i
point NN 2_i
group NN 2_i
( ( N
group NN N
A NNP N
, , N
n JJ N
= NNP N
60 CD N
) ) N
, , N
transcutaneous JJ 2_i
electrical JJ 2_i
stimulation NN 2_i
of IN 2_i
auricular JJ 2_i
Eye NNP 2_i
point NN 2_i
group NN 2_i
( ( N
group NN N
B NNP N
, , N
n JJ N
= NNP N
60 CD N
) ) N
and CC N
control NN 7_i
group NN 7_i
( ( N
group NN N
C NNP N
, , N
n JJ N
= NNP N
60 CD N
) ) N
. . N

Women NNP N
of IN N
group NN N
A NNP N
received VBD N
transcutaneous JJ 2_i
electrical JJ 2_i
stimulation NN 2_i
of IN N
auricular JJ N
Shenmen NNP N
point NN N
( ( N
frequency NN N
1.5 CD N
HZ NNP N
) ) N
at IN N
the DT N
time NN N
of IN N
preoperation NN N
, , N
4 CD N
, , N
10 CD N
and CC N
22 CD N
hours NNS N
of IN N
postoperation NN N
for IN N
30 CD N
minutes NNS N
. . N

The DT N
strength NN N
was VBD N
controlled VBN N
by IN N
themselves PRP N
. . N

Women NNP N
of IN N
group NN N
B NNP N
received VBD N
stimulation NN N
of IN N
auricular JJ N
Eye NNP N
point NN N
as IN N
group NN N
A NNP N
. . N

Women NNP N
of IN N
group NN N
C NNP N
received VBD N
pressurization NN N
and CC N
connected VBN N
line NN N
were VBD N
the DT N
same JJ N
with IN N
group NN N
A NNP N
, , N
but CC N
without IN N
electrical JJ 7_i
stimulation NN 7_i
. . N

The DT N
following JJ N
indexes NNS N
was VBD N
observed VBN N
: : N
the DT N
incidence NN N
of IN N
postoperative JJ N
nausea NN N
and CC N
vomiting NN N
( ( N
PONV NNP N
) ) N
for IN N
48 CD N
hours NNS N
; : N
the DT N
rate NN N
of IN N
metoclopramide NN N
; : N
the DT N
visual JJ N
analogue NN N
scale NN N
( ( N
VAS NNP N
) ) N
score NN N
of IN N
rest NN N
pain NN N
, , N
uterine JJ N
contration NN N
pain NN N
and CC N
dynamic JJ N
pain NN N
at IN N
the DT N
time NN N
of IN N
postoperation NN N
for IN N
6 CD N
, , N
12 CD N
, , N
24 CD N
and CC N
48 CD N
hours NNS N
( ( N
T NNP N
( ( N
1 CD N
) ) N
-T NN N
( ( N
4 CD N
) ) N
) ) N
; : N
the DT N
total JJ N
number NN N
and CC N
effective JJ N
compressions NNS N
number NN N
of IN N
patient-controlled JJ N
epidural JJ N
analgesia NN N
( ( N
PCEA NNP N
) ) N
; : N
the DT N
dose NN N
of IN N
analgesia JJ N
mixture NN N
; : N
the DT N
anal JJ N
exhaust JJ N
time NN N
; : N
the DT N
volume NN N
of IN N
postoperative JJ N
bleeding NN N
for IN N
6 CD N
hours NNS N
of IN N
postoperation NN N
and CC N
the DT N
other JJ N
side NN N
effects NNS N
. . N

RESULTS NNP N
Compared NNP N
with IN N
group NN N
B NNP N
and CC N
group NN N
C NNP N
, , N
the DT N
incidence NN N
of IN N
PONV NNP N
, , N
the DT N
rate NN N
of IN N
metoclopramide NN N
, , N
the DT N
VAS NNP N
score NN N
at IN N
the DT N
time NN N
T NNP N
( ( N
1 CD N
) ) N
-T NN N
( ( N
4 CD N
) ) N
, , N
the DT N
total JJ N
number NN N
and CC N
effective JJ N
compressions NNS N
number NN N
of IN N
PCEA NNP N
, , N
the DT N
ratio NN N
of IN N
the DT N
total JJ N
number NN N
with IN N
effective JJ N
compressions NNS N
number NN N
and CC N
the DT N
dose NN N
of IN N
analgesia JJ N
mixture NN N
were VBD N
decreased VBN N
in IN N
group NN N
A NNP N
( ( N
P NNP N
< NNP N
0.05 CD N
) ) N
, , N
but CC N
no DT N
difference NN N
compared VBN N
group NN N
B NNP N
with IN N
group NN N
C NNP N
( ( N
P NNP N
> NNP N
0.05 CD N
) ) N
. . N

The DT N
anal JJ N
exhaust NN N
time NN N
and CC N
the DT N
volume NN N
of IN N
postoperative JJ N
bleeding NN N
for IN N
6 CD N
hours NNS N
of IN N
postoperation NN N
were VBD N
no DT N
difference NN N
in IN N
the DT N
three CD N
groups NNS N
( ( N
P NNP N
> NNP N
0.05 CD N
) ) N
. . N

No UH N
other JJ N
side NN N
effects NNS N
were VBD N
observed VBN N
. . N

CONCLUSION NNP N
Transcutaneous NNP N
electrical JJ N
stimulation NN N
of IN N
auricular JJ N
Shenmen NNS N
point NN N
can MD N
reduce VB N
the DT N
incidence NN N
of IN N
PONV NNP N
and CC N
improves VBZ N
analgesia JJ N
effect NN N
of IN N
PCEA NNP N
in IN N
postoperation NN N
of IN N
cesarean JJ N
section NN N
. . N

-DOCSTART- -X- O O

Effect NN N
of IN N
patient NN N
withdrawal NN N
on IN N
a DT N
study NN N
evaluating VBG N
pharmacist JJ 6_i
management NN 6_i
of IN 6_i
hypertension NN 6_i
. . N

STUDY NNP N
OBJECTIVES NNP N
To TO N
examine VB N
potential JJ N
threats NNS N
to TO N
internal JJ N
and CC N
external JJ N
study NN N
validity NN N
caused VBN N
by IN N
differential JJ N
patient NN N
withdrawal NN N
from IN N
a DT N
randomized VBN N
controlled VBN N
trial NN N
evaluating VBG N
pharmacist JJ N
management NN N
of IN N
hypertension NN N
, , N
to TO N
compare VB N
the DT N
characteristics NNS N
of IN N
patients NNS N
who WP N
withdrew VBP N
with IN N
those DT N
of IN N
patients NNS N
who WP N
completed VBD N
the DT N
study NN N
, , N
and CC N
to TO N
identify VB N
characteristics NNS N
that WDT N
predispose VBP N
patients NNS N
to TO N
withdraw VB N
from IN N
hypertension NN N
management NN N
. . N

DESIGN NNP N
Prospective NNP N
, , N
randomized VBD N
, , N
comparative JJ N
study NN N
. . N

SETTING NNP N
Network NNP N
of IN N
primary JJ N
care NN N
clinics NNS N
. . N

PATIENTS VB N
Four CD N
hundred JJ N
sixty-three JJ N
patients NNS N
with IN N
a DT N
diagnosis NN N
of IN N
hypertension NN N
and CC N
a DT N
last JJ N
documented JJ N
systolic JJ N
blood NN N
pressure NN N
of IN N
160 CD N
mm NNS N
Hg NNP N
or CC N
greater JJR N
and/or NNS N
diastolic JJ N
blood NN N
pressure NN N
of IN N
100 CD N
mm NNS N
Hg NNP N
or CC N
greater JJR N
. . N

INTERVENTION NN N
Patients NNPS N
were VBD N
randomly RB N
allocated VBN N
to TO N
the DT N
pharmacist NN 6_i
intervention NN 6_i
or CC N
usual-care JJ 7_i
( ( 7_i
control NN 7_i
) ) 7_i
group NN 6_i
. . N

Those DT N
in IN N
the DT N
pharmacist NN N
intervention NN N
group NN N
were VBD N
collaboratively RB N
managed VBN 6_i
by IN 6_i
a DT 6_i
primary JJ 6_i
care NN 6_i
clinical JJ 6_i
pharmacy NN 6_i
specialist NN 6_i
and CC 6_i
their PRP$ 6_i
primary JJ 6_i
care NN 6_i
provider NN 6_i
. . N

Patients NNS N
in IN N
the DT N
control NN N
group NN N
received VBD N
usual JJ 7_i
care NN 7_i
from IN N
only RB N
their PRP$ N
primary JJ 6_i
care NN 6_i
provider NN 6_i
. . N

MEASUREMENTS NNP N
AND CC N
MAIN NNP N
RESULTS NNP N
Of IN N
the DT N
463 CD N
patients NNS N
, , N
191 CD N
( ( N
41 CD N
% NN N
) ) N
withdrew NN N
from IN N
the DT N
study NN N
after IN N
randomization NN N
and CC N
272 CD N
( ( N
59 CD N
% NN N
) ) N
completed VBD N
the DT N
study NN N
. . N

Patients NNS N
who WP N
withdrew VBP N
from IN N
the DT N
pharmacist NN 6_i
intervention NN 6_i
group NN N
were VBD N
similar JJ N
to TO N
patients NNS N
who WP N
withdrew VBP N
from IN N
the DT N
usual-care JJ N
group NN N
with IN N
respect NN N
to TO N
age NN N
, , N
sex NN N
, , N
insurance NN N
status NN N
, , N
and CC N
chronic JJ N
conditions NNS N
. . N

Patients NNS N
who WP N
smoked VBD N
or CC N
had VBD N
commercial JJ N
insurance NN N
were VBD N
more RBR N
likely JJ N
to TO N
withdraw VB N
from IN N
the DT N
study NN N
than IN N
the DT N
other JJ N
participants NNS N
. . N

However RB N
, , N
multivariate JJ N
analysis NN N
of IN N
all DT N
variables NNS N
, , N
when WRB N
adjusted VBN N
for IN N
the DT N
effect NN N
of IN N
the DT N
intervention NN N
, , N
revealed VBD N
that IN N
insurance NN N
status NN N
was VBD N
the DT N
only JJ N
variable NN N
associated VBN N
with IN N
a DT N
heightened JJ N
probability NN N
of IN N
withdrawal NN N
( ( N
p=0.002 NN N
) ) N
. . N

CONCLUSION NNP N
Although IN N
this DT N
study NN N
had VBD N
a DT N
high JJ N
withdrawal NN N
rate NN N
, , N
between-group JJ N
patient NN N
characteristics NNS N
remained VBD N
balanced JJ N
. . N

Therefore RB N
, , N
internal JJ N
validity NN N
was VBD N
preserved VBN N
, , N
and CC N
outcomes RB N
from IN N
the DT N
study NN N
groups NNS N
could MD N
be VB N
reliably RB N
compared VBN N
. . N

A DT N
lack NN N
of IN N
significant JJ N
differences NNS N
between IN N
patients NNS N
who WP N
withdrew VBD N
versus FW N
those DT N
who WP N
completed VBD N
, , N
with IN N
the DT N
exception NN N
of IN N
insurance NN N
status NN N
, , N
suggests VBZ N
that IN N
external JJ N
validity NN N
was VBD N
not RB N
jeopardized VBN N
. . N

-DOCSTART- -X- O O

Memantine NNP 3_i
add-on JJ N
to TO N
risperidone VB 3_i
for IN N
treatment NN N
of IN N
negative JJ N
symptoms NNS N
in IN N
patients NNS N
with IN N
stable JJ N
schizophrenia NN N
: : N
randomized VBN N
, , N
double-blind JJ N
, , N
placebo-controlled JJ N
study NN N
. . N

We PRP N
aimed VBD N
to TO N
evaluate VB N
the DT N
efficacy NN N
of IN N
memantine JJ 3_i
add-on JJ N
in IN N
the DT N
treatment NN N
of IN N
primary JJ N
negative JJ N
symptoms NNS N
of IN N
patients NNS N
with IN N
stable JJ N
schizophrenia NN N
. . N

In IN N
a DT N
double-blind JJ N
placebo-controlled JJ N
clinical JJ N
trial NN N
, , N
40 CD N
patients NNS N
with IN N
schizophrenia NN N
( ( N
Diagnostic NNP N
and CC N
Statistical NNP N
Manual NNP N
of IN N
Mental NNP N
Disorders NNP N
, , N
Fourth NNP N
Edition NNP N
) ) N
who WP N
were VBD N
stabilized VBN N
on IN N
risperidone NN 3_i
for IN N
a DT N
minimum NN N
of IN N
8 CD N
weeks NNS N
were VBD N
randomized VBN N
to TO N
either DT N
memantine NN 3_i
( ( N
20 CD N
mg NN N
) ) N
or CC N
placebo NN 7_i
in IN N
addition NN N
to TO N
risperidone VB 3_i
, , N
6 CD N
mg/d NN N
, , N
for IN N
eight CD N
weeks NNS N
. . N

Assessment NNP N
was VBD N
done VBN N
using VBG N
the DT N
Positive NNP N
and CC N
Negative NNP N
Syndrome NNP N
Scale NNP N
at IN N
baseline NN N
, , N
week NN N
4 CD N
, , N
and CC N
week NN N
8 CD N
. . N

The DT N
Hamilton NNP N
Depression NNP N
Rating NNP N
Scale NNP N
and CC N
the DT N
Extrapyramidal NNP N
Symptom NNP N
Rating NNP N
Scale NNP N
at IN N
baseline NN N
and CC N
week NN N
8 CD N
were VBD N
used VBN N
to TO N
assess VB N
depression NN N
and CC N
extrapyramidal NN N
symptoms NNS N
, , N
respectively RB N
. . N

All DT N
40 CD N
patients NNS N
had VBD N
at IN N
least JJS N
one CD N
postbaseline NN N
measurement NN N
, , N
and CC N
38 CD N
patients NNS N
completed VBD N
the DT N
trial NN N
. . N

Patients NNS N
in IN N
the DT N
memantine NN N
group NN N
showed VBD N
a DT N
significantly RB N
greater JJR N
improvement NN N
on IN N
negative JJ N
subscale NN N
than IN N
the DT N
placebo NN 7_i
group NN N
at IN N
end NN N
point NN N
( ( N
P NNP N
< NNP N
0.001 CD N
) ) N
. . N

The DT N
same JJ N
effect NN N
was VBD N
observed VBN N
for IN N
the DT N
total JJ N
score NN N
( ( N
P NNP N
< NNP N
0.001 CD N
) ) N
and CC N
the DT N
general JJ N
psychopathology NN N
subscale NN N
score NN N
( ( N
P NNP N
= NNP N
0.002 CD N
) ) N
. . N

There EX N
was VBD N
no DT N
significant JJ N
difference NN N
in IN N
reduction NN N
of IN N
positive JJ N
symptoms NNS N
score VBP N
between IN N
the DT N
2 CD N
groups NNS N
( ( N
P NNP N
= NNP N
0.757 CD N
) ) N
. . N

Changes NNS N
in IN N
the DT N
Hamilton NNP N
Depression NNP N
Rating NNP N
Scale NNP N
and CC N
the DT N
Extrapyramidal NNP N
Symptom NNP N
Rating NNP N
Scale NNP N
scores NNS N
and CC N
frequency NN N
of IN N
adverse JJ N
effects NNS N
did VBD N
not RB N
differ VB N
between IN N
the DT N
2 CD N
groups NNS N
. . N

Our PRP$ N
study NN N
showed VBD N
that IN N
memantine NN N
is VBZ N
a DT N
tolerable JJ N
and CC N
efficacious JJ N
add-on JJ N
treatment NN N
for IN N
primary JJ N
negative JJ N
symptoms NNS N
of IN N
schizophrenia NN N
. . N

-DOCSTART- -X- O O

Hydrogen NNP 3_i
peroxide NN 3_i
mouth NN 3_i
rinse NN 3_i
: : N
an DT N
analgesic JJ N
post-tonsillectomy NN N
. . N

OBJECTIVE UH N
To TO N
compare VB N
the DT N
analgesic JJ N
efficacy NN N
of IN N
hydrogen NN 3_i
peroxide NN 3_i
( ( 3_i
H2O2 NNP 3_i
) ) 3_i
mouth NN 3_i
rinse NN 3_i
with IN N
control NN 7_i
for IN N
post-tonsillectomy JJ N
pain NN N
management NN N
. . N

DESIGN NNP N
Double-blinded NNP N
, , N
prospective JJ N
, , N
randomized VBN N
, , N
controlled VBD N
clinical JJ N
trial NN N
. . N

PATIENTS NNP N
AND CC N
METHODS NNP N
Thirty-seven JJ N
patients NNS N
from IN N
5 CD N
to TO N
14 CD N
years NNS N
old JJ N
undergoing JJ N
electrocautery NN 1_i
tonsillectomy NN 1_i
were VBD N
randomized VBN N
to TO N
either CC N
the DT N
H2O2 NNP 3_i
mouth NN 3_i
rinse NN 3_i
or CC N
the DT N
water NN 7_i
rinse NN 7_i
( ( 7_i
control NN 7_i
) ) 7_i
group NN 7_i
. . N

For IN N
14 CD N
days NNS N
, , N
patients NNS N
recorded VBD N
pain NN N
levels NNS N
twice RB N
daily RB N
using VBG N
a DT N
visual JJ N
analogue NN N
scale NN N
. . N

Analgesic JJ N
uses NNS N
, , N
as RB N
well RB N
as IN N
any DT N
complications NNS N
, , N
were VBD N
also RB N
noted VBN N
by IN N
the DT N
patients NNS N
. . N

RESULTS NNP N
Thirty-seven JJ N
patients NNS N
completed VBD N
the DT N
study NN N
, , N
21 CD N
in IN N
the DT N
treatment NN N
group NN N
and CC N
16 CD N
in IN N
the DT N
control NN N
group NN N
. . N

Mean NNP N
postoperative JJ N
days NNS N
of IN N
pain NN N
were VBD N
10.3 CD N
and CC N
8.3 CD N
, , N
respectively RB N
, , N
and CC N
differed VBD N
significantly RB N
( ( N
p JJ N
= NNP N
.008 NNP N
) ) N
. . N

Mean JJ N
postoperative JJ N
days NNS N
of IN N
analgesic JJ N
use NN N
were VBD N
9.0 CD N
and CC N
6.7 CD N
, , N
respectively RB N
, , N
and CC N
differed VBD N
significantly RB N
( ( N
p JJ N
= NNP N
.005 NNP N
) ) N
. . N

Only RB N
one CD N
incidence NN N
of IN N
postoperative JJ N
hemorrhage NN N
occurred VBD N
in IN N
the DT N
study NN N
group NN N
. . N

CONCLUSION NNP N
In IN N
our PRP$ N
study NN N
, , N
the DT N
H2O2 NNP 3_i
mouth NN 3_i
rinse NN 3_i
does VBZ N
not RB N
provide VB N
a DT N
better JJR N
analgesic JJ N
effect NN N
than IN N
the DT N
water NN N
rinse NN N
for IN N
post-tonsillectomy JJ N
pain NN N
relief NN N
. . N

-DOCSTART- -X- O O

Anxiety NN N
sensitivity NN N
as IN N
an DT N
incremental JJ N
predictor NN N
of IN N
later JJ N
anxiety NN N
symptoms NNS N
and CC N
syndromes NNS N
. . N

Although IN N
anxiety NN N
sensitivity NN N
( ( N
AS NNP N
) ) N
has VBZ N
been VBN N
shown VBN N
to TO N
predict VB N
anxiety NN N
symptoms NNS N
and CC N
panic NN N
, , N
this DT N
literature NN N
is VBZ N
limited VBN N
in IN N
regard NN N
to TO N
evaluating VBG N
AS NNP N
as IN N
an DT N
incremental JJ N
predictor NN N
of IN N
anxiety NN 5_i
psychopathology NN 5_i
relative VBP N
to TO N
other JJ N
established VBN N
risk NN N
factors NNS N
including VBG N
sex NN N
and CC N
negative JJ N
affect NN N
. . N

The DT N
present JJ N
report NN N
prospectively RB N
evaluated VBD N
whether IN N
AS NNP N
was VBD N
predictive NN N
of IN N
later JJ N
changes NNS N
in IN N
anxiety NN N
symptoms NNS N
after IN N
controlling VBG 6_i
for IN 6_i
potential JJ 6_i
confounding NN 6_i
factors NNS 6_i
. . 6_i

Consistent JJ N
with IN N
hypothesis NN N
, , N
AS NNP N
was VBD N
found VBN N
to TO N
be VB N
a DT N
significant JJ N
, , N
incremental JJ N
predictor NN N
of IN N
anxiety NN N
symptoms NNS N
over IN N
time NN N
, , N
even RB N
after IN N
controlling VBG N
for IN N
sex NN N
and CC N
negative JJ N
affectivity NN N
. . N

These DT N
data NNS N
provide VBP N
novel JJ N
evidence NN N
for IN N
the DT N
unique JJ N
association NN N
between IN N
AS NNP N
of IN N
the DT N
development NN N
of IN N
anxiety NN N
symptoms NNS N
. . N

-DOCSTART- -X- O O

How WRB N
does VBZ N
Cash NNP 6_i
and CC N
Counseling NNP 6_i
affect NN N
costs NNS N
? . N
OBJECTIVE NNP N
To TO N
test VB N
the DT N
effect NN N
of IN N
a DT N
consumer-directed JJ N
model NN N
( ( N
Cash NNP 6_i
and CC N
Counseling NNP 6_i
) ) N
of IN N
Medicaid NNP N
personal JJ N
care NN N
services NNS N
( ( N
PCS NNPS N
) ) N
or CC N
home- JJ N
and CC N
community-based JJ N
waiver NN N
services NNS N
( ( N
HCBS NNP N
) ) N
on IN N
the DT N
cost NN N
of IN N
Medicaid NNP N
services NNS N
. . N

DATA NNP N
SOURCES/STUDY NNP N
SETTING NNP N
Medicaid NNP N
claims NNS N
data NNS N
were VBD N
collected VBN N
for IN N
all DT N
enrollees NNS N
in IN N
the DT N
Cash NNP N
and CC N
Counseling NNP N
demonstration NN N
. . N

Demonstration NNP N
enrollees NNS N
included VBD N
those DT N
eligible JJ N
for IN N
PCS NNP N
( ( N
in IN N
Arkansas NNP N
) ) N
, , N
those DT N
assessed VBN N
to TO N
receive VB N
such JJ N
services NNS N
( ( N
in IN N
New NNP N
Jersey NNP N
) ) N
, , N
and CC N
recipients NNS N
of IN N
Medicaid NNP N
HCBS NNP N
( ( N
in IN N
Florida NNP N
) ) N
. . N

Enrollment NN N
occurred VBD N
from IN N
December NNP N
1998 CD N
through IN N
April NNP N
2001 CD N
. . N

The DT N
follow-up JJ N
period NN N
covered VBD N
up RB N
to TO N
24 CD N
months NNS N
after IN N
enrollment NN N
. . N

STUDY NNP N
DESIGN NNP N
Demonstration NNP N
volunteers NNS N
were VBD N
randomly RB N
assigned VBN N
to TO N
have VB N
the DT N
option NN N
to TO N
participate VB N
in IN N
Cash NNP 6_i
and CC N
Counseling NNP 6_i
( ( N
the DT N
treatment NN N
group NN N
) ) N
, , N
or CC N
to TO N
receive VB N
Medicaid NNP 7_i
services NNS 7_i
as RB 7_i
usual JJ 7_i
from IN 7_i
an DT 7_i
agency NN 7_i
( ( N
the DT N
control NN N
group NN N
) ) N
. . N

Ordinary JJ N
least JJS N
squares NNS N
regressions NNS N
were VBD N
used VBN N
to TO N
estimate VB N
the DT N
effect NN N
of IN N
the DT N
program NN N
on IN N
costs NNS N
for IN N
Medicaid NNP N
PCS/waiver NNP N
services NNS N
and CC N
other JJ N
Medicaid NNP N
services NNS N
, , N
while IN N
controlling VBG N
for IN N
consumers NNS N
' POS N
preenrollment NN N
characteristics NNS N
and CC N
preenrollment NN N
Medicaid NNP N
spending NN N
. . N

Models NNS N
were VBD N
estimated VBN N
separately RB N
for IN N
nonelderly RB N
and CC N
elderly JJ N
adults NNS N
in IN N
each DT N
state NN N
and CC N
for IN N
children NNS N
in IN N
Florida NNP N
. . N

DATA NNP N
EXTRACTION NNP N
METHODS NNP N
Each DT N
state NN N
supplied VBD N
claims NNS N
data NNS N
for IN N
demonstration NN N
enrollees NNS N
. . N

PRINCIPAL NNP N
FINDINGS NNP N
Largely NNP N
because IN N
the DT N
program NN N
increased VBD N
consumers NNS N
' POS N
ability NN N
to TO N
get VB N
the DT N
authorized JJ N
amount NN N
of IN N
paid VBN N
care NN N
, , N
expenditures VBZ N
for IN N
personal JJ N
care/waiver NN N
services NNS N
were VBD N
higher JJR N
for IN N
the DT N
treatment NN N
group NN N
than IN N
for IN N
the DT N
control NN N
group NN N
in IN N
each DT N
state NN N
and CC N
age NN N
group NN N
, , N
except IN N
among IN N
the DT N
elderly JJ N
in IN N
Florida NNP N
. . N

Higher JJR N
costs NNS N
for IN N
personal JJ N
care/waiver NN N
services NNS N
were VBD N
partially RB N
offset VBN N
by IN N
savings NNS N
in IN N
other JJ N
Medicaid NNP N
services NNS N
, , N
particularly RB N
those DT N
related VBN N
to TO N
long-term JJ N
care NN N
. . N

During IN N
year NN N
1 CD N
, , N
total JJ N
Medicaid NNP N
costs NNS N
were VBD N
generally RB N
higher JJR N
for IN N
the DT N
treatment NN N
group NN N
than IN N
for IN N
the DT N
control NN N
group NN N
, , N
with IN N
treatment-control JJ N
cost NN N
differences NNS N
ranging VBG N
from IN N
1 CD N
percent NN N
( ( N
and CC N
statistically RB N
insignificant JJ N
) ) N
for IN N
the DT N
elderly JJ N
in IN N
Florida NNP N
to TO N
17 CD N
percent NN N
for IN N
the DT N
elderly JJ N
in IN N
Arkansas NNP N
. . N

In IN N
year NN N
2 CD N
, , N
these DT N
cost NN N
differences NNS N
were VBD N
generally RB N
greater JJR N
than IN N
in IN N
year NN N
1 CD N
. . N

Only RB N
in IN N
Arkansas NNP N
did VBD N
the DT N
treatment-control NN N
difference NN N
in IN N
total JJ N
cost NN N
shrink NN N
over IN N
time-to JJ N
less JJR N
than IN N
5 CD N
percent NN N
( ( N
and CC N
statistically RB N
insignificant JJ N
) ) N
in IN N
year NN N
2 CD N
. . N

CONCLUSIONS NNP N
Medicaid NNP N
costs NNS N
were VBD N
generally RB N
higher JJR N
under IN N
Cash NNP 6_i
and CC N
Counseling NNP 6_i
because IN N
those DT N
in IN N
the DT N
traditional JJ N
system NN N
did VBD N
not RB N
get VB N
the DT N
services NNS N
they PRP N
were VBD N
entitled VBN N
to TO N
. . N

Compared VBN N
with IN N
the DT N
treatment NN N
group NN N
, , N
( ( N
1 CD N
) ) N
control NN N
group NN N
members NNS N
were VBD N
less RBR N
likely JJ N
to TO N
receive VB N
any DT N
services NNS N
at IN N
all DT N
( ( N
despite IN N
being VBG N
authorized VBN N
for IN N
them PRP N
) ) N
, , N
and CC N
( ( N
2 CD N
) ) N
service NN N
recipients NNS N
received VBD N
a DT N
lower JJR N
proportion NN N
of IN N
the DT N
amount NN N
of IN N
care NN N
that WDT N
was VBD N
authorized VBN N
. . N

In IN N
addition NN N
, , N
a DT N
flaw NN N
in IN N
Florida NNP N
's POS N
reassessment NN N
procedures NNS N
led VBD N
to TO N
treatment NN N
group NN N
members NNS N
receiving VBG N
more RBR N
generous JJ N
benefit NN N
amounts NNS N
than IN N
control NN N
group NN N
members NNS N
. . N

To TO N
keep VB N
total JJ N
Medicaid NNP N
costs NNS N
per IN N
recipient NN N
at IN N
the DT N
level NN N
incurred VBN N
under IN N
the DT N
traditional JJ N
system NN N
, , N
consumer-directed JJ N
programs NNS N
need VBP N
to TO N
be VB N
carefully RB N
designed VBN N
and CC N
closely RB N
monitored VBN N
. . N

-DOCSTART- -X- O O

Randomized VBN N
trial NN N
of IN N
fenretinide NN 3_i
in IN N
superficial JJ N
bladder NN N
cancer NN N
using VBG N
DNA NNP N
flow JJ N
cytometry NN N
as IN N
an DT N
intermediate JJ N
end NN N
point NN N
. . N

Retinoids NNS N
have VBP N
shown VBN N
a DT N
potential JJ N
activity NN N
in IN N
preventing VBG N
tumor NN N
recurrence NN N
in IN N
superficial JJ N
bladder NN N
cancer NN N
. . N

We PRP N
assessed VBD N
the DT N
activity NN N
of IN N
the DT N
synthetic JJ 3_i
retinoid NN 3_i
fenretinide NN 3_i
in IN N
superficial JJ N
bladder NN N
cancer NN N
using VBG N
DNA NNP N
flow JJ N
cytometry NN N
and CC N
conventional JJ N
cytology NN N
as IN N
surrogate JJ N
biomarkers NNS N
. . N

A DT N
total NN N
of IN N
99 CD N
subjects NNS N
with IN N
resected JJ N
superficial JJ N
bladder NN N
cancer NN N
( ( N
pTa NN N
, , N
pT1 NN N
) ) N
were VBD N
randomized VBN N
to TO N
either DT N
fenretinide NN 3_i
( ( N
200 CD N
mg NNS N
day NN N
p.o NN N
. . N

for IN N
24 CD N
months NNS N
) ) N
or CC N
no DT 7_i
intervention NN 7_i
. . N

Cystoscopy NNP N
and CC N
bladder NN N
washing NN N
for IN N
DNA NNP N
flow NN N
cytometry NN N
end NN N
points NNS N
( ( N
proportion NN N
of IN N
DNA NNP N
aneuploid JJ N
histograms NN N
, , N
hyperdiploid JJ N
fraction NN N
, , N
and CC N
percentage NN N
of IN N
apoptotic JJ N
cells NNS N
) ) N
and CC N
proportion NN N
of IN N
abnormal JJ N
cytological JJ N
examinations NNS N
were VBD N
repeated VBN N
every DT N
4 CD N
months NNS N
for IN N
up IN N
to TO N
36 CD N
months NNS N
. . N

The DT N
primary JJ N
study NN N
end NN N
point NN N
was VBD N
the DT N
proportion NN N
of IN N
DNA NNP N
aneuploid JJ N
histograms NNS N
after IN N
12 CD N
months NNS N
. . N

This DT N
figure NN N
was VBD N
48.9 CD N
% NN N
in IN N
the DT N
fenretinide JJ 3_i
arm NN N
and CC N
41.9 CD N
% NN N
in IN N
the DT N
control NN N
arm NN N
( ( N
odds NNS N
ratio NN N
, , N
1.16 CD N
; : N
95 CD N
% NN N
confidence NN N
interval NN N
, , N
0.44-3.07 JJ N
) ) N
. . N

There EX N
was VBD N
no DT N
difference NN N
in IN N
any DT N
other JJ N
response NN N
biomarker NN N
between IN N
the DT N
two CD N
groups NNS N
up RB N
to TO N
36 CD N
months NNS N
, , N
nor CC N
was VBD N
any DT N
biomarker NN N
able JJ N
to TO N
predict VB N
recurrence NN N
risk NN N
. . N

Recurrence-free JJ N
survival NN N
was VBD N
comparable JJ N
between IN N
the DT N
arms NNS N
( ( N
27 CD N
events NNS N
in IN N
the DT N
fenretinide JJ N
arm NN N
versus NN N
21 CD N
in IN N
the DT N
control NN N
arm NN N
; : N
P NNP N
= NNP N
0.36 CD N
) ) N
. . N

Twelve NNP N
subjects VBZ N
in IN N
the DT N
fenretinide JJ N
arm NN N
complained VBD N
of IN N
diminished JJ N
dark NN N
adaptability NN N
, , N
and CC N
nine CD N
subjects NNS N
in IN N
the DT N
fenretinide JJ N
arm NN N
versus IN N
one CD N
control NN N
subject NN N
had VBD N
mild JJ N
dermatological JJ N
alterations NNS N
. . N

We PRP N
conclude VBP N
that DT N
fenretinide NN N
showed VBD N
a DT N
lack NN N
of IN N
effect NN N
on IN N
the DT N
DNA NNP N
content NN N
distribution NN N
and CC N
the DT N
morphology NN N
of IN N
urothelial JJ N
cells NNS N
obtained VBN N
in IN N
serial JJ N
bladder NN N
washings NNS N
. . N

Recurrence-free JJ N
survival NN N
was VBD N
comparable JJ N
between IN N
groups NNS N
. . N

Because IN N
our PRP$ N
data NNS N
are VBP N
hampered VBN N
by IN N
the DT N
lack NN N
of IN N
predictivity NN N
of IN N
the DT N
selected VBN N
biomarkers NNS N
, , N
additional JJ N
studies NNS N
are VBP N
necessary JJ N
to TO N
assess VB N
the DT N
activity NN N
of IN N
fenretinide NN N
in IN N
preventing VBG N
bladder NN N
cancer NN N
. . N

-DOCSTART- -X- O O

Psychosocial JJ 5_i
nursing NN 5_i
therapy NN 5_i
following VBG N
sudden JJ N
cardiac JJ N
arrest NN N
: : N
impact NN N
on IN N
two-year JJ N
survival NN N
. . N

BACKGROUND NNP N
Although IN N
psychosocial JJ 5_i
therapy NN 5_i
has VBZ N
been VBN N
shown VBN N
to TO N
reduce VB N
mortality NN N
after IN N
myocardial JJ N
infarction NN N
, , N
it PRP N
is VBZ N
unknown JJ N
whether IN N
the DT N
benefits NNS N
of IN N
psychosocial JJ 5_i
therapy NN 5_i
on IN N
mortality NN N
reduction NN N
extend VBP N
to TO N
out-of-hospital JJ N
sudden JJ N
cardiac NN N
arrest NN N
, , N
a DT N
main JJ N
cause NN N
of IN N
cardiovascular JJ N
mortality NN N
. . N

OBJECTIVE NNP N
Describe NNP N
efficacy NN N
of IN N
psychosocial JJ 5_i
therapy NN 5_i
on IN N
two-year JJ N
cardiovascular JJ N
mortality NN N
in IN N
sudden JJ N
cardiac JJ N
arrest NN N
survivors NNS N
. . N

METHOD NNP N
Survivors NNPS N
of IN N
out-of-hospital JJ N
ventricular JJ N
fibrillation NN N
or CC N
asystole NN N
( ( N
N NNP N
= NNP N
129 CD N
) ) N
, , N
documented VBN N
by IN N
electrocardiograms NNS N
from IN N
registries NNS N
of IN N
a DT N
citywide NN N
Medic NNP N
One NNP N
unit NN N
and CC N
two CD N
countywide NN N
emergency NN N
units NNS N
, , N
were VBD N
randomized VBN N
into IN N
a DT N
two CD N
group NN N
, , N
experimental JJ N
, , N
longitudinal JJ N
design NN N
. . N

The DT N
intervention NN N
consisted VBD N
of IN N
11 CD N
individual JJ N
sessions NNS N
, , N
implementing VBG N
three CD N
components NNS N
: : N
physiologic JJ N
relaxation NN N
with IN N
biofeedback NN N
training NN N
focused VBD N
on IN N
altering VBG N
autonomic JJ N
tone NN N
; : N
cognitive JJ 5_i
behavioral JJ 5_i
therapy NN 5_i
aimed VBN N
at IN N
self-management JJ N
and CC N
coping VBG N
strategies NNS N
for IN N
depression NN N
, , N
anxiety NN N
, , N
and CC N
anger NN N
; : N
and CC N
cardiovascular JJ N
health NN N
education NN N
. . N

The DT N
primary JJ N
outcome NN N
measure NN N
was VBD N
cardiovascular JJ N
mortality NN N
. . N

RESULTS NNP N
Risk NNP N
of IN N
cardiovascular JJ N
death NN N
was VBD N
significantly RB N
reduced VBN N
86 CD N
% NN N
by IN N
psychosocial JJ N
therapy NN N
, , N
p NN N
= NNP N
.03 NNP N
. . N

Six NNP N
of IN N
the DT N
seven CD N
cardiovascular JJ N
deaths NNS N
in IN N
the DT N
control NN N
group NN N
were VBD N
caused VBN N
by IN N
ventricular JJ N
arrhythmias NN N
. . N

The DT N
cardiovascular JJ N
death NN N
in IN N
the DT N
therapy NN N
group NN N
was VBD N
due JJ N
to TO N
stroke VB N
. . N

Controlling VBG N
for IN N
depression NN N
, , N
previous JJ N
myocardial JJ N
infarction NN N
, , N
low JJ N
ejection NN N
fraction NN N
, , N
decreased JJ N
heart NN N
rate NN N
variability NN N
, , N
and CC N
ventricular JJ N
ectopic NN N
beats NNS N
had VBD N
little JJ N
impact NN N
on IN N
estimated VBN N
treatment NN N
effect NN N
. . N

The DT N
risk NN N
of IN N
all-cause JJ N
mortality NN N
was VBD N
reduced VBN N
by IN N
62 CD N
% NN N
in IN N
the DT N
therapy NN N
group NN N
, , N
p VBP N
= JJ N
.13 NNP N
. . N

There EX N
were VBD N
a DT N
total NN N
of IN N
three CD N
deaths NNS N
in IN N
the DT N
therapy NN N
group NN N
and CC N
eight CD N
deaths NNS N
in IN N
the DT N
control NN 7_i
group NN N
. . N

CONCLUSIONS NNP N
Psychosocial NNP 5_i
therapy NN 5_i
significantly RB N
reduced VBD N
the DT N
risk NN N
of IN N
cardiovascular JJ N
death NN N
in IN N
sudden JJ N
cardiac JJ N
arrest NN N
survivors NNS N
. . N

-DOCSTART- -X- O O

A DT N
randomized VBN N
controlled VBN N
study NN N
of IN N
parent-assisted JJ 4_i
Children NNP 4_i
's POS 4_i
Friendship NNP 4_i
Training NNP 4_i
with IN N
children NNS N
having VBG N
autism NN N
spectrum NN N
disorders NNS N
. . N

This DT N
study NN N
evaluated VBD N
Children NNP 4_i
's POS 4_i
Friendship NNP 4_i
Training NNP 4_i
( ( 4_i
CFT NNP 4_i
) ) 4_i
, , 4_i
a DT 4_i
manualized JJ 4_i
parent-assisted JJ 4_i
intervention NN 4_i
to TO N
improve VB N
social JJ N
skills NNS N
among IN N
second JJ N
to TO N
fifth VB N
grade JJ N
children NNS N
with IN N
autism NN N
spectrum NN N
disorders NNS N
. . N

Comparison NNP N
was VBD N
made VBN N
with IN N
a DT N
delayed JJ 4_i
treatment NN 4_i
control NN 4_i
group NN 4_i
( ( 4_i
DTC NNP 4_i
) ) 4_i
. . N

Targeted VBN N
skills NNS N
included VBD N
conversational JJ N
skills NNS N
, , N
peer VBP N
entry NN N
skills NNS N
, , N
developing VBG N
friendship JJ N
networks NNS N
, , N
good JJ N
sportsmanship NN N
, , N
good JJ N
host NN N
behavior NN N
during IN N
play NN N
dates NNS N
, , N
and CC N
handling VBG N
teasing NN N
. . N

At IN N
post-testing NN N
, , N
the DT N
CFT NNP N
group NN N
was VBD N
superior JJ N
to TO N
the DT N
DTC NNP N
group NN N
on IN N
parent NN N
measures NNS N
of IN N
social JJ N
skill NN N
and CC N
play NN N
date NN N
behavior NN N
, , N
and CC N
child JJ N
measures NNS N
of IN N
popularity NN N
and CC N
loneliness NN N
, , N
At IN N
3-month JJ N
follow-up NN N
, , N
parent NN N
measures NNS N
showed VBD N
significant JJ N
improvement NN N
from IN N
baseline NN N
. . N

Post-hoc JJ N
analysis NN N
indicated VBD N
more JJR N
than IN N
87 CD N
% NN N
of IN N
children NNS N
receiving VBG N
CFT NNP 4_i
showed VBD N
reliable JJ N
change NN N
on IN N
at IN N
least JJS N
one CD N
measure NN N
at IN N
post-test NN N
and CC N
66.7 CD N
% NN N
after IN N
3 CD N
months NNS N
follow-up RB N
. . N

-DOCSTART- -X- O O

Cyclosporin NNP 3_i
versus NN N
cyclophosphamide NN 3_i
for IN N
patients NNS N
with IN N
steroid-dependent JJ N
and CC N
frequently RB N
relapsing VBG N
idiopathic JJ N
nephrotic JJ N
syndrome NN N
: : N
a DT N
multicentre NN N
randomized VBN N
controlled VBN N
trial NN N
. . N

OBJECTIVE UH N
To TO N
compare VB N
the DT N
efficacy NN N
( ( N
maintenance NN N
of IN N
remission NN N
) ) N
, , N
safety NN N
and CC N
tolerability NN N
of IN N
cyclosporin NN 3_i
( ( 3_i
CsA NNP 3_i
) ) 3_i
with IN N
those DT N
of IN N
cyclophosphamide NN 3_i
in IN N
patients NNS N
with IN N
steroid-dependent JJ N
or CC N
frequently RB N
relapsing VBG N
nephrotic JJ N
syndrome NN N
( ( N
NS NNP N
) ) N
. . N

DESIGN NNP N
Open NNP N
, , N
prospective JJ N
, , N
randomized VBN N
, , N
multicentre FW N
, , N
controlled VBD N
study NN N
for IN N
parallel JJ N
groups NNS N
, , N
stratified VBN N
for IN N
adults NNS N
and CC N
children NNS N
. . N

The DT N
setting NN N
was VBD N
in IN N
nephrological JJ N
departments NNS N
in IN N
Italy NNP N
. . N

SUBJECTS NNP N
AND CC N
INTERVENTIONS NNP N
Seventy-three JJ N
patients NNS N
with IN N
steroid-sensitive JJ N
idiopathic JJ N
NS NNP N
admitted VBD N
to TO N
the DT N
study NN N
were VBD N
randomly RB N
assigned VBN N
to TO N
cyclophosphamide VB 3_i
( ( N
2.5 CD N
mg/kg/day NN N
) ) N
for IN N
8 CD N
weeks NNS N
or CC N
CsA NNP 3_i
( ( N
5 CD N
mg/kg/day NN N
in IN N
adults NNS N
, , N
6 CD N
mg/kg/day NN N
in IN N
children NNS N
) ) N
for IN N
9 CD N
months NNS N
, , N
tapered VBD N
off RP N
by IN N
25 CD N
% NN N
every DT N
month NN N
until IN N
complete JJ N
discontinuation NN N
at IN N
month NN N
12 CD N
. . N

Seven CD N
patients NNS N
lost VBN N
to TO N
follow VB N
up RP N
were VBD N
not RB N
considered VBN N
in IN N
the DT N
analysis NN N
. . N

The DT N
remaining VBG N
66 CD N
patients NNS N
were VBD N
followed VBN N
up RP N
for IN N
3-24 JJ N
months NNS N
after IN N
randomization NN N
. . N

MAIN NNP N
OUTCOME NNP N
MEASURES NNP N
Relapse-free NNP N
survival NN N
; : N
number NN N
of IN N
N.S NNP N
. . N

relapses/patient/year NN N
; : N
cumulative JJ N
dose NN N
of IN N
prednisone/patient NN N
; : N
laboratory JJ N
investigations NNS N
( ( N
kidney NN N
and CC N
liver NN N
functions NNS N
, , N
haematological JJ N
parameters NNS N
) ) N
; : N
incidence NN N
of IN N
adverse JJ N
events NNS N
. . N

RESULTS NNP N
At IN N
month NN N
9 CD N
, , N
26 CD N
of IN N
35 CD N
CsA-treated JJ N
patients NNS N
were VBD N
still RB N
in IN N
complete JJ N
remission NN N
and CC N
a DT N
further JJ N
five CD N
patients NNS N
were VBD N
in IN N
partial JJ N
remission NN N
; : N
18 CD N
of IN N
28 CD N
cyclophosphamide-treated JJ 3_i
patients NNS N
were VBD N
in IN N
complete JJ N
remission NN N
, , N
and CC N
one CD N
in IN N
partial JJ N
remission NN N
( ( N
P NNP N
= NNP N
NS NNP N
) ) N
. . N

No DT N
difference NN N
between IN N
adults NNS N
and CC N
children NNS N
was VBD N
seen VBN N
with IN N
either DT N
treatment NN N
. . N

The DT N
risk NN N
of IN N
relapse NN N
was VBD N
similar JJ N
between IN N
frequent JJ N
relapsers NNS N
( ( N
19 CD N
of IN N
22 CD N
) ) N
and CC N
steroid-dependent JJ N
patients NNS N
( ( N
8 CD N
of IN N
14 CD N
) ) N
given VBN N
CsA NNP N
, , N
and CC N
those DT N
given VBN N
cyclophosphamide NN 3_i
( ( N
5 CD N
of IN N
15 CD N
and CC N
6 CD N
of IN N
15 CD N
) ) N
. . N

The DT N
mean JJ N
number NN N
of IN N
relapses NNS N
per IN N
year NN N
and CC N
the DT N
mean NN N
dose NN N
of IN N
prednisone NN N
per IN N
year NN N
were VBD N
significantly RB N
less JJR N
( ( N
P NNP N
< NNP N
0.001 CD N
) ) N
in IN N
both DT N
groups NNS N
for IN N
the DT N
experimental JJ N
year NN N
than IN N
for IN N
the DT N
year NN N
before IN N
randomization NN N
. . N

At IN N
2 CD N
years NNS N
, , N
25 CD N
% NN N
of IN N
the DT N
patients NNS N
given VBN N
CsA NNP 3_i
( ( N
50 CD N
% NN N
adults NNS N
and CC N
20 CD N
% NN N
children NNS N
) ) N
and CC N
63 CD N
% NN N
of IN N
those DT N
given VBN N
cyclophosphamide NN 3_i
( ( N
40 CD N
% NN N
adults NNS N
and CC N
68 CD N
% NN N
children NNS N
) ) N
had VBD N
not RB N
had VBN N
any DT N
relapse NN N
of IN N
NS NNP N
. . N

Tolerance NN N
to TO N
the DT N
two CD N
drugs NNS N
was VBD N
generally RB N
good JJ N
. . N

The DT N
CsA-related JJ 3_i
side-effects NNS N
were VBD N
mild JJ N
and CC N
disappeared VBD N
after IN N
drug NN N
discontinuation NN N
. . N

CONCLUSIONS VB N
This DT N
study NN N
shows VBZ N
that IN N
both DT N
treatments NNS N
are VBP N
effective JJ N
and CC N
well RB N
tolerated VBD N
; : N
more RBR N
patients NNS N
given VBN N
cyclophosphamide JJ 3_i
had VBD N
stable JJ N
remissions NNS N
. . N

-DOCSTART- -X- O O

The DT N
additional JJ N
value NN N
of IN N
a DT N
night NN 2_i
splint NN 2_i
to TO N
eccentric VB 2_i
exercises NNS 2_i
in IN N
chronic JJ N
midportion NN N
Achilles NNP N
tendinopathy NN N
: : N
a DT N
randomised JJ N
controlled VBN N
trial NN N
. . N

AIM NNP N
To TO N
assess VB N
whether IN N
the DT N
use NN N
of IN N
a DT N
night NN 2_i
splint NN 2_i
is VBZ N
of IN N
added JJ N
benefit NN N
on IN N
functional JJ N
outcome NN N
in IN N
treating VBG N
chronic JJ N
midportion NN N
Achilles NNP N
tendinopathy NN N
. . N

METHODS NNP N
This DT N
was VBD N
a DT N
single-blind JJ N
, , N
prospective JJ N
, , N
single JJ N
centre NN N
, , N
randomised VBD N
controlled VBN N
trial NN N
set NN N
in IN N
the DT N
Sports NNP N
Medical NNP N
Department NNP N
, , N
The DT N
Hague NNP N
Medical NNP N
Centre NNP N
, , N
The DT N
Netherlands NNP N
. . N

Inclusion NNP N
criteria NNS N
were VBD N
: : N
age NN N
18-70 CD N
years NNS N
, , N
active JJ N
participation NN N
in IN N
sports NNS N
, , N
and CC N
tendon VB N
pain NN N
localised VBN N
at IN N
2-7 JJ N
cm NN N
from IN N
distal JJ N
insertion NN N
. . N

Exclusion NN N
criteria NNS N
were VBD N
: : N
insertional JJ N
disorders NNS N
, , N
partial JJ N
or CC N
complete JJ N
ruptures NNS N
, , N
or CC N
systemic JJ N
illness NN N
. . N

70 CD N
tendons NNS N
were VBD N
included VBN N
and CC N
randomised VBN N
into IN N
one CD N
of IN N
two CD N
treatment NN N
groups NNS N
: : N
eccentric JJ 2_i
exercises NNS 2_i
with IN 2_i
a DT 2_i
night NN 2_i
splint NN 2_i
( ( N
night NN N
splint NN N
group NN N
, , N
n RB N
= VBZ N
36 CD N
) ) N
or CC N
eccentric JJ 2_i
exercises NNS 2_i
only RB 2_i
( ( N
eccentric JJ N
group NN N
, , N
n RB N
= VBZ N
34 CD N
) ) N
. . N

INTERVENTIONS NNP N
Both DT N
groups NNS N
completed VBD N
a DT N
12-week JJ N
heavy-load NN 2_i
eccentric JJ 2_i
training NN 2_i
programme NN 2_i
. . 2_i

One CD N
group NN N
received VBD N
a DT N
night NN 2_i
splint NN 2_i
in IN N
addition NN N
to TO N
eccentric JJ 2_i
exercises NNS 2_i
. . N

At IN N
baseline NN N
and CC N
follow-up NN N
at IN N
12 CD N
weeks NNS N
, , N
patient JJ N
satisfaction NN N
, , N
Victorian NNP N
Institute NNP N
of IN N
Sport NNP N
Assessment-Achilles NNP N
questionnaire NN N
( ( N
VISA-A NNP N
) ) N
score NN N
and CC N
reported VBD N
compliance NN N
were VBD N
recorded VBN N
by IN N
a DT N
single-blind NN N
trained JJ N
researcher NN N
who WP N
was VBD N
blinded VBN N
to TO N
the DT N
treatment NN N
. . N

RESULTS NNP N
After IN N
12 CD N
weeks NNS N
, , N
patient JJ N
satisfaction NN N
in IN N
the DT N
eccentric JJ N
group NN N
was VBD N
63 CD N
% NN N
compared VBN N
with IN N
48 CD N
% NN N
in IN N
the DT N
night NN 2_i
splint NN 2_i
group NN N
. . N

The DT N
VISA-A NNP N
score NN N
significantly RB N
improved VBN N
in IN N
both DT N
groups NNS N
; : N
in IN N
the DT N
eccentric JJ N
group NN N
from IN N
50.1 CD N
to TO N
68.8 CD N
( ( N
p NN N
= RB N
0.001 CD N
) ) N
and CC N
in IN N
the DT N
night NN N
splint NN N
group NN N
from IN N
49.4 CD N
to TO N
67.0 CD N
( ( N
p NN N
< RB N
0.001 CD N
) ) N
. . N

There EX N
was VBD N
no DT N
significant JJ N
difference NN N
between IN N
the DT N
two CD N
groups NNS N
in IN N
VISA-A NNP N
score NN N
( ( N
p JJ N
= NNP N
0.815 CD N
) ) N
and CC N
patient JJ N
satisfaction NN N
( ( N
p JJ N
= NNP N
0.261 CD N
) ) N
. . N

CONCLUSION VB N
A DT N
night NN 2_i
splint NN 2_i
is VBZ N
not RB N
beneficial JJ N
in IN N
addition NN N
to TO N
eccentric VB N
exercises NNS N
in IN N
the DT N
treatment NN N
of IN N
chronic JJ N
midportion NN N
Achilles NNP N
tendinopathy NN N
. . N

-DOCSTART- -X- O O

Genotyping VBG 6_i
of IN 6_i
CYP21 NNP 6_i
, , N
linked VBD N
chromosome NN N
6p CD N
markers NNS N
, , N
and CC N
a DT N
sex-specific JJ N
gene NN N
in IN N
neonatal JJ N
screening NN N
for IN N
congenital JJ N
adrenal JJ N
hyperplasia NN N
. . N

We PRP N
investigated VBD N
the DT N
feasibility NN N
and CC N
diagnostic JJ N
utility NN N
of IN N
genotyping VBG 6_i
9 CD 6_i
CYP21 NNP 6_i
mutations NNS N
, , N
linked VBD N
chromosome NN N
6p CD N
markers NNS N
, , N
and CC N
a DT N
dimorphic JJ N
X-Y JJ N
marker NN N
from IN N
neonatal JJ N
screening NN N
samples NNS N
. . N

Blood-impregnated JJ 6_i
filter NN 6_i
papers NNS 6_i
( ( N
Guthrie NNP N
cards NNS N
) ) N
from IN N
603 CD N
randomly RB N
chosen VBN N
New NNP N
Zealand NNP N
neonates NNS N
were VBD N
genotyped VBN N
blind IN N
to TO N
17-hydroxyprogesterone CD 6_i
( ( N
17-OHP CD N
) ) N
levels NNS N
. . N

Another DT N
50 CD N
samples NNS N
from IN N
Swiss NNP N
and CC N
North NNP N
American JJ N
infants NNS N
with IN N
correlative JJ N
hormonal JJ N
data NNS N
were VBD N
also RB N
genotyped VBN N
. . N

DNA NN N
was VBD N
extracted VBN N
, , N
and CC N
gene-specific JJ N
PCR NNP N
was VBD N
performed VBN N
. . N

CYP21 NNP 6_i
PCR NNP 6_i
products NNS N
were VBD N
subjected VBN N
to TO N
ligase VB N
detection NN N
reaction NN N
, , N
simultaneously RB N
analyzing VBG N
9 CD N
CYP21 NNP N
mutations NNS N
; : N
PCR NNP N
products NNS N
of IN N
other JJ N
genes NNS N
were VBD N
subjected VBN N
to TO N
direct VB N
gel JJ N
analysis NN N
. . N

CYP21 NNP 6_i
genotyping VBG N
indicated VBD N
a DT N
heterozygote NN N
rate NN N
of IN N
2.8 CD N
% NN N
for IN N
classic JJ N
mutations NNS N
( ( N
excluding VBG N
CYP21 NNP N
deletions NNS N
) ) N
, , N
and CC N
2.0 CD N
% NN N
for IN N
nonclassic JJ N
mutations NNS N
in IN N
New NNP N
Zealanders NNP N
. . N

Ten CD N
full-term JJ N
affected JJ N
neonates NNS N
showed VBD N
a DT N
wide JJ N
range NN N
of IN N
17-OHP JJ N
levels NNS N
( ( N
15-1400 JJ N
nmol/L NN N
) ) N
. . N

Sick NNP N
or CC N
preterm JJ N
infants NNS N
or CC N
infants NNS N
screened VBN N
on IN N
the DT N
first JJ N
day NN N
of IN N
life NN N
with IN N
high JJ N
17-OHP JJ N
proved VBN N
genetically RB N
unaffected JJ N
. . N

Genetic JJ N
linkage NN N
disequilibrium NN N
was VBD N
found VBN N
between IN N
two CD N
CYP21 NNP N
mutations NNS N
and CC N
chromosome NN N
6p CD N
markers NNS N
. . N

Guthrie NNP N
cards NNS N
can MD N
be VB N
used VBN N
to TO N
accurately RB N
genotype VB N
CYP21 NNP N
and CC N
other JJ N
relevant JJ N
markers NNS N
, , N
potentially RB N
enhancing VBG N
the DT N
specificity NN N
and CC N
sensitivity NN N
of IN N
congenital JJ N
adrenal JJ N
hyperplasia NN N
screening NN N
. . N

CYP21 NNP 6_i
heterozygote JJ N
frequency NN N
for IN N
classic JJ N
mutations NNS N
is VBZ N
higher JJR N
than IN N
expected VBN N
based VBN N
on IN N
genotype NN N
compared VBN N
with IN N
that DT N
predicted VBN N
by IN N
hormonal JJ N
newborn JJ N
screening NN N
. . N

-DOCSTART- -X- O O

Lack NN N
of IN N
effect NN N
of IN N
food NN 2_i
on IN N
the DT N
steady JJ N
state NN N
pharmacokinetics NNS N
of IN N
BMS-181101 NNP N
, , N
an DT N
antidepressant NN N
, , N
in IN N
healthy JJ N
subjects NNS N
. . N

The DT N
effect NN N
of IN N
food NN N
on IN N
the DT N
pharmacokinetics NNS N
of IN N
BMS-181101 NNP 3_i
, , N
a DT N
new JJ N
anti-depressant JJ N
under IN N
development NN N
, , N
was VBD N
investigated VBN N
in IN N
12 CD N
healthy JJ N
male NN N
volunteers NNS N
at IN N
steady JJ N
state NN N
. . N

Each DT N
subject NN N
received VBD N
a DT N
15 CD N
mg JJ N
oral JJ N
dose NN N
of IN N
BMS-181101 NNP 3_i
twice NN N
a DT N
day NN N
( ( N
q JJ N
12 CD N
h NN N
) ) N
for IN N
11 CD N
days NNS N
and CC N
a DT N
morning NN N
dose NN N
of IN N
BMS-181101 NNP 3_i
on IN N
day NN N
12 CD N
. . N

Six CD N
subjects NNS N
were VBD N
randomly RB N
assigned VBN N
to TO N
receive VB N
BMS-181101 NNP 3_i
under IN N
fasted VBN N
conditions NNS N
from IN N
days NNS N
1 CD N
to TO N
6 CD N
and CC N
then RB N
crossed VBD N
over IN N
to TO N
fed VB N
conditions NNS N
from IN N
days NNS N
7 CD N
to TO N
12 CD N
. . N

The DT N
other JJ N
six CD N
subjects NNS N
received VBD N
the DT N
reverse NN N
conditions NNS N
, , N
fed VBN N
for IN N
days NNS N
1-6 CD N
and CC N
fasted VBN N
for IN N
days NNS N
7-12 CD N
. . N

Serial JJ N
blood NN N
samples NNS N
were VBD N
collected VBN N
up RB N
to TO N
12 CD N
h NNS N
on IN N
days NNS N
6 CD N
and CC N
12 CD N
following VBG N
the DT N
administration NN N
of IN N
the DT N
morning NN N
dose NN N
. . N

In IN N
addition NN N
, , N
trough IN N
blood NN N
samples NNS N
were VBD N
collected VBN N
on IN N
days NNS N
4 CD N
, , N
5 CD N
, , N
10 CD N
, , N
and CC N
11 CD N
prior RB N
to TO N
the DT N
morning NN N
dose NN N
. . N

Plasma NNP N
samples NNS N
were VBD N
analyzed VBN N
for IN N
intact JJ N
BMS-181101 NNP 3_i
using VBG N
a DT N
validated JJ N
high-performance NN N
liquid NN N
chromatography NN N
method NN N
with IN N
an DT N
electrochemical JJ N
detector NN N
. . N

BMS-181101 NNP N
was VBD N
well RB N
tolerated VBN N
both DT N
with IN N
and CC N
without IN N
ingestion NN N
of IN N
food NN N
. . N

The DT N
statistical JJ N
evaluation NN N
of IN N
the DT N
Cmin NNP N
values NNS N
indicated VBD N
that IN N
steady JJ N
state NN N
of IN N
BMS-181101 NNP 3_i
was VBD N
achieved VBN N
by IN N
the DT N
fourth JJ N
day NN N
of IN N
dosing VBG N
regardless NN N
of IN N
whether IN N
the DT N
subject NN N
was VBD N
fasted VBN N
or CC N
fed VBN N
. . N

When WRB N
BMS-181101 NNP N
was VBD N
administered VBN N
with IN N
food NN N
, , N
Cmax NNP N
was VBD N
reduced VBN N
by IN N
about IN N
25 CD N
% NN N
and CC N
tmax NN N
was VBD N
prolonged VBN N
by IN N
1 CD N
h. NN N
However RB N
, , N
AUCtau NNP N
, , N
t1/2 NN N
, , N
and CC N
time NN N
to TO N
attain VB N
steady JJ N
state NN N
of IN N
BMS-181101 NNP N
were VBD N
not RB N
altered VBN N
by IN N
ingestion NN N
of IN N
food NN N
. . N

In IN N
summary JJ N
, , N
BMS-181101 NNP 3_i
can MD N
be VB N
given VBN N
with IN N
food NN N
without IN N
adversely RB N
impacting VBG N
the DT N
safety NN N
or CC N
pharmacokinetic JJ N
profiles NNS N
of IN N
the DT N
drug NN N
. . N

-DOCSTART- -X- O O

[ JJ N
Radiotherapy NNP 1_i
of IN N
malignant JJ N
brain NN N
gliomas NN N
using VBG N
teniposide JJ 3_i
] NNP N
. . N

Efficacy NN N
of IN N
radiochemotherapy NN 3_i
of IN N
malignantly-converted JJ N
brain NN N
gliomas NN N
using VBG N
teniposide NN 3_i
was VBD N
evaluated VBN N
in IN N
a DT N
randomized JJ N
prospective JJ N
study NN N
. . N

Combined VBN N
use NN N
of IN N
cytostatics NNS 3_i
and CC N
irradiation NN 1_i
appeared VBD N
safe JJ N
, , N
tolerable JJ N
and CC N
significantly RB N
more RBR N
effective JJ N
than IN N
radiotherapy RB 1_i
alone RB N
as IN N
assessed VBN N
by IN N
local JJ N
control NN N
of IN N
tumor NN N
and CC N
survival NN N
. . N

-DOCSTART- -X- O O

Low-dose JJ 3_i
aspirin NN 3_i
and CC N
incidence NN N
of IN N
colorectal JJ N
tumors NNS N
in IN N
a DT N
randomized JJ N
trial NN N
. . N

BACKGROUND NNP N
Laboratory NNP N
, , N
clinical JJ N
, , N
and CC N
epidemiologic JJ N
studies NNS N
have VBP N
recently RB N
suggested VBN N
that IN N
regular JJ N
use NN N
of IN N
aspirin NN 3_i
can MD N
reduce VB N
colorectal JJ N
cancer NN N
incidence NN N
or CC N
mortality NN N
. . N

However RB N
, , N
observational JJ N
epidemiologic NN N
analyses NNS N
have VBP N
had VBN N
limited VBN N
opportunity NN N
to TO N
control VB N
for IN N
confounding VBG N
bias NN N
or CC N
to TO N
specify VB N
aspirin JJ 3_i
doses NNS N
used VBN N
. . N

PURPOSE VB N
Our PRP$ N
purpose NN N
was VBD N
to TO N
examine VB N
the DT N
relationship NN N
between IN N
regular JJ N
use NN N
of IN N
low-dose JJ 3_i
aspirin NN 3_i
and CC N
incidence NN N
of IN N
invasive JJ N
and CC N
noninvasive JJ N
colorectal NN N
tumors NNS N
by IN N
utilizing VBG N
data NNS N
from IN N
the DT N
Physicians NNPS N
' POS N
Health NNP N
Study NNP N
, , N
a DT N
randomized VBN N
, , N
double-blinded JJ N
, , N
placebo-controlled JJ 7_i
trial NN N
of IN N
aspirin NN 3_i
and CC N
beta NN 3_i
carotene NN 3_i
. . N

We PRP N
also RB N
attempted VBD N
to TO N
determine VB N
whether IN N
invasive JJ N
cancers NNS N
among IN N
aspirin JJ 3_i
users NNS N
were VBD N
associated VBN N
with IN N
rectal JJ N
bleeding NN N
and CC N
early JJ N
stage NN N
at IN N
diagnosis NN N
. . N

METHODS NNP N
The DT N
Physicians NNPS N
' POS N
Health NNP N
Study NNP N
includes VBZ N
22071 CD N
U.S. NNP N
male JJ N
physicians NNS N
. . N

The DT N
aspirin JJ N
arm NN N
was VBD N
terminated VBN N
in IN N
1988 CD N
after IN N
a DT N
mean JJ N
follow-up NN N
of IN N
5 CD N
years NNS N
. . N

Stage NN N
at IN N
diagnosis NN N
and CC N
signs NNS N
and/or VBP N
symptoms NNS N
during IN N
presentation NN N
were VBD N
abstracted VBN N
from IN N
medical JJ N
records NNS N
. . N

Cox NNP N
proportional JJ N
hazards NNS N
models NNS N
were VBD N
used VBN N
to TO N
estimate VB N
relative JJ N
risk NN N
( ( N
RR NNP N
) ) N
, , N
95 CD N
% NN N
confidence NN N
intervals NNS N
( ( N
CIs NNP N
) ) N
, , N
and CC N
the DT N
association NN N
between IN N
aspirin NN N
and CC N
bleeding NN N
. . N

Differences NNS N
between IN N
aspirin NN 3_i
and CC N
placebo NN 7_i
groups NNS N
in IN N
tumor NN N
risk NN N
over IN N
time NN N
were VBD N
visualized VBN N
with IN N
Kaplan-Meier NNP N
curves NNS N
. . N

We PRP N
assessed VBD N
the DT N
association NN N
between IN N
aspirin NN N
and CC N
stage NN N
at IN N
diagnosis NN N
with IN N
a DT N
Mann-Whitney NNP N
rank NN N
sum NN N
statistic NN N
for IN N
non-parametric JJ N
comparison NN N
of IN N
two CD N
ordinal JJ N
distributions NNS N
. . N

RESULTS VB N
The DT N
RR NNP N
of IN N
developing VBG N
colorectal JJ N
cancer NN N
for IN N
aspirin NNS N
compared VBN N
with IN N
placebo NN N
was VBD N
1.15 CD N
( ( N
95 CD N
% NN N
CI NNP N
= NNP N
0.80-1.65 NN N
) ) N
. . N

For IN N
in IN N
situ NN N
cancers NNS N
and CC N
polyps NNS N
, , N
the DT N
RR NNP N
was VBD N
0.86 CD N
( ( N
95 CD N
% NN N
CI NNP N
= NNP N
0.68-1.10 NN N
) ) N
. . N

There EX N
was VBD N
no DT N
significant JJ N
trend NN N
for IN N
decreasing VBG N
RR NNP N
by IN N
year NN N
of IN N
follow-up NN N
for IN N
invasive JJ N
cancers NNS N
( ( N
P NNP N
= NNP N
.09 NNP N
) ) N
or CC N
noninvasive JJ N
tumors NNS N
( ( N
P NNP N
= NNP N
.96 NNP N
) ) N
. . N

Aspirin NNP N
and CC N
placebo NN N
groups NNS N
did VBD N
not RB N
differ VB N
in IN N
stage NN N
or CC N
prevalence NN N
of IN N
rectal JJ N
bleeding NN N
at IN N
diagnosis NN N
. . N

CONCLUSIONS NNP N
Regular NNP N
aspirin NN 3_i
use NN N
, , N
at IN N
a DT N
dose JJ N
adequate NN N
for IN N
preventing VBG N
myocardial JJ N
infarction NN N
, , N
was VBD N
not RB N
associated VBN N
with IN N
a DT N
substantial JJ N
reduction NN N
in IN N
the DT N
incidence NN N
of IN N
colorectal JJ N
cancer NN N
during IN N
5 CD N
years NNS N
of IN N
randomized JJ N
treatment NN N
and CC N
follow-up NN N
. . N

A DT N
small JJ N
decrease NN N
in IN N
polyps NNS N
in IN N
the DT N
aspirin NN N
group NN N
could MD N
not RB N
be VB N
reliably RB N
distinguished VBN N
from IN N
a DT N
chance NN N
association NN N
. . N

Our PRP$ N
results NNS N
suggest VBP N
that IN N
among IN N
low-dose JJ N
aspirin NN 3_i
users NNS N
, , N
( ( N
a DT N
) ) N
colorectal NN N
cancer NN N
mortality NN N
is VBZ N
not RB N
likely JJ N
to TO N
be VB N
reduced VBN N
by IN N
earlier JJR N
detection NN N
and CC N
( ( N
b NN N
) ) N
incidence NN N
is VBZ N
not RB N
likely JJ N
to TO N
be VB N
increased VBN N
due JJ N
to TO N
aspirin-induced JJ N
gastrointestinal JJ N
bleeding NN N
. . N

IMPLICATIONS VBZ N
The DT N
potential NN N
for IN N
a DT N
benefit NN N
from IN N
higher JJR N
doses NNS N
of IN N
aspirin NN N
or CC N
longer JJR N
duration NN N
of IN N
use NN N
should MD N
be VB N
addressed VBN N
by IN N
more JJR N
detailed JJ N
observational JJ N
epidemiologic NN N
studies NNS N
and CC N
prevention NN N
trials NNS N
with IN N
longer JJR N
follow-up NN N
of IN N
randomized JJ N
participants NNS N
. . N

-DOCSTART- -X- O O

Co-administration NN N
of IN N
pethidine NN 3_i
and CC N
clonidine NN 3_i
: : N
a DT N
spinal JJ N
anaesthetic JJ N
technique NN N
for IN N
total JJ 1_i
hip NN 1_i
replacement NN 1_i
. . 1_i

Co-administration NN N
of IN N
pethidine NN 3_i
0.75 CD N
mg NN N
kg-1 NN N
and CC N
clonidine NN 3_i
75 CD N
micrograms NNS N
intrathecally RB N
provided VBD N
good JJ N
intraoperative JJ N
anaesthesia NN N
for IN N
total JJ 1_i
hip NN 1_i
replacement NN 1_i
, , N
similar JJ N
to TO N
that DT N
obtained VBN N
using VBG N
0.5 CD 3_i
% NN 3_i
isobaric JJ 3_i
bupivacaine NN 3_i
. . 3_i

Sensory NNP N
and CC N
motor NN N
block NN N
were VBD N
of IN N
shorter JJR N
duration NN N
than IN N
that DT N
after IN N
0.5 CD N
% NN N
isobaric JJ 3_i
bupivacaine NN 3_i
and CC N
0.5 CD N
% NN N
isobaric JJ 3_i
bupivacaine NN 3_i
with IN N
morphine JJ 3_i
0.5 CD N
mg NN N
( ( N
P NNP N
< VBZ N
0.001 CD N
sensory JJ N
block NN N
, , N
P NNP N
< VBZ N
0.001 CD N
motor NN N
block NN N
) ) N
. . N

Postoperative JJ N
morphine NN 3_i
consumption NN N
, , N
measured VBN N
using VBG N
a DT N
patient-controlled JJ N
system NN N
, , N
was VBD N
similar JJ N
to TO N
that DT N
in IN N
patients NNS N
in IN N
the DT N
bupivacaine NN 3_i
only RB N
group NN N
( ( N
pethidine-clonidine JJ 3_i
: : N
median JJ N
39 CD N
mg/24 NN N
h NN N
; : N
bupivacaine NN 3_i
: : N
median JJ N
34 CD N
mg/24 NN N
h NN N
) ) N
but CC N
greater JJR N
than IN N
that DT N
in IN N
the DT N
bupivacaine-morphine JJ 3_i
group NN N
( ( N
median JJ N
8 CD N
mg/24 NN N
h NN N
) ) N
( ( N
P NNP N
< NNP N
0.001 CD N
) ) N
. . N

Visual JJ N
analogue NN N
pain NN N
scores NNS N
after IN N
operation NN N
were VBD N
similar JJ N
to TO N
those DT N
with IN N
bupivacaine JJ 3_i
alone NN 3_i
at IN N
all DT N
but CC N
one CD N
of IN N
the DT N
recording NN N
times NNS N
but CC N
were VBD N
greater JJR N
than IN N
those DT N
in IN N
patients NNS N
who WP N
received VBD N
bupivacaine NN 3_i
and CC N
morphine NN 3_i
at IN N
4 CD N
, , N
6 CD N
and CC N
10 CD N
h NN N
after IN N
operation NN N
( ( N
P NNP N
< NNP N
0.001 CD N
, , N
P NNP N
< NNP N
0.04 CD N
, , N
P NNP N
< NNP N
0.02 CD N
) ) N
. . N

The DT N
combination NN N
did VBD N
not RB N
offer VB N
any DT N
major JJ N
advantage NN N
over IN N
conventional JJ N
agents NNS N
. . N

-DOCSTART- -X- O O

Aminocaproic NNP 3_i
acid VBZ 3_i
versus FW N
prednisone NN 3_i
for IN N
the DT N
treatment NN N
of IN N
traumatic JJ N
hyphema NN N
. . N

A DT N
randomized JJ N
clinical JJ N
trial NN N
. . N

One CD N
hundred VBD N
twelve NN N
patients NNS N
who WP N
sustained VBD N
hyphema NN N
after IN N
blunt NN N
trauma NN N
were VBD N
enrolled VBN N
in IN N
a DT N
double-blind JJ N
randomized JJ N
clinical JJ N
trial NN N
to TO N
determine VB N
the DT N
relative JJ N
efficacies NNS N
of IN N
aminocaproic JJ 3_i
acid NN 3_i
( ( 3_i
Amicar NNP 3_i
) ) 3_i
and CC N
systemic JJ 3_i
prednisone NN 3_i
for IN N
reducing VBG N
the DT N
rate NN N
of IN N
secondary JJ N
hemorrhage NN N
. . N

Fifty-six JJ N
patients NNS N
received VBD N
an DT N
oral JJ N
dosage NN N
of IN N
50 CD N
mg/kg NN N
of IN N
aminocaproic JJ 3_i
acid NN 3_i
every DT N
4 CD N
hours NNS N
for IN N
5 CD N
days NNS N
, , N
up RB N
to TO N
a DT N
maximum NN N
of IN N
30 CD N
g JJ N
daily JJ N
, , N
and CC N
56 CD N
patients NNS N
received VBD N
an DT N
oral JJ N
dosage NN N
of IN N
40 CD N
mg NN N
of IN N
prednisone JJ 3_i
daily JJ N
( ( N
adjusted VBN N
for IN N
weight NN N
) ) N
in IN N
two CD N
divided JJ N
doses NNS N
. . N

Placebo NNP 7_i
pills NNS N
and CC N
liquids NNS N
were VBD N
given VBN N
to TO N
each DT N
patient NN N
to TO N
mask VB N
the DT N
treatment NN N
schedules NNS N
. . N

There EX N
were VBD N
no DT N
statistically RB N
significant JJ N
differences NNS N
between IN N
the DT N
patient NN N
populations NNS N
for IN N
any DT N
demographic JJ N
or CC N
clinical JJ N
characteristic NN N
( ( N
e.g. JJ N
, , N
visual JJ N
acuity NN N
, , N
intraocular JJ N
pressure NN N
[ NNP N
IOP NNP N
] NNP N
, , N
initial JJ N
hyphema NN N
size NN N
) ) N
measured VBN N
in IN N
the DT N
study NN N
. . N

Blacks NNS N
comprised VBD N
53 CD N
% NN N
of IN N
the DT N
study NN N
population NN N
, , N
and CC N
the DT N
mean JJ N
age NN N
of IN N
the DT N
patients NNS N
was VBD N
23.5 CD N
years NNS N
. . N

Four CD N
patients NNS N
in IN N
each DT N
of IN N
the DT N
treatment NN N
groups NNS N
experienced VBD N
a DT N
secondary JJ N
hemorrhage NN N
; : N
the DT N
rebleed NN N
rate NN N
was VBD N
7.1 CD N
% NN N
in IN N
each DT N
group NN N
. . N

-DOCSTART- -X- O O

Double-blind NNP N
comparison NN N
of IN N
doxepin NN 3_i
versus NN N
bupropion NN 3_i
in IN N
outpatients NNS N
with IN N
a DT N
major JJ N
depressive JJ N
disorder NN N
. . N

A DT N
double-blind NN N
controlled VBN N
study NN N
comparing VBG N
the DT N
effects NNS N
of IN N
bupropion NN 3_i
to TO N
doxepin VB 3_i
in IN N
outpatients NNS N
with IN N
primary JJ N
depression NN N
was VBD N
conducted VBN N
to TO N
evaluate VB N
efficacy NN N
and CC N
safety NN N
differences NNS N
between IN N
the DT N
two CD N
drugs NNS N
. . N

Following VBG N
a DT N
7-day JJ N
placebo NN 7_i
washout NN N
period NN N
, , N
patients NNS N
could MD N
be VB N
treated VBN N
for IN N
up RB N
to TO N
13 CD N
weeks NNS N
on IN N
either DT N
treatment NN N
. . N

Antidepressant JJ N
response NN N
was VBD N
assessed VBN N
by IN N
the DT N
Hamilton NNP N
Depression NNP N
and CC N
Anxiety NNP N
Scales NNP N
, , N
Clinical NNP N
Global NNP N
Severity NNP N
and CC N
Improvement NNP N
Ratings NNP N
, , N
and CC N
the DT N
Zung NNP N
Self-Rating NNP N
Depression NNP N
Scale NNP N
. . N

Comparable JJ N
efficacy NN N
between IN N
the DT N
compounds NNS N
was VBD N
found VBN N
across IN N
the DT N
13-week JJ N
study NN N
. . N

Doxepin NNP 3_i
differed VBD N
from IN N
bupropion NN 3_i
mainly RB N
on IN N
the DT N
sleep JJ N
factor NN N
of IN N
the DT N
Hamilton NNP N
Depression NNP N
Scale NNP N
, , N
with IN N
doxepin NN 3_i
improving VBG N
sleep NN N
to TO N
a DT N
greater JJR N
extent NN N
than IN N
bupropion NN 3_i
. . 3_i

Doxepin NNP 3_i
produced VBD N
a DT N
greater JJR N
incidence NN N
of IN N
anticholinergic JJ N
side NN N
effects NNS N
, , N
including VBG N
dry JJ N
mouth NN N
, , N
constipation NN N
, , N
sleepiness NN N
, , N
and CC N
tiredness NN N
, , N
in IN N
comparison NN N
to TO N
bupropion NN 3_i
. . 3_i

Also RB N
, , N
increased VBD N
appetite NN N
and CC N
weight JJ N
gain NN N
were VBD N
consistent JJ N
side NN N
effects NNS N
of IN N
doxepin NN 3_i
relative NN N
to TO N
bupropion NN 3_i
. . 3_i

-DOCSTART- -X- O O

Direct JJ 2_i
trocar NN 2_i
insertion NN 2_i
vs. FW N
Verres NNP 2_i
needle FW 2_i
use NN 2_i
for IN N
laparoscopic JJ N
sterilization NN N
. . N

A DT N
randomized JJ N
, , N
prospective JJ N
trial NN N
was VBD N
designed VBN N
to TO N
compare VB N
direct JJ 2_i
trocar NN 2_i
insertion NN 2_i
with IN N
prior JJ N
peritoneal JJ N
insufflation NN N
with IN N
a DT N
Verres NNP 2_i
needle NN 2_i
for IN N
laparoscopic NN N
tubal JJ N
sterilization NN N
. . N

Direct JJ 2_i
trocar NN 2_i
insertion NN 2_i
resulted VBD N
in IN N
fewer JJR N
instrument NN N
insertions NNS N
( ( N
21.8 CD N
% NN N
vs. FW N
7.8 CD N
% NN N
) ) N
and CC N
use NN N
of IN N
smaller JJR N
volumes NNS N
of IN N
CO2 NNP N
( ( N
2.67 CD N
vs. FW N
2.32 CD N
L NNP N
) ) N
. . N

Direct JJ 2_i
trocar NN 2_i
use NN N
resulted VBD N
in IN N
a DT N
decrease NN N
in IN N
operating NN N
time NN N
from IN N
9 CD N
minutes NNS N
, , N
40 CD N
seconds NNS N
in IN N
the DT N
needle JJ N
group NN N
to TO N
7 CD N
minutes NNS N
, , N
30 CD N
seconds NNS N
in IN N
the DT N
trocar NN N
group NN N
. . N

Minor NNP N
omental JJ N
injuries NNS N
occurred VBD N
in IN N
a DT N
small JJ N
percentage NN N
of IN N
each DT N
group NN N
, , N
while IN N
serious JJ N
complications NNS N
occurred VBD N
once RB N
in IN N
each DT N
group NN N
. . N

-DOCSTART- -X- O O

Is VBZ N
a DT N
calculated JJ N
total JJ N
hip NN N
BMD NNP N
of IN N
clinical JJ N
use NN N
? . N
The DT N
diagnosis NN N
of IN N
osteoporosis NN N
is VBZ N
based VBN N
on IN N
bone NN N
mass NN N
measurement NN N
. . N

To TO N
avoid VB N
the DT N
errors NNS N
associated VBN N
with IN N
the DT N
measurement NN N
of IN N
spinal JJ N
bone NN N
density NN N
the DT N
total JJ N
hip NN N
has VBZ N
been VBN N
accepted VBN N
as IN N
the DT N
standard JJ N
measurement NN N
site NN N
. . N

This DT N
information NN N
is VBZ N
not RB N
available JJ N
for IN N
many JJ N
early JJ N
measurements NNS N
. . N

We PRP N
have VBP N
assessed VBN N
whether IN N
it PRP N
is VBZ N
possible JJ N
to TO N
derive VB N
clinically RB N
useful JJ N
information NN N
about IN N
total JJ 6_i
hip NN 6_i
bone NN 6_i
mineral JJ 6_i
density NN 6_i
( ( N
BMD NNP N
) ) N
from IN N
measurements NNS N
at IN N
other JJ N
hip NN N
sites NNS N
. . N

The DT N
bone NN N
mass NN N
measurements NNS N
of IN N
46 CD N
patients NNS N
participating VBG N
in IN N
a DT N
current JJ N
trial NN N
of IN N
therapy NN N
for IN N
osteoporosis NN N
were VBD N
reviewed VBN N
. . N

The DT N
total JJ N
hip NN N
BMD NNP N
as IN N
directly RB N
measured VBN N
was VBD N
compared VBN N
with IN N
that DT N
obtained VBN N
from IN N
the DT N
formula NN N
: : N
Total JJ N
hip NN N
BMD NNP N
= VBZ N
0.48 CD N
x NN N
Neck NNP N
BMD NNP N
+ VBD N
0.62 CD N
x NNP N
Trochanteric NNP N
BMD NNP N
+ VBD N
0.03 CD N
. . N

In IN N
30 CD N
patients NNS N
with IN N
follow-up JJ N
data NNS N
the DT N
rate NN N
of IN N
change NN N
in IN N
hip NN N
BMD NNP N
over IN N
a DT N
year NN N
was VBD N
also RB N
determined VBN N
by IN N
both DT N
methods NNS N
. . N

In IN N
the DT N
pretreatment NN N
state NN N
there EX N
was VBD N
good JJ N
agreement NN N
between IN N
the DT N
two CD N
measures NNS N
( ( N
r2 VB N
= RB N
0.96 CD N
, , N
SEE NNP N
0.012 CD N
g/cm2 NN N
) ) N
. . N

If IN N
the DT N
formula NN N
was VBD N
used VBN N
to TO N
compute VB N
a DT N
change NN N
in IN N
total JJ N
hip NN N
BMD NNP N
, , N
the DT N
agreement NN N
between IN N
both DT N
methods NNS N
remained VBD N
good JJ N
. . N

However RB N
, , N
the DT N
standard JJ N
error NN N
of IN N
the DT N
estimate NN N
of IN N
the DT N
change NN N
represented VBD N
59 CD N
% NN N
of IN N
the DT N
observed JJ N
change NN N
. . N

This DT N
indicates VBZ N
that IN N
the DT N
error NN N
associated VBN N
with IN N
this DT N
estimate NN N
is VBZ N
too RB N
great JJ N
to TO N
allow VB N
clinically RB N
meaningful JJ N
conclusions NNS N
to TO N
be VB N
drawn VBN N
from IN N
calculated VBN N
total JJ N
hip NN N
BMD NNP N
. . N

We PRP N
conclude VBP N
that IN N
, , N
whilst VB N
it PRP N
may MD N
be VB N
possible JJ N
to TO N
obtain VB N
reasonable JJ N
point NN N
estimates NNS N
of IN N
total JJ N
hip NN N
BMD NNP N
from IN N
other JJ N
measures NNS N
in IN N
the DT N
hip NN N
, , N
these DT N
estimates NNS N
are VBP N
too RB N
imprecise JJ N
to TO N
allow VB N
conclusions NNS N
about IN N
change NN N
in IN N
BMD NNP N
to TO N
be VB N
made VBN N
. . N

-DOCSTART- -X- O O

Predictors NNS N
of IN N
postdischarge NN N
outcomes NNS N
from IN N
information NN N
acquired VBN N
shortly RB N
after IN N
admission NN N
for IN N
acute JJ N
heart NN N
failure NN N
: : N
a DT N
report NN N
from IN N
the DT N
Placebo-Controlled NNP 7_i
Randomized NNP N
Study NNP N
of IN N
the DT N
Selective NNP N
A1 NNP N
Adenosine NNP N
Receptor NNP N
Antagonist NNP N
Rolofylline NNP 3_i
for IN N
Patients NNP N
Hospitalized NNP N
With IN N
Acute NNP N
Decompensated NNP N
Heart NNP N
Failure NNP N
and CC N
Volume NN N
Overload NNP N
to TO N
Assess NNP N
Treatment NNP N
Effect NNP N
on IN N
Congestion NNP N
and CC N
Renal NNP N
Function NNP N
( ( N
PROTECT NNP N
) ) N
Study NNP N
. . N

BACKGROUND NNP N
Acute NNP N
heart NN N
failure NN N
is VBZ N
a DT N
common JJ N
reason NN N
for IN N
admission NN N
, , N
and CC N
outcome NN N
is VBZ N
often RB N
poor JJ N
. . N

Improved VBN N
prognostic JJ N
risk NN N
stratification NN N
may MD N
assist VB N
in IN N
the DT N
design NN N
of IN N
future JJ N
trials NNS N
and CC N
in IN N
patient JJ N
management NN N
. . N

Using VBG N
data NNS N
from IN N
a DT N
large JJ N
randomized JJ N
trial NN N
, , N
we PRP N
explored VBD N
the DT N
prognostic JJ N
value NN N
of IN N
clinical JJ N
variables NNS N
, , N
measured VBN N
at IN N
hospital JJ N
admission NN N
for IN N
acute JJ N
heart NN N
failure NN N
, , N
to TO N
determine VB N
whether IN N
a DT N
few JJ N
selected VBN N
variables NNS N
were VBD N
inferior JJ N
to TO N
an DT N
extended VBN N
data NN N
set NN N
. . N

METHODS NNP N
AND CC N
RESULTS NNP N
The DT N
prognostic JJ N
model NN N
included VBD N
37 CD N
clinical JJ N
characteristics NNS N
collected VBN N
at IN N
baseline NN N
in IN N
PROTECT NNP N
, , N
a DT N
study NN N
comparing VBG N
rolofylline NN 3_i
and CC N
placebo NN 7_i
in IN N
2033 CD N
patients NNS N
admitted VBN N
with IN N
acute JJ N
heart NN N
failure NN N
. . N

Prespecified VBN N
outcomes NNS N
at IN N
30 CD N
days NNS N
were VBD N
death NN N
or CC N
rehospitalization NN N
for IN N
any DT N
reason NN N
; : N
death NN N
or CC N
rehospitalization NN N
for IN N
cardiovascular NN N
or CC N
renal JJ N
reasons NNS N
; : N
and CC N
, , N
at IN N
both DT N
30 CD N
and CC N
180 CD N
days NNS N
, , N
all-cause JJ N
mortality NN N
. . N

No DT N
variable JJ N
had VBD N
a DT N
c-index NN N
> NN N
0.70 CD N
, , N
and CC N
few JJ N
had VBD N
values NNS N
> $ N
0.60 CD N
; : N
c-indices NNS N
were VBD N
lower JJR N
for IN N
composite JJ N
outcomes NNS N
than IN N
for IN N
mortality NN N
. . N

Blood NNP N
urea NN N
was VBD N
generally RB N
the DT N
strongest JJS N
single JJ N
predictor NN N
. . N

Eighteen NNP N
variables NNS N
contributed VBD N
independent JJ N
prognostic JJ N
information NN N
, , N
but CC N
a DT N
reduced JJ N
model NN N
using VBG N
only RB N
8 CD N
items NNS N
( ( N
age NN N
, , N
previous JJ N
heart NN N
failure NN N
hospitalization NN N
, , N
peripheral JJ N
edema NN N
, , N
systolic JJ N
blood NN N
pressure NN N
, , N
serum NN N
sodium NN N
, , N
urea JJ N
, , N
creatinine NN N
, , N
and CC N
albumin NN N
) ) N
performed VBD N
similarly RB N
. . N

For IN N
prediction NN N
of IN N
all-cause JJ N
mortality NN N
at IN N
180 CD N
days NNS N
, , N
the DT N
model NN N
c-index NN N
using VBG N
all DT N
variables NNS N
was VBD N
0.72 CD N
and CC N
for IN N
the DT N
simplified JJ N
model NN N
, , N
also RB N
0.72 CD N
. . N

CONCLUSIONS VB N
A NNP N
few JJ N
simple JJ N
clinical JJ N
variables NNS N
measured VBN N
on IN N
admission NN N
in IN N
patients NNS N
with IN N
acute JJ N
heart NN N
failure NN N
predict VBP N
a DT N
variety NN N
of IN N
adverse JJ N
outcomes NNS N
with IN N
accuracy NN N
similar JJ N
to TO N
more RBR N
complex JJ N
models NNS N
. . N

However RB N
, , N
predictive JJ N
models NNS N
were VBD N
of IN N
only RB N
moderate JJ N
accuracy NN N
, , N
especially RB N
for IN N
outcomes NNS N
that WDT N
included VBD N
nonfatal JJ N
events NNS N
. . N

Better NNP N
methods NNS N
of IN N
risk NN N
stratification NN N
are VBP N
required VBN N
. . N

CLINICAL JJ N
TRIAL NNP N
REGISTRATION NNP N
URL NNP N
: : N
http NN N
: : N
//www.clinicaltrials.gov NN N
. . N

Unique JJ N
identifiers NNS N
: : N
NCT00328692 NNP N
and CC N
NCT00354458 NNP N
. . N

-DOCSTART- -X- O O

Study NN N
of IN N
the DT N
therapeutic JJ N
effects NNS N
of IN N
a DT N
hippotherapy NN 2_i
simulator NN 2_i
in IN N
children NNS N
with IN N
cerebral JJ N
palsy NN N
: : N
a DT N
stratified JJ N
single-blind NN N
randomized VBD N
controlled JJ N
trial NN N
. . N

OBJECTIVE UH N
To TO N
investigate VB N
whether IN N
hippotherapy NN 2_i
( ( 2_i
when WRB 2_i
applied VBN 2_i
by IN 2_i
a DT 2_i
simulator NN 2_i
) ) 2_i
improves VBZ N
postural JJ N
control NN N
and CC N
balance NN N
in IN N
children NNS N
with IN N
cerebral JJ N
palsy NN N
. . N

DESIGN NNP N
Stratified VBD N
single-blind JJ N
randomized NN N
controlled VBD N
trial NN N
with IN N
an DT N
independent JJ N
assessor NN N
. . N

Stratification NN N
was VBD N
made VBN N
by IN N
gross JJ N
motor NN N
function NN N
classification NN N
system NN N
levels NNS N
, , N
and CC N
allocation NN N
was VBD N
concealed VBN N
. . N

SUBJECTS NNP N
Children NNP N
between IN N
4 CD N
and CC N
18 CD N
years NNS N
old JJ N
with IN N
cerebral JJ N
palsy NN N
. . N

INTERVENTIONS JJ N
Participants NNS N
were VBD N
randomized VBN N
to TO N
an DT N
intervention NN 2_i
( ( 2_i
simulator NN 2_i
ON NNP 2_i
) ) 2_i
or CC N
control NN 7_i
( ( 7_i
simulator VB 7_i
OFF NNP 7_i
) ) 7_i
group NN N
after IN N
getting VBG N
informed JJ N
consent NN N
. . N

Treatment NNP N
was VBD N
provided VBN N
once RB N
a DT N
week NN N
( ( N
15 CD N
minutes NNS N
) ) N
for IN N
10 CD N
weeks NNS N
. . N

MAIN NNP N
MEASURES NNP N
Gross NNP N
Motor NNP N
Function NNP N
Measure NNP N
( ( N
dimension NN N
B NNP N
for IN N
balance NN N
and CC N
the DT N
Total NNP N
Score NNP N
) ) N
and CC N
Sitting VBG N
Assessment NNP N
Scale NNP N
were VBD N
carried VBN N
out RP N
at IN N
baseline NN N
( ( N
prior JJ N
to TO N
randomization NN N
) ) N
, , N
end NN N
of IN N
intervention NN N
and CC N
12 CD N
weeks NNS N
after IN N
completing VBG N
the DT N
intervention NN N
. . N

RESULTS NNP N
Thirty-eight JJ N
children NNS N
participated VBN N
. . N

The DT N
groups NNS N
were VBD N
balanced VBN N
at IN N
baseline NN N
. . N

Sitting VBG N
balance NN N
( ( N
measured VBN N
by IN N
dimension NN N
B NNP N
of IN N
the DT N
Gross NNP N
Motor NNP N
Function NNP N
Measure NNP N
) ) N
improved VBD N
significantly RB N
in IN N
the DT N
treatment NN N
group NN N
( ( N
effect NN N
size NN N
= $ N
0.36 CD N
; : N
95 CD N
% NN N
CI NNP N
0.01-0.71 NN N
) ) N
and CC N
the DT N
effect NN N
size NN N
was VBD N
greater JJR N
in IN N
the DT N
severely RB N
disabled JJ N
group NN N
( ( N
effect NN N
size NN N
= $ N
0.80 CD N
; : N
95 CD N
% NN N
CI NNP N
0.13-1.47 NN N
) ) N
. . N

The DT N
improvements NNS N
in IN N
sitting VBG N
balance NN N
were VBD N
not RB N
maintained VBN N
over IN N
the DT N
follow-up JJ N
period NN N
. . N

Changes NNS N
in IN N
the DT N
total JJ N
score NN N
of IN N
the DT N
Gross NNP N
Motor NNP N
Function NNP N
Measure NNP N
and CC N
the DT N
Sitting NNP N
Assessment NNP N
Scale NNP N
were VBD N
not RB N
significant JJ N
. . N

CONCLUSION NNP N
Hippotherapy NNP 2_i
with IN N
a DT N
simulator NN N
can MD N
improve VB N
sitting VBG N
balance NN N
in IN N
cerebral JJ N
palsy NN N
children NNS N
who WP N
have VBP N
higher JJR N
levels NNS N
of IN N
disability NN N
. . N

However RB N
, , N
this DT N
did VBD N
not RB N
lead VB N
to TO N
a DT N
change NN N
in IN N
the DT N
overall JJ N
function NN N
of IN N
these DT N
children NNS N
( ( N
Gross NNP N
Motor NNP N
Function NNP N
Classification NNP N
System NNP N
level JJ N
V NNP N
) ) N
. . N

-DOCSTART- -X- O O

No DT N
effect NN N
of IN N
acetylsalicylic JJ 3_i
acid NN 3_i
on IN N
B-thromboglobulin NNP N
and CC N
platelet VB N
factor NN N
4 CD N
plasma NN N
levels NNS N
in IN N
patients NNS N
with IN N
transient JJ N
ischaemic JJ N
attacks NNS N
. . N

We PRP N
studied VBD N
the DT N
effect NN N
of IN N
acetylsalicylic JJ 3_i
acid NN 3_i
( ( 3_i
ASA NNP 3_i
) ) 3_i
versus NN N
placebo NN 7_i
on IN N
B-thromboglobulin NNP N
( ( N
B-TG NNP N
) ) N
and CC N
platelet JJ N
factor NN N
4 CD N
( ( N
PF4 NNP N
) ) N
plasma NN N
levels NNS N
and CC N
ADP-induced NNP N
platelet NN N
aggregation NN N
in IN N
25 CD N
male JJ N
patients NNS N
with IN N
transient JJ N
ischaemic JJ N
attacks NNS N
( ( N
TIA NNP N
) ) N
. . N

The DT N
patients NNS N
were VBD N
allocated VBN N
randomly RB N
to TO N
two CD N
groups NNS N
: : N
14 CD N
patients NNS N
received JJ N
oral JJ N
treatment NN N
with IN N
ASA NNP 3_i
500 CD N
mg NN N
b.i.d NN N
. . N

for IN N
14 CD N
days NNS N
, , N
11 CD N
patients NNS N
placebo JJ 7_i
b.i.d NN N
. . N

for IN N
the DT N
same JJ N
period NN N
. . N

B-TG NNP N
and CC N
PF4 NNP N
plasma NN N
levels NNS N
and CC N
ADP-induced NNP N
platelet NN N
aggregation NN N
were VBD N
determined VBN N
in IN N
basal NN N
conditions NNS N
, , N
and CC N
two CD N
hours NNS N
, , N
and CC N
seven CD N
and CC N
fourteen JJ N
days NNS N
after IN N
starting VBG N
with IN N
ASA NNP N
or CC N
placebo NN N
. . N

In IN N
addition NN N
, , N
the DT N
same JJ N
parameters NNS N
were VBD N
studied VBN N
in IN N
a DT N
group NN N
of IN N
20 CD N
healthy JJ N
males NNS N
of IN N
matched JJ N
age NN N
. . N

Basal NNP N
levels NNS N
of IN N
plasma JJ N
B-TG NNP N
and CC N
PF4 NNP N
and CC N
the DT N
maximal JJ N
amplitude NN N
of IN N
ADP-induced NNP N
platelet NN N
aggregation NN N
were VBD N
abnormally RB N
high JJ N
in IN N
TIA NNP N
patients NNS N
. . N

ASA NNP N
caused VBD N
a DT N
significant JJ N
reduction NN N
of IN N
B-TG NNP N
plasma NN N
levels NNS N
in IN N
TIA NNP N
patients NNS N
2 CD N
hours NNS N
after IN N
the DT N
first JJ N
administration NN N
, , N
but CC N
no DT N
effect NN N
was VBD N
observed VBN N
at IN N
the DT N
7th CD N
and CC N
14th CD N
day NN N
of IN N
treatment NN N
. . N

PF4 NNP N
plasma NN N
levels NNS N
were VBD N
unaffected VBN N
by IN N
ASA NNP N
treatment NN N
. . N

It PRP N
is VBZ N
concluded VBN N
that IN N
ASA NNP N
, , N
at IN N
the DT N
dose NN N
conventionally RB N
used VBN N
in IN N
clinical JJ N
trials NNS N
, , N
does VBZ N
not RB N
affect VB N
the DT N
release NN N
of IN N
two CD N
alpha-granule JJ N
proteins NNS N
. . N

-DOCSTART- -X- O O

The DT N
influence NN N
of IN N
dietary JJ 3_i
fibre NN 3_i
source NN 3_i
and CC N
gender NN N
on IN N
the DT N
postprandial JJ N
glucose NN N
and CC N
lipid JJ N
response NN N
in IN N
healthy JJ N
subjects NNS N
. . N

BACKGROUND NNP N
Consumption NNP N
of IN N
soluble JJ 3_i
dietary JJ 3_i
fibre NN 3_i
is VBZ N
correlated VBN N
with IN N
decreased JJ N
postprandial JJ N
glucose NN N
and CC N
insulin NN N
responses NNS N
and CC N
hence NN N
has VBZ N
beneficial JJ N
effects NNS N
on IN N
the DT N
metabolic JJ N
syndrome NN N
. . N

AIM NNP N
OF IN N
THE NNP N
STUDY NNP N
To TO N
investigate VB N
the DT N
effects NNS N
on IN N
postprandial JJ N
glucose NN N
, , N
insulin NN N
and CC N
triglyceride JJ N
concentrations NNS N
of IN N
meals NNS N
enriched VBN N
with IN N
soluble JJ N
dietary JJ N
fibres NNS N
from IN N
oats NNS N
, , N
rye NN N
bran NN N
, , N
sugar JJ N
beet NN N
fibre NN N
or CC N
a DT N
mixture NN N
of IN N
these DT N
three CD N
fibres NNS N
. . N

METHODS NNP N
Thirteen NNP N
healthy JJ N
human JJ N
volunteers NNS N
( ( N
6 CD N
men NNS N
and CC N
7 CD N
women NNS N
, , N
aged VBN N
20-28 CD N
years NNS N
) ) N
were VBD N
included VBN N
in IN N
the DT N
study NN N
. . N

The DT N
subjects NNS N
came VBD N
to TO N
the DT N
study NN N
centre NN N
once RB N
a DT N
week NN N
after IN N
an DT N
overnight JJ N
fast NN N
to TO N
ingest VB N
test NN N
meals NNS 3_i
and CC N
a DT N
control NN N
meal NN N
in IN N
random JJ N
order NN N
. . N

The DT N
meals NNS N
contained VBD N
either CC N
oat JJ 3_i
powder NN 3_i
( ( N
62 CD N
g NN N
, , N
of IN N
which WDT N
2.7 CD N
soluble JJ N
fibre NN N
) ) N
, , N
rye NN 3_i
bran NN 3_i
( ( N
31 CD N
g NN N
, , N
of IN N
which WDT N
1.7 CD N
g NN N
soluble JJ N
fibre NN N
) ) N
, , N
sugar JJ 3_i
beet NN 3_i
fibre NN 3_i
( ( N
19 CD N
g NN N
, , N
of IN N
which WDT N
5 CD N
g NN N
soluble JJ N
fibre NN N
) ) N
, , N
a DT N
mixture NN 6_i
of IN N
these DT N
three CD N
fibres NNS N
( ( N
74 CD N
g NN N
, , N
of IN N
which WDT N
1.7 CD N
g NN N
soluble JJ N
fibre NN N
from IN N
each DT N
source NN N
, , N
giving VBG N
5 CD N
g NN N
soluble JJ N
fibre NN N
) ) N
or CC N
no DT N
added JJ 7_i
fibre NN 7_i
( ( 7_i
control NN 7_i
) ) 7_i
and CC N
were VBD N
all DT N
adjusted VBN N
to TO N
contain VB N
the DT N
same JJ N
total JJ N
amount NN N
of IN N
available JJ N
carbohydrates NNS 6_i
. . 6_i

Blood NN N
samples NNS N
were VBD N
drawn VBN N
before RB N
and CC N
every DT N
30 CD N
min NN N
up RB N
to TO N
180 CD N
min NN N
after IN N
the DT N
meals NNS N
. . N

RESULTS NNP N
Meals NNP 3_i
with IN 3_i
rye NN 3_i
bran NN 3_i
gave VBD N
a DT N
lower JJR N
postprandial JJ N
glucose NN N
peak NN N
when WRB N
compared VBN N
with IN N
the DT N
control NN N
meal NN N
, , N
and CC N
this DT N
effect NN N
was VBD N
more RBR N
pronounced JJ N
in IN N
women NNS N
compared VBN N
to TO N
men NNS N
. . N

Oat NNP 3_i
powder NN 3_i
, , N
containing VBG N
a DT N
low JJ N
amount NN N
of IN N
total JJ N
fibre NN N
and CC N
a DT N
high JJ N
amount NN N
of IN N
carbohydrates NNS N
in IN N
liquid NN N
matrix NN N
, , N
gave VBD N
a DT N
higher JJR N
incremental JJ N
glucose JJ N
peak NN N
concentration NN N
compared VBN N
to TO N
rye VB N
bran NN N
and CC N
sugar NN N
beet NN N
fibre NN N
and CC N
higher JJR N
insulin NN N
incremental JJ N
area NN N
under IN N
curve NN N
compared VBN N
to TO N
control VB N
. . N

The DT N
oat NN 3_i
powder NN 3_i
also RB N
influenced VBD N
the DT N
effects NNS N
of IN N
the DT N
mixed JJ N
meal NN N
, , N
diminishing VBG N
the DT N
glucose-lowering JJ N
effects NNS N
. . N

Postprandial NNP N
triglyceride NN N
levels NNS N
tended VBD N
to TO N
be VB N
higher JJR N
after IN N
all DT N
fibre-rich JJ N
meals NNS N
, , N
but CC N
only RB N
significant JJ N
for IN N
oat NN N
powder NN N
and CC N
the DT N
mixed JJ N
meal NN 3_i
when WRB N
compared VBN N
with IN N
the DT N
control NN N
meal NN 7_i
. . 3_i

CONCLUSIONS NNP N
Postprandial NNP N
glucose NN N
, , N
insulin NN N
and CC N
triglyceride JJ N
concentrations NNS N
are VBP N
influenced VBN N
by IN N
dietary JJ 3_i
fibre-rich JJ 3_i
meals NNS 3_i
, , N
depending VBG N
on IN N
fibre NN N
source NN N
, , N
dose NN N
of IN N
soluble JJ N
and CC N
total JJ N
fibre NN N
and CC N
possibly RB N
gender NN N
. . N

-DOCSTART- -X- O O

Effect NNP N
of IN N
four CD 2_i
intermediate JJ 2_i
layer NN 2_i
treatments NNS 2_i
on IN N
microleakage NN N
of IN N
Class NNP N
II NNP N
composite JJ N
restorations NNS N
. . N

This DT N
in IN N
vitro NN N
study NN N
examines VBZ N
the DT N
marginal JJ N
sealing NN N
ability NN N
of IN N
four CD 6_i
different JJ 6_i
intermediate JJ 6_i
materials NNS 6_i
applied VBN N
before IN N
placement NN N
of IN N
a DT N
condensable JJ 6_i
composite NN 6_i
. . 6_i

Class NNP N
II NNP N
preparations NNS N
were VBD N
made VBN N
with IN N
gingival JJ N
margins NNS N
placed VBD N
1.0 CD N
mm JJ N
apical JJ N
to TO N
the DT N
cementoenamel JJ N
junction NN N
of IN N
60 CD N
extracted JJ N
teeth NNS N
, , N
randomly RB N
assigned VBN N
to TO N
five CD N
groups NNS N
of IN N
12 CD N
. . N

Following VBG N
restoration NN N
, , N
teeth EX N
were VBD N
thermocycled VBN N
, , N
soaked VBN N
in IN N
0.5 CD N
% NN N
basic JJ N
fuchsin NN N
, , N
and CC N
sectioned VBD N
longitudinally RB N
. . N

The DT N
resin-modified JJ 6_i
glass NN 6_i
ionomer NN 6_i
cement NN 6_i
demonstrated VBD N
significantly RB N
less JJR N
microleakage NN N
than IN N
the DT N
use NN N
of IN N
a DT N
dentin NN 6_i
bonding NN 6_i
agent NN 6_i
alone RB 6_i
or CC N
in IN N
combination NN 6_i
with IN 6_i
flowable JJ 6_i
composite JJ 6_i
, , N
flowable JJ N
compomer NN N
, , N
or CC N
autoploymerizing VBG N
composite JJ N
( ( N
p JJ N
< NN N
0.05 CD N
, , N
Dunn NNP N
's POS N
test NN N
) ) N
. . N

This DT N
study NN N
supports VBZ N
the DT N
use NN N
of IN N
the DT N
glass NN 2_i
ionomer NN 2_i
open JJ 2_i
sandwich NN 2_i
technique NN 2_i
in IN N
deep JJ N
Class NNP N
II NNP N
direct JJ N
composite JJ N
restorations NNS N
. . N

-DOCSTART- -X- O O

Long-term JJ N
exposure NN N
to TO N
belatacept VB N
in IN N
recipients NNS N
of IN N
extended JJ N
criteria NNS N
donor JJ N
kidneys NNS N
. . N

Patients NNS N
in IN N
the DT N
BENEFIT-EXT NNP N
study NN N
received VBD N
extended JJ N
criteria NNS N
donor JJ N
kidneys NNS N
and CC N
a DT N
more RBR N
intensive JJ 3_i
( ( 3_i
MI NNP 3_i
) ) 3_i
or CC 3_i
less RBR 3_i
intensive JJ 3_i
( ( 3_i
LI NNP 3_i
) ) 3_i
belatacept IN 3_i
immunosuppression NN 3_i
regimen NNS 3_i
, , N
or CC N
cyclosporine VB 3_i
A NNP 3_i
( ( 3_i
CsA NNP 3_i
) ) 3_i
. . N

Patients NNS N
who WP N
remained VBD N
on IN N
assigned JJ N
therapy NN N
through IN N
year NN N
3 CD N
were VBD N
eligible JJ N
to TO N
enter VB N
a DT N
long-term JJ N
extension NN N
( ( N
LTE NNP N
) ) N
study NN N
. . N

Three CD N
hundred VBD N
four CD N
patients NNS N
entered VBD N
the DT N
LTE NNP N
( ( N
n JJ N
= $ N
104 CD N
MI NNP N
; : N
n CC N
= $ N
113 CD N
LI NNP N
; : N
n CC N
= $ N
87 CD N
CsA NNP N
) ) N
, , N
and CC N
260 CD N
continued VBD N
treatment NN N
through IN N
year NN N
5 CD N
( ( N
n JJ N
= $ N
91 CD N
MI NNP N
; : N
n CC N
= $ N
100 CD N
LI NNP N
; : N
n CC N
= $ N
69 CD N
CsA NNP N
) ) N
. . N

Twenty CD N
patients NNS N
died VBD N
during IN N
the DT N
LTE NNP N
( ( N
n JJ N
= $ N
5 CD N
MI NNP N
; : N
n CC N
= $ N
9 CD N
LI NNP N
; : N
n CC N
= $ N
6 CD N
CsA NNP N
) ) N
, , N
and CC N
eight CD N
experienced VBD N
graft NN N
loss NN N
( ( N
n JJ N
= $ N
2 CD N
MI NNP N
; : N
n CC N
= $ N
1 CD N
LI NNP N
; : N
n CC N
= $ N
5 CD N
CsA NNP N
) ) N
. . N

Three CD N
patients NNS N
experienced VBD N
an DT N
acute JJ N
rejection NN N
episode NN N
( ( N
n JJ N
= $ N
2 CD N
MI NNP N
; : N
n CC N
= $ N
1 CD N
LI NNP N
) ) N
. . N

The DT N
incidence NN N
rate NN N
of IN N
serious JJ N
adverse JJ N
events NNS N
, , N
viral JJ N
infections NNS N
and CC N
fungal JJ N
infections NNS N
was VBD N
similar JJ N
across IN N
groups NNS N
during IN N
the DT N
LTE NNP N
. . N

There EX N
were VBD N
four CD N
cases NNS N
of IN N
posttransplant JJ N
lymphoproliferative JJ N
disorder NN N
( ( N
PTLD NNP N
) ) N
from IN N
the DT N
beginning NN N
of IN N
the DT N
LTE NNP N
to TO N
year NN N
5 CD N
( ( N
n JJ N
= $ N
3 CD N
LI NNP N
; : N
n CC N
= $ N
1 CD N
CsA NNP N
) ) N
; : N
two CD N
of IN N
three CD N
PTLD NNP N
cases NNS N
in IN N
the DT N
LI NNP N
group NN N
were VBD N
in IN N
patients NNS N
who WP N
were VBD N
seronegative JJ N
for IN N
Epstein-Barr NNP N
virus NN N
( ( N
EBV NNP N
( ( N
- : N
) ) N
) ) N
at IN N
transplantation NN N
. . N

Mean NNP N
? . N
SD NNP N
calculated VBD N
GFR NNP N
at IN N
year NN N
5 CD N
was VBD N
55.9 CD N
? . N
17.5 CD N
( ( N
MI NNP N
) ) N
, , N
59.0 CD N
? . N
29.1 CD N
( ( N
LI NNP N
) ) N
and CC N
44.6 CD N
? . N
16.4 CD N
( ( N
CsA NNP N
) ) N
mL/min/1.73 NN N
m NN N
( ( N
2 CD N
) ) N
. . N

Continued VBN N
treatment NN N
with IN N
belatacept NN N
was VBD N
associated VBN N
with IN N
a DT N
consistent JJ N
safety NN N
profile NN N
and CC N
sustained VBD N
improvement NN N
in IN N
renal JJ N
function NN N
versus NN N
CsA NNP N
over IN N
time NN N
. . N

-DOCSTART- -X- O O

18F-FDG JJ N
PET/CT NNP N
for IN N
early JJ N
prediction NN N
of IN N
response NN N
to TO N
neoadjuvant JJ 3_i
lapatinib NN 3_i
, , N
trastuzumab NN 3_i
, , N
and CC N
their PRP$ 3_i
combination NN 3_i
in IN N
HER2-positive JJ N
breast NN N
cancer NN N
: : N
results NNS N
from IN N
Neo-ALTTO NNP N
. . N

UNLABELLED NNP N
Molecular NNP N
imaging VBG N
receives NNS N
increased VBD N
attention NN N
for IN N
selecting VBG N
patients NNS N
who WP N
will MD N
benefit VB N
from IN N
targeted JJ N
anticancer NN N
therapies NNS N
. . N

Neo-ALTTO NNP N
( ( N
Neoadjuvant NNP 3_i
Lapatinib NNP 3_i
and/or VBZ N
Trastuzumab NNP 3_i
Treatment NNP N
Optimisation NNP N
) ) N
enrolled VBD N
455 CD N
women NNS N
with IN N
invasive JJ N
human JJ N
epidermal JJ N
growth NN N
factor NN N
receptor NN N
2 CD N
( ( N
HER2 NNP N
) ) N
-positive VBP N
breast NN N
cancer NN N
and CC N
compared VBN N
rates NNS N
of IN N
pathologic JJ N
complete JJ N
response NN N
( ( N
pCR NN N
) ) N
to TO N
neoadjuvant JJ 3_i
lapatinib NN 3_i
, , N
trastuzumab NN 3_i
, , N
and CC N
their PRP$ N
combination NN 3_i
. . N

Each DT N
anti-HER2 JJ 3_i
therapy NN 3_i
was VBD N
given VBN N
alone RB N
for IN N
6 CD N
wk NN N
, , N
followed VBN N
by IN N
12 CD N
wk NN N
of IN N
the DT N
same JJ N
therapy NN N
plus CC N
weekly JJ N
paclitaxel NN 3_i
. . 3_i

The DT N
early JJ N
metabolic JJ N
effects NNS N
of IN N
the DT N
anti-HER2 JJ 3_i
therapies NNS 3_i
on IN N
the DT N
primary JJ N
tumors NNS N
and CC N
their PRP$ N
predictive JJ N
values NNS N
for IN N
pCR NN N
were VBD N
assessed VBN N
in IN N
a DT N
subset NN N
of IN N
patients NNS N
. . N

METHODS NNP N
Eighty-six JJ N
patients NNS N
underwent JJ N
( ( N
18 CD N
) ) N
F-FDG CD N
PET/CT NNP N
at IN N
baseline NN N
and CC N
weeks NNS N
2 CD N
and CC N
6 CD N
of IN N
anti-HER2 JJ 3_i
treatment NN 3_i
. . 3_i

An DT N
imaging VBG N
core NN N
laboratory NN N
provided VBD N
central JJ N
validation NN N
, , N
and CC N
2 CD N
independent JJ N
reviewers NNS N
, , N
masked VBD N
to TO N
assigned VB N
treatment NN N
arm NN N
and CC N
clinical JJ N
outcomes NNS N
, , N
performed VBN N
consensus NN N
( ( N
18 CD N
) ) N
F-FDG NNP N
PET/CT NNP N
readings NNS N
. . N

Maximum NNP N
standardized VBD N
uptake JJ N
value NN N
( ( N
SUVmax NNP N
) ) N
reductions NNS N
from IN N
baseline NN N
were VBD N
used VBN N
to TO N
measure VB N
metabolic JJ N
response NN N
. . N

RESULTS NNP N
Seventy-seven NNP N
of IN N
the DT N
86 CD N
enrolled VBD N
patients NNS N
presented VBD N
an DT N
evaluable JJ N
baseline NN N
( ( N
18 CD N
) ) N
F-FDG NNP N
PET/CT NNP N
scan JJ N
; : N
of IN N
these DT N
, , N
68 CD N
and CC N
66 CD N
were VBD N
evaluable JJ N
at IN N
weeks NNS N
2 CD N
and CC N
6 CD N
, , N
respectively RB N
. . N

Metabolic JJ N
responses NNS N
in IN N
the DT N
primary JJ N
tumors NNS N
were VBD N
evident JJ N
after IN N
2 CD N
wk NN N
of IN N
targeted JJ N
therapy NN N
and CC N
correlated VBN N
highly RB N
with IN N
metabolic JJ N
responses NNS N
at IN N
week NN N
6 CD N
( ( N
R NNP N
( ( N
2 CD N
) ) N
= FW N
0.81 CD N
) ) N
. . N

pCRs NN N
were VBD N
associated VBN N
with IN N
greater JJR N
SUVmax NNP N
reductions NNS N
at IN N
both DT N
time NN N
points NNS N
. . N

Mean NNP N
SUVmax NNP N
reductions NNS N
for IN N
pCR NN N
and CC N
non-pCR JJ N
, , N
respectively RB N
, , N
were VBD N
54.3 CD N
% NN N
versus IN N
32.8 CD N
% NN N
at IN N
week NN N
2 CD N
( ( N
P NNP N
= NNP N
0.02 CD N
) ) N
and CC N
61.5 CD N
% NN N
versus IN N
34.1 CD N
% NN N
at IN N
week NN N
6 CD N
( ( N
P NNP N
= NNP N
0.02 CD N
) ) N
. . N

( ( N
18 CD N
) ) N
F-FDG NNP N
PET/CT NNP N
metabolic JJ N
response NN N
rates NNS N
at IN N
weeks NNS N
2 CD N
and CC N
6 CD N
were VBD N
71.6 CD N
% NN N
and CC N
60 CD N
% NN N
, , N
respectively RB N
using VBG N
European JJ N
Organization NNP N
for IN N
Research NNP N
and CC N
Treatment NNP N
of IN N
Cancer NNP N
criteria NNS N
; : N
pCR VBN N
rates NNS N
were VBD N
twice RB N
as RB N
high JJ N
for IN N
( ( N
18 CD N
) ) N
F-FDG NNP N
PET/CT NNP N
responders NNS N
than IN N
nonresponders NNS N
( ( N
week NN N
2 CD N
: : N
42 CD N
% NN N
vs. FW N
21 CD N
% NN N
, , N
P NNP N
= NNP N
0.12 CD N
; : N
week NN N
6 CD N
: : N
44 CD N
% NN N
vs. FW N
19 CD N
% NN N
, , N
P NNP N
= NNP N
0.05 CD N
) ) N
. . N

CONCLUSION NNP N
Early NNP N
metabolic JJ N
assessment NN N
using VBG N
( ( N
18 CD N
) ) N
F-FDG CD N
PET/CT NNP N
can MD N
identify VB N
patients NNS N
with IN N
an DT N
increased VBN N
likelihood NN N
of IN N
pCR NN N
after IN N
neoadjuvant JJ 3_i
trastuzumab NN 3_i
, , N
lapatinib NN 3_i
, , N
or CC N
their PRP$ N
combination NN 3_i
when WRB N
given VBN N
with IN N
chemotherapy NN 3_i
. . 3_i

-DOCSTART- -X- O O

Recombinant JJ 3_i
human JJ 3_i
erythropoietin NN 3_i
therapy NN 3_i
for IN N
anemic JJ N
cancer NN N
patients NNS N
on IN N
combination NN N
chemotherapy NN N
. . N

BACKGROUND NNP N
Patients NNPS N
with IN N
advanced JJ N
cancer NN N
frequently RB N
experience VBZ N
clinically RB N
significant JJ N
anemia NN N
, , N
which WDT N
is VBZ N
often RB N
exacerbated VBN N
by IN N
myelosuppressive JJ N
chemotherapy NN N
. . N

Consistent JJ N
with IN N
the DT N
anemia NN N
of IN N
chronic JJ N
disease NN N
, , N
studies NNS N
have VBP N
documented VBN N
serum JJ N
erythropoietin NN N
levels NNS N
that WDT N
are VBP N
inappropriately RB N
low JJ N
for IN N
the DT N
degree NN N
of IN N
anemia NN N
in IN N
cancer NN N
patients NNS N
. . N

Myelosuppressive JJ N
chemotherapy NN N
impairs NNS N
erythropoiesis NN N
, , N
which WDT N
may MD N
not RB N
fully RB N
recover VB N
between IN N
treatment NN N
cycles NNS N
. . N

Recombinant NNP 3_i
human JJ 3_i
erythropoietin NN 3_i
( ( 3_i
rHuEPO NN 3_i
) ) 3_i
has VBZ N
been VBN N
used VBN N
safely RB N
and CC N
effectively RB N
to TO N
treat VB N
anemia NN N
in IN N
AIDS NNP N
patients NNS N
receiving VBG N
zidovudine NN N
( ( N
AZT NNP N
) ) N
and CC N
in IN N
patients NNS N
with IN N
chronic JJ N
renal JJ N
failure NN N
. . N

PURPOSE VB N
This DT N
study NN N
was VBD N
designed VBN N
to TO N
evaluate VB N
the DT N
clinical JJ N
role NN N
of IN N
rHuEPO NN N
in IN N
reducing VBG N
symptomatic JJ N
anemia NN N
in IN N
patients NNS N
with IN N
advanced JJ N
cancer NN N
who WP N
were VBD N
receiving VBG N
myelosuppressive JJ N
chemotherapy NN N
( ( N
excluding VBG N
cisplatin NN N
) ) N
. . N

METHODS NNP N
We PRP N
studied VBD N
153 CD N
anemic JJ N
cancer NN N
patients NNS N
receiving VBG N
cyclic JJ 3_i
combination NN 3_i
chemotherapy NN 3_i
in IN N
a DT N
prospective JJ N
multicenter NN N
, , N
double-blind JJ N
, , N
placebo-controlled JJ N
trial NN N
. . N

The DT N
patients NNS N
were VBD N
randomly RB N
assigned VBN N
to TO N
receive VB N
either DT N
rHuEPO NN 3_i
( ( N
150 CD N
U/kg NNP N
) ) N
or CC N
placebo NN 7_i
subcutaneously RB N
three CD N
times NNS N
a DT N
week NN N
for IN N
a DT N
maximum NN N
of IN N
12 CD N
weeks NNS N
or CC N
until IN N
the DT N
hematocrit JJ N
level NN N
increased VBD N
to TO N
38 CD N
% NN N
-40 JJ N
% NN N
. . N

If IN N
the DT N
hematocrit NN N
reached VBD N
this DT N
target NN N
level NN N
before IN N
12 CD N
weeks NNS N
, , N
the DT N
rHuEPO NN 3_i
dose NN N
could MD N
be VB N
reduced VBN N
to TO N
maintain VB N
the DT N
hematocrit NN N
at IN N
that DT N
level NN N
for IN N
the DT N
duration NN N
of IN N
the DT N
study NN N
. . N

Response NNP N
to TO N
rHuEPO VB 3_i
therapy NN N
was VBD N
assessed VBN N
by IN N
measuring VBG N
changes NNS N
in IN N
hematocrit NN N
level NN N
, , N
transfusion NN N
requirements NNS N
, , N
and CC N
quality NN N
of IN N
life NN N
. . N

Quality-of-life JJ N
assessment NN N
was VBD N
based VBN N
on IN N
patients NNS N
' POS N
responses NNS N
to TO N
questionnaires NNS N
before IN N
and CC N
after IN N
the DT N
courses NNS N
of IN N
therapy NN N
. . N

RESULTS VB N
The DT N
increase NN N
in IN N
hematocrit NN N
in IN N
the DT N
rHuEPO-treated JJ 3_i
group NN N
compared VBN N
with IN N
hematocrit NN N
in IN N
the DT N
placebo-treated JJ 7_i
group NN N
was VBD N
statistically RB N
significant JJ N
( ( N
P NNP N
= NNP N
.0001 NNP N
) ) N
as IN N
measured VBN N
by IN N
percentage NN N
point NN N
of IN N
change NN N
from IN N
baseline NN N
to TO N
final JJ N
evaluation NN N
, , N
by IN N
an DT N
increase NN N
in IN N
hematocrit JJ N
level NN N
of IN N
six CD N
percentage NN N
points NNS N
or CC N
more JJR N
unrelated JJ N
to TO N
transfusion NN N
, , N
and CC N
by IN N
a DT N
rise NN N
in IN N
hematocrit NN N
level NN N
to TO N
38 CD N
% NN N
or CC N
more JJR N
unrelated JJ N
to TO N
transfusion NN N
. . N

There EX N
was VBD N
a DT N
trend NN N
toward IN N
the DT N
reduction NN N
in IN N
mean JJ N
units NNS N
of IN N
blood NN N
transfused VBN N
per IN N
patient NN N
during IN N
months NNS N
2 CD N
and CC N
3 CD N
of IN N
therapy NN N
combined VBN N
in IN N
rHuEPO-treated JJ 3_i
patients NNS N
compared VBN N
with IN N
placebo-treated JJ N
patients NNS N
( ( N
0.91 CD N
U NNP N
versus NN N
1.65 CD N
U NNP N
; : N
P NNP N
= NNP N
.056 NNP N
) ) N
. . N

In IN N
addition NN N
, , N
rHuEPO-treated JJ 3_i
patients NNS N
experienced VBD N
a DT N
statistically RB N
significant JJ N
improvement NN N
in IN N
energy NN N
level NN N
and CC N
ability NN N
to TO N
perform VB N
daily JJ N
activities NNS N
( ( N
P NNP N
< NNP N
or CC N
= NNP N
.05 NNP N
) ) N
. . N

The DT N
two CD N
treatment NN N
groups NNS N
showed VBD N
no DT N
statistically RB N
significant JJ N
differences NNS N
in IN N
toxic JJ N
effects NNS N
except IN N
for IN N
increased JJ N
incidence NN N
of IN N
diaphoresis NN N
( ( N
P NNP N
< NNP N
.05 NNP N
) ) N
and CC N
diarrhea NN N
( ( N
P NNP N
= NNP N
.05 NNP N
) ) N
in IN N
the DT N
rHuEPO-treated JJ N
group NN N
. . N

CONCLUSIONS NNP N
We PRP N
conclude VBP N
that DT N
rHuEPO NN 3_i
is VBZ N
safe JJ N
and CC N
effective JJ N
for IN N
reversing VBG N
anemia RB N
related VBN N
to TO N
advanced JJ N
cancer NN N
or CC N
to TO N
chemotherapy VB N
for IN N
cancer NN N
. . N

-DOCSTART- -X- O O

The DT N
relationship NN N
between IN N
repetitive JJ N
behaviors NNS N
and CC N
growth NN N
hormone NN N
response NN N
to TO N
sumatriptan VB 3_i
challenge NN N
in IN N
adult NN N
autistic JJ N
disorder NN N
. . N

Autism NNP N
is VBZ N
heterogeneous JJ N
with IN N
respect NN N
to TO N
clinical JJ N
symptoms NNS N
and CC N
etiology NN N
. . N

To TO N
sort VB N
out RP N
this DT N
heterogeneity NN N
in IN N
autism NN N
, , N
we PRP N
investigated VBD N
whether IN N
specific JJ N
neurobiological JJ N
markers NNS N
vary VBP N
in IN N
parallel NN N
to TO N
core VB N
symptomatology NN N
. . N

Specifically RB N
, , N
we PRP N
assessed VBD N
growth NN N
hormone NN N
response NN N
to TO N
the DT N
5-HT JJ 3_i
1d CD 3_i
agonist NN 3_i
, , 3_i
sumatriptan NN 3_i
, , N
and CC N
linked VBD N
this DT N
measure NN N
of IN N
serotonergic JJ N
function NN N
to TO N
the DT N
severity NN N
of IN N
repetitive JJ N
behaviors NNS N
in IN N
adult NN N
autistic JJ N
patients NNS N
. . N

Eleven NNP N
adult NN N
patients NNS N
with IN N
autism NN N
or CC N
Asperger NNP N
's POS N
disorder NN N
were VBD N
randomized VBN N
to TO N
single JJ N
dose JJ N
sumatriptan NN 3_i
( ( N
6 CD N
mg RB N
SQ NNP N
) ) N
and CC N
placebo NN 7_i
challenges NNS N
, , N
separated VBN N
by IN N
a DT N
one-week JJ N
interval NN N
. . N

In IN N
adult JJ N
autistic JJ N
disorders NNS N
, , N
severity NN N
of IN N
repetitive JJ N
behaviors NNS N
at IN N
baseline NN N
, , N
as IN N
measured VBN N
by IN N
YBOCS-compulsion NNP N
score NN N
, , N
significantly RB N
positively RB N
correlated VBN N
with IN N
both DT N
peak JJ N
delta NN N
growth NN N
hormone NN N
response NN N
and CC N
area NN N
under IN N
the DT N
curve NN N
growth NN N
hormone NN N
response NN N
to TO N
sumatriptan VB 3_i
. . 3_i

Thus RB N
, , N
the DT N
severity NN N
of IN N
a DT N
specific JJ N
behavioral JJ N
dimension NN N
in IN N
autism NN N
( ( N
repetitive JJ N
behaviors NNS N
) ) N
parallels VBP N
the DT N
sensitivity NN N
of IN N
the DT N
5-HT JJ 3_i
1d CD 3_i
receptor NN 3_i
, , N
as IN N
manifest NN N
by IN N
sumatriptan NN 3_i
elicited VBN N
GH NNP N
response NN N
. . N

-DOCSTART- -X- O O

Teacher DT N
and CC N
child JJ N
predictors NNS N
of IN N
achieving VBG N
IEP NNP 4_i
goals NNS N
of IN N
children NNS N
with IN N
autism NN N
. . N

It PRP N
is VBZ N
encouraging VBG N
that IN N
children NNS N
with IN N
autism NN N
show VBP N
a DT N
strong JJ N
response NN N
to TO N
early JJ N
intervention NN N
, , N
yet RB N
more JJR N
research NN N
is VBZ N
needed VBN N
for IN N
understanding VBG N
the DT N
variability NN N
in IN N
responsiveness NN N
to TO N
specialized JJ N
programs NNS N
. . N

Treatment NNP N
predictor NN N
variables NNS N
from IN N
47 CD N
teachers NNS N
and CC N
children NNS N
who WP N
were VBD N
randomized VBN N
to TO N
receive VB N
the DT N
COMPASS NNP 4_i
intervention NN 4_i
( ( N
Ruble JJ N
et NN N
al NN N
. . N

in IN N
The DT N
collaborative JJ N
model NN N
for IN N
promoting VBG N
competence NN N
and CC N
success NN N
for IN N
students NNS N
with IN N
ASD NNP N
. . N

Springer NNP N
, , N
New NNP N
York NNP N
, , N
2012a CD N
) ) N
were VBD N
analyzed VBN N
. . N

Predictors NNS N
evaluated VBD N
against IN N
child NN N
IEP NNP N
goal NN N
attainment NN N
included VBD N
child NN N
, , N
teacher NN N
, , N
intervention NN N
practice NN N
, , N
and CC N
implementation NN N
practice NN N
variables NNS N
based VBN N
on IN N
an DT N
implementation NN N
science NN N
framework NN N
( ( N
Dunst NNP N
and CC N
Trivette NNP N
in IN N
J NNP N
Soc NNP N
Sci NNP N
8:143-148 CD N
, , N
2012 CD N
) ) N
. . N

Findings NNS N
revealed VBD N
one CD N
child NN N
( ( N
engagement NN N
) ) N
, , N
one CD N
teacher NN N
( ( N
exhaustion NN N
) ) N
, , N
two CD N
intervention NN N
quality NN N
( ( N
IEP NNP N
quality NN N
for IN N
targeted VBN N
and CC N
not RB N
targeted JJ N
elements NNS N
) ) N
, , N
and CC N
no DT N
implementation NN N
quality NN N
variables NNS N
accounted VBD N
for IN N
variance NN N
in IN N
child NN N
outcomes NNS N
when WRB N
analyzed VBN N
separately RB N
. . N

When WRB N
the DT N
four CD N
significant JJ N
variables NNS N
were VBD N
compared VBN N
against IN N
each DT N
other JJ N
in IN N
a DT N
single JJ N
regression NN N
analysis NN N
, , N
IEP NNP 4_i
quality NN N
accounted VBD N
for IN N
one CD N
quarter NN N
of IN N
the DT N
variance NN N
in IN N
child NN N
outcomes NNS N
. . N

-DOCSTART- -X- O O

Is VBZ N
chronic JJ 3_i
sildenafil NN 3_i
therapy NN 3_i
safe JJ N
and CC N
clinically RB N
beneficial JJ N
in IN N
patients NNS N
with IN N
systolic JJ N
heart NN N
failure NN N
? . N
Sildenafil NNP 3_i
is VBZ N
a DT N
selective JJ N
phosphodiesterase-5 JJ N
inhibitor NN N
and CC N
causes VBZ N
vasodilatation NN N
, , N
particularly RB N
in IN N
pulmonary JJ N
circulation NN N
. . N

Since IN N
left JJ N
heart NN N
failure NN N
may MD N
be VB N
associated VBN N
with IN N
pulmonary JJ N
hypertension NN N
out IN N
of IN N
proportion NN N
to TO N
left VB N
heart NN N
disease NN N
, , N
sildenafil NN 3_i
may MD N
have VB N
beneficial JJ N
effect NN N
in IN N
such JJ N
patients NNS N
. . N

The DT N
present JJ N
investigation NN N
was VBD N
designed VBN N
as IN N
a DT N
12-week JJ N
, , N
single-center JJ N
, , N
randomized VBN N
, , N
double-blind JJ N
, , N
placebo-controlled JJ 7_i
study NN N
evaluating VBG N
the DT N
effects NNS N
of IN N
sildenafil NN 3_i
on IN N
mean JJ N
blood NN N
pressure NN N
( ( N
primary JJ N
endpoint NN N
) ) N
in IN N
patients NNS N
with IN N
left JJ N
systolic JJ N
heart NN N
failure NN N
. . N

Secondary JJ N
endpoints NNS N
included VBD N
exercise NN N
capacity NN N
assessed VBN N
by IN N
6-minute JJ N
walk NN N
test NN N
. . N

A DT N
total NN N
of IN N
106 CD N
patients NNS N
were VBD N
randomized VBN N
1:1 CD N
to TO N
sildenafil VB 3_i
( ( N
n=53 NN N
) ) N
or CC N
placebo NN 7_i
( ( N
n=53 JJ N
) ) N
. . N

Patients NNS N
received VBD N
sildenafil JJ 3_i
25 CD N
mg NN N
twice RB N
a DT N
day NN N
or CC N
matching VBG N
placebo NN 7_i
for IN N
the DT N
first JJ N
2 CD N
weeks NNS N
and CC N
50 CD N
mg NN N
3 CD N
times NNS N
a DT N
week NN N
for IN N
the DT N
remainder NN N
of IN N
the DT N
trial NN N
. . N

The DT N
placebo-corrected JJ N
effect NN N
on IN N
mean JJ N
blood NN N
pressure NN N
was VBD N
1.16 CD N
mm NN N
Hg NNP N
( ( N
95 CD N
% NN N
confidence NN N
interval NN N
, , N
-1.6 VBP N
to TO N
5.1 CD N
, , N
P NNP N
> NNP N
.05 NNP N
) ) N
, , N
demonstrating VBG N
that IN N
sildenafil NN N
did VBD N
not RB N
decrease VB N
mean JJ N
blood NN N
pressure NN N
. . N

Compared VBN N
with IN N
placebo NN N
, , N
sildenafil NN 3_i
increased VBD N
the DT N
6-minute JJ N
walk NN N
test NN N
by IN N
a DT N
nonsignificant JJ N
treatment NN N
effect NN N
of IN N
14 CD N
m NN N
( ( N
P=.67 NNP N
) ) N
. . N

Adverse JJ N
effects NNS N
occurred VBD N
in IN N
a DT N
comparable JJ N
proportion NN N
of IN N
patients NNS N
taking VBG N
sildenafil JJ 3_i
and CC N
placebo NN N
, , N
and CC N
none NN N
of IN N
the DT N
patients NNS N
needed VBN N
to TO N
discontinue VB N
therapy NN N
. . N

Sildenafil NNP N
is VBZ N
well RB N
tolerated VBN N
in IN N
left JJ N
heart NN N
failure NN N
patients NNS N
and CC N
does VBZ N
not RB N
decrease VB N
blood NN N
pressure NN N
. . N

It PRP N
can MD N
be VB N
safely RB N
added VBN N
to TO N
standard VB N
heart NN N
failure NN N
therapy NN N
. . N

-DOCSTART- -X- O O

Long RB 1_i
pediatric JJ 1_i
colonoscope NN 1_i
versus NN N
intermediate JJ 1_i
length NN 1_i
adult NN 1_i
colonoscope NN 1_i
for IN N
colonoscopy NN N
. . N

BACKGROUND NNP N
Controversy NNP N
exists VBZ N
on IN N
how WRB N
the DT N
length NN N
and CC N
diameter NN N
of IN N
colonoscopes NNS N
affect VBP N
the DT N
quality NN N
of IN N
colonoscopy NN N
. . N

The DT N
aim NN N
of IN N
this DT N
study NN N
was VBD N
to TO N
compare VB N
a DT N
long JJ 1_i
pediatric JJ 1_i
colonoscope NN 1_i
with IN N
an DT N
intermediate JJ 1_i
length NN 1_i
adult NN 1_i
colonoscope NN 1_i
with IN N
regards NNS N
to TO N
completion NN N
rate NN N
and CC N
cecal JJ N
intubation NN N
time NN N
. . N

Whether CC N
either DT N
scope NN N
may MD N
be VB N
more RBR N
efficient JJ N
in IN N
any DT N
subgroups NN N
was VBD N
also RB N
investigated VBN N
. . N

METHODS NNP N
Asymptomatic JJ N
patients NNS N
admitted VBN N
to TO N
the DT N
physical JJ N
check-up JJ N
department NN N
of IN N
Buddhist NNP N
Dalin NNP N
Tzu NNP N
Chi NNP N
General NNP N
Hospital NNP N
were VBD N
included VBN N
. . N

A DT N
single JJ N
endoscopist NN N
performed VBD N
all DT N
of IN N
the DT N
colonoscopic NN 2_i
examinations NNS 2_i
under IN N
sedation NN N
. . N

Consecutive JJ N
patients NNS N
were VBD N
randomized VBN N
to TO N
undergo VB N
colonoscopy NN 1_i
with IN 1_i
either DT 1_i
intermediate JJ 1_i
length NN 1_i
adult NN 1_i
colonoscope NN 1_i
( ( 1_i
CF-240I NNP 1_i
) ) 1_i
or CC N
long JJ 1_i
pediatric JJ 1_i
colonoscope NN 1_i
( ( 1_i
PCF-240L NNP 1_i
) ) 1_i
. . N

The DT N
success NN N
rate NN N
and CC N
time NN N
required VBN N
to TO N
reach VB N
cecum NN N
were VBD N
compared VBN N
between IN N
the DT N
two CD N
groups NNS N
. . N

RESULTS NNP N
Between NNP N
April NNP N
2005 CD N
and CC N
February NNP N
2006 CD N
, , N
a DT N
total NN N
of IN N
918 CD N
patients NNS N
were VBD N
enrolled VBN N
. . N

Incomplete NNP N
colonoscopy NN N
occurred VBD N
in IN N
21 CD N
( ( N
2.3 CD N
% NN N
) ) N
cases NNS N
( ( N
14 CD N
in IN N
the DT N
CF-240I NNP N
group NN N
and CC N
seven CD N
in IN N
the DT N
PCF-240L NNP N
group NN N
, , N
P NNP N
> NNP N
0.1 CD N
) ) N
. . N

The DT N
overall JJ N
cecal JJ N
mean NN N
insertion NN N
time NN N
was VBD N
6.00 CD N
+/- JJ N
3.66 CD N
min NN N
. . N

There EX N
was VBD N
no DT N
significant JJ N
difference NN N
between IN N
the DT N
CF-240I NNP 1_i
and CC N
PCF NNP 1_i
240L CD 1_i
groups NNS N
with IN N
regard NN N
to TO N
the DT N
cecal JJ N
intubation NN N
rate NN N
( ( N
96.9 CD N
% NN N
vs JJ N
98.5 CD N
% NN N
, , N
P NNP N
= NNP N
0.18 CD N
) ) N
, , N
the DT N
need NN N
for IN N
abdominal JJ N
pressure NN N
( ( N
71.7 CD N
% NN N
vs JJ N
73.4 CD N
% NN N
, , N
P NNP N
= NNP N
0.55 CD N
) ) N
and CC N
change NN N
of IN N
position NN N
( ( N
13.5 CD N
% NN N
vs JJ N
11.5 CD N
% NN N
, , N
P NNP N
= NNP N
0.37 CD N
) ) N
. . N

However RB N
, , N
the DT N
cecal JJ N
intubation NN N
time NN N
was VBD N
shorter RBR N
in IN N
the DT N
CF-240I NNP N
group NN N
( ( N
5.75 CD N
+/- JJ N
3.18 CD N
vs JJ N
6.26 CD N
+/- JJ N
3.30 CD N
min NN N
, , N
P NNP N
= NNP N
0.02 CD N
) ) N
. . N

Subgroup NNP N
analysis NN N
by IN N
sex NN N
, , N
age NN N
, , N
and CC N
body NN N
mass NN N
index NN N
showed VBD N
comparable JJ N
outcomes NNS N
between IN N
the DT N
two CD N
groups NNS N
except IN N
that IN N
the DT N
cecal JJ N
intubation NN N
times NNS N
were VBD N
significantly RB N
shorter JJR N
in IN N
the DT N
CF-240I NNP N
group NN N
when WRB N
only RB N
men NNS N
( ( N
4.78 CD N
+/- JJ N
2.57 CD N
vs JJ N
5.50 CD N
+/- JJ N
2.93 CD N
min NN N
, , N
P NNP N
< NNP N
0.01 CD N
) ) N
or CC N
those DT N
younger JJR N
than IN N
50 CD N
years NNS N
( ( N
5.50 CD N
+/- JJ N
2.90 CD N
vs JJ N
6.25 CD N
+/- JJ N
3.68 CD N
min NN N
, , N
P NNP N
= NNP N
0.02 CD N
) ) N
were VBD N
considered VBN N
. . N

CONCLUSION NNP N
Cecal NNP N
intubation NN N
time NN N
is VBZ N
shorter RBR N
in IN N
patients NNS N
examined VBN N
with IN N
an DT N
intermediate JJ 1_i
length NN 1_i
adult NN 1_i
colonoscope NN 1_i
, , N
mainly RB N
in IN N
the DT N
subgroups NNS N
of IN N
men NNS N
and CC N
those DT N
younger JJR N
than IN N
50 CD N
years NNS N
of IN N
age NN N
. . N

-DOCSTART- -X- O O

An DT N
open JJ N
and CC N
randomized JJ N
study NN N
comparing VBG N
the DT N
efficacy NN N
of IN N
standard JJ 3_i
danazol NN 3_i
and CC N
modified VBD 3_i
triptorelin NN 3_i
regimens NNS 3_i
for IN N
postoperative JJ N
disease NN N
management NN N
of IN N
moderate JJ N
to TO N
severe JJ N
endometriosis NN N
. . N

OBJECTIVE UH N
To TO N
compare VB N
the DT N
efficacy NN N
of IN N
danazol NN 3_i
and CC N
triptorelin NN 3_i
( ( N
Decapeptyl NNP N
CR NNP N
, , N
Ferring NNP N
, , N
Kiel NNP N
, , N
Germany NNP N
) ) N
in IN N
the DT N
management NN N
of IN N
moderate JJ N
and CC N
severe JJ N
endometriosis NN N
in IN N
terms NNS N
of IN N
symptom NN N
control NN N
and CC N
revised VBN N
American JJ N
Fertility NNP N
Society NNP N
( ( N
AFS NNP N
) ) N
score NN N
reduction NN N
, , N
and CC N
to TO N
evaluate VB N
the DT N
hormonal JJ N
profile NN N
of IN N
patients NNS N
treated VBN N
with IN N
triptorelin NN 3_i
every DT N
6 CD N
weeks NNS N
. . N

DESIGN NNP N
Open NNP N
and CC N
randomized VBN N
trial NN N
. . N

SETTING NN N
Kwong NNP N
Wah NNP N
Hospital NNP N
, , N
a DT N
large JJ N
public JJ N
hospital NN N
in IN N
an DT N
urban JJ N
location NN N
( ( N
Hong NNP N
Kong NNP N
) ) N
. . N

PATIENT NNP N
( ( N
S NNP N
) ) N
Forty NNP N
patients NNS N
after IN N
their PRP$ N
first JJ N
conservative JJ N
operation NN N
for IN N
endometriosis NN N
, , N
with IN N
surgical JJ N
confirmation NN N
of IN N
revised VBN N
AFS NNP N
stage NN N
III NNP N
or CC N
IV NNP N
endometriosis NN N
. . N

INTERVENTION NNP N
( ( N
S NNP N
) ) N
Postoperative VBP N
6 CD N
months NNS N
' POS N
therapy NN N
of IN N
danazol NN 3_i
or CC N
triptorelin NN 3_i
every DT N
6 CD N
weeks NNS N
, , N
postmedical JJ N
therapy NN N
second-look NN N
laparoscopy NN N
. . N

MAIN NNP N
OUTCOME NNP N
MEASURE NNP N
( ( N
S NNP N
) ) N
Symptom NNP N
control NN N
and CC N
patients NNS N
' POS N
tolerance NN N
during IN N
medical JJ N
therapy NN N
, , N
posttherapy NN N
revised VBD N
AFS NNP N
score NN N
, , N
hormonal JJ N
profile NN N
during IN N
triptorelin JJ N
therapy NN N
. . N

RESULT NNP N
( ( N
S NNP N
) ) N
Pain NNP N
control NN N
was VBD N
similar JJ N
between IN N
danazol NN 3_i
and CC N
triptorelin NN 3_i
therapy NN N
. . N

There EX N
was VBD N
less JJR N
breakthrough IN N
bleeding NN N
with IN N
triptorelin NN 3_i
. . 3_i

More JJR N
patients NNS N
failed VBD N
to TO N
complete VB N
the DT N
whole JJ N
course NN N
of IN N
danazol NN 3_i
because IN N
of IN N
its PRP$ N
side NN N
effects NNS N
. . N

The DT N
revised JJ N
AFS NNP N
score NN N
at IN N
second-look JJ N
laparoscopy NN N
did VBD N
not RB N
show VB N
a DT N
significant JJ N
difference NN N
between IN N
the DT N
two CD N
medications NNS N
. . N

Adequate NNP N
pituitary JJ N
suppression NN N
was VBD N
observed VBN N
with IN N
injection NN N
of IN N
triptorelin NN 3_i
every DT N
6 CD N
weeks NNS N
. . N

CONCLUSION NNP N
( ( N
S NNP N
) ) N
Lengthening NNP N
of IN N
triptorelin JJ 3_i
administration NN N
intervals NNS N
from IN N
4 CD N
weeks NNS N
to TO N
6 CD N
weeks NNS N
is VBZ N
effective JJ N
in IN N
maintaining VBG N
a DT N
hypoestrogenic JJ N
state NN N
. . N

Patients NNS N
were VBD N
more RBR N
compliant JJ N
with IN N
triptorelin NN 3_i
than IN N
danazol NN 3_i
. . 3_i

Thus RB N
, , N
triptorelin JJ 3_i
injection NN N
every DT N
6 CD N
weeks NNS N
is VBZ N
more JJR N
cost-effective JJ N
than IN N
conventional JJ N
regimens NNS N
. . N

-DOCSTART- -X- O O

Does NNP N
temporary JJ 1_i
clamping NN 1_i
of IN 1_i
drains NNS 1_i
following VBG N
knee NN N
arthroplasty JJ N
reduce VB N
blood NN N
loss NN N
? . N
A DT N
randomised JJ N
controlled VBN N
trial NN N
. . N

In IN N
a DT N
randomised JJ N
, , N
blinded VBD N
study NN N
76 CD N
patients NNS N
undergoing JJ N
primary JJ N
total JJ N
knee NN N
arthroplasty NN N
were VBD N
assigned VBN N
to TO N
either DT N
immediate JJ 1_i
drain NN 1_i
opening NN 1_i
( ( N
n JJ N
= NNP N
45 CD N
) ) N
or CC N
drains NNS 1_i
opened VBN 1_i
at IN 1_i
2 CD 1_i
h NN 1_i
( ( N
n JJ N
= NNP N
31 CD N
) ) N
. . N

No DT N
significant JJ N
differences NNS N
were VBD N
found VBN N
between IN N
the DT N
groups NNS N
for IN N
the DT N
volume NN N
of IN N
drained JJ N
blood NN N
, , N
transfusion NN N
requirements NNS N
, , N
knee JJ N
motion NN N
or CC N
wound NN N
status NN N
. . N

The DT N
authors NNS N
conclude VBP N
that IN N
the DT N
practice NN N
of IN N
clamping VBG 1_i
drains NNS 1_i
has VBZ N
no DT N
benefit NN N
in IN N
routine JJ N
knee NN N
arthroplasty NN N
. . N

However RB N
, , N
when WRB N
faced VBN N
with IN N
immediate JJ N
brisk JJ N
blood NN N
loss NN N
, , N
the DT N
results NNS N
suggest VBP N
that IN N
drains NNS 1_i
can MD N
be VB N
clamped VBN N
without IN N
any DT N
excess JJ N
morbidity NN N
. . N

-DOCSTART- -X- O O

Long-term JJ N
evaluation NN N
of IN N
tamsulosin NN 3_i
in IN N
benign JJ N
prostatic JJ N
hyperplasia NN N
: : N
placebo-controlled JJ 7_i
, , N
double-blind JJ N
extension NN N
of IN N
phase NN N
III NNP N
trial NN N
. . N

Tamsulosin NNP N
Investigator NNP N
Group NNP N
. . N

OBJECTIVES NNP N
To TO N
evaluate VB N
the DT N
long-term JJ N
efficacy NN N
and CC N
safety NN N
of IN N
once-daily JJ N
tamsulosin NN 3_i
( ( N
0.4 CD N
and CC N
0.8 CD N
mg NN N
) ) N
, , N
a DT N
unique JJ N
selective JJ N
alpha1A-adrenoceptor NN N
antagonist NN N
in IN N
patients NNS N
with IN N
benign JJ N
prostatic JJ N
hyperplasia NN N
( ( N
BPH NNP N
) ) N
. . N

METHODS NNP N
This DT N
trial NN N
extended VBD N
a DT N
13-week JJ N
, , N
Phase NNP N
III NNP N
multicenter NN N
placebo-controlled JJ N
, , N
double-blind JJ N
outpatient JJ N
trial NN N
for IN N
an DT N
additional JJ N
40 CD N
weeks NNS N
. . N

Of IN N
618 CD N
patients NNS N
, , N
418 CD N
( ( N
68 CD N
% NN N
) ) N
continued VBD N
into IN N
the DT N
extension NN N
phase NN N
on IN N
the DT N
same JJ N
double-blind JJ N
medication NN N
and CC N
dose NN N
. . N

The DT N
primary JJ N
efficacy NN N
parameters NNS N
were VBD N
total JJ N
American NNP N
Urological NNP N
Association NNP N
( ( N
AUA NNP N
) ) N
symptom NN N
score NN N
and CC N
maximum JJ N
urinary JJ N
flow NN N
( ( N
Qmax NNP N
) ) N
. . N

RESULTS VB N
The DT N
mean JJ N
changes NNS N
in IN N
AUA NNP N
symptom NN N
score NN N
from IN N
baseline NN N
to TO N
end VB N
point NN N
were VBD N
statistically RB N
significant JJ N
in IN N
all DT N
groups NNS N
( ( N
P NNP N
< NNP N
0.001 CD N
) ) N
. . N

Significant JJ N
improvements NNS N
were VBD N
observed VBN N
in IN N
Qmax NNP N
for IN N
both DT N
tamsulosin JJ 3_i
groups NNS N
but CC N
not RB N
for IN N
the DT N
placebo NN 7_i
group NN N
. . N

The DT N
statistically RB N
significant JJ N
improvements NNS N
from IN N
baseline NN N
in IN N
efficacy NN N
parameters NNS N
observed VBD N
for IN N
each DT N
tamsulosin NN 3_i
group NN N
at IN N
the DT N
end NN N
of IN N
the DT N
13-week JJ N
Phase NNP N
III NNP N
trial NN N
were VBD N
maintained VBN N
during IN N
the DT N
long-term JJ N
extension NN N
phase NN N
. . N

Tamsulosin NN N
at IN N
both DT N
dosages NNS N
was VBD N
well RB N
tolerated VBN N
as IN N
maintenance NN N
therapy NN N
. . N

Clinically NNP N
significant JJ N
orthostatic JJ N
hypotension NN N
was VBD N
not RB N
observed VBN N
. . N

Vital JJ N
sign NN N
changes NNS N
in IN N
either DT N
hypertensive JJ N
or CC N
normotensive JJ N
patients NNS N
were VBD N
not RB N
clinically RB N
significantly RB N
different JJ N
across IN N
the DT N
three CD N
groups NNS N
. . N

CONCLUSIONS NNP N
Tamsulosin NNP 3_i
once-daily RB N
at IN N
0.4 CD N
or CC N
0.8 CD N
mg NN N
was VBD N
shown VBN N
to TO N
be VB N
effective JJ N
, , N
safe JJ N
, , N
and CC N
well RB N
tolerated VBN N
in IN N
the DT N
target NN N
BPH NNP N
population NN N
during IN N
long-term JJ N
use NN N
. . N

-DOCSTART- -X- O O

The DT N
prophylactic JJ N
effect NN N
of IN N
valproate NN 3_i
on IN N
glyceryltrinitrate NN N
induced VBN N
migraine NN N
. . N

In IN N
this DT N
study NN N
the DT N
human JJ N
glyceryltrinitrate NN N
( ( N
GTN NNP N
) ) N
model NN N
of IN N
migraine NN N
was VBD N
for IN N
the DT N
first JJ N
time NN N
used VBN N
to TO N
test VB N
the DT N
effect NN N
of IN N
a DT N
prophylactic JJ N
drug NN N
. . N

We PRP N
chose VBD N
to TO N
test VB N
valproate NN 3_i
due JJ N
to TO N
its PRP$ N
well RB N
documented JJ N
effect NN N
as IN N
a DT N
migraine JJ 3_i
prophylactic JJ 3_i
drug NN 3_i
. . 3_i

Efficacy NN N
of IN N
this DT N
compound NN N
would MD N
support VB N
the DT N
usefulness NN N
of IN N
the DT N
model NN N
in IN N
prophylactic JJ N
antimigraine JJ N
drug NN N
development NN N
. . N

Twelve CD N
patients NNS N
with IN N
migraine NN N
without IN N
aura NN N
were VBD N
included VBN N
in IN N
a DT N
randomized JJ N
double JJ N
blind NN N
crossover NN N
study NN N
. . N

Valproate VB 3_i
1000 CD N
mg NN N
or CC N
placebo NN 7_i
was VBD N
given VBN N
daily RB N
, , N
each DT N
for IN N
a DT N
minimum NN N
of IN N
13 CD N
days NNS N
. . N

On IN N
the DT N
last JJ N
treatment NN N
day NN N
of IN N
each DT N
arm NN N
a DT N
20 CD N
min NN N
intravenous JJ N
infusion NN N
of IN N
GTN NNP 3_i
( ( N
0.25 CD N
microg/kg/min NN N
) ) N
was VBD N
given VBN N
. . N

Headache NNP N
was VBD N
registered VBN N
for IN N
12 CD N
h NN N
after IN N
the DT N
infusion NN N
and CC N
headache NN N
intensity NN N
was VBD N
scored VBN N
on IN N
a DT N
scale NN N
from IN N
0 CD N
to TO N
10 CD N
. . N

Fulfillment NN N
of IN N
IHS NNP N
criteria NNS N
was VBD N
recorded VBN N
for IN N
24 CD N
h. PDT N
The DT N
middle JJ N
cerebral JJ N
arteries NNS N
were VBD N
evaluated VBN N
by IN N
transcranial JJ N
Doppler NNP N
and CC N
the DT N
diameter NN N
of IN N
the DT N
superficial JJ N
temporal JJ N
and CC N
radial JJ N
arteries NNS N
were VBD N
measured VBN N
with IN N
high JJ N
frequency NN N
ultrasound NN N
. . N

GTN NNP 3_i
evoked VBD N
migraine JJ N
fulfilling NN N
IHS NNP N
criteria NNS N
1.1 CD N
in IN N
6 CD N
patients NNS N
after IN N
placebo NN 7_i
and CC N
in IN N
2 CD N
patients NNS N
after IN N
valproate NN 3_i
( ( N
P NNP N
= NNP N
0.125 CD N
) ) N
. . N

Including VBG N
additionally RB N
3 CD N
patients NNS N
on IN N
placebo NN 7_i
and CC N
1 CD N
patient NN N
on IN N
valproate NN 3_i
who WP N
felt VBD N
they PRP N
had VBD N
suffered VBN N
a DT N
migraine JJ N
attack NN N
, , N
but CC N
who WP N
had VBD N
as IN N
associated VBN N
symptoms NNS N
only RB N
photophobia VBP N
or CC N
phonophobia VBP N
, , N
a DT N
significant JJ N
reduction NN N
in IN N
the DT N
number NN N
of IN N
patients NNS N
with IN N
induced JJ N
migraine NN N
after IN N
valproate NN 3_i
was VBD N
seen VBN N
( ( N
P NNP N
= NNP N
0.031 CD N
) ) N
. . N

Median JJ N
peak NN N
headache NN N
intensity NN N
was VBD N
1 CD N
( ( N
range VB N
0-9 NN N
) ) N
after IN N
valproate NN 3_i
compared VBN N
to TO N
4.5 CD N
( ( N
range VB N
0-8 NN N
) ) N
after IN N
placebo NN 7_i
( ( N
P NNP N
= NNP N
0.120 CD N
) ) N
. . N

Pretreatment NN N
with IN N
valproate NN 3_i
as IN N
compared VBN N
to TO N
placebo VB 7_i
reduced VBN N
the DT N
velocity NN N
in IN N
both DT N
middle JJ N
cerebral NN N
arteries NNS N
after IN N
GTN NNP N
( ( N
left VBN N
P NNP N
= NNP N
0.021 CD N
, , N
right JJ N
P NNP N
= NNP N
0.031 CD N
) ) N
. . N

No DT N
effect NN N
of IN N
valproate NN 3_i
was VBD N
seen VBN N
in IN N
the DT N
diameter NN N
of IN N
the DT N
superficial JJ N
temporal JJ N
artery NN N
( ( N
P NNP N
= NNP N
0.781 CD N
) ) N
or CC N
the DT N
radial JJ N
artery NN N
( ( N
P NNP N
= NNP N
0.367 CD N
) ) N
before IN N
or CC N
after IN N
GTN NNP N
. . N

The DT N
study NN N
indicates VBZ N
that IN N
a DT N
prophylactic JJ N
effect NN N
of IN N
valproate NN 3_i
may MD N
be VB N
demonstrated VBN N
using VBG N
the DT N
GTN NNP 3_i
human JJ 3_i
migraine NN 3_i
model NN 3_i
. . 3_i

Although IN N
, , N
all DT N
headache NN N
parameters NNS N
were VBD N
reduced VBN N
after IN N
valproate NN 3_i
compared VBN N
to TO N
placebo VB 7_i
, , N
only RB N
one CD N
parameter NN N
was VBD N
statistically RB N
significantly RB N
reduced VBN N
probably RB N
because IN N
of IN N
the DT N
small JJ N
number NN N
of IN N
patients NNS N
. . N

The DT N
size NN N
of IN N
the DT N
effect NN N
was VBD N
similar JJ N
to TO N
that DT N
of IN N
valproate NN N
in IN N
clinical JJ N
trials NNS N
. . N

The DT N
GTN NNP 3_i
model NN 3_i
may MD N
therefore RB N
be VB N
a DT N
valid JJ N
tool NN N
for IN N
testing VBG N
new JJ N
prophylactic JJ N
antimigraine NN N
drugs NNS N
. . N

-DOCSTART- -X- O O

A DT N
randomized JJ N
trial NN N
of IN N
radiation NN 1_i
therapy NN 1_i
compared VBN N
to TO N
split VB 1_i
course NN 1_i
radiation NN 1_i
therapy NN 1_i
combined VBN N
with IN N
mitomycin JJ 3_i
C NNP 3_i
and CC N
5 CD 3_i
fluorouracil NN 3_i
as IN N
initial JJ N
treatment NN N
for IN N
advanced JJ N
laryngeal NN N
and CC N
hypopharyngeal NN N
squamous JJ N
carcinoma NN N
. . N

Two CD N
hundred VBD N
and CC N
twelve JJ N
patients NNS N
with IN N
previously RB N
untreated VBN N
advanced JJ N
squamous JJ N
carcinoma NN N
of IN N
the DT N
larynx NN N
or CC N
hypopharynx NN N
were VBD N
randomized VBN N
to TO N
receive VB N
initial JJ N
treatment NN N
with IN N
radiotherapy NN 1_i
, , N
50 CD N
Gy NNP N
in IN N
20 CD N
fractions NNS N
in IN N
28 CD N
days NNS N
or CC N
split JJ 1_i
course NN 1_i
radiotherapy NN 1_i
and CC N
concurrent NN 3_i
chemotherapy NN 3_i
, , N
25 CD N
Gy NNP N
in IN N
10 CD N
fractions NNS N
in IN N
14 CD N
days NNS N
followed VBN N
by IN N
a DT N
4 CD N
week NN N
rest NN N
and CC N
a DT N
further JJ N
25 CD N
Gy NNP N
in IN N
10 CD N
fractions NNS N
in IN N
14 CD N
days NNS N
starting VBG N
on IN N
day NN N
43 CD N
; : N
Mitomycin NNP 3_i
C NNP 3_i
was VBD N
given VBN N
on IN N
day NN N
1 CD N
and CC N
day NN N
43 CD N
and CC N
5FU CD 3_i
continuous JJ N
infusions NNS N
on IN N
days NNS N
1 CD N
-- : N
4 CD N
and CC N
days NNS N
43 CD N
-- : N
46 CD N
. . N

Surgery NN N
was VBD N
reserved VBN N
for IN N
persistent NN N
or CC N
recurrent JJ N
disease NN N
. . N

Two CD N
hundred VBD N
and CC N
nine CD N
of IN N
the DT N
212 CD N
patients NNS N
randomized VBN N
were VBD N
included VBN N
in IN N
the DT N
analyses NNS N
. . N

Outcome NN N
analyses NNS N
were VBD N
performed VBN N
at IN N
a DT N
median JJ N
follow-up JJ N
interval NN N
of IN N
4.4 CD N
years NNS N
. . N

No DT N
patients NNS N
were VBD N
lost VBN N
to TO N
follow-up NN N
. . N

No DT N
significant JJ N
difference NN N
was VBD N
found VBN N
between IN N
the DT N
two CD N
arms NNS N
for IN N
the DT N
end NN N
points NNS N
of IN N
local JJ N
relapse-free JJ N
rate NN N
( ( N
p JJ N
= NNP N
0.91 CD N
) ) N
, , N
regional JJ N
relapse-free JJ N
rate NN N
( ( N
p JJ N
= NN N
0.17 CD N
, , N
adjusted VBN N
) ) N
or CC N
overall JJ N
survival NN N
( ( N
p JJ N
= NNP N
0.86 CD N
) ) N
. . N

Eight-eight JJ N
patients NNS N
had VBD N
attempted VBN N
surgical JJ N
resection NN N
following VBG N
radiotherapy JJ 1_i
failure NN N
. . N

The DT N
contribution NN N
of IN N
salvage NN N
surgery NN N
to TO N
overall JJ N
survival NN N
was VBD N
similar JJ N
for IN N
both DT N
arms NNS N
of IN N
the DT N
study NN N
as IN N
was VBD N
the DT N
surgical JJ N
complication NN N
rate NN N
. . N

Serious JJ N
late JJ N
radiation NN N
toxicity NN N
was VBD N
minimal JJ N
( ( N
3 CD N
% NN N
in IN N
the DT N
RT NNP N
group NN N
, , N
0 CD N
% NN N
in IN N
the DT N
radiation NN N
therapy NN N
plus CC N
chemotherapy NN N
group NN N
) ) N
. . N

The DT N
result NN N
of IN N
the DT N
trial NN N
shows VBZ N
no DT N
advantage NN N
in IN N
terms NNS N
of IN N
local JJ N
control NN N
or CC N
survival NN N
for IN N
the DT N
experimental JJ N
treatment NN N
arm NN N
of IN N
split NN N
course NN N
radiotherapy NN 1_i
and CC N
concurrent JJ 3_i
chemotherapy NN 3_i
with IN N
Mitomycin NNP 3_i
C NNP 3_i
and CC N
5 CD 3_i
Fluorouracil NNP 3_i
compared VBN N
to TO N
radiotherapy VB N
alone RB N
. . N

-DOCSTART- -X- O O

Failure NN N
of IN N
naltrexone NN 3_i
hydrochloride NN 3_i
to TO N
reduce VB N
self-injurious JJ N
and CC N
autistic JJ N
behavior NN N
in IN N
mentally RB N
retarded JJ N
adults NNS N
. . N

Double-blind JJ N
placebo-controlled JJ 7_i
studies NNS N
. . N

BACKGROUND IN N
It PRP N
is VBZ N
hypothesized VBN N
that IN N
self-injurious JJ N
behavior NN N
( ( N
SIB NNP N
) ) N
and CC N
symptoms NNS N
of IN N
autism NN N
may MD N
be VB N
due JJ N
to TO N
overactivity NN N
in IN N
some DT N
opioid JJ N
systems NNS N
in IN N
the DT N
brain NN N
. . N

We PRP N
examined VBD N
the DT N
efficacy NN N
and CC N
safety NN N
of IN N
naltrexone JJ 3_i
hydrochloride NN 3_i
, , N
an DT N
opioid JJ N
antagonist NN N
, , N
in IN N
the DT N
treatment NN N
of IN N
SIB NNP N
and CC N
autism NN N
in IN N
mentally RB N
retarded JJ N
adults NNS N
. . N

METHOD NNP N
Thirty-three NNP N
mentally RB N
retarded VBD N
adults NNS N
with IN N
autism NN N
and/or NN N
SIB NNP N
participated VBD N
in IN N
double-blind NN N
, , N
placebo-controlled JJ 7_i
crossover NN N
studies NNS N
. . N

Active JJ N
treatment NN N
was VBD N
first RB N
a DT N
single JJ N
100-mg JJ N
dose NN N
of IN N
naltrexone JJ 3_i
hydrochloride NN 3_i
. . 3_i

Subsequently NNP N
, , N
19 CD N
subjects NNS N
were VBD N
treated VBN N
with IN N
50 CD N
mg/d NNS N
and CC N
14 CD N
with IN N
150 CD N
mg/d NNS N
of IN N
naltrexone NN 3_i
hydrochloride NN 3_i
for IN N
4 CD N
weeks NNS N
. . N

The DT N
outcome NN N
was VBD N
assessed VBN N
by IN N
means NNS N
of IN N
direct JJ N
observations NNS N
( ( N
n JJ N
= NNP N
11 CD N
) ) N
and CC N
on IN N
the DT N
basis NN N
of IN N
scores NNS N
on IN N
a DT N
list NN N
of IN N
target NN N
behaviors NNS N
, , N
the DT N
Aberrant NNP N
Behavior NNP N
Checklist NNP N
, , N
and CC N
the DT N
Clinical NNP N
Global NNP N
Impression NNP N
Scale NNP N
. . N

RESULTS NNP N
Thirty-two JJ N
subjects NNS N
( ( N
seven CD N
with IN N
autism NN N
, , N
16 CD N
with IN N
autism NN N
and CC N
SIB NNP N
, , N
and CC N
nine CD N
with IN N
SIB NNP N
) ) N
completed VBD N
the DT N
trial NN N
. . N

Naltrexone CD 3_i
treatment NN N
failed VBD N
to TO N
have VB N
therapeutic JJ N
effects NNS N
on IN N
SIB NNP N
and CC N
autism NN N
. . N

On IN N
the DT N
contrary JJ N
, , N
naltrexone RB 3_i
increased VBD N
the DT N
incidence NN N
of IN N
stereotypic JJ N
behavior NN N
on IN N
the DT N
Aberrant NNP N
Behavior NNP N
Checklist NNP N
, , N
and CC N
the DT N
care NN N
staff NN N
evaluated VBD N
the DT N
effect NN N
of IN N
the DT N
50-mg/d JJ N
treatment NN N
as IN N
being VBG N
significantly RB N
worse JJR N
than IN N
that DT N
of IN N
the DT N
placebo NN N
treatment NN N
as IN N
measured VBN N
by IN N
the DT N
Clinical NNP N
Global NNP N
Impression NNP N
Scale NNP N
. . N

CONCLUSION NNP N
Our PRP$ N
findings NNS N
suggest VBP N
that IN N
naltrexone NN N
has VBZ N
no DT N
clinical JJ N
value NN N
for IN N
a DT N
broad JJ N
group NN N
of IN N
mentally RB N
retarded JJ N
subjects NNS N
with IN N
SIB NNP N
and/or JJ N
autism NN N
. . N

-DOCSTART- -X- O O

Online NNP 6_i
conductivity NN 6_i
monitoring NN 6_i
: : N
validation NN N
and CC N
usefulness NN N
in IN N
a DT N
clinical JJ N
trial NN N
of IN N
reduced JJ 6_i
dialysate NN 6_i
conductivity NN 6_i
. . N

Relatively RB 6_i
low JJ 6_i
dialysate NN 6_i
conductivity NN 6_i
( ( 6_i
Cndi NNP 6_i
) ) 6_i
may MD N
improve VB N
outcomes NNS N
by IN N
reducing VBG N
the DT N
overall JJ N
sodium NN N
burden NN N
in IN N
dialysis NN N
patients NNS N
. . N

Excess NNP N
sodium NN N
removal NN N
, , N
however RB N
, , N
could MD N
lead VB N
to TO N
hemodynamic JJ N
instability NN N
. . N

We PRP N
performed VBD N
a DT N
randomized VBN N
controlled JJ N
trial NN N
of IN N
reduction NN 6_i
of IN 6_i
Cndi NNP 6_i
. . 6_i

For IN N
the DT N
study NN N
, , N
28 CD N
patients NNS N
were VBD N
randomized VBN N
to TO N
maintenance NN N
of IN N
Cndi NNP 6_i
at IN N
13.6 CD N
mS/cm NNS N
( ( N
equivalent JJ N
to TO N
135 CD N
mmol/L NN N
of IN N
Na+ NNP N
) ) N
or CC N
serial JJ N
reduction NN N
of IN N
Cndi NNP 6_i
in IN N
steps NNS N
of IN N
0.2 CD N
mS/cm NNS N
, , N
guided VBN N
by IN N
symptoms NNS N
and CC N
blood NN N
pressure NN N
. . N

Sodium NNP N
removal NN N
estimated VBN N
from IN N
pre- NN N
and CC N
postplasma JJ N
concentrations NNS N
correlated VBN N
well RB N
with IN N
removal NN N
measured VBN N
by IN N
conductivity NN N
monitoring NN N
as IN N
ionic JJ N
mass NN N
balance NN N
( ( N
R2 NNP N
0.66 CD N
, , N
p NN N
< NNP N
0.0001 CD N
) ) N
. . N

Of IN N
the DT N
16 CD N
patients NNS N
randomized VBN N
to TO N
reduction NN 6_i
of IN 6_i
Cndi NNP 6_i
, , N
6 CD N
achieved VBD N
Cndi NNP N
13.4 CD N
mS/cm NN N
, , N
6 CD N
achieved VBD N
13.2 CD N
mS/cm NN N
, , N
and CC N
4 CD N
achieved VBD N
13.0 CD N
mS/cm NN N
. . N

No DT N
episodes NNS N
of IN N
disequilibrium NN N
occurred VBD N
. . N

Interdialytic JJ N
weight NN N
gain NN N
was VBD N
reduced VBN N
from IN N
2.34 CD N
+/- JJ N
0.10 CD N
kg NN N
to TO N
1.57 CD N
+/- JJ N
0.11 CD N
kg NN N
( ( N
p JJ N
< NNP N
0.0001 CD N
) ) N
. . N

Predialysis NNP N
systolic JJ N
blood NN N
pressure NN N
fell VBD N
from IN N
144 CD N
+/- JJ N
3 CD N
mm NN N
Hg NNP N
to TO N
137 CD N
+/- JJ N
4 CD N
mm NN N
Hg NNP N
( ( N
p JJ N
< NNP N
0.05 CD N
) ) N
. . N

The DT N
reduction NN N
in IN N
convective JJ 2_i
sodium NN 2_i
removal NN 2_i
was VBD N
balanced VBN N
by IN N
an DT N
increase NN N
in IN N
diffusive JJ N
sodium NN N
removal NN N
( ( N
95 CD N
+/- JJ N
9 CD N
mmol NN N
cf NN N
. . N

175 CD N
+/- JJ N
14 CD N
mmol NN N
, , N
p NN N
< NNP N
0.0001 CD N
) ) N
. . N

Reduction NN 6_i
in IN 6_i
Cndi NNP 6_i
monitored VBN N
by IN N
IMB NNP N
is VBZ N
safe JJ N
and CC N
practical JJ N
and CC N
leads VBZ N
to TO N
improved VBN N
interdialytic JJ N
weight NN N
gains NNS N
and CC N
blood NN N
pressure NN N
control NN N
, , N
while IN N
avoiding VBG N
excessive JJ N
sodium NN N
removal NN N
. . N

-DOCSTART- -X- O O

Observer NNP N
variation NN N
in IN N
the DT N
assessment NN N
of IN N
outcome NN N
in IN N
traumatic JJ N
brain NN N
injury NN N
: : N
experience NN N
from IN N
a DT N
multicenter NN N
, , N
international JJ N
randomized VBD N
clinical JJ N
trial NN N
. . N

OBJECTIVE NNP N
Accurate NNP N
and CC N
consistent JJ N
outcome NN N
assessment NN N
is VBZ N
essential JJ N
to TO N
randomized VB N
clinical JJ N
trials NNS N
. . N

We PRP N
aimed VBD N
to TO N
explore VB N
observer JJ N
variation NN N
in IN N
the DT N
assessment NN N
of IN N
outcome NN N
in IN N
a DT N
recently RB N
completed VBN N
trial NN N
of IN N
dexanabinol NN 3_i
in IN N
head JJ N
injury NN N
and CC N
to TO N
consider VB N
steps NNS N
to TO N
reduce VB N
such JJ N
variation NN N
. . N

METHODS NNP N
Eight NNP N
hundred VBD N
sixty-one JJ N
patients NNS N
with IN N
severe JJ N
traumatic JJ N
brain NN N
injury NN N
who WP N
were VBD N
admitted VBN N
to TO N
86 CD N
centers NNS N
were VBD N
included VBN N
in IN N
a DT N
multicenter NN N
, , N
placebo-controlled JJ 7_i
, , N
Phase NNP N
III NNP N
trial NN N
. . N

Outcome NNP N
was VBD N
assessed VBN N
at IN N
3 CD N
and CC N
6 CD N
months NNS N
postinjury NN N
using VBG N
the DT N
extended JJ N
Glasgow NNP N
Outcome NNP N
Scale NNP N
; : N
standardized VBD N
assessment NN N
was VBD N
facilitated VBN N
by IN N
the DT N
use NN N
of IN N
a DT N
structured JJ N
interview NN N
. . N

Before IN N
initiation NN N
of IN N
trial NN N
centers NNS N
, , N
outcome JJ N
ratings NNS N
were VBD N
obtained VBN N
for IN N
sample JJ N
cases NNS N
to TO N
establish VB N
initial JJ N
levels NNS N
of IN N
agreement NN N
. . N

Training NN N
sessions NNS N
in IN N
outcome JJ N
assessment NN N
were VBD N
held VBN N
, , N
and CC N
problems NNS N
in IN N
assigning VBG N
outcome NN N
were VBD N
investigated VBN N
. . N

During IN N
the DT N
trial NN N
, , N
a DT N
process NN N
of IN N
central JJ N
review NN N
was VBD N
established VBN N
to TO N
monitor VB N
performance NN N
. . N

Interobserver NNP N
variation NN N
was VBD N
analyzed VBN N
using VBG N
the DT N
kappa NN N
statistic JJ N
. . N

RESULTS NNP N
Substantial NNP N
observer JJ N
variation NN N
was VBD N
found VBN N
in IN N
the DT N
rating NN N
of IN N
sample JJ N
cases NNS N
( ( N
weighted JJ N
kappa NN N
, , N
0.72 CD N
; : N
confidence NN N
interval NN N
, , N
0.68-0.75 JJ N
) ) N
and CC N
in IN N
assigning VBG N
outcome NN N
based VBN N
on IN N
completed VBN N
structured JJ N
interviews NNS N
( ( N
weighted JJ N
kappa NN N
, , N
0.61 CD N
; : N
confidence NN N
interval NN N
, , N
0.57-0.64 JJ N
) ) N
. . N

In IN N
the DT N
early JJ N
stages NNS N
of IN N
the DT N
trial NN N
, , N
a DT N
relatively RB N
large JJ N
number NN N
of IN N
discrepancies NNS N
( ( N
29-37 CD N
% NN N
) ) N
were VBD N
identified VBN N
on IN N
central JJ N
review NN N
. . N

This DT N
number NN N
declined VBD N
as IN N
the DT N
trial NN N
progressed VBD N
and CC N
coincided VBD N
with IN N
investigator NN N
training NN N
and CC N
feedback NN N
from IN N
central JJ N
review NN N
. . N

Centers NNS N
with IN N
higher JJR N
enrollment NN N
rates NNS N
showed VBD N
better JJR N
performance NN N
. . N

CONCLUSION NNP N
Observer NNP N
variation NN N
in IN N
outcome JJ N
assessment NN N
is VBZ N
a DT N
significant JJ N
problem NN N
for IN N
head NN N
injury NN N
trials NNS N
. . N

Consistency NN N
can MD N
be VB N
improved VBN N
by IN N
standardizing VBG N
procedures NNS N
, , N
training VBG N
assessors NNS N
, , N
and CC N
monitoring VBG N
the DT N
quality NN N
of IN N
assessments NNS N
and CC N
providing VBG N
feedback NN N
to TO N
interviewers NNS N
. . N

-DOCSTART- -X- O O

Effect NN N
of IN N
cigarette NN N
smoking NN N
on IN N
gastric JJ N
emptying NN N
of IN N
solids NNS N
in IN N
Japanese JJ N
smokers NNS N
: : N
a DT N
crossover NN N
study NN N
using VBG N
the DT N
13C-octanoic JJ N
acid NN N
breath NN N
test NN N
. . N

BACKGROUND NNP N
Cigarette NNP N
smoking NN N
is VBZ N
associated VBN N
with IN N
an DT N
increased VBN N
risk NN N
of IN N
peptic JJ N
ulcer NN N
and CC N
gastroesophageal NN N
reflux NN N
disease NN N
. . N

Gastric NNP N
emptying VBG N
disorders NNS N
may MD N
play VB N
a DT N
role NN N
in IN N
the DT N
development NN N
of IN N
these DT N
upper JJ N
gastrointestinal NN N
diseases NNS N
. . N

Thus RB N
, , N
studies NNS N
examining VBG N
a DT N
link NN N
between IN N
smoking VBG N
and CC N
gastric JJ N
emptying VBG N
disorders NNS N
have VBP N
clinical JJ N
relevance NN N
. . N

This DT N
study NN N
was VBD N
conducted VBN N
to TO N
investigate VB N
the DT N
effect NN N
of IN N
smoking VBG N
on IN N
gastric JJ N
emptying NN N
of IN N
solids NNS N
in IN N
Japanese JJ N
smokers NNS N
. . N

METHODS PDT N
The DT N
( ( 6_i
13 CD 6_i
) ) 6_i
C-octanoic NNP 6_i
acid JJ 6_i
breath NN 6_i
test NN 6_i
was VBD N
performed VBN N
in IN N
eight CD N
male JJ N
habitual JJ N
smokers NNS N
on IN N
two CD N
randomized JJ N
occasions NNS N
( ( N
either DT N
sham NN N
smoking NN N
or CC N
actively RB N
smoking VBG N
) ) N
. . N

The DT N
time NN N
vs NN N
( ( N
13 CD N
) ) N
CO NNP N
( ( N
2 CD N
) ) N
excretion NN N
rate NN N
curve NN N
was VBD N
mathematically RB N
fitted VBN N
to TO N
a DT N
conventional JJ N
formula NN N
of IN N
y NN N
( ( N
t NN N
) ) N
= NN N
m*k*beta*e NN N
( ( N
-k*t NNP N
) ) N
* NNP N
( ( N
1 CD N
- : N
e NN N
( ( N
-k*t NNP N
) ) N
) ) N
( ( N
beta-1 NN N
) ) N
, , N
and CC N
the DT N
parameters NNS N
of IN N
k NN N
and CC N
beta NN N
were VBD N
determined VBN N
: : N
under IN N
the DT N
crossover NN N
protocol NN N
, , N
a DT N
larger JJR N
( ( N
smaller JJR N
) ) N
beta NN N
indicates VBZ N
slower JJR N
( ( N
faster RBR N
) ) N
emptying VBG N
in IN N
the DT N
early JJ N
phase NN N
, , N
and CC N
a DT N
larger JJR N
( ( N
smaller JJR N
) ) N
k NN N
indicates VBZ N
faster RBR N
( ( N
slower JJR N
) ) N
emptying VBG N
in IN N
the DT N
later JJ N
phase NN N
. . N

The DT N
half NN N
( ( N
13 CD N
) ) N
CO NNP N
( ( N
2 CD N
) ) N
excretion NN N
time NN N
( ( N
t NN N
( ( N
1/2b CD N
) ) N
= SYM N
- : N
[ NN N
ln NN N
( ( N
1 CD N
- : N
2 CD N
( ( N
-1/beta NNP N
) ) N
) ) N
] FW N
/k NN N
) ) N
and CC N
the DT N
time NN N
of IN N
maximal NN N
( ( N
13 CD N
) ) N
CO NNP N
( ( N
2 CD N
) ) N
excretion NN N
rate NN N
( ( N
t NN N
( ( N
max NN N
) ) N
= VBZ N
[ JJ N
lnbeta NN N
] NNP N
/k NNP N
) ) N
were VBD N
also RB N
calculated VBN N
. . N

Between IN N
the DT N
two CD N
occasions NNS N
, , N
k NN N
, , N
beta NN N
, , N
t NN N
( ( N
1/2b CD N
) ) N
, , N
and CC N
t NN N
( ( N
max NN N
) ) N
were VBD N
compared VBN N
by IN N
the DT N
Wilcoxon NNP N
signed-rank JJ N
test NN N
. . N

RESULTS NNP N
After IN N
smoking VBG N
, , N
k NN N
was VBD N
significantly RB N
increased VBN N
. . N

No DT N
significant JJ N
differences NNS N
were VBD N
found VBN N
in IN N
beta NN N
, , N
t NN N
( ( N
1/2 CD N
) ) N
, , N
and CC N
t NN N
( ( N
max NN N
) ) N
between IN N
the DT N
two CD N
occasions NNS N
. . N

CONCLUSIONS VB N
The DT N
increase NN N
in IN N
k JJ N
suggests VBZ N
the DT N
acceleration NN N
of IN N
gastric JJ N
emptying VBG N
in IN N
the DT N
later JJ N
phase NN N
. . N

For IN N
the DT N
first JJ N
time NN N
, , N
this DT N
study NN N
has VBZ N
revealed VBN N
that IN N
acute JJ N
smoking NN N
speeds VBZ N
the DT N
gastric JJ N
emptying NN N
of IN N
solids NNS N
in IN N
Japanese JJ N
habitual JJ N
smokers NNS N
. . N

-DOCSTART- -X- O O

Optimization NN N
of IN N
acid JJ N
suppression NN N
for IN N
patients NNS N
with IN N
peptic JJ N
ulcer NN N
bleeding NN N
: : N
an DT N
intragastric JJ N
pH-metry NN N
study NN N
with IN N
omeprazole NN 3_i
. . 3_i

OBJECTIVE UH N
To TO N
study VB N
whether IN N
an DT N
intravenous JJ N
infusion NN N
dose NN N
of IN N
omeprazole NN 3_i
( ( N
80 CD N
mg NN N
+ VBD N
8 CD N
mg/h NN N
) ) N
during IN N
24 CD N
h NNS N
can MD N
be VB N
subsequently RB N
reduced VBN N
with IN N
maintained JJ N
effect NN N
. . N

Second NNP N
, , N
to TO N
study VB N
the DT N
effect NN N
of IN N
oral JJ N
omeprazole JJ 3_i
20 CD N
mg NN N
given VBN N
once RB N
or CC N
twice RB N
daily RB N
up IN N
to TO N
day NN N
10 CD N
, , N
after IN N
cessation NN N
of IN N
a DT N
3-day JJ N
intravenous JJ N
infusion NN N
( ( N
80 CD N
mg NN N
+ VBD N
8 CD N
mg/h NN N
) ) N
. . N

DESIGN NNP N
Prospective NNP N
, , N
randomized VBD N
, , N
partly RB N
blinded VBD N
study NN N
. . N

METHODS NNP N
Twelve NNP N
Helicobacter NNP N
pylori NN N
( ( N
+ NNP N
) ) N
patients NNS N
and CC N
12 CD N
H. NNP N
pylori NN N
( ( N
- : N
) ) N
subjects NNS N
were VBD N
included VBN N
. . N

In IN N
part NN N
I PRP N
the DT N
patients NNS N
received VBD N
omeprazole JJ 3_i
, , N
80 CD N
mg NN N
+ VBD N
8 CD N
mg/h NN N
, , N
during IN N
24 CD N
h NN N
followed VBN N
by IN N
8 CD N
, , N
4 CD N
or CC N
2 CD N
mg/h NN N
. . N

In IN N
part NN N
II NNP N
the DT N
subjects NNS N
received VBD N
80 CD N
mg NNS N
+ VBD N
8 CD N
mg/h NN N
during IN N
3 CD N
days NNS N
followed VBN N
by IN N
20 CD N
mg NNS N
omeprazole JJ 3_i
orally RB N
, , N
once RB N
or CC N
twice JJ N
daily JJ N
until IN N
day NN N
10 CD N
. . N

Intragastric NNP N
pH NN N
was VBD N
measured VBN N
. . N

RESULTS NNP N
All NNP N
H. NNP N
pylori FW N
( ( N
+ NN N
) ) N
patients NNS N
showed VBD N
a DT N
rapid JJ N
increase NN N
of IN N
intragastric JJ N
pH NN N
with IN N
a DT N
mean JJ N
intragastric JJ N
pH NN N
of IN N
6.7 CD N
during IN N
the DT N
second JJ N
half NN N
of IN N
the DT N
first JJ N
day NN N
. . N

After IN N
the DT N
subsequent JJ N
dose NN N
reduction NN N
, , N
the DT N
mean JJ N
pH NN N
decreased VBD N
to TO N
6.1-6.2 JJ N
. . N

Patients NNPS N
continuing VBG N
on IN N
8 CD N
mg/h NN N
showed VBD N
the DT N
best JJS N
results NNS N
. . N

Likewise NNP N
, , N
all DT N
H. NNP N
pylori NN N
( ( N
- : N
) ) N
subjects VBZ N
showed VBD N
a DT N
rapid JJ N
and CC N
sustained JJ N
reduction NN N
of IN N
intragastric JJ N
acidity NN N
during IN N
the DT N
infusion NN N
. . N

Subsequent NNP N
dose JJ N
reduction NN N
to TO N
20 CD N
mg NNS N
once RB N
daily RB N
led VBN N
to TO N
a DT N
stable JJ N
fraction NN N
of IN N
time NN N
with IN N
pH JJ N
> JJ N
3 CD N
of IN N
72 CD N
% NN N
. . N

CONCLUSIONS NNP N
Omeprazole NNP 3_i
given VBN N
as IN N
a DT N
continuous JJ N
infusion NN N
of IN N
80 CD N
mg NNS N
+ VBD N
8 CD N
mg/h NN N
for IN N
72 CD N
h NN N
followed VBN N
by IN N
omeprazole JJ 3_i
20 CD N
mg NN N
once RB N
daily RB N
raised VBD N
the DT N
intragastric JJ N
pH NN N
to TO N
and CC N
above JJ N
levels NNS N
alleged VBN N
to TO N
allow VB N
haemostasis NN N
in IN N
patients NNS N
with IN N
peptic JJ N
ulcer NN N
bleeding NN N
and CC N
subsequent JJ N
healing NN N
of IN N
the DT N
ulcer NN N
. . N

-DOCSTART- -X- O O

Long-term JJ N
prospective JJ N
, , N
randomized VBN N
, , N
controlled VBN N
study NN N
using VBG N
repetitive JJ N
education NN N
at IN N
six-month JJ N
intervals NNS N
and CC N
monitoring NN N
for IN N
adherence NN N
in IN N
heart NN N
failure NN N
outpatients NNS N
: : N
the DT N
REMADHE NNP N
trial NN N
. . N

BACKGROUND VB N
The DT N
effectiveness NN N
of IN N
heart NN N
failure NN N
disease NN N
management NN N
programs NNS N
in IN N
patients NNS N
under IN N
cardiologists NNS N
' POS N
care NN N
over IN N
long-term JJ N
follow-up NN N
is VBZ N
not RB N
established VBN N
. . N

METHODS NNP N
AND CC N
RESULTS NNP N
We PRP N
investigated VBD N
the DT N
effects NNS N
of IN N
a DT N
disease JJ 6_i
management NN 6_i
program NN 6_i
with IN 6_i
repetitive JJ 6_i
education NN 6_i
and CC N
telephone NN 6_i
monitoring NN 6_i
on IN N
primary JJ N
( ( N
combined VBN N
death NN N
or CC N
unplanned JJ N
first JJ N
hospitalization NN N
and CC N
quality-of-life JJ N
changes NNS N
) ) N
and CC N
secondary JJ N
end NN N
points NNS N
( ( N
hospitalization NN N
, , N
death NN N
, , N
and CC N
adherence NN N
) ) N
. . N

The DT N
REMADHE NNP N
[ NNP N
Repetitive NNP N
Education NNP 6_i
and CC 6_i
Monitoring NNP 6_i
for IN N
ADherence NNP N
for IN N
Heart NNP N
Failure NNP N
] NNP N
trial NN N
is VBZ N
a DT N
long-term JJ N
randomized NN N
, , N
prospective JJ N
, , N
parallel JJ N
trial NN N
designed VBN N
to TO N
compare VB N
intervention NN N
with IN N
control NN 7_i
. . 7_i

One CD N
hundred VBD N
seventeen JJ N
patients NNS N
were VBD N
randomized VBN N
to TO N
usual JJ N
care NN N
, , N
and CC N
233 CD N
to TO N
additional JJ N
intervention NN N
. . N

The DT N
mean JJ N
follow-up NN N
was VBD N
2.47+/-1.75 CD N
years NNS N
, , N
with IN N
54 CD N
% NN N
adherence NN N
to TO N
the DT N
program NN N
. . N

In IN N
the DT N
intervention NN N
group NN N
, , N
the DT N
primary JJ N
end NN N
point NN N
composite NN N
of IN N
death NN N
or CC N
unplanned JJ N
hospitalization NN N
was VBD N
reduced VBN N
( ( N
hazard JJ N
ratio NN N
, , N
0.64 CD N
; : N
confidence NN N
interval NN N
, , N
0.43 CD N
to TO N
0.88 CD N
; : N
P=0.008 NNP N
) ) N
, , N
driven VBN N
by IN N
reduction NN N
in IN N
hospitalization NN N
. . N

The DT N
quality-of-life JJ N
questionnaire NN N
score NN N
improved VBD N
only RB N
in IN N
the DT N
intervention NN N
group NN N
( ( N
P NNP N
< NNP N
0.003 CD N
) ) N
. . N

Mortality NNP N
was VBD N
similar JJ N
in IN N
both DT N
groups NNS N
. . N

Number NNP N
of IN N
hospitalizations NNS N
( ( N
1.3+/-1.7 JJ N
versus NN N
0.8+/-1.3 NN N
, , N
P NNP N
< NNP N
0.0001 CD N
) ) N
, , N
total JJ N
hospital NN N
days NNS N
during IN N
the DT N
follow-up JJ N
( ( N
19.9+/-51 JJ N
versus NN N
11.1+/-24 JJ N
days NNS N
, , N
P NNP N
< NNP N
0.0001 CD N
) ) N
, , N
and CC N
the DT N
need NN N
for IN N
emergency NN N
visits NNS N
( ( N
4.5+/-10.6 JJ N
versus NN N
1.6+/-2.4 CD N
, , N
P NNP N
< NNP N
0.0001 CD N
) ) N
were VBD N
lower JJR N
in IN N
the DT N
intervention NN N
group NN N
. . N

Beneficial JJ N
effects NNS N
were VBD N
homogeneous JJ N
for IN N
sex NN N
, , N
race NN N
, , N
diabetes NNS N
and CC N
no DT N
diabetes NN N
, , N
age NN N
, , N
functional JJ N
class NN N
, , N
and CC N
etiology NN N
. . N

CONCLUSIONS NNP N
For IN N
a DT N
longer RBR N
follow-up JJ N
period NN N
than IN N
in IN N
previous JJ N
studies NNS N
, , N
this DT N
heart NN N
failure NN N
disease JJ N
management NN N
program NN N
model NN N
of IN N
patients NNS N
under IN N
the DT N
supervision NN N
of IN N
a DT N
cardiologist NN N
is VBZ N
associated VBN N
with IN N
a DT N
reduction NN N
in IN N
unplanned JJ N
hospitalization NN N
, , N
a DT N
reduction NN N
of IN N
total JJ N
hospital NN N
days NNS N
, , N
and CC N
a DT N
reduced JJ N
need NN N
for IN N
emergency NN N
care NN N
, , N
as RB N
well RB N
as IN N
improved VBN N
quality NN N
of IN N
life NN N
, , N
despite IN N
modest JJ N
program NN N
adherence NN N
over IN N
time NN N
. . N

